<SEC-DOCUMENT>0001558370-24-012527.txt : 20240829
<SEC-HEADER>0001558370-24-012527.hdr.sgml : 20240829
<ACCEPTANCE-DATETIME>20240829070716
ACCESSION NUMBER:		0001558370-24-012527
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		48
CONFORMED PERIOD OF REPORT:	20240630
FILED AS OF DATE:		20240829
DATE AS OF CHANGE:		20240829

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			RedHill Biopharma Ltd.
		CENTRAL INDEX KEY:			0001553846
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35773
		FILM NUMBER:		241258554

	BUSINESS ADDRESS:	
		STREET 1:		21 HA'ARBA'A STREET
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			64739
		BUSINESS PHONE:		972-3-541-3131

	MAIL ADDRESS:	
		STREET 1:		21 HA'ARBA'A STREET
		CITY:			TEL AVIV
		STATE:			L3
		ZIP:			64739
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>rdhl-20240630x6k.htm
<DESCRIPTION>6-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.7.0.1 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 8/29/2024 10:57:34 AM -->
<!-- iXBRL Library version: 1.0.8923.15446 -->
<!-- iXBRL Service Job ID: 1bafbd29-c26b-40ee-9c97-f09142cd1a3a -->
<html xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns="http://www.w3.org/1999/xhtml" xmlns:rdhl="http://www.redhillbio.com/20240630" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:srt="http://fasb.org/srt/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta http-equiv="content-type" content="text/html"/><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" name="dei:EntityCentralIndexKey" id="Tc_s0pP6sPyDkuJetUda52EoQ_2_1">0001553846</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" name="dei:CurrentFiscalYearEndDate" id="Tc_HK_UcVhzCEmrb5mNgLQ2bQ_3_1">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" name="dei:DocumentFiscalYearFocus" id="Tc_MTX1Z99tJkKfRjYNAjcHTg_4_1">2024</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" name="dei:DocumentFiscalPeriodFocus" id="Tc_V9DSx8kOwkGvWGvfQ9qEKg_5_1">Q2</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" name="dei:AmendmentFlag" id="Tc_tb2-lXCIREWbfbV83Pavlw_6_1">false</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" name="dei:EntityRegistrantName" id="Tc_jC7umccUU0ytNG16r8Tz9w_7_1">RedHill Biopharma Ltd.</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" name="dei:DocumentType" id="Tc_W35658ZSGkquL37jqtNpkw_8_1">6-K</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" name="dei:DocumentPeriodEndDate" id="Tc_BP9nG0iBWk-aJHaM3gy7SA_9_1">2024-06-30</ix:nonNumeric></ix:hidden><ix:references><link:schemaRef xlink:href="rdhl-20240630.xsd" xlink:type="simple"/></ix:references><ix:resources><xbrli:context id="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_NewIFRSsAxis_rdhl_Ias1AmendmentsMember_6IOwDM618kGNeECku1awvg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NewIFRSsAxis">rdhl:Ias1AmendmentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_8_20_2024_To_8_20_2024_ifrs-full_ClassesOfOrdinarySharesAxis_dei_AdrMember_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_ifrs-full_MajorOrdinaryShareTransactionsMember_RX7kvctHAE2Q6Z9cdW-n0g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">dei:AdrMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorOrdinaryShareTransactionsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-08-20</xbrli:startDate><xbrli:endDate>2024-08-20</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_23_2023_To_3_23_2023_ifrs-full_ClassesOfOrdinarySharesAxis_dei_AdrMember_xDmTu-XomE-QX_HsBKKWmA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">dei:AdrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-23</xbrli:startDate><xbrli:endDate>2023-03-23</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_3_22_2023_To_3_22_2023_ifrs-full_ClassesOfOrdinarySharesAxis_dei_AdrMember_bVgXh3NRiE65_Oa5kANs7A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">dei:AdrMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-03-22</xbrli:startDate><xbrli:endDate>2023-03-22</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_CounterpartiesAxis_rdhl_GaelanMedicalTradeLlcMember_ifrs-full_ProductsAndServicesAxis_rdhl_TaliciaMember_0Cf0K8YIskWI-fe7fzrpxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">rdhl:GaelanMedicalTradeLlcMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdhl:TaliciaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_ProductsAndServicesAxis_rdhl_TaliciaMember_K2Ipuy8Jc065NyMxnj96Og"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdhl:TaliciaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_ProductsAndServicesAxis_rdhl_TaliciaMember_bJeEtRwXpUOUmdyfShRWow"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdhl:TaliciaMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_7_15_2024_To_7_15_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_rdhl_GlobalTerminationAgreementMember_srt_CounterpartyNameAxis_rdhl_MovantikAcquisitionValinorPharmaLlcHcrRedhillSpvLlcMember_4pd8zpat4UqiB1Cifr2ikA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">rdhl:GlobalTerminationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rdhl:MovantikAcquisitionValinorPharmaLlcHcrRedhillSpvLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-07-15</xbrli:startDate><xbrli:endDate>2024-07-15</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_3_2024_To_4_3_2024_ifrs-full_ComponentsOfEquityAxis_rdhl_AmericanDepositoryShareMember_i9PW7CfORkKunWqEkaIlfA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">rdhl:AmericanDepositoryShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-03</xbrli:startDate><xbrli:endDate>2024-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_26_2024_To_1_26_2024_ifrs-full_ComponentsOfEquityAxis_rdhl_AmericanDepositoryShareMember_6NQerov18ESxxuLFDfcOog"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">rdhl:AmericanDepositoryShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-26</xbrli:startDate><xbrli:endDate>2024-01-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_26_2024_ifrs-full_ComponentsOfEquityAxis_rdhl_IfrsWarrantMember_2DHClqF2Qk-paY34dAQVhQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">rdhl:IfrsWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_ProductsAndServicesAxis_rdhl_MovantikMember_vMAuogPiaUK-988AAqqd3A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdhl:MovantikMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_ProductsAndServicesAxis_rdhl_MovantikMember_NxqJvzQaaEK6GKQWpIqWZw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdhl:MovantikMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_21_2024_GMdZTmx5DEK7BZ7CRDSNdw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-03-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_24_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_rdhl_DirectorsAndChiefExecutiveOfficerMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_rdhl_IfrsRestrictedStockUnitsRsuMember_o4Du92Jem0mmcqx2GDZY1g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">rdhl:DirectorsAndChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">rdhl:IfrsRestrictedStockUnitsRsuMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_24_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_rdhl_IfrsRestrictedStockUnitsRsuMember_w7Isi7m0tka2iRJ24DO5Fw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">rdhl:IfrsRestrictedStockUnitsRsuMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_UnobservableInputsAxis_ifrs-full_InterestRateMeasurementInputMember_teenRBiuRkGg1uO4tRE-mQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:InterestRateMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_UnobservableInputsAxis_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_mTVtiUNnuUSkyBFbN8TE6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_UnobservableInputsAxis_ifrs-full_InterestRateMeasurementInputMember_Vcvjf-Um0kSPabpRIwMIwA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:InterestRateMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_UnobservableInputsAxis_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_zejd0Q0P70OkmQekwOSjkw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_UnobservableInputsAxis_ifrs-full_InterestRateMeasurementInputMember_41fW1aKaCUmxWkrY4H-2hg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:InterestRateMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_UnobservableInputsAxis_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_KazBZZXGN0muagfyEB6zqQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_UnobservableInputsAxis_ifrs-full_InterestRateMeasurementInputMember_oOWejR1pzEKHOWOqEBCqlw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:InterestRateMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_UnobservableInputsAxis_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_wfwD34Lnw0G6p7TDXvEZ7A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_7_15_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_rdhl_GlobalTerminationAgreementMember_srt_CounterpartyNameAxis_rdhl_MovantikAcquisitionValinorPharmaLlcHcrRedhillSpvLlcMember_ZmyihQPxD0iGrsKP1MNtWw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">rdhl:GlobalTerminationAgreementMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rdhl:MovantikAcquisitionValinorPharmaLlcHcrRedhillSpvLlcMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-07-15</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_4_3_2024_To_4_3_2024_ifrs-full_ComponentsOfEquityAxis_rdhl_IfrsWarrantMember_MJAPHqwRZkK8j3cPNSQ-DQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">rdhl:IfrsWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-03</xbrli:startDate><xbrli:endDate>2024-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_3_2024_To_4_3_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfEquityComponentOfConvertibleInstrumentsMember_eYL19KtWRk2RX2MXCnVjkw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfEquityComponentOfConvertibleInstrumentsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-03</xbrli:startDate><xbrli:endDate>2024-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_4_3_2024_To_4_3_2024_xAzFjFHyA02Un3POz8VYMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-04-03</xbrli:startDate><xbrli:endDate>2024-04-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_26_2024_To_1_26_2024_ifrs-full_ComponentsOfEquityAxis_rdhl_IfrsWarrantMember_try5X0D-VEimOWrLlTXBdw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">rdhl:IfrsWarrantMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-26</xbrli:startDate><xbrli:endDate>2024-01-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_26_2024_To_1_26_2024__j6PCY90FUmwW0bnS-0ZyQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-26</xbrli:startDate><xbrli:endDate>2024-01-26</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_3_2024_ifrs-full_ComponentsOfEquityAxis_rdhl_AmericanDepositoryShareMember_nhnjGt_XE0ij6Oga9k_JNw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">rdhl:AmericanDepositoryShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-04-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_26_2024_ifrs-full_ComponentsOfEquityAxis_rdhl_AmericanDepositoryShareMember_earRV5J5lEem3IOZmkajMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">rdhl:AmericanDepositoryShareMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-01-26</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_21_2024_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_PreferenceSharesMember_RA41LoI2wE2KQ4D5_pwTlQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:PreferenceSharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_3_21_2024_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember_Ej8jvZlqGkeT63oCOmaVmg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-03-21</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_rdhl_IfrsEmployeeStockOptionMember_ITJCorKc8UWnxsVgxsWbxA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">rdhl:IfrsEmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_rdhl_IfrsRestrictedStockUnitsRsuMember_5fNRhXT34kedMYDPV9PNfA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">rdhl:IfrsRestrictedStockUnitsRsuMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_24_2024_To_6_24_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_rdhl_DirectorsAndChiefExecutiveOfficerMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_rdhl_IfrsRestrictedStockUnitsRsuMember_HlO_DU02TUiIerX8stVCzQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">rdhl:DirectorsAndChiefExecutiveOfficerMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">rdhl:IfrsRestrictedStockUnitsRsuMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-24</xbrli:startDate><xbrli:endDate>2024-06-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_6_24_2024_To_6_24_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_rdhl_IfrsRestrictedStockUnitsRsuMember_sjZ0svU9fUaW52OaNR-8sQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">rdhl:IfrsRestrictedStockUnitsRsuMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-06-24</xbrli:startDate><xbrli:endDate>2024-06-24</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember_ifrs-full_ClassesOfLiabilitiesAxis_rdhl_FairValueOfWarrantsMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_bh9izY_nwk2QNVQRdIq8MQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">rdhl:FairValueOfWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember_ifrs-full_ClassesOfLiabilitiesAxis_rdhl_FairValueOfWarrantsMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_KpTPdCsFCkCR24LGQXoX_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">rdhl:FairValueOfWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember_ifrs-full_ClassesOfLiabilitiesAxis_rdhl_FairValueOfWarrantsMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_0zRaQna2fk2MTgU3jRhH5w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">rdhl:FairValueOfWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember_ifrs-full_ClassesOfLiabilitiesAxis_rdhl_FairValueOfWarrantsMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_Y9wiYGhs4U-MxGWOO7SysA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">rdhl:FairValueOfWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_hQziAgWDuESfatZXZuDWKg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_WUJJNdtgkUmTbxC0es9vGA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_WC_VpnnmJEurMcXdPGqAAA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_ME6JQrLs4kCObaTBOn_26Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_f7VpnqzdG0eBMbQ0_PH15g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_FdLWqdRnzEeYm1z5Q53cfg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_ClassesOfProvisionsAxis_rdhl_RebatesAndPatientDiscountProgramsMember_qttEPmHMoE6w_c5KccwpGw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">rdhl:RebatesAndPatientDiscountProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_ClassesOfProvisionsAxis_rdhl_ProductReturnsMember_HT0SSNr17UuTj9RHXWQHKg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">rdhl:ProductReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_ClassesOfProvisionsAxis_rdhl_RebatesAndPatientDiscountProgramsMember__3ztoVhkKk2SJ4D3UbPO_A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">rdhl:RebatesAndPatientDiscountProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_ClassesOfProvisionsAxis_rdhl_ProductReturnsMember_9x6Pj5KuWkWJDcCsTqsLnA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">rdhl:ProductReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember_ifrs-full_ClassesOfLiabilitiesAxis_rdhl_FairValueOfWarrantsMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_XsHFmv9nQky9EyNZwd-RWw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">rdhl:FairValueOfWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2024-01-01</xbrli:startDate><xbrli:endDate>2024-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember_ifrs-full_ClassesOfLiabilitiesAxis_rdhl_FairValueOfWarrantsMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_JUJ1h0rhhUi0IPjIFY9Y2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">rdhl:FairValueOfWarrantsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_iXJ3_uR3qkyjYahn5cu1hg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_ULnTaRXf1k2sfiQlt2ZrxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_pt7V-puUQUK2FnS6Bj5qwA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_LOEJOyxWXU26M6zuQvwiJw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_ZNNvPFR40UGCID0ZfJxAmQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_WIaiT8u6y0CHEd67KoeeuQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_cnP-pEbtykmp58TplJXbRw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_QWxXKkKqr0CvPrcIr11d4g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_MYPHkdkUC02VHj9u1f1FRA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_t4QHHZ5Wp0OEOQnVhfCjxQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_ZgoHvobcPU2rpUbaBgakWg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_Y7iGsPaVjkeiB7bpTvHRwg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_ClassesOfProvisionsAxis_rdhl_RebatesAndPatientDiscountProgramsMember_CqyXkqtSmEKb7iUSQ8eaSw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">rdhl:RebatesAndPatientDiscountProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_ifrs-full_ClassesOfProvisionsAxis_rdhl_ProductReturnsMember_QRm2PIhBJEeuckWrAEejMg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">rdhl:ProductReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_ClassesOfProvisionsAxis_rdhl_RebatesAndPatientDiscountProgramsMember_uIEoPLILYUedGsgrxLouxA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">rdhl:RebatesAndPatientDiscountProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_ifrs-full_ClassesOfProvisionsAxis_rdhl_ProductReturnsMember_JgwA-XfDBkSzQ2XdwWxN8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">rdhl:ProductReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_ifrs-full_ClassesOfProvisionsAxis_rdhl_RebatesAndPatientDiscountProgramsMember_LALfYhyhQ0qxyfiZPt60JA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">rdhl:RebatesAndPatientDiscountProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_ifrs-full_ClassesOfProvisionsAxis_rdhl_ProductReturnsMember_P7rAd3_jxEamZoSwvrmIKw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">rdhl:ProductReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_ClassesOfProvisionsAxis_rdhl_RebatesAndPatientDiscountProgramsMember_vf1AdzJz3Uqw4ZUCrYrNWQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">rdhl:RebatesAndPatientDiscountProgramsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_ifrs-full_ClassesOfProvisionsAxis_rdhl_ProductReturnsMember_8Uz3eWP1LEa7NOwt5dXb2Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">rdhl:ProductReturnsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2023_XZFu_w7MpEqlzzSlD3xkQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_jV2f_7krOUScpr2kI0mJcw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2024_lm1Lh8C52kquuyx0qsrPDw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2024-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2023_XGghR9I2w0KmrTtJVNkj1A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001553846</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2023-01-01</xbrli:startDate><xbrli:endDate>2023-06-30</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_shares_XGdimIWcf0OdGjo7fryoGw"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_CKQZNDkEe0eDAz2GdtdFSg"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Divide_ILS_shares_LnWGktS0CkGllLF6Jva9vA"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:ILS</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_pure_yhcnVVwWa0i2EX2hTkNGPA"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_ILS_19CAiapBLkWinll-yZ3PnA"><xbrli:measure>iso4217:ILS</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_installment_wykoJbCfrk-_WeAKgSm6lA"><xbrli:measure>rdhl:installment</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1px solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:5pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><a id="_b70508ae_5f80_4652_9ee9_8577cc68cfd9"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Washington, D.C.&#160;20549</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:14pt;font-weight:bold;">FORM 6-K</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Report of Foreign Private Issuer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Pursuant to Rule 13a-16 or 15d-16</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">of&#160;the Securities Exchange Act of 1934</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:12pt;">For the month of August 2024</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:12pt;">Commission File No.:001-35773</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:16pt;font-weight:bold;">REDHILL BIOPHARMA LTD.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:12pt;">(Translation of registrant&#8217;s name into English)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">21 Ha&#8217;arba&#8217;a Street, Tel Aviv, 6473921, Israel</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:12pt;">(Address of principal executive offices)</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-size:12pt;">Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form&#160;40-F.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="font-size:12pt;">Form 20-F </span><span style="font-family:'Segoe UI Symbol';font-size:12pt;">&#9746;</span><span style="font-size:12pt;">&#160;Form 40-F </span><span style="font-family:'Segoe UI Symbol';font-size:12pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-size:12pt;">Indicate by check mark if the Registrant is&#160;submitting&#160;the Form 6-K in paper as permitted by Regulation S-T Rule&#160;101(b)(1): ____</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-size:12pt;">Indicate by check mark if the Registrant is&#160;submitting&#160;the Form 6-K in paper as permitted by Regulation S-T Rule&#160;101(b)(7): ____</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-size:12pt;">Attached hereto and incorporated by reference herein are the following:</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:12pt;" href="rdhl-20240630xex99d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Exhibit 99.1: Registrant&#8217;s press release entitled &#8220;RedHill Biopharma Announces First Half 2024 Business Highlights&#8221;.</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:12pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;font-size:12pt;" href="rdhl-20240630xex99d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Exhibit 99.2: Registrant&#8217;s condensed consolidated interim unaudited financial information as of June 30, 2024, and for the six months then ended.</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;background:#ffffff;margin:0pt 0pt 3pt 0pt;"><span style="font-size:12pt;">This Form 6-K, including Exhibits 99.1 (solely with respect to &#8220;Financial results for the six months ended June 30, 2024 (Unaudited)&#8221;, &#8220;R&amp;D and Commercial Highlights&#8221;, &#8220;Condensed Consolidated Interim Statements of Comprehensive Income (Loss)&#8221;, &#8220;Condensed Consolidated Interim Statements of Financial Position&#8221;, and &#8220;Condensed Consolidated Interim Statements of Cash Flows&#8221;) and 99.2 to this Report on Form 6-K, is hereby incorporated by reference into the Company&#8217;s Registration Statements on Form S-8 filed with the Securities and Exchange Commission on May 2, 2013 (Registration No. 333-188286), on October 29, 2015 (Registration No. 333-207654), on July 25, 2017 (Registration No. 333-219441), on May 23, 2018 (Registration No. 333-225122), on July 24, 2019 (File No. 333-232776), on March 25, 2021 (File No. 333-254692), on May 3, 2021 (File No. 333-255710), on January 11, 2022 (File No. 333-262099), on June 27, 2022 (File No. 333-265845), on June 29, 2023 (File No. 333-273001) and on June 20, 2024 (File No. 333-280327), and its Registration Statements on Form F-3 filed with the Securities and Exchange Commission on March 30, 2021 (File No. 333-254848), on August 4, 2023 (File No. 333-273709), on October 13, 2023 (File No. 333-274957), as amended, and on August 9, 2024 (File No. 333-281417).</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1pt;padding-bottom:1pt;padding-top:1pt;text-align:justify;border-bottom:3.0pt solid #000000;border-top:1px solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';line-height:0pt;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:88.24%;border:0;margin:30pt 5.88% 30pt 5.88%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><a id="_f5b0cec7_db55_4a3b_8c0b_24b9ccd6858c"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">SIGNATURES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><span style="font-size:12pt;">Pursuant to the requirements of&#160;the&#160;Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.0978775%;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:middle;width:52.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;">&#160;</span></p></td><td colspan="2" style="vertical-align:middle;width:40.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;">REDHILL BIOPHARMA LTD.</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;">&#160;</span></p></td></tr><tr><td style="vertical-align:middle;width:52.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;">&#160;</span></p></td><td colspan="2" style="vertical-align:middle;width:40.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;">(the &#8220;Registrant&#8221;)</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;">&#160;</span></p></td></tr><tr><td style="vertical-align:middle;width:52.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;">&#160;</span></p></td><td style="vertical-align:middle;width:6.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;">&#160;</span></p></td><td style="vertical-align:middle;width:33.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;">&#160;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;">&#160;</span></p></td></tr><tr><td style="vertical-align:middle;width:52.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;">Date: August 29, 2024</span></p></td><td style="vertical-align:middle;width:6.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;">By:</span></p></td><td style="vertical-align:middle;width:33.94%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;">&#160;/s/ Dror Ben-Asher&#160;</span></p></td><td style="vertical-align:bottom;width:6.6%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;">&#160;</span></p></td></tr><tr><td style="vertical-align:middle;width:52.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:6.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;">Name:</span></p></td><td style="vertical-align:middle;width:33.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;">&#160;Dror Ben-Asher&#160;</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:52.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:6.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;">Title:</span></p></td><td style="vertical-align:middle;width:33.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;">&#160;Chief Executive Officer</span></p></td><td style="vertical-align:bottom;width:6.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="direction:rtl;font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="direction:rtl;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>rdhl-20240630xex99d1.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  10.6.125.0--><!--Created on: 8/29/2024 10:57:15 AM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;"><img src="rdhl-20240630xex99d1001.jpg" alt="Graphic" style="display:inline-block;height:50.62pt;left:0%;padding-bottom:0.4pt;position:relative;top:0pt;width:89.5pt;"></font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:2pt;padding-right:3pt;padding-top:1pt;text-align:center;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:4.5pt solid #000000;margin:0pt -3pt 8pt -2pt;"><font style="font-size:25pt;">Press Release</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-size:18pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">RedHill Biopharma Announces First Half 2024 Business Highlights</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;font-style:italic;font-weight:bold;">A transformed RedHill:</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:28.8pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:12pt;font-style:italic;font-weight:bold;">Numerous potential catalysts</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:28.8pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:12pt;font-style:italic;font-weight:bold;">Strengthened cash balance and control over our destiny following the Termination Agreement with Movantik Acquisition Co. and others</font><i style="font-size:12pt;font-style:italic;">: Executing on our plan to ensure a value-driven focus, operational efficiency and financial streamlining with a low cost-base</i></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:28.9pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:12pt;font-style:italic;font-weight:bold;">U.S. government collaborations</font><i style="font-size:12pt;font-style:italic;">: Developing a promising, advancing and largely financially de-risked pipeline via U.S. government and other collaborations</i></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:28.9pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:12pt;font-style:italic;font-weight:bold;">Addressing</font><font style="font-size:12pt;font-style:italic;font-weight:bold;"> substantial and underserved indications</font><i style="font-size:12pt;font-style:italic;">: In oncology viral pandemic preparedness, nuclear/radioprotection, and obesity/diabetes</i></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:28.9pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:12pt;font-style:italic;font-weight:bold;">Building value</font><i style="font-size:12pt;font-style:italic;">: </i><i style="font-size:12pt;font-style:italic;">In the lab and in the clinic through new studies, generating new intellectual property and publications and forging the right partnerships for our assets</i></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:28.8pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:12pt;font-style:italic;font-weight:bold;">Streamlined U.S. commercial organization</font><i style="font-size:12pt;font-style:italic;">: Cost reduction measures resulted in a much smaller, more efficient and cost-effective organization while still maintaining a leadership position with Talicia</i><sup style="font-size:9pt;font-style:italic;vertical-align:top;">&#174;</sup></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;font-style:italic;font-weight:bold;">R&amp;D and Commercial Highlights</font><i style="font-size:12pt;font-style:italic;">:</i></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:28.9pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:12pt;font-style:italic;font-weight:bold;">Opaganib:</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:64.9pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">o</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><i style="font-size:12pt;font-style:italic;">U.S. Army program for </i><font style="font-size:12pt;font-style:italic;font-weight:bold;">Ebola</font><i style="font-size:12pt;font-style:italic;"> (believed to be the first host-directed molecule to show activity in vivo in Ebola virus disease)</i></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:64.9pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">o</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><i style="font-size:12pt;font-style:italic;">Orphan drug designation granted by FDA for </i><font style="font-size:12pt;font-style:italic;font-weight:bold;">neuroblastoma</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:64.9pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">o</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><i style="font-size:12pt;font-style:italic;">Discussions ongoing for a potential externally-funded, mid-stage clinical study in an additional </i><font style="font-size:12pt;font-style:italic;font-weight:bold;">underserved oncology indication</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:64.8pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">o</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><i style="font-size:12pt;font-style:italic;">U.S. government-funded programs ongoing with the NIH / BARDA-funded nuclear and chemical medical countermeasure programs for Acute </i><font style="font-size:12pt;font-style:italic;font-weight:bold;">Radiation Syndrome (ARS)</font><i style="font-size:12pt;font-style:italic;"> and </i><font style="font-size:12pt;font-style:italic;font-weight:bold;">Sulfur Mustard exposure</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:64.9pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">o</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><i style="font-size:12pt;font-style:italic;">Positive in vivo study results support potential of opaganib therapy in </i><font style="font-size:12pt;font-style:italic;font-weight:bold;">diabetes / obesity</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:28.9pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:12pt;font-style:italic;font-weight:bold;">RHB-107:</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:64.9pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:12pt;">o</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:12pt;font-style:italic;font-weight:bold;">COVID-19: </font><i style="font-size:12pt;font-style:italic;">Enrollment ongoing in the U.S Department of Defense-supported 300-patient Phase 2 ACESO PROTECT platform trial for early</i></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 64.9pt;"><font style="font-size:12pt;font-style:italic;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="display:none;line-height:0pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 64.9pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 82.9pt;"><i style="font-size:12pt;font-style:italic;">COVID-19 outpatient treatment; enrollment estimated to be completed in the first half of 2025</i></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:64.9pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:12pt;">o</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><i style="font-size:12pt;font-style:italic;">U.S. Army-funded </i><font style="font-size:12pt;font-style:italic;font-weight:bold;">Ebola </font><i style="font-size:12pt;font-style:italic;">development program ongoing; RHB-107 also demonstrated robust synergistic effect in vitro when combined with remdesivir</i></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:28.9pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:12pt;font-style:italic;font-weight:bold;">RHB-104</font><i style="font-size:12pt;font-style:italic;">: Newly published positive Phase 3 data demonstrated 64% increased efficacy with RHB-104 in </i><font style="font-size:12pt;font-style:italic;font-weight:bold;">Crohn&#39;s disease</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:28.9pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:12pt;font-style:italic;font-weight:bold;">Talicia: </font><i style="font-size:12pt;font-style:italic;">The leading prescribed branded H. pylori therapy in the U.S., maintaining leadership position with a streamlined commercial team:</i></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:64.9pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:12pt;">o</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><i style="font-size:12pt;font-style:italic;">Expected upcoming new H. pylori treatment guidelines may further enhance positioning and use</i></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:64.9pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-size:12pt;">o</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><i style="font-size:12pt;font-style:italic;">Potential manufacturing developments aiming to open additional new markets underway</i></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:64.8pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><font style="font-size:12pt;">o</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;"><i style="font-size:12pt;font-style:italic;">Commercially launched in the UAE, triggering RedHill&#8217;s eligibility for potential milestone and royalty payments; Additional ex-US partnerships under discussions</i></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:12pt;font-style:italic;font-weight:bold;">Financial highlights</font><i style="font-size:12pt;font-style:italic;">:</i></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:28.9pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><i style="font-size:12pt;font-style:italic;">Cash balance of $8.2 million as of June 30, 2024</i><sup style="font-size:9pt;font-style:italic;vertical-align:top;">1</sup><i style="font-size:12pt;font-style:italic;">; Net revenues for the first half of 2024 totaled $2.6 million. Talicia contributed $3.5 million, down from the first half of 2023 due to a 12% reduction in U.S. prescriptions, driven by employee terminations and other cost-cutting measures. Movantik recorded negative revenues of $0.9 million, primarily due to product returns. Excluding one-time items in the first half of 2023 related to the Movantik</i><sup style="font-size:9pt;font-style:italic;vertical-align:top;">&#174;</sup><i style="font-size:12pt;font-style:italic;"> divestiture, the operating loss and net loss improved by $9.9 million and $9.5 million, respectively, as these cost-cutting measures significantly reduced overall expenses</i></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:28.9pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;"><i style="font-size:12pt;font-style:italic;">Post-balance sheet date, RedHill signed a Global Termination Agreement with Movantik Acquisition Co. and others (the &#8220;Agreement&#8221;). The Agreement resulted in RedHill receiving $9.9 million in cash and gaining full control over $0.74 million in a restricted account, while assuming $12.2 million in liabilities, leading to a net balance sheet reduction of approximately $2.3 million. The Agreement ended all existing credit ties and removed the lien against Talicia</i></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 28.9pt;"><font style="font-size:12pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">TEL AVIV, Israel and RALEIGH, NC, August 29, 2024, </b><font style="font-size:12pt;">RedHill Biopharma Ltd. (Nasdaq: RDHL) (&#8220;RedHill&#8221; or the &#8220;Company&#8221;), a specialty biopharmaceutical company, today reported its first half 2024 financial results and operational highlights, for the six months ended June 30, 2024.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">&#8220;The first six months of this year have realized significant accomplishments, laying the groundwork for numerous potential upcoming catalysts. RedHill is now in possession of a promising, advancing and largely financially de-risked development pipeline designed to address substantial and underserved indications in oncology, viral pandemic preparedness, nuclear/radioprotection and diabetes and obesity-related disorders,&#8221; </font><b style="font-size:12pt;font-weight:bold;">said Dror Ben-Asher, RedHill&#8217;s Chief Executive Officer</b><font style="font-size:12pt;">. &#8220;There is no doubt that the last four years have been a challenge, primarily as a result of the pandemic&#8217;s negative impact on our commercial launches in the United States in the first half of 2020. However, we have been turning the ship around and I am immensely proud of our team that works tirelessly to create opportunities, deliver on plans and create value in the lab and in the clinic through new studies, generating additional patents and publications, identifying important new indications and forging the right partnerships for our assets, while maintaining a market leadership position with Talicia. We are executing on our plans to ensure a clear value-driven focus, operational efficiency and financial streamlining with a low cost-base, as well as a strengthened cash balance and solid control over all elements of our business.&#8221;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Financial results for the six months ended June 30, 2024 (Unaudited)</b><sup style="font-size:9pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;vertical-align:top;">2</sup></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Net Revenues</b><font style="font-size:12pt;"> for the first half of 2024 were $2.6 million, compared to $5.4 million for the first half of 2023. Talicia net revenues were $3.5 million for the six months ended June 30, 2024, compared to $5.1 million for the six months ended June 30, 2023, mainly due to a 26% decrease in gross revenues and a 9% increase in Gross-to-Net deductions, mainly from increased Medicaid rebates. In the first half of 2024, $0.5 million of net revenues came from sales in the UAE. Talicia scripts in the U.S. in the first half of 2024 were down by approximately 12%, compared to the same period in 2023, mainly due to reduced promotion and marketing following employee terminations and other cost-cutting measures in the United States. These measures had a significant positive impact on reducing expenses, as detailed below.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Movantik had negative net revenues of $0.9 million in the first half of 2024, compared to negative net revenues of $0.1 million in the first half of 2023, mainly due to returns related to sales in the second and third quarters of 2020.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Gross Profit </b><font style="font-size:12pt;">for the first half of 2024 was $1.2 million, compared to $3 million for the first half of 2023, in line with the decrease in Net Revenues as explained above and primarily attributable to the reduction in Talicia prescriptions following employee terminations and other cost-cutting measures.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Research and Development Expenses </b><font style="font-size:12pt;">for the first half of 2024 were $0.7 million, as compared to $2.3 million for the first half of 2023. The decrease is mainly attributable to the costs from closing the RHB-204 clinical trial, which were recognized in the first half of 2023, and to ongoing cost-reduction measures.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Selling, Marketing, and General and Administrative Expenses </b><font style="font-size:12pt;">for the first half of 2024 were $9 million, compared to $19 million for the first half of 2023. This decrease was primarily due to downsizing the U.S. workforce following the Movantik divestiture, leading to lower payroll and related expenses, and reduced sales force expenses.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Other Income &#8211; </b><font style="font-size:12pt;">There was no other income for the first half of 2024, as compared to $43 million of other income for the first half of 2023. The other income recognized in the first half of 2023 was comprised of (i) $35.5 million from the divestiture of Movantik and (ii) $7.5 million from transitional services fees provided to the buyer of Movantik.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Operating Loss </b><font style="font-size:12pt;">for the first half of 2024 was $8.4 million, compared to operating income of $24.7 million for the first half of 2023. The difference is primarily attributable to the changes resulting from the divestiture of Movantik the previous year, as detailed above. Excluding the other income from the Movantik transaction in 2023, the operating loss decreased by approximately $9.9 million, from an operating loss of $18.3 million for the first half of 2023, reflecting the positive operating impact of the cost-cutting measures.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Financial Income, net </b><font style="font-size:12pt;">for the first half of 2024 was $5.</font><font style="direction:rtl;font-size:12pt;">4</font><font style="font-size:12pt;"> million, compared to $26.3 million for the first half of 2023. In the first half of 2024, the income recognized was mainly attributable to warrants&#8217; revaluation, offset by offerings&#8217; expenses. In the first half of 2023, the income recognized was primarily attributable to a $20.6 million gain resulting from the extinguishment of the HCR Collateral Management LLC debt in exchange for the transfer of rights to Movantik.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Net Loss </b><font style="font-size:12pt;">was $</font><font style="direction:rtl;font-size:12pt;">3.1</font><font style="font-size:12pt;"> million for the first half of 2024, compared to net income of $51 million for the first half of 2023. This change was primarily attributable to the effects resulting from the sale of Movantik and ongoing cost-reduction measures, as detailed above. Excluding the other income and financial income from the Movantik transaction in 2023, the net loss decreased by approximately $9.5 million, from a net loss of $12.6 million for the first half of 2023, reflecting the positive net impact of the cost-cutting measures.</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Total Assets</b><font style="font-size:12pt;"> as of June 30, 2024 were $22 million, as compared to $23 million as of December 31, 2023. The decrease was primarily attributable to a reduction in the inventory balance due to sales, as well as a reduction in right-of-use assets, due to termination of car leases in the six months ended June 30, 2024.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Total Liabilities</b><font style="font-size:12pt;"> as of June 30, 2024 were $22 million, as compared to $21 million as of December 31, 2023. The increase is mainly due to higher allowance from deductions from revenues and increased warrant-related derivative liabilities, partially offset by lower accounts payable, accrued expenses and lease liabilities (due to the car leases&#8217; termination).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Net Cash Used in Operating Activities</b><font style="font-size:12pt;"> for the six months ended June 30, 2024 was $6.2 million, compared to $17.8 million for the same period in 2023. The decrease in cash used was primarily due to settling pre-closing liabilities associated with Movantik and other operational activities in the six months ended June 30, 2023. Furthermore, this reduction is attributable to the cost-cutting measures mentioned above.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Net Cash Provided by Financing Activities</b><font style="font-size:12pt;"> for the six months ended June 30, 2024 was $7.9 million, comprised primarily of the net proceeds from securities offerings in the six months ended June 30, 2024. For the six months ended June 30, 2023, Net Cash Provided by Financing Activities was $4.8 million, comprised primarily of the net proceeds from securities offerings in the six months ended June 30, 2023, and the decrease in restricted cash, partially offset by the repayment of payables related to the purchase of intangible assets.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">Cash Balance</b><font style="font-size:12pt;"> as of June 30, 2024 was $8.2 million</font><sup style="font-size:8.25pt;vertical-align:top;">1</sup><font style="font-size:12pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">R&amp;D and Commercial Highlights</b><u style="font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">:</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">R&amp;D:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">RedHill&#8217;s pipeline is centered around opaganib</font><sup style="font-size:9pt;vertical-align:top;">3</sup><font style="font-size:12pt;"> &amp; RHB-107</font><sup style="font-size:9pt;vertical-align:top;">4</sup><font style="font-size:12pt;">, two promising, potentially broad utility, novel, oral, host-directed small molecule drugs with demonstrated safety and efficacy profiles. Both candidates are advancing in predominantly U.S. government-supported, externally-funded programs, directed at multiple underserved indications with sizeable multi-billion-dollar market opportunities and potentially advantageous pathways to approval.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Between them, they are in development for multiple oncology, viral, inflammatory and diabetes and obesity-related indications, including COVID-19, Ebola, acute respiratory distress syndrome (ARDS) and radio/chemical protection (Acute Radiation Syndrome (ARS) and Sulfur Mustard exposure).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-size:12pt;">Being (i) easy to administer and distribute and (ii) viral mutation-resistant, they are ideally suited for stockpiling strategies in the event of nuclear/chemical incidents and viral pandemic scenarios.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Opaganib:</b></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:28.9pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">U.S. Army program for </font><b style="font-size:12pt;font-weight:bold;">Ebola. </b><font style="font-size:12pt;">Opaganib is believed to be the first host-directed molecule to show activity in vivo in Ebola virus disease, delivering a statistically significant increase in survival and, separately, demonstrating a robust synergistic effect in vitro when combined with remdesivir (Veklury</font><sup style="font-size:9pt;vertical-align:top;">&#174;</sup><font style="font-size:12pt;">; Gilead Sciences, Inc.), improving viral inhibition while maintaining cell viability</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:28.9pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Orphan drug designation granted by FDA for </font><b style="font-size:12pt;font-weight:bold;">neuroblastoma </b><font style="font-size:12pt;">(opaganib has several such designations in multiple indications, with three in oncology)</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:28.9pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Discussions ongoing for a potential externally-funded, late-stage study in an additional </font><b style="font-size:12pt;font-weight:bold;">underserved oncology indication</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:28.9pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Positive </font><i style="font-size:12pt;font-style:italic;">in vivo</i><font style="font-size:12pt;"> study results support potential of opaganib therapy in </font><b style="font-size:12pt;font-weight:bold;">diabetes / obesity-related disorders</b><font style="font-size:12pt;"> - a market projected to be worth approximately $100 billion within the next decade</font></p></td></tr></table></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:28.9pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">U.S. government-funded programs ongoing with the NIH / BARDA-funded nuclear and chemical medical countermeasure programs for </font><b style="font-size:12pt;font-weight:bold;">ARS</b><font style="font-size:12pt;"> and </font><b style="font-size:12pt;font-weight:bold;">Sulfur Mustard exposure</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:28.9pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Late-stage </font><b style="font-size:12pt;font-weight:bold;">COVID-19</b><font style="font-size:12pt;"> program continues to address a multi-hundreds of millions of dollars market</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:28.9pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">New opaganib publications:</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:64.9pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">o</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">The Sphingolipid-Modulating Drug Opaganib Protects against Radiation-Induced Lung Inflammation and Fibrosis: Potential Uses as a Medical Countermeasure and in Cancer Radiotherapy. Publication showed that opaganib significantly improved long-term survival in an </font><i style="font-size:12pt;font-style:italic;">in vivo</i><font style="font-size:12pt;"> model of lung damage following exposure to ionizing radiation</font><sup style="font-size:9pt;vertical-align:top;">5</sup></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:64.9pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">o</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Effect of Opaganib on Supplemental Oxygen and Mortality in Patients with Severe SARS-CoV-2 Based Upon FiO2 Requirements. Publication showed that oral opaganib reduced mortality by 62% and delivered improved time to room air, and faster time to hospital discharge in a large group of 251 hospitalized, moderately severe COVID-19 patients requiring a Fraction of inspired Oxygen up to and including 60% (FiO2&#8804;60%). The paper also indicates that due to the lack of treatment effect in patients requiring FiO</font><font style="font-size:12pt;">2</font><font style="font-size:12pt;">&gt;60%, this may represent a threshold level for disease irreversibility (likely due to more severe COVID-19 lung disease) and be an important patient selection clinical biomarker, a key finding for future therapeutic strategies and studies</font><sup style="font-size:9pt;vertical-align:top;">6</sup></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:28.9pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">New Chinese patents granted for opaganib:</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:64.9pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">o</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">In combination with immune checkpoint inhibitors (ICIs) as a method of inducing an anti-cancer immune response. Provides protection for opaganib&#39;s potential use in combination with a range of approved and in-development ICIs across a growing range of indications through</font><b style="font-size:12pt;font-weight:bold;"> 2040</b></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:64.8pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">o</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">As a therapy for inhibition of single-stranded RNA virus replication (notably Ebola Disease Virus); valid through 2035</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">RHB-107 (upamostat):</b></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:28.9pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><b style="font-size:12pt;font-weight:bold;">COVID-19: </b><font style="font-size:12pt;">Enrollment ongoing in the U.S Department of Defense-supported 300-patient Phase 2 ACESO PROTECT platform trial for early COVID-19 outpatient treatment. Enrollment is estimated to be completed in the first half of 2025</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:28.8pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">U.S. Army-funded </font><b style="font-size:12pt;font-weight:bold;">Ebola </b><font style="font-size:12pt;">development program ongoing; RHB-107 also demonstrated a robust synergistic effect in vitro when combined with remdesivir. Management of potential Ebola virus pandemic outbreaks represents a significant opportunity and is a key concern for global health agencies</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"><b style="font-size:12pt;font-weight:bold;">RHB-104</b><sup style="font-size:9pt;font-weight:bold;vertical-align:top;">7</sup><font style="font-size:12pt;">: Newly published positive Phase 3 data demonstrated 64% increased efficacy with RHB-104 in </font><b style="font-size:12pt;font-weight:bold;">Crohn&#39;s disease</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Commercial:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Talicia</b><font style="font-size:12pt;">: The leading prescribed branded </font><i style="font-size:12pt;font-style:italic;">H. pylori</i><font style="font-size:12pt;"> therapy in the U.S., maintaining leadership position with a streamlined commercial team:</font></p><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:28.8pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Expected upcoming new </font><i style="font-size:12pt;font-style:italic;">H. pylori</i><font style="font-size:12pt;"> treatment guidelines may further enhance positioning and use</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:28.8pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Potential manufacturing developments aiming to open additional new markets underway</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:28.8pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Now commercially launched in the UAE, triggering RedHill&#8217;s eligibility for potential milestone and royalty payments</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:28.9pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-family:'Symbol';">&#183;</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Two new U.S. patent grants covering Talicia as:</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:64.9pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">o</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">A method for eradicating </font><i style="font-size:12pt;font-style:italic;">H. pylori</i><font style="font-size:12pt;"> regardless of BMI, valid until May 2042</font></p></td></tr></table><table border="0" cellpadding="0" cellspacing="0"><tr><td style="width:64.8pt;padding:0pt;"></td><td style="vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">o</font></p></td><td style="padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;text-align:justify;"><font style="font-size:12pt;">Use as an all-in-one treatment of </font><i style="font-size:12pt;font-style:italic;">H. pylori</i><font style="font-size:12pt;"> infection, valid until 2034</font></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">About RedHill Biopharma</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><font style="font-size:12pt;">RedHill Biopharma Ltd. (Nasdaq: RDHL) is a specialty biopharmaceutical company primarily focused on gastrointestinal and infectious diseases. RedHill promotes the gastrointestinal drugs </font><b style="font-size:12pt;font-weight:bold;">Talicia</b><font style="font-size:12pt;">, for the treatment of </font><i style="font-size:12pt;font-style:italic;">Helicobacter pylori (H. pylori)</i><font style="font-size:12pt;"> infection in adults</font><sup style="font-size:9pt;vertical-align:top;">8</sup><font style="font-size:12pt;">, and </font><b style="font-size:12pt;font-weight:bold;">Aemcolo</b><sup style="font-size:9pt;font-weight:bold;vertical-align:top;">&#174;</sup><font style="font-size:12pt;">, for the treatment of travelers&#8217; diarrhea in adults</font><sup style="font-size:9pt;vertical-align:top;">9</sup><font style="font-size:12pt;">. RedHill&#8217;s key clinical late-stage development programs include: (i)&#160;</font><b style="font-size:12pt;font-weight:bold;">opaganib (ABC294640)</b><font style="font-size:12pt;">, a first</font><b style="font-size:12pt;font-weight:bold;">-</b><font style="font-size:12pt;">in</font><b style="font-size:12pt;font-weight:bold;">-</b></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;">class oral broad-acting, host-directed SPHK2 selective inhibitor with potential for pandemic preparedness, targeting multiple indications with a U.S. government collaboration for development for Acute Radiation Syndrome (ARS), a Phase 2/3 program for hospitalized COVID-19, and a Phase 2 program in oncology; (ii)&#160;</font><b style="font-size:12pt;font-weight:bold;">RHB-107&#160;</b><font style="font-size:12pt;">(</font><b style="font-size:12pt;font-weight:bold;">upamostat</b><font style="font-size:12pt;">), an oral broad-acting, host-directed, serine protease inhibitor with potential for pandemic preparedness is in late-stage development as a treatment for non-hospitalized symptomatic COVID-19, with non-dilutive external funding covering the entirety of the RHB-107 arm of the 300-patient Phase 2 adaptive platform trial, and is also targeting multiple other cancer and inflammatory gastrointestinal diseases; (iii)&#160;</font><b style="font-size:12pt;font-weight:bold;">RHB-102</b><font style="font-size:12pt;">, with potential UK submission for chemotherapy and radiotherapy induced nausea and vomiting, positive results from a Phase 3 study for acute gastroenteritis and gastritis and positive results from a Phase 2 study for IBS-D; (iv)&#160;</font><b style="font-size:12pt;font-weight:bold;">RHB-104</b><font style="font-size:12pt;">, with positive results from a first Phase 3 study for Crohn&#39;s disease; and (v)&#160;</font><b style="font-size:12pt;font-weight:bold;">RHB-204</b><font style="font-size:12pt;">,&#160;a Phase 3-stage program for pulmonary nontuberculous mycobacteria (NTM) disease.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 8pt 0pt;"><font style="font-size:12pt;">More information about the Company is available at www.redhillbio.com / X.com/RedHillBio.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><b style="font-size:12pt;font-weight:bold;">Forward Looking Statements</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-size:12pt;font-style:italic;">This press release contains &quot;forward-looking statements&quot; within the meaning of the Private Securities Litigation Reform Act of 1995 and may discuss investment opportunities, stock analysis, financial performance, investor relations, and market trends. Such statements may be preceded by the words &quot;intends,&quot; &quot;may,&quot; &quot;will,&quot; &quot;plans,&quot; &quot;expects,&quot; &quot;anticipates,&quot; &quot;projects,&quot; &quot;predicts,&quot; &quot;estimates,&quot; &quot;aims,&quot; &quot;believes,&quot; &quot;hopes,&quot; &quot;potential&quot; or similar words and include, among others, statements regarding the progress of the research and development activities for opaganib and RHB-107, including (i) timing of opaganib&#8217;s development for Acute Radiation Syndrome, (ii) the potential market opportunity for opaganib and RHB-107, (iii) delays in the research and development activities for opaganib or RHB-107, including the ACESO PROTECT platform trial for early COVID-19 outpatient treatment, (iv) the risk that opaganib or RHB-107 are not found to be well-suited to counter nuclear/chemical exposure and viral pandemic scenarios, and (v) non-dilutive development funding from RHB-107 and its inclusion in a key platform study. Forward-looking statements are based on certain assumptions and are subject to various known and unknown risks and uncertainties, many of which are beyond the Company&#8217;s control and cannot be predicted or quantified, and consequently, actual results may differ materially from those expressed or implied by such forward-looking statements. Such risks and uncertainties include, without limitation: market and other conditions; the Company&#39;s ability to regain compliance with the Nasdaq Capital Market&#39;s minimum bid price requirements; the risk that the addition of new revenue generating products or out-licensing transactions will not occur; the risk that acceptance onto the RNCP Product Development Pipeline will not guarantee ongoing development or that any such development will not be completed or successful; the risk that the FDA does not agree with the Company&#39;s proposed development plans for opaganib for any indication; the risk that observations from preclinical studies are not indicative or predictive of results in clinical trials; the risk that the FDA pre-study requirements will not be met and/or that the Phase 3 study of RHB-107 in COVID-19 outpatients will not be approved to commence or if approved, will not be completed or, should that be the case, that we will not be successful in obtaining alternative non-dilutive development funding for RHB-107; the risk that RHB-107&#39;s late-stage development for non-hospitalized COVID-19 will not benefit from the resources redirected from the terminated RHB-204 Phase 3 study, and that the Phase 2/3 COVID-19 study for RHB-107 may not be successful and, even if successful, such studies and results may not be sufficient for regulatory applications, including emergency use or marketing applications, and that additional COVID-19 studies for opaganib and RHB-107 are likely to be required; the risk that the Company will not successfully commercialize its products; as well as risks and uncertainties associated with (i) the initiation, timing, progress and results of the Company&#39;s research, manufacturing, pre-clinical studies, clinical trials, and other therapeutic candidate development efforts, and the timing of the commercial launch of its commercial products and ones it may acquire or develop in the future; (ii) the Company&#39;s ability to advance its therapeutic candidates into clinical trials or to successfully complete its pre-clinical studies or clinical trials or the development of a commercial companion diagnostic for the detection of MAP; (iii) the extent and number and type of additional studies that the Company may be required to conduct and the Company&#39;s receipt of regulatory approvals for its therapeutic candidates, </i></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><i style="font-size:12pt;font-style:italic;">and the timing of other regulatory filings, approvals and feedback; (iv) the manufacturing, clinical development, commercialization, and market acceptance of the Company&#39;s therapeutic candidates and Talicia; (v) the Company&#39;s ability to successfully commercialize and promote Talicia and Aemcolo; (vi) the Company&#39;s ability to establish and maintain corporate collaborations; (vii) the Company&#39;s ability to acquire products approved for marketing in the U.S. that achieve commercial success and build its own marketing and commercialization capabilities; (viii) the interpretation of the properties and characteristics of the Company&#39;s therapeutic candidates and the results obtained with its therapeutic candidates in research, pre-clinical studies or clinical trials; (ix) the implementation of the Company&#39;s business model, strategic plans for its business and therapeutic candidates; (x) the scope of protection the Company is able to establish and maintain for intellectual property rights covering its therapeutic candidates and its ability to operate its business without infringing the intellectual property rights of others; (xi) parties from whom the Company licenses its intellectual property defaulting in their obligations to the Company; (xii) estimates of the Company&#39;s expenses, future revenues, capital requirements and needs for additional financing; (xiii) the effect of patients suffering adverse experiences using investigative drugs under the Company&#39;s Expanded Access Program; (xiv) competition from other companies and technologies within the Company&#39;s industry; and (xv) the hiring and employment commencement date of executive managers. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company&#39;s filings with the Securities and Exchange Commission (SEC), including the Company&#39;s Annual Report on Form 20-F filed with the SEC on April 8, 2024. All forward-looking statements included in this press release are made only as of the date of this press release. The Company assumes no obligation to update any written or oral forward-looking statement, whether as a result of new information, future events or otherwise unless required by law.</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 5pt 0pt;"><b style="font-size:11pt;font-weight:bold;">Company contact:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;">Adi Frish</font><font style="font-size:11pt;"><br></font><font style="font-size:11pt;">Chief Corporate and Business Development Officer</font><font style="font-size:11pt;"><br></font><font style="font-size:11pt;">RedHill Biopharma</font><font style="font-size:11pt;"><br></font><font style="font-size:11pt;">+972-54-6543-112</font><font style="font-size:11pt;"><br></font><font style="font-size:11pt;">adi@redhillbio.com</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><font style="font-size:11pt;">Category: Financials</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:11.0pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><hr noshade="true" color="#000000" size="1" width="25.0%" style="background-color:#000000;color:#000000;height:1pt;position:relative;top:0.6em;border:none;margin:0pt;" align="left"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:8.25pt;vertical-align:top;">1</sup><font style="font-size:11pt;"> Including cash, cash equivalents, short-term bank deposits and restricted cash.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:8.25pt;vertical-align:top;">2 </sup><font style="font-size:11pt;">All financial highlights are approximate and are rounded to the nearest hundreds of thousands.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:8.25pt;vertical-align:top;">3 </sup><font style="font-size:11pt;">Opaganib is an investigational new drug, not available for commercial distribution.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:7.5pt;vertical-align:top;">4 </sup>RHB-107 (upamostat) is an investigational new drug, not available for commercial distribution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:8.25pt;vertical-align:top;">5 </sup><font style="font-size:11pt;">Maines LW, Keller SN, Smith RA, Green CL, Smith CD. The Sphingolipid-Modulating Drug Opaganib Protects against Radiation-Induced Lung Inflammation and Fibrosis: Potential Uses as a Medical Countermeasure and in Cancer Radiotherapy. International Journal of Molecular Sciences. 2024; 25(4):2322. https://doi.org/10.3390/ijms25042322</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:8.25pt;vertical-align:top;">6 </sup><font style="font-size:11pt;">Neuenschwander FC, Barnett-Griness O, Piconi S, Maor Y, Sprinz E, Assy N, Khmelnitskiy O, Lomakin NV, Goloshchekin BM, Nahorecka E, et al. Effect of Opaganib on Supplemental Oxygen and Mortality in Patients with Severe SARS-CoV-2 Based upon FIO2 Requirements. Microorganisms. 2024; 12(9):1767. https://doi.org/10.3390/microorganisms12091767</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:8.25pt;vertical-align:top;">7 </sup><font style="font-size:11pt;">RHB-104 is an investigational new drug, not available for commercial distribution.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><sup style="font-size:8.25pt;vertical-align:top;">8 </sup><font style="font-size:11pt;">Talicia (omeprazole magnesium, amoxicillin and rifabutin) is indicated for the treatment of </font><i style="font-size:11pt;font-style:italic;">H. pylori </i><font style="font-size:11pt;">infection in adults. For full prescribing information see: </font><font style="font-size:11pt;">www.Talicia.com</font><font style="font-size:11pt;">.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 8pt 0pt;"><sup style="font-size:8.25pt;vertical-align:top;">9 </sup><font style="font-size:11pt;">Aemcolo (rifamycin) is indicated for the treatment of travelers&#8217; diarrhea caused by noninvasive strains of </font><i style="font-size:11pt;font-style:italic;">Escherichia coli</i><font style="font-size:11pt;"> in adults. For full prescribing information see: www.Aemcolo.com</font><font style="color:#0000ff;font-size:11pt;">.</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">REDHILL BIOPHARMA LTD.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 6pt 0pt;">CONDENSED CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 6pt 0pt;">(Unaudited)</p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.71%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">U.S. dollars in thousands</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">NET REVENUES</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,572</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5,395</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">COST OF REVENUES</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,404</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,418</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">GROSS PROFIT</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,168</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,977</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">RESEARCH AND DEVELOPMENT EXPENSES</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">659</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,331</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">SELLING AND MARKETING EXPENSES</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,487</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">9,632</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">GENERAL AND ADMINISTRATIVE EXPENSES</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5,470</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">9,335</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">OTHER INCOME</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">42,993</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">OPERATING INCOME (LOSS)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(8,448)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">24,672</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">FINANCIAL INCOME</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7,157</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">28,677</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">FINANCIAL EXPENSES</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,797</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,347</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">FINANCIAL INCOME, </b>net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5,360</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">26,330</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">INCOME (LOSS) AND COMPREHENSIVE INCOME (LOSS) FOR THE PERIOD</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(3,088)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">51,002</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">EARNINGS (LOSS) PER ORDINARY SHARE, basic and diluted (U.S. dollars)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(0.00)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;background:#cceeff;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.04</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">WEIGHTED AVERAGE OF ORDINARY SHARE (in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">11,760,458</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.91%;border-bottom:3px double #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,277,931</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.46%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of these condensed consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">REDHILL BIOPHARMA LTD.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 6pt 0pt;">CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30,</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December 31,</b></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;white-space:normal;width:25.88%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">U.S. dollars in thousands</b></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">CURRENT ASSETS:</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7,277</p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5,569</p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">739</p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">790</p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Trade receivables</p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">974</p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,591</p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Prepaid expenses and other receivables</p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,909</p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,801</p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Inventory</p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,804</p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4,389</p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">15,703</p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">16,140</p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">NON-CURRENT ASSETS:</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">143</p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">147</p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Fixed assets</p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">147</p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">193</p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Right-of-use assets</p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">469</p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">989</p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Intangible assets</p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5,562</p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5,578</p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6,321</p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6,907</p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">TOTAL ASSETS</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">22,024</p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">23,047</p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;background:#cceeff;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">CURRENT LIABILITIES:</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Account payable</p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,912</p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,278</p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Lease liabilities</p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">368</p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">718</p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Allowance for deductions from revenue</p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">12,451</p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">10,654</p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Derivative financial instruments</p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,541</p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">*741</p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Accrued expenses and other current liabilities</p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3,961</p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4,592</p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">21,233</p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">19,983</p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">NON-CURRENT LIABILITIES:</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Lease liabilities</p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">190</p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">455</p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Royalty obligation</p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">540</p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">540</p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">730</p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">995</p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">TOTAL LIABILITIES</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">21,963</p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">20,978</p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">EQUITY:</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Ordinary shares</p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">34,785</p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">21,441</p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">375,333</p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">388,363</p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(410,057)</p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">(407,735)</p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">TOTAL EQUITY</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">61</p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">2,069</p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">TOTAL LIABILITIES AND EQUITY</b></p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">22,024</p></td><td style="vertical-align:bottom;white-space:normal;width:1.96%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:normal;width:11.96%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">23,047</p></td><td style="vertical-align:bottom;white-space:normal;width:0.18%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">*See note 2b</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of these condensed consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:always;width:88.24%;border-width:0;"><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 6pt 0pt;"><b style="font-weight:bold;">REDHILL BIOPHARMA LTD.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 6pt 0pt;">CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.69%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six Months Ended</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.69%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June 30,</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:25.69%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">U.S. dollars in thousands</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">OPERATING ACTIVITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Comprehensive income (loss)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(3,088)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">51,002</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Adjustments in respect of income and expenses not involving cash flow:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Share-based compensation to employees and service providers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">229</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">849</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">402</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,055</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Amortization of intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">16</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">530</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Gains from the transfer of rights in Movantik&#174; and extinguishment of debt obligations, (see below)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(56,082)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Gains from early termination of leases, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(23)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(694)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Fair value gains on derivative financial instruments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(7,108)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(8,071)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Loss from modification of warrants terms as part of a new issuance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,084</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Issuance costs in respect of warrants</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,497</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">922</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Exchange differences and revaluation of bank deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(13)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><font style="font-size:9pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(4,991)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(60,420)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Changes in assets and liability items:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Decrease in trade receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,617</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">31,618</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Decrease (increase) in prepaid expenses and other receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(108)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,337</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Decrease in inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">585</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,837</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Decrease in accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(1,366)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(1,118)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Decrease in accrued expenses and other liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(631)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(10,545)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 12pt;">Increase (decrease) in allowance for deductions from revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,797</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(31,486)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,894</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(8,357)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Net cash used in operating activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">(6,185)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">(17,775)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">INVESTING ACTIVITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Purchase of fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Net cash used in investing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">(1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">(7)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">FINANCING ACTIVITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Proceeds from issuance of ordinary shares and warrants, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">8,263</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5,097</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Repayment of payable in respect of intangible asset purchase</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">&#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(6,555)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Decrease in restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">51</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6,860</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Payment of principal with respect to lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(414)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(589)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Net cash provided by financing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">7,900</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><b style="font-weight:bold;">4,813</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1,714</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(12,969)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">EXCHANGE DIFFERENCES ON CASH AND CASH EQUIVALENTS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(6)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(3)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5,569</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">19,968</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">BALANCE OF CASH AND CASH EQUIVALENTS AT THE END OF PERIOD</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7,277</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">6,996</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;background:#cceeff;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">SUPPLEMENTARY INFORMATION ON INTEREST RECEIVED IN CASH</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">38</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;border-top:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">123</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">SUPPLEMENTARY INFORMATION ON INTEREST PAID IN CASH</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">28</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">315</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><b style="font-weight:bold;">SUPPLEMENTARY INFORMATION ON NON-CASH INVESTING AND FINANCING ACTIVITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Acquisition of right-of-use assets by means of lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">224</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Decrease in lease liability (with corresponding decrease in right of use asset in amount of $170 in the six months ended June 30, 2024, and $4,117 in the six months ended June 30,2023) resulting from early termination of lease.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">193</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;">4,811</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Transfer of rights in Movantik&#174; and extinguishment of debt obligations:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Decrease in Intangible asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(59,503)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Decrease in Inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">(4,233)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Decrease in Payable in respect of Intangible asset</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="font-size:9pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">4,602</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Decrease in Borrowing</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="font-size:9pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">115,216</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;background:#cceeff;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:71.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt 0pt 0pt 6pt;">Gains from the transfer of the rights in Movantik&#174; and extinguishment of debt obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><font style="font-size:9pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.89%;border-bottom:3px double #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">56,082</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.5%;border-bottom:3px double transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:9pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of these condensed consolidated financial statements.</b></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.2
<SEQUENCE>3
<FILENAME>rdhl-20240630xex99d2.htm
<DESCRIPTION>EX-99.2
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.7.0.1 -->
<!-- Based on: iXBRL 1.1 -->
<!-- Created on: 8/29/2024 10:57:17 AM -->
<!-- iXBRL Library version: 1.0.8923.15446 -->
<!-- iXBRL Service Job ID: 1bafbd29-c26b-40ee-9c97-f09142cd1a3a -->
<html xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2023" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:rdhl="http://www.redhillbio.com/20240630" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type"/><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Divide_USD_shares_CKQZNDkEe0eDAz2GdtdFSg" contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" decimals="2" name="ifrs-full:DilutedEarningsLossPerShare" id="Hidden_CBPMNzwfuUORcl_djyrohw">0.00</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_CKQZNDkEe0eDAz2GdtdFSg" contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw" decimals="2" name="ifrs-full:DilutedEarningsLossPerShare" id="Hidden_IpNvRjpMP0apmTzhzb5k4g">0.04</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_XGdimIWcf0OdGjo7fryoGw" contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" decimals="-3" name="ifrs-full:AdjustedWeightedAverageShares" id="Hidden_kZxc1tjo6ki8z7duotg_RQ">11760458000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_XGdimIWcf0OdGjo7fryoGw" contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw" decimals="-3" name="ifrs-full:AdjustedWeightedAverageShares" id="Hidden_Hy0KM8Qg3kS14kbM4Z6Obw">1277931000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_12_31_2023_XGghR9I2w0KmrTtJVNkj1A" decimals="-3" name="ifrs-full:CurrentDerivativeFinancialLiabilities" id="Hidden_E1bPtC31Lk21mAsoCYSzDA">741000</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_XGdimIWcf0OdGjo7fryoGw" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_rdhl_IfrsEmployeeStockOptionMember_ITJCorKc8UWnxsVgxsWbxA" decimals="0" name="ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" id="Hidden_nMtd2n9yDkm_DmI_AXUlBw">24000</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="rdhl-20240630.xsd"/></ix:references><ix:resources></ix:resources></ix:header></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 30pt 0pt;"><a style="font-size:10pt;" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit&#160;99.2</b></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_7da55165_d94a_4dee_a3e3_9afab01da08a"></a><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.79;text-align:center;margin:0pt;"><b style="font-weight:bold;">REDHILL BIOPHARMA LTD.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.79;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.79;text-align:center;margin:0pt;">(UNAUDITED)</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.79;text-align:center;margin:0pt;">June 30, 2024</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:1pt 0pt 0pt 0pt;">&#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:1pt 0pt 0pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;text-align:center;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">1</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.33%;padding-right:10.33%;position:relative;"><div style="margin-top:21.6pt;min-height:40.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 30pt 0pt;"><a style="font-size:10pt;" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_3af94fc4_4a8f_411b_8332_d3da44b4bd6e"></a><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.79;text-align:center;margin:0pt;"><b style="font-weight:bold;">REDHILL BIOPHARMA LTD.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.79;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED INTERIM FINANCIAL INFORMATION</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.79;text-align:center;margin:0pt;">(UNAUDITED)</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.79;text-align:center;margin:0pt;">June 30, 202<span style="direction:rtl;">4</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">TABLE OF CONTENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="direction:rtl;font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.0010299683%;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:89.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;text-decoration-line:underline;text-decoration-style:solid;text-transform:uppercase;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:89.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:17.9pt;text-indent:-17.9pt;margin:0pt;"><b style="font-weight:bold;">UNAUDITED CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS AS OF JUNE 30, 202</b><b style="direction:rtl;font-weight:bold;">4</b><b style="font-weight:bold;">, IN U.S. DOLLARS:</b><b style="font-weight:bold;"> </b></p></td><td style="vertical-align:top;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">Page</b><span style="text-transform:uppercase;"> </span></p></td></tr><tr><td style="vertical-align:top;width:89.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;padding-left:17.9pt;text-indent:-17.9pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;text-transform:uppercase;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:89.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 16.6pt;"><a href="#COMPREHENSIVELOSS_668224"><span style="font-style:normal;font-weight:normal;">Condensed consolidated interim statements of comprehensive </span><span style="font-style:normal;font-weight:normal;">income</span><span style="font-style:normal;font-weight:normal;"> (loss</span></a>) </p></td><td style="vertical-align:top;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 4.05pt 0pt 0pt;"><span style="font-size:8pt;">3</span></p></td></tr><tr><td style="vertical-align:top;width:89.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:89.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 0pt 16.6pt;"><a style="font-size:8pt;" href="#CONDENSEDINTERIMSTATEMENTSOFFINANCIALPOS"><span style="font-style:normal;font-weight:normal;">Condensed consolidated interim statements of financial position</span></a></p></td><td style="vertical-align:top;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 4.05pt 0pt 0pt;"><span style="direction:rtl;font-size:8pt;">4</span></p></td></tr><tr><td style="vertical-align:top;width:89.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:89.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 16.6pt;"><a href="#STATEMENTSOFCHANGESINEQUITY_365490"><span style="font-style:normal;font-weight:normal;">Condensed consolidated interim statements of changes in equity</span></a><span style="direction:rtl;"> </span></p></td><td style="vertical-align:top;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 4.05pt 0pt 0pt;"><span style="font-size:8pt;">5</span></p></td></tr><tr><td style="vertical-align:top;width:89.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:89.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 0pt 16.6pt;"><a style="font-size:8pt;" href="#STATEMENTSOFCASHFLOWS_271369"><span style="font-style:normal;font-weight:normal;">Condensed consolidated interim statements of cash flows</span></a></p></td><td style="vertical-align:top;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 4.05pt 0pt 0pt;"><span style="font-size:8pt;">6</span></p></td></tr><tr><td style="vertical-align:top;width:89.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:89.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 0pt 16.6pt;"><a style="font-size:8pt;" href="#notes"><span style="font-style:normal;font-weight:normal;">Notes to the </span><span style="font-style:normal;font-weight:normal;">condensed </span><span style="font-style:normal;font-weight:normal;">consolidated interim financial statements</span></a></p></td><td style="vertical-align:top;width:10.33%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 4.05pt 0pt 0pt;">7-1<span style="direction:rtl;">2</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="direction:rtl;font-size:8pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:17.85pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">2</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.35%;border:0;margin:30pt 10.33% 30pt 10.33%;"></div><div style="max-width:100%;padding-left:10.33%;padding-right:10.33%;position:relative;"><div style="margin-top:21.6pt;min-height:40.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 30pt 0pt;"><a style="font-size:10pt;" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_c743209b_0b3e_4e09_9b7d_94ed92569b09"></a><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.79;text-align:center;margin:0pt;"><b style="font-weight:bold;">REDHILL BIOPHARMA LTD.</b></p><a id="COMPREHENSIVELOSS_668224"></a><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.79;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.79;text-align:center;margin:0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><a id="_9223e343_a22d_4b08_b7e5_875472c04d95"></a><a id="Tc_N7veTgm1ake23JFWTtlyPw_1_3"></a><a id="Tc_Rg7lLnzwOUSwWNBj9SOBHA_2_3"></a><a id="Tc_m3pJMsZ5FkGZ8tbOBGL2IQ_3_3"></a><a id="Tc_tjC85ipaCEuudiqTA4HMHA_3_5"></a><a id="Tc_Tmw0vsvvyUqKlt3VmavCMA_4_3"></a><a id="Tc_1GNzeagYx06kroeW0cSGFA_5_0"></a><a id="Tc_LUYiVhmJu0mCQPAmPOm2tA_6_0"></a><a id="Tc_uL7w2KveIEe_CsyberRa_w_7_0"></a><a id="Tc_FFCzhTPQPEmq5Jx5w8QkoQ_8_0"></a><a id="Tc_lCRxJDQ0LkOpjgybZhV01w_9_0"></a><a id="Tc_2Cyn_NRT9kmG5WUJS9eFxA_10_0"></a><a id="Tc_OjOHGu5rZ0GRuR1EEcP1Tg_11_0"></a><a id="Tc_BertPFn8a0us8oitWMxreA_11_3"></a><a id="Tc_kBFwmbWBOkS_4s-_VT7vAQ_12_0"></a><a id="Tc_aXFMFt2Qw0a5XFlkquxIzQ_13_0"></a><a id="Tc_n6PYuH4MwEq2bmMZ0ccwwg_14_0"></a><a id="Tc_QOZV07zmMEKUkdz7EVXJ5A_15_0"></a><a id="Tc_sEG6e0Tq50GD20U82c4Z4w_16_0"></a><a id="Tc_jZEcdGVEYkqJ--0xP8RV7Q_17_0"></a><a id="Tc_5YC3c92GiEKFhRMyOMSdPA_18_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.24300385%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.99%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.25%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:72.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="6" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:72.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:24.25%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">U.S.&#160;dollars&#160;in&#160;thousands</b></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:72.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">NET REVENUES</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Revenue" scale="3" id="Tc_IHuYtkXDgEiTBPTUvVeOCA_5_3">2,572</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Revenue" scale="3" id="Tc_IyTPWMIuc0u6y55nGUJJXw_5_5">5,395</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:72.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">COST OF REVENUES</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CostOfSales" scale="3" id="Tc_9xd_r5bivkiNWi-bqqJUUQ_6_3">1,404</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CostOfSales" scale="3" id="Tc_97gpHXR4-UKy0Es5ao6xhQ_6_5">2,418</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:72.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">GROSS PROFIT </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:GrossProfit" scale="3" id="Tc_gGPDUfmH5UiBM6FXSTuULw_7_3">1,168</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:GrossProfit" scale="3" id="Tc_7CUneKiLk0-jlYt2rZdPVQ_7_5">2,977</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:72.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">RESEARCH AND DEVELOPMENT EXPENSES</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" id="Tc_dJlBJJfeyUikk973x2Gvxw_8_3">659</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ResearchAndDevelopmentExpense" scale="3" id="Tc_pyNYwcFNEUWIMgvWZEJ1Mg_8_5">2,331</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:72.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">SELLING AND MARKETING EXPENSES</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:SalesAndMarketingExpense" scale="3" id="Tc_kuT99nBNrku0o4EEXl_dEw_9_3">3,487</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:SalesAndMarketingExpense" scale="3" id="Tc_ap2TM926pEiJI7mZ4fhveQ_9_5">9,632</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:72.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">GENERAL AND ADMINISTRATIVE EXPENSES</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_82E-5Xc4Fki6gjSOnEsYPA_10_3">5,470</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:SellingGeneralAndAdministrativeExpense" scale="3" id="Tc_X36HKp1Xaka3UnSWGoGBCg_10_5">9,335</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:72.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">OTHER INCOME </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:OtherOperatingIncomeExpense" scale="3" id="Tc_eYL-bKB2w0-wRCm7eoUkBg_11_5">42,993</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:72.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">OPERATING INCOME (LOSS)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLossFromOperatingActivities" sign="-" scale="3" id="Tc_cfXgUWwiw0GBic3AZmFQRQ_12_3">8,448</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLossFromOperatingActivities" scale="3" id="Tc_IqwokPSlZUuu6a5AB41Cvw_12_5">24,672</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:72.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">FINANCIAL INCOME </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinanceIncome" scale="3" id="Tc_jLxtsxHsR0K2r2_P-Z_Y_g_13_3">7,157</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinanceIncome" scale="3" id="Tc_A03AdLYNjEmaSHe05zDzxw_13_5">28,677</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:72.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">FINANCIAL EXPENSES</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinanceCosts" scale="3" id="Tc_HURuSj0gWkKT53m2U1fCEQ_14_3">1,797</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinanceCosts" scale="3" id="Tc_FhUgL7QGCE6sq7I_KDkE6g_14_5">2,347</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:72.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">FINANCIAL INCOME, </b>net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinanceIncomeCost" scale="3" id="Tc_VP7fxodCeEKj0RZe5rEdGg_15_3">5,360</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinanceIncomeCost" scale="3" id="Tc_az7cnhcNkUu3erf1vda51w_15_5">26,330</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:72.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">INCOME (LOSS) AND COMPREHENSIVE INCOME (LOSS) FOR THE PERIOD</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" sign="-" scale="3" id="Tc_PbQL8KUp0kGZ-B2SAR6s8A_16_3">3,088</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" scale="3" id="Tc_gWPi29_u_ECuQeMWBOLPgA_16_5">51,002</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:72.99%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">EARNINGS (LOSS) PER ORDINARY SHARE, basic and diluted (U.S. dollars)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_CKQZNDkEe0eDAz2GdtdFSg" contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="Tc_MEEAkvXTeEWs7RKK5Xrizw_17_3">0.00</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_CKQZNDkEe0eDAz2GdtdFSg" contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw" decimals="2" format="ixt:numdotdecimal" name="ifrs-full:BasicEarningsLossPerShare" scale="0" id="Tc_Qd37aRWMs0ywW9g3QzgJvw_17_5">0.04</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:72.99%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">WEIGHTED AVERAGE OF ORDINARY SHARE (in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.85%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XGdimIWcf0OdGjo7fryoGw" contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageShares" scale="3" id="Tc_Fzz9dGzCxkucKZe72K0iog_18_3">11,760,458</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_XGdimIWcf0OdGjo7fryoGw" contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageShares" scale="3" id="Tc_8ERgVYraMUas4crENwAqUA_18_5">1,277,931</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"> <span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of these condensed consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="direction:rtl;font-size:8pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:17.85pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.35%;border:0;margin:30pt 10.33% 30pt 10.33%;"></div><div style="max-width:100%;padding-left:10.33%;padding-right:10.33%;position:relative;"><div style="margin-top:21.6pt;min-height:40.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 30pt 0pt;"><a style="font-size:10pt;" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_26d56f8b_de9e_4d25_ba21_f418af7e5d87"></a><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.79;text-align:center;margin:0pt;"><b style="font-weight:bold;">REDHILL BIOPHARMA LTD.</b></p><a id="FinancialPosition"></a><a id="CONDENSEDINTERIMSTATEMENTSOFFINANCIALPOS"></a><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.79;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.79;text-align:center;margin:0pt;">(Unaudited)</p><a id="_c237bdc8_0746_45fa_8104_6dc0f6cac88b"></a><a id="Tc_vRBWcWRolkCLWyBeRHjcBA_2_2"></a><a id="Tc_trQi18ux1U2hJgKvCukKsQ_2_4"></a><a id="Tc_NhSgc6oXv0avTx3WIa2SmA_3_2"></a><a id="Tc_mwFBEQ4dNU-epARU80CzMg_3_4"></a><a id="Tc_beKXxoEPZEe92GVhGl7PUQ_4_2"></a><a id="Tc_Nxhd_qHk00yFyCdzbbN2EA_5_0"></a><a id="Tc_FLEppVGukkeeIbSN69RJBg_6_0"></a><a id="Tc_W_eDXuNCrkmgU-LBiDW9rw_7_0"></a><a id="Tc_TR2rChi3Jke8QyJRUm1gEw_8_0"></a><a id="Tc_FjyHMEtdlkiZRnzHUT9W7Q_9_0"></a><a id="Tc_CZdT090tj0yN2RsuV7W4zQ_10_0"></a><a id="Tc_1xfTI2qlWU6DBZSjK0tvpw_12_0"></a><a id="Tc_MNM-M3LEb0a8FpljxEvp7w_13_0"></a><a id="Tc_l_yYLD2lwEiey3PdxpWu8w_14_0"></a><a id="Tc_vgfHHXCj70y-4bLx8D2xuQ_15_0"></a><a id="Tc_vTYRY35Mc022UUhv0gS3Mw_16_0"></a><a id="Tc_hztIqmb6lUa7NmQPW-mlMA_18_0"></a><a id="Tc_-nicZqSzC0GFsH2TkES43A_21_0"></a><a id="Tc_ktyuzfdPL0qD-Lq3xkdJ8A_22_0"></a><a id="Tc_FhyMmsVyAkK8PL-M3ARZvg_23_0"></a><a id="Tc_GT6johcQxkGd8d60qXqSjQ_24_0"></a><a id="Tc_vmXBtKr0EESdPhunULt0Bw_25_0"></a><a id="Tc_HTsf5wYeFUWEZ_MkU9qudg_26_0"></a><a id="Tc_PbyMFqauS0yd29IcJ8nnPA_29_0"></a><a id="Tc_bX_Gmo-EHECABlC4G0isog_30_0"></a><a id="Tc_ok8_YMrHtkCqCOcVMesDlw_31_0"></a><a id="Tc_p2AO40ExTUKOKYGCUgatsA_33_0"></a><a id="Tc_RAxp0fs6aU-DNKZV35lmmQ_35_0"></a><a id="Tc_-R0Bp90B_kOLKVzRLMJO9Q_36_0"></a><a id="Tc_XqlYJAorkU-7cZAnBIoS_g_37_0"></a><a id="Tc_1AIHSgxa-0mWe_p-IqOtYg_38_0"></a><a id="Tc_X2dTlPK5KE22bhOHNtOGhQ_39_0"></a><a id="Tc_LZy2nfgRiUORS7ioWYhldw_40_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.0010299683%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:62.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:18.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:15.41%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:62.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.39%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.41%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.06%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.39%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.41%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:62.06%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;width:18.39%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;width:2.05%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.41%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="5" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:62.06%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:35.87%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;U.S.&#160;dollars&#160;in&#160;thousands</b></p></td></tr><tr><td style="vertical-align:top;width:62.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">CURRENT ASSETS:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_6_30_2024_lm1Lh8C52kquuyx0qsrPDw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="3" id="Tc_59TH-dCVm0CFBONBtHiTcg_6_2">7,277</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_12_31_2023_XGghR9I2w0KmrTtJVNkj1A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="3" id="Tc_wqWWHAwzlUKw2wMEP6bF7A_6_4">5,569</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:62.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_6_30_2024_lm1Lh8C52kquuyx0qsrPDw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentRestrictedCashAndCashEquivalents" scale="3" id="Tc_rFEso0AEP0yw4MRXcc89YA_7_2">739</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_12_31_2023_XGghR9I2w0KmrTtJVNkj1A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentRestrictedCashAndCashEquivalents" scale="3" id="Tc_6p1QWWdkbUq_tIDvY5C-vw_7_4">790</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:62.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Trade receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_6_30_2024_lm1Lh8C52kquuyx0qsrPDw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:TradeAndOtherCurrentReceivables" scale="3" id="Tc_GJEYznSuQEybrkQzMva2rg_8_2">974</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_12_31_2023_XGghR9I2w0KmrTtJVNkj1A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:TradeAndOtherCurrentReceivables" scale="3" id="Tc_R5WwssLSDUKBHyHAdoWjAA_8_4">2,591</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:62.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Prepaid expenses and other receivables </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_6_30_2024_lm1Lh8C52kquuyx0qsrPDw" decimals="-3" format="ixt:numdotdecimal" name="rdhl:CurrentPrepaidExpensesAndReceivables" scale="3" id="Tc_peKmoFEf5EGIKBFrT13u-w_9_2">2,909</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_12_31_2023_XGghR9I2w0KmrTtJVNkj1A" decimals="-3" format="ixt:numdotdecimal" name="rdhl:CurrentPrepaidExpensesAndReceivables" scale="3" id="Tc_4bUSnCF77Ei_ytU6g11hFQ_9_4">2,801</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:62.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Inventory</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_6_30_2024_lm1Lh8C52kquuyx0qsrPDw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Inventories" scale="3" id="Tc_gpmozm_FQUKCb1LTDe2_og_10_2">3,804</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_12_31_2023_XGghR9I2w0KmrTtJVNkj1A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Inventories" scale="3" id="Tc_DP3FOd1WYkSbbJ1QB2ZJcA_10_4">4,389</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:62.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_6_30_2024_lm1Lh8C52kquuyx0qsrPDw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentAssets" scale="3" id="Tc_396beK-5sk2S-z1xthFvYQ_11_2">15,703</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_12_31_2023_XGghR9I2w0KmrTtJVNkj1A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentAssets" scale="3" id="Tc_AxYdcVTSkkW4IFqbFjdcCA_11_4">16,140</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:62.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">NON-CURRENT ASSETS:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Restricted cash</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_6_30_2024_lm1Lh8C52kquuyx0qsrPDw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentRestrictedCashAndCashEquivalents" scale="3" id="Tc_Ez2DC1AaTEW_xHG8Iglhgg_13_2">143</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_12_31_2023_XGghR9I2w0KmrTtJVNkj1A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentRestrictedCashAndCashEquivalents" scale="3" id="Tc_mIdJA2NRX0WSOjmIFIj27A_13_4">147</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:62.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_6_30_2024_lm1Lh8C52kquuyx0qsrPDw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="Tc_blqvq4zZq06T5hIJLKkESA_14_2">147</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_12_31_2023_XGghR9I2w0KmrTtJVNkj1A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PropertyPlantAndEquipment" scale="3" id="Tc_39MTpr3lL0KIjCnokq2QPQ_14_4">193</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:62.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Right-of-use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_6_30_2024_lm1Lh8C52kquuyx0qsrPDw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RightofuseAssets" scale="3" id="Tc_6O4WU0p4CkqLWGqn9eznKw_15_2">469</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_12_31_2023_XGghR9I2w0KmrTtJVNkj1A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RightofuseAssets" scale="3" id="Tc_xH52XkFFvEap8Od9YRKexQ_15_4">989</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:62.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_6_30_2024_lm1Lh8C52kquuyx0qsrPDw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_AVH4QjFT9EK_JuO87tlLHg_16_2">5,562</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_12_31_2023_XGghR9I2w0KmrTtJVNkj1A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_bHCbK5uLAkibbP4JNQEomw_16_4">5,578</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:62.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_6_30_2024_lm1Lh8C52kquuyx0qsrPDw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentAssets" scale="3" id="Tc_OmU3tWRXF0WSDnOzBTE68g_17_2">6,321</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_12_31_2023_XGghR9I2w0KmrTtJVNkj1A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentAssets" scale="3" id="Tc_hRguDc2fb0ai3z4Nsmt-GA_17_4">6,907</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:62.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">TOTAL ASSETS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_6_30_2024_lm1Lh8C52kquuyx0qsrPDw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Assets" scale="3" id="Tc_cz0z2ErcPkeKien7sD6AZw_18_2">22,024</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_12_31_2023_XGghR9I2w0KmrTtJVNkj1A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Assets" scale="3" id="Tc_KJOhZPaNJUOritMMTQG6oQ_18_4">23,047</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:62.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">CURRENT LIABILITIES:  </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Account payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_6_30_2024_lm1Lh8C52kquuyx0qsrPDw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="3" id="Tc_CJchPB-pU0S_8iZ6MHXbCw_22_2">1,912</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_12_31_2023_XGghR9I2w0KmrTtJVNkj1A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:TradeAndOtherCurrentPayables" scale="3" id="Tc_iAHGNprs0Eigi8QVL-II_g_22_4">3,278</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:62.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_6_30_2024_lm1Lh8C52kquuyx0qsrPDw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentLeaseLiabilities" scale="3" id="Tc_EisQOu-nPkm6BrG4Hym9fA_23_2">368</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_12_31_2023_XGghR9I2w0KmrTtJVNkj1A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentLeaseLiabilities" scale="3" id="Tc_-QfYoNCR5EWKdDwlaiugaw_23_4">718</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:62.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Allowance for deductions from revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:18.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_6_30_2024_lm1Lh8C52kquuyx0qsrPDw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentRefundsProvision" scale="3" id="Tc_Qq2GQUHfPEeHEJmpS2S5mw_24_2">12,451</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_12_31_2023_XGghR9I2w0KmrTtJVNkj1A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentRefundsProvision" scale="3" id="Tc_CY2qftGRB06dnpXdWpv1AQ_24_4">10,654</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:62.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Derivative financial instruments </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:18.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_6_30_2024_lm1Lh8C52kquuyx0qsrPDw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentDerivativeFinancialLiabilities" scale="3" id="Tc_RVyn0awL_Uuhrp36L8MBKQ_25_2">2,541</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_E1bPtC31Lk21mAsoCYSzDA;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">*741</span></span></p></td></tr><tr><td style="vertical-align:top;width:62.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accrued expenses and other current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:18.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_6_30_2024_lm1Lh8C52kquuyx0qsrPDw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities" scale="3" id="Tc_-mIeUGrTZUSTaCNEEZtdRg_26_2">3,961</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_12_31_2023_XGghR9I2w0KmrTtJVNkj1A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities" scale="3" id="Tc_SHVcar7RDEO41014PWzxcw_26_4">4,592</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:62.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.39%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_6_30_2024_lm1Lh8C52kquuyx0qsrPDw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentLiabilities" scale="3" id="Tc_bvjPWSuzTEimuacHokoiXw_27_2">21,233</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.41%;background:#cceeff;border-bottom:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_12_31_2023_XGghR9I2w0KmrTtJVNkj1A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentLiabilities" scale="3" id="Tc_oE4xtPd08keVTXjdCmefew_27_4">19,983</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:62.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">NON-CURRENT LIABILITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:18.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:18.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_6_30_2024_lm1Lh8C52kquuyx0qsrPDw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentLeaseLiabilities" scale="3" id="Tc_8xk7F0SinUuEDS2kXXR4Xw_30_2">190</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_12_31_2023_XGghR9I2w0KmrTtJVNkj1A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentLeaseLiabilities" scale="3" id="Tc_LsOL-BJCWU2PJcDTqP0mNQ_30_4">455</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:62.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Royalty obligation </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_6_30_2024_lm1Lh8C52kquuyx0qsrPDw" decimals="-3" format="ixt:numdotdecimal" name="rdhl:NoncurrentRoyaltyObligation" scale="3" id="Tc_9olrIa7HbEeLJtBBOHLcNg_31_2">540</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_12_31_2023_XGghR9I2w0KmrTtJVNkj1A" decimals="-3" format="ixt:numdotdecimal" name="rdhl:NoncurrentRoyaltyObligation" scale="3" id="Tc_H8sa_AMm6kK6ufSz9A-vTg_31_4">540</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:62.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_6_30_2024_lm1Lh8C52kquuyx0qsrPDw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentLiabilities" scale="3" id="Tc_Kp8N1qQJ0Eq24lP2z0YoRg_32_2">730</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_12_31_2023_XGghR9I2w0KmrTtJVNkj1A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:NoncurrentLiabilities" scale="3" id="Tc_yJ5QiaFPS0yoH4xlTDHdyg_32_4">995</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:62.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">TOTAL LIABILITIES</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_6_30_2024_lm1Lh8C52kquuyx0qsrPDw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Liabilities" scale="3" id="Tc_aOIfcx4iTkOX9Ex6kc50Pw_33_2">21,963</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_12_31_2023_XGghR9I2w0KmrTtJVNkj1A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Liabilities" scale="3" id="Tc_ovssZoXDVECV_gCsujKBAw_33_4">20,978</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:62.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:62.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">EQUITY:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:62.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Ordinary shares</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_6_30_2024_lm1Lh8C52kquuyx0qsrPDw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IssuedCapital" scale="3" id="Tc_4FpDUTZDCUi2nj1j_H9azg_36_2">34,785</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.41%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_12_31_2023_XGghR9I2w0KmrTtJVNkj1A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IssuedCapital" scale="3" id="Tc_jvEtrgtb5k254tmktaJCJg_36_4">21,441</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:62.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_6_30_2024_lm1Lh8C52kquuyx0qsrPDw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:SharePremium" scale="3" id="Tc_LRHQsHdAlUqL4Yl15PjA3g_37_2">375,333</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.41%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_12_31_2023_XGghR9I2w0KmrTtJVNkj1A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:SharePremium" scale="3" id="Tc_P-zfEkgnhEuFlcPpxxHbQQ_37_4">388,363</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:62.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accumulated deficit </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_6_30_2024_lm1Lh8C52kquuyx0qsrPDw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RetainedEarnings" sign="-" scale="3" id="Tc_lb3TqREIdEGlxu0yEyS-rQ_38_2">410,057</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.41%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">(<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_12_31_2023_XGghR9I2w0KmrTtJVNkj1A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:RetainedEarnings" sign="-" scale="3" id="Tc_ry-ZwPdYz0i_azEIPwv7lg_38_4">407,735</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:62.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">TOTAL EQUITY </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.39%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_6_30_2024_lm1Lh8C52kquuyx0qsrPDw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_691opR9nu0KZziByI-ToUg_39_2">61</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.41%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_12_31_2023_XGghR9I2w0KmrTtJVNkj1A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_cNqY8diLmUKzxfWq7jjxVA_39_4">2,069</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:62.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">TOTAL LIABILITIES AND EQUITY</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.39%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_6_30_2024_lm1Lh8C52kquuyx0qsrPDw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:EquityAndLiabilities" scale="3" id="Tc_aC9jSRzFdEGf_EgJb1GRAA_40_2">22,024</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.05%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:15.41%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 3.5pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_12_31_2023_XGghR9I2w0KmrTtJVNkj1A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:EquityAndLiabilities" scale="3" id="Tc_K0Nn7opQHEKIFVnLH-XmDA_40_4">23,047</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">*See note 2b</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt -18.4pt 0pt 0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of these condensed consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:17.85pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.35%;border:0;margin:30pt 10.33% 30pt 10.33%;"></div><div style="max-width:100%;padding-left:10.33%;padding-right:10.33%;position:relative;"><div style="margin-top:21.6pt;min-height:40.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 30pt 0pt;"><a style="font-size:10pt;" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.79;text-align:center;margin:0pt;"><b style="font-weight:bold;">REDHILL BIOPHARMA LTD.</b></p><a id="STATEMENTSOFCHANGESINEQUITY_365490"></a><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.79;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN EQUITY<span style="direction:rtl;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.79;text-align:center;margin:0pt;">(Unaudited)</p><a id="Equity"></a><a id="_8472b78f_8852_4f62_88a7_421cd10b63ce"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><a id="_18a29c77_6553_463f_8458_1893fbe4787e"></a><a id="Tc_bqoL3TVfOkyx_hek-60Pdg_2_2"></a><a id="Tc_z_YrSmx28kyCNSc573pLyg_2_4"></a><a id="Tc_UVBi0fc6dUOmhjMdVJRX3Q_2_6"></a><a id="Tc_aO21jDO12Ey19V9sje-_aA_2_8"></a><a id="Tc_r719WPBZvkCfxTGhKX09Mw_3_2"></a><a id="Tc_1dUlwSAnw0CTJDJ4UbpD1g_5_0"></a><a id="Tc_ec_Uq8DZv022GGpo-KtmvQ_7_0"></a><a id="Tc_shgbp3SGXky7sHVh0Z2aWg_8_0"></a><a id="Tc_-8R3veJB2EuqpO9E5o3u7w_8_2"></a><a id="Tc_ZzRtSO7Fyk22DKyySjkN0Q_8_4"></a><a id="Tc_wbyVjvPMWEGNJo0BKsAt7A_9_0"></a><a id="Tc_Hn_T4R8EaUi_JErvJyFI0A_9_6"></a><a id="Tc_YOIMP8eFoUGQwWT5tAQnIA_10_0"></a><a id="Tc_7hQS7jmKA0-P7j_-iIHtmg_10_6"></a><a id="Tc_cez3Ini2uUOfLvbp5x1PQw_10_8"></a><a id="Tc_tknYZVFli0aZjxuPeY-I6A_11_0"></a><a id="Tc_miuvaAYf5UyZbo-mdpv9jg_11_2"></a><a id="Tc_Jlw4ssk7p0aFj8yF-gcgjg_11_4"></a><a id="Tc_xAYeim823E6LPAeSEAUt9w_12_0"></a><a id="Tc_l2jEBpULtkOhH7ih3E5a5g_14_0"></a><a id="Tc_vXaXuAWeJUiWvQySPUswYA_15_0"></a><a id="Tc_6bPd7TNQEkexs9h8A_UDDQ_16_0"></a><a id="Tc_fHv0x1fK7UOsHCuliTg0gQ_16_2"></a><a id="Tc_AfOjqhm6m0S1OAAf67awsQ_16_4"></a><a id="Tc_m0krmv2kxkuMqGOqd0WDvQ_17_0"></a><a id="Tc_akg-nSSv80meUwwKEeWkWQ_17_6"></a><a id="Tc_ovka2L7X2kmT_U-BMw8New_18_0"></a><a id="Tc_QH_WNX2EdkyYCpsuZsVIDQ_18_6"></a><a id="Tc_6rjWkaOZokSeuVZaQXrJkQ_18_8"></a><a id="Tc_Zubbw1f3D0yShV6ZUr52bw_19_0"></a><a id="Tc_iwFqMozEWUOBAKujmw7wrQ_19_2"></a><a id="Tc_NQIXO4fh3ES-9Nkqq0bHDA_19_4"></a><a id="Tc_3eVVX-J0oUubGnyr6CGRgg_20_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.0010299683%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51.23%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Ordinary shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional paid-in&#160;capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:9.88%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:9.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total equity </b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="9" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:51.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="7" style="vertical-align:bottom;white-space:nowrap;width:46.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">U.S.&#160;dollars&#160;in&#160;thousands</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:51.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:51.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">BALANCE AT JANUARY 1, 2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_WIaiT8u6y0CHEd67KoeeuQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_RR-JeU2MgEa1dt-6kbX_Rg_5_2">21,441</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_LOEJOyxWXU26M6zuQvwiJw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_qkhsS9bN6E6GmXBZcgU7Wg_5_4">388,363</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_ZNNvPFR40UGCID0ZfJxAmQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="3" id="Tc_M6_kXZ8fcEmCvUREo3QM3w_5_6">407,735</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_12_31_2023_XGghR9I2w0KmrTtJVNkj1A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_KpCyryYzqE2XizdcmtneJA_5_8">2,069</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:51.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:51.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">CHANGES IN THE SIX-MONTHS PERIOD ENDED JUNE&#160;30,&#160;2024:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:51.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share-based compensation to employees and service providers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_f7VpnqzdG0eBMbQ0_PH15g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="3" id="Tc_KqrmsEsfU0WvrfqCNa9Glw_8_6">766</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="3" id="Tc_Rbrh8EGGjEGKYrB_-A7R2g_8_8">766</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:51.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Issuance of ordinary shares, net of expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_WUJJNdtgkUmTbxC0es9vGA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IssueOfEquity" scale="3" id="Tc_6iRtFwwE50y1GIMmihErtA_9_2">13,135</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_hQziAgWDuESfatZXZuDWKg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IssueOfEquity" sign="-" scale="3" id="Tc_oVbc44vzCUCyZPbMhhyDvQ_9_4">12,821</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IssueOfEquity" scale="3" id="Tc_K7pjw45dv0mJ7kBYXYMj-w_9_8">314</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:51.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Issuance of ordinary shares for vested RSUs </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_WUJJNdtgkUmTbxC0es9vGA" decimals="-3" format="ixt:numdotdecimal" name="rdhl:StockIssuedDuringPeriodValueRestrictedStockAward" scale="3" id="Tc_ebCiXzfHlkK2K-cxD4pHog_10_2">209</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_hQziAgWDuESfatZXZuDWKg" decimals="-3" format="ixt:numdotdecimal" name="rdhl:StockIssuedDuringPeriodValueRestrictedStockAward" sign="-" scale="3" id="Tc_AwduUyepdkaMc08ZKToBOA_10_4">209</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:51.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_f7VpnqzdG0eBMbQ0_PH15g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" sign="-" scale="3" id="Tc_ZLO3Fo2LN0OJF7n-IRNYUQ_11_6">3,088</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" sign="-" scale="3" id="Tc_lgJEm-n0Ak-WdLHI-nubgg_11_8">3,088</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:51.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">BALANCE AT JUNE&#160;30,&#160;2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_pt7V-puUQUK2FnS6Bj5qwA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_gzce8UUkNEaGlPacorlckQ_12_2">34,785</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_iXJ3_uR3qkyjYahn5cu1hg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_e3M83fcXaEOs9r-OOaqD3w_12_4">375,333</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_ULnTaRXf1k2sfiQlt2ZrxQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="3" id="Tc_gpKMIrbafku5w1Fh_TLqfg_12_6">410,057</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_6_30_2024_lm1Lh8C52kquuyx0qsrPDw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_7OBztrKvrEWl3IH0LCa7eA_12_8">61</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:51.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:51.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">BALANCE AT JANUARY 1, 2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_Y7iGsPaVjkeiB7bpTvHRwg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_ahUMq4g3dkKxPD1axp87Jg_14_2">2,835</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_t4QHHZ5Wp0OEOQnVhfCjxQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_rlN1rug_5kyhYHHC8LROHQ_14_4">382,625</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_ZgoHvobcPU2rpUbaBgakWg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="3" id="Tc_LdD1cGyeLUSleiUtJEj1sw_14_6">433,860</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_12_31_2022_jV2f_7krOUScpr2kI0mJcw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="3" id="Tc_GzjTaCoGb0m6MEW6UFzgDQ_14_8">48,400</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:51.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">CHANGES IN THE SIX-MONTHS PERIOD ENDED JUNE&#160;30,&#160;2023:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:51.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Share-based compensation to employees and service providers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_FdLWqdRnzEeYm1z5Q53cfg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="3" id="Tc_aiilqI4eEkm2tlpEz5Vbhg_16_6">849</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions" scale="3" id="Tc_S-AdjDmLZk-G5z3NIRCF0A_16_8">849</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:51.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Issuance of ordinary shares, net of expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_ME6JQrLs4kCObaTBOn_26Q" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IssueOfEquity" scale="3" id="Tc_94DxTy_C2kSfEhWQCb52Cw_17_2">1,761</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_WC_VpnnmJEurMcXdPGqAAA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IssueOfEquity" sign="-" scale="3" id="Tc_zs3bJVhTlECU1wDDIRu9QQ_17_4">1,741</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IssueOfEquity" scale="3" id="Tc_KsU1bCKU1UegFAoOkFyYrg_17_8">20</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:51.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Issuance of ordinary shares for vested RSUs </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_ME6JQrLs4kCObaTBOn_26Q" decimals="-3" format="ixt:numdotdecimal" name="rdhl:StockIssuedDuringPeriodValueRestrictedStockAward" scale="3" id="Tc_j29MvVGShECT35RpWjIJAA_18_2">24</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_WC_VpnnmJEurMcXdPGqAAA" decimals="-3" format="ixt:numdotdecimal" name="rdhl:StockIssuedDuringPeriodValueRestrictedStockAward" sign="-" scale="3" id="Tc_LEJrivB64EKClqNfJDDIDA_18_4">24</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:51.23%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Comprehensive income </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_FdLWqdRnzEeYm1z5Q53cfg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" scale="3" id="Tc_4gLwXJyBi0exeLF-w82Naw_19_6">51,002</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" scale="3" id="Tc_bgTPa6H_FECXVVkOaOq6mw_19_8">51,002</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:51.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">BALANCE AT JUNE&#160;30,&#160;2023</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_MYPHkdkUC02VHj9u1f1FRA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_lhLrBVCd5U6XnjRb0G1msQ_20_2">4,620</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_cnP-pEbtykmp58TplJXbRw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_lL2u4slWckCiR7vieY5rTA_20_4">380,860</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.88%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_QWxXKkKqr0CvPrcIr11d4g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" sign="-" scale="3" id="Tc_m2lKEGdk_EuEKco-JwwBwQ_20_6">382,009</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.84%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_6_30_2023_XZFu_w7MpEqlzzSlD3xkQg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Equity" scale="3" id="Tc_NjwidpXu4Uq8uRcTT_pWYw_20_8">3,471</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.79;text-align:center;margin:0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of these condensed consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><a id="Equity_End"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:0pt;text-align:center;margin:0pt;"><span style="font-size:0pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:17.85pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.35%;border:0;margin:30pt 10.33% 30pt 10.33%;"></div><div style="max-width:100%;padding-left:10.33%;padding-right:10.33%;position:relative;"><div style="margin-top:21.6pt;min-height:40.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt 0pt 30pt 0pt;"><a style="font-size:10pt;" href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Cash_Flows"></a><a id="_a7941b2e_5144_4ec4_9e2d_06e22427ed45"></a><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.79;text-align:center;margin:0pt;"><b style="font-weight:bold;">REDHILL BIOPHARMA LTD.</b></p><a id="STATEMENTSOFCASHFLOWS_271369"></a><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.79;text-align:center;margin:0pt;">CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.79;text-align:center;margin:0pt;">(Unaudited)</p><a id="_c05f3e6a_19ea_4894_a1d2_16e612780b57"></a><a id="Tc_98bjz64lJ0SDg4HKdVob2g_1_3"></a><a id="Tc_Krl6Ur1T7EyVLI6axnWhRA_2_3"></a><a id="Tc_eYw6da0AZkSAPLP2jIa7XA_3_3"></a><a id="Tc_-9MnZyyxGU2ruXnWqisyJA_3_5"></a><a id="Tc_zAhqBukYz06rd2lNPgNIsw_4_3"></a><a id="Tc_xM0dP5uR4kWM-No_qyZQhg_5_0"></a><a id="Tc_Svbu2LVmzEq2whXBIgp9Tg_6_0"></a><a id="Tc_W56_ey-z10yx9bGDJ71ZrA_7_0"></a><a id="Tc_j5LCGtd7kk--w7VhmAHjeA_8_0"></a><a id="Tc_qHNbwmFN-EeyRUBX_NB4hg_9_0"></a><a id="Tc_G0pcYGI6WECETjTbxSVtWA_10_0"></a><a id="Tc_QFH8zCHldESe_Dw8hmo8ZA_11_0"></a><a id="Tc_UZgmahklm0qikODf__604A_11_3"></a><a id="Tc_cQwvhCNgIESJ7XPp5L9pkg_12_0"></a><a id="Tc_YyDhmQj7i0mTTObWbT9IFg_13_0"></a><a id="Tc_2hLS_ZiabEaCaoP93fMygw_14_0"></a><a id="Tc__wIeyXpFYUawKvOLSxpx8A_14_3"></a><a id="Tc_HKhbXJFEMkWFrC1gMS1XHw_15_0"></a><a id="Tc_FteIgdBnvkyDWt0Z6aFKkg_16_0"></a><a id="Tc_IJFPwfrPrUiwJhj-i8OMHw_18_0"></a><a id="Tc_Bq81RoMhf02CW3djVKwQ3A_19_0"></a><a id="Tc_8hRhO0liHECz1n6e593p1g_20_0"></a><a id="Tc_K0EBQr5BtkOSkBVAgYfz6A_21_0"></a><a id="Tc_T6tBNIOOWkCG3rTO8USYwA_22_0"></a><a id="Tc_PX6jV9qhvkmLFoGRu3MHww_23_0"></a><a id="Tc_gucdzqw2f0--Ehi3lIyEMA_24_0"></a><a id="Tc_F1KG7H4kdUuIJEQ5zomoLw_26_0"></a><a id="Tc_DRLHmyJHVECCAzUxRXU3cQ_27_0"></a><a id="Tc_Y6GbPQuAgEqHPdHYAbL0sg_28_0"></a><a id="Tc_poCSZd2IcEKal_vmPda9Lw_29_0"></a><a id="Tc_jFHiu1k3t0K1e0fu01O0uQ_30_0"></a><a id="Tc_ZQybsTvtQ0S8xWMaNy2ixQ_31_0"></a><a id="Tc_nH_C1XQ6c0WN87xJFKgK2g_32_0"></a><a id="Tc__VGP14y9zk2EzybXbPVF9g_32_3"></a><a id="Tc_3xqR3e-u1EeAHOlUzjMUdw_33_0"></a><a id="Tc_vT9bH_4B8UKeY5V745BEfA_34_0"></a><a id="Tc_zKbmccexfkKzv4YhT3TrMg_35_0"></a><a id="Tc_0n7rLfIVF0axcKI4I2rxww_36_0"></a><a id="Tc_EsVYUThVU0SHeTBe14gVIg_37_0"></a><a id="Tc_Z_aeqr2ruUuO4ESa4FTBCA_38_0"></a><a id="Tc_I_ozuD1U5kGknQQPDYYrgw_39_0"></a><a id="Tc_2eLbMQ1Wp02KPG4z6wYKew_40_0"></a><a id="Tc_REysO5sRTUikwdht9hEDUA_41_0"></a><a id="Tc_dApRakJgbEWea6Yf62zxcQ_42_0"></a><a id="Tc_X8OhjEsxEkmkhSmU5oS09A_43_0"></a><a id="Tc_xLMwIGy7aE6E5pq1DXj5Kg_44_0"></a><a id="Tc_jAOnZ2CG702XFxve4A2puw_45_0"></a><a id="Tc_il-FxpIfZUueuIjl-eFhfA_46_0"></a><a id="Tc_C1fcx5Q4zEaGgA7ZKOraZg_47_0"></a><a id="Tc_YU07kz28k0qF8_T3BWPjgQ_48_0"></a><a id="Tc_5G1P5ncdZkuH6oz69tDYZw_49_0"></a><a id="Tc_E0SI-Df9fEaNSNLVPAGTyQ_50_0"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.0010299683%;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:77.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:8.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:1.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:10%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:77.17%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.61%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six Months Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:77.17%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:20.61%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:77.17%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;width:1.39%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:8.94%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;width:1.65%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="6" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:77.17%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:20.61%;background:#ffffff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">U.S.&#160;dollars&#160;in&#160;thousands</b></p></td></tr><tr><td style="vertical-align:top;width:77.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">OPERATING ACTIVITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:77.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Comprehensive income (loss)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" sign="-" scale="3" id="Tc_Qr7xrBrxi0SjxTEz8fViJg_6_3">3,088</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" scale="3" id="Tc_k7Ej2BpK4UumAm4Kj06jbg_6_5">51,002</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:77.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Adjustments in respect of income and expenses not involving cash flow:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:77.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Share-based compensation to employees and service providers</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" id="Tc_uJxE4YkKRUGEsRxEXtc2AA_8_3">229</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForSharebasedPayments" scale="3" id="Tc_x6zy5vsqBEahMGOBGE096w_8_5">849</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:77.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Depreciation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForDepreciationExpense" scale="3" id="Tc_qZAuJ5oLiUOo4OHHS0XajA_9_3">402</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForDepreciationExpense" scale="3" id="Tc_7e0nOVIQSEuE_Tqh1at84A_9_5">1,055</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:77.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Amortization of intangible assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForAmortisationExpense" scale="3" id="Tc_a4rJonszj0eg-FwuakpITg_10_3">16</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForAmortisationExpense" scale="3" id="Tc_-YrQI27j6U61PpFH360Dfg_10_5">530</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:77.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Gains from the transfer of rights in Movantik&#174; and extinguishment of debt obligations, (see below)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw" decimals="-3" format="ixt:numdotdecimal" name="rdhl:AdjustmentsForGainsFromTransferOfRightsInMovantikAndExtinguishmentOfDebtObligations" sign="-" scale="3" id="Tc_i4Zq1hUBvEy69dAe6ktwNw_11_5">56,082</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:77.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Gains from early termination of leases, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" decimals="-3" format="ixt:numdotdecimal" name="rdhl:AdjustmentsForGainsFromEarlyTerminationOfLeasesNet" sign="-" scale="3" id="Tc_RR7VbBedpUudRZDjsytIlw_12_3">23</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw" decimals="-3" format="ixt:numdotdecimal" name="rdhl:AdjustmentsForGainsFromEarlyTerminationOfLeasesNet" sign="-" scale="3" id="Tc_sBJLEcaTekC2pRAhLw8EEA_12_5">694</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:77.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Fair value gains on derivative financial instruments </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives" scale="3" id="Tc_D1NzShwtF0iawuutBOc4vg_13_3">7,108</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives" scale="3" id="Tc_7KWALyT3HESYFReA0wtUoA_13_5">8,071</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:77.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Loss from modification of warrants terms as part of a new issuance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw" decimals="-3" format="ixt:numdotdecimal" name="rdhl:AdjustmentsForLossFromModificationOfWarrantsTermsAsPartOfNewIssuance." scale="3" id="Tc_6tuHXxJuqkeBzH19p1SIjQ_14_5">1,084</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:77.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Issuance costs in respect of warrants </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" decimals="-3" format="ixt:numdotdecimal" name="rdhl:AdjustmentForIssuanceCostInRespectOfWarrants" scale="3" id="Tc_BhVeyvbmg06pBQ5OPrmrMg_15_3">1,497</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw" decimals="-3" format="ixt:numdotdecimal" name="rdhl:AdjustmentForIssuanceCostInRespectOfWarrants" scale="3" id="Tc_RbpdL7d_50C09OIEnTLUFg_15_5">922</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:77.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Exchange differences and revaluation of bank deposits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" decimals="-3" format="ixt:numdotdecimal" name="rdhl:AdjustmentsForRevaluationOfBankDeposits" scale="3" id="Tc_i7ryXCyOc0OefIjrlhcn4A_16_3">4</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw" decimals="-3" format="ixt:numdotdecimal" name="rdhl:AdjustmentsForRevaluationOfBankDeposits" scale="3" id="Tc_k-_NLAi1gECsMkZ9YB8VWw_16_5">13</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:77.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" sign="-" scale="3" id="Tc_KLr_IUQRHk-0PvQnjFSndw_17_3">4,991</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" sign="-" scale="3" id="Tc_de6W5O-RjEWVje3OQKkrfg_17_5">60,420</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:77.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Changes in assets and liability items:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:77.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Decrease in trade receivables</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" scale="3" id="Tc_WUONFxYCRUWDHBfhZUK13g_19_3">1,617</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" scale="3" id="Tc_XfAH66wfiEmAL-rhUsrfGQ_19_5">31,618</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:77.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Decrease (increase) in prepaid expenses and other receivables </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" sign="-" scale="3" id="Tc_HVw3FqBIsk-fd_qL2oPA3A_20_3">108</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" scale="3" id="Tc_Bj7hqwcTc0CQd8qn9221tA_20_5">1,337</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:77.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Decrease in inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" scale="3" id="Tc_2knrArhlvki5D__zjA46AA_21_3">585</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForDecreaseIncreaseInInventories" scale="3" id="Tc_ep2H0pR5S0u4f035mPyxpA_21_5">1,837</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:77.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Decrease in accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" sign="-" scale="3" id="Tc_WUxiAh6qBEGGm6iPrChhqg_22_3">1,366</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable" sign="-" scale="3" id="Tc_u1BpEDKrRU6CRUee2a-ZnA_22_5">1,118</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:77.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Decrease in accrued expenses and other liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" decimals="-3" format="ixt:numdotdecimal" name="rdhl:AdjustmentsForDecreaseIncreaseInAccruedExpenses" sign="-" scale="3" id="Tc_1TCv17L7yEKDr0tvKo5wDg_23_3">631</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw" decimals="-3" format="ixt:numdotdecimal" name="rdhl:AdjustmentsForDecreaseIncreaseInAccruedExpenses" sign="-" scale="3" id="Tc_CUHOUpky2UCt0z6hldkALQ_23_5">10,545</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:77.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 12pt;">Increase (decrease) in allowance for deductions from revenue</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" decimals="-3" format="ixt:numdotdecimal" name="rdhl:AdjustmentsForIncreaseDecreaseInAllowanceForDeductionsFromRevenue" scale="3" id="Tc_WGJDeFYV-kWVujxFm8nN2w_24_3">1,797</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw" decimals="-3" format="ixt:numdotdecimal" name="rdhl:AdjustmentsForIncreaseDecreaseInAllowanceForDeductionsFromRevenue" sign="-" scale="3" id="Tc_d5MUR4qRr0W-_Nn5VEi9ug_24_5">31,486</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:77.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseInWorkingCapital" sign="-" scale="3" id="Tc_mdmgAwSh1k-Rji9wEO2e2g_25_3">1,894</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseInWorkingCapital" scale="3" id="Tc_3TpvvOiaE0yT0vt01jxrSw_25_5">8,357</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:77.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Net cash used in operating activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" sign="-" scale="3" id="Tc_cvTxl98auEquL8N37r1SvQ_26_3">6,185</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInOperatingActivities" sign="-" scale="3" id="Tc_FJGMLVptpEeBIQgCeOeWug_26_5">17,775</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:top;width:77.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">INVESTING ACTIVITIES: </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:77.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Purchase of fixed assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="3" id="Tc_OCmEFm1kfE6DuHooCpbDDw_28_3">1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" scale="3" id="Tc_uPd4NZKq8UOjOWTj-T_Tmg_28_5">7</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:77.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Net cash used in investing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" sign="-" scale="3" id="Tc_PPAmOHt90kam4XU5_5ib1A_29_3">1</ix:nonFraction>)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"><b style="font-weight:bold;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInInvestingActivities" sign="-" scale="3" id="Tc_3W2lOTSamk-s2C-GI7-srA_29_5">7</ix:nonFraction>)</b></p></td></tr><tr><td style="vertical-align:top;width:77.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">FINANCING ACTIVITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="color:#ffffff;font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:77.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Proceeds from issuance of ordinary shares and warrants, net of issuance costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" scale="3" id="Tc__diuj9_nIU-U6IbP2XF1Sg_31_3">8,263</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProceedsFromIssueOfOrdinaryShares" scale="3" id="Tc_KuqvKVEMBkqn5m73_7fpJA_31_5">5,097</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:77.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Repayment of payable in respect of intangible asset purchase</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw" decimals="-3" format="ixt:numdotdecimal" name="rdhl:RepaymentOfPayableInRespectOfIntangibleAssetPurchase" scale="3" id="Tc_LovhidJqekiLtH92Ukt6bA_32_5">6,555</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:77.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Decrease in restricted cash </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" decimals="-3" format="ixt:numdotdecimal" name="rdhl:IfrsDecreaseInRestrictedCash" scale="3" id="Tc_9W5ThIvfikOUFvX00bCf7A_33_3">51</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw" decimals="-3" format="ixt:numdotdecimal" name="rdhl:IfrsDecreaseInRestrictedCash" scale="3" id="Tc_1eQUOgG6QUS41TSwKbMGjQ_33_5">6,860</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:77.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Payment of principal with respect to lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="3" id="Tc_RN-jdGpr50CLibpnDgeS_A_34_3">414</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" scale="3" id="Tc_2_BT-UHptUSbCi2FDG4oqA_34_5">589</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:77.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;"><b style="font-weight:bold;">Net cash provided by financing activities</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="3" id="Tc_ItOF8mFUik-1u8Sy2TBraA_35_3">7,900</ix:nonFraction></b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"><b style="font-weight:bold;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashFlowsFromUsedInFinancingActivities" scale="3" id="Tc_yhVhwkock0qupJXt4grPcA_35_5">4,813</ix:nonFraction></b></p></td></tr><tr><td style="vertical-align:top;width:77.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" scale="3" id="Tc_zOcUjhtm9U6tNSbjRvO4Zw_36_3">1,714</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" sign="-" scale="3" id="Tc_xSGX1GockEWnFZ1qtvzMbQ_36_5">12,969</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:77.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">EXCHANGE DIFFERENCES ON CASH AND CASH EQUIVALENTS</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" sign="-" scale="3" id="Tc_M-iqo1KRlECfdsakrNcesQ_37_3">6</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents" sign="-" scale="3" id="Tc_aVQlq6wrKU6I9838pbPp7Q_37_5">3</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:77.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_12_31_2023_XGghR9I2w0KmrTtJVNkj1A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="3" id="Tc_6li-fIsBj0ecUeaAM9-hDw_38_3">5,569</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_12_31_2022_jV2f_7krOUScpr2kI0mJcw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="3" id="Tc_RTU4Pftw9k-qfHgujSK_3g_38_5">19,968</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:77.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">BALANCE OF CASH AND CASH EQUIVALENTS AT THE END OF PERIOD</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_6_30_2024_lm1Lh8C52kquuyx0qsrPDw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="3" id="Tc_knuwef9OtUGuNrsnlH_YOA_39_3">7,277</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_6_30_2023_XZFu_w7MpEqlzzSlD3xkQg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CashAndCashEquivalents" scale="3" id="Tc_3U-13Q-qkEec8JcZQX07iQ_39_5">6,996</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">SUPPLEMENTARY INFORMATION ON INTEREST RECEIVED IN CASH</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" decimals="-3" format="ixt:numdotdecimal" name="rdhl:SupplementalInformationInterestReceivedInCash" scale="3" id="Tc_BYyh_R8y2kKI09qzpeT_cQ_40_3">38</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw" decimals="-3" format="ixt:numdotdecimal" name="rdhl:SupplementalInformationInterestReceivedInCash" scale="3" id="Tc_yKhgqrglo02yuRyLJEeVcQ_40_5">123</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">SUPPLEMENTARY INFORMATION ON INTEREST PAID IN CASH</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" decimals="-3" format="ixt:numdotdecimal" name="rdhl:SupplementalInformationInterestPaidInCash" scale="3" id="Tc_h8mKaEd--EO6YROCSL4dAg_41_3">28</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw" decimals="-3" format="ixt:numdotdecimal" name="rdhl:SupplementalInformationInterestPaidInCash" scale="3" id="Tc_UJnqSXUNoEyirso7SxS2qg_41_5">315</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:77.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">SUPPLEMENTARY INFORMATION ON NON-CASH INVESTING AND FINANCING ACTIVITIES:</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:77.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Acquisition of right-of-use assets by means of lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" decimals="-3" format="ixt:numdotdecimal" name="rdhl:AcquisitionOfRightOfUseAssetsByMeansOfLeaseLiabilities" scale="3" id="Tc_aP3AsdcVLkOJbt_RBCaaJA_43_3">5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw" decimals="-3" format="ixt:numdotdecimal" name="rdhl:AcquisitionOfRightOfUseAssetsByMeansOfLeaseLiabilities" scale="3" id="Tc_7kyJl1_PXkWeMim2-BwinA_43_5">224</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:77.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Decrease in lease liability (with corresponding decrease in right of use asset in amount of $<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" decimals="-3" format="ixt:numdotdecimal" name="rdhl:DecreaseInRightOfUseAssetFromEarlyTerminationOfLease" scale="3" id="Narr_5cbyLmrvikqw0KPunJ8RRw">170</ix:nonFraction> in the six months ended June 30, 2024, and $<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw" decimals="-3" format="ixt:numdotdecimal" name="rdhl:DecreaseInRightOfUseAssetFromEarlyTerminationOfLease" scale="3" id="Narr_VnD4WMaD2kOH4sN7QO7HlQ">4,117</ix:nonFraction> in the six months ended June 30,2023) resulting from early termination of lease.</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" decimals="-3" format="ixt:numdotdecimal" name="rdhl:DecreaseInLeaseLiabilityFromEarlyTerminationOfLease" scale="3" id="Tc_vPC259inZUuQIUM-bMsYIQ_44_3">193</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw" decimals="-3" format="ixt:numdotdecimal" name="rdhl:DecreaseInLeaseLiabilityFromEarlyTerminationOfLease" scale="3" id="Tc_OYR6e0To2ka2gdH8ogT5oQ_44_5">4,811</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:77.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Transfer of rights in Movantik&#174; and extinguishment of debt obligations: </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:77.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Decrease in Intangible asset </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ChangesInIntangibleAssetsOtherThanGoodwill" sign="-" scale="3" id="Tc_ey_vXf-eQkyWUJq-pwgCeA_46_5">59,503</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:77.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Decrease in Inventories</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw" decimals="-3" format="ixt:numdotdecimal" name="rdhl:DecreaseInInventories" sign="-" scale="3" id="Tc_EZbPQ59ZH0a_PXc4SM7PYg_47_5">4,233</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:77.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Decrease in Payable in respect of Intangible asset </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw" decimals="-3" format="ixt:numdotdecimal" name="rdhl:DecreaseIncreaseInPayablesInRespectOfIntangibleAssets" scale="3" id="Tc_uasSedCM3EuMIWpjGt_B1g_48_5">4,602</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:77.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Decrease in Borrowing </p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw" decimals="-3" format="ixt:numdotdecimal" name="rdhl:DecreaseIncreaseInBorrowings" scale="3" id="Tc_nPmMc4aQ20SVIlj4TCZnUg_49_5">115,216</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:77.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 6pt;">Gains from the transfer of the rights in Movantik&#174; and extinguishment of debt obligations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:right;margin:0pt 2.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw" decimals="-3" format="ixt:numdotdecimal" name="rdhl:GainsFromTransferOfRightsInMovantikAndExtinguishmentOfDebtObligations" scale="3" id="Tc_hc_WBSMPeUmTJalOgh0HAw_50_5">56,082</ix:nonFraction></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:18pt;text-align:center;text-indent:-18pt;margin:0pt;"><b style="font-weight:bold;">The accompanying notes are an integral part of these condensed consolidated financial statements.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="direction:rtl;font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="direction:rtl;font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="direction:rtl;font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="direction:rtl;font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:17.85pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">6</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.35%;border:0;margin:30pt 10.33% 30pt 10.33%;"></div><div style="max-width:100%;padding-left:10.33%;padding-right:10.33%;position:relative;"><div style="margin-top:21.6pt;min-height:40.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="display:inline-block;width:167.25pt;"></span><span style="color:#0563c1;font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="color:#0563c1;font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">REDHILL BIOPHARMA LTD.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="color:#0563c1;font-size:10pt;text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><a id="notes"></a><a id="_Hlk141793917"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" name="ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" id="Tb_4mzlYWHZKUWB1j4pR-L3Cg" continuedAt="Tb_4mzlYWHZKUWB1j4pR-L3Cg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">NOTE 1 - GENERAL:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 144pt;"><span style="font-size:8pt;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:49.65pt;margin-top:0pt;padding-left:94.35pt;text-align:justify;text-indent:-94.35pt;"><span style="display:inline-block;font-size:8pt;font-weight:bold;min-width:21.25pt;text-indent:0pt;white-space:nowrap;">a.</span><b style="font-size:8pt;font-weight:bold;">General</b></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 144pt;"><span style="font-size:8pt;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:49.6pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">RedHill Biopharma Ltd. (the &#8220;Company&#8221;), incorporated on August 3, 2009, together with its wholly-owned subsidiary, RedHill Biopharma Inc. (&#8220;RedHill Inc.&#8221;), incorporated in Delaware, U.S. on January 19, 2017, is a specialty biopharmaceutical company primarily focused on gastrointestinal (&#8220;GI&#8221;) diseases and infectious diseases. </span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 67.75pt;">The Company&#8217;s American Depositary Shares (&#8220;ADSs&#8221;) were traded on the Nasdaq Capital Market from December 27, 2012, were listed on the Nasdaq Global Market (&#8220;Nasdaq&#8221;) from July 20, 2018, and have been again listed on the Nasdaq Capital Market since November 15, 2023. On March 23, 2023, the Company changed the ADS ratio from 1 ADS representing <ix:nonFraction unitRef="Unit_Standard_shares_XGdimIWcf0OdGjo7fryoGw" contextRef="Duration_3_22_2023_To_3_22_2023_ifrs-full_ClassesOfOrdinarySharesAxis_dei_AdrMember_bVgXh3NRiE65_Oa5kANs7A" decimals="INF" format="ixt:numdotdecimal" name="rdhl:NumberOfOrdinarySharesIssuedInExchangeOfAmericanDepositoryReceipts" scale="0" id="Narr_Pu9Wckb7N0CtuyLj3xnpJA">10</ix:nonFraction> ordinary shares to 1 ADS representing <ix:nonFraction unitRef="Unit_Standard_shares_XGdimIWcf0OdGjo7fryoGw" contextRef="Duration_3_23_2023_To_3_23_2023_ifrs-full_ClassesOfOrdinarySharesAxis_dei_AdrMember_xDmTu-XomE-QX_HsBKKWmA" decimals="INF" format="ixt:numdotdecimal" name="rdhl:NumberOfOrdinarySharesIssuedInExchangeOfAmericanDepositoryReceipts" scale="0" id="Narr_wrAzlaeq_UWg8MYLiYpuqA">400</ix:nonFraction> ordinary shares. On August 20, 2024, after the condensed consolidated interim financial statements date, the Company changed the ADS to ordinary share ratio from 1 ADS representing <ix:nonFraction unitRef="Unit_Standard_shares_XGdimIWcf0OdGjo7fryoGw" contextRef="Duration_3_23_2023_To_3_23_2023_ifrs-full_ClassesOfOrdinarySharesAxis_dei_AdrMember_xDmTu-XomE-QX_HsBKKWmA" decimals="INF" format="ixt:numdotdecimal" name="rdhl:NumberOfOrdinarySharesIssuedInExchangeOfAmericanDepositoryReceipts" scale="0" id="Narr_x_5qjAF92kqkEpPeLb5GKw">400</ix:nonFraction> ordinary shares to 1 ADS representing <ix:nonFraction unitRef="Unit_Standard_shares_XGdimIWcf0OdGjo7fryoGw" contextRef="Duration_8_20_2024_To_8_20_2024_ifrs-full_ClassesOfOrdinarySharesAxis_dei_AdrMember_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_ifrs-full_MajorOrdinaryShareTransactionsMember_RX7kvctHAE2Q6Z9cdW-n0g" decimals="INF" format="ixt:numdotdecimal" name="rdhl:NumberOfOrdinarySharesIssuedInExchangeOfAmericanDepositoryReceipts" scale="0" id="Narr_WuUS12iyDkij3wWm_EIGOQ">10,000</ix:nonFraction> ordinary shares. The ADSs and per ADS amounts in these interim financial statements reflect the old ratio of 1 ADS to <ix:nonFraction unitRef="Unit_Standard_shares_XGdimIWcf0OdGjo7fryoGw" contextRef="Duration_3_23_2023_To_3_23_2023_ifrs-full_ClassesOfOrdinarySharesAxis_dei_AdrMember_xDmTu-XomE-QX_HsBKKWmA" decimals="INF" format="ixt:numdotdecimal" name="rdhl:NumberOfOrdinarySharesIssuedInExchangeOfAmericanDepositoryReceipts" scale="0" id="Narr_2KoCtSP40UWdK-datSWmng">400</ix:nonFraction> ordinary shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 67.75pt;">The Company&#8217;s registered address is 21 Ha&#8217;arba&#8217;a St, Tel-Aviv, Israel<span style="direction:rtl;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:49.6pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Since the Company established its commercial presence in the U.S. in 2017, it has promoted or commercialized various GI-related products that were either developed internally or acquired through in-licensing agreements. As of the date of approval of these condensed consolidated interim financial statements, the Company commercializes in the U.S., mainly Talicia&#174;, for the treatment of Helicobacter pylori infection in adults, the first product approved by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) being developed primarily</span><span style="direction:rtl;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">internally by the Company. Until </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">F</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ebruary</span><span style="direction:rtl;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1,</span><span style="direction:rtl;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2023, the Company commercialized Movantik&#174; in the U.S, for the treatment of opioid-induced constipation. See also note 15(6) in the annual financial statements as of December 31, 2023 regarding the transfer of the Company&#8217;s rights in Movantik&#174; to HCR Collateral Management, LLC (&#8220;HCRM&#8221;) in exchange for all the Company&#8217;s debt obligations under the Credit Agreement with HCRM (see also note 10). The Company also continues to advance the development of part of its late-stage therapeutic candidates. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:49.6pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Through June 30, 202</span><span style="direction:rtl;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, the Company has an accumulated deficit and negative working capital, and its activities have been funded primarily through public and private offerings of the Company&#8217;s securities and secured borrowing (now fully extinguished, see note 15(6) in the annual financial statements as of December 31, 2023</span><span style="direction:rtl;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. There is no assurance that the Company&#8217;s business will generate sustainable positive cash flows to fund its business.</span><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> </span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 67.6pt;">The Company plans to further fund its future operations through commercialization and out-licensing of its therapeutic candidates, commercialization of in-licensed or acquired products and raising additional capital through equity or debt financing or through other non-dilutive financing. Furthermore, the Company is actively pursuing and in discussions with multiple parties regarding strategic business development transactions, including potential divestment of certain of the Company&#8217;s assets and/or its commercial operations, which the Company expects would provide it with additional capital, although there is no guarantee that the Company will complete such a transaction on favorable terms. The Company&#8217;s current cash resources are not sufficient to complete the research and development of any of its therapeutic candidates and to fully support its commercial operations until generation of sustainable positive cash flows. Management expects that the Company will incur additional losses as it continues to focus its resources on advancing the development of its therapeutic candidates, as well as advancing its commercial operations, based on a prioritized plan that will result in negative cash flows from operating activities. Management believes that there is presently insufficient funding available to allow </p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:17.85pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.35%;border:0;margin:30pt 10.33% 30pt 10.33%;"></div><div style="max-width:100%;padding-left:10.33%;padding-right:10.33%;position:relative;"><div style="margin-top:21.6pt;min-height:40.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="display:inline-block;width:167.25pt;"></span><span style="color:#0563c1;font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="color:#0563c1;font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">REDHILL BIOPHARMA LTD.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="color:#0563c1;font-size:10pt;text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_4mzlYWHZKUWB1j4pR-L3Cg_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 67.6pt;">the Company to fund its activities for a period exceeding one year from the date of this filing. These conditions and events indicate that a material uncertainty exists that may cast significant doubt (or raise substantial doubt as contemplated by PCAOB standards) about the Company&#8217;s ability to continue as a going concern. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 67.7pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 67.7pt;">The accompanying condensed consolidated interim financial statements have been prepared assuming that the Company will continue as a going concern and do not include any adjustments that might result from the outcome of this uncertainty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 67.7pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:49.6pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In October 2023, Israel was attacked by a terrorist organization and entered a state of war. As of the date of these </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">condensed consolidated interim financial statements</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, the war in Israel is ongoing and continues to evolve. During six months ended of June 30,2024, the impact of this war on the Company results and financial condition was immaterial, but such impact may increase</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:13.5pt;text-indent:-13.5pt;margin:0pt 0pt 0pt 49.6pt;"><b style="font-weight:bold;white-space:pre-wrap;">b.      Approval of the condensed consolidated interim financial statements:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 50.4pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 67.75pt;">These condensed consolidated interim financial statements were approved by the Board of Directors (the "BoD") on August 28, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:4.5pt;margin:0pt 0pt 0pt 4.5pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" name="rdhl:DisclosureOfBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsTextBlock" id="Tb_Wd6CCzVXeEK8P7ZVJpee0g" continuedAt="Tb_Wd6CCzVXeEK8P7ZVJpee0g_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:67.5pt;text-indent:-67.5pt;margin:0pt 0pt 0pt 4.5pt;"><b style="font-weight:bold;">NOTE 2 - BASIS OF PREPARATION OF THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS AND </b><b style="font-weight:bold;">SIGNIFICANT ACCOUNTING POLICIES</b><b style="font-weight:bold;">:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:4.5pt;text-align:justify;text-indent:-4.5pt;margin:0pt 0pt 0pt 67.7pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:49.6pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">  </span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"> </b><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">BASIS OF PREPARATION</b></td></tr></table><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" name="ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" id="Tb_zaPOJ8Bhe0uVx1tkDTbU9w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:4.5pt;text-align:justify;text-indent:-4.5pt;margin:0pt 0pt 0pt 67.7pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:4.5pt;text-align:justify;text-indent:-4.5pt;margin:0pt 0pt 0pt 49.6pt;"> &#160;<span style="font-size:10pt;">The Company&#8217;s condensed consolidated interim financial statements for the six months</span><span style="font-size:10pt;"> ended June 30, 2024 (the "Condensed Consolidated Interim Financial Statements"), have </span><span style="font-size:10pt;">been prepared</span><span style="font-size:10pt;"> </span><span style="font-size:10pt;">in accordance with</span><span style="font-size:10pt;"> International Accounting Standard IAS 34, &#8220;Interim Financial Reporting</span><span style="font-size:10pt;">&#8221;.</span><span style="font-size:10pt;"> These Condensed Consolidated Interim Financial Statements,</span><span style="direction:rtl;font-size:10pt;"> </span><span style="font-size:10pt;">that are unaudited, do not include all the information and disclosures that would otherwise be required in a complete set of annual financial statements and </span><span style="font-size:10pt;">should be read in conjunction with the annual financial statements as of December 31, 2023, and their accompanying notes, which have been prepared in accordance with International Financial Reporting Standards (&#8220;IFRS&#8221;) as published by the International Accounting Standards Board (&#8220;IASB&#8221;).</span><span style="font-size:10pt;"> The results of operations for the six months ended June 30, 2024, are not necessarily indicative of the results that may be expected for the entire fiscal year </span><span style="font-size:10pt;">or for</span><span style="font-size:10pt;"> any other interim period</span><span style="font-size:10pt;">.</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:4.5pt;text-align:justify;text-indent:-4.5pt;margin:0pt 0pt 0pt 49.6pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:49.6pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">SIGNIFICANT ACCOUNTING POLICIES</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:49.6pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1)</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">General</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 67.6pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 67.6pt;">The accounting policies applied in the preparation of the Condensed Consolidated Interim Financial Statements are consistent with those applied in the preparation of the annual financial statements as of December 31, 2023, except for the reclassification of derivative financial instruments from non-current liabilities to current liabilities, as described in note 2b(2).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 67.6pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:49.6pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2)</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">New international financial reporting standards, amendments to standards and new interpretations</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 67.6pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 67.6pt;"><i style="font-style:italic;">Classification of Liabilities as Current or Non-Current (Amendment to IAS 1)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-style:italic;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 67.6pt;">The narrow-scope amendments to IAS 1, &#8220;Presentation of Financial Statements,&#8221; clarify that liabilities are classified as either current or noncurrent, depending on the rights that exist at the end of the reporting period. Classification is unaffected by the entity&#8217;s expectations or events after the reporting date. The amendments also clarify what IAS 1 means when it refers to the settlement&#8217; of a liability. The amendments may affect the classification of liabilities, particularly for entities that previously considered </p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:17.85pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.35%;border:0;margin:30pt 10.33% 30pt 10.33%;"></div><div style="max-width:100%;padding-left:10.33%;padding-right:10.33%;position:relative;"><div style="margin-top:21.6pt;min-height:40.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="display:inline-block;width:167.25pt;"></span><span style="color:#0563c1;font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="color:#0563c1;font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">REDHILL BIOPHARMA LTD.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="color:#0563c1;font-size:10pt;text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_Wd6CCzVXeEK8P7ZVJpee0g_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 67.6pt;">management&#8217;s intentions to determine classification and for some liabilities that can be converted into equity. The Company adopted these amendments effective January 1, 2024. The impact on the Company&#8217;s financial statements of these amendments was the reclassification of the Company&#8217;s derivative financial instruments from non-current to current as of its effective date. The Company has retrospectively applied the amendments in these interim financial statements and, accordingly, has retrospectively adjusted the comparative balance sheet for December 31, 2023 to reclassify its warrant liabilities ($<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_12_31_2023_ifrs-full_NewIFRSsAxis_rdhl_Ias1AmendmentsMember_6IOwDM618kGNeECku1awvg" decimals="0" format="ixt:numdotdecimal" name="rdhl:ReclassificationOfWarrantLiability" scale="0" id="Narr_p2afodfCrUepds61oPoxfg">741</ix:nonFraction> as of December 31, 2023) from non-current to current. Adoption of the amendments had no other impact on the Company&#8217;s financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 67.6pt;"><i style="font-style:italic;">IFRS 18, Presentation and Disclosure in the Financial Statements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 67.6pt;">This standard replaces the international accounting standard IAS 1, &#8220;Presentation of Financial Statements.&#8221; As part of the new disclosure requirements, companies will be required to present new defined subtotals in the statements of income, as follows: (1) operating profit and (2) profit before financing and tax. In addition, income statement items will be classified into three defined categories: operating, investment and financing. The standard also includes a requirement to provide a separate disclosure in the financial statements regarding the use of management-defined performance measures (&#8220;non-GAAP measures&#8221;), and specific instructions were added for the grouping and splitting of items in the financial statements and in the notes to the financial statements. IFRS 18 is effective for annual reporting periods beginning on or after January 1, 2027, with an option for early adoption.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:4.5pt;text-align:justify;text-indent:-4.5pt;margin:0pt 0pt 0pt 49.6pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" name="rdhl:SignificantEventsDuringCurrentReportingPeriodTextBlock" id="Tb_TxhrHEFwnUCLgxWJyLPscw" continuedAt="Tb_TxhrHEFwnUCLgxWJyLPscw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:67.7pt;text-align:justify;text-indent:-67.7pt;margin:0pt 0pt 12pt 4.3pt;"><b style="font-weight:bold;background:#ffffff;">NOTE </b><b style="font-weight:bold;background:#ffffff;">3 - SIGNIFICANT EVENTS DURING THE CURRENT REPORTING PERIOD:</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:49.6pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">On January 26, 2024, the Company issued </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_XGdimIWcf0OdGjo7fryoGw" contextRef="As_Of_1_26_2024_ifrs-full_ComponentsOfEquityAxis_rdhl_AmericanDepositoryShareMember_earRV5J5lEem3IOZmkajMg" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfSharesIssued" scale="0" id="Narr_LL2Br5xQYU2Djay0QOQ5rA">10,000,000</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> ADSs at a purchase price of $</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_CKQZNDkEe0eDAz2GdtdFSg" contextRef="Duration_1_26_2024_To_1_26_2024_ifrs-full_ComponentsOfEquityAxis_rdhl_AmericanDepositoryShareMember_6NQerov18ESxxuLFDfcOog" decimals="INF" format="ixt:numdotdecimal" name="rdhl:IfrsSharesIssuedPricePerShare" scale="0" id="Narr_kAKMjULyZEKqc_T4Xw3b4A">0.80</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per ADS and warrants to purchase </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_XGdimIWcf0OdGjo7fryoGw" contextRef="Duration_1_26_2024_To_1_26_2024_ifrs-full_ComponentsOfEquityAxis_rdhl_IfrsWarrantMember_try5X0D-VEimOWrLlTXBdw" decimals="INF" format="ixt:numdotdecimal" name="rdhl:WarrantsNumberIssued" scale="0" id="Narr_YGzVqQobakWIoavQiPl2tA">10,000,000</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> ADSs at an exercise price of $</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_CKQZNDkEe0eDAz2GdtdFSg" contextRef="As_Of_1_26_2024_ifrs-full_ComponentsOfEquityAxis_rdhl_IfrsWarrantMember_2DHClqF2Qk-paY34dAQVhQ" decimals="INF" format="ixt:numdotdecimal" name="rdhl:IfrsClassOfWarrantsOrRightExercisePriceOfWarrantsOrRights" scale="0" id="Narr_Ti9TtibxTUeWIRbQfbQ8Kg">1.00</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per ADS. These warrants may be exercised in cash or on a cashless basis, are immediately exercisable, and expire in </span><ix:nonNumeric contextRef="Duration_1_26_2024_To_1_26_2024_ifrs-full_ComponentsOfEquityAxis_rdhl_IfrsWarrantMember_try5X0D-VEimOWrLlTXBdw" format="ixt-sec:durwordsen" name="rdhl:IfrsWarrantsAndRightsOutstandingTerm" id="Narr_FUyIZvI0gEaIqnh-vU1HxA"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five years</span></ix:nonNumeric><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. The Company also issued to the placement agent warrants to purchase </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_XGdimIWcf0OdGjo7fryoGw" contextRef="Duration_1_26_2024_To_1_26_2024__j6PCY90FUmwW0bnS-0ZyQ" decimals="INF" format="ixt:numdotdecimal" name="rdhl:WarrantsNumberIssued" scale="0" id="Narr_tWanCXKwl0uaw2ONGVB5Wg">600,000</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> ADSs under the same terms. The gross proceeds from the offering were $</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_26_2024_To_1_26_2024__j6PCY90FUmwW0bnS-0ZyQ" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ProceedsFromIssuingShares" scale="6" id="Narr_lcDcQSTqLEuY2HMH-e0Cbw">8</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> million, before deducting approximately $</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_26_2024_To_1_26_2024__j6PCY90FUmwW0bnS-0ZyQ" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:PaymentsForShareIssueCosts" scale="6" id="Narr_vdlPacfxr0-t7fHlVxlW5A">0.9</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> million in fees and expenses.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 67.6pt;"><span style="background:#ffffff;">The warrants were classified as a financial liability due to a net settlement provision. These derivatives were recognized and subsequently measured at fair value through profit or loss. Upon initial recognition the fair value of the warrants was adjusted to reflect the unrecognized day 1 loss. This unrecognized day 1 loss is amortized over the warrants&#8217; contractual life. Consequently, $</span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_26_2024_To_1_26_2024_ifrs-full_ComponentsOfEquityAxis_rdhl_IfrsWarrantMember_try5X0D-VEimOWrLlTXBdw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:PaymentsForShareIssueCosts" scale="6" id="Narr_nkoKNKsDpUOS4eE9D6RqrQ">0.9</ix:nonFraction></span><span style="background:#ffffff;"> million of issuance costs allocated to the warrants, were included directly in the Consolidated Statements of Comprehensive Income (Loss). See also note 7.</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:14pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:49.6pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">On March 21, 2024, the Annual General Meeting of shareholders approved the increase of the authorized share capital of the Company to NIS </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_ILS_19CAiapBLkWinll-yZ3PnA" contextRef="As_Of_3_21_2024_GMdZTmx5DEK7BZ7CRDSNdw" decimals="INF" format="ixt:numdotdecimal" name="rdhl:AuthorisedShareCapital" scale="0" id="Narr_j_VX16P4s0yLukVcYWO4Jw">400,000,000</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> divided into (i) </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_XGdimIWcf0OdGjo7fryoGw" contextRef="As_Of_3_21_2024_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember_Ej8jvZlqGkeT63oCOmaVmg" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfSharesAuthorised" scale="0" id="Narr_hDOeP9tpgEm9lbEYWGePCg">39,994,000,000</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> registered Ordinary Shares of NIS </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Divide_ILS_shares_LnWGktS0CkGllLF6Jva9vA" contextRef="As_Of_3_21_2024_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember_Ej8jvZlqGkeT63oCOmaVmg" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:ParValuePerShare" scale="0" id="Narr_NX9OHJnQfEauvyhY-AFQ1g">0.01</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> par value each, and (ii) </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_XGdimIWcf0OdGjo7fryoGw" contextRef="As_Of_3_21_2024_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_PreferenceSharesMember_RA41LoI2wE2KQ4D5_pwTlQ" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfSharesAuthorised" scale="0" id="Narr___uaaE5wD06B318BW9z0Yw">6,000,000</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> preferred shares of NIS </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Divide_ILS_shares_LnWGktS0CkGllLF6Jva9vA" contextRef="As_Of_3_21_2024_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_PreferenceSharesMember_RA41LoI2wE2KQ4D5_pwTlQ" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:ParValuePerShare" scale="0" id="Narr_6VKHvRO280-mWOJyF0XePQ">0.01</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> par value each.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:49.6pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">c.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">On April 3, 2024, the Company issued </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_XGdimIWcf0OdGjo7fryoGw" contextRef="As_Of_4_3_2024_ifrs-full_ComponentsOfEquityAxis_rdhl_AmericanDepositoryShareMember_nhnjGt_XE0ij6Oga9k_JNw" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfSharesIssued" scale="0" id="Narr_G4wmKiSoN0merAkQpStJJQ">2,144,487</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> ADSs at a purchase price of $</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_CKQZNDkEe0eDAz2GdtdFSg" contextRef="Duration_4_3_2024_To_4_3_2024_ifrs-full_ComponentsOfEquityAxis_rdhl_AmericanDepositoryShareMember_i9PW7CfORkKunWqEkaIlfA" decimals="INF" format="ixt:numdotdecimal" name="rdhl:IfrsSharesIssuedPricePerShare" scale="0" id="Narr_7uRWVM571UaljMp1RDgrpA">0.58289</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per ADS and warrants to purchase </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_shares_XGdimIWcf0OdGjo7fryoGw" contextRef="Duration_4_3_2024_To_4_3_2024_ifrs-full_ComponentsOfEquityAxis_rdhl_IfrsWarrantMember_MJAPHqwRZkK8j3cPNSQ-DQ" decimals="INF" format="ixt:numdotdecimal" name="rdhl:WarrantsNumberIssued" scale="0" id="Narr_UYcn2kwz3ECXNdPkEiro1w">2,144,487</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> ADSs at an exercise price of $</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Divide_USD_shares_CKQZNDkEe0eDAz2GdtdFSg" contextRef="Duration_4_3_2024_To_4_3_2024_ifrs-full_ComponentsOfEquityAxis_rdhl_IfrsWarrantMember_MJAPHqwRZkK8j3cPNSQ-DQ" decimals="INF" format="ixt:numdotdecimal" name="rdhl:IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" scale="0" id="Narr_ZAEHqPxmP0CCN1oxtzKk4Q">0.75</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per ADS. These warrants may be exercised in cash or on a cashless basis, are &#160;immediately exercisable and expire in </span><ix:nonNumeric contextRef="Duration_4_3_2024_To_4_3_2024_ifrs-full_ComponentsOfEquityAxis_rdhl_IfrsWarrantMember_MJAPHqwRZkK8j3cPNSQ-DQ" format="ixt-sec:durwordsen" name="rdhl:IfrsWarrantsAndRightsOutstandingTerm" id="Narr_RQB-Yhl7LUu-A4EyqBKppg"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five years</span></ix:nonNumeric><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. The gross proceeds from the offering were $</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_4_3_2024_To_4_3_2024_xAzFjFHyA02Un3POz8VYMg" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ProceedsFromIssuingShares" scale="6" id="Narr__gyzAc5NkU-8IFlRLlLO3Q">1.25</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> million, before deducting offering expenses approximately $</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_4_3_2024_To_4_3_2024_xAzFjFHyA02Un3POz8VYMg" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:PaymentsForShareIssueCosts" scale="6" id="Narr_2J5ifYGAt0yjXjeXGdhkyw">0.1</ix:nonFraction></span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> million in expesnses.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 67.6pt;"><span style="background:#ffffff;">The warrants were classified as a financial liability due to a net settlement provision. These derivatives were recognized and subsequently measured at fair value through profit or loss. The consideration, net of issue expenses, was allocated to the various issued instruments. Out of the gross consideration, $</span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_4_3_2024_To_4_3_2024_ifrs-full_ComponentsOfEquityAxis_rdhl_IfrsWarrantMember_MJAPHqwRZkK8j3cPNSQ-DQ" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ProceedsFromIssuingShares" scale="6" id="Narr_B6ZZqjISf0qeB1fTnmcZig">0.9</ix:nonFraction></span><span style="background:#ffffff;"> million was allocated to the warrants. The remainder of approximately $</span><span style="background:#ffffff;"><ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_4_3_2024_To_4_3_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfEquityComponentOfConvertibleInstrumentsMember_eYL19KtWRk2RX2MXCnVjkw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:ProceedsFromIssuingShares" scale="6" id="Narr_1vNGhyA35EKY2XsZerRliw">0.35</ix:nonFraction></span><span style="background:#ffffff;"> million was allocated to </span></p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:17.85pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.35%;border:0;margin:30pt 10.33% 30pt 10.33%;"></div><div style="max-width:100%;padding-left:10.33%;padding-right:10.33%;position:relative;"><div style="margin-top:21.6pt;min-height:40.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="display:inline-block;width:167.25pt;"></span><span style="color:#0563c1;font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="color:#0563c1;font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">REDHILL BIOPHARMA LTD.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="color:#0563c1;font-size:10pt;text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_TxhrHEFwnUCLgxWJyLPscw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 67.6pt;"><span style="background:#ffffff;">equity. Issuance expenses allocated &#160;to the liability instruments were recorded directly in the Consolidated Statements of Comprehensive Income (Loss) and , while those allocated to equity were recorded against additional paid in capital. See also note 7.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:14pt 0pt 12pt 67.6pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-left:0pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p></ix:continuation><a id="_Hlk510102932"></a><a id="Tc_L4JJcfJnM0GMje30x6Qg3g_1_2"></a><a id="Tc_nw-05u727kyAskWGObvjJA_1_4"></a><a id="Tc_C4PF5Vxt7ESXO8EMS76lPQ_1_6"></a><a id="Tc_WrpYg3soE0KV3ug76iobrA_2_2"></a><a id="Tc_S8dcO2mqdUmUC9366AT55A_3_0"></a><a id="Tc_csDBYNevKU6Psu7P-n_4rA_4_0"></a><a id="Tc_9ZP-80bN5UizgAIqwi8lww_5_0"></a><a id="Tc_H0u4PQUmpEiu21_bqxMcKA_6_0"></a><a id="Tc_fKkRhrrWyEOzzGw9Kcm9eg_7_0"></a><a id="Tc_MFLmvbdzQ0uk8KytCZTgJA_8_2"></a><a id="Tc_WfBY_Metg0ufdkw_c-CDwg_8_4"></a><a id="Tc_bfodoYMK3EeGSE3CmlVTGw_8_6"></a><a id="Tc_4ih19_xhjU-kP0vrFLMfMw_9_2"></a><a id="Tc_lNNYTVEIeUynYPmE5D2XNQ_10_0"></a><a id="Tc_Tc58-yHGfUOXVR6Wy_5R0A_11_0"></a><a id="Tc_T0YwU5iwoEmzJ8buvICTkA_12_0"></a><a id="Tc_akPArxo_MUOl-BkiyoU_FA_13_0"></a><a id="Tc_5rALf84SxkaidLBEOqPh4w_14_0"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" name="rdhl:AllowanceForDeductionsFromRevenuesDisclosureTextBlock" id="Tb_NYmahA1GpUWYN_JF1ChGjw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">NOTE 4</b><b style="direction:rtl;font-weight:bold;">:</b><b style="font-weight:bold;"> - ALLOWANCE FOR DEDUCTIONS FROM REVENUES:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 67.75pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 67.7pt;">The following table shows the movement of the allowance for deductions from revenues:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" name="rdhl:ScheduleOfMovementOfAllowanceForDeductionsFromRevenuesTableTextBlock" id="Tb_oaowqZiFlEKTMK_HsOiQ2w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 67.75pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:69.55pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:85.5%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:34.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:18.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:34.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:18.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Rebates and patient discount programs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Product returns</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:34.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:middle;width:60.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">U.S.&#160;dollars&#160;in&#160;thousands</b></p></td></tr><tr><td style="vertical-align:bottom;width:34.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As of January 1, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfProvisionsAxis_rdhl_RebatesAndPatientDiscountProgramsMember_uIEoPLILYUedGsgrxLouxA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentRefundsProvision" scale="3" id="Tc_kw0UlqXPBkakgkKhoeoeBQ_3_2">8,087</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfProvisionsAxis_rdhl_ProductReturnsMember_JgwA-XfDBkSzQ2XdwWxN8Q" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentRefundsProvision" scale="3" id="Tc__mVYjaMk0k-1Mr3T6IDuKQ_3_4">2,567</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_12_31_2023_XGghR9I2w0KmrTtJVNkj1A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentRefundsProvision" scale="3" id="Tc_QuGqIHSeZ0CuHcYsMSvkHQ_3_6">10,654</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:34.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Increases </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_ClassesOfProvisionsAxis_rdhl_RebatesAndPatientDiscountProgramsMember_qttEPmHMoE6w_c5KccwpGw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseInExistingProvisionsOtherProvisions" scale="3" id="Tc_kqYCg3ProU6rcV_-qyhh0g_4_2">4,565</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_ClassesOfProvisionsAxis_rdhl_ProductReturnsMember_HT0SSNr17UuTj9RHXWQHKg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseInExistingProvisionsOtherProvisions" scale="3" id="Tc_6-GH7g2Zy0y-LzlBgJnmRQ_4_4">103</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseInExistingProvisionsOtherProvisions" scale="3" id="Tc_GMsNOK6d4UuQCkJkffjUTw_4_6">4,668</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:34.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Decreases (utilized) </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_ClassesOfProvisionsAxis_rdhl_RebatesAndPatientDiscountProgramsMember_qttEPmHMoE6w_c5KccwpGw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProvisionUsedOtherProvisions" scale="3" id="Tc_k2DupS-o50mzcATmbN3OUQ_5_2">3,184</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_ClassesOfProvisionsAxis_rdhl_ProductReturnsMember_HT0SSNr17UuTj9RHXWQHKg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProvisionUsedOtherProvisions" scale="3" id="Tc_wae0lohNK0-nbxWSxFy35A_5_4">518</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProvisionUsedOtherProvisions" scale="3" id="Tc_h-skB1lX2kyPM2wzBefKRw_5_6">3,702</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:34.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Adjustments </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_ClassesOfProvisionsAxis_rdhl_RebatesAndPatientDiscountProgramsMember_qttEPmHMoE6w_c5KccwpGw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions" scale="3" id="Tc_jsIFodPvT0yC0WoJ1GWO0Q_6_2">423</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_ClassesOfProvisionsAxis_rdhl_ProductReturnsMember_HT0SSNr17UuTj9RHXWQHKg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions" scale="3" id="Tc_U0Kqc2MD6U2KgamdPrpY9w_6_4">408</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions" scale="3" id="Tc_yhmEqRtHl0CZJ1fyxOEymw_6_6">831</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:34.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">As of June  30, 2024</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_6_30_2024_ifrs-full_ClassesOfProvisionsAxis_rdhl_RebatesAndPatientDiscountProgramsMember_CqyXkqtSmEKb7iUSQ8eaSw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentRefundsProvision" scale="3" id="Tc_zPuvZ4yBgkiRC0TiMqLDvg_7_2">9,891</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_6_30_2024_ifrs-full_ClassesOfProvisionsAxis_rdhl_ProductReturnsMember_QRm2PIhBJEeuckWrAEejMg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentRefundsProvision" scale="3" id="Tc_DllGplNVeECtRYb1IEqp_Q_7_4">2,560</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_6_30_2024_lm1Lh8C52kquuyx0qsrPDw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentRefundsProvision" scale="3" id="Tc_y9JEXSGLJk-gjScLjxfkPQ_7_6">12,451</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:34.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:18.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Rebates and patient discount programs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Product returns</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:34.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:middle;width:60.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">U.S.&#160;dollars&#160;in&#160;thousands</b></p></td></tr><tr><td style="vertical-align:bottom;width:34.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As of January 1, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_12_31_2022_ifrs-full_ClassesOfProvisionsAxis_rdhl_RebatesAndPatientDiscountProgramsMember_vf1AdzJz3Uqw4ZUCrYrNWQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentRefundsProvision" scale="3" id="Tc_ZvMhALAymUaS0izKJx09pw_10_2">46,636</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_12_31_2022_ifrs-full_ClassesOfProvisionsAxis_rdhl_ProductReturnsMember_8Uz3eWP1LEa7NOwt5dXb2Q" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentRefundsProvision" scale="3" id="Tc_l9mSbSyWxUe4qos1ctZm1A_10_4">1,234</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_12_31_2022_jV2f_7krOUScpr2kI0mJcw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentRefundsProvision" scale="3" id="Tc_B7XJzGEan0exzl5sTJi_iA_10_6">47,870</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:34.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Increases </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ClassesOfProvisionsAxis_rdhl_RebatesAndPatientDiscountProgramsMember__3ztoVhkKk2SJ4D3UbPO_A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseInExistingProvisionsOtherProvisions" scale="3" id="Tc_JqPgpDtBQU6P2sutoMdccQ_11_2">16,918</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ClassesOfProvisionsAxis_rdhl_ProductReturnsMember_9x6Pj5KuWkWJDcCsTqsLnA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseInExistingProvisionsOtherProvisions" scale="3" id="Tc_gQ75efZWqkypjtHMA7z0qQ_11_4">759</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseInExistingProvisionsOtherProvisions" scale="3" id="Tc_95XguOJMuEyllC_gYoUdGA_11_6">17,677</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:34.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Decreases (utilized) </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ClassesOfProvisionsAxis_rdhl_RebatesAndPatientDiscountProgramsMember__3ztoVhkKk2SJ4D3UbPO_A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProvisionUsedOtherProvisions" scale="3" id="Tc_hHSMbEUCckC_NE6D2b4QgQ_12_2">48,598</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ClassesOfProvisionsAxis_rdhl_ProductReturnsMember_9x6Pj5KuWkWJDcCsTqsLnA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProvisionUsedOtherProvisions" scale="3" id="Tc_1w75DpHiVEC8MCpp1GbSpg_12_4">1,072</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProvisionUsedOtherProvisions" scale="3" id="Tc_gA9KpdGsRkKQQDEDnsKC4A_12_6">49,670</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:34.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Adjustments </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ClassesOfProvisionsAxis_rdhl_RebatesAndPatientDiscountProgramsMember__3ztoVhkKk2SJ4D3UbPO_A" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions" scale="3" id="Tc_X17vxtV-P02BMorrFkkQJA_13_2">910</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ClassesOfProvisionsAxis_rdhl_ProductReturnsMember_9x6Pj5KuWkWJDcCsTqsLnA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions" sign="-" scale="3" id="Tc_9n1Q7Q9qc0q8F7KSffJshw_13_4">403</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions" scale="3" id="Tc_gRbi5y3BBUK7Cl1aSaCobA_13_6">507</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:34.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As of June 30, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_6_30_2023_ifrs-full_ClassesOfProvisionsAxis_rdhl_RebatesAndPatientDiscountProgramsMember_LALfYhyhQ0qxyfiZPt60JA" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentRefundsProvision" scale="3" id="Tc_8lsbXn4cyEGQAESIuA--Mg_14_2">15,866</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_6_30_2023_ifrs-full_ClassesOfProvisionsAxis_rdhl_ProductReturnsMember_P7rAd3_jxEamZoSwvrmIKw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentRefundsProvision" scale="3" id="Tc_b6im4AHctUOGF6S9sutXkw_14_4">518</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_6_30_2023_XZFu_w7MpEqlzzSlD3xkQg" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:CurrentRefundsProvision" scale="3" id="Tc_yD-0HD3UVEGwU9VheWVXVA_14_6">16,384</ix:nonFraction></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="direction:rtl;font-size:8pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" name="ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory" id="Tb_-iLR6uo0B0ConMWEyIJbQA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">NOTE </b><b style="direction:rtl;font-weight:bold;">5</b><b style="font-weight:bold;"> - SHARE-BASED PAYMENTS:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="direction:rtl;font-weight:bold;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:67.7pt;margin-top:0pt;padding-left:18pt;text-align:justify;text-indent:-18pt;"><span style="display:inline-block;min-width:17.35pt;text-indent:0pt;white-space:nowrap;">1.</span>On June 24, 2024, the BoD granted <ix:nonFraction unitRef="Unit_Standard_shares_XGdimIWcf0OdGjo7fryoGw" contextRef="Duration_6_24_2024_To_6_24_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_rdhl_IfrsRestrictedStockUnitsRsuMember_sjZ0svU9fUaW52OaNR-8sQ" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" scale="0" id="Narr_CKAitcYfwE6j1XFRvUIPug">1,044,000</ix:nonFraction> RSUs to employees and consultants. These RSUs will vest in <ix:nonFraction unitRef="Unit_Standard_installment_wykoJbCfrk-_WeAKgSm6lA" contextRef="Duration_6_24_2024_To_6_24_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_rdhl_IfrsRestrictedStockUnitsRsuMember_sjZ0svU9fUaW52OaNR-8sQ" decimals="INF" format="ixt:numdotdecimal" name="rdhl:NumberOfRsuQuarterlyInstallments" scale="0" id="Narr_OeIU97JIQkud_AmGx7vGMQ">8</ix:nonFraction> equal quarterly installments over two years and had a fair value of $<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_6_24_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_rdhl_IfrsRestrictedStockUnitsRsuMember_w7Isi7m0tka2iRJ24DO5Fw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" scale="6" id="Narr_7aByrOmYtE2ZajmwCAi2rw">0.4</ix:nonFraction> million on the grant date, based on the ADS price on that date. In addition, the BoD approved the grant of <ix:nonFraction unitRef="Unit_Standard_shares_XGdimIWcf0OdGjo7fryoGw" contextRef="Duration_6_24_2024_To_6_24_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_rdhl_DirectorsAndChiefExecutiveOfficerMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_rdhl_IfrsRestrictedStockUnitsRsuMember_HlO_DU02TUiIerX8stVCzQ" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted" scale="0" id="Narr_oUu5hAtT2E6uObUQvEkqmg">383,000</ix:nonFraction> RSUs for directors and the Company's Chief Executive Officer in the same terms, subject to Annual General Meeting approval. The fair value of these RSUs on the date of approval was $<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_6_24_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_rdhl_DirectorsAndChiefExecutiveOfficerMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_rdhl_IfrsRestrictedStockUnitsRsuMember_o4Du92Jem0mmcqx2GDZY1g" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" scale="6" id="Narr_uMfTyEbTVk-nJ13AEHNKRQ">0.1</ix:nonFraction> million.</div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 144pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:67.7pt;margin-top:0pt;padding-left:18pt;text-align:justify;text-indent:-18pt;"><span style="display:inline-block;min-width:17.35pt;text-indent:0pt;white-space:nowrap;">2.</span>During the six months ended June 30, 2024, approximately <ix:nonFraction unitRef="Unit_Standard_shares_XGdimIWcf0OdGjo7fryoGw" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_rdhl_IfrsRestrictedStockUnitsRsuMember_5fNRhXT34kedMYDPV9PNfA" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" scale="0" id="Narr_Zu7-Sz2Ss0m70fjsEatL9g">24,000</ix:nonFraction> <span style="-sec-ix-hidden:Hidden_nMtd2n9yDkm_DmI_AXUlBw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">options</span></span> and RSUs were forfeited, mainly due to a reduction in the number of employees, leading to an expense reversal of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" decimals="0" format="ixt:numdotdecimal" name="rdhl:ReversedExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" scale="6" id="Narr_-f8pLl2e30aO3PChb66NNQ">0.3</ix:nonFraction> million<span style="direction:rtl;font-size:8pt;">.</span></div></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 36.15pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 85.7pt;"><span style="direction:rtl;font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><a id="Tc_yothLMe0TkuqDq2bBoCwUg_1_2"></a><a id="Tc_nMI9Dgn75EugPgfGQTLZ5Q_2_2"></a><a id="Tc_DlR16wbCbkOi42WOAGGV-w_2_4"></a><a id="Tc_aFKfO_4AdE2fT-O-8hgsKQ_3_2"></a><a id="Tc_Lu57WdDo5EWLgggQjZmQYw_4_0"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" name="ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory" id="Tb_nyLD3DioDEW614rNObd87w" continuedAt="Tb_nyLD3DioDEW614rNObd87w_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 4.55pt;"><b style="font-size:10pt;font-weight:bold;">NOTE </b><b style="direction:rtl;font-size:10pt;font-weight:bold;">6</b><b style="font-size:10pt;font-weight:bold;"> - NET REVENUES:</b><b style="font-weight:bold;"> </b></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" name="ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" id="Tb_2AO-NEJKs0iue3d1B6nMkw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 4.55pt;"><span style="font-size:8pt;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:66.6pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:85.5%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:16.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:20.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:40.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six Months Ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:16.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;width:3.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:20.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="5" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:55.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:40.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">U.S&#160;dollars&#160;in&#160;thousands</b></p></td></tr><tr><td style="vertical-align:top;width:55.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sales of products </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Revenue" scale="3" id="Tc_c56NTAkfuUGNfrhDdEtVgg_4_2">2,572</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Revenue" scale="3" id="Tc_svEtfsk2lkal3divcNEbXw_4_4">5,395</ix:nonFraction></p></td></tr></table></div></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 67.7pt;">During the six months ended June 30, 2024, and June 30, 2023, the Company recorded contra-revenues of ($<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_ProductsAndServicesAxis_rdhl_MovantikMember_vMAuogPiaUK-988AAqqd3A" decimals="0" format="ixt:numdotdecimal" name="rdhl:ContraRevenueForMovantik" scale="6" id="Narr_CksLgnQsJkK0FtJ96MhkNg">0.9</ix:nonFraction>) million and ($<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ProductsAndServicesAxis_rdhl_MovantikMember_NxqJvzQaaEK6GKQWpIqWZw" decimals="0" format="ixt:numdotdecimal" name="rdhl:ContraRevenueForMovantik" scale="6" id="Narr_RwYW4BEP-0Cn46VIq_PWNA">0.2</ix:nonFraction>) million for Movantik&#174;, respectively, primarily due to returns following its divestiture on February 1, 2023 (see note 15(6) in the annual financial statements as of December 31, 2023). Correspondingly, net revenues from other products (mainly Talicia&#174;) were $<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_ProductsAndServicesAxis_rdhl_TaliciaMember_K2Ipuy8Jc065NyMxnj96Og" decimals="0" format="ixt:numdotdecimal" name="rdhl:NetRevenue" scale="6" id="Narr_-wmnfpPpuE-D-EufjuwBEg">3.5</ix:nonFraction> million in the first half of 2024, including $<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_CounterpartiesAxis_rdhl_GaelanMedicalTradeLlcMember_ifrs-full_ProductsAndServicesAxis_rdhl_TaliciaMember_0Cf0K8YIskWI-fe7fzrpxQ" decimals="0" format="ixt:numdotdecimal" name="rdhl:NetRevenue" scale="6" id="Narr_v5kEhQdKkkKHWkP0JnKNFQ">0.5</ix:nonFraction></p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:17.85pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.35%;border:0;margin:30pt 10.33% 30pt 10.33%;"></div><div style="max-width:100%;padding-left:10.33%;padding-right:10.33%;position:relative;"><div style="margin-top:21.6pt;min-height:40.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="display:inline-block;width:167.25pt;"></span><span style="color:#0563c1;font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="color:#0563c1;font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">REDHILL BIOPHARMA LTD.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="color:#0563c1;font-size:10pt;text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_nyLD3DioDEW614rNObd87w_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 67.7pt;"> million from sales to Gaelan Medical Trade LLC, which has an exclusive license for Talicia&#174; in the UAE (see note 15(7) in the annual financial statements as of December 31, 2023). In the first half of 2023, net revenues from other products (mainly Talicia&#174;) were $<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ProductsAndServicesAxis_rdhl_TaliciaMember_bJeEtRwXpUOUmdyfShRWow" decimals="0" format="ixt:numdotdecimal" name="rdhl:NetRevenue" scale="6" id="Narr_avWYk9V2t0mxOKJyFI-sWw">5.6</ix:nonFraction> million, all from U.S. sales<span style="direction:rtl;">.</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="direction:rtl;font-size:8pt;visibility:hidden;">&#8203;</span></p><a id="Tc_fpijgWqjSEySomBj9L7qXw_1_1"></a><a id="Tc_FhNzl5mCVkixfzR54vHhTA_2_1"></a><a id="Tc_RaQj3gwsnkalQyYvYxNs8g_3_1"></a><a id="Tc_EZwxsFpJSUGwb-Hixj_7-Q_3_3"></a><a id="Tc_C3aOyMjN0UG-DzwWHCh_Og_4_1"></a><a id="Tc_vg7RXXkavEGe1ZyAiARCfA_5_0"></a><a id="Tc_GtSf4lkxsEKruPTXBjgQ3w_6_0"></a><a id="Tc_go1NJiLJTEWBySIcouNyxQ_7_0"></a><a id="Tc_bPrEwjBVsUKOTOq8srGqaw_7_3"></a><a id="Tc_ZPPjxLKh_keGHyNNH_U_-Q_8_0"></a><a id="Tc_nh2YYJ2FEkiSvMxxtH1VEA_9_0"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" name="ifrs-full:DisclosureOfFinancialInstrumentsExplanatory" id="Tb_HYoVg0ENRESBK2QI1W3ttg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 4.55pt;"><b style="font-weight:bold;">NOTE </b><b style="direction:rtl;font-weight:bold;">7</b><b style="font-weight:bold;"> - FINANCIAL INSTRUMENTS:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 72pt;"><span style="direction:rtl;font-size:8pt;font-weight:bold;margin-bottom:5pt;margin-left:0pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:31.6pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Company&#8217;s derivative financial liability, represented by warrants, is measured at fair value and classified as level 3. Fair value adjustments are recognized in profit or loss as financial income or expenses. The following table presents the change in this level 3 derivative liability for the six months ended June 30, 2024, and June 30, 2023</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">:</span></td></tr></table><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" name="ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory" id="Tb_Syux20ySOUCz8dM5jitteA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 49.6pt;"><span style="font-size:8pt;margin-bottom:5pt;margin-left:0pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:94.1pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:70.28%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:41.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Derivative</b><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">financial&#160;instruments</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:41.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six Months Ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="4" style="padding:0pt;"/></tr><tr><td style="vertical-align:bottom;width:58.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:41.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">U.S.&#160;dollars&#160;in&#160;thousands</b></p></td></tr><tr><td style="vertical-align:top;width:58.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0.05pt 0pt 0.05pt 0pt;">Balance at beginning of the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember_ifrs-full_ClassesOfLiabilitiesAxis_rdhl_FairValueOfWarrantsMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_KpTPdCsFCkCR24LGQXoX_Q" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Liabilities" scale="3" id="Tc_FAabSX24wUuJ8a2PE9JtzA_5_1">741</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_12_31_2022_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember_ifrs-full_ClassesOfLiabilitiesAxis_rdhl_FairValueOfWarrantsMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_Y9wiYGhs4U-MxGWOO7SysA" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:Liabilities" scale="3" id="Tc_POPR3bw-60ywOUCTTNA2lg_5_3">2,623</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:58.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0.05pt 0pt 0.05pt 0pt;">Initial recognition of financial liability </p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember_ifrs-full_ClassesOfLiabilitiesAxis_rdhl_FairValueOfWarrantsMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_XsHFmv9nQky9EyNZwd-RWw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IssuesFairValueMeasurementLiabilities" scale="3" id="Tc_6vQuU5-sfU2e5kepDP8Opw_6_1">9,860</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember_ifrs-full_ClassesOfLiabilitiesAxis_rdhl_FairValueOfWarrantsMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_JUJ1h0rhhUi0IPjIFY9Y2g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IssuesFairValueMeasurementLiabilities" scale="3" id="Tc_m_v_3tYfFU23L8xsp9j2pg_6_3">7,083</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:58.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0.05pt 0pt 0.05pt 0pt;">Initial recognition of unrecognized day 1 loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember_ifrs-full_ClassesOfLiabilitiesAxis_rdhl_FairValueOfWarrantsMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_XsHFmv9nQky9EyNZwd-RWw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:IncreaseDecreaseInFairValueMeasurementLiabilities" sign="-" scale="3" id="Tc_fh8ExVxwUk2feD8aDpWncg_7_1">952</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:58.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0.05pt 0pt 0.05pt 0pt;">Fair value adjustments recognized in profit or loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember_ifrs-full_ClassesOfLiabilitiesAxis_rdhl_FairValueOfWarrantsMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_XsHFmv9nQky9EyNZwd-RWw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" sign="-" scale="3" id="Tc_iAf3AA77hEOzfjBkuqScOA_8_1">7,108</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember_ifrs-full_ClassesOfLiabilitiesAxis_rdhl_FairValueOfWarrantsMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_JUJ1h0rhhUi0IPjIFY9Y2g" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" sign="-" scale="3" id="Tc_H76om1eC4EWSLP22O9VjFg_8_3">8,071</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:58.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at end of the period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_6_30_2024_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember_ifrs-full_ClassesOfLiabilitiesAxis_rdhl_FairValueOfWarrantsMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_bh9izY_nwk2QNVQRdIq8MQ" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Liabilities" scale="3" id="Tc_5CacmIEMrEurR3NjtQoIzA_9_1">2,541</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_6_30_2023_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember_ifrs-full_ClassesOfLiabilitiesAxis_rdhl_FairValueOfWarrantsMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_0zRaQna2fk2MTgU3jRhH5w" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:Liabilities" scale="3" id="Tc_TXxiqn2njUmxv94nOD7XQA_9_3">1,635</ix:nonFraction></p></td></tr></table></div></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 72pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:5pt;margin-left:0pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 49.6pt;">The fair value of the warrants is computed using the Black-Scholes model. As of June 30,2024, it is based on the ADS price on that date and the following key parameters: risk-free interest rate of <ix:nonFraction unitRef="Unit_Standard_pure_yhcnVVwWa0i2EX2hTkNGPA" contextRef="As_Of_6_30_2024_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_UnobservableInputsAxis_ifrs-full_InterestRateMeasurementInputMember_teenRBiuRkGg1uO4tRE-mQ" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="Narr_x6JaRnNtRUKWPDFnU_m1LQ">4.35</ix:nonFraction>%-<ix:nonFraction unitRef="Unit_Standard_pure_yhcnVVwWa0i2EX2hTkNGPA" contextRef="As_Of_6_30_2024_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_UnobservableInputsAxis_ifrs-full_InterestRateMeasurementInputMember_Vcvjf-Um0kSPabpRIwMIwA" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="Narr_OBs_yVvLWkCZkDciWi1Y9Q">4.48</ix:nonFraction>% and volatility of <ix:nonFraction unitRef="Unit_Standard_pure_yhcnVVwWa0i2EX2hTkNGPA" contextRef="As_Of_6_30_2024_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_UnobservableInputsAxis_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_zejd0Q0P70OkmQekwOSjkw" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="Narr_qYh5Febm50OTYOKGfJey1Q">120.5</ix:nonFraction>%-<ix:nonFraction unitRef="Unit_Standard_pure_yhcnVVwWa0i2EX2hTkNGPA" contextRef="As_Of_6_30_2024_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_UnobservableInputsAxis_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_mTVtiUNnuUSkyBFbN8TE6Q" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="Narr_nRiNiuvSqEer7t3T0JxlzA">133.6</ix:nonFraction>%. As of June 30,2023, it is based on the ADS price on that date and the following key parameters: risk-free interest rate of <ix:nonFraction unitRef="Unit_Standard_pure_yhcnVVwWa0i2EX2hTkNGPA" contextRef="As_Of_6_30_2023_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_UnobservableInputsAxis_ifrs-full_InterestRateMeasurementInputMember_oOWejR1pzEKHOWOqEBCqlw" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="Narr_EfxwI1XXP0qOI4DnZe_K6Q">4.17</ix:nonFraction>%-<ix:nonFraction unitRef="Unit_Standard_pure_yhcnVVwWa0i2EX2hTkNGPA" contextRef="As_Of_6_30_2023_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_UnobservableInputsAxis_ifrs-full_InterestRateMeasurementInputMember_41fW1aKaCUmxWkrY4H-2hg" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="Narr_k2bnVLsdM0W_gfWm7DwpUQ">5.47</ix:nonFraction>% and volatility of <ix:nonFraction unitRef="Unit_Standard_pure_yhcnVVwWa0i2EX2hTkNGPA" contextRef="As_Of_6_30_2023_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_UnobservableInputsAxis_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_wfwD34Lnw0G6p7TDXvEZ7A" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="Narr_kbJjbgPwYkKLAyrHPaKRDw">86.6</ix:nonFraction>%-<ix:nonFraction unitRef="Unit_Standard_pure_yhcnVVwWa0i2EX2hTkNGPA" contextRef="As_Of_6_30_2023_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_UnobservableInputsAxis_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_KazBZZXGN0muagfyEB6zqQ" decimals="INF" format="ixt:numdotdecimal" name="ifrs-full:SignificantUnobservableInputLiabilities" scale="0" id="Narr_Rs8i3b-C3UmLwgHx8xfHmA">99.5</ix:nonFraction>%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 89.55pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:5pt;margin-left:0pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:31.75pt;margin-top:0pt;padding-left:18pt;text-align:justify;text-indent:-18pt;"><span style="display:inline-block;font-size:8pt;min-width:10.8pt;text-indent:0pt;white-space:nowrap;">b.</span><span style="white-space:pre-wrap;">  </span>The carrying amount of cash equivalents, bank deposits, restricted cash, receivables, account payables and accrued expenses approximate their fair value due to their short-term characteristics<span style="font-size:8pt;">.</span></div></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 90pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><a id="NOTE7SEGMENTINFORMATION_736670"></a><a id="Tc_wzHYqMlP3kaA2CaD0VQR1g_1_2"></a><a id="Tc_-npHWklE90WkFi_x3rSHaw_2_2"></a><a id="Tc_s7Qc3IbWkUO1PAY62Tb_zQ_2_4"></a><a id="Tc_Nc7Bac8Jv0-I9A7Ag9nv9A_3_2"></a><a id="Tc_Ufu7TRXbXUe2BFYNrzoLvA_4_0"></a><a id="Tc_KWSQDxWMzEapP9N9NjoaHg_5_0"></a><a id="Tc_zKv4wq-VWEuGAfIDnpfNjw_6_0"></a><a id="Tc_rwhgU8dmvEiaCc9whcVf6A_7_0"></a><a id="Tc_FyR__dPZGkyIUZyOdnC1KQ_8_0"></a><a id="Tc_rioVYLDlGUW3noQ3g31aig_9_0"></a><a id="Tc_rltgdqKjFUO7tBMaMAQfyw_10_0"></a><a id="Tc_Lot9oWfnLkGpCI8q3a7gIA_11_0"></a><a id="Tc_1gEWF5mDlke17zsYMspkvg_11_2"></a><a id="Tc_I1ZeBG-8oUKQBIsAkXsBDg_12_0"></a><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" name="ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory" id="Tb_m1dm6O1U_Eana8iHznkBug" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 4.55pt;"><b style="font-weight:bold;">NOTE 8 - SEGMENT INFORMATION: </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 49.6pt;">The Chief Executive Officer is the Company&#8217;s Chief Operating Decision Maker (&#8220;CODM&#8221;). The CODM allocates resources and assesses the Company&#8217;s performance based on the following segmentation: Commercial Operations and Research &amp; Development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 49.6pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 49.6pt;">Adjusted EBITDA represents net loss before depreciation, amortization, and financial income (expenses), adjusted to exclude share-based compensation, gains from early termination of leases, and other income, which includes income from service provided to HCRM and gain from the sale of Movantik&#174;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 49.6pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 49.6pt;">The following table presents segment profitability and a reconciliation to the consolidated net income (loss) and comprehensive income (loss) for the periods indicated:</p><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" name="ifrs-full:DisclosureOfOperatingSegmentsExplanatory" id="Tb_3zz09U1ZhUK4t9FCSXfwmQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 49.65pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:75%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:4.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:18.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:18.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:39.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six Months Ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:18.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;width:0.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:18.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;width:0.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="4" style="vertical-align:bottom;width:39.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">U.S.&#160;dollars&#160;in&#160;thousands</b></p></td></tr><tr><td style="vertical-align:middle;width:56.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Commercial Operations Segment Adjusted EBITDA</p></td><td style="vertical-align:top;white-space:nowrap;width:4.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" decimals="-3" format="ixt:numdotdecimal" name="rdhl:CommercialOperationsSegmentAdjustedEarningsBeforeInterestTaxesDepreciationAndAmortisation" sign="-" scale="3" id="Tc_7NeqacTkO0adXvUMYiFm3Q_4_2">4,681</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw" decimals="-3" format="ixt:numdotdecimal" name="rdhl:CommercialOperationsSegmentAdjustedEarningsBeforeInterestTaxesDepreciationAndAmortisation" sign="-" scale="3" id="Tc_Iaur1kmRSk-spN2-gfuTyg_4_4">11,031</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:56.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Research And Development Adjusted EBITDA</p></td><td style="vertical-align:top;width:4.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" decimals="-3" format="ixt:numdotdecimal" name="rdhl:ResearchAndDevelopmentAdjustedEarningsBeforeInterestTaxesDepreciationAndAmortisation" sign="-" scale="3" id="Tc_XYnLcFYcFEOOc32BKEVwKA_5_2">3,143</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw" decimals="-3" format="ixt:numdotdecimal" name="rdhl:ResearchAndDevelopmentAdjustedEarningsBeforeInterestTaxesDepreciationAndAmortisation" sign="-" scale="3" id="Tc_ySaacoAA90CkgnfC_hgNqA_5_4">5,550</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:56.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Financial income, net</p></td><td style="vertical-align:top;width:4.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinanceIncomeCost" scale="3" id="Tc_MPcFByruxUSVgP9r2i4kyw_6_2">5,360</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:FinanceIncomeCost" scale="3" id="Tc_YrsGrE3RME2zo-We8yY7PQ_6_4">26,330</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:56.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Share-based compensation to employees and service providers</p></td><td style="vertical-align:top;width:4.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="3" id="Tc_vjrHoG5aKkOWZwhEjzRheg_7_2">229</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees" scale="3" id="Tc_-i1dPPY4c0yDcqTVaPxanw_7_4">849</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:56.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Depreciation</p></td><td style="vertical-align:top;width:4.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DepreciationExpense" scale="3" id="Tc_sCKRrvKZZUeJSQE66PVgCw_8_2">402</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:DepreciationExpense" scale="3" id="Tc_GnbgtYYX20KFAw5YvZlGdw_8_4">1,055</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:56.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Amortization of intangible assets</p></td><td style="vertical-align:top;width:4.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" decimals="-3" format="ixt:numdotdecimal" name="rdhl:AmortisationAndImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_3OjfHZTK9E6TXcPLye8_1A_9_2">16</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw" decimals="-3" format="ixt:numdotdecimal" name="rdhl:AmortisationAndImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" scale="3" id="Tc_cQsLVlBoAES8AsnsRcCPIQ_9_4">530</ix:nonFraction>)</p></td><td style="vertical-align:middle;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:56.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Gain from early termination of lease, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" decimals="-3" format="ixt:numdotdecimal" name="rdhl:GainLossOnTerminationOfLeases" scale="3" id="Tc_G-MqpYtDKkW6Kn0amGQtuw_10_2">23</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw" decimals="-3" format="ixt:numdotdecimal" name="rdhl:GainLossOnTerminationOfLeases" scale="3" id="Tc_vzeeio5WpEi7Y0QrftD_yQ_10_4">694</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:56.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Other income </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:MiscellaneousOtherOperatingIncome" scale="3" id="Tc_12GszC-yC02XsQIsLZJngg_11_4">42,993</ix:nonFraction></p></td><td style="vertical-align:middle;white-space:nowrap;width:0.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:56.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Consolidated Comprehensive income (loss) </p></td><td style="vertical-align:top;width:4.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" sign="-" scale="3" id="Tc_7v9xgXmwFkSk2akpVTJ1ew_12_2">3,088</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw" decimals="-3" format="ixt:numdotdecimal" name="ifrs-full:ProfitLoss" scale="3" id="Tc_xHK1kJ9fWEy9RpAsPxNQbw_12_4">51,002</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 49.65pt;"><span style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 49.65pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:17.85pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.35%;border:0;margin:30pt 10.33% 30pt 10.33%;"></div><div style="max-width:100%;padding-left:10.33%;padding-right:10.33%;position:relative;"><div style="margin-top:21.6pt;min-height:40.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="display:inline-block;width:167.25pt;"></span><span style="color:#0563c1;font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;margin:0pt;"><span style="color:#0563c1;font-size:10pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">REDHILL BIOPHARMA LTD.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">NOTES TO THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;">(Unaudited)</p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><span style="color:#0563c1;font-size:10pt;text-decoration-line:none;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" name="ifrs-full:DisclosureOfEarningsPerShareExplanatory" id="Tb_IpMCxmASyEi58xa3Ng0uZw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">NOTE 9 - EARNING (LOSS) PER SHARE:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 49.6pt;">The basic and diluted earnings (loss) per share are the same since the effect of all potentially diluted ordinary shares for all reporting periods is anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw" name="ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory" id="Tb_kC4833ZAMU6oeI1r39ibQA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">NOTE 10 - EVENT SUBSEQUENT TO JUNE 30, 2024: </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 67.6pt;">On July 15, 2024, the Company and RedHill Inc signed a Global Termination Agreement with Movantik Acquisition Co., Valinor Pharma, LLC, and HCR Redhill SPV, LLC, affiliates of HCRM (the &#8220;Global Termination Agreement&#8221;). This agreement terminates the Credit Agreement from February 23, 2020, which was amended on February 2, 2023, as part of the transaction where the rights to Movantik&#174; were sold to HCRM in exchange for extinguishing all debt obligations under the Credit Agreement. The February 2023 agreement had placed a lien Talicia&#174; and Aemcolo&#174; assets and established an escrow account with restricted funds for Movantik&#174; liabilities (for further details, see note 1(a)(2) above and notes 14(a), 15(4), 15(5), and 15(6) to the annual financial statements as of December 31, 2023).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 49.6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 67.6pt;">The Global Termination Agreement terminates all existing credit ties, removing the aforementioned lien and restoring control over the restricted escrow funds. The Company received approximately $<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_7_15_2024_To_7_15_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_rdhl_GlobalTerminationAgreementMember_srt_CounterpartyNameAxis_rdhl_MovantikAcquisitionValinorPharmaLlcHcrRedhillSpvLlcMember_4pd8zpat4UqiB1Cifr2ikA" decimals="0" format="ixt:numdotdecimal" name="rdhl:ProceedsReceivedFollowingGlobalTerminationAgreement" scale="6" id="Narr_mRGLEbtEzk-3mkJEqKnsDw">9.9</ix:nonFraction> million in cash and gained full control over $<ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="As_Of_7_15_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_rdhl_GlobalTerminationAgreementMember_srt_CounterpartyNameAxis_rdhl_MovantikAcquisitionValinorPharmaLlcHcrRedhillSpvLlcMember_ZmyihQPxD0iGrsKP1MNtWw" decimals="0" format="ixt:numdotdecimal" name="ifrs-full:RestrictedCashAndCashEquivalents" scale="6" id="Narr_6KM9kNLh_U-cI1d-v5_HVw">0.7</ix:nonFraction><span style="white-space:pre-wrap;"> million previously held in the restricted account.  Under the Global Termination Agreement, the Company assumed certain liabilities related to Movantik&#174; from the other parties and settled additional liabilities between the parties. This resulted in an increase of approximately $</span><ix:nonFraction unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg" contextRef="Duration_7_15_2024_To_7_15_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_rdhl_GlobalTerminationAgreementMember_srt_CounterpartyNameAxis_rdhl_MovantikAcquisitionValinorPharmaLlcHcrRedhillSpvLlcMember_4pd8zpat4UqiB1Cifr2ikA" decimals="0" format="ixt:numdotdecimal" name="rdhl:IncreaseInLiabilities" scale="6" id="Narr_WImpO6wWjk-xyLKO-8jOww">12.2</ix:nonFraction> million in the Company's future obligations, reflecting these assumed and settled amounts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 67.6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 49.65pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="direction:rtl;font-size:8pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:30pt;min-height:17.85pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.33%;margin-right:10.33%;margin-top:30pt;page-break-after:avoid;width:79.35%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>rdhl-20240630xex99d1001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 rdhl-20240630xex99d1001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !H +<# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#]4**** "B
MBB@ HHK$\9>,=,\!^'+S6]8G,%A:IN=E7<Q]%4=R>PJ9244Y2=DBZ=.=6:A!
M7;T274VS29KXL^+_ /P4(-CIDMMX#\-7,EZXP-0U@!(XO<1*26/U('UKYH\*
M?MN?%WPGJVH7DGB$:R;PEGMM6A$L43=C&HV[,>@X]J\>>;X6,K1=_0_3\M\-
M\]S'#RK\L:=ME)V;^2O;YV/UJ!I:_./X1_\ !1[Q/H=S]E\>:?%XCM)IP?M]
MH%MIK9">?D5=L@'8<'W-?7?P_P#VM?A;\3/$-KH>A>)EEU6Y4F*VN;6: N1U
M4%U"EO8'-==#'4*_PRU[/<\+..#LZR23^LT&XI7YH^]&W>ZV^=CV&BDS2UWG
MQ04444 %%%% !1110 4444 %%%% !1110 4444 %%%&: (YYDMX7DD8)&@+,
MS< "OD#X_P#BN[^)6IBVB,B:):,?)A)XE;_GH1_+VKZ'^(5[-J5LVG0$B#_E
MJP/W_P#9^E>.ZKX3!W?)7S&;59U8^QAMU\S[[ANG2PM58NKK+IY>?J?*FN>"
M <_N_P!*\Y\0?#Y7W?N\-_> YKZ]U?P@#GY/TKA]9\&@[OW=?$RI3IO0_>,O
MX@<;>\?'VI^%KNP9B%,BCVYK+MKFXTZ[BN+>62VN87$D<L9*NC Y!![$5],:
MWX(#!OW?Z5YUX@^'RR;CY6#Z@54:[C\1^B83.Z6(CR5=;G1>%_VW_B[H6LZ=
M<WGBF;5["VD7S;&Z@AVSQC@J6"!LX[YSFOT-^!7[3?A#X_B^BT#[;;7U@B-<
M6M_"L;88?>3#'<N<C/'TK\DM4\*75@Q*J9$'YU1TS5]2T"[$^GWUWIMT,?O;
M69X7X.1RI!ZU]!A,TJ4GJ^:)\CG_  #E&?4.;!1C1JK9Q22W^U%;_F?NON%&
M>*_(JP_;1^,%CJNE7I\7SW"Z?&(A:S1(8+A1U\Y0!O)Q][.?0BNY\2?\%&OB
M?JU];RZ9;:-H=M"RLUO';&?SL=0[.<X/^R ?>O?CF^':N[KY'XO5\*L_A.,8
M.$DUOS62\M5?7R7J?I[G-%?!4?\ P5!82:>K^ -T>U1>N-2PP;^(Q+LP1Z;B
M*](^(_\ P4)\#Z%X T[6/"8_X2'6[]]JZ1/N@:U"D;S.<';Z+C.X\C@&NR./
MPTDVI['RM;@?B&A4ITIX65YNRLTU\VFTOG8^K,XI:_,OQ]_P48\?^(-=TRY\
M-V=GX9TVT=));)@+IKM@/F61V PAYP$"GOG-?4WPG_;I^''CW0-/?7-5A\)Z
M_-,EK+IMZ6*B5C@,D@&TQG^\V,=\5-+,</5DXQE]^ES7,N!<^RO#PQ-:A=2W
M4?><?\5K_>KKN[GT=12*01D<BEKTCX **** "BBB@ /-?!NH^&/$7QP_;R^*
M?@FX^)_COPGX?T?1[*_M;7PSK+6J+(T< 8;6#* =[$X .>]?>5?GI-\;?#OP
M,_X*,_&'5O$D6K2VMYH=A:Q+I&ES7\F_RK=OF6)25& >3QGB@#V__AA^8=/C
M[\9L_P#8SK_\9KAO!_BGXC_LQ?M)^%OAAXN\9ZA\2/ WC1)5TC5M; ^WV-PA
MSY;RC_6 Y4<GG.0%Q@]NW_!1#X5JI;[%XUX&?^10O_\ XW7G7PL\27_[;G[1
M?ASXEVD46B_#?P%YITVTN+R&6_O;R0;?,E@1V, 7' ;!X[Y^4 ^R+[1$D4D"
MN0EL;#4I)([2[M;MT&76WF20K]0I)'XUX'\8DU_]J7]I"?X-VFL:EX?^'?AB
MQBU'Q1-IK-!/J$LA_=6HE'W5(Y/KR<';6IX[_P""?'P\TKPZVI_"VRNOAWXY
MTR,SZ=K&CWDP:251E1.&9A*&(YR,\URU,/"9W4L74I;'H^J>%P<_)^E</K^A
MVEFRK<SP6SORBSRJA;Z!B,_A7'W'[5>J+^QG)\0KC3HAXZAF;0'LBN$.IB3R
M2P7.2-Q#$#WXQ47@?]@CPAJOAN#6?BE:3_$#QQJD2W-_J.KW,Q$$C@$I"@91
M&%SC\*\BKE\7JSZ/#YS4C91W]3RS]HVUOO#^O?#F*TN;BS2^UU8)TA<H)4*$
M[6QU'M7!?&ZTOM(^,GPWTVVNI[>UOYIEG@CD*I*!G&X#@_C6Q\;/A/JGP6^+
M_P *_"MEJ5[JG@6^UU+O38=2G:>;3I0"KP+(W+1D'(STJW^V2]WX.^-GPEOK
M#1+KQ!=Q2W+QZ79<37)Y^5>#S^':N)X%1<$M=)'L0SJHXU)N37O0Z]FKAKG@
MD,6_=_I7B7QL\+MHO@G5+^'=#+"%*R(=I'S =17L&H?&KQM.3N^ /C&/_><?
M_&J\F^.?Q"\2:Y\.-9M;_P"%7B+PY;2(N_4+Y@8H<,#\WR#KTZUXV'R^M3KP
M;2M==5W/T&OQ=2E@:U.$VI.,DM);M=[:'&W'A+4+GPS 8)766>"-Q, 2P/!/
MYCC\:YGQ3-<6=[HR+))%ON=K@$C<,#@^M>U?%'0&L/@587B91FBL1N4X/++W
M%<C\9?"PL=2\&KLVFYOQ'GN>%_QK;#M^TCS;-R_!'TF*SV-7!UH)M3Y:/O<S
M_G73IUOW.1N9'77]-C#$1O;7#,@/!(*X)^E:&:E\1>'IM,\9Z1;*"[/9W+ =
M\;EJ-T:-BKJ58=B*YZK3C!KM^K/TK(:_MJV-?-=>U=O3DB)1GC'8]J**P/K3
MZ4^!W[<OCGX8MHNBZO<1:_X4M6C@>*[BW7,-N" 1'*""2J_=#;AQBOU$T76+
M+Q#I-GJ>G7"75C>0K/!/&<K(C %6'U!K\)Z^_?\ @G;\?Q=V4OPRUJZ'GVX:
MXT9I#RT?62 ?[O+J/0L.PKZ7*\=+G]C5=T]O\C^=O$C@W#QPO]KY;2490^-1
M5KI_:LNJ>_D[]#[HHI!2U]6?S&%%%% !7QG\(N?^"FOQO&2/^*:L.AQ_!;5]
MF5XEHGPB\*^ _P!I#QE\4Y_%JIK/B/3X+"?2;N:".*!8Q& R\A\D1CKZF@#V
MPKGN?S-?$_CS1;+X2_\ !1GX;ZEX>@CT]?'&E7=GJ]M;KY<<[1C*R,%X+<KU
M_N"OL"+QGH$\BQQZYILCL<*JWD9)/L-U<!\3?V?].^)?Q0^'WCO^U[K2M7\(
M7+S0&UBC=;J)P-\3EAD*0.J\\T ?)]K\"_#WQ _;G^+/AWQ3K_BGP_>ZC9VF
ML:5_8FK2:=]KB"[) =O,FTCCTPU>Q:C^P=X!TJPN+R[\??$J&U@C:661_&%Q
MA5 R2?PKO/CW^S-HOQSNM(UVQUW4?!WC?0F;^S/$VB2 3V^?O1NO21#W4X^O
M)KSS7?V3?BS\2M.30?B)^T)?:YX2D(%YIFB^'+;2Y;M!UC>=&8[3W&.: /GS
MXI>!/A_:?L9P>*/A9+K][X2TSQ=#JUU-K8>2XGV2JLLJ%@/D_BW'KS7Z,>&]
M9T_Q?X<TW5["19[*^MH[B&12""K*".1]:S+#X7>%]-^'4?@6WT:VC\*I9FP&
MFA?W?DD8*GUSDDGJ2<U\_P"A_LB_$GX6Q3:/\+/CSJ/A;P<7+6VBZSH5OJYL
MP3RD,LC*53G@8I-7&G;8XS]M_P 4Z8GQM^!'A*)XI-2?Q NH2*K@O''C8,CJ
M 35']JO2!'^UM^SY%M_UEW=<?@U>E6?[!OA\ZOH/B/5O%>M:[XULM736+[Q'
M?K$]Q?LBX6'&,10CLB?K7HOQ/_9[TGXC_%?X?^.KW6;JPN_"<TDEO9Q)&8KD
MN",.6&1U_AK*5*+-XUI1_#\"IJGA8$M\GZ5\T?MM^'19?LX^,I]F-L41SC_I
MHM?=T^A03YR2,^@KS?XW?L\:7\;/AMK/@^]U2[TNWU-%1[JUC1I(]K!N PQV
M[UY/U"U2,UT9] LWO1E3;W31\$?'C0?LW[+&C7.W&Z/3!T]62N>_:3\/"SUO
MX5+MQY^MJG_CJ5]Y>/OV0=$\>_"FQ\#3Z]J%I:VHM0+R&*,RMY!!&01CG'-4
M_B;^Q=H/Q,O_  C=7/B'4K%O#M^+^)8(8F$[ *-K;AP/E[>M<ZR^HG%VV<OQ
M1Z/]N4W"<6]U!?\ @+N? _CSPP(_C?X2M-G^MTJ];&/1EI/$'@!)-Q,7/J!7
MWKKW[%&@:]\0=%\5OXAU*&?3+2>T2V2&(QN)#DDDC.1CM5Z[_8\T*\SNUR_7
M/I#'_A7CU\HQ4E#D6RMNN[/T#)^-\'@:E:4YM<\N;9]DOT/R\U7P?=6+$Q N
MOH>M8$D;1,5=2K#L17ZC7O["7AR\SN\2:FN?2"+_  KG]0_X)P^%-1SO\4ZL
MI]1;P_X5$,KQR^**^]'Z-A_%#)+6K3?_ ("_\C\UZMZ1J][H&J6NHZ;=2V5_
M:R+-!<P.5>-P<A@1T(-?H,?^"8?A;/'C76P/3[-!_A2'_@F%X7_Z'?6O_ 6#
M_"MEE>+6T?Q1WS\2^&:D7"=1M/IR2_R/4_V2OVGK/X\^%5LM3FBM_&>G1@7M
ML,+]H4<">,>A_B ^Z?8BOH*ODCP-_P $^-.^'7BO3?$6A_$#6[34["42Q2"U
M@(/8JPQRI&01W!KZU12% 8Y..3C&:^MPKK>S2KK5?B?RYQ)'*/KTJN2S;I2U
MLTUROMKNNWW#J***[#Y0*\)\$?#_ ,+^+?B[\8;C7/#>D:S<1ZW9QI-J%A#.
MZK_9EJ=H9U) SDX]Z]VKYT\/:WX\TSXR?%^/PKX4T77K)M9LVDGU+77L71_[
M-MOE"+;2Y&,'.1U/'% 'JX^"?P]!R/ OAD$?]0:V_P#B*P-%T>W^&_Q1LM"T
M0/:>'M:L;B<Z4A)M[6XB9#OA4G$:LKL&1<+D*0 <Y@D\6_&CRV\OX<>$M^/E
MW>,9@,^_^@5!\-+O4K_QS=W7CJ%M,\;FT:.UTR, V,5KO!D-I+DF?+>7O=@C
M<+^[0=0#O_!FA66@6NHQV-]]O2>_GN9&#*?+D<@LGR^F._-9GB3XT^!?".IM
MIVK^*M+LK]/];;-<!I(1ZR!<E!R.6P*\]AU._M?!VIZ5I$QM-1UOQ3<:='=(
M.;=7<>9*.1\RH&(]\5Z_X4\)Z3X+T6'2]&LH[*SCYVH/FD8]7=CR[GJ68DD]
M30!;T?6M/\0Z=#?Z7?6VHV,PS%<VDRRQ./564D&H-3\4Z-HVFW.H7^K65E86
MK%)[JXN42*)AU#,3@'GH:X75=(3X<_$'1]4T>#[+I.O77V+5+.WC B,[C]U<
M;1P'+#:Q Y!YS@5SOPO\&?\ "2>.?&.JZ]:)<6&F:[.FD6TV'B#[8R]SM/&_
M/R@D9 !QUH [_P ,?&+P3XRU 6&C>)],O[U@62VCG DD7^\BG!<>ZY%4/BT?
MWG@[_L8+;_T%ZZ#QOX(TOQ[H4NFZG '!^>"X48EMI1]V6)NJNIY!!_2O%O&-
MWK?CCX6^$;&2]:UUL>(H=,N;Y#\QV%U>12IR&9!U'0MF@#U/7/C9X#\-ZI)I
MVI>+-)M+R)MLT3W*DP'TD(R(_P#@1%==8ZA;:I9PW=G<17=K,H>*>!PZ2*>A
M5@<$>XJCX9\+:5X/T2#2=(L8;&PA&U88D !]2?4GJ2>2>M</X1TU_"7Q*\4Z
M%I<<,&DSV4.JVUDGR1PS.SI(%4#"JS)N..Y- '3^+?B=X4\"2PPZ]X@L-,N9
MAF*UGF'GR#GE8QEF'!Y JWX5\<>'_'%D]WX?UFRUB"-MDC6<ZR>6W]UP.5/L
M0#6#X"\-VW@+1S<Z[=61\2:@QFU+4G=5:>0G. [8)1<X4= !@5RWBGQ-X9C^
M-/@S^QM5LY/$=ZUQ:WT5BR2/+:B$N//*YQAE4IN(ZOCO0!ZAJ?BC1]$LKR\U
M#5;*QL[-@MS<7-PD<<!.,!V) 4G<.#ZCUJEHOC_P[XAL/MMAK-G/:^4]QYGF
MA!Y2$AI/FP=@(/S?=XZUYKX-\"6_B#XT^/-=U9(;ZVTS4H4TRTECW+!,;2 R
MSX/RES\JAL94*0,;CG.\=^$H?&_[36AZ9J*>=HB>&GNKRU9<I=E+L>5%)ZH&
M)<H>&*+D$"@#TC0/C-X&\4ZXNCZ3XJTJ_P!2?=Y5O#<J6G SN,7:0#!R4)QB
MK/B[XI^$O =S%:Z]X@L--O)4\R.UFF!F9.?G$8RVWY3\V,<'FD^)OA6S\5^
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MTWR-V&3A1A1V K@_#?P]TOQF^NW<[W-AJUEKMW]DU73IS!=0;EC# ..JGNC
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J'4G YHHH GHHHH **** "BBB@ HHHH **** "BBB@ HHHH **** /__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>5
<FILENAME>rdhl-20240630.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.7.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/29/2024 10:57:41 AM-->
<!--Modified on: 8/29/2024 10:57:41 AM-->
<xsd:schema targetNamespace="http://www.redhillbio.com/20240630" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:country="http://xbrl.sec.gov/country/2023" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:attributeFormDefault="unqualified" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:srt="http://fasb.org/srt/2023" xmlns:srt-types="http://fasb.org/srt-types/2023" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2022-03-31" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:currency="http://xbrl.sec.gov/currency/2023" xmlns:fact-explanatoryFact="http://www.xbrl.org/2009/arcrole/fact-explanatoryFact" xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full" xmlns:srt-roles="http://fasb.org/srt-roles/2023" xmlns:sic="http://xbrl.sec.gov/sic/2023" xmlns:stpr="http://xbrl.sec.gov/stpr/2023" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:naics="http://xbrl.sec.gov/naics/2023" xmlns:dei="http://xbrl.sec.gov/dei/2023" xmlns:exch="http://xbrl.sec.gov/exch/2023" xmlns:us-gaap="http://fasb.org/us-gaap/2023" xmlns:us-roles="http://fasb.org/us-roles/2023" xmlns:us-types="http://fasb.org/us-types/2023" xmlns:rdhl="http://www.redhillbio.com/20240630">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.redhillbio.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveIncomeLoss" id="StatementCondensedConsolidatedInterimStatementsOfComprehensiveIncomeLoss">
        <link:definition>00100 - Statement - CONDENSED CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition" id="StatementCondensedConsolidatedInterimStatementsOfFinancialPosition">
        <link:definition>00200 - Statement - CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" id="StatementCondensedConsolidatedInterimStatementsOfCashFlows">
        <link:definition>00400 - Statement - CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.redhillbio.com/role/DisclosureSegmentInformationDetails" id="DisclosureSegmentInformationDetails">
        <link:definition>40801 - Disclosure - SEGMENT INFORMATION (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.redhillbio.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfChangesInEquity" id="StatementCondensedConsolidatedInterimStatementsOfChangesInEquity">
        <link:definition>00300 - Statement - CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.redhillbio.com/role/DisclosureGeneralDetails" id="DisclosureGeneralDetails">
        <link:definition>40101 - Disclosure - GENERAL (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.redhillbio.com/role/DisclosureBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsAndSignificantAccountingPoliciesDetails" id="DisclosureBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsAndSignificantAccountingPoliciesDetails">
        <link:definition>40201 - Disclosure - BASIS OF PREPARATION OF THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodEquityOfferingsDetails" id="DisclosureSignificantEventsDuringCurrentReportingPeriodEquityOfferingsDetails">
        <link:definition>40301 - Disclosure - SIGNIFICANT EVENTS DURING THE CURRENT REPORTING PERIOD - Equity Offerings (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.redhillbio.com/role/DisclosureAllowanceForDeductionsFromRevenuesDetails" id="DisclosureAllowanceForDeductionsFromRevenuesDetails">
        <link:definition>40401 - Disclosure - ALLOWANCE FOR DEDUCTIONS FROM REVENUES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" id="DisclosureShareBasedPaymentsDetails">
        <link:definition>40501 - Disclosure - SHARE-BASED PAYMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.redhillbio.com/role/DisclosureNetRevenuesDetails" id="DisclosureNetRevenuesDetails">
        <link:definition>40601 - Disclosure - NET REVENUES (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails" id="DisclosureFinancialInstrumentsDetails">
        <link:definition>40701 - Disclosure - FINANCIAL INSTRUMENTS (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.redhillbio.com/role/DisclosureEventSubsequentToJune302024Details" id="DisclosureEventSubsequentToJune302024Details">
        <link:definition>41001 - Disclosure - EVENT SUBSEQUENT TO JUNE 30,2024 (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlowsParenthetical" id="StatementCondensedConsolidatedInterimStatementsOfCashFlowsParenthetical">
        <link:definition>00405 - Statement - CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.redhillbio.com/role/DisclosureGeneral" id="DisclosureGeneral">
        <link:definition>10101 - Disclosure - GENERAL</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.redhillbio.com/role/DisclosureBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsAndSignificantAccountingPolicies" id="DisclosureBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsAndSignificantAccountingPolicies">
        <link:definition>10201 - Disclosure - BASIS OF PREPARATION OF THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriod" id="DisclosureSignificantEventsDuringCurrentReportingPeriod">
        <link:definition>10301 - Disclosure - SIGNIFICANT EVENTS DURING THE CURRENT REPORTING PERIOD</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.redhillbio.com/role/DisclosureAllowanceForDeductionsFromRevenues" id="DisclosureAllowanceForDeductionsFromRevenues">
        <link:definition>10401 - Disclosure - ALLOWANCE FOR DEDUCTIONS FROM REVENUES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.redhillbio.com/role/DisclosureShareBasedPayments" id="DisclosureShareBasedPayments">
        <link:definition>10501 - Disclosure - SHARE-BASED PAYMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.redhillbio.com/role/DisclosureNetRevenues" id="DisclosureNetRevenues">
        <link:definition>10601 - Disclosure - NET REVENUES</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.redhillbio.com/role/DisclosureFinancialInstruments" id="DisclosureFinancialInstruments">
        <link:definition>10701 - Disclosure - FINANCIAL INSTRUMENTS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.redhillbio.com/role/DisclosureSegmentInformation" id="DisclosureSegmentInformation">
        <link:definition>10801 - Disclosure - SEGMENT INFORMATION</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.redhillbio.com/role/DisclosureEarningLossPerShare" id="DisclosureEarningLossPerShare">
        <link:definition>10901 - Disclosure - EARNING (LOSS) PER SHARE</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.redhillbio.com/role/DisclosureEventSubsequentToJune302024" id="DisclosureEventSubsequentToJune302024">
        <link:definition>11001 - Disclosure - EVENT SUBSEQUENT TO JUNE 30, 2024</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.redhillbio.com/role/DisclosureBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsAndSignificantAccountingPoliciesPolicies" id="DisclosureBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsAndSignificantAccountingPoliciesPolicies">
        <link:definition>20202 - Disclosure - BASIS OF PREPARATION OF THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.redhillbio.com/role/DisclosureAllowanceForDeductionsFromRevenuesTables" id="DisclosureAllowanceForDeductionsFromRevenuesTables">
        <link:definition>30403 - Disclosure - ALLOWANCE FOR DEDUCTIONS FROM REVENUES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.redhillbio.com/role/DisclosureNetRevenuesTables" id="DisclosureNetRevenuesTables">
        <link:definition>30603 - Disclosure - NET REVENUES (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.redhillbio.com/role/DisclosureFinancialInstrumentsTables" id="DisclosureFinancialInstrumentsTables">
        <link:definition>30703 - Disclosure - FINANCIAL INSTRUMENTS (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.redhillbio.com/role/DisclosureSegmentInformationTables" id="DisclosureSegmentInformationTables">
        <link:definition>30803 - Disclosure - SEGMENT INFORMATION (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="rdhl-20240630_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="rdhl-20240630_cal.xml" xlink:title="Calculation Links, all" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="rdhl-20240630_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="rdhl-20240630_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://fasb.org/us-roles/2023" schemaLocation="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/dei/2023" schemaLocation="https://xbrl.sec.gov/dei/2023/dei-2023.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2022-03-31" schemaLocation="https://www.xbrl.org/dtr/type/2022-03-31/types.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full" schemaLocation="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd" />
  <xsd:import namespace="http://xbrl.sec.gov/currency/2023" schemaLocation="https://xbrl.sec.gov/currency/2023/currency-2023.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2023" schemaLocation="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd" />
  <xsd:element id="rdhl_CurrentPrepaidExpensesAndReceivables" name="CurrentPrepaidExpensesAndReceivables" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element name="AdjustmentsForRevaluationOfBankDeposits" id="rdhl_AdjustmentsForRevaluationOfBankDeposits" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="credit" xbrli:periodType="duration" />
  <xsd:element name="ChangesInAssetsAndLiabilityItemsAbstract" id="rdhl_ChangesInAssetsAndLiabilityItemsAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="GeneralInformationAbstract" id="rdhl_GeneralInformationAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="SupplementalInformationInterestReceivedInCash" id="rdhl_SupplementalInformationInterestReceivedInCash" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:balance="debit" xbrli:periodType="duration" />
  <xsd:element name="TypeOfArrangementTransactionsAxis" id="rdhl_TypeOfArrangementTransactionsAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="ArrangementsTransactionsMember" id="rdhl_ArrangementsTransactionsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="MilestoneAxis" id="rdhl_MilestoneAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="MilestoneDomain" id="rdhl_MilestoneDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsEmployeeStockOptionMember" id="rdhl_IfrsEmployeeStockOptionMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="WarrantsNumberIssued" id="rdhl_WarrantsNumberIssued" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsClassOfWarrantsOrRightExercisePriceOfWarrantsOrRights" id="rdhl_IfrsClassOfWarrantsOrRightExercisePriceOfWarrantsOrRights" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" />
  <xsd:element id="rdhl_IfrsIncomeStatementLocationAxis" name="IfrsIncomeStatementLocationAxis" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rdhl_IfrsIncomeStatementLocationDomain" name="IfrsIncomeStatementLocationDomain" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rdhl_AdjustmentsForDecreaseIncreaseInAccruedExpenses" name="AdjustmentsForDecreaseIncreaseInAccruedExpenses" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="rdhl_IfrsAccountingPoliciesAbstract" name="IfrsAccountingPoliciesAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rdhl_GeneralTable" name="GeneralTable" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:hypercubeItem" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rdhl_GeneralLineItems" name="GeneralLineItems" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rdhl_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" name="IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" nillable="true" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" abstract="false" />
  <xsd:element id="rdhl_IfrsStatementScenarioAxis" name="IfrsStatementScenarioAxis" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rdhl_IfrsScenarioUnspecifiedDomain" name="IfrsScenarioUnspecifiedDomain" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rdhl_DisclosureOfBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsAbstract" name="DisclosureOfBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rdhl_DisclosureOfBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsTextBlock" name="DisclosureOfBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="rdhl_NoncurrentRoyaltyObligation" name="NoncurrentRoyaltyObligation" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="rdhl_RepaymentOfPayableInRespectOfIntangibleAssetPurchase" name="RepaymentOfPayableInRespectOfIntangibleAssetPurchase" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="rdhl_AcquisitionOfRightOfUseAssetsByMeansOfLeaseLiabilities" name="AcquisitionOfRightOfUseAssetsByMeansOfLeaseLiabilities" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="rdhl_IfrsAwardDateAxis" name="IfrsAwardDateAxis" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rdhl_IfrsAwardDateDomain" name="IfrsAwardDateDomain" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rdhl_IfrsVestingAxis" name="IfrsVestingAxis" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rdhl_IfrsVestingDomain" name="IfrsVestingDomain" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rdhl_IfrsWarrantsAndRightsOutstandingTerm" name="IfrsWarrantsAndRightsOutstandingTerm" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="rdhl_SupplementalInformationInterestPaidInCash" name="SupplementalInformationInterestPaidInCash" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="rdhl_MovantikMember" name="MovantikMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rdhl_SignificantEventsDuringCurrentReportingPeriodAbstract" name="SignificantEventsDuringCurrentReportingPeriodAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rdhl_SignificantEventsDuringCurrentReportingPeriodTextBlock" name="SignificantEventsDuringCurrentReportingPeriodTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="rdhl_SaleOfStockAxis" name="SaleOfStockAxis" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rdhl_SaleOfStockDomain" name="SaleOfStockDomain" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rdhl_IfrsDecreaseInRestrictedCash" name="IfrsDecreaseInRestrictedCash" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="rdhl_AdjustmentsForIncreaseDecreaseInAllowanceForDeductionsFromRevenue" name="AdjustmentsForIncreaseDecreaseInAllowanceForDeductionsFromRevenue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="debit" />
  <xsd:element id="rdhl_TaliciaMember" name="TaliciaMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rdhl_AllowanceForDeductionsFromRevenuesAbstract" name="AllowanceForDeductionsFromRevenuesAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rdhl_AllowanceForDeductionsFromRevenuesDisclosureTextBlock" name="AllowanceForDeductionsFromRevenuesDisclosureTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="rdhl_ScheduleOfMovementOfAllowanceForDeductionsFromRevenuesTableTextBlock" name="ScheduleOfMovementOfAllowanceForDeductionsFromRevenuesTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="rdhl_RebatesAndPatientDiscountProgramsMember" name="RebatesAndPatientDiscountProgramsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rdhl_ProductReturnsMember" name="ProductReturnsMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="rdhl_IfrsWarrantMember" name="IfrsWarrantMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element name="IfrsRestrictedStockUnitsRsuMember" id="rdhl_IfrsRestrictedStockUnitsRsuMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IfrsSharesIssuedPricePerShare" id="rdhl_IfrsSharesIssuedPricePerShare" type="dtr-types:perShareItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="AmortisationAndImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" id="rdhl_AmortisationAndImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="GaelanMedicalTradeLlcMember" id="rdhl_GaelanMedicalTradeLlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ReversedExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" id="rdhl_ReversedExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="StockIssuedDuringPeriodValueRestrictedStockAward" id="rdhl_StockIssuedDuringPeriodValueRestrictedStockAward" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="DecreaseInLeaseLiabilityFromEarlyTerminationOfLease" id="rdhl_DecreaseInLeaseLiabilityFromEarlyTerminationOfLease" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DecreaseInRightOfUseAssetFromEarlyTerminationOfLease" id="rdhl_DecreaseInRightOfUseAssetFromEarlyTerminationOfLease" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="IfrsClassOfWarrantOrRightAxis" id="rdhl_IfrsClassOfWarrantOrRightAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IfrsClassOfWarrantOrRightDomain" id="rdhl_IfrsClassOfWarrantOrRightDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NumberOfOrdinarySharesIssuedInExchangeOfAmericanDepositoryReceipts" id="rdhl_NumberOfOrdinarySharesIssuedInExchangeOfAmericanDepositoryReceipts" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="IfrsSaleOfStockAxis" id="rdhl_IfrsSaleOfStockAxis" type="xbrli:stringItemType" substitutionGroup="xbrldt:dimensionItem" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IfrsSaleOfStockDomain" id="rdhl_IfrsSaleOfStockDomain" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NetRevenue" id="rdhl_NetRevenue" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="DecreaseIncreaseInPayablesInRespectOfIntangibleAssets" id="rdhl_DecreaseIncreaseInPayablesInRespectOfIntangibleAssets" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DecreaseIncreaseInBorrowings" id="rdhl_DecreaseIncreaseInBorrowings" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="GainLossOnTerminationOfLeases" id="rdhl_GainLossOnTerminationOfLeases" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="DecreaseInInventories" id="rdhl_DecreaseInInventories" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="AdjustmentsForGainsFromTransferOfRightsInMovantikAndExtinguishmentOfDebtObligations" id="rdhl_AdjustmentsForGainsFromTransferOfRightsInMovantikAndExtinguishmentOfDebtObligations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="AdjustmentsForGainsFromEarlyTerminationOfLeasesNet" id="rdhl_AdjustmentsForGainsFromEarlyTerminationOfLeasesNet" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="AdjustmentsForLossFromModificationOfWarrantsTermsAsPartOfNewIssuance." id="rdhl_AdjustmentsForLossFromModificationOfWarrantsTermsAsPartOfNewIssuance." type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="AdjustmentForIssuanceCostInRespectOfWarrants" id="rdhl_AdjustmentForIssuanceCostInRespectOfWarrants" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="GainsFromTransferOfRightsInMovantikAndExtinguishmentOfDebtObligations" id="rdhl_GainsFromTransferOfRightsInMovantikAndExtinguishmentOfDebtObligations" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="ContraRevenueForMovantik" id="rdhl_ContraRevenueForMovantik" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="AmericanDepositoryShareMember" id="rdhl_AmericanDepositoryShareMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="FairValueOfWarrantsMember" id="rdhl_FairValueOfWarrantsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="CommercialOperationsSegmentAdjustedEarningsBeforeInterestTaxesDepreciationAndAmortisation" id="rdhl_CommercialOperationsSegmentAdjustedEarningsBeforeInterestTaxesDepreciationAndAmortisation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="ResearchAndDevelopmentAdjustedEarningsBeforeInterestTaxesDepreciationAndAmortisation" id="rdhl_ResearchAndDevelopmentAdjustedEarningsBeforeInterestTaxesDepreciationAndAmortisation" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="MovantikAcquisitionValinorPharmaLlcHcrRedhillSpvLlcMember" id="rdhl_MovantikAcquisitionValinorPharmaLlcHcrRedhillSpvLlcMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="GlobalTerminationAgreementMember" id="rdhl_GlobalTerminationAgreementMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ProceedsReceivedFollowingGlobalTerminationAgreement" id="rdhl_ProceedsReceivedFollowingGlobalTerminationAgreement" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="AuthorisedShareCapital" id="rdhl_AuthorisedShareCapital" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="NumberOfRsuQuarterlyInstallments" id="rdhl_NumberOfRsuQuarterlyInstallments" type="xbrli:integerItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" />
  <xsd:element name="DirectorsAndChiefExecutiveOfficerMember" id="rdhl_DirectorsAndChiefExecutiveOfficerMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="IncreaseInLiabilities" id="rdhl_IncreaseInLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="Ias1AmendmentsMember" id="rdhl_Ias1AmendmentsMember" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="ReclassificationOfWarrantLiability" id="rdhl_ReclassificationOfWarrantLiability" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>6
<FILENAME>rdhl-20240630_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.7.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/29/2024 10:57:41 AM-->
<!--Modified on: 8/29/2024 10:57:41 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="rdhl-20240630.xsd#StatementCondensedConsolidatedInterimStatementsOfComprehensiveIncomeLoss" roleURI="http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveIncomeLoss" />
  <roleRef xlink:type="simple" xlink:href="rdhl-20240630.xsd#StatementCondensedConsolidatedInterimStatementsOfFinancialPosition" roleURI="http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition" />
  <roleRef xlink:type="simple" xlink:href="rdhl-20240630.xsd#StatementCondensedConsolidatedInterimStatementsOfCashFlows" roleURI="http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="rdhl-20240630.xsd#DisclosureSegmentInformationDetails" roleURI="http://www.redhillbio.com/role/DisclosureSegmentInformationDetails" />
  <calculationLink xlink:role="http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveIncomeLoss" xlink:type="extended" xlink:title="00100 - Statement - CONDENSED CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE INCOME (LOSS)">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss" xlink:label="ProfitLoss" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_638605258596754346" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ProfitLoss" xlink:to="ifrs-full_ProfitLossFromOperatingActivities_638605258596754346" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossProfit" xlink:label="ifrs-full_GrossProfit_638605258596754346" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities_638605258596754346" xlink:to="ifrs-full_GrossProfit_638605258596754346" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue_638605258596754346" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_GrossProfit_638605258596754346" xlink:to="ifrs-full_Revenue_638605258596754346" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfSales" xlink:label="ifrs-full_CostOfSales_638605258596754346" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_GrossProfit_638605258596754346" xlink:to="ifrs-full_CostOfSales_638605258596754346" order="2" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_638605258596754346" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities_638605258596754346" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_638605258596754346" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SalesAndMarketingExpense" xlink:label="ifrs-full_SalesAndMarketingExpense_638605258596754346" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities_638605258596754346" xlink:to="ifrs-full_SalesAndMarketingExpense_638605258596754346" order="3" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpense_638605258596764345" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities_638605258596754346" xlink:to="ifrs-full_SellingGeneralAndAdministrativeExpense_638605258596764345" order="4" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherOperatingIncomeExpense" xlink:label="ifrs-full_OtherOperatingIncomeExpense_638605258596764345" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLossFromOperatingActivities_638605258596754346" xlink:to="ifrs-full_OtherOperatingIncomeExpense_638605258596764345" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncomeCost" xlink:label="ifrs-full_FinanceIncomeCost_638605258596764345" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ProfitLoss" xlink:to="ifrs-full_FinanceIncomeCost_638605258596764345" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome" xlink:label="ifrs-full_FinanceIncome_638605258596764345" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinanceIncomeCost_638605258596764345" xlink:to="ifrs-full_FinanceIncome_638605258596764345" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts_638605258596764345" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_FinanceIncomeCost_638605258596764345" xlink:to="ifrs-full_FinanceCosts_638605258596764345" order="2" use="optional" weight="-1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition" xlink:type="extended" xlink:title="00200 - Statement - CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Assets" xlink:label="Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssets" xlink:label="ifrs-full_CurrentAssets_638605258596764345" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="ifrs-full_CurrentAssets_638605258596764345" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents_638605258596764345" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets_638605258596764345" xlink:to="ifrs-full_CashAndCashEquivalents_638605258596764345" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables_638605258596774349" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets_638605258596764345" xlink:to="ifrs-full_TradeAndOtherCurrentReceivables_638605258596774349" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_CurrentPrepaidExpensesAndReceivables" xlink:label="rdhl_CurrentPrepaidExpensesAndReceivables_638605258596774349" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets_638605258596764345" xlink:to="rdhl_CurrentPrepaidExpensesAndReceivables_638605258596774349" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Inventories" xlink:label="ifrs-full_Inventories_638605258596774349" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets_638605258596764345" xlink:to="ifrs-full_Inventories_638605258596774349" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentRestrictedCashAndCashEquivalents" xlink:label="ifrs-full_CurrentRestrictedCashAndCashEquivalents_638605258596774349" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentAssets_638605258596764345" xlink:to="ifrs-full_CurrentRestrictedCashAndCashEquivalents_638605258596774349" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssets" xlink:label="ifrs-full_NoncurrentAssets_638605258596774349" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="Assets" xlink:to="ifrs-full_NoncurrentAssets_638605258596774349" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentRestrictedCashAndCashEquivalents" xlink:label="ifrs-full_NoncurrentRestrictedCashAndCashEquivalents_638605258596774349" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets_638605258596774349" xlink:to="ifrs-full_NoncurrentRestrictedCashAndCashEquivalents_638605258596774349" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="ifrs-full_PropertyPlantAndEquipment_638605258596774349" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets_638605258596774349" xlink:to="ifrs-full_PropertyPlantAndEquipment_638605258596774349" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RightofuseAssets" xlink:label="ifrs-full_RightofuseAssets_638605258596774349" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets_638605258596774349" xlink:to="ifrs-full_RightofuseAssets_638605258596774349" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_638605258596774349" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentAssets_638605258596774349" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill_638605258596774349" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilities" xlink:label="EquityAndLiabilities" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Liabilities" xlink:label="ifrs-full_Liabilities_638605258596784345" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EquityAndLiabilities" xlink:to="ifrs-full_Liabilities_638605258596784345" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilities" xlink:label="ifrs-full_CurrentLiabilities_638605258596784345" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Liabilities_638605258596784345" xlink:to="ifrs-full_CurrentLiabilities_638605258596784345" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_638605258596784345" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities_638605258596784345" xlink:to="ifrs-full_TradeAndOtherCurrentPayables_638605258596784345" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="ifrs-full_CurrentLeaseLiabilities_638605258596784345" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities_638605258596784345" xlink:to="ifrs-full_CurrentLeaseLiabilities_638605258596784345" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:label="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_638605258596784345" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities_638605258596784345" xlink:to="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_638605258596784345" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentRefundsProvision" xlink:label="ifrs-full_CurrentRefundsProvision_638605258596784345" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities_638605258596784345" xlink:to="ifrs-full_CurrentRefundsProvision_638605258596784345" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:label="ifrs-full_CurrentDerivativeFinancialLiabilities_638605258596784345" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CurrentLiabilities_638605258596784345" xlink:to="ifrs-full_CurrentDerivativeFinancialLiabilities_638605258596784345" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="ifrs-full_NoncurrentLiabilities_638605258596794354" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Liabilities_638605258596784345" xlink:to="ifrs-full_NoncurrentLiabilities_638605258596794354" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_638605258596794354" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentLiabilities_638605258596794354" xlink:to="ifrs-full_NoncurrentLeaseLiabilities_638605258596794354" order="1" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_NoncurrentRoyaltyObligation" xlink:label="rdhl_NoncurrentRoyaltyObligation_638605258596794354" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_NoncurrentLiabilities_638605258596794354" xlink:to="rdhl_NoncurrentRoyaltyObligation_638605258596794354" order="2" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity_638605258596794354" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="EquityAndLiabilities" xlink:to="ifrs-full_Equity_638605258596794354" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapital" xlink:label="ifrs-full_IssuedCapital_638605258596794354" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity_638605258596794354" xlink:to="ifrs-full_IssuedCapital_638605258596794354" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharePremium" xlink:label="ifrs-full_SharePremium_638605258596794354" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity_638605258596794354" xlink:to="ifrs-full_SharePremium_638605258596794354" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarnings" xlink:label="ifrs-full_RetainedEarnings_638605258596794354" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_Equity_638605258596794354" xlink:to="ifrs-full_RetainedEarnings_638605258596794354" order="3" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_638605258596804350" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_1" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_638605258596804350" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss_638605258596804350" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638605258596804350" xlink:to="ifrs-full_ProfitLoss_638605258596804350" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" xlink:label="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital_638605258596804350" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638605258596804350" xlink:to="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital_638605258596804350" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_638605258596804350" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital_638605258596804350" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_638605258596804350" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDepreciationExpense" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense_638605258596804350" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital_638605258596804350" xlink:to="ifrs-full_AdjustmentsForDepreciationExpense_638605258596804350" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_AdjustmentsForGainsFromTransferOfRightsInMovantikAndExtinguishmentOfDebtObligations" xlink:label="rdhl_AdjustmentsForGainsFromTransferOfRightsInMovantikAndExtinguishmentOfDebtObligations_638605258596804350" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital_638605258596804350" xlink:to="rdhl_AdjustmentsForGainsFromTransferOfRightsInMovantikAndExtinguishmentOfDebtObligations_638605258596804350" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_AdjustmentForIssuanceCostInRespectOfWarrants" xlink:label="rdhl_AdjustmentForIssuanceCostInRespectOfWarrants_638605258596804350" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital_638605258596804350" xlink:to="rdhl_AdjustmentForIssuanceCostInRespectOfWarrants_638605258596804350" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForAmortisationExpense" xlink:label="ifrs-full_AdjustmentsForAmortisationExpense_638605258596814351" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital_638605258596804350" xlink:to="ifrs-full_AdjustmentsForAmortisationExpense_638605258596814351" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_AdjustmentsForGainsFromEarlyTerminationOfLeasesNet" xlink:label="rdhl_AdjustmentsForGainsFromEarlyTerminationOfLeasesNet_638605258596814351" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital_638605258596804350" xlink:to="rdhl_AdjustmentsForGainsFromEarlyTerminationOfLeasesNet_638605258596814351" order="6" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives" xlink:label="ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives_638605258596814351" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital_638605258596804350" xlink:to="ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives_638605258596814351" order="7" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_AdjustmentsForRevaluationOfBankDeposits" xlink:label="rdhl_AdjustmentsForRevaluationOfBankDeposits_638605258596814351" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital_638605258596804350" xlink:to="rdhl_AdjustmentsForRevaluationOfBankDeposits_638605258596814351" order="8" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_AdjustmentsForLossFromModificationOfWarrantsTermsAsPartOfNewIssuance." xlink:label="rdhl_AdjustmentsForLossFromModificationOfWarrantsTermsAsPartOfNewIssuance._638605258596814351" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital_638605258596804350" xlink:to="rdhl_AdjustmentsForLossFromModificationOfWarrantsTermsAsPartOfNewIssuance._638605258596814351" order="9" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:label="ifrs-full_IncreaseDecreaseInWorkingCapital_638605258596814351" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities_638605258596804350" xlink:to="ifrs-full_IncreaseDecreaseInWorkingCapital_638605258596814351" order="3" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_638605258596814351" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInWorkingCapital_638605258596814351" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_638605258596814351" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_638605258596814351" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInWorkingCapital_638605258596814351" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_638605258596814351" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_638605258596824351" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInWorkingCapital_638605258596814351" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_638605258596824351" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_638605258596824351" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInWorkingCapital_638605258596814351" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_638605258596824351" order="4" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_AdjustmentsForDecreaseIncreaseInAccruedExpenses" xlink:label="rdhl_AdjustmentsForDecreaseIncreaseInAccruedExpenses_638605258596824351" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInWorkingCapital_638605258596814351" xlink:to="rdhl_AdjustmentsForDecreaseIncreaseInAccruedExpenses_638605258596824351" order="5" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_AdjustmentsForIncreaseDecreaseInAllowanceForDeductionsFromRevenue" xlink:label="rdhl_AdjustmentsForIncreaseDecreaseInAllowanceForDeductionsFromRevenue_638605258596824351" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_IncreaseDecreaseInWorkingCapital_638605258596814351" xlink:to="rdhl_AdjustmentsForIncreaseDecreaseInAllowanceForDeductionsFromRevenue_638605258596824351" order="6" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_638605258596824351" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_1" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_638605258596824351" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_638605258596824351" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities_638605258596824351" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_638605258596824351" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_638605258596824351" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_1" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_638605258596824351" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:label="ifrs-full_ProceedsFromIssueOfOrdinaryShares_638605258596834353" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities_638605258596824351" xlink:to="ifrs-full_ProceedsFromIssueOfOrdinaryShares_638605258596834353" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_IfrsDecreaseInRestrictedCash" xlink:label="rdhl_IfrsDecreaseInRestrictedCash_638605258596834353" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities_638605258596824351" xlink:to="rdhl_IfrsDecreaseInRestrictedCash_638605258596834353" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_638605258596834353" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities_638605258596824351" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_638605258596834353" order="3" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_RepaymentOfPayableInRespectOfIntangibleAssetPurchase" xlink:label="rdhl_RepaymentOfPayableInRespectOfIntangibleAssetPurchase_638605258596964335" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities_638605258596824351" xlink:to="rdhl_RepaymentOfPayableInRespectOfIntangibleAssetPurchase_638605258596964335" order="4" use="optional" weight="-1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.redhillbio.com/role/DisclosureSegmentInformationDetails" xlink:type="extended" xlink:title="40801 - Disclosure - SEGMENT INFORMATION (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MiscellaneousOtherOperatingIncome" xlink:label="ifrs-full_MiscellaneousOtherOperatingIncome_638605258596974333" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_MiscellaneousOtherOperatingIncome_638605258596974333" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_CommercialOperationsSegmentAdjustedEarningsBeforeInterestTaxesDepreciationAndAmortisation" xlink:label="rdhl_CommercialOperationsSegmentAdjustedEarningsBeforeInterestTaxesDepreciationAndAmortisation_638605258596974333" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss" xlink:to="rdhl_CommercialOperationsSegmentAdjustedEarningsBeforeInterestTaxesDepreciationAndAmortisation_638605258596974333" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_ResearchAndDevelopmentAdjustedEarningsBeforeInterestTaxesDepreciationAndAmortisation" xlink:label="rdhl_ResearchAndDevelopmentAdjustedEarningsBeforeInterestTaxesDepreciationAndAmortisation_638605258596974333" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss" xlink:to="rdhl_ResearchAndDevelopmentAdjustedEarningsBeforeInterestTaxesDepreciationAndAmortisation_638605258596974333" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncomeCost" xlink:label="ifrs-full_FinanceIncomeCost_638605258596974333" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_FinanceIncomeCost_638605258596974333" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_638605258596974333" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_638605258596974333" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationExpense" xlink:label="ifrs-full_DepreciationExpense_638605258596974333" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_DepreciationExpense_638605258596974333" order="6" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_AmortisationAndImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:label="rdhl_AmortisationAndImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_638605258596984368" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss" xlink:to="rdhl_AmortisationAndImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_638605258596984368" order="7" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_GainLossOnTerminationOfLeases" xlink:label="rdhl_GainLossOnTerminationOfLeases_638605258596984368" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="ifrs-full_ProfitLoss" xlink:to="rdhl_GainLossOnTerminationOfLeases_638605258596984368" order="8" use="optional" weight="1" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>7
<FILENAME>rdhl-20240630_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.7.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/29/2024 10:57:41 AM-->
<!--Modified on: 8/29/2024 10:57:41 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="rdhl-20240630.xsd#StatementCondensedConsolidatedInterimStatementsOfChangesInEquity" roleURI="http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfChangesInEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rdhl-20240630.xsd#DisclosureGeneralDetails" roleURI="http://www.redhillbio.com/role/DisclosureGeneralDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rdhl-20240630.xsd#DisclosureBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsAndSignificantAccountingPoliciesDetails" roleURI="http://www.redhillbio.com/role/DisclosureBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsAndSignificantAccountingPoliciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rdhl-20240630.xsd#DisclosureSignificantEventsDuringCurrentReportingPeriodEquityOfferingsDetails" roleURI="http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodEquityOfferingsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rdhl-20240630.xsd#DisclosureAllowanceForDeductionsFromRevenuesDetails" roleURI="http://www.redhillbio.com/role/DisclosureAllowanceForDeductionsFromRevenuesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rdhl-20240630.xsd#DisclosureShareBasedPaymentsDetails" roleURI="http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rdhl-20240630.xsd#DisclosureNetRevenuesDetails" roleURI="http://www.redhillbio.com/role/DisclosureNetRevenuesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rdhl-20240630.xsd#DisclosureFinancialInstrumentsDetails" roleURI="http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rdhl-20240630.xsd#DisclosureEventSubsequentToJune302024Details" roleURI="http://www.redhillbio.com/role/DisclosureEventSubsequentToJune302024Details" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:roleRef roleURI="http://www.redhillbio.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="rdhl-20240630.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <roleRef xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:definitionLink xlink:role="http://www.redhillbio.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis_1" xlink:title="ifrs-full_ComponentsOfEquityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember_1" xlink:title="ifrs-full_EquityMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_ComponentsOfEquityAxis_1" xlink:to="ifrs-full_EquityMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_ComponentsOfEquityAxis_1 To ifrs-full_EquityMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis" xlink:label="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_1" xlink:title="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipmentMember" xlink:label="ifrs-full_PropertyPlantAndEquipmentMember_1" xlink:title="ifrs-full_PropertyPlantAndEquipmentMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_1" xlink:to="ifrs-full_PropertyPlantAndEquipmentMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_ClassesOfPropertyPlantAndEquipmentAxis_1 To ifrs-full_PropertyPlantAndEquipmentMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="ifrs-full_ProductsAndServicesAxis_1" xlink:title="ifrs-full_ProductsAndServicesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="ifrs-full_ProductsAndServicesMember_1" xlink:title="ifrs-full_ProductsAndServicesMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_ProductsAndServicesAxis_1" xlink:to="ifrs-full_ProductsAndServicesMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_ProductsAndServicesAxis_1 To ifrs-full_ProductsAndServicesMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis_1" xlink:title="ifrs-full_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember_1" xlink:title="ifrs-full_RangesMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_RangeAxis_1" xlink:to="ifrs-full_RangesMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_RangeAxis_1 To ifrs-full_RangesMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InitiallyAppliedIFRSsAxis" xlink:label="ifrs-full_InitiallyAppliedIFRSsAxis_1" xlink:title="ifrs-full_InitiallyAppliedIFRSsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InitiallyAppliedIFRSsMember" xlink:label="ifrs-full_InitiallyAppliedIFRSsMember_1" xlink:title="ifrs-full_InitiallyAppliedIFRSsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_InitiallyAppliedIFRSsAxis_1" xlink:to="ifrs-full_InitiallyAppliedIFRSsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_InitiallyAppliedIFRSsAxis_1 To ifrs-full_InitiallyAppliedIFRSsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsAxis" xlink:label="ifrs-full_ClassesOfAssetsAxis_1" xlink:title="ifrs-full_ClassesOfAssetsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfAssetsMember" xlink:label="ifrs-full_ClassesOfAssetsMember_1" xlink:title="ifrs-full_ClassesOfAssetsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_ClassesOfAssetsAxis_1" xlink:to="ifrs-full_ClassesOfAssetsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_ClassesOfAssetsAxis_1 To ifrs-full_ClassesOfAssetsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsAxis" xlink:label="ifrs-full_UnobservableInputsAxis_1" xlink:title="ifrs-full_UnobservableInputsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsMember" xlink:label="ifrs-full_UnobservableInputsMember_1" xlink:title="ifrs-full_UnobservableInputsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_UnobservableInputsAxis_1" xlink:to="ifrs-full_UnobservableInputsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_UnobservableInputsAxis_1 To ifrs-full_UnobservableInputsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksAxis" xlink:label="ifrs-full_TypesOfRisksAxis_1" xlink:title="ifrs-full_TypesOfRisksAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfRisksMember" xlink:label="ifrs-full_TypesOfRisksMember_1" xlink:title="ifrs-full_TypesOfRisksMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_TypesOfRisksAxis_1" xlink:to="ifrs-full_TypesOfRisksMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_TypesOfRisksAxis_1 To ifrs-full_TypesOfRisksMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfInterestRatesAxis" xlink:label="ifrs-full_TypesOfInterestRatesAxis_1" xlink:title="ifrs-full_TypesOfInterestRatesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRateTypesMember" xlink:label="ifrs-full_InterestRateTypesMember_1" xlink:title="ifrs-full_InterestRateTypesMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_TypesOfInterestRatesAxis_1" xlink:to="ifrs-full_InterestRateTypesMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_TypesOfInterestRatesAxis_1 To ifrs-full_InterestRateTypesMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis_1" xlink:title="ifrs-full_LevelsOfFairValueHierarchyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="ifrs-full_AllLevelsOfFairValueHierarchyMember_1" xlink:title="ifrs-full_AllLevelsOfFairValueHierarchyMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis_1" xlink:to="ifrs-full_AllLevelsOfFairValueHierarchyMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_LevelsOfFairValueHierarchyAxis_1 To ifrs-full_AllLevelsOfFairValueHierarchyMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MeasurementAxis" xlink:label="ifrs-full_MeasurementAxis_1" xlink:title="ifrs-full_MeasurementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="ifrs-full_AggregatedMeasurementMember_1" xlink:title="ifrs-full_AggregatedMeasurementMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_MeasurementAxis_1" xlink:to="ifrs-full_AggregatedMeasurementMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_MeasurementAxis_1 To ifrs-full_AggregatedMeasurementMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfLiabilitiesAxis_1" xlink:title="ifrs-full_ClassesOfLiabilitiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesMember" xlink:label="ifrs-full_LiabilitiesMember_1" xlink:title="ifrs-full_LiabilitiesMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_ClassesOfLiabilitiesAxis_1" xlink:to="ifrs-full_LiabilitiesMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_ClassesOfLiabilitiesAxis_1 To ifrs-full_LiabilitiesMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_1" xlink:title="srt_StatementScenarioAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_1" xlink:title="srt_ScenarioUnspecifiedDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementScenarioAxis_1" xlink:to="srt_ScenarioUnspecifiedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementScenarioAxis_1 To srt_ScenarioUnspecifiedDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialAssetsAxis" xlink:label="ifrs-full_CategoriesOfFinancialAssetsAxis_1" xlink:title="ifrs-full_CategoriesOfFinancialAssetsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialAssetsCategoryMember" xlink:label="ifrs-full_FinancialAssetsCategoryMember_1" xlink:title="ifrs-full_FinancialAssetsCategoryMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_CategoriesOfFinancialAssetsAxis_1" xlink:to="ifrs-full_FinancialAssetsCategoryMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_CategoriesOfFinancialAssetsAxis_1 To ifrs-full_FinancialAssetsCategoryMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAxis_1" xlink:title="ifrs-full_CategoriesOfFinancialLiabilitiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="ifrs-full_FinancialLiabilitiesCategoryMember_1" xlink:title="ifrs-full_FinancialLiabilitiesCategoryMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAxis_1" xlink:to="ifrs-full_FinancialLiabilitiesCategoryMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_CategoriesOfFinancialLiabilitiesAxis_1 To ifrs-full_FinancialLiabilitiesCategoryMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CurrencyAxis" xlink:label="srt_CurrencyAxis_1" xlink:title="srt_CurrencyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/currency/2023/currency-2023.xsd#currency_AllCurrenciesDomain" xlink:label="currency_AllCurrenciesDomain_1" xlink:title="currency_AllCurrenciesDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CurrencyAxis_1" xlink:to="currency_AllCurrenciesDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CurrencyAxis_1 To currency_AllCurrenciesDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MaturityAxis" xlink:label="ifrs-full_MaturityAxis_1" xlink:title="ifrs-full_MaturityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedTimeBandsMember" xlink:label="ifrs-full_AggregatedTimeBandsMember_1" xlink:title="ifrs-full_AggregatedTimeBandsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_MaturityAxis_1" xlink:to="ifrs-full_AggregatedTimeBandsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_MaturityAxis_1 To ifrs-full_AggregatedTimeBandsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis" xlink:label="ifrs-full_CounterpartiesAxis_1" xlink:title="ifrs-full_CounterpartiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember" xlink:label="ifrs-full_CounterpartiesMember_1" xlink:title="ifrs-full_CounterpartiesMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_CounterpartiesAxis_1" xlink:to="ifrs-full_CounterpartiesMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_CounterpartiesAxis_1 To ifrs-full_CounterpartiesMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis" xlink:label="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_1" xlink:title="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CarryingAmountMember" xlink:label="ifrs-full_CarryingAmountMember_1" xlink:title="ifrs-full_CarryingAmountMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_1" xlink:to="ifrs-full_CarryingAmountMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_CarryingAmountAccumulatedDepreciationAmortisationAndImpairmentAndGrossCarryingAmountAxis_1 To ifrs-full_CarryingAmountMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis" xlink:label="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_1" xlink:title="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwillMember" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwillMember_1" xlink:title="ifrs-full_IntangibleAssetsOtherThanGoodwillMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_1" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwillMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_ClassesOfIntangibleAssetsOtherThanGoodwillAxis_1 To ifrs-full_IntangibleAssetsOtherThanGoodwillMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_IfrsIncomeStatementLocationAxis" xlink:label="rdhl_IfrsIncomeStatementLocationAxis_1" xlink:title="rdhl_IfrsIncomeStatementLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_IfrsIncomeStatementLocationDomain" xlink:label="rdhl_IfrsIncomeStatementLocationDomain_1" xlink:title="rdhl_IfrsIncomeStatementLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="rdhl_IfrsIncomeStatementLocationAxis_1" xlink:to="rdhl_IfrsIncomeStatementLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:rdhl_IfrsIncomeStatementLocationAxis_1 To rdhl_IfrsIncomeStatementLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfProvisionsAxis" xlink:label="ifrs-full_ClassesOfProvisionsAxis_1" xlink:title="ifrs-full_ClassesOfProvisionsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherProvisionsMember" xlink:label="ifrs-full_OtherProvisionsMember_1" xlink:title="ifrs-full_OtherProvisionsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_ClassesOfProvisionsAxis_1" xlink:to="ifrs-full_OtherProvisionsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_ClassesOfProvisionsAxis_1 To ifrs-full_OtherProvisionsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameAxis" xlink:label="ifrs-full_BorrowingsByNameAxis_1" xlink:title="ifrs-full_BorrowingsByNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BorrowingsByNameMember" xlink:label="ifrs-full_BorrowingsByNameMember_1" xlink:title="ifrs-full_BorrowingsByNameMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_BorrowingsByNameAxis_1" xlink:to="ifrs-full_BorrowingsByNameMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_BorrowingsByNameAxis_1 To ifrs-full_BorrowingsByNameMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_IfrsStatementScenarioAxis" xlink:label="rdhl_IfrsStatementScenarioAxis_1" xlink:title="rdhl_IfrsStatementScenarioAxis_1" />
    <link:loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_IfrsScenarioUnspecifiedDomain" xlink:label="rdhl_IfrsScenarioUnspecifiedDomain_1" xlink:title="rdhl_IfrsScenarioUnspecifiedDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="rdhl_IfrsStatementScenarioAxis_1" xlink:to="rdhl_IfrsScenarioUnspecifiedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:rdhl_IfrsStatementScenarioAxis_1 To rdhl_IfrsScenarioUnspecifiedDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfOrdinarySharesAxis" xlink:label="ifrs-full_ClassesOfOrdinarySharesAxis_1" xlink:title="ifrs-full_ClassesOfOrdinarySharesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember" xlink:label="ifrs-full_OrdinarySharesMember_1" xlink:title="ifrs-full_OrdinarySharesMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_ClassesOfOrdinarySharesAxis_1" xlink:to="ifrs-full_OrdinarySharesMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_ClassesOfOrdinarySharesAxis_1 To ifrs-full_OrdinarySharesMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_TypeOfArrangementTransactionsAxis" xlink:label="rdhl_TypeOfArrangementTransactionsAxis_1" xlink:title="rdhl_TypeOfArrangementTransactionsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_ArrangementsTransactionsMember" xlink:label="rdhl_ArrangementsTransactionsMember_1" xlink:title="rdhl_ArrangementsTransactionsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="rdhl_TypeOfArrangementTransactionsAxis_1" xlink:to="rdhl_ArrangementsTransactionsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:rdhl_TypeOfArrangementTransactionsAxis_1 To rdhl_ArrangementsTransactionsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_MilestoneAxis" xlink:label="rdhl_MilestoneAxis_1" xlink:title="rdhl_MilestoneAxis_1" />
    <link:loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_MilestoneDomain" xlink:label="rdhl_MilestoneDomain_1" xlink:title="rdhl_MilestoneDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="rdhl_MilestoneAxis_1" xlink:to="rdhl_MilestoneDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:rdhl_MilestoneAxis_1 To rdhl_MilestoneDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_1" xlink:title="srt_CounterpartyNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_1" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CounterpartyNameAxis_1" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CounterpartyNameAxis_1 To srt_RepurchaseAgreementCounterpartyNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis_1" xlink:title="ifrs-full_ClassesOfShareCapitalAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ifrs-full_ClassesOfShareCapitalMember_1" xlink:title="ifrs-full_ClassesOfShareCapitalMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_ClassesOfShareCapitalAxis_1" xlink:to="ifrs-full_ClassesOfShareCapitalMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_ClassesOfShareCapitalAxis_1 To ifrs-full_ClassesOfShareCapitalMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_SaleOfStockAxis" xlink:label="rdhl_SaleOfStockAxis_1" xlink:title="rdhl_SaleOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_SaleOfStockDomain" xlink:label="rdhl_SaleOfStockDomain_1" xlink:title="rdhl_SaleOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="rdhl_SaleOfStockAxis_1" xlink:to="rdhl_SaleOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:rdhl_SaleOfStockAxis_1 To rdhl_SaleOfStockDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasAxis" xlink:label="ifrs-full_GeographicalAreasAxis_1" xlink:title="ifrs-full_GeographicalAreasAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GeographicalAreasMember" xlink:label="ifrs-full_GeographicalAreasMember_1" xlink:title="ifrs-full_GeographicalAreasMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_GeographicalAreasAxis_1" xlink:to="ifrs-full_GeographicalAreasMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_GeographicalAreasAxis_1 To ifrs-full_GeographicalAreasMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_1" xlink:title="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember" xlink:label="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_1" xlink:title="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_1" xlink:to="ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsAxis_1 To ifrs-full_TemporaryDifferenceUnusedTaxLossesAndUnusedTaxCreditsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantInvestmentsInSubsidiariesAxis" xlink:label="ifrs-full_SignificantInvestmentsInSubsidiariesAxis_1" xlink:title="ifrs-full_SignificantInvestmentsInSubsidiariesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSubsidiariesMember" xlink:label="ifrs-full_EntitysTotalForSubsidiariesMember_1" xlink:title="ifrs-full_EntitysTotalForSubsidiariesMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_SignificantInvestmentsInSubsidiariesAxis_1" xlink:to="ifrs-full_EntitysTotalForSubsidiariesMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_SignificantInvestmentsInSubsidiariesAxis_1 To ifrs-full_EntitysTotalForSubsidiariesMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_1" xlink:title="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_1" xlink:title="ifrs-full_SharebasedPaymentArrangementsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_1" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_1 To ifrs-full_SharebasedPaymentArrangementsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsAxis" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsAxis_1" xlink:title="ifrs-full_ClassesOfFinancialInstrumentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfFinancialInstrumentsMember" xlink:label="ifrs-full_ClassesOfFinancialInstrumentsMember_1" xlink:title="ifrs-full_ClassesOfFinancialInstrumentsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_ClassesOfFinancialInstrumentsAxis_1" xlink:to="ifrs-full_ClassesOfFinancialInstrumentsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_ClassesOfFinancialInstrumentsAxis_1 To ifrs-full_ClassesOfFinancialInstrumentsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis_1" xlink:title="ifrs-full_CategoriesOfRelatedPartiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_1" xlink:title="ifrs-full_EntitysTotalForRelatedPartiesMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis_1" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_CategoriesOfRelatedPartiesAxis_1 To ifrs-full_EntitysTotalForRelatedPartiesMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_1" xlink:title="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="ifrs-full_NonadjustingEventsMember_1" xlink:title="ifrs-full_NonadjustingEventsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_1" xlink:to="ifrs-full_NonadjustingEventsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_1 To ifrs-full_NonadjustingEventsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_IfrsAwardDateAxis" xlink:label="rdhl_IfrsAwardDateAxis_1" xlink:title="rdhl_IfrsAwardDateAxis_1" />
    <link:loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_IfrsAwardDateDomain" xlink:label="rdhl_IfrsAwardDateDomain_1" xlink:title="rdhl_IfrsAwardDateDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="rdhl_IfrsAwardDateAxis_1" xlink:to="rdhl_IfrsAwardDateDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:rdhl_IfrsAwardDateAxis_1 To rdhl_IfrsAwardDateDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_IfrsVestingAxis" xlink:label="rdhl_IfrsVestingAxis_1" xlink:title="rdhl_IfrsVestingAxis_1" />
    <link:loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_IfrsVestingDomain" xlink:label="rdhl_IfrsVestingDomain_1" xlink:title="rdhl_IfrsVestingDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="rdhl_IfrsVestingAxis_1" xlink:to="rdhl_IfrsVestingDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:rdhl_IfrsVestingAxis_1 To rdhl_IfrsVestingDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis" xlink:label="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_1" xlink:title="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember" xlink:label="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_1" xlink:title="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_1" xlink:to="ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsAxis_1 To ifrs-full_RangesOfExercisePricesForOutstandingShareOptionsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsAxis" xlink:label="ifrs-full_SegmentsAxis_1" xlink:title="ifrs-full_SegmentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentsMember" xlink:label="ifrs-full_SegmentsMember_1" xlink:title="ifrs-full_SegmentsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_SegmentsAxis_1" xlink:to="ifrs-full_SegmentsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_SegmentsAxis_1 To ifrs-full_SegmentsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersAxis" xlink:label="ifrs-full_MajorCustomersAxis_1" xlink:title="ifrs-full_MajorCustomersAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorCustomersMember" xlink:label="ifrs-full_MajorCustomersMember_1" xlink:title="ifrs-full_MajorCustomersMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_MajorCustomersAxis_1" xlink:to="ifrs-full_MajorCustomersMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_MajorCustomersAxis_1 To ifrs-full_MajorCustomersMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_1" xlink:title="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember" xlink:label="ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_1" xlink:title="ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_1" xlink:to="ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_LiabilitiesArisingFromFinancingActivitiesAxis_1 To ifrs-full_LiabilitiesArisingFromFinancingActivitiesMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HedgedItemsAxis" xlink:label="ifrs-full_HedgedItemsAxis_1" xlink:title="ifrs-full_HedgedItemsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HedgedItemsMember" xlink:label="ifrs-full_HedgedItemsMember_1" xlink:title="ifrs-full_HedgedItemsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_HedgedItemsAxis_1" xlink:to="ifrs-full_HedgedItemsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_HedgedItemsAxis_1 To ifrs-full_HedgedItemsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnderlyingEquityInstrumentAndDepositaryReceiptsAxis" xlink:label="ifrs-full_UnderlyingEquityInstrumentAndDepositaryReceiptsAxis_1" xlink:title="ifrs-full_UnderlyingEquityInstrumentAndDepositaryReceiptsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnderlyingEquityInstrumentMember" xlink:label="ifrs-full_UnderlyingEquityInstrumentMember_1" xlink:title="ifrs-full_UnderlyingEquityInstrumentMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_UnderlyingEquityInstrumentAndDepositaryReceiptsAxis_1" xlink:to="ifrs-full_UnderlyingEquityInstrumentMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_UnderlyingEquityInstrumentAndDepositaryReceiptsAxis_1 To ifrs-full_UnderlyingEquityInstrumentMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SegmentConsolidationItemsAxis" xlink:label="ifrs-full_SegmentConsolidationItemsAxis_1" xlink:title="ifrs-full_SegmentConsolidationItemsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForSegmentConsolidationItemsMember" xlink:label="ifrs-full_EntitysTotalForSegmentConsolidationItemsMember_1" xlink:title="ifrs-full_EntitysTotalForSegmentConsolidationItemsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_SegmentConsolidationItemsAxis_1" xlink:to="ifrs-full_EntitysTotalForSegmentConsolidationItemsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_SegmentConsolidationItemsAxis_1 To ifrs-full_EntitysTotalForSegmentConsolidationItemsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityAddressesAddressTypeAxis" xlink:label="dei_EntityAddressesAddressTypeAxis_1" xlink:title="dei_EntityAddressesAddressTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AddressTypeDomain" xlink:label="dei_AddressTypeDomain_1" xlink:title="dei_AddressTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_EntityAddressesAddressTypeAxis_1" xlink:to="dei_AddressTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_EntityAddressesAddressTypeAxis_1 To dei_AddressTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis" xlink:label="ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_1" xlink:title="ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ValuationTechniquesMember" xlink:label="ifrs-full_ValuationTechniquesMember_1" xlink:title="ifrs-full_ValuationTechniquesMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_1" xlink:to="ifrs-full_ValuationTechniquesMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_ValuationTechniquesUsedInFairValueMeasurementAxis_1 To ifrs-full_ValuationTechniquesMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_IfrsClassOfWarrantOrRightAxis" xlink:label="rdhl_IfrsClassOfWarrantOrRightAxis_1" xlink:title="rdhl_IfrsClassOfWarrantOrRightAxis_1" />
    <link:loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_IfrsClassOfWarrantOrRightDomain" xlink:label="rdhl_IfrsClassOfWarrantOrRightDomain_1" xlink:title="rdhl_IfrsClassOfWarrantOrRightDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="rdhl_IfrsClassOfWarrantOrRightAxis_1" xlink:to="rdhl_IfrsClassOfWarrantOrRightDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:rdhl_IfrsClassOfWarrantOrRightAxis_1 To rdhl_IfrsClassOfWarrantOrRightDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_IfrsSaleOfStockAxis" xlink:label="rdhl_IfrsSaleOfStockAxis_1" xlink:title="rdhl_IfrsSaleOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_IfrsSaleOfStockDomain" xlink:label="rdhl_IfrsSaleOfStockDomain_1" xlink:title="rdhl_IfrsSaleOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="rdhl_IfrsSaleOfStockAxis_1" xlink:to="rdhl_IfrsSaleOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:rdhl_IfrsSaleOfStockAxis_1 To rdhl_IfrsSaleOfStockDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NewIFRSsAxis" xlink:label="ifrs-full_NewIFRSsAxis_1" xlink:title="ifrs-full_NewIFRSsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NewIFRSsMember" xlink:label="ifrs-full_NewIFRSsMember_1" xlink:title="ifrs-full_NewIFRSsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="ifrs-full_NewIFRSsAxis_1" xlink:to="ifrs-full_NewIFRSsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:ifrs-full_NewIFRSsAxis_1 To ifrs-full_NewIFRSsMember_1" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfChangesInEquity" xlink:type="extended" xlink:title="00300 - Statement - CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="ifrs-full_StatementOfChangesInEquityTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember" xlink:label="ifrs-full_IssuedCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_IssuedCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharePremiumMember" xlink:label="ifrs-full_SharePremiumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_SharePremiumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarningsMember" xlink:label="ifrs-full_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_StatementOfChangesInEquityTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_Equity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssueOfEquity" xlink:label="ifrs-full_IssueOfEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_IssueOfEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_StockIssuedDuringPeriodValueRestrictedStockAward" xlink:label="rdhl_StockIssuedDuringPeriodValueRestrictedStockAward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="rdhl_StockIssuedDuringPeriodValueRestrictedStockAward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_ProfitLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.redhillbio.com/role/DisclosureGeneralDetails" xlink:type="extended" xlink:title="40101 - Disclosure - GENERAL (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_GeneralTable" xlink:label="rdhl_GeneralTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="rdhl_GeneralTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="ifrs-full_NonadjustingEventsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:label="ifrs-full_MajorOrdinaryShareTransactionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_NonadjustingEventsMember" xlink:to="ifrs-full_MajorOrdinaryShareTransactionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfOrdinarySharesAxis" xlink:label="ifrs-full_ClassesOfOrdinarySharesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="rdhl_GeneralTable" xlink:to="ifrs-full_ClassesOfOrdinarySharesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember" xlink:label="ifrs-full_OrdinarySharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:to="ifrs-full_OrdinarySharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AdrMember" xlink:label="dei_AdrMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_OrdinarySharesMember" xlink:to="dei_AdrMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_GeneralLineItems" xlink:label="rdhl_GeneralLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="rdhl_GeneralLineItems" xlink:to="rdhl_GeneralTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_NumberOfOrdinarySharesIssuedInExchangeOfAmericanDepositoryReceipts" xlink:label="rdhl_NumberOfOrdinarySharesIssuedInExchangeOfAmericanDepositoryReceipts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="rdhl_GeneralLineItems" xlink:to="rdhl_NumberOfOrdinarySharesIssuedInExchangeOfAmericanDepositoryReceipts" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.redhillbio.com/role/DisclosureBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsAndSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40201 - Disclosure - BASIS OF PREPARATION OF THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsTable" xlink:label="ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NewIFRSsAxis" xlink:label="ifrs-full_NewIFRSsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsTable" xlink:to="ifrs-full_NewIFRSsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NewIFRSsMember" xlink:label="ifrs-full_NewIFRSsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_NewIFRSsAxis" xlink:to="ifrs-full_NewIFRSsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_Ias1AmendmentsMember" xlink:label="rdhl_Ias1AmendmentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_NewIFRSsMember" xlink:to="rdhl_Ias1AmendmentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems" xlink:label="ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems" xlink:to="ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_ReclassificationOfWarrantLiability" xlink:label="rdhl_ReclassificationOfWarrantLiability" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems" xlink:to="rdhl_ReclassificationOfWarrantLiability" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodEquityOfferingsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - SIGNIFICANT EVENTS DURING THE CURRENT REPORTING PERIOD - Equity Offerings (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="ifrs-full_ClassesOfShareCapitalAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ifrs-full_ClassesOfShareCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember" xlink:label="ifrs-full_OrdinarySharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="ifrs-full_OrdinarySharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PreferenceSharesMember" xlink:label="ifrs-full_PreferenceSharesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="ifrs-full_PreferenceSharesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="ifrs-full_ComponentsOfEquityAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_EquityMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_IfrsWarrantMember" xlink:label="rdhl_IfrsWarrantMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_EquityMember" xlink:to="rdhl_IfrsWarrantMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfEquityComponentOfConvertibleInstrumentsMember" xlink:label="ifrs-full_ReserveOfEquityComponentOfConvertibleInstrumentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_ReserveOfEquityComponentOfConvertibleInstrumentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_AmericanDepositoryShareMember" xlink:label="rdhl_AmericanDepositoryShareMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_EquityMember" xlink:to="rdhl_AmericanDepositoryShareMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="ifrs-full_NumberOfSharesIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_NumberOfSharesIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_IfrsClassOfWarrantsOrRightExercisePriceOfWarrantsOrRights" xlink:label="rdhl_IfrsClassOfWarrantsOrRightExercisePriceOfWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="rdhl_IfrsClassOfWarrantsOrRightExercisePriceOfWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_FinanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_IfrsSharesIssuedPricePerShare" xlink:label="rdhl_IfrsSharesIssuedPricePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="rdhl_IfrsSharesIssuedPricePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_ProceedsFromIssuingShares" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_WarrantsNumberIssued" xlink:label="rdhl_WarrantsNumberIssued" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="rdhl_WarrantsNumberIssued" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:label="rdhl_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="rdhl_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_IfrsWarrantsAndRightsOutstandingTerm" xlink:label="rdhl_IfrsWarrantsAndRightsOutstandingTerm" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="rdhl_IfrsWarrantsAndRightsOutstandingTerm" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_NumberOfOrdinarySharesIssuedInExchangeOfAmericanDepositoryReceipts" xlink:label="rdhl_NumberOfOrdinarySharesIssuedInExchangeOfAmericanDepositoryReceipts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="rdhl_NumberOfOrdinarySharesIssuedInExchangeOfAmericanDepositoryReceipts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsForShareIssueCosts" xlink:label="ifrs-full_PaymentsForShareIssueCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_PaymentsForShareIssueCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesAuthorised" xlink:label="ifrs-full_NumberOfSharesAuthorised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_NumberOfSharesAuthorised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParValuePerShare" xlink:label="ifrs-full_ParValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_ParValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_AuthorisedShareCapital" xlink:label="rdhl_AuthorisedShareCapital" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="rdhl_AuthorisedShareCapital" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.redhillbio.com/role/DisclosureAllowanceForDeductionsFromRevenuesDetails" xlink:type="extended" xlink:title="40401 - Disclosure - ALLOWANCE FOR DEDUCTIONS FROM REVENUES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherProvisionsTable" xlink:label="ifrs-full_DisclosureOfOtherProvisionsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfProvisionsAxis" xlink:label="ifrs-full_ClassesOfProvisionsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfOtherProvisionsTable" xlink:to="ifrs-full_ClassesOfProvisionsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherProvisionsMember" xlink:label="ifrs-full_OtherProvisionsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfProvisionsAxis" xlink:to="ifrs-full_OtherProvisionsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_RebatesAndPatientDiscountProgramsMember" xlink:label="rdhl_RebatesAndPatientDiscountProgramsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_OtherProvisionsMember" xlink:to="rdhl_RebatesAndPatientDiscountProgramsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_ProductReturnsMember" xlink:label="rdhl_ProductReturnsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_OtherProvisionsMember" xlink:to="rdhl_ProductReturnsMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:label="ifrs-full_DisclosureOfOtherProvisionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:to="ifrs-full_DisclosureOfOtherProvisionsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentRefundsProvision" xlink:label="ifrs-full_CurrentRefundsProvision" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:to="ifrs-full_CurrentRefundsProvision" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInExistingProvisionsOtherProvisions" xlink:label="ifrs-full_IncreaseDecreaseInExistingProvisionsOtherProvisions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:to="ifrs-full_IncreaseDecreaseInExistingProvisionsOtherProvisions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProvisionUsedOtherProvisions" xlink:label="ifrs-full_ProvisionUsedOtherProvisions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:to="ifrs-full_ProvisionUsedOtherProvisions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions" xlink:label="ifrs-full_IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:to="ifrs-full_IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" xlink:type="extended" xlink:title="40501 - Disclosure - SHARE-BASED PAYMENTS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_IfrsRestrictedStockUnitsRsuMember" xlink:label="rdhl_IfrsRestrictedStockUnitsRsuMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="rdhl_IfrsRestrictedStockUnitsRsuMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_IfrsEmployeeStockOptionMember" xlink:label="rdhl_IfrsEmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="rdhl_IfrsEmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_DirectorsAndChiefExecutiveOfficerMember" xlink:label="rdhl_DirectorsAndChiefExecutiveOfficerMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="rdhl_DirectorsAndChiefExecutiveOfficerMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_NumberOfRsuQuarterlyInstallments" xlink:label="rdhl_NumberOfRsuQuarterlyInstallments" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="rdhl_NumberOfRsuQuarterlyInstallments" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_ReversedExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:label="rdhl_ReversedExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="rdhl_ReversedExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.redhillbio.com/role/DisclosureNetRevenuesDetails" xlink:type="extended" xlink:title="40601 - Disclosure - NET REVENUES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="ifrs-full_ProductsAndServicesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="ifrs-full_ProductsAndServicesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="ifrs-full_ProductsAndServicesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ProductsAndServicesAxis" xlink:to="ifrs-full_ProductsAndServicesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_TaliciaMember" xlink:label="rdhl_TaliciaMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_ProductsAndServicesMember" xlink:to="rdhl_TaliciaMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_MovantikMember" xlink:label="rdhl_MovantikMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_ProductsAndServicesMember" xlink:to="rdhl_MovantikMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis" xlink:label="ifrs-full_CounterpartiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="ifrs-full_CounterpartiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember" xlink:label="ifrs-full_CounterpartiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="ifrs-full_CounterpartiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_GaelanMedicalTradeLlcMember" xlink:label="rdhl_GaelanMedicalTradeLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_CounterpartiesMember" xlink:to="rdhl_GaelanMedicalTradeLlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueAbstract" xlink:label="ifrs-full_RevenueAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ifrs-full_RevenueAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_RevenueAbstract" xlink:to="ifrs-full_Revenue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_ContraRevenueForMovantik" xlink:label="rdhl_ContraRevenueForMovantik" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_RevenueAbstract" xlink:to="rdhl_ContraRevenueForMovantik" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_NetRevenue" xlink:label="rdhl_NetRevenue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_RevenueAbstract" xlink:to="rdhl_NetRevenue" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails" xlink:type="extended" xlink:title="40701 - Disclosure - FINANCIAL INSTRUMENTS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_LevelsOfFairValueHierarchyAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="ifrs-full_AllLevelsOfFairValueHierarchyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="ifrs-full_AllLevelsOfFairValueHierarchyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level3OfFairValueHierarchyMember" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:to="ifrs-full_Level3OfFairValueHierarchyMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MeasurementAxis" xlink:label="ifrs-full_MeasurementAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_MeasurementAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="ifrs-full_AggregatedMeasurementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_MeasurementAxis" xlink:to="ifrs-full_AggregatedMeasurementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AtFairValueMember" xlink:label="ifrs-full_AtFairValueMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_AggregatedMeasurementMember" xlink:to="ifrs-full_AtFairValueMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="ifrs-full_FinancialLiabilitiesCategoryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_FinancialLiabilitiesCategoryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_FinancialLiabilitiesCategoryMember" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfLiabilitiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_ClassesOfLiabilitiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesMember" xlink:label="ifrs-full_LiabilitiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_ClassesOfLiabilitiesAxis" xlink:to="ifrs-full_LiabilitiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_FairValueOfWarrantsMember" xlink:label="rdhl_FairValueOfWarrantsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_LiabilitiesMember" xlink:to="rdhl_FairValueOfWarrantsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsAxis" xlink:label="ifrs-full_UnobservableInputsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="5" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_UnobservableInputsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsMember" xlink:label="ifrs-full_UnobservableInputsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_UnobservableInputsAxis" xlink:to="ifrs-full_UnobservableInputsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRateMeasurementInputMember" xlink:label="ifrs-full_InterestRateMeasurementInputMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_UnobservableInputsMember" xlink:to="ifrs-full_InterestRateMeasurementInputMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember" xlink:label="ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_UnobservableInputsMember" xlink:to="ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="6" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_BottomOfRangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_TopOfRangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Liabilities" xlink:label="ifrs-full_Liabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_Liabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuesFairValueMeasurementLiabilities" xlink:label="ifrs-full_IssuesFairValueMeasurementLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_IssuesFairValueMeasurementLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInFairValueMeasurementLiabilities" xlink:label="ifrs-full_IncreaseDecreaseInFairValueMeasurementLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_IncreaseDecreaseInFairValueMeasurementLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" xlink:label="ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantUnobservableInputLiabilities" xlink:label="ifrs-full_SignificantUnobservableInputLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_SignificantUnobservableInputLiabilities" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.redhillbio.com/role/DisclosureEventSubsequentToJune302024Details" xlink:type="extended" xlink:title="41001 - Disclosure - EVENT SUBSEQUENT TO JUNE 30,2024 (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="ifrs-full_NonadjustingEventsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_GlobalTerminationAgreementMember" xlink:label="rdhl_GlobalTerminationAgreementMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="ifrs-full_NonadjustingEventsMember" xlink:to="rdhl_GlobalTerminationAgreementMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:to="srt_CounterpartyNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_MovantikAcquisitionValinorPharmaLlcHcrRedhillSpvLlcMember" xlink:label="rdhl_MovantikAcquisitionValinorPharmaLlcHcrRedhillSpvLlcMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="rdhl_MovantikAcquisitionValinorPharmaLlcHcrRedhillSpvLlcMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_ProceedsReceivedFollowingGlobalTerminationAgreement" xlink:label="rdhl_ProceedsReceivedFollowingGlobalTerminationAgreement" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="rdhl_ProceedsReceivedFollowingGlobalTerminationAgreement" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RestrictedCashAndCashEquivalents" xlink:label="ifrs-full_RestrictedCashAndCashEquivalents" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="ifrs-full_RestrictedCashAndCashEquivalents" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_IncreaseInLiabilities" xlink:label="rdhl_IncreaseInLiabilities" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="rdhl_IncreaseInLiabilities" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>8
<FILENAME>rdhl-20240630_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.7.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/29/2024 10:57:41 AM-->
<!--Modified on: 8/29/2024 10:57:41 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cover [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationTable" xlink:label="dei_DocumentInformationTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationTable" xlink:to="dei_DocumentInformationTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentInformationLineItems" xlink:label="dei_DocumentInformationLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentInformationLineItems" xlink:to="dei_DocumentInformationLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentInformationLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Information [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="ifrs-full_IncomeStatementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_IncomeStatementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncomeStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONDENSED CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Revenue" xlink:to="ifrs-full_Revenue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Revenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of products</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Revenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NET REVENUES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfSales" xlink:label="ifrs-full_CostOfSales" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CostOfSales" xlink:to="ifrs-full_CostOfSales_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CostOfSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost of sales</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CostOfSales_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">COST OF REVENUES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossProfit" xlink:label="ifrs-full_GrossProfit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GrossProfit" xlink:to="ifrs-full_GrossProfit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GrossProfit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross profit</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_GrossProfit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">GROSS PROFIT</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ResearchAndDevelopmentExpense" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development expenses, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RESEARCH AND DEVELOPMENT EXPENSES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SalesAndMarketingExpense" xlink:label="ifrs-full_SalesAndMarketingExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SalesAndMarketingExpense" xlink:to="ifrs-full_SalesAndMarketingExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SalesAndMarketingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales and marketing expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_SalesAndMarketingExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SELLING AND MARKETING EXPENSES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:to="ifrs-full_SellingGeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Selling, general and administrative expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">GENERAL AND ADMINISTRATIVE EXPENSES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherOperatingIncomeExpense" xlink:label="ifrs-full_OtherOperatingIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherOperatingIncomeExpense" xlink:to="ifrs-full_OtherOperatingIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherOperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other operating income (expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_OtherOperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OTHER INCOME</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="ifrs-full_ProfitLossFromOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLossFromOperatingActivities" xlink:to="ifrs-full_ProfitLossFromOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Profit (loss) from operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OPERATING INCOME (LOSS)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome" xlink:label="ifrs-full_FinanceIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceIncome" xlink:to="ifrs-full_FinanceIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinanceIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinanceIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">FINANCIAL INCOME</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceCosts" xlink:to="ifrs-full_FinanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">FINANCIAL EXPENSES</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_FinanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncomeCost" xlink:label="ifrs-full_FinanceIncomeCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinanceIncomeCost" xlink:to="ifrs-full_FinanceIncomeCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinanceIncomeCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Finance income (cost)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_FinanceIncomeCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial income, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_FinanceIncomeCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">FINANCIAL INCOME, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProfitLoss" xlink:to="ifrs-full_ProfitLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Profit (loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive income (loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">INCOME (LOSS) AND COMPREHENSIVE INCOME (LOSS) FOR THE PERIOD</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Consolidated Comprehensive income (loss)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="ifrs-full_BasicEarningsLossPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BasicEarningsLossPerShare" xlink:to="ifrs-full_BasicEarningsLossPerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BasicEarningsLossPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LOSS PER ORDINARY SHARE, basic (U.S. dollars):</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_BasicEarningsLossPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">EARNINGS (LOSS) PER ORDINARY SHARE, basic (U.S. dollars)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="ifrs-full_DilutedEarningsLossPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DilutedEarningsLossPerShare" xlink:to="ifrs-full_DilutedEarningsLossPerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DilutedEarningsLossPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LOSS PER ORDINARY SHARE, diluted (U.S. dollars):</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DilutedEarningsLossPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">EARNINGS (LOSS) PER ORDINARY SHARE, diluted (U.S. dollars)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageShares" xlink:label="ifrs-full_WeightedAverageShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageShares" xlink:to="ifrs-full_WeightedAverageShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average number of ordinary shares outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_WeightedAverageShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">WEIGHTED AVERAGE OF ORDINARY SHARE, Basic (in thousands)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustedWeightedAverageShares" xlink:label="ifrs-full_AdjustedWeightedAverageShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustedWeightedAverageShares" xlink:to="ifrs-full_AdjustedWeightedAverageShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustedWeightedAverageShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average number of ordinary shares outstanding during the period (in thousands)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_AdjustedWeightedAverageShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">WEIGHTED AVERAGE OF ORDINARY SHARE, diluted (in thousands)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="ifrs-full_CurrentAssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssetsAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CURRENT ASSETS:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashAndCashEquivalents" xlink:to="ifrs-full_CashAndCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents, value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BALANCE OF CASH AND CASH EQUIVALENTS AT THE END OF PERIOD</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentRestrictedCashAndCashEquivalents" xlink:label="ifrs-full_CurrentRestrictedCashAndCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentRestrictedCashAndCashEquivalents" xlink:to="ifrs-full_CurrentRestrictedCashAndCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentRestrictedCashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current restricted cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentRestrictedCashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentReceivables" xlink:to="ifrs-full_TradeAndOtherCurrentReceivables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade and other current receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade receivables</label>
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_CurrentPrepaidExpensesAndReceivables" xlink:label="rdhl_CurrentPrepaidExpensesAndReceivables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rdhl_CurrentPrepaidExpensesAndReceivables" xlink:to="rdhl_CurrentPrepaidExpensesAndReceivables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rdhl_CurrentPrepaidExpensesAndReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised, and the amount of receivables.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rdhl_CurrentPrepaidExpensesAndReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Prepaid Expenses and Receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rdhl_CurrentPrepaidExpensesAndReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other receivables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Inventories" xlink:label="ifrs-full_Inventories" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Inventories" xlink:to="ifrs-full_Inventories_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Inventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_Inventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Inventory</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssets" xlink:label="ifrs-full_CurrentAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAssets" xlink:to="ifrs-full_CurrentAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:label="ifrs-full_NoncurrentAssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssetsAbstract" xlink:to="ifrs-full_NoncurrentAssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current assets [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentAssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NON-CURRENT ASSETS:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentRestrictedCashAndCashEquivalents" xlink:label="ifrs-full_NoncurrentRestrictedCashAndCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentRestrictedCashAndCashEquivalents" xlink:to="ifrs-full_NoncurrentRestrictedCashAndCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentRestrictedCashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current restricted cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentRestrictedCashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="ifrs-full_PropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PropertyPlantAndEquipment" xlink:to="ifrs-full_PropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, plant and equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fixed assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RightofuseAssets" xlink:label="ifrs-full_RightofuseAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RightofuseAssets" xlink:to="ifrs-full_RightofuseAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RightofuseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RightofuseAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible assets other than goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Intangible assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssets" xlink:label="ifrs-full_NoncurrentAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentAssets" xlink:to="ifrs-full_NoncurrentAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_NoncurrentAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total non-current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Assets" xlink:label="ifrs-full_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Assets" xlink:to="ifrs-full_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">TOTAL ASSETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesAbstract" xlink:label="ifrs-full_LiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LiabilitiesAbstract" xlink:to="ifrs-full_LiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_LiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">LIABILITIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="ifrs-full_CurrentLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilitiesAbstract" xlink:to="ifrs-full_CurrentLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CURRENT LIABILITIES:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="ifrs-full_TradeAndOtherCurrentPayables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TradeAndOtherCurrentPayables" xlink:to="ifrs-full_TradeAndOtherCurrentPayables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trade and other current payables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Account payable</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="ifrs-full_CurrentLeaseLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLeaseLiabilities" xlink:to="ifrs-full_CurrentLeaseLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:label="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:to="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current accrued expenses and other current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued expenses and other current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentRefundsProvision" xlink:label="ifrs-full_CurrentRefundsProvision" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentRefundsProvision" xlink:to="ifrs-full_CurrentRefundsProvision_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentRefundsProvision_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current refunds provision</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_CurrentRefundsProvision_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_CurrentRefundsProvision_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at Beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentRefundsProvision_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allowance for deductions from revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:label="ifrs-full_CurrentDerivativeFinancialLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:to="ifrs-full_CurrentDerivativeFinancialLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentDerivativeFinancialLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current derivative financial liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CurrentDerivativeFinancialLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Derivative financial instruments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilities" xlink:label="ifrs-full_CurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CurrentLiabilities" xlink:to="ifrs-full_CurrentLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilitiesAbstract" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current liabilities [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NON-CURRENT LIABILITIES:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="ifrs-full_NoncurrentLeaseLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLeaseLiabilities" xlink:to="ifrs-full_NoncurrentLeaseLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current lease liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liabilities</label>
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_NoncurrentRoyaltyObligation" xlink:label="rdhl_NoncurrentRoyaltyObligation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rdhl_NoncurrentRoyaltyObligation" xlink:to="rdhl_NoncurrentRoyaltyObligation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rdhl_NoncurrentRoyaltyObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of noncurrent royalty obligation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rdhl_NoncurrentRoyaltyObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncurrent Royalty Obligation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rdhl_NoncurrentRoyaltyObligation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Royalty obligation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="ifrs-full_NoncurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NoncurrentLiabilities" xlink:to="ifrs-full_NoncurrentLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NoncurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-current liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_NoncurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total non-current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Liabilities" xlink:label="ifrs-full_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Liabilities" xlink:to="ifrs-full_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the end of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at beginning of the period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">TOTAL LIABILITIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAbstract" xlink:label="ifrs-full_EquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAbstract" xlink:to="ifrs-full_EquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">EQUITY:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapital" xlink:label="ifrs-full_IssuedCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapital" xlink:to="ifrs-full_IssuedCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssuedCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issued capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IssuedCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ordinary shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharePremium" xlink:label="ifrs-full_SharePremium" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharePremium" xlink:to="ifrs-full_SharePremium_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SharePremium_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share premium</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_SharePremium_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarnings" xlink:label="ifrs-full_RetainedEarnings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarnings" xlink:to="ifrs-full_RetainedEarnings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetainedEarnings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained earnings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_RetainedEarnings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Equity" xlink:to="ifrs-full_Equity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_Equity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">TOTAL EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilities" xlink:label="ifrs-full_EquityAndLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityAndLiabilities" xlink:to="ifrs-full_EquityAndLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityAndLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity and liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_EquityAndLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">TOTAL LIABILITIES AND EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="ifrs-full_StatementOfChangesInEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityAbstract" xlink:to="ifrs-full_StatementOfChangesInEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfChangesInEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="ifrs-full_StatementOfChangesInEquityTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityTable" xlink:to="ifrs-full_StatementOfChangesInEquityTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfChangesInEquityTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of changes in equity [table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ComponentsOfEquityAxis" xlink:to="ifrs-full_ComponentsOfEquityAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ComponentsOfEquityAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of equity [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EquityMember" xlink:to="ifrs-full_EquityMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EquityMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity [member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember" xlink:label="ifrs-full_IssuedCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuedCapitalMember" xlink:to="ifrs-full_IssuedCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssuedCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ordinary shares.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharePremiumMember" xlink:label="ifrs-full_SharePremiumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharePremiumMember" xlink:to="ifrs-full_SharePremiumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SharePremiumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarningsMember" xlink:label="ifrs-full_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RetainedEarningsMember" xlink:to="ifrs-full_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems" xlink:to="ifrs-full_StatementOfChangesInEquityLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of changes in equity [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement of changes in equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) through share-based payment transactions, equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation to employees and service providers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssueOfEquity" xlink:label="ifrs-full_IssueOfEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssueOfEquity" xlink:to="ifrs-full_IssueOfEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssueOfEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issue of equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IssueOfEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of ordinary shares, net of expenses</label>
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_StockIssuedDuringPeriodValueRestrictedStockAward" xlink:label="rdhl_StockIssuedDuringPeriodValueRestrictedStockAward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rdhl_StockIssuedDuringPeriodValueRestrictedStockAward" xlink:to="rdhl_StockIssuedDuringPeriodValueRestrictedStockAward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rdhl_StockIssuedDuringPeriodValueRestrictedStockAward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Value of stock related to restricted stock awards issued during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rdhl_StockIssuedDuringPeriodValueRestrictedStockAward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period Value Restricted Stock Award</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rdhl_StockIssuedDuringPeriodValueRestrictedStockAward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of ordinary shares for vested RSUs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="ifrs-full_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_StatementOfCashFlowsAbstract" xlink:to="ifrs-full_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from (used in) operating activities [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">OPERATING ACTIVITIES:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile profit (loss) [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments in respect of income and expenses not involving cash flow:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForSharebasedPayments" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for share-based payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation to employees and service providers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDepreciationExpense" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDepreciationExpense" xlink:to="ifrs-full_AdjustmentsForDepreciationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for depreciation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForAmortisationExpense" xlink:label="ifrs-full_AdjustmentsForAmortisationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForAmortisationExpense" xlink:to="ifrs-full_AdjustmentsForAmortisationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForAmortisationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for amortisation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForAmortisationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of intangible assets</label>
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_AdjustmentsForGainsFromTransferOfRightsInMovantikAndExtinguishmentOfDebtObligations" xlink:label="rdhl_AdjustmentsForGainsFromTransferOfRightsInMovantikAndExtinguishmentOfDebtObligations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rdhl_AdjustmentsForGainsFromTransferOfRightsInMovantikAndExtinguishmentOfDebtObligations" xlink:to="rdhl_AdjustmentsForGainsFromTransferOfRightsInMovantikAndExtinguishmentOfDebtObligations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rdhl_AdjustmentsForGainsFromTransferOfRightsInMovantikAndExtinguishmentOfDebtObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustment for gains from the transfer of rights In movantik And extinguishment of debt obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rdhl_AdjustmentsForGainsFromTransferOfRightsInMovantikAndExtinguishmentOfDebtObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments For Gains From The Transfer Of Rights In Movantik And Extinguishment Of Debt Obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rdhl_AdjustmentsForGainsFromTransferOfRightsInMovantikAndExtinguishmentOfDebtObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gains from the transfer of rights in Movantik and extinguishment of debt obligations, (see below)</label>
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_AdjustmentsForGainsFromEarlyTerminationOfLeasesNet" xlink:label="rdhl_AdjustmentsForGainsFromEarlyTerminationOfLeasesNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rdhl_AdjustmentsForGainsFromEarlyTerminationOfLeasesNet" xlink:to="rdhl_AdjustmentsForGainsFromEarlyTerminationOfLeasesNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rdhl_AdjustmentsForGainsFromEarlyTerminationOfLeasesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustment for gains from early termination of leases, net.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rdhl_AdjustmentsForGainsFromEarlyTerminationOfLeasesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments For Gains From Early Termination Of Leases Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rdhl_AdjustmentsForGainsFromEarlyTerminationOfLeasesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gains from early termination of leases, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives" xlink:label="ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives" xlink:to="ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for gains (losses) on change in fair value of derivatives</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value gains on derivative financial instruments</label>
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_AdjustmentsForLossFromModificationOfWarrantsTermsAsPartOfNewIssuance." xlink:label="rdhl_AdjustmentsForLossFromModificationOfWarrantsTermsAsPartOfNewIssuance." xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rdhl_AdjustmentsForLossFromModificationOfWarrantsTermsAsPartOfNewIssuance." xlink:to="rdhl_AdjustmentsForLossFromModificationOfWarrantsTermsAsPartOfNewIssuance._lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rdhl_AdjustmentsForLossFromModificationOfWarrantsTermsAsPartOfNewIssuance._lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of loss due to from modification of warrants terms as part of a new issuance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rdhl_AdjustmentsForLossFromModificationOfWarrantsTermsAsPartOfNewIssuance._lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments For Loss From Modification Of Warrants Terms As Part Of A New Issuance.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rdhl_AdjustmentsForLossFromModificationOfWarrantsTermsAsPartOfNewIssuance._lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from modification of warrants terms as part of a new issuance, see note 3b</label>
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_AdjustmentForIssuanceCostInRespectOfWarrants" xlink:label="rdhl_AdjustmentForIssuanceCostInRespectOfWarrants" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rdhl_AdjustmentForIssuanceCostInRespectOfWarrants" xlink:to="rdhl_AdjustmentForIssuanceCostInRespectOfWarrants_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rdhl_AdjustmentForIssuanceCostInRespectOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for issuance cost in respect of warrants.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rdhl_AdjustmentForIssuanceCostInRespectOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustment For Issuance Cost In respect Of Warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rdhl_AdjustmentForIssuanceCostInRespectOfWarrants_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance costs in respect of warrants</label>
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_AdjustmentsForRevaluationOfBankDeposits" xlink:label="rdhl_AdjustmentsForRevaluationOfBankDeposits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rdhl_AdjustmentsForRevaluationOfBankDeposits" xlink:to="rdhl_AdjustmentsForRevaluationOfBankDeposits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rdhl_AdjustmentsForRevaluationOfBankDeposits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for revaluation of bank deposits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rdhl_AdjustmentsForRevaluationOfBankDeposits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments For Revaluation Of Bank Deposits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="rdhl_AdjustmentsForRevaluationOfBankDeposits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exchange differences and revaluation of bank deposits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" xlink:label="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" xlink:to="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile profit (loss) other than changes in working capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total adjustments in respect of income and expenses not involving cash flow</label>
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_ChangesInAssetsAndLiabilityItemsAbstract" xlink:label="rdhl_ChangesInAssetsAndLiabilityItemsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rdhl_ChangesInAssetsAndLiabilityItemsAbstract" xlink:to="rdhl_ChangesInAssetsAndLiabilityItemsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rdhl_ChangesInAssetsAndLiabilityItemsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">No definition available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rdhl_ChangesInAssetsAndLiabilityItemsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes In Assets And Liability Items [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rdhl_ChangesInAssetsAndLiabilityItemsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in assets and liability items:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for decrease (increase) in trade accounts receivable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease in trade receivables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for decrease (increase) in other operating receivables</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease (increase) in prepaid expenses and other receivables</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for decrease (increase) in inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease in inventories</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for increase (decrease) in trade accounts payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease in accounts payable</label>
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_AdjustmentsForDecreaseIncreaseInAccruedExpenses" xlink:label="rdhl_AdjustmentsForDecreaseIncreaseInAccruedExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rdhl_AdjustmentsForDecreaseIncreaseInAccruedExpenses" xlink:to="rdhl_AdjustmentsForDecreaseIncreaseInAccruedExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rdhl_AdjustmentsForDecreaseIncreaseInAccruedExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for decrease (increase) in accrued expenses to reconcile profit (loss) to net cash flow from (used in) operating activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rdhl_AdjustmentsForDecreaseIncreaseInAccruedExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for decrease (increase) in accrued expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="rdhl_AdjustmentsForDecreaseIncreaseInAccruedExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease in accrued expenses and other liabilities</label>
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_AdjustmentsForIncreaseDecreaseInAllowanceForDeductionsFromRevenue" xlink:label="rdhl_AdjustmentsForIncreaseDecreaseInAllowanceForDeductionsFromRevenue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rdhl_AdjustmentsForIncreaseDecreaseInAllowanceForDeductionsFromRevenue" xlink:to="rdhl_AdjustmentsForIncreaseDecreaseInAllowanceForDeductionsFromRevenue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rdhl_AdjustmentsForIncreaseDecreaseInAllowanceForDeductionsFromRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for increase (decrease) in allowance for deductions from revenue.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rdhl_AdjustmentsForIncreaseDecreaseInAllowanceForDeductionsFromRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments For Increase Decrease In Allowance For Deductions From Revenue</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rdhl_AdjustmentsForIncreaseDecreaseInAllowanceForDeductionsFromRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) in allowance for deductions from revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:label="ifrs-full_IncreaseDecreaseInWorkingCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:to="ifrs-full_IncreaseDecreaseInWorkingCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseInWorkingCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) in working capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="ifrs-full_IncreaseDecreaseInWorkingCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total changes in assets and liability items</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from (used in) operating activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from (used in) investing activities [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">INVESTING ACTIVITIES:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of property, plant and equipment, classified as investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase of fixed assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from (used in) investing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from (used in) financing activities [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">FINANCING ACTIVITIES:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:label="ifrs-full_ProceedsFromIssueOfOrdinaryShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:to="ifrs-full_ProceedsFromIssueOfOrdinaryShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromIssueOfOrdinaryShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issue of ordinary shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromIssueOfOrdinaryShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of ordinary shares and warrants, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_RepaymentOfPayableInRespectOfIntangibleAssetPurchase" xlink:label="rdhl_RepaymentOfPayableInRespectOfIntangibleAssetPurchase" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rdhl_RepaymentOfPayableInRespectOfIntangibleAssetPurchase" xlink:to="rdhl_RepaymentOfPayableInRespectOfIntangibleAssetPurchase_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rdhl_RepaymentOfPayableInRespectOfIntangibleAssetPurchase_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayment of payable in respect of intangible asset purchase</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rdhl_RepaymentOfPayableInRespectOfIntangibleAssetPurchase_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayment of payable in respect of intangible asset purchase</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="rdhl_RepaymentOfPayableInRespectOfIntangibleAssetPurchase_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayment of payable in respect of intangible asset purchase</label>
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_IfrsDecreaseInRestrictedCash" xlink:label="rdhl_IfrsDecreaseInRestrictedCash" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rdhl_IfrsDecreaseInRestrictedCash" xlink:to="rdhl_IfrsDecreaseInRestrictedCash_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rdhl_IfrsDecreaseInRestrictedCash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of cash inflow associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rdhl_IfrsDecreaseInRestrictedCash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Decrease In Restricted Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rdhl_IfrsDecreaseInRestrictedCash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease in restricted cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of lease liabilities, classified as financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payment of principal with respect to lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from (used in) financing activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) in cash and cash equivalents before effect of exchange rate changes</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effect of exchange rate changes on cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">EXCHANGE DIFFERENCES ON CASH AND CASH EQUIVALENTS</label>
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_SupplementalInformationInterestReceivedInCash" xlink:label="rdhl_SupplementalInformationInterestReceivedInCash" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rdhl_SupplementalInformationInterestReceivedInCash" xlink:to="rdhl_SupplementalInformationInterestReceivedInCash_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rdhl_SupplementalInformationInterestReceivedInCash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental information on interest received in cash.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rdhl_SupplementalInformationInterestReceivedInCash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental Information Interest Received in Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rdhl_SupplementalInformationInterestReceivedInCash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SUPPLEMENTARY INFORMATION ON INTEREST RECEIVED IN CASH</label>
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_SupplementalInformationInterestPaidInCash" xlink:label="rdhl_SupplementalInformationInterestPaidInCash" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rdhl_SupplementalInformationInterestPaidInCash" xlink:to="rdhl_SupplementalInformationInterestPaidInCash_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rdhl_SupplementalInformationInterestPaidInCash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental information on interest paid in cash.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rdhl_SupplementalInformationInterestPaidInCash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental Information Interest Paid In Cash</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rdhl_SupplementalInformationInterestPaidInCash_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SUPPLEMENTARY INFORMATION ON INTEREST PAID IN CASH</label>
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_AcquisitionOfRightOfUseAssetsByMeansOfLeaseLiabilities" xlink:label="rdhl_AcquisitionOfRightOfUseAssetsByMeansOfLeaseLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rdhl_AcquisitionOfRightOfUseAssetsByMeansOfLeaseLiabilities" xlink:to="rdhl_AcquisitionOfRightOfUseAssetsByMeansOfLeaseLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rdhl_AcquisitionOfRightOfUseAssetsByMeansOfLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of acquisition of right-of-use assets by means of lease liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rdhl_AcquisitionOfRightOfUseAssetsByMeansOfLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquisition of Right of Use Assets by Means of Lease Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rdhl_AcquisitionOfRightOfUseAssetsByMeansOfLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Acquisition of right-of-use assets by means of lease liabilities</label>
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_DecreaseInLeaseLiabilityFromEarlyTerminationOfLease" xlink:label="rdhl_DecreaseInLeaseLiabilityFromEarlyTerminationOfLease" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rdhl_DecreaseInLeaseLiabilityFromEarlyTerminationOfLease" xlink:to="rdhl_DecreaseInLeaseLiabilityFromEarlyTerminationOfLease_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rdhl_DecreaseInLeaseLiabilityFromEarlyTerminationOfLease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents decrease in lease liability from early termination of lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rdhl_DecreaseInLeaseLiabilityFromEarlyTerminationOfLease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease In Lease Liability From Early Termination Of Lease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rdhl_DecreaseInLeaseLiabilityFromEarlyTerminationOfLease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease in lease liability (with corresponding decrease in right of use asset in amount of $170 in the six months ended June 30, 2024, and $4,117 in the six months ended June 30,2023) resulting from early termination of lease</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ChangesInIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_ChangesInIntangibleAssetsOtherThanGoodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ChangesInIntangibleAssetsOtherThanGoodwill" xlink:to="ifrs-full_ChangesInIntangibleAssetsOtherThanGoodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ChangesInIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) in intangible assets other than goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ChangesInIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease in Intangible asset</label>
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_DecreaseInInventories" xlink:label="rdhl_DecreaseInInventories" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rdhl_DecreaseInInventories" xlink:to="rdhl_DecreaseInInventories_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rdhl_DecreaseInInventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of decrease in inventories during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rdhl_DecreaseInInventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decreases in Inventories</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rdhl_DecreaseInInventories_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease in Inventories</label>
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_DecreaseIncreaseInPayablesInRespectOfIntangibleAssets" xlink:label="rdhl_DecreaseIncreaseInPayablesInRespectOfIntangibleAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rdhl_DecreaseIncreaseInPayablesInRespectOfIntangibleAssets" xlink:to="rdhl_DecreaseIncreaseInPayablesInRespectOfIntangibleAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rdhl_DecreaseIncreaseInPayablesInRespectOfIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for decrease (increase) in payables in respect of intangible assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rdhl_DecreaseIncreaseInPayablesInRespectOfIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease Increase In Payables In Respect Of Intangible Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rdhl_DecreaseIncreaseInPayablesInRespectOfIntangibleAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease in Payable in respect of Intangible asset</label>
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_DecreaseIncreaseInBorrowings" xlink:label="rdhl_DecreaseIncreaseInBorrowings" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rdhl_DecreaseIncreaseInBorrowings" xlink:to="rdhl_DecreaseIncreaseInBorrowings_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rdhl_DecreaseIncreaseInBorrowings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments for decrease (increase) in borrowings.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rdhl_DecreaseIncreaseInBorrowings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease Increase in Borrowings</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rdhl_DecreaseIncreaseInBorrowings_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease in Borrowing</label>
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_GainsFromTransferOfRightsInMovantikAndExtinguishmentOfDebtObligations" xlink:label="rdhl_GainsFromTransferOfRightsInMovantikAndExtinguishmentOfDebtObligations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rdhl_GainsFromTransferOfRightsInMovantikAndExtinguishmentOfDebtObligations" xlink:to="rdhl_GainsFromTransferOfRightsInMovantikAndExtinguishmentOfDebtObligations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rdhl_GainsFromTransferOfRightsInMovantikAndExtinguishmentOfDebtObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gains From The Transfer Of The Rights In Movantik And Extinguishment Of Debt Obligations</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rdhl_GainsFromTransferOfRightsInMovantikAndExtinguishmentOfDebtObligations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gains from the transfer of the rights in Movantik and extinguishment of debt obligations</label>
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_DecreaseInRightOfUseAssetFromEarlyTerminationOfLease" xlink:label="rdhl_DecreaseInRightOfUseAssetFromEarlyTerminationOfLease" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rdhl_DecreaseInRightOfUseAssetFromEarlyTerminationOfLease" xlink:to="rdhl_DecreaseInRightOfUseAssetFromEarlyTerminationOfLease_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rdhl_DecreaseInRightOfUseAssetFromEarlyTerminationOfLease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents decrease in right of use asset from early termination of lease.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rdhl_DecreaseInRightOfUseAssetFromEarlyTerminationOfLease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease In Right Of Use Asset From Early Termination Of Lease</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rdhl_DecreaseInRightOfUseAssetFromEarlyTerminationOfLease_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decrease in right of use asset</label>
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_GeneralInformationAbstract" xlink:label="rdhl_GeneralInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rdhl_GeneralInformationAbstract" xlink:to="rdhl_GeneralInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rdhl_GeneralInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">N/A.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rdhl_GeneralInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">GENERAL</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:label="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:to="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of general information about financial statements [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General</label>
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_DisclosureOfBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsAbstract" xlink:label="rdhl_DisclosureOfBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rdhl_DisclosureOfBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsAbstract" xlink:to="rdhl_DisclosureOfBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rdhl_DisclosureOfBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rdhl_DisclosureOfBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BASIS OF PREPARATION OF THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_DisclosureOfBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsTextBlock" xlink:label="rdhl_DisclosureOfBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rdhl_DisclosureOfBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsTextBlock" xlink:to="rdhl_DisclosureOfBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rdhl_DisclosureOfBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure for basis of preparation of condensed consolidated interim financial statements.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rdhl_DisclosureOfBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure Of Basis Of Preparation Of Condensed Consolidated Interim Financial Statements [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rdhl_DisclosureOfBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BASIS OF PREPARATION OF THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_SignificantEventsDuringCurrentReportingPeriodAbstract" xlink:label="rdhl_SignificantEventsDuringCurrentReportingPeriodAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rdhl_SignificantEventsDuringCurrentReportingPeriodAbstract" xlink:to="rdhl_SignificantEventsDuringCurrentReportingPeriodAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rdhl_SignificantEventsDuringCurrentReportingPeriodAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">N/A</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rdhl_SignificantEventsDuringCurrentReportingPeriodAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SIGNIFICANT EVENTS DURING THE CURRENT REPORTING PERIOD</label>
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_SignificantEventsDuringCurrentReportingPeriodTextBlock" xlink:label="rdhl_SignificantEventsDuringCurrentReportingPeriodTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rdhl_SignificantEventsDuringCurrentReportingPeriodTextBlock" xlink:to="rdhl_SignificantEventsDuringCurrentReportingPeriodTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rdhl_SignificantEventsDuringCurrentReportingPeriodTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure of significant events during the current reporting period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rdhl_SignificantEventsDuringCurrentReportingPeriodTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Events During Current Reporting Period [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rdhl_SignificantEventsDuringCurrentReportingPeriodTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SIGNIFICANT EVENTS DURING THE CURRENT REPORTING PERIOD</label>
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_AllowanceForDeductionsFromRevenuesAbstract" xlink:label="rdhl_AllowanceForDeductionsFromRevenuesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rdhl_AllowanceForDeductionsFromRevenuesAbstract" xlink:to="rdhl_AllowanceForDeductionsFromRevenuesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rdhl_AllowanceForDeductionsFromRevenuesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">n.a.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rdhl_AllowanceForDeductionsFromRevenuesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ALLOWANCE FOR DEDUCTIONS FROM REVENUES</label>
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_AllowanceForDeductionsFromRevenuesDisclosureTextBlock" xlink:label="rdhl_AllowanceForDeductionsFromRevenuesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rdhl_AllowanceForDeductionsFromRevenuesDisclosureTextBlock" xlink:to="rdhl_AllowanceForDeductionsFromRevenuesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rdhl_AllowanceForDeductionsFromRevenuesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure of allowance for deductions from revenues.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rdhl_AllowanceForDeductionsFromRevenuesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allowance For Deductions From Revenues Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rdhl_AllowanceForDeductionsFromRevenuesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ALLOWANCE FOR DEDUCTIONS FROM REVENUES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SHARE-BASED PAYMENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of share-based payment arrangements [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SHARE-BASED PAYMENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NET REVENUES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:label="ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:to="ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of revenue from contracts with customers [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">NET REVENUES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">FINANCIAL INSTRUMENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of financial instruments [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">FINANCIAL INSTRUMENTS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SEGMENT INFORMATION</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:label="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:to="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of entity's operating segments [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SEGMENT INFORMATION</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareAbstract" xlink:label="ifrs-full_EarningsPerShareAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EarningsPerShareAbstract" xlink:to="ifrs-full_EarningsPerShareAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">EARNING (LOSS) PER SHARE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:label="ifrs-full_DisclosureOfEarningsPerShareExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:to="ifrs-full_DisclosureOfEarningsPerShareExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfEarningsPerShareExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of earnings per share [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfEarningsPerShareExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">EARNING (LOSS) PER SHARE</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">EVENT SUBSEQUENT TO JUNE 30,2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of events after reporting period [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">EVENT SUBSEQUENT TO JUNE 30, 2024</label>
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_IfrsAccountingPoliciesAbstract" xlink:label="rdhl_IfrsAccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rdhl_IfrsAccountingPoliciesAbstract" xlink:to="rdhl_IfrsAccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rdhl_IfrsAccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">n/a</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rdhl_IfrsAccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:to="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of basis of preparation of financial statements [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of preparation</label>
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_ScheduleOfMovementOfAllowanceForDeductionsFromRevenuesTableTextBlock" xlink:label="rdhl_ScheduleOfMovementOfAllowanceForDeductionsFromRevenuesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rdhl_ScheduleOfMovementOfAllowanceForDeductionsFromRevenuesTableTextBlock" xlink:to="rdhl_ScheduleOfMovementOfAllowanceForDeductionsFromRevenuesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rdhl_ScheduleOfMovementOfAllowanceForDeductionsFromRevenuesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of movement of allowance for deductions from revenues.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rdhl_ScheduleOfMovementOfAllowanceForDeductionsFromRevenuesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Movement Of Allowance For Deductions From Revenues [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rdhl_ScheduleOfMovementOfAllowanceForDeductionsFromRevenuesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of movement of allowance for deductions from revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of disaggregation of revenue from contracts with customers [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of net revenues</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory" xlink:label="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory" xlink:to="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of significant unobservable inputs used in fair value measurement of liabilities [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of change in derivative financial instrument</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsExplanatory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of operating segments [text block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsExplanatory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of segment profitability and reconciliation to consolidated net income (loss) and comprehensive income (loss)</label>
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_GeneralTable" xlink:label="rdhl_GeneralTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rdhl_GeneralTable" xlink:to="rdhl_GeneralTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rdhl_GeneralTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General information.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rdhl_GeneralTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-adjusting events after reporting period [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="ifrs-full_NonadjustingEventsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NonadjustingEventsMember" xlink:to="ifrs-full_NonadjustingEventsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NonadjustingEventsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-adjusting events after reporting period [member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:label="ifrs-full_MajorOrdinaryShareTransactionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:to="ifrs-full_MajorOrdinaryShareTransactionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MajorOrdinaryShareTransactionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Major ordinary share transactions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfOrdinarySharesAxis" xlink:label="ifrs-full_ClassesOfOrdinarySharesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfOrdinarySharesAxis" xlink:to="ifrs-full_ClassesOfOrdinarySharesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfOrdinarySharesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Classes of ordinary shares [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember" xlink:label="ifrs-full_OrdinarySharesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OrdinarySharesMember" xlink:to="ifrs-full_OrdinarySharesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OrdinarySharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ordinary shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AdrMember" xlink:label="dei_AdrMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AdrMember" xlink:to="dei_AdrMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AdrMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ADS</label>
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_GeneralLineItems" xlink:label="rdhl_GeneralLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rdhl_GeneralLineItems" xlink:to="rdhl_GeneralLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rdhl_GeneralLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rdhl_GeneralLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General [Line Items]</label>
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_NumberOfOrdinarySharesIssuedInExchangeOfAmericanDepositoryReceipts" xlink:label="rdhl_NumberOfOrdinarySharesIssuedInExchangeOfAmericanDepositoryReceipts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rdhl_NumberOfOrdinarySharesIssuedInExchangeOfAmericanDepositoryReceipts" xlink:to="rdhl_NumberOfOrdinarySharesIssuedInExchangeOfAmericanDepositoryReceipts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rdhl_NumberOfOrdinarySharesIssuedInExchangeOfAmericanDepositoryReceipts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of ordinary shares issued in exchange of American Depository Receipts.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rdhl_NumberOfOrdinarySharesIssuedInExchangeOfAmericanDepositoryReceipts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Ordinary Shares Issued in Exchange of American Depository Receipts</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rdhl_NumberOfOrdinarySharesIssuedInExchangeOfAmericanDepositoryReceipts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of ordinary shares issued in exchange of ADS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsAbstract" xlink:label="ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsAbstract" xlink:to="ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of expected impact of initial application of new standards or interpretations [abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsTable" xlink:label="ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsTable" xlink:to="ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of expected impact of initial application of new standards or interpretations [table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NewIFRSsAxis" xlink:label="ifrs-full_NewIFRSsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NewIFRSsAxis" xlink:to="ifrs-full_NewIFRSsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NewIFRSsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New IFRSs [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NewIFRSsMember" xlink:label="ifrs-full_NewIFRSsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NewIFRSsMember" xlink:to="ifrs-full_NewIFRSsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NewIFRSsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New IFRSs [member]</label>
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_Ias1AmendmentsMember" xlink:label="rdhl_Ias1AmendmentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rdhl_Ias1AmendmentsMember" xlink:to="rdhl_Ias1AmendmentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rdhl_Ias1AmendmentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for the narrow-scope amendments to IAS 1 "Presentation of Financial Statements".</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rdhl_Ias1AmendmentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IAS 1 Amendments [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rdhl_Ias1AmendmentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IAS 1 Amendments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems" xlink:label="ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems" xlink:to="ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of expected impact of initial application of new standards or interpretations [line items]</label>
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_ReclassificationOfWarrantLiability" xlink:label="rdhl_ReclassificationOfWarrantLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rdhl_ReclassificationOfWarrantLiability" xlink:to="rdhl_ReclassificationOfWarrantLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rdhl_ReclassificationOfWarrantLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of reclassification of warrant liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rdhl_ReclassificationOfWarrantLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reclassification Of Warrant Liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of classes of share capital [table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfShareCapitalAxis" xlink:to="ifrs-full_ClassesOfShareCapitalAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfShareCapitalAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Classes of share capital [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ifrs-full_ClassesOfShareCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfShareCapitalMember" xlink:to="ifrs-full_ClassesOfShareCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfShareCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share capital [member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PreferenceSharesMember" xlink:label="ifrs-full_PreferenceSharesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PreferenceSharesMember" xlink:to="ifrs-full_PreferenceSharesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PreferenceSharesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preference shares [member]</label>
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_IfrsWarrantMember" xlink:label="rdhl_IfrsWarrantMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rdhl_IfrsWarrantMember" xlink:to="rdhl_IfrsWarrantMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rdhl_IfrsWarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rdhl_IfrsWarrantMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfEquityComponentOfConvertibleInstrumentsMember" xlink:label="ifrs-full_ReserveOfEquityComponentOfConvertibleInstrumentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ReserveOfEquityComponentOfConvertibleInstrumentsMember" xlink:to="ifrs-full_ReserveOfEquityComponentOfConvertibleInstrumentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ReserveOfEquityComponentOfConvertibleInstrumentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity component</label>
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_AmericanDepositoryShareMember" xlink:label="rdhl_AmericanDepositoryShareMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rdhl_AmericanDepositoryShareMember" xlink:to="rdhl_AmericanDepositoryShareMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rdhl_AmericanDepositoryShareMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for American Depository Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rdhl_AmericanDepositoryShareMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">American Depository Share [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rdhl_AmericanDepositoryShareMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ADS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of classes of share capital [line items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="ifrs-full_NumberOfSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesIssued" xlink:to="ifrs-full_NumberOfSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued</label>
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_IfrsClassOfWarrantsOrRightExercisePriceOfWarrantsOrRights" xlink:label="rdhl_IfrsClassOfWarrantsOrRightExercisePriceOfWarrantsOrRights" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rdhl_IfrsClassOfWarrantsOrRightExercisePriceOfWarrantsOrRights" xlink:to="rdhl_IfrsClassOfWarrantsOrRightExercisePriceOfWarrantsOrRights_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rdhl_IfrsClassOfWarrantsOrRightExercisePriceOfWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price per share or per unit of warrants or rights outstanding.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rdhl_IfrsClassOfWarrantsOrRightExercisePriceOfWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ifrs Class of Warrants or Right, Exercise Price of Warrants or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rdhl_IfrsClassOfWarrantsOrRightExercisePriceOfWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price of warrants</label>
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_IfrsSharesIssuedPricePerShare" xlink:label="rdhl_IfrsSharesIssuedPricePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rdhl_IfrsSharesIssuedPricePerShare" xlink:to="rdhl_IfrsSharesIssuedPricePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rdhl_IfrsSharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Per share or per unit amount of equity securities issued.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rdhl_IfrsSharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Shares Issued Price Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rdhl_IfrsSharesIssuedPricePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchase price (per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProceedsFromIssuingShares" xlink:to="ifrs-full_ProceedsFromIssuingShares_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProceedsFromIssuingShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuing shares</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_ProceedsFromIssuingShares_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of shares</label>
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_WarrantsNumberIssued" xlink:label="rdhl_WarrantsNumberIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rdhl_WarrantsNumberIssued" xlink:to="rdhl_WarrantsNumberIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rdhl_WarrantsNumberIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of warrants issued during the period.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rdhl_WarrantsNumberIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants, Number Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rdhl_WarrantsNumberIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants issued</label>
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:label="rdhl_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rdhl_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:to="rdhl_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rdhl_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise price per share or per unit of warrants or rights outstanding.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rdhl_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Class Of Warrant Or Right Exercise Price Of Warrants Or Rights</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rdhl_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants exercise price</label>
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_IfrsWarrantsAndRightsOutstandingTerm" xlink:label="rdhl_IfrsWarrantsAndRightsOutstandingTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rdhl_IfrsWarrantsAndRightsOutstandingTerm" xlink:to="rdhl_IfrsWarrantsAndRightsOutstandingTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rdhl_IfrsWarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rdhl_IfrsWarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IFRS Warrants And Rights Outstanding Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rdhl_IfrsWarrantsAndRightsOutstandingTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsForShareIssueCosts" xlink:label="ifrs-full_PaymentsForShareIssueCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_PaymentsForShareIssueCosts" xlink:to="ifrs-full_PaymentsForShareIssueCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_PaymentsForShareIssueCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments for share issue costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_PaymentsForShareIssueCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Placement agent fees and offering expenses.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesAuthorised" xlink:label="ifrs-full_NumberOfSharesAuthorised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfSharesAuthorised" xlink:to="ifrs-full_NumberOfSharesAuthorised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfSharesAuthorised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares authorised</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParValuePerShare" xlink:label="ifrs-full_ParValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ParValuePerShare" xlink:to="ifrs-full_ParValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ParValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Par value per share</label>
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_AuthorisedShareCapital" xlink:label="rdhl_AuthorisedShareCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rdhl_AuthorisedShareCapital" xlink:to="rdhl_AuthorisedShareCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rdhl_AuthorisedShareCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The nominal value of authorised share capital.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rdhl_AuthorisedShareCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Authorised Share Capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherProvisionsTable" xlink:label="ifrs-full_DisclosureOfOtherProvisionsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOtherProvisionsTable" xlink:to="ifrs-full_DisclosureOfOtherProvisionsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOtherProvisionsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of other provisions [table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfProvisionsAxis" xlink:label="ifrs-full_ClassesOfProvisionsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfProvisionsAxis" xlink:to="ifrs-full_ClassesOfProvisionsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfProvisionsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Classes of other provisions [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherProvisionsMember" xlink:label="ifrs-full_OtherProvisionsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_OtherProvisionsMember" xlink:to="ifrs-full_OtherProvisionsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_OtherProvisionsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other provisions [member]</label>
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_RebatesAndPatientDiscountProgramsMember" xlink:label="rdhl_RebatesAndPatientDiscountProgramsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rdhl_RebatesAndPatientDiscountProgramsMember" xlink:to="rdhl_RebatesAndPatientDiscountProgramsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rdhl_RebatesAndPatientDiscountProgramsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the information pertaining to Rebates and patient discount programs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rdhl_RebatesAndPatientDiscountProgramsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rebates and patient discount programs</label>
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_ProductReturnsMember" xlink:label="rdhl_ProductReturnsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rdhl_ProductReturnsMember" xlink:to="rdhl_ProductReturnsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rdhl_ProductReturnsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stands for Product returns.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rdhl_ProductReturnsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Product returns</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:label="ifrs-full_DisclosureOfOtherProvisionsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:to="ifrs-full_DisclosureOfOtherProvisionsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOtherProvisionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of other provisions [line items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInExistingProvisionsOtherProvisions" xlink:label="ifrs-full_IncreaseDecreaseInExistingProvisionsOtherProvisions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInExistingProvisionsOtherProvisions" xlink:to="ifrs-full_IncreaseDecreaseInExistingProvisionsOtherProvisions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseInExistingProvisionsOtherProvisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase in existing provisions, other provisions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseInExistingProvisionsOtherProvisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProvisionUsedOtherProvisions" xlink:label="ifrs-full_ProvisionUsedOtherProvisions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProvisionUsedOtherProvisions" xlink:to="ifrs-full_ProvisionUsedOtherProvisions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProvisionUsedOtherProvisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Provision used, other provisions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ProvisionUsedOtherProvisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Decreases (Utilized)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions" xlink:label="ifrs-full_IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions" xlink:to="ifrs-full_IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase through adjustments arising from passage of time, other provisions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of terms and conditions of share-based payment arrangement [table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Types of share-based payment arrangements [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based payment arrangements [member]</label>
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_IfrsRestrictedStockUnitsRsuMember" xlink:label="rdhl_IfrsRestrictedStockUnitsRsuMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rdhl_IfrsRestrictedStockUnitsRsuMember" xlink:to="rdhl_IfrsRestrictedStockUnitsRsuMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rdhl_IfrsRestrictedStockUnitsRsuMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rdhl_IfrsRestrictedStockUnitsRsuMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">RSUs</label>
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_IfrsEmployeeStockOptionMember" xlink:label="rdhl_IfrsEmployeeStockOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rdhl_IfrsEmployeeStockOptionMember" xlink:to="rdhl_IfrsEmployeeStockOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rdhl_IfrsEmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Although there are variations, normally, after vesting, when an option is exercised, the employee-holder pays the strike value in cash to the issuing employer-entity and receives equity shares. The equity shares can be sold into the market for cash at the current market price without restriction. Options may be used to attract, retain and incentivize employees, in addition to their regular salary and other benefits.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rdhl_IfrsEmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Categories of related parties [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity's total for related parties [member]</label>
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_DirectorsAndChiefExecutiveOfficerMember" xlink:label="rdhl_DirectorsAndChiefExecutiveOfficerMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rdhl_DirectorsAndChiefExecutiveOfficerMember" xlink:to="rdhl_DirectorsAndChiefExecutiveOfficerMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rdhl_DirectorsAndChiefExecutiveOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for directors and chief executive officers</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rdhl_DirectorsAndChiefExecutiveOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Directors And Chief Executive Officer [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rdhl_DirectorsAndChiefExecutiveOfficerMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Directors and chief executive officer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of terms and conditions of share-based payment arrangement [line items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of share options forfeited in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share options forfeited</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of other equity instruments granted in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of RSUs granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of other equity instruments forfeited in share-based payment arrangement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of RSU forfeited</label>
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_NumberOfRsuQuarterlyInstallments" xlink:label="rdhl_NumberOfRsuQuarterlyInstallments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rdhl_NumberOfRsuQuarterlyInstallments" xlink:to="rdhl_NumberOfRsuQuarterlyInstallments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rdhl_NumberOfRsuQuarterlyInstallments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of quarterly installments in which RSUs will vest equally over a two-year period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rdhl_NumberOfRsuQuarterlyInstallments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of RSU Quarterly Installments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xlink:to="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average fair value at measurement date, other equity instruments granted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of RSU grant</label>
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_ReversedExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:label="rdhl_ReversedExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rdhl_ReversedExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:to="rdhl_ReversedExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rdhl_ReversedExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of reversed expense from share-based payment transactions in which the goods or services received did not qualify for recognition as assets.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rdhl_ReversedExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reversed Expense From Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rdhl_ReversedExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Shares forfeited, reversed expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of disaggregation of revenue from contracts with customers [table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="ifrs-full_ProductsAndServicesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProductsAndServicesAxis" xlink:to="ifrs-full_ProductsAndServicesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProductsAndServicesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Products and services [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="ifrs-full_ProductsAndServicesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ProductsAndServicesMember" xlink:to="ifrs-full_ProductsAndServicesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ProductsAndServicesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Products and services [member]</label>
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_TaliciaMember" xlink:label="rdhl_TaliciaMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rdhl_TaliciaMember" xlink:to="rdhl_TaliciaMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rdhl_TaliciaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Talicia prescription medicine.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rdhl_TaliciaMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Talicia</label>
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_MovantikMember" xlink:label="rdhl_MovantikMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rdhl_MovantikMember" xlink:to="rdhl_MovantikMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rdhl_MovantikMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Movantik prescription medicine.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rdhl_MovantikMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Movantik</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis" xlink:label="ifrs-full_CounterpartiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CounterpartiesAxis" xlink:to="ifrs-full_CounterpartiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CounterpartiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparties [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember" xlink:label="ifrs-full_CounterpartiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CounterpartiesMember" xlink:to="ifrs-full_CounterpartiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CounterpartiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparties [member]</label>
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_GaelanMedicalTradeLlcMember" xlink:label="rdhl_GaelanMedicalTradeLlcMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rdhl_GaelanMedicalTradeLlcMember" xlink:to="rdhl_GaelanMedicalTradeLlcMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rdhl_GaelanMedicalTradeLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Gaelan Medical Trade LLC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rdhl_GaelanMedicalTradeLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gaelan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rdhl_GaelanMedicalTradeLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gaelan Medical Trade LLC</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of disaggregation of revenue from contracts with customers [line items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueAbstract" xlink:label="ifrs-full_RevenueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RevenueAbstract" xlink:to="ifrs-full_RevenueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RevenueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue [abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="ifrs-full_RevenueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenues</label>
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_ContraRevenueForMovantik" xlink:label="rdhl_ContraRevenueForMovantik" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rdhl_ContraRevenueForMovantik" xlink:to="rdhl_ContraRevenueForMovantik_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rdhl_ContraRevenueForMovantik_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contra Revenue For Movantik</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rdhl_ContraRevenueForMovantik_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contra Revenue For Movantik</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="rdhl_ContraRevenueForMovantik_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Contra Revenue For Movantik</label>
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_NetRevenue" xlink:label="rdhl_NetRevenue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rdhl_NetRevenue" xlink:to="rdhl_NetRevenue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rdhl_NetRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The net income arising in the course of an entity's ordinary activities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rdhl_NetRevenue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Revenue</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about financial instruments [table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:to="ifrs-full_LevelsOfFairValueHierarchyAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Levels of fair value hierarchy [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="ifrs-full_AllLevelsOfFairValueHierarchyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:to="ifrs-full_AllLevelsOfFairValueHierarchyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AllLevelsOfFairValueHierarchyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">All levels of fair value hierarchy [member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level3OfFairValueHierarchyMember" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_Level3OfFairValueHierarchyMember" xlink:to="ifrs-full_Level3OfFairValueHierarchyMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Level 3</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MeasurementAxis" xlink:label="ifrs-full_MeasurementAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MeasurementAxis" xlink:to="ifrs-full_MeasurementAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MeasurementAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="ifrs-full_AggregatedMeasurementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AggregatedMeasurementMember" xlink:to="ifrs-full_AggregatedMeasurementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AggregatedMeasurementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregated measurement [member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AtFairValueMember" xlink:label="ifrs-full_AtFairValueMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_AtFairValueMember" xlink:to="ifrs-full_AtFairValueMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_AtFairValueMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">At fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Categories of financial liabilities [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="ifrs-full_FinancialLiabilitiesCategoryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilitiesCategoryMember" xlink:to="ifrs-full_FinancialLiabilitiesCategoryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialLiabilitiesCategoryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial liabilities, category [member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial liabilities at fair value through profit or loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfLiabilitiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ClassesOfLiabilitiesAxis" xlink:to="ifrs-full_ClassesOfLiabilitiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ClassesOfLiabilitiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Classes of liabilities [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesMember" xlink:label="ifrs-full_LiabilitiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_LiabilitiesMember" xlink:to="ifrs-full_LiabilitiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_LiabilitiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities [member]</label>
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_FairValueOfWarrantsMember" xlink:label="rdhl_FairValueOfWarrantsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rdhl_FairValueOfWarrantsMember" xlink:to="rdhl_FairValueOfWarrantsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rdhl_FairValueOfWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for warrants</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rdhl_FairValueOfWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Of Warrants [Member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rdhl_FairValueOfWarrantsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Warrants</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsAxis" xlink:label="ifrs-full_UnobservableInputsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_UnobservableInputsAxis" xlink:to="ifrs-full_UnobservableInputsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_UnobservableInputsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unobservable inputs [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsMember" xlink:label="ifrs-full_UnobservableInputsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_UnobservableInputsMember" xlink:to="ifrs-full_UnobservableInputsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_UnobservableInputsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unobservable inputs [member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRateMeasurementInputMember" xlink:label="ifrs-full_InterestRateMeasurementInputMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_InterestRateMeasurementInputMember" xlink:to="ifrs-full_InterestRateMeasurementInputMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_InterestRateMeasurementInputMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk-free interest rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember" xlink:label="ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember" xlink:to="ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Volatility</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RangeAxis" xlink:to="ifrs-full_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RangesMember" xlink:to="ifrs-full_RangesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RangesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Ranges [member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_BottomOfRangeMember" xlink:to="ifrs-full_BottomOfRangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_BottomOfRangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_TopOfRangeMember" xlink:to="ifrs-full_TopOfRangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_TopOfRangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of detailed information about financial instruments [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial instruments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuesFairValueMeasurementLiabilities" xlink:label="ifrs-full_IssuesFairValueMeasurementLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IssuesFairValueMeasurementLiabilities" xlink:to="ifrs-full_IssuesFairValueMeasurementLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IssuesFairValueMeasurementLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issues, fair value measurement, liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IssuesFairValueMeasurementLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial recognition of financial liability</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInFairValueMeasurementLiabilities" xlink:label="ifrs-full_IncreaseDecreaseInFairValueMeasurementLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_IncreaseDecreaseInFairValueMeasurementLiabilities" xlink:to="ifrs-full_IncreaseDecreaseInFairValueMeasurementLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_IncreaseDecreaseInFairValueMeasurementLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (decrease) in fair value measurement, liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_IncreaseDecreaseInFairValueMeasurementLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Initial recognition of unrecognized day 1 loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" xlink:label="ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" xlink:to="ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gains (losses) recognised in profit or loss, fair value measurement, liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value adjustments recognized in profit or loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantUnobservableInputLiabilities" xlink:label="ifrs-full_SignificantUnobservableInputLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_SignificantUnobservableInputLiabilities" xlink:to="ifrs-full_SignificantUnobservableInputLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_SignificantUnobservableInputLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant unobservable input, liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_SignificantUnobservableInputLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant unobservable input</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsTable" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of operating segments [table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsLineItems" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of operating segments [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of operating segments</label>
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_CommercialOperationsSegmentAdjustedEarningsBeforeInterestTaxesDepreciationAndAmortisation" xlink:label="rdhl_CommercialOperationsSegmentAdjustedEarningsBeforeInterestTaxesDepreciationAndAmortisation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rdhl_CommercialOperationsSegmentAdjustedEarningsBeforeInterestTaxesDepreciationAndAmortisation" xlink:to="rdhl_CommercialOperationsSegmentAdjustedEarningsBeforeInterestTaxesDepreciationAndAmortisation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rdhl_CommercialOperationsSegmentAdjustedEarningsBeforeInterestTaxesDepreciationAndAmortisation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Operations Segment Amount of adjusted earnings before interest, taxes, depreciation, and Amortisation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rdhl_CommercialOperationsSegmentAdjustedEarningsBeforeInterestTaxesDepreciationAndAmortisation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commercial Operations Segment Adjusted EBITDA</label>
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_ResearchAndDevelopmentAdjustedEarningsBeforeInterestTaxesDepreciationAndAmortisation" xlink:label="rdhl_ResearchAndDevelopmentAdjustedEarningsBeforeInterestTaxesDepreciationAndAmortisation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rdhl_ResearchAndDevelopmentAdjustedEarningsBeforeInterestTaxesDepreciationAndAmortisation" xlink:to="rdhl_ResearchAndDevelopmentAdjustedEarningsBeforeInterestTaxesDepreciationAndAmortisation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rdhl_ResearchAndDevelopmentAdjustedEarningsBeforeInterestTaxesDepreciationAndAmortisation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development Adjusted earnings before interest, taxes, depreciation, and Amortisation.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rdhl_ResearchAndDevelopmentAdjustedEarningsBeforeInterestTaxesDepreciationAndAmortisation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research And Development Adjusted EBITDA</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expense from share-based payment transactions with employees</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation to employees and service providers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationExpense" xlink:label="ifrs-full_DepreciationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DepreciationExpense" xlink:to="ifrs-full_DepreciationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DepreciationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="ifrs-full_DepreciationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation</label>
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_AmortisationAndImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:label="rdhl_AmortisationAndImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rdhl_AmortisationAndImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:to="rdhl_AmortisationAndImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rdhl_AmortisationAndImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of amortisation and  impairment loss recognised in profit or loss for intangible assets other than goodwill.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rdhl_AmortisationAndImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortisation and Impairment Loss Recognised in Profit or Loss, Intangible Assets Other Than Goodwill</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="rdhl_AmortisationAndImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of intangible assets</label>
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_GainLossOnTerminationOfLeases" xlink:label="rdhl_GainLossOnTerminationOfLeases" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rdhl_GainLossOnTerminationOfLeases" xlink:to="rdhl_GainLossOnTerminationOfLeases_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rdhl_GainLossOnTerminationOfLeases_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of gain (loss) on termination of lease before expiration of lease term.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rdhl_GainLossOnTerminationOfLeases_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain from early termination of lease, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MiscellaneousOtherOperatingIncome" xlink:label="ifrs-full_MiscellaneousOtherOperatingIncome" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_MiscellaneousOtherOperatingIncome" xlink:to="ifrs-full_MiscellaneousOtherOperatingIncome_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_MiscellaneousOtherOperatingIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Miscellaneous other operating income</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_MiscellaneousOtherOperatingIncome_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of non-adjusting events after reporting period [table]</label>
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_GlobalTerminationAgreementMember" xlink:label="rdhl_GlobalTerminationAgreementMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rdhl_GlobalTerminationAgreementMember" xlink:to="rdhl_GlobalTerminationAgreementMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rdhl_GlobalTerminationAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for global termination agreement signed by the company.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rdhl_GlobalTerminationAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Global Termination Agreement [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rdhl_GlobalTerminationAgreementMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The Agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_CounterpartyNameAxis" xlink:to="srt_CounterpartyNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_CounterpartyNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Counterparty Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_MovantikAcquisitionValinorPharmaLlcHcrRedhillSpvLlcMember" xlink:label="rdhl_MovantikAcquisitionValinorPharmaLlcHcrRedhillSpvLlcMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rdhl_MovantikAcquisitionValinorPharmaLlcHcrRedhillSpvLlcMember" xlink:to="rdhl_MovantikAcquisitionValinorPharmaLlcHcrRedhillSpvLlcMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rdhl_MovantikAcquisitionValinorPharmaLlcHcrRedhillSpvLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">This member stands for Movantik Acquisition, Valinor Pharma LLC, HCR Redhill SPV LLC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rdhl_MovantikAcquisitionValinorPharmaLlcHcrRedhillSpvLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Movantik Acquisition, Valinor Pharma LLC, HCR Redhill SPV LLC [member]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rdhl_MovantikAcquisitionValinorPharmaLlcHcrRedhillSpvLlcMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Movantik Acquisition Co, Valinor Pharma, LLC, and HCR Redhill SPV, LLC</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of non-adjusting events after reporting period [line items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of non-adjusting events after reporting period</label>
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_ProceedsReceivedFollowingGlobalTerminationAgreement" xlink:label="rdhl_ProceedsReceivedFollowingGlobalTerminationAgreement" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rdhl_ProceedsReceivedFollowingGlobalTerminationAgreement" xlink:to="rdhl_ProceedsReceivedFollowingGlobalTerminationAgreement_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rdhl_ProceedsReceivedFollowingGlobalTerminationAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash inflow following global termination agreement signed between the company and Movantik acquisition Co, Valinor Pharma LLC, nd HCR Redhill SPV, LLC.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rdhl_ProceedsReceivedFollowingGlobalTerminationAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds Received Following Global Termination Agreement</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="rdhl_ProceedsReceivedFollowingGlobalTerminationAgreement_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds received following global termination agreement</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RestrictedCashAndCashEquivalents" xlink:label="ifrs-full_RestrictedCashAndCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="ifrs-full_RestrictedCashAndCashEquivalents" xlink:to="ifrs-full_RestrictedCashAndCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="ifrs-full_RestrictedCashAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_IncreaseInLiabilities" xlink:label="rdhl_IncreaseInLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="rdhl_IncreaseInLiabilities" xlink:to="rdhl_IncreaseInLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="rdhl_IncreaseInLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of increase in liabilities following Global Termination Agreement.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="rdhl_IncreaseInLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase in future obligations</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>9
<FILENAME>rdhl-20240630_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="utf-8"?>
<!--XBRL document created with Toppan Merrill Bridge  10.7.0.1 -->
<!--Based on XBRL 2.1-->
<!--Created on: 8/29/2024 10:57:41 AM-->
<!--Modified on: 8/29/2024 10:57:41 AM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="rdhl-20240630.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.redhillbio.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rdhl-20240630.xsd#StatementCondensedConsolidatedInterimStatementsOfComprehensiveIncomeLoss" roleURI="http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rdhl-20240630.xsd#StatementCondensedConsolidatedInterimStatementsOfFinancialPosition" roleURI="http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rdhl-20240630.xsd#StatementCondensedConsolidatedInterimStatementsOfChangesInEquity" roleURI="http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfChangesInEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rdhl-20240630.xsd#StatementCondensedConsolidatedInterimStatementsOfCashFlows" roleURI="http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rdhl-20240630.xsd#StatementCondensedConsolidatedInterimStatementsOfCashFlowsParenthetical" roleURI="http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlowsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rdhl-20240630.xsd#DisclosureGeneral" roleURI="http://www.redhillbio.com/role/DisclosureGeneral" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rdhl-20240630.xsd#DisclosureBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsAndSignificantAccountingPolicies" roleURI="http://www.redhillbio.com/role/DisclosureBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsAndSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rdhl-20240630.xsd#DisclosureSignificantEventsDuringCurrentReportingPeriod" roleURI="http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rdhl-20240630.xsd#DisclosureAllowanceForDeductionsFromRevenues" roleURI="http://www.redhillbio.com/role/DisclosureAllowanceForDeductionsFromRevenues" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rdhl-20240630.xsd#DisclosureShareBasedPayments" roleURI="http://www.redhillbio.com/role/DisclosureShareBasedPayments" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rdhl-20240630.xsd#DisclosureNetRevenues" roleURI="http://www.redhillbio.com/role/DisclosureNetRevenues" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rdhl-20240630.xsd#DisclosureFinancialInstruments" roleURI="http://www.redhillbio.com/role/DisclosureFinancialInstruments" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rdhl-20240630.xsd#DisclosureSegmentInformation" roleURI="http://www.redhillbio.com/role/DisclosureSegmentInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rdhl-20240630.xsd#DisclosureEarningLossPerShare" roleURI="http://www.redhillbio.com/role/DisclosureEarningLossPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rdhl-20240630.xsd#DisclosureEventSubsequentToJune302024" roleURI="http://www.redhillbio.com/role/DisclosureEventSubsequentToJune302024" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rdhl-20240630.xsd#DisclosureBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsAndSignificantAccountingPoliciesPolicies" roleURI="http://www.redhillbio.com/role/DisclosureBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsAndSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rdhl-20240630.xsd#DisclosureAllowanceForDeductionsFromRevenuesTables" roleURI="http://www.redhillbio.com/role/DisclosureAllowanceForDeductionsFromRevenuesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rdhl-20240630.xsd#DisclosureNetRevenuesTables" roleURI="http://www.redhillbio.com/role/DisclosureNetRevenuesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rdhl-20240630.xsd#DisclosureFinancialInstrumentsTables" roleURI="http://www.redhillbio.com/role/DisclosureFinancialInstrumentsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rdhl-20240630.xsd#DisclosureSegmentInformationTables" roleURI="http://www.redhillbio.com/role/DisclosureSegmentInformationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rdhl-20240630.xsd#DisclosureGeneralDetails" roleURI="http://www.redhillbio.com/role/DisclosureGeneralDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rdhl-20240630.xsd#DisclosureBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsAndSignificantAccountingPoliciesDetails" roleURI="http://www.redhillbio.com/role/DisclosureBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsAndSignificantAccountingPoliciesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rdhl-20240630.xsd#DisclosureSignificantEventsDuringCurrentReportingPeriodEquityOfferingsDetails" roleURI="http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodEquityOfferingsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rdhl-20240630.xsd#DisclosureAllowanceForDeductionsFromRevenuesDetails" roleURI="http://www.redhillbio.com/role/DisclosureAllowanceForDeductionsFromRevenuesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rdhl-20240630.xsd#DisclosureShareBasedPaymentsDetails" roleURI="http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rdhl-20240630.xsd#DisclosureNetRevenuesDetails" roleURI="http://www.redhillbio.com/role/DisclosureNetRevenuesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rdhl-20240630.xsd#DisclosureFinancialInstrumentsDetails" roleURI="http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rdhl-20240630.xsd#DisclosureSegmentInformationDetails" roleURI="http://www.redhillbio.com/role/DisclosureSegmentInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="rdhl-20240630.xsd#DisclosureEventSubsequentToJune302024Details" roleURI="http://www.redhillbio.com/role/DisclosureEventSubsequentToJune302024Details" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" />
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" />
  <presentationLink xlink:role="http://www.redhillbio.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638605258597174360" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_638605258597174360" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638605258597184367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638605258597184367" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638605258597184367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_638605258597184367" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638605258597184367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638605258597184367" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_638605258597184367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_638605258597184367" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_638605258597184367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_638605258597184367" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_638605258597184367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_638605258597184367" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638605258597184367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_638605258597184367" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveIncomeLoss" xlink:type="extended" xlink:title="00100 - Statement - CONDENSED CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE INCOME (LOSS)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncomeStatementAbstract" xlink:label="ifrs-full_IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue_638605258597184367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_Revenue_638605258597184367" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CostOfSales" xlink:label="ifrs-full_CostOfSales_638605258597194361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_CostOfSales_638605258597194361" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GrossProfit" xlink:label="ifrs-full_GrossProfit_638605258597194361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_GrossProfit_638605258597194361" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ResearchAndDevelopmentExpense" xlink:label="ifrs-full_ResearchAndDevelopmentExpense_638605258597194361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ResearchAndDevelopmentExpense_638605258597194361" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SalesAndMarketingExpense" xlink:label="ifrs-full_SalesAndMarketingExpense_638605258597194361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_SalesAndMarketingExpense_638605258597194361" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SellingGeneralAndAdministrativeExpense" xlink:label="ifrs-full_SellingGeneralAndAdministrativeExpense_638605258597194361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_SellingGeneralAndAdministrativeExpense_638605258597194361" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherOperatingIncomeExpense" xlink:label="ifrs-full_OtherOperatingIncomeExpense_638605258597194361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_OtherOperatingIncomeExpense_638605258597194361" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLossFromOperatingActivities" xlink:label="ifrs-full_ProfitLossFromOperatingActivities_638605258597194361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLossFromOperatingActivities_638605258597194361" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncome" xlink:label="ifrs-full_FinanceIncome_638605258597194361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_FinanceIncome_638605258597194361" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts_638605258597194361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_FinanceCosts_638605258597194361" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncomeCost" xlink:label="ifrs-full_FinanceIncomeCost_638605258597194361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_FinanceIncomeCost_638605258597194361" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss_638605258597194361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_ProfitLoss_638605258597194361" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BasicEarningsLossPerShare" xlink:label="ifrs-full_BasicEarningsLossPerShare_638605258597194361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_BasicEarningsLossPerShare_638605258597194361" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DilutedEarningsLossPerShare" xlink:label="ifrs-full_DilutedEarningsLossPerShare_638605258597204363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_DilutedEarningsLossPerShare_638605258597204363" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageShares" xlink:label="ifrs-full_WeightedAverageShares_638605258597204363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_WeightedAverageShares_638605258597204363" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustedWeightedAverageShares" xlink:label="ifrs-full_AdjustedWeightedAverageShares_638605258597204363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_IncomeStatementAbstract" xlink:to="ifrs-full_AdjustedWeightedAverageShares_638605258597204363" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition" xlink:type="extended" xlink:title="00200 - Statement - CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfFinancialPositionAbstract" xlink:label="StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssetsAbstract" xlink:label="ifrs-full_CurrentAssetsAbstract_638605258597204363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_CurrentAssetsAbstract_638605258597204363" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents_638605258597204363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract_638605258597204363" xlink:to="ifrs-full_CashAndCashEquivalents_638605258597204363" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentRestrictedCashAndCashEquivalents" xlink:label="ifrs-full_CurrentRestrictedCashAndCashEquivalents_638605258597204363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract_638605258597204363" xlink:to="ifrs-full_CurrentRestrictedCashAndCashEquivalents_638605258597204363" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentReceivables" xlink:label="ifrs-full_TradeAndOtherCurrentReceivables_638605258597204363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract_638605258597204363" xlink:to="ifrs-full_TradeAndOtherCurrentReceivables_638605258597204363" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_CurrentPrepaidExpensesAndReceivables" xlink:label="rdhl_CurrentPrepaidExpensesAndReceivables_638605258597204363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract_638605258597204363" xlink:to="rdhl_CurrentPrepaidExpensesAndReceivables_638605258597204363" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Inventories" xlink:label="ifrs-full_Inventories_638605258597214362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract_638605258597204363" xlink:to="ifrs-full_Inventories_638605258597214362" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAssets" xlink:label="ifrs-full_CurrentAssets_638605258597214362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentAssetsAbstract_638605258597204363" xlink:to="ifrs-full_CurrentAssets_638605258597214362" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssetsAbstract" xlink:label="ifrs-full_NoncurrentAssetsAbstract_638605258597214362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_NoncurrentAssetsAbstract_638605258597214362" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentRestrictedCashAndCashEquivalents" xlink:label="ifrs-full_NoncurrentRestrictedCashAndCashEquivalents_638605258597214362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract_638605258597214362" xlink:to="ifrs-full_NoncurrentRestrictedCashAndCashEquivalents_638605258597214362" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PropertyPlantAndEquipment" xlink:label="ifrs-full_PropertyPlantAndEquipment_638605258597214362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract_638605258597214362" xlink:to="ifrs-full_PropertyPlantAndEquipment_638605258597214362" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RightofuseAssets" xlink:label="ifrs-full_RightofuseAssets_638605258597214362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract_638605258597214362" xlink:to="ifrs-full_RightofuseAssets_638605258597214362" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_IntangibleAssetsOtherThanGoodwill_638605258597214362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract_638605258597214362" xlink:to="ifrs-full_IntangibleAssetsOtherThanGoodwill_638605258597214362" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentAssets" xlink:label="ifrs-full_NoncurrentAssets_638605258597214362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentAssetsAbstract_638605258597214362" xlink:to="ifrs-full_NoncurrentAssets_638605258597214362" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Assets" xlink:label="ifrs-full_Assets_638605258597214362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_Assets_638605258597214362" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesAbstract" xlink:label="ifrs-full_LiabilitiesAbstract_638605258597214362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_LiabilitiesAbstract_638605258597214362" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilitiesAbstract" xlink:label="ifrs-full_CurrentLiabilitiesAbstract_638605258597214362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LiabilitiesAbstract_638605258597214362" xlink:to="ifrs-full_CurrentLiabilitiesAbstract_638605258597214362" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TradeAndOtherCurrentPayables" xlink:label="ifrs-full_TradeAndOtherCurrentPayables_638605258597224362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract_638605258597214362" xlink:to="ifrs-full_TradeAndOtherCurrentPayables_638605258597224362" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLeaseLiabilities" xlink:label="ifrs-full_CurrentLeaseLiabilities_638605258597224362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract_638605258597214362" xlink:to="ifrs-full_CurrentLeaseLiabilities_638605258597224362" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities" xlink:label="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_638605258597224362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract_638605258597214362" xlink:to="ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities_638605258597224362" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentRefundsProvision" xlink:label="ifrs-full_CurrentRefundsProvision_638605258597224362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract_638605258597214362" xlink:to="ifrs-full_CurrentRefundsProvision_638605258597224362" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentDerivativeFinancialLiabilities" xlink:label="ifrs-full_CurrentDerivativeFinancialLiabilities_638605258597224362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract_638605258597214362" xlink:to="ifrs-full_CurrentDerivativeFinancialLiabilities_638605258597224362" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentLiabilities" xlink:label="ifrs-full_CurrentLiabilities_638605258597224362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CurrentLiabilitiesAbstract_638605258597214362" xlink:to="ifrs-full_CurrentLiabilities_638605258597224362" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilitiesAbstract" xlink:label="ifrs-full_NoncurrentLiabilitiesAbstract_638605258597224362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LiabilitiesAbstract_638605258597214362" xlink:to="ifrs-full_NoncurrentLiabilitiesAbstract_638605258597224362" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLeaseLiabilities" xlink:label="ifrs-full_NoncurrentLeaseLiabilities_638605258597224362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract_638605258597224362" xlink:to="ifrs-full_NoncurrentLeaseLiabilities_638605258597224362" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_NoncurrentRoyaltyObligation" xlink:label="rdhl_NoncurrentRoyaltyObligation_638605258597234361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract_638605258597224362" xlink:to="rdhl_NoncurrentRoyaltyObligation_638605258597234361" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NoncurrentLiabilities" xlink:label="ifrs-full_NoncurrentLiabilities_638605258597234361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NoncurrentLiabilitiesAbstract_638605258597224362" xlink:to="ifrs-full_NoncurrentLiabilities_638605258597234361" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Liabilities" xlink:label="ifrs-full_Liabilities_638605258597234361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LiabilitiesAbstract_638605258597214362" xlink:to="ifrs-full_Liabilities_638605258597234361" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAbstract" xlink:label="ifrs-full_EquityAbstract_638605258597234361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_EquityAbstract_638605258597234361" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapital" xlink:label="ifrs-full_IssuedCapital_638605258597234361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract_638605258597234361" xlink:to="ifrs-full_IssuedCapital_638605258597234361" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharePremium" xlink:label="ifrs-full_SharePremium_638605258597234361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract_638605258597234361" xlink:to="ifrs-full_SharePremium_638605258597234361" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarnings" xlink:label="ifrs-full_RetainedEarnings_638605258597234361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityAbstract_638605258597234361" xlink:to="ifrs-full_RetainedEarnings_638605258597234361" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity_638605258597234361" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_Equity_638605258597234361" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityAndLiabilities" xlink:label="ifrs-full_EquityAndLiabilities_638605258597244363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfFinancialPositionAbstract" xlink:to="ifrs-full_EquityAndLiabilities_638605258597244363" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfChangesInEquity" xlink:type="extended" xlink:title="00300 - Statement - CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityAbstract" xlink:label="StatementOfChangesInEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityTable" xlink:label="ifrs-full_StatementOfChangesInEquityTable_638605258597244363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfChangesInEquityAbstract" xlink:to="ifrs-full_StatementOfChangesInEquityTable_638605258597244363" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis_638605258597244363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable_638605258597244363" xlink:to="ifrs-full_ComponentsOfEquityAxis_638605258597244363" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuedCapitalMember" xlink:label="ifrs-full_IssuedCapitalMember_638605258597244363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis_638605258597244363" xlink:to="ifrs-full_IssuedCapitalMember_638605258597244363" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharePremiumMember" xlink:label="ifrs-full_SharePremiumMember_638605258597244363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis_638605258597244363" xlink:to="ifrs-full_SharePremiumMember_638605258597244363" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RetainedEarningsMember" xlink:label="ifrs-full_RetainedEarningsMember_638605258597244363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis_638605258597244363" xlink:to="ifrs-full_RetainedEarningsMember_638605258597244363" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember_638605258597244363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis_638605258597244363" xlink:to="ifrs-full_EquityMember_638605258597244363" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfChangesInEquityLineItems" xlink:label="ifrs-full_StatementOfChangesInEquityLineItems_638605258597244363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityTable_638605258597244363" xlink:to="ifrs-full_StatementOfChangesInEquityLineItems_638605258597244363" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity_638605258597254363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638605258597244363" xlink:to="ifrs-full_Equity_638605258597254363" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions" xlink:label="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_638605258597254363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638605258597244363" xlink:to="ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions_638605258597254363" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssueOfEquity" xlink:label="ifrs-full_IssueOfEquity_638605258597254363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638605258597244363" xlink:to="ifrs-full_IssueOfEquity_638605258597254363" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_StockIssuedDuringPeriodValueRestrictedStockAward" xlink:label="rdhl_StockIssuedDuringPeriodValueRestrictedStockAward_638605258597254363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638605258597244363" xlink:to="rdhl_StockIssuedDuringPeriodValueRestrictedStockAward_638605258597254363" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss_638605258597254363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638605258597244363" xlink:to="ifrs-full_ProfitLoss_638605258597254363" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Equity" xlink:label="ifrs-full_Equity_6386052585972543631" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfChangesInEquityLineItems_638605258597244363" xlink:to="ifrs-full_Equity_6386052585972543631" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="StatementOfCashFlowsAbstract_ifrs-full_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_638605258597254363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract_ifrs-full_2" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_638605258597254363" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss_638605258597254363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_638605258597254363" xlink:to="ifrs-full_ProfitLoss_638605258597254363" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForReconcileProfitLossAbstract" xlink:label="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638605258597254363" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_638605258597254363" xlink:to="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638605258597254363" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForSharebasedPayments" xlink:label="ifrs-full_AdjustmentsForSharebasedPayments_638605258597264362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638605258597254363" xlink:to="ifrs-full_AdjustmentsForSharebasedPayments_638605258597264362" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDepreciationExpense" xlink:label="ifrs-full_AdjustmentsForDepreciationExpense_638605258597264362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638605258597254363" xlink:to="ifrs-full_AdjustmentsForDepreciationExpense_638605258597264362" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForAmortisationExpense" xlink:label="ifrs-full_AdjustmentsForAmortisationExpense_638605258597264362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638605258597254363" xlink:to="ifrs-full_AdjustmentsForAmortisationExpense_638605258597264362" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_AdjustmentsForGainsFromTransferOfRightsInMovantikAndExtinguishmentOfDebtObligations" xlink:label="rdhl_AdjustmentsForGainsFromTransferOfRightsInMovantikAndExtinguishmentOfDebtObligations_638605258597264362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638605258597254363" xlink:to="rdhl_AdjustmentsForGainsFromTransferOfRightsInMovantikAndExtinguishmentOfDebtObligations_638605258597264362" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_AdjustmentsForGainsFromEarlyTerminationOfLeasesNet" xlink:label="rdhl_AdjustmentsForGainsFromEarlyTerminationOfLeasesNet_638605258597264362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638605258597254363" xlink:to="rdhl_AdjustmentsForGainsFromEarlyTerminationOfLeasesNet_638605258597264362" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives" xlink:label="ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives_638605258597264362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638605258597254363" xlink:to="ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives_638605258597264362" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_AdjustmentsForLossFromModificationOfWarrantsTermsAsPartOfNewIssuance." xlink:label="rdhl_AdjustmentsForLossFromModificationOfWarrantsTermsAsPartOfNewIssuance._638605258597264362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638605258597254363" xlink:to="rdhl_AdjustmentsForLossFromModificationOfWarrantsTermsAsPartOfNewIssuance._638605258597264362" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_AdjustmentForIssuanceCostInRespectOfWarrants" xlink:label="rdhl_AdjustmentForIssuanceCostInRespectOfWarrants_638605258597264362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638605258597254363" xlink:to="rdhl_AdjustmentForIssuanceCostInRespectOfWarrants_638605258597264362" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_AdjustmentsForRevaluationOfBankDeposits" xlink:label="rdhl_AdjustmentsForRevaluationOfBankDeposits_638605258597264362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638605258597254363" xlink:to="rdhl_AdjustmentsForRevaluationOfBankDeposits_638605258597264362" order="9" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital" xlink:label="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital_638605258597264362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AdjustmentsForReconcileProfitLossAbstract_638605258597254363" xlink:to="ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital_638605258597264362" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_ChangesInAssetsAndLiabilityItemsAbstract" xlink:label="rdhl_ChangesInAssetsAndLiabilityItemsAbstract_638605258597264362" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_638605258597254363" xlink:to="rdhl_ChangesInAssetsAndLiabilityItemsAbstract_638605258597264362" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_638605258597274366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rdhl_ChangesInAssetsAndLiabilityItemsAbstract_638605258597264362" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable_638605258597274366" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_638605258597274366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rdhl_ChangesInAssetsAndLiabilityItemsAbstract_638605258597264362" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables_638605258597274366" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForDecreaseIncreaseInInventories" xlink:label="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_638605258597274366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rdhl_ChangesInAssetsAndLiabilityItemsAbstract_638605258597264362" xlink:to="ifrs-full_AdjustmentsForDecreaseIncreaseInInventories_638605258597274366" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="8" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable" xlink:label="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_638605258597274366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rdhl_ChangesInAssetsAndLiabilityItemsAbstract_638605258597264362" xlink:to="ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable_638605258597274366" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_AdjustmentsForDecreaseIncreaseInAccruedExpenses" xlink:label="rdhl_AdjustmentsForDecreaseIncreaseInAccruedExpenses_638605258597274366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rdhl_ChangesInAssetsAndLiabilityItemsAbstract_638605258597264362" xlink:to="rdhl_AdjustmentsForDecreaseIncreaseInAccruedExpenses_638605258597274366" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_AdjustmentsForIncreaseDecreaseInAllowanceForDeductionsFromRevenue" xlink:label="rdhl_AdjustmentsForIncreaseDecreaseInAllowanceForDeductionsFromRevenue_638605258597274366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rdhl_ChangesInAssetsAndLiabilityItemsAbstract_638605258597264362" xlink:to="rdhl_AdjustmentsForIncreaseDecreaseInAllowanceForDeductionsFromRevenue_638605258597274366" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInWorkingCapital" xlink:label="ifrs-full_IncreaseDecreaseInWorkingCapital_638605258597274366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rdhl_ChangesInAssetsAndLiabilityItemsAbstract_638605258597264362" xlink:to="ifrs-full_IncreaseDecreaseInWorkingCapital_638605258597274366" order="7" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInOperatingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInOperatingActivities_638605258597274366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract_638605258597254363" xlink:to="ifrs-full_CashFlowsFromUsedInOperatingActivities_638605258597274366" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_638605258597274366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract_ifrs-full_2" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_638605258597274366" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities" xlink:label="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_638605258597284364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_638605258597274366" xlink:to="ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities_638605258597284364" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInInvestingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInInvestingActivities_638605258597284364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract_638605258597274366" xlink:to="ifrs-full_CashFlowsFromUsedInInvestingActivities_638605258597284364" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_638605258597284364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract_ifrs-full_2" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_638605258597284364" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssueOfOrdinaryShares" xlink:label="ifrs-full_ProceedsFromIssueOfOrdinaryShares_638605258597284364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_638605258597284364" xlink:to="ifrs-full_ProceedsFromIssueOfOrdinaryShares_638605258597284364" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_RepaymentOfPayableInRespectOfIntangibleAssetPurchase" xlink:label="rdhl_RepaymentOfPayableInRespectOfIntangibleAssetPurchase_638605258597284364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_638605258597284364" xlink:to="rdhl_RepaymentOfPayableInRespectOfIntangibleAssetPurchase_638605258597284364" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_IfrsDecreaseInRestrictedCash" xlink:label="rdhl_IfrsDecreaseInRestrictedCash_638605258597284364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_638605258597284364" xlink:to="rdhl_IfrsDecreaseInRestrictedCash_638605258597284364" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities" xlink:label="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_638605258597284364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_638605258597284364" xlink:to="ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities_638605258597284364" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashFlowsFromUsedInFinancingActivities" xlink:label="ifrs-full_CashFlowsFromUsedInFinancingActivities_638605258597284364" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract_638605258597284364" xlink:to="ifrs-full_CashFlowsFromUsedInFinancingActivities_638605258597284364" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges" xlink:label="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_638605258597294368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract_ifrs-full_2" xlink:to="ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges_638605258597294368" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents" xlink:label="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_638605258597294368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract_ifrs-full_2" xlink:to="ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents_638605258597294368" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents_638605258597294368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract_ifrs-full_2" xlink:to="ifrs-full_CashAndCashEquivalents_638605258597294368" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CashAndCashEquivalents" xlink:label="ifrs-full_CashAndCashEquivalents_6386052585972943681" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract_ifrs-full_2" xlink:to="ifrs-full_CashAndCashEquivalents_6386052585972943681" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_SupplementalInformationInterestReceivedInCash" xlink:label="rdhl_SupplementalInformationInterestReceivedInCash_638605258597294368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract_ifrs-full_2" xlink:to="rdhl_SupplementalInformationInterestReceivedInCash_638605258597294368" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_SupplementalInformationInterestPaidInCash" xlink:label="rdhl_SupplementalInformationInterestPaidInCash_638605258597294368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract_ifrs-full_2" xlink:to="rdhl_SupplementalInformationInterestPaidInCash_638605258597294368" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_AcquisitionOfRightOfUseAssetsByMeansOfLeaseLiabilities" xlink:label="rdhl_AcquisitionOfRightOfUseAssetsByMeansOfLeaseLiabilities_638605258597304367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract_ifrs-full_2" xlink:to="rdhl_AcquisitionOfRightOfUseAssetsByMeansOfLeaseLiabilities_638605258597304367" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_DecreaseInLeaseLiabilityFromEarlyTerminationOfLease" xlink:label="rdhl_DecreaseInLeaseLiabilityFromEarlyTerminationOfLease_638605258597304367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract_ifrs-full_2" xlink:to="rdhl_DecreaseInLeaseLiabilityFromEarlyTerminationOfLease_638605258597304367" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ChangesInIntangibleAssetsOtherThanGoodwill" xlink:label="ifrs-full_ChangesInIntangibleAssetsOtherThanGoodwill_638605258597304367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract_ifrs-full_2" xlink:to="ifrs-full_ChangesInIntangibleAssetsOtherThanGoodwill_638605258597304367" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_DecreaseInInventories" xlink:label="rdhl_DecreaseInInventories_638605258597304367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract_ifrs-full_2" xlink:to="rdhl_DecreaseInInventories_638605258597304367" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_DecreaseIncreaseInPayablesInRespectOfIntangibleAssets" xlink:label="rdhl_DecreaseIncreaseInPayablesInRespectOfIntangibleAssets_638605258597304367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract_ifrs-full_2" xlink:to="rdhl_DecreaseIncreaseInPayablesInRespectOfIntangibleAssets_638605258597304367" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_DecreaseIncreaseInBorrowings" xlink:label="rdhl_DecreaseIncreaseInBorrowings_638605258597304367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract_ifrs-full_2" xlink:to="rdhl_DecreaseIncreaseInBorrowings_638605258597304367" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_GainsFromTransferOfRightsInMovantikAndExtinguishmentOfDebtObligations" xlink:label="rdhl_GainsFromTransferOfRightsInMovantikAndExtinguishmentOfDebtObligations_638605258597314366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="StatementOfCashFlowsAbstract_ifrs-full_2" xlink:to="rdhl_GainsFromTransferOfRightsInMovantikAndExtinguishmentOfDebtObligations_638605258597314366" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlowsParenthetical" xlink:type="extended" xlink:title="00405 - Statement - CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_StatementOfCashFlowsAbstract" xlink:label="ifrs-full_StatementOfCashFlowsAbstract_1" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_DecreaseInRightOfUseAssetFromEarlyTerminationOfLease" xlink:label="rdhl_DecreaseInRightOfUseAssetFromEarlyTerminationOfLease_638605258597314366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_StatementOfCashFlowsAbstract_1" xlink:to="rdhl_DecreaseInRightOfUseAssetFromEarlyTerminationOfLease_638605258597314366" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.redhillbio.com/role/DisclosureGeneral" xlink:type="extended" xlink:title="10101 - Disclosure - GENERAL" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_GeneralInformationAbstract" xlink:label="GeneralInformationAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory" xlink:label="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_638605258597314366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="GeneralInformationAbstract" xlink:to="ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory_638605258597314366" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.redhillbio.com/role/DisclosureBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsAndSignificantAccountingPolicies" xlink:type="extended" xlink:title="10201 - Disclosure - BASIS OF PREPARATION OF THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_DisclosureOfBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsAbstract" xlink:label="rdhl_DisclosureOfBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_DisclosureOfBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsTextBlock" xlink:label="rdhl_DisclosureOfBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsTextBlock_638605258597314366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rdhl_DisclosureOfBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsAbstract" xlink:to="rdhl_DisclosureOfBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsTextBlock_638605258597314366" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriod" xlink:type="extended" xlink:title="10301 - Disclosure - SIGNIFICANT EVENTS DURING THE CURRENT REPORTING PERIOD" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_SignificantEventsDuringCurrentReportingPeriodAbstract" xlink:label="rdhl_SignificantEventsDuringCurrentReportingPeriodAbstract" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_SignificantEventsDuringCurrentReportingPeriodTextBlock" xlink:label="rdhl_SignificantEventsDuringCurrentReportingPeriodTextBlock_638605258597324367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rdhl_SignificantEventsDuringCurrentReportingPeriodAbstract" xlink:to="rdhl_SignificantEventsDuringCurrentReportingPeriodTextBlock_638605258597324367" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.redhillbio.com/role/DisclosureAllowanceForDeductionsFromRevenues" xlink:type="extended" xlink:title="10401 - Disclosure - ALLOWANCE FOR DEDUCTIONS FROM REVENUES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_AllowanceForDeductionsFromRevenuesAbstract" xlink:label="rdhl_AllowanceForDeductionsFromRevenuesAbstract" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_AllowanceForDeductionsFromRevenuesDisclosureTextBlock" xlink:label="rdhl_AllowanceForDeductionsFromRevenuesDisclosureTextBlock_638605258597324367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rdhl_AllowanceForDeductionsFromRevenuesAbstract" xlink:to="rdhl_AllowanceForDeductionsFromRevenuesDisclosureTextBlock_638605258597324367" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.redhillbio.com/role/DisclosureShareBasedPayments" xlink:type="extended" xlink:title="10501 - Disclosure - SHARE-BASED PAYMENTS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory" xlink:label="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_638605258597324367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:to="ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory_638605258597324367" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.redhillbio.com/role/DisclosureNetRevenues" xlink:type="extended" xlink:title="10601 - Disclosure - NET REVENUES" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:label="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory" xlink:label="ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_638605258597324367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:to="ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory_638605258597324367" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.redhillbio.com/role/DisclosureFinancialInstruments" xlink:type="extended" xlink:title="10701 - Disclosure - FINANCIAL INSTRUMENTS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract_636646498066496900" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsExplanatory" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_638605258597334366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract_636646498066496900" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsExplanatory_638605258597334366" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.redhillbio.com/role/DisclosureSegmentInformation" xlink:type="extended" xlink:title="10801 - Disclosure - SEGMENT INFORMATION" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory" xlink:label="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_638605258597334366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory_638605258597334366" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.redhillbio.com/role/DisclosureEarningLossPerShare" xlink:type="extended" xlink:title="10901 - Disclosure - EARNING (LOSS) PER SHARE" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EarningsPerShareAbstract" xlink:label="EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEarningsPerShareExplanatory" xlink:label="ifrs-full_DisclosureOfEarningsPerShareExplanatory_638605258597334366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="EarningsPerShareAbstract" xlink:to="ifrs-full_DisclosureOfEarningsPerShareExplanatory_638605258597334366" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.redhillbio.com/role/DisclosureEventSubsequentToJune302024" xlink:type="extended" xlink:title="11001 - Disclosure - EVENT SUBSEQUENT TO JUNE 30, 2024" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:label="DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory" xlink:label="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_638605258597334366" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:to="ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory_638605258597334366" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="7" />
  </presentationLink>
  <presentationLink xlink:role="http://www.redhillbio.com/role/DisclosureBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsAndSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20202 - Disclosure - BASIS OF PREPARATION OF THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_IfrsAccountingPoliciesAbstract" xlink:label="rdhl_IfrsAccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory" xlink:label="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_638605258597344367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rdhl_IfrsAccountingPoliciesAbstract" xlink:to="ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory_638605258597344367" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.redhillbio.com/role/DisclosureAllowanceForDeductionsFromRevenuesTables" xlink:type="extended" xlink:title="30403 - Disclosure - ALLOWANCE FOR DEDUCTIONS FROM REVENUES (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_AllowanceForDeductionsFromRevenuesAbstract" xlink:label="rdhl_AllowanceForDeductionsFromRevenuesAbstract" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_ScheduleOfMovementOfAllowanceForDeductionsFromRevenuesTableTextBlock" xlink:label="rdhl_ScheduleOfMovementOfAllowanceForDeductionsFromRevenuesTableTextBlock_638605258597344367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rdhl_AllowanceForDeductionsFromRevenuesAbstract" xlink:to="rdhl_ScheduleOfMovementOfAllowanceForDeductionsFromRevenuesTableTextBlock_638605258597344367" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.redhillbio.com/role/DisclosureNetRevenuesTables" xlink:type="extended" xlink:title="30603 - Disclosure - NET REVENUES (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_638605258597344367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory_638605258597344367" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.redhillbio.com/role/DisclosureFinancialInstrumentsTables" xlink:type="extended" xlink:title="30703 - Disclosure - FINANCIAL INSTRUMENTS (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract_636646498702042016" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory" xlink:label="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory_638605258597344367" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract_636646498702042016" xlink:to="ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory_638605258597344367" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.redhillbio.com/role/DisclosureSegmentInformationTables" xlink:type="extended" xlink:title="30803 - Disclosure - SEGMENT INFORMATION (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsExplanatory" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsExplanatory_638605258597354370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="ifrs-full_DisclosureOfOperatingSegmentsExplanatory_638605258597354370" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.redhillbio.com/role/DisclosureGeneralDetails" xlink:type="extended" xlink:title="40101 - Disclosure - GENERAL (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_GeneralInformationAbstract" xlink:label="rdhl_GeneralInformationAbstract_2" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_GeneralTable" xlink:label="rdhl_GeneralTable_638605258597354370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rdhl_GeneralInformationAbstract_2" xlink:to="rdhl_GeneralTable_638605258597354370" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_638605258597354370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rdhl_GeneralTable_638605258597354370" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_638605258597354370" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="ifrs-full_NonadjustingEventsMember_638605258597354370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_638605258597354370" xlink:to="ifrs-full_NonadjustingEventsMember_638605258597354370" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MajorOrdinaryShareTransactionsMember" xlink:label="ifrs-full_MajorOrdinaryShareTransactionsMember_638605258597354370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsMember_638605258597354370" xlink:to="ifrs-full_MajorOrdinaryShareTransactionsMember_638605258597354370" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfOrdinarySharesAxis" xlink:label="ifrs-full_ClassesOfOrdinarySharesAxis_638605258597354370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rdhl_GeneralTable_638605258597354370" xlink:to="ifrs-full_ClassesOfOrdinarySharesAxis_638605258597354370" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember" xlink:label="ifrs-full_OrdinarySharesMember_638605258597354370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfOrdinarySharesAxis_638605258597354370" xlink:to="ifrs-full_OrdinarySharesMember_638605258597354370" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2023/dei-2023.xsd#dei_AdrMember" xlink:label="dei_AdrMember_638605258597354370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_OrdinarySharesMember_638605258597354370" xlink:to="dei_AdrMember_638605258597354370" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_GeneralLineItems" xlink:label="rdhl_GeneralLineItems_638605258597354370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rdhl_GeneralTable_638605258597354370" xlink:to="rdhl_GeneralLineItems_638605258597354370" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_NumberOfOrdinarySharesIssuedInExchangeOfAmericanDepositoryReceipts" xlink:label="rdhl_NumberOfOrdinarySharesIssuedInExchangeOfAmericanDepositoryReceipts_638605258597354370" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rdhl_GeneralLineItems_638605258597354370" xlink:to="rdhl_NumberOfOrdinarySharesIssuedInExchangeOfAmericanDepositoryReceipts_638605258597354370" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.redhillbio.com/role/DisclosureBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsAndSignificantAccountingPoliciesDetails" xlink:type="extended" xlink:title="40201 - Disclosure - BASIS OF PREPARATION OF THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsAbstract" xlink:label="ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsTable" xlink:label="ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsTable_638605258597364368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsAbstract" xlink:to="ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsTable_638605258597364368" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NewIFRSsAxis" xlink:label="ifrs-full_NewIFRSsAxis_638605258597364368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsTable_638605258597364368" xlink:to="ifrs-full_NewIFRSsAxis_638605258597364368" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NewIFRSsMember" xlink:label="ifrs-full_NewIFRSsMember_638605258597364368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NewIFRSsAxis_638605258597364368" xlink:to="ifrs-full_NewIFRSsMember_638605258597364368" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_Ias1AmendmentsMember" xlink:label="rdhl_Ias1AmendmentsMember_638605258597364368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NewIFRSsMember_638605258597364368" xlink:to="rdhl_Ias1AmendmentsMember_638605258597364368" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems" xlink:label="ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems_638605258597364368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsTable_638605258597364368" xlink:to="ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems_638605258597364368" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_ReclassificationOfWarrantLiability" xlink:label="rdhl_ReclassificationOfWarrantLiability_638605258597364368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems_638605258597364368" xlink:to="rdhl_ReclassificationOfWarrantLiability_638605258597364368" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodEquityOfferingsDetails" xlink:type="extended" xlink:title="40301 - Disclosure - SIGNIFICANT EVENTS DURING THE CURRENT REPORTING PERIOD - Equity Offerings (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_SignificantEventsDuringCurrentReportingPeriodAbstract" xlink:label="rdhl_SignificantEventsDuringCurrentReportingPeriodAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalTable" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638605258597364368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rdhl_SignificantEventsDuringCurrentReportingPeriodAbstract" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638605258597364368" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalAxis" xlink:label="ifrs-full_ClassesOfShareCapitalAxis_638605258597364368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638605258597364368" xlink:to="ifrs-full_ClassesOfShareCapitalAxis_638605258597364368" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfShareCapitalMember" xlink:label="ifrs-full_ClassesOfShareCapitalMember_638605258597364368" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalAxis_638605258597364368" xlink:to="ifrs-full_ClassesOfShareCapitalMember_638605258597364368" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OrdinarySharesMember" xlink:label="ifrs-full_OrdinarySharesMember_638605258597374372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalMember_638605258597364368" xlink:to="ifrs-full_OrdinarySharesMember_638605258597374372" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PreferenceSharesMember" xlink:label="ifrs-full_PreferenceSharesMember_638605258597374372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfShareCapitalMember_638605258597364368" xlink:to="ifrs-full_PreferenceSharesMember_638605258597374372" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ComponentsOfEquityAxis" xlink:label="ifrs-full_ComponentsOfEquityAxis_638605258597374372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638605258597364368" xlink:to="ifrs-full_ComponentsOfEquityAxis_638605258597374372" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EquityMember" xlink:label="ifrs-full_EquityMember_638605258597374372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ComponentsOfEquityAxis_638605258597374372" xlink:to="ifrs-full_EquityMember_638605258597374372" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_IfrsWarrantMember" xlink:label="rdhl_IfrsWarrantMember_638605258597374372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityMember_638605258597374372" xlink:to="rdhl_IfrsWarrantMember_638605258597374372" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ReserveOfEquityComponentOfConvertibleInstrumentsMember" xlink:label="ifrs-full_ReserveOfEquityComponentOfConvertibleInstrumentsMember_638605258597374372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityMember_638605258597374372" xlink:to="ifrs-full_ReserveOfEquityComponentOfConvertibleInstrumentsMember_638605258597374372" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_AmericanDepositoryShareMember" xlink:label="rdhl_AmericanDepositoryShareMember_638605258597374372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EquityMember_638605258597374372" xlink:to="rdhl_AmericanDepositoryShareMember_638605258597374372" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfClassesOfShareCapitalLineItems" xlink:label="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638605258597374372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalTable_638605258597364368" xlink:to="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638605258597374372" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesIssued" xlink:label="ifrs-full_NumberOfSharesIssued_638605258597374372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638605258597374372" xlink:to="ifrs-full_NumberOfSharesIssued_638605258597374372" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_IfrsClassOfWarrantsOrRightExercisePriceOfWarrantsOrRights" xlink:label="rdhl_IfrsClassOfWarrantsOrRightExercisePriceOfWarrantsOrRights_638605258597374372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638605258597374372" xlink:to="rdhl_IfrsClassOfWarrantsOrRightExercisePriceOfWarrantsOrRights_638605258597374372" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceCosts" xlink:label="ifrs-full_FinanceCosts_638605258597374372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638605258597374372" xlink:to="ifrs-full_FinanceCosts_638605258597374372" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_IfrsSharesIssuedPricePerShare" xlink:label="rdhl_IfrsSharesIssuedPricePerShare_638605258597384369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638605258597374372" xlink:to="rdhl_IfrsSharesIssuedPricePerShare_638605258597384369" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProceedsFromIssuingShares" xlink:label="ifrs-full_ProceedsFromIssuingShares_638605258597384369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638605258597374372" xlink:to="ifrs-full_ProceedsFromIssuingShares_638605258597384369" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_WarrantsNumberIssued" xlink:label="rdhl_WarrantsNumberIssued_638605258597384369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638605258597374372" xlink:to="rdhl_WarrantsNumberIssued_638605258597384369" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights" xlink:label="rdhl_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_638605258597384369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638605258597374372" xlink:to="rdhl_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights_638605258597384369" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_IfrsWarrantsAndRightsOutstandingTerm" xlink:label="rdhl_IfrsWarrantsAndRightsOutstandingTerm_638605258597384369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638605258597374372" xlink:to="rdhl_IfrsWarrantsAndRightsOutstandingTerm_638605258597384369" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_NumberOfOrdinarySharesIssuedInExchangeOfAmericanDepositoryReceipts" xlink:label="rdhl_NumberOfOrdinarySharesIssuedInExchangeOfAmericanDepositoryReceipts_638605258597384369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638605258597374372" xlink:to="rdhl_NumberOfOrdinarySharesIssuedInExchangeOfAmericanDepositoryReceipts_638605258597384369" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_PaymentsForShareIssueCosts" xlink:label="ifrs-full_PaymentsForShareIssueCosts_638605258597384369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638605258597374372" xlink:to="ifrs-full_PaymentsForShareIssueCosts_638605258597384369" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfSharesAuthorised" xlink:label="ifrs-full_NumberOfSharesAuthorised_638605258597384369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638605258597374372" xlink:to="ifrs-full_NumberOfSharesAuthorised_638605258597384369" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ParValuePerShare" xlink:label="ifrs-full_ParValuePerShare_638605258597384369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638605258597374372" xlink:to="ifrs-full_ParValuePerShare_638605258597384369" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_AuthorisedShareCapital" xlink:label="rdhl_AuthorisedShareCapital_638605258597394369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfClassesOfShareCapitalLineItems_638605258597374372" xlink:to="rdhl_AuthorisedShareCapital_638605258597394369" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.redhillbio.com/role/DisclosureAllowanceForDeductionsFromRevenuesDetails" xlink:type="extended" xlink:title="40401 - Disclosure - ALLOWANCE FOR DEDUCTIONS FROM REVENUES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_AllowanceForDeductionsFromRevenuesAbstract" xlink:label="rdhl_AllowanceForDeductionsFromRevenuesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherProvisionsTable" xlink:label="ifrs-full_DisclosureOfOtherProvisionsTable_638605258597394369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="rdhl_AllowanceForDeductionsFromRevenuesAbstract" xlink:to="ifrs-full_DisclosureOfOtherProvisionsTable_638605258597394369" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfProvisionsAxis" xlink:label="ifrs-full_ClassesOfProvisionsAxis_638605258597394369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOtherProvisionsTable_638605258597394369" xlink:to="ifrs-full_ClassesOfProvisionsAxis_638605258597394369" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_OtherProvisionsMember" xlink:label="ifrs-full_OtherProvisionsMember_638605258597394369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfProvisionsAxis_638605258597394369" xlink:to="ifrs-full_OtherProvisionsMember_638605258597394369" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_RebatesAndPatientDiscountProgramsMember" xlink:label="rdhl_RebatesAndPatientDiscountProgramsMember_638605258597394369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_OtherProvisionsMember_638605258597394369" xlink:to="rdhl_RebatesAndPatientDiscountProgramsMember_638605258597394369" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_ProductReturnsMember" xlink:label="rdhl_ProductReturnsMember_638605258597394369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_OtherProvisionsMember_638605258597394369" xlink:to="rdhl_ProductReturnsMember_638605258597394369" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOtherProvisionsLineItems" xlink:label="ifrs-full_DisclosureOfOtherProvisionsLineItems_638605258597394369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOtherProvisionsTable_638605258597394369" xlink:to="ifrs-full_DisclosureOfOtherProvisionsLineItems_638605258597394369" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentRefundsProvision" xlink:label="ifrs-full_CurrentRefundsProvision_638605258597394369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOtherProvisionsLineItems_638605258597394369" xlink:to="ifrs-full_CurrentRefundsProvision_638605258597394369" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInExistingProvisionsOtherProvisions" xlink:label="ifrs-full_IncreaseDecreaseInExistingProvisionsOtherProvisions_638605258597394369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOtherProvisionsLineItems_638605258597394369" xlink:to="ifrs-full_IncreaseDecreaseInExistingProvisionsOtherProvisions_638605258597394369" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProvisionUsedOtherProvisions" xlink:label="ifrs-full_ProvisionUsedOtherProvisions_638605258597404371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOtherProvisionsLineItems_638605258597394369" xlink:to="ifrs-full_ProvisionUsedOtherProvisions_638605258597404371" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions" xlink:label="ifrs-full_IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions_638605258597404371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOtherProvisionsLineItems_638605258597394369" xlink:to="ifrs-full_IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions_638605258597404371" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CurrentRefundsProvision" xlink:label="ifrs-full_CurrentRefundsProvision_638605258597404371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOtherProvisionsLineItems_638605258597394369" xlink:to="ifrs-full_CurrentRefundsProvision_638605258597404371" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
  </presentationLink>
  <presentationLink xlink:role="http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails" xlink:type="extended" xlink:title="40501 - Disclosure - SHARE-BASED PAYMENTS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract" xlink:label="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638605258597404371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract_1" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638605258597404371" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TypesOfSharebasedPaymentArrangementsAxis" xlink:label="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638605258597404371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638605258597404371" xlink:to="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638605258597404371" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SharebasedPaymentArrangementsMember" xlink:label="ifrs-full_SharebasedPaymentArrangementsMember_638605258597404371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_638605258597404371" xlink:to="ifrs-full_SharebasedPaymentArrangementsMember_638605258597404371" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_IfrsRestrictedStockUnitsRsuMember" xlink:label="rdhl_IfrsRestrictedStockUnitsRsuMember_638605258597404371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638605258597404371" xlink:to="rdhl_IfrsRestrictedStockUnitsRsuMember_638605258597404371" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_IfrsEmployeeStockOptionMember" xlink:label="rdhl_IfrsEmployeeStockOptionMember_638605258597404371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_SharebasedPaymentArrangementsMember_638605258597404371" xlink:to="rdhl_IfrsEmployeeStockOptionMember_638605258597404371" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfRelatedPartiesAxis" xlink:label="ifrs-full_CategoriesOfRelatedPartiesAxis_638605258597404371" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638605258597404371" xlink:to="ifrs-full_CategoriesOfRelatedPartiesAxis_638605258597404371" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_EntitysTotalForRelatedPartiesMember" xlink:label="ifrs-full_EntitysTotalForRelatedPartiesMember_638605258597414369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfRelatedPartiesAxis_638605258597404371" xlink:to="ifrs-full_EntitysTotalForRelatedPartiesMember_638605258597414369" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_DirectorsAndChiefExecutiveOfficerMember" xlink:label="rdhl_DirectorsAndChiefExecutiveOfficerMember_638605258597414369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_EntitysTotalForRelatedPartiesMember_638605258597414369" xlink:to="rdhl_DirectorsAndChiefExecutiveOfficerMember_638605258597414369" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems" xlink:label="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638605258597414369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable_638605258597404371" xlink:to="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638605258597414369" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_638605258597414369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638605258597414369" xlink:to="ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement_638605258597414369" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted" xlink:label="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_638605258597414369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638605258597414369" xlink:to="ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted_638605258597414369" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement" xlink:label="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_638605258597414369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638605258597414369" xlink:to="ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement_638605258597414369" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_NumberOfRsuQuarterlyInstallments" xlink:label="rdhl_NumberOfRsuQuarterlyInstallments_638605258597414369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638605258597414369" xlink:to="rdhl_NumberOfRsuQuarterlyInstallments_638605258597414369" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted" xlink:label="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_638605258597414369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638605258597414369" xlink:to="ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted_638605258597414369" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_ReversedExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets" xlink:label="rdhl_ReversedExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_638605258597414369" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems_638605258597414369" xlink:to="rdhl_ReversedExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets_638605258597414369" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.redhillbio.com/role/DisclosureNetRevenuesDetails" xlink:type="extended" xlink:title="40601 - Disclosure - NET REVENUES (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract_636529273974255912" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_638605258597424372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract_636529273974255912" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_638605258597424372" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesAxis" xlink:label="ifrs-full_ProductsAndServicesAxis_638605258597424372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_638605258597424372" xlink:to="ifrs-full_ProductsAndServicesAxis_638605258597424372" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProductsAndServicesMember" xlink:label="ifrs-full_ProductsAndServicesMember_638605258597424372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProductsAndServicesAxis_638605258597424372" xlink:to="ifrs-full_ProductsAndServicesMember_638605258597424372" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_TaliciaMember" xlink:label="rdhl_TaliciaMember_638605258597424372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProductsAndServicesMember_638605258597424372" xlink:to="rdhl_TaliciaMember_638605258597424372" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_MovantikMember" xlink:label="rdhl_MovantikMember_638605258597424372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ProductsAndServicesMember_638605258597424372" xlink:to="rdhl_MovantikMember_638605258597424372" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesAxis" xlink:label="ifrs-full_CounterpartiesAxis_638605258597424372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_638605258597424372" xlink:to="ifrs-full_CounterpartiesAxis_638605258597424372" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CounterpartiesMember" xlink:label="ifrs-full_CounterpartiesMember_638605258597424372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CounterpartiesAxis_638605258597424372" xlink:to="ifrs-full_CounterpartiesMember_638605258597424372" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_GaelanMedicalTradeLlcMember" xlink:label="rdhl_GaelanMedicalTradeLlcMember_638605258597424372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CounterpartiesMember_638605258597424372" xlink:to="rdhl_GaelanMedicalTradeLlcMember_638605258597424372" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems" xlink:label="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_638605258597424372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable_638605258597424372" xlink:to="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_638605258597424372" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RevenueAbstract" xlink:label="ifrs-full_RevenueAbstract_638605258597424372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems_638605258597424372" xlink:to="ifrs-full_RevenueAbstract_638605258597424372" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Revenue" xlink:label="ifrs-full_Revenue_638605258597424372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RevenueAbstract_638605258597424372" xlink:to="ifrs-full_Revenue_638605258597424372" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="9" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_ContraRevenueForMovantik" xlink:label="rdhl_ContraRevenueForMovantik_638605258597424372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RevenueAbstract_638605258597424372" xlink:to="rdhl_ContraRevenueForMovantik_638605258597424372" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_NetRevenue" xlink:label="rdhl_NetRevenue_638605258597434372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RevenueAbstract_638605258597424372" xlink:to="rdhl_NetRevenue_638605258597434372" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails" xlink:type="extended" xlink:title="40701 - Disclosure - FINANCIAL INSTRUMENTS (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsAbstract" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsAbstract_636646501191962390" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsTable" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsTable_638605258597434372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsAbstract_636646501191962390" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsTable_638605258597434372" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LevelsOfFairValueHierarchyAxis" xlink:label="ifrs-full_LevelsOfFairValueHierarchyAxis_638605258597434372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable_638605258597434372" xlink:to="ifrs-full_LevelsOfFairValueHierarchyAxis_638605258597434372" order="1" use="optional" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AllLevelsOfFairValueHierarchyMember" xlink:label="ifrs-full_AllLevelsOfFairValueHierarchyMember_638605258597434372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LevelsOfFairValueHierarchyAxis_638605258597434372" xlink:to="ifrs-full_AllLevelsOfFairValueHierarchyMember_638605258597434372" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Level3OfFairValueHierarchyMember" xlink:label="ifrs-full_Level3OfFairValueHierarchyMember_638605258597434372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AllLevelsOfFairValueHierarchyMember_638605258597434372" xlink:to="ifrs-full_Level3OfFairValueHierarchyMember_638605258597434372" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MeasurementAxis" xlink:label="ifrs-full_MeasurementAxis_638605258597434372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable_638605258597434372" xlink:to="ifrs-full_MeasurementAxis_638605258597434372" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AggregatedMeasurementMember" xlink:label="ifrs-full_AggregatedMeasurementMember_638605258597434372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_MeasurementAxis_638605258597434372" xlink:to="ifrs-full_AggregatedMeasurementMember_638605258597434372" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_AtFairValueMember" xlink:label="ifrs-full_AtFairValueMember_638605258597434372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_AggregatedMeasurementMember_638605258597434372" xlink:to="ifrs-full_AtFairValueMember_638605258597434372" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_CategoriesOfFinancialLiabilitiesAxis" xlink:label="ifrs-full_CategoriesOfFinancialLiabilitiesAxis_638605258597434372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable_638605258597434372" xlink:to="ifrs-full_CategoriesOfFinancialLiabilitiesAxis_638605258597434372" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesCategoryMember" xlink:label="ifrs-full_FinancialLiabilitiesCategoryMember_638605258597444372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_CategoriesOfFinancialLiabilitiesAxis_638605258597434372" xlink:to="ifrs-full_FinancialLiabilitiesCategoryMember_638605258597444372" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember" xlink:label="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember_638605258597444372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_FinancialLiabilitiesCategoryMember_638605258597444372" xlink:to="ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember_638605258597444372" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ClassesOfLiabilitiesAxis" xlink:label="ifrs-full_ClassesOfLiabilitiesAxis_638605258597444372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable_638605258597434372" xlink:to="ifrs-full_ClassesOfLiabilitiesAxis_638605258597444372" order="4" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_LiabilitiesMember" xlink:label="ifrs-full_LiabilitiesMember_638605258597444372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_ClassesOfLiabilitiesAxis_638605258597444372" xlink:to="ifrs-full_LiabilitiesMember_638605258597444372" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_FairValueOfWarrantsMember" xlink:label="rdhl_FairValueOfWarrantsMember_638605258597444372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_LiabilitiesMember_638605258597444372" xlink:to="rdhl_FairValueOfWarrantsMember_638605258597444372" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsAxis" xlink:label="ifrs-full_UnobservableInputsAxis_638605258597444372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable_638605258597434372" xlink:to="ifrs-full_UnobservableInputsAxis_638605258597444372" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_UnobservableInputsMember" xlink:label="ifrs-full_UnobservableInputsMember_638605258597444372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_UnobservableInputsAxis_638605258597444372" xlink:to="ifrs-full_UnobservableInputsMember_638605258597444372" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_InterestRateMeasurementInputMember" xlink:label="ifrs-full_InterestRateMeasurementInputMember_638605258597444372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_UnobservableInputsMember_638605258597444372" xlink:to="ifrs-full_InterestRateMeasurementInputMember_638605258597444372" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember" xlink:label="ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_638605258597444372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_UnobservableInputsMember_638605258597444372" xlink:to="ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_638605258597444372" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangeAxis" xlink:label="ifrs-full_RangeAxis_638605258597594355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable_638605258597434372" xlink:to="ifrs-full_RangeAxis_638605258597594355" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RangesMember" xlink:label="ifrs-full_RangesMember_638605258597594355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangeAxis_638605258597594355" xlink:to="ifrs-full_RangesMember_638605258597594355" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_BottomOfRangeMember" xlink:label="ifrs-full_BottomOfRangeMember_638605258597594355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesMember_638605258597594355" xlink:to="ifrs-full_BottomOfRangeMember_638605258597594355" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_TopOfRangeMember" xlink:label="ifrs-full_TopOfRangeMember_638605258597594355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_RangesMember_638605258597594355" xlink:to="ifrs-full_TopOfRangeMember_638605258597594355" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfFinancialInstrumentsLineItems" xlink:label="ifrs-full_DisclosureOfFinancialInstrumentsLineItems_638605258597594355" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsTable_638605258597434372" xlink:to="ifrs-full_DisclosureOfFinancialInstrumentsLineItems_638605258597594355" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Liabilities" xlink:label="ifrs-full_Liabilities_638605258597604351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems_638605258597594355" xlink:to="ifrs-full_Liabilities_638605258597604351" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IssuesFairValueMeasurementLiabilities" xlink:label="ifrs-full_IssuesFairValueMeasurementLiabilities_638605258597604351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems_638605258597594355" xlink:to="ifrs-full_IssuesFairValueMeasurementLiabilities_638605258597604351" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_IncreaseDecreaseInFairValueMeasurementLiabilities" xlink:label="ifrs-full_IncreaseDecreaseInFairValueMeasurementLiabilities_638605258597604351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems_638605258597594355" xlink:to="ifrs-full_IncreaseDecreaseInFairValueMeasurementLiabilities_638605258597604351" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities" xlink:label="ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities_638605258597604351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems_638605258597594355" xlink:to="ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities_638605258597604351" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_Liabilities" xlink:label="ifrs-full_Liabilities_6386052585976043511" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems_638605258597594355" xlink:to="ifrs-full_Liabilities_6386052585976043511" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_SignificantUnobservableInputLiabilities" xlink:label="ifrs-full_SignificantUnobservableInputLiabilities_638605258597604351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfFinancialInstrumentsLineItems_638605258597594355" xlink:to="ifrs-full_SignificantUnobservableInputLiabilities_638605258597604351" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.redhillbio.com/role/DisclosureSegmentInformationDetails" xlink:type="extended" xlink:title="40801 - Disclosure - SEGMENT INFORMATION (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:label="ifrs-full_DisclosureOfOperatingSegmentsAbstract" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_CommercialOperationsSegmentAdjustedEarningsBeforeInterestTaxesDepreciationAndAmortisation" xlink:label="rdhl_CommercialOperationsSegmentAdjustedEarningsBeforeInterestTaxesDepreciationAndAmortisation_638605258597604351" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="rdhl_CommercialOperationsSegmentAdjustedEarningsBeforeInterestTaxesDepreciationAndAmortisation_638605258597604351" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_ResearchAndDevelopmentAdjustedEarningsBeforeInterestTaxesDepreciationAndAmortisation" xlink:label="rdhl_ResearchAndDevelopmentAdjustedEarningsBeforeInterestTaxesDepreciationAndAmortisation_638605258597614372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="rdhl_ResearchAndDevelopmentAdjustedEarningsBeforeInterestTaxesDepreciationAndAmortisation_638605258597614372" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_FinanceIncomeCost" xlink:label="ifrs-full_FinanceIncomeCost_638605258597614372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="ifrs-full_FinanceIncomeCost_638605258597614372" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees" xlink:label="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_638605258597614372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees_638605258597614372" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DepreciationExpense" xlink:label="ifrs-full_DepreciationExpense_638605258597614372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="ifrs-full_DepreciationExpense_638605258597614372" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_AmortisationAndImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill" xlink:label="rdhl_AmortisationAndImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_638605258597614372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="rdhl_AmortisationAndImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill_638605258597614372" order="6" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_GainLossOnTerminationOfLeases" xlink:label="rdhl_GainLossOnTerminationOfLeases_638605258597614372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="rdhl_GainLossOnTerminationOfLeases_638605258597614372" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_MiscellaneousOtherOperatingIncome" xlink:label="ifrs-full_MiscellaneousOtherOperatingIncome_638605258597614372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="ifrs-full_MiscellaneousOtherOperatingIncome_638605258597614372" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_ProfitLoss" xlink:label="ifrs-full_ProfitLoss_638605258597614372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfOperatingSegmentsAbstract" xlink:to="ifrs-full_ProfitLoss_638605258597614372" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.redhillbio.com/role/DisclosureEventSubsequentToJune302024Details" xlink:type="extended" xlink:title="41001 - Disclosure - EVENT SUBSEQUENT TO JUNE 30,2024 (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_638605258597614372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract_1" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_638605258597614372" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsAfterReportingPeriodAxis" xlink:label="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_638605258597614372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_638605258597614372" xlink:to="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_638605258597614372" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_NonadjustingEventsMember" xlink:label="ifrs-full_NonadjustingEventsMember_638605258597624372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_638605258597614372" xlink:to="ifrs-full_NonadjustingEventsMember_638605258597624372" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_GlobalTerminationAgreementMember" xlink:label="rdhl_GlobalTerminationAgreementMember_638605258597624372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_NonadjustingEventsMember_638605258597624372" xlink:to="rdhl_GlobalTerminationAgreementMember_638605258597624372" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_638605258597624372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_638605258597614372" xlink:to="srt_CounterpartyNameAxis_638605258597624372" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_638605258597624372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_CounterpartyNameAxis_638605258597624372" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_638605258597624372" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_MovantikAcquisitionValinorPharmaLlcHcrRedhillSpvLlcMember" xlink:label="rdhl_MovantikAcquisitionValinorPharmaLlcHcrRedhillSpvLlcMember_638605258597624372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RepurchaseAgreementCounterpartyNameDomain_638605258597624372" xlink:to="rdhl_MovantikAcquisitionValinorPharmaLlcHcrRedhillSpvLlcMember_638605258597624372" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems" xlink:label="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_638605258597624372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable_638605258597614372" xlink:to="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_638605258597624372" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_ProceedsReceivedFollowingGlobalTerminationAgreement" xlink:label="rdhl_ProceedsReceivedFollowingGlobalTerminationAgreement_638605258597624372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_638605258597624372" xlink:to="rdhl_ProceedsReceivedFollowingGlobalTerminationAgreement_638605258597624372" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd#ifrs-full_RestrictedCashAndCashEquivalents" xlink:label="ifrs-full_RestrictedCashAndCashEquivalents_638605258597624372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_638605258597624372" xlink:to="ifrs-full_RestrictedCashAndCashEquivalents_638605258597624372" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="rdhl-20240630.xsd#rdhl_IncreaseInLiabilities" xlink:label="rdhl_IncreaseInLiabilities_638605258597624372" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems_638605258597624372" xlink:to="rdhl_IncreaseInLiabilities_638605258597624372" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140010810385056">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">6-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Jun. 30,  2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">RedHill Biopharma Ltd.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001553846<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2024<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">Q2<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>12
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140010810282432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($)<br> shares in Thousands, $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncomeStatementAbstract', window );"><strong>CONDENSED CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">NET REVENUES</a></td>
<td class="nump">$ 2,572<span></span>
</td>
<td class="nump">$ 5,395<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CostOfSales', window );">COST OF REVENUES</a></td>
<td class="nump">1,404<span></span>
</td>
<td class="nump">2,418<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GrossProfit', window );">GROSS PROFIT</a></td>
<td class="nump">1,168<span></span>
</td>
<td class="nump">2,977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ResearchAndDevelopmentExpense', window );">RESEARCH AND DEVELOPMENT EXPENSES</a></td>
<td class="nump">659<span></span>
</td>
<td class="nump">2,331<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SalesAndMarketingExpense', window );">SELLING AND MARKETING EXPENSES</a></td>
<td class="nump">3,487<span></span>
</td>
<td class="nump">9,632<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SellingGeneralAndAdministrativeExpense', window );">GENERAL AND ADMINISTRATIVE EXPENSES</a></td>
<td class="nump">5,470<span></span>
</td>
<td class="nump">9,335<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_OtherOperatingIncomeExpense', window );">OTHER INCOME</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(42,993)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLossFromOperatingActivities', window );">OPERATING INCOME (LOSS)</a></td>
<td class="num">(8,448)<span></span>
</td>
<td class="nump">24,672<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncome', window );">FINANCIAL INCOME</a></td>
<td class="nump">7,157<span></span>
</td>
<td class="nump">28,677<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">FINANCIAL EXPENSES</a></td>
<td class="nump">1,797<span></span>
</td>
<td class="nump">2,347<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncomeCost', window );">FINANCIAL INCOME, net</a></td>
<td class="nump">5,360<span></span>
</td>
<td class="nump">26,330<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">INCOME (LOSS) AND COMPREHENSIVE INCOME (LOSS) FOR THE PERIOD</a></td>
<td class="num">$ (3,088)<span></span>
</td>
<td class="nump">$ 51,002<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_BasicEarningsLossPerShare', window );">EARNINGS (LOSS) PER ORDINARY SHARE, basic (U.S. dollars)</a></td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="nump">$ 0.04<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DilutedEarningsLossPerShare', window );">EARNINGS (LOSS) PER ORDINARY SHARE, diluted (U.S. dollars)</a></td>
<td class="nump">$ 0.00<span></span>
</td>
<td class="nump">$ 0.04<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageShares', window );">WEIGHTED AVERAGE OF ORDINARY SHARE, Basic (in thousands)</a></td>
<td class="nump">11,760,458<span></span>
</td>
<td class="nump">1,277,931<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustedWeightedAverageShares', window );">WEIGHTED AVERAGE OF ORDINARY SHARE, diluted (in thousands)</a></td>
<td class="nump">11,760,458<span></span>
</td>
<td class="nump">1,277,931<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustedWeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustedWeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_BasicEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_BasicEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CostOfSales">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 99<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_99&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CostOfSales</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DilutedEarningsLossPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 67<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_67&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DilutedEarningsLossPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income or cost associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GrossProfit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of revenue less cost of sales. [Refer: Cost of sales; Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GrossProfit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncomeStatementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncomeStatementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_OtherOperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of operating income (expense) that the entity does not separately disclose in the same statement or note.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_OtherOperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLossFromOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 32<br> -IssueDate 2023-01-01<br> -Paragraph IE33<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=32&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IE33&amp;doctype=Illustrative%20Examples<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLossFromOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expenditure directly attributable to research or development activities, recognised in profit or loss.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 126<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_126&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2023-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SalesAndMarketingExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to the marketing and selling of goods or services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SalesAndMarketingExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SellingGeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense relating to selling, general and administrative activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SellingGeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Paragraph 70<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_70_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140010809861872">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Dec. 31, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssetsAbstract', window );"><strong>CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 7,277<span></span>
</td>
<td class="nump">$ 5,569<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentRestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
<td class="nump">739<span></span>
</td>
<td class="nump">790<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentReceivables', window );">Trade receivables</a></td>
<td class="nump">974<span></span>
</td>
<td class="nump">2,591<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rdhl_CurrentPrepaidExpensesAndReceivables', window );">Prepaid expenses and other receivables</a></td>
<td class="nump">2,909<span></span>
</td>
<td class="nump">2,801<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Inventories', window );">Inventory</a></td>
<td class="nump">3,804<span></span>
</td>
<td class="nump">4,389<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAssets', window );">Total current assets</a></td>
<td class="nump">15,703<span></span>
</td>
<td class="nump">16,140<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssetsAbstract', window );"><strong>NON-CURRENT ASSETS:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentRestrictedCashAndCashEquivalents', window );">Restricted cash</a></td>
<td class="nump">143<span></span>
</td>
<td class="nump">147<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PropertyPlantAndEquipment', window );">Fixed assets</a></td>
<td class="nump">147<span></span>
</td>
<td class="nump">193<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RightofuseAssets', window );">Right-of-use assets</a></td>
<td class="nump">469<span></span>
</td>
<td class="nump">989<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IntangibleAssetsOtherThanGoodwill', window );">Intangible assets</a></td>
<td class="nump">5,562<span></span>
</td>
<td class="nump">5,578<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentAssets', window );">Total non-current assets</a></td>
<td class="nump">6,321<span></span>
</td>
<td class="nump">6,907<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Assets', window );">TOTAL ASSETS</a></td>
<td class="nump">22,024<span></span>
</td>
<td class="nump">23,047<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilitiesAbstract', window );"><strong>CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TradeAndOtherCurrentPayables', window );">Account payable</a></td>
<td class="nump">1,912<span></span>
</td>
<td class="nump">3,278<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">368<span></span>
</td>
<td class="nump">718<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities', window );">Accrued expenses and other current liabilities</a></td>
<td class="nump">3,961<span></span>
</td>
<td class="nump">4,592<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentRefundsProvision', window );">Allowance for deductions from revenue</a></td>
<td class="nump">12,451<span></span>
</td>
<td class="nump">10,654<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentDerivativeFinancialLiabilities', window );">Derivative financial instruments</a></td>
<td class="nump">2,541<span></span>
</td>
<td class="nump">741<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentLiabilities', window );">Total current liabilities</a></td>
<td class="nump">21,233<span></span>
</td>
<td class="nump">19,983<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilitiesAbstract', window );"><strong>NON-CURRENT LIABILITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLeaseLiabilities', window );">Lease liabilities</a></td>
<td class="nump">190<span></span>
</td>
<td class="nump">455<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rdhl_NoncurrentRoyaltyObligation', window );">Royalty obligation</a></td>
<td class="nump">540<span></span>
</td>
<td class="nump">540<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NoncurrentLiabilities', window );">Total non-current liabilities</a></td>
<td class="nump">730<span></span>
</td>
<td class="nump">995<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">TOTAL LIABILITIES</a></td>
<td class="nump">21,963<span></span>
</td>
<td class="nump">20,978<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAbstract', window );"><strong>EQUITY:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuedCapital', window );">Ordinary shares</a></td>
<td class="nump">34,785<span></span>
</td>
<td class="nump">21,441<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SharePremium', window );">Additional paid-in capital</a></td>
<td class="nump">375,333<span></span>
</td>
<td class="nump">388,363<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RetainedEarnings', window );">Accumulated deficit</a></td>
<td class="num">(410,057)<span></span>
</td>
<td class="num">(407,735)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">TOTAL EQUITY</a></td>
<td class="nump">61<span></span>
</td>
<td class="nump">2,069<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EquityAndLiabilities', window );">TOTAL LIABILITIES AND EQUITY</a></td>
<td class="nump">$ 22,024<span></span>
</td>
<td class="nump">$ 23,047<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current accrued expenses and other current liabilities. [Refer: Accruals; Other current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_i&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentDerivativeFinancialLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current derivative financial liabilities. [Refer: Derivative financial liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentDerivativeFinancialLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_iii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentRefundsProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current provision for refunds. [Refer: Refunds provision]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2023-01-01<br> -Section Example 4 Refunds policy<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2023-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS37_IE_C_ex4_TI<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2023-01-01<br> -Paragraph 87<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_87&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentRefundsProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentRestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current restricted cash and cash equivalents. [Refer: Restricted cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentRestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EquityAndLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EquityAndLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Inventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current inventories. [Refer: Inventories]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 36<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_36_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph g<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_g&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 68<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_68&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Inventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuedCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value of capital issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuedCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that do not meet the definition of current assets. [Refer: Current assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_ii&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 66<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_66&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentAssetsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentAssetsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current lease liabilities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause iv<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_iv&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 69<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_69&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentLiabilitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentLiabilitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NoncurrentRestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of non-current restricted cash and cash equivalents. [Refer: Restricted cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NoncurrentRestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 73<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_73_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RetainedEarnings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A component of equity representing the entity's cumulative undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph IG6<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_IG6&amp;doctype=Implementation%20Guidance<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RetainedEarnings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RightofuseAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 53<br> -Subparagraph j<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_53_j&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 16<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=16&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RightofuseAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SharePremium">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount received or receivable from the issuance of the entity's shares in excess of nominal value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SharePremium</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentPayables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph k<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_k&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentPayables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TradeAndOtherCurrentReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph h<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_h&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TradeAndOtherCurrentReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rdhl_CurrentPrepaidExpensesAndReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised, and the amount of receivables.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rdhl_CurrentPrepaidExpensesAndReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rdhl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rdhl_NoncurrentRoyaltyObligation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent royalty obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rdhl_NoncurrentRoyaltyObligation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rdhl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>14
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140010807956800">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Ordinary shares.</div></th>
<th class="th"><div>Additional paid-in capital</div></th>
<th class="th"><div>Accumulated deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at beginning of period at Dec. 31, 2022</a></td>
<td class="nump">$ 2,835<span></span>
</td>
<td class="nump">$ 382,625<span></span>
</td>
<td class="num">$ (433,860)<span></span>
</td>
<td class="num">$ (48,400)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based compensation to employees and service providers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">849<span></span>
</td>
<td class="nump">849<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issuance of ordinary shares, net of expenses</a></td>
<td class="nump">1,761<span></span>
</td>
<td class="num">(1,741)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">20<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rdhl_StockIssuedDuringPeriodValueRestrictedStockAward', window );">Issuance of ordinary shares for vested RSUs</a></td>
<td class="nump">24<span></span>
</td>
<td class="num">(24)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">51,002<span></span>
</td>
<td class="nump">51,002<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at end of period at Jun. 30, 2023</a></td>
<td class="nump">4,620<span></span>
</td>
<td class="nump">380,860<span></span>
</td>
<td class="num">(382,009)<span></span>
</td>
<td class="nump">3,471<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at beginning of period at Dec. 31, 2023</a></td>
<td class="nump">21,441<span></span>
</td>
<td class="nump">388,363<span></span>
</td>
<td class="num">(407,735)<span></span>
</td>
<td class="nump">2,069<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions', window );">Share-based compensation to employees and service providers</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">766<span></span>
</td>
<td class="nump">766<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssueOfEquity', window );">Issuance of ordinary shares, net of expenses</a></td>
<td class="nump">13,135<span></span>
</td>
<td class="num">(12,821)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">314<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rdhl_StockIssuedDuringPeriodValueRestrictedStockAward', window );">Issuance of ordinary shares for vested RSUs</a></td>
<td class="nump">209<span></span>
</td>
<td class="num">(209)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Comprehensive income (loss)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,088)<span></span>
</td>
<td class="num">(3,088)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Equity', window );">Balance at end of period at Jun. 30, 2024</a></td>
<td class="nump">$ 34,785<span></span>
</td>
<td class="nump">$ 375,333<span></span>
</td>
<td class="num">$ (410,057)<span></span>
</td>
<td class="nump">$ 61<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Equity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of residual interest in the assets of the entity after deducting all its liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 78<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_78_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Equity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssueOfEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in equity through the issue of equity instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssueOfEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rdhl_StockIssuedDuringPeriodValueRestrictedStockAward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock related to restricted stock awards issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rdhl_StockIssuedDuringPeriodValueRestrictedStockAward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rdhl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>15
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140010810358640">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract', window );"><strong>OPERATING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Comprehensive income (loss)</a></td>
<td class="num">$ (3,088)<span></span>
</td>
<td class="nump">$ 51,002<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract', window );"><strong>Adjustments in respect of income and expenses not involving cash flow:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForSharebasedPayments', window );">Share-based compensation to employees and service providers</a></td>
<td class="nump">229<span></span>
</td>
<td class="nump">849<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDepreciationExpense', window );">Depreciation</a></td>
<td class="nump">402<span></span>
</td>
<td class="nump">1,055<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForAmortisationExpense', window );">Amortization of intangible assets</a></td>
<td class="nump">16<span></span>
</td>
<td class="nump">530<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rdhl_AdjustmentsForGainsFromTransferOfRightsInMovantikAndExtinguishmentOfDebtObligations', window );">Gains from the transfer of rights in Movantik and extinguishment of debt obligations, (see below)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(56,082)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rdhl_AdjustmentsForGainsFromEarlyTerminationOfLeasesNet', window );">Gains from early termination of leases, net</a></td>
<td class="num">(23)<span></span>
</td>
<td class="num">(694)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives', window );">Fair value gains on derivative financial instruments</a></td>
<td class="num">(7,108)<span></span>
</td>
<td class="num">(8,071)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rdhl_AdjustmentsForLossFromModificationOfWarrantsTermsAsPartOfNewIssuance.', window );">Loss from modification of warrants terms as part of a new issuance, see note 3b</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,084<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rdhl_AdjustmentForIssuanceCostInRespectOfWarrants', window );">Issuance costs in respect of warrants</a></td>
<td class="nump">1,497<span></span>
</td>
<td class="nump">922<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rdhl_AdjustmentsForRevaluationOfBankDeposits', window );">Exchange differences and revaluation of bank deposits</a></td>
<td class="num">(4)<span></span>
</td>
<td class="num">(13)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital', window );">Total adjustments in respect of income and expenses not involving cash flow</a></td>
<td class="num">(4,991)<span></span>
</td>
<td class="num">(60,420)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rdhl_ChangesInAssetsAndLiabilityItemsAbstract', window );"><strong>Changes in assets and liability items:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable', window );">Decrease in trade receivables</a></td>
<td class="nump">1,617<span></span>
</td>
<td class="nump">31,618<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables', window );">Decrease (increase) in prepaid expenses and other receivables</a></td>
<td class="num">(108)<span></span>
</td>
<td class="nump">1,337<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories', window );">Decrease in inventories</a></td>
<td class="nump">585<span></span>
</td>
<td class="nump">1,837<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable', window );">Decrease in accounts payable</a></td>
<td class="num">(1,366)<span></span>
</td>
<td class="num">(1,118)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rdhl_AdjustmentsForDecreaseIncreaseInAccruedExpenses', window );">Decrease in accrued expenses and other liabilities</a></td>
<td class="num">(631)<span></span>
</td>
<td class="num">(10,545)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rdhl_AdjustmentsForIncreaseDecreaseInAllowanceForDeductionsFromRevenue', window );">Increase (decrease) in allowance for deductions from revenue</a></td>
<td class="nump">1,797<span></span>
</td>
<td class="num">(31,486)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInWorkingCapital', window );">Total changes in assets and liability items</a></td>
<td class="nump">1,894<span></span>
</td>
<td class="num">(8,357)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(6,185)<span></span>
</td>
<td class="num">(17,775)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract', window );"><strong>INVESTING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities', window );">Purchase of fixed assets</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInInvestingActivities', window );">Net cash used in investing activities</a></td>
<td class="num">(1)<span></span>
</td>
<td class="num">(7)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract', window );"><strong>FINANCING ACTIVITIES:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares', window );">Proceeds from issuance of ordinary shares and warrants, net of issuance costs</a></td>
<td class="nump">8,263<span></span>
</td>
<td class="nump">5,097<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rdhl_RepaymentOfPayableInRespectOfIntangibleAssetPurchase', window );">Repayment of payable in respect of intangible asset purchase</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(6,555)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rdhl_IfrsDecreaseInRestrictedCash', window );">Decrease in restricted cash</a></td>
<td class="nump">51<span></span>
</td>
<td class="nump">6,860<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities', window );">Payment of principal with respect to lease liabilities</a></td>
<td class="num">(414)<span></span>
</td>
<td class="num">(589)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashFlowsFromUsedInFinancingActivities', window );">Net cash provided by financing activities</a></td>
<td class="nump">7,900<span></span>
</td>
<td class="nump">4,813<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges', window );">INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS</a></td>
<td class="nump">1,714<span></span>
</td>
<td class="num">(12,969)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents', window );">EXCHANGE DIFFERENCES ON CASH AND CASH EQUIVALENTS</a></td>
<td class="num">(6)<span></span>
</td>
<td class="num">(3)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD</a></td>
<td class="nump">5,569<span></span>
</td>
<td class="nump">19,968<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CashAndCashEquivalents', window );">BALANCE OF CASH AND CASH EQUIVALENTS AT THE END OF PERIOD</a></td>
<td class="nump">7,277<span></span>
</td>
<td class="nump">6,996<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rdhl_SupplementalInformationInterestReceivedInCash', window );">SUPPLEMENTARY INFORMATION ON INTEREST RECEIVED IN CASH</a></td>
<td class="nump">38<span></span>
</td>
<td class="nump">123<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rdhl_SupplementalInformationInterestPaidInCash', window );">SUPPLEMENTARY INFORMATION ON INTEREST PAID IN CASH</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">315<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rdhl_AcquisitionOfRightOfUseAssetsByMeansOfLeaseLiabilities', window );">Acquisition of right-of-use assets by means of lease liabilities</a></td>
<td class="nump">5<span></span>
</td>
<td class="nump">224<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rdhl_DecreaseInLeaseLiabilityFromEarlyTerminationOfLease', window );">Decrease in lease liability (with corresponding decrease in right of use asset in amount of $170 in the six months ended June 30, 2024, and $4,117 in the six months ended June 30,2023) resulting from early termination of lease</a></td>
<td class="nump">$ 193<span></span>
</td>
<td class="nump">4,811<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ChangesInIntangibleAssetsOtherThanGoodwill', window );">Decrease in Intangible asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(59,503)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rdhl_DecreaseInInventories', window );">Decrease in Inventories</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(4,233)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rdhl_DecreaseIncreaseInPayablesInRespectOfIntangibleAssets', window );">Decrease in Payable in respect of Intangible asset</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,602<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rdhl_DecreaseIncreaseInBorrowings', window );">Decrease in Borrowing</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,216<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rdhl_GainsFromTransferOfRightsInMovantikAndExtinguishmentOfDebtObligations', window );">Gains from the transfer of the rights in Movantik and extinguishment of debt obligations</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 56,082<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForAmortisationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss); Depreciation and amortisation expense]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForAmortisationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in other operating receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in trade accounts receivable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForDepreciationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for depreciation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForDepreciationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for gains (losses) on changes in the fair value of derivatives to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: At fair value [member]; Derivatives [member]; Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in trade accounts payable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForReconcileProfitLossAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForReconcileProfitLossAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsForSharebasedPayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsForSharebasedPayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments, other than changes in working capital, to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B13<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B13_a&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 54<br> -Subparagraph i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_54_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 50<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_50_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ChangesInIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 38<br> -IssueDate 2023-01-01<br> -Paragraph 118<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=38&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_118_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ChangesInIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 25<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_25&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInWorkingCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in working capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 20<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_20&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInWorkingCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssueOfOrdinaryShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssueOfOrdinaryShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 16<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_16_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rdhl_AcquisitionOfRightOfUseAssetsByMeansOfLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of acquisition of right-of-use assets by means of lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rdhl_AcquisitionOfRightOfUseAssetsByMeansOfLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rdhl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rdhl_AdjustmentForIssuanceCostInRespectOfWarrants">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for issuance cost in respect of warrants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rdhl_AdjustmentForIssuanceCostInRespectOfWarrants</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rdhl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rdhl_AdjustmentsForDecreaseIncreaseInAccruedExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in accrued expenses to reconcile profit (loss) to net cash flow from (used in) operating activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rdhl_AdjustmentsForDecreaseIncreaseInAccruedExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rdhl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rdhl_AdjustmentsForGainsFromEarlyTerminationOfLeasesNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustment for gains from early termination of leases, net.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rdhl_AdjustmentsForGainsFromEarlyTerminationOfLeasesNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rdhl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rdhl_AdjustmentsForGainsFromTransferOfRightsInMovantikAndExtinguishmentOfDebtObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustment for gains from the transfer of rights In movantik And extinguishment of debt obligations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rdhl_AdjustmentsForGainsFromTransferOfRightsInMovantikAndExtinguishmentOfDebtObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rdhl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rdhl_AdjustmentsForIncreaseDecreaseInAllowanceForDeductionsFromRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for increase (decrease) in allowance for deductions from revenue.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rdhl_AdjustmentsForIncreaseDecreaseInAllowanceForDeductionsFromRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rdhl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rdhl_AdjustmentsForLossFromModificationOfWarrantsTermsAsPartOfNewIssuance.">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of loss due to from modification of warrants terms as part of a new issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rdhl_AdjustmentsForLossFromModificationOfWarrantsTermsAsPartOfNewIssuance.</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rdhl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rdhl_AdjustmentsForRevaluationOfBankDeposits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for revaluation of bank deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rdhl_AdjustmentsForRevaluationOfBankDeposits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rdhl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rdhl_ChangesInAssetsAndLiabilityItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rdhl_ChangesInAssetsAndLiabilityItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rdhl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rdhl_DecreaseInInventories">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of decrease in inventories during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rdhl_DecreaseInInventories</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rdhl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rdhl_DecreaseInLeaseLiabilityFromEarlyTerminationOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents decrease in lease liability from early termination of lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rdhl_DecreaseInLeaseLiabilityFromEarlyTerminationOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rdhl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rdhl_DecreaseIncreaseInBorrowings">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in borrowings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rdhl_DecreaseIncreaseInBorrowings</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rdhl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rdhl_DecreaseIncreaseInPayablesInRespectOfIntangibleAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjustments for decrease (increase) in payables in respect of intangible assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rdhl_DecreaseIncreaseInPayablesInRespectOfIntangibleAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rdhl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rdhl_GainsFromTransferOfRightsInMovantikAndExtinguishmentOfDebtObligations">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gains From The Transfer Of The Rights In Movantik And Extinguishment Of Debt Obligations</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rdhl_GainsFromTransferOfRightsInMovantikAndExtinguishmentOfDebtObligations</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rdhl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rdhl_IfrsDecreaseInRestrictedCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rdhl_IfrsDecreaseInRestrictedCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rdhl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rdhl_RepaymentOfPayableInRespectOfIntangibleAssetPurchase">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Repayment of payable in respect of intangible asset purchase</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rdhl_RepaymentOfPayableInRespectOfIntangibleAssetPurchase</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rdhl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rdhl_SupplementalInformationInterestPaidInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental information on interest paid in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rdhl_SupplementalInformationInterestPaidInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rdhl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rdhl_SupplementalInformationInterestReceivedInCash">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Supplemental information on interest received in cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rdhl_SupplementalInformationInterestReceivedInCash</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rdhl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>16
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140010809788288">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_StatementOfCashFlowsAbstract', window );"><strong>CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rdhl_DecreaseInRightOfUseAssetFromEarlyTerminationOfLease', window );">Decrease in right of use asset</a></td>
<td class="nump">$ 170<span></span>
</td>
<td class="nump">$ 4,117<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_StatementOfCashFlowsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_StatementOfCashFlowsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rdhl_DecreaseInRightOfUseAssetFromEarlyTerminationOfLease">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents decrease in right of use asset from early termination of lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rdhl_DecreaseInRightOfUseAssetFromEarlyTerminationOfLease</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rdhl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140010818060992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>GENERAL<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rdhl_GeneralInformationAbstract', window );"><strong>GENERAL</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory', window );">General</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">NOTE 1 - GENERAL:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 144pt;"><span style="font-size:8pt;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:49.65pt;margin-top:0pt;padding-left:94.35pt;text-align:justify;text-indent:-94.35pt;"><span style="display:inline-block;font-size:8pt;font-weight:bold;min-width:21.25pt;text-indent:0pt;white-space:nowrap;">a.</span><b style="font-size:8pt;font-weight:bold;">General</b></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 144pt;"><span style="font-size:8pt;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:49.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">RedHill Biopharma Ltd. (the &#8220;Company&#8221;), incorporated on August 3, 2009, together with its wholly-owned subsidiary, RedHill Biopharma Inc. (&#8220;RedHill Inc.&#8221;), incorporated in Delaware, U.S. on January 19, 2017, is a specialty biopharmaceutical company primarily focused on gastrointestinal (&#8220;GI&#8221;) diseases and infectious diseases. </span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 67.75pt;">The Company&#8217;s American Depositary Shares (&#8220;ADSs&#8221;) were traded on the Nasdaq Capital Market from December 27, 2012, were listed on the Nasdaq Global Market (&#8220;Nasdaq&#8221;) from July 20, 2018, and have been again listed on the Nasdaq Capital Market since November 15, 2023. On March 23, 2023, the Company changed the ADS ratio from 1 ADS representing 10 ordinary shares to 1 ADS representing 400 ordinary shares. On August 20, 2024, after the condensed consolidated interim financial statements date, the Company changed the ADS to ordinary share ratio from 1 ADS representing 400 ordinary shares to 1 ADS representing 10,000 ordinary shares. The ADSs and per ADS amounts in these interim financial statements reflect the old ratio of 1 ADS to 400 ordinary shares.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 67.75pt;">The Company&#8217;s registered address is 21 Ha&#8217;arba&#8217;a St, Tel-Aviv, Israel<span style="direction:rtl;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:49.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Since the Company established its commercial presence in the U.S. in 2017, it has promoted or commercialized various GI-related products that were either developed internally or acquired through in-licensing agreements. As of the date of approval of these condensed consolidated interim financial statements, the Company commercializes in the U.S., mainly Talicia&#174;, for the treatment of Helicobacter pylori infection in adults, the first product approved by the U.S. Food and Drug Administration (&#8220;FDA&#8221;) being developed primarily</span><span style="direction:rtl;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">internally by the Company. Until </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">F</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">ebruary</span><span style="direction:rtl;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1,</span><span style="direction:rtl;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2023, the Company commercialized Movantik&#174; in the U.S, for the treatment of opioid-induced constipation. See also note 15(6) in the annual financial statements as of December 31, 2023 regarding the transfer of the Company&#8217;s rights in Movantik&#174; to HCR Collateral Management, LLC (&#8220;HCRM&#8221;) in exchange for all the Company&#8217;s debt obligations under the Credit Agreement with HCRM (see also note 10). The Company also continues to advance the development of part of its late-stage therapeutic candidates. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:49.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">3)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Through June 30, 202</span><span style="direction:rtl;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">4</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, the Company has an accumulated deficit and negative working capital, and its activities have been funded primarily through public and private offerings of the Company&#8217;s securities and secured borrowing (now fully extinguished, see note 15(6) in the annual financial statements as of December 31, 2023</span><span style="direction:rtl;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">(</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. There is no assurance that the Company&#8217;s business will generate sustainable positive cash flows to fund its business.</span><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"> </span></td></tr></table><div style="margin-top:10pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 67.6pt;">The Company plans to further fund its future operations through commercialization and out-licensing of its therapeutic candidates, commercialization of in-licensed or acquired products and raising additional capital through equity or debt financing or through other non-dilutive financing. Furthermore, the Company is actively pursuing and in discussions with multiple parties regarding strategic business development transactions, including potential divestment of certain of the Company&#8217;s assets and/or its commercial operations, which the Company expects would provide it with additional capital, although there is no guarantee that the Company will complete such a transaction on favorable terms. The Company&#8217;s current cash resources are not sufficient to complete the research and development of any of its therapeutic candidates and to fully support its commercial operations until generation of sustainable positive cash flows. Management expects that the Company will incur additional losses as it continues to focus its resources on advancing the development of its therapeutic candidates, as well as advancing its commercial operations, based on a prioritized plan that will result in negative cash flows from operating activities. Management believes that there is presently insufficient funding available to allow </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 67.6pt;">the Company to fund its activities for a period exceeding one year from the date of this filing. These conditions and events indicate that a material uncertainty exists that may cast significant doubt (or raise substantial doubt as contemplated by PCAOB standards) about the Company&#8217;s ability to continue as a going concern. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 67.7pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 67.7pt;">The accompanying condensed consolidated interim financial statements have been prepared assuming that the Company will continue as a going concern and do not include any adjustments that might result from the outcome of this uncertainty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 67.7pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:49.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">4)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In October 2023, Israel was attacked by a terrorist organization and entered a state of war. As of the date of these </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">condensed consolidated interim financial statements</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">, the war in Israel is ongoing and continues to evolve. During six months ended of June 30,2024, the impact of this war on the Company results and financial condition was immaterial, but such impact may increase</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">.</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:13.5pt;text-indent:-13.5pt;margin:0pt 0pt 0pt 49.6pt;"><b style="font-weight:bold;white-space:pre-wrap;">b.      Approval of the condensed consolidated interim financial statements:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 50.4pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 67.75pt;">These condensed consolidated interim financial statements were approved by the Board of Directors (the "BoD") on August 28, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:4.5pt;margin:0pt 0pt 0pt 4.5pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for general information about financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 51<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_51&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rdhl_GeneralInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>N/A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rdhl_GeneralInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rdhl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>18
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140010851315472">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PREPARATION OF THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rdhl_DisclosureOfBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsAbstract', window );"><strong>BASIS OF PREPARATION OF THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rdhl_DisclosureOfBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsTextBlock', window );">BASIS OF PREPARATION OF THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:67.5pt;text-indent:-67.5pt;margin:0pt 0pt 0pt 4.5pt;"><b style="font-weight:bold;">NOTE 2 - BASIS OF PREPARATION OF THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS AND </b><b style="font-weight:bold;">SIGNIFICANT ACCOUNTING POLICIES</b><b style="font-weight:bold;">:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:4.5pt;text-align:justify;text-indent:-4.5pt;margin:0pt 0pt 0pt 67.7pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:49.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;white-space:pre-wrap;">  </span><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"> </b><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">BASIS OF PREPARATION</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:4.5pt;text-align:justify;text-indent:-4.5pt;margin:0pt 0pt 0pt 67.7pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:4.5pt;text-align:justify;text-indent:-4.5pt;margin:0pt 0pt 0pt 49.6pt;"> &#160;<span style="font-size:10pt;">The Company&#8217;s condensed consolidated interim financial statements for the six months</span><span style="font-size:10pt;"> ended June 30, 2024 (the "Condensed Consolidated Interim Financial Statements"), have </span><span style="font-size:10pt;">been prepared</span><span style="font-size:10pt;"> </span><span style="font-size:10pt;">in accordance with</span><span style="font-size:10pt;"> International Accounting Standard IAS 34, &#8220;Interim Financial Reporting</span><span style="font-size:10pt;">&#8221;.</span><span style="font-size:10pt;"> These Condensed Consolidated Interim Financial Statements,</span><span style="direction:rtl;font-size:10pt;"> </span><span style="font-size:10pt;">that are unaudited, do not include all the information and disclosures that would otherwise be required in a complete set of annual financial statements and </span><span style="font-size:10pt;">should be read in conjunction with the annual financial statements as of December 31, 2023, and their accompanying notes, which have been prepared in accordance with International Financial Reporting Standards (&#8220;IFRS&#8221;) as published by the International Accounting Standards Board (&#8220;IASB&#8221;).</span><span style="font-size:10pt;"> The results of operations for the six months ended June 30, 2024, are not necessarily indicative of the results that may be expected for the entire fiscal year </span><span style="font-size:10pt;">or for</span><span style="font-size:10pt;"> any other interim period</span><span style="font-size:10pt;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:4.5pt;text-align:justify;text-indent:-4.5pt;margin:0pt 0pt 0pt 49.6pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:49.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">SIGNIFICANT ACCOUNTING POLICIES</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:49.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">1)</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">General</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 67.6pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 67.6pt;">The accounting policies applied in the preparation of the Condensed Consolidated Interim Financial Statements are consistent with those applied in the preparation of the annual financial statements as of December 31, 2023, except for the reclassification of derivative financial instruments from non-current liabilities to current liabilities, as described in note 2b(2).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 67.6pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:49.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">2)</td><td style="padding:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;">New international financial reporting standards, amendments to standards and new interpretations</b></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 67.6pt;"><span style="font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 67.6pt;"><i style="font-style:italic;">Classification of Liabilities as Current or Non-Current (Amendment to IAS 1)</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="font-style:italic;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 67.6pt;">The narrow-scope amendments to IAS 1, &#8220;Presentation of Financial Statements,&#8221; clarify that liabilities are classified as either current or noncurrent, depending on the rights that exist at the end of the reporting period. Classification is unaffected by the entity&#8217;s expectations or events after the reporting date. The amendments also clarify what IAS 1 means when it refers to the settlement&#8217; of a liability. The amendments may affect the classification of liabilities, particularly for entities that previously considered </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 67.6pt;">management&#8217;s intentions to determine classification and for some liabilities that can be converted into equity. The Company adopted these amendments effective January 1, 2024. The impact on the Company&#8217;s financial statements of these amendments was the reclassification of the Company&#8217;s derivative financial instruments from non-current to current as of its effective date. The Company has retrospectively applied the amendments in these interim financial statements and, accordingly, has retrospectively adjusted the comparative balance sheet for December 31, 2023 to reclassify its warrant liabilities ($741 as of December 31, 2023) from non-current to current. Adoption of the amendments had no other impact on the Company&#8217;s financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 67.6pt;"><i style="font-style:italic;">IFRS 18, Presentation and Disclosure in the Financial Statements</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 67.6pt;">This standard replaces the international accounting standard IAS 1, &#8220;Presentation of Financial Statements.&#8221; As part of the new disclosure requirements, companies will be required to present new defined subtotals in the statements of income, as follows: (1) operating profit and (2) profit before financing and tax. In addition, income statement items will be classified into three defined categories: operating, investment and financing. The standard also includes a requirement to provide a separate disclosure in the financial statements regarding the use of management-defined performance measures (&#8220;non-GAAP measures&#8221;), and specific instructions were added for the grouping and splitting of items in the financial statements and in the notes to the financial statements. IFRS 18 is effective for annual reporting periods beginning on or after January 1, 2027, with an option for early adoption.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:4.5pt;text-align:justify;text-indent:-4.5pt;margin:0pt 0pt 0pt 49.6pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rdhl_DisclosureOfBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rdhl_DisclosureOfBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rdhl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rdhl_DisclosureOfBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for basis of preparation of condensed consolidated interim financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rdhl_DisclosureOfBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rdhl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>19
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140010815328976">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT EVENTS DURING THE CURRENT REPORTING PERIOD<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rdhl_SignificantEventsDuringCurrentReportingPeriodAbstract', window );"><strong>SIGNIFICANT EVENTS DURING THE CURRENT REPORTING PERIOD</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rdhl_SignificantEventsDuringCurrentReportingPeriodTextBlock', window );">SIGNIFICANT EVENTS DURING THE CURRENT REPORTING PERIOD</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:67.7pt;text-align:justify;text-indent:-67.7pt;margin:0pt 0pt 12pt 4.3pt;"><b style="font-weight:bold;background:#ffffff;">NOTE </b><b style="font-weight:bold;background:#ffffff;">3 - SIGNIFICANT EVENTS DURING THE CURRENT REPORTING PERIOD:</b></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:49.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">On January 26, 2024, the Company issued </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10,000,000</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> ADSs at a purchase price of $</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">0.80</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per ADS and warrants to purchase </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">10,000,000</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> ADSs at an exercise price of $</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.00</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per ADS. These warrants may be exercised in cash or on a cashless basis, are immediately exercisable, and expire in </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five years</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. The Company also issued to the placement agent warrants to purchase </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">600,000</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> ADSs under the same terms. The gross proceeds from the offering were $</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">8</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> million, before deducting approximately $</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">0.9</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> million in fees and expenses.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 67.6pt;"><span style="background:#ffffff;">The warrants were classified as a financial liability due to a net settlement provision. These derivatives were recognized and subsequently measured at fair value through profit or loss. Upon initial recognition the fair value of the warrants was adjusted to reflect the unrecognized day 1 loss. This unrecognized day 1 loss is amortized over the warrants&#8217; contractual life. Consequently, $</span><span style="background:#ffffff;">0.9</span><span style="background:#ffffff;"> million of issuance costs allocated to the warrants, were included directly in the Consolidated Statements of Comprehensive Income (Loss). See also note 7.</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:14pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:49.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">On March 21, 2024, the Annual General Meeting of shareholders approved the increase of the authorized share capital of the Company to NIS </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">400,000,000</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> divided into (i) </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">39,994,000,000</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> registered Ordinary Shares of NIS </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">0.01</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> par value each, and (ii) </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">6,000,000</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> preferred shares of NIS </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">0.01</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> par value each.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:49.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">c.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">On April 3, 2024, the Company issued </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2,144,487</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> ADSs at a purchase price of $</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">0.58289</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per ADS and warrants to purchase </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">2,144,487</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> ADSs at an exercise price of $</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">0.75</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> per ADS. These warrants may be exercised in cash or on a cashless basis, are &#160;immediately exercisable and expire in </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">five years</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. The gross proceeds from the offering were $</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1.25</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> million, before deducting offering expenses approximately $</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">0.1</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> million in expesnses.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 67.6pt;"><span style="background:#ffffff;">The warrants were classified as a financial liability due to a net settlement provision. These derivatives were recognized and subsequently measured at fair value through profit or loss. The consideration, net of issue expenses, was allocated to the various issued instruments. Out of the gross consideration, $</span><span style="background:#ffffff;">0.9</span><span style="background:#ffffff;"> million was allocated to the warrants. The remainder of approximately $</span><span style="background:#ffffff;">0.35</span><span style="background:#ffffff;"> million was allocated to </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 67.6pt;"><span style="background:#ffffff;">equity. Issuance expenses allocated &#160;to the liability instruments were recorded directly in the Consolidated Statements of Comprehensive Income (Loss) and , while those allocated to equity were recorded against additional paid in capital. See also note 7.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:14pt 0pt 12pt 67.6pt;"><span style="font-size:10pt;margin-bottom:5pt;margin-left:0pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rdhl_SignificantEventsDuringCurrentReportingPeriodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>N/A</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rdhl_SignificantEventsDuringCurrentReportingPeriodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rdhl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rdhl_SignificantEventsDuringCurrentReportingPeriodTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of significant events during the current reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rdhl_SignificantEventsDuringCurrentReportingPeriodTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rdhl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140010815245712">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ALLOWANCE FOR DEDUCTIONS FROM REVENUES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rdhl_AllowanceForDeductionsFromRevenuesAbstract', window );"><strong>ALLOWANCE FOR DEDUCTIONS FROM REVENUES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rdhl_AllowanceForDeductionsFromRevenuesDisclosureTextBlock', window );">ALLOWANCE FOR DEDUCTIONS FROM REVENUES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">NOTE 4</b><b style="direction:rtl;font-weight:bold;">:</b><b style="font-weight:bold;"> - ALLOWANCE FOR DEDUCTIONS FROM REVENUES:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 67.75pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 67.7pt;">The following table shows the movement of the allowance for deductions from revenues:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 67.75pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:69.55pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:85.5%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:34.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:18.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:34.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:18.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Rebates and patient discount programs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Product returns</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:34.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:middle;width:60.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">U.S.&#160;dollars&#160;in&#160;thousands</b></p></td></tr><tr><td style="vertical-align:bottom;width:34.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As of January 1, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 8,087</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,567</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10,654</p></td></tr><tr><td style="vertical-align:bottom;width:34.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Increases </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,565</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 103</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,668</p></td></tr><tr><td style="vertical-align:bottom;width:34.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Decreases (utilized) </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,184)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (518)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,702)</p></td></tr><tr><td style="vertical-align:bottom;width:34.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Adjustments </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 423</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 408</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 831</p></td></tr><tr><td style="vertical-align:bottom;width:34.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">As of June  30, 2024</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 9,891</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,560</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 12,451</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:34.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:18.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Rebates and patient discount programs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Product returns</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:34.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:middle;width:60.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">U.S.&#160;dollars&#160;in&#160;thousands</b></p></td></tr><tr><td style="vertical-align:bottom;width:34.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As of January 1, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 46,636</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,234</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 47,870</p></td></tr><tr><td style="vertical-align:bottom;width:34.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Increases </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 16,918</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 759</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 17,677</p></td></tr><tr><td style="vertical-align:bottom;width:34.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Decreases (utilized) </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (48,598)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,072)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (49,670)</p></td></tr><tr><td style="vertical-align:bottom;width:34.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Adjustments </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 910</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (403)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 507</p></td></tr><tr><td style="vertical-align:bottom;width:34.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As of June 30, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 15,866</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 518</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 16,384</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rdhl_AllowanceForDeductionsFromRevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>n.a.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rdhl_AllowanceForDeductionsFromRevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rdhl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rdhl_AllowanceForDeductionsFromRevenuesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure of allowance for deductions from revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rdhl_AllowanceForDeductionsFromRevenuesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rdhl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140010815320160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED PAYMENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract', window );"><strong>SHARE-BASED PAYMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory', window );">SHARE-BASED PAYMENTS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">NOTE </b><b style="direction:rtl;font-weight:bold;">5</b><b style="font-weight:bold;"> - SHARE-BASED PAYMENTS:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="direction:rtl;font-weight:bold;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:67.7pt;margin-top:0pt;padding-left:18pt;text-align:justify;text-indent:-18pt;"><span style="display:inline-block;min-width:17.35pt;text-indent:0pt;white-space:nowrap;">1.</span>On June 24, 2024, the BoD granted 1,044,000 RSUs to employees and consultants. These RSUs will vest in 8 equal quarterly installments over two years and had a fair value of $0.4 million on the grant date, based on the ADS price on that date. In addition, the BoD approved the grant of 383,000 RSUs for directors and the Company's Chief Executive Officer in the same terms, subject to Annual General Meeting approval. The fair value of these RSUs on the date of approval was $0.1 million.</div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 144pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:67.7pt;margin-top:0pt;padding-left:18pt;text-align:justify;text-indent:-18pt;"><span style="display:inline-block;min-width:17.35pt;text-indent:0pt;white-space:nowrap;">2.</span>During the six months ended June 30, 2024, approximately 24,000 <span style="-sec-ix-hidden:Hidden_nMtd2n9yDkm_DmI_AXUlBw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">options</span></span> and RSUs were forfeited, mainly due to a reduction in the number of employees, leading to an expense reversal of approximately $0.3 million<span style="direction:rtl;font-size:8pt;">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 44<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_44&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140010815262608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET REVENUES<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract', window );"><strong>NET REVENUES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory', window );">NET REVENUES</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 4.55pt;"><b style="font-size:10pt;font-weight:bold;">NOTE </b><b style="direction:rtl;font-size:10pt;font-weight:bold;">6</b><b style="font-size:10pt;font-weight:bold;"> - NET REVENUES:</b><b style="font-weight:bold;"> </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 4.55pt;"><span style="font-size:8pt;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:66.6pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:85.5%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:16.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:20.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:40.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six Months Ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:16.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;width:3.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:20.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="5" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:55.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:40.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">U.S&#160;dollars&#160;in&#160;thousands</b></p></td></tr><tr><td style="vertical-align:top;width:55.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sales of products </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,572</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,395</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 67.7pt;">During the six months ended June 30, 2024, and June 30, 2023, the Company recorded contra-revenues of ($0.9) million and ($0.2) million for Movantik&#174;, respectively, primarily due to returns following its divestiture on February 1, 2023 (see note 15(6) in the annual financial statements as of December 31, 2023). Correspondingly, net revenues from other products (mainly Talicia&#174;) were $3.5 million in the first half of 2024, including $0.5</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 67.7pt;"> million from sales to Gaelan Medical Trade LLC, which has an exclusive license for Talicia&#174; in the UAE (see note 15(7) in the annual financial statements as of December 31, 2023). In the first half of 2023, net revenues from other products (mainly Talicia&#174;) were $5.6 million, all from U.S. sales<span style="direction:rtl;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for revenue from contracts with customers.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Section Presentation<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IFRS15_g105-109_TI<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IFRS15_g110-129_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140010815256208">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract', window );"><strong>FINANCIAL INSTRUMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory', window );">FINANCIAL INSTRUMENTS</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 4.55pt;"><b style="font-weight:bold;">NOTE </b><b style="direction:rtl;font-weight:bold;">7</b><b style="font-weight:bold;"> - FINANCIAL INSTRUMENTS:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 72pt;"><span style="direction:rtl;font-size:8pt;font-weight:bold;margin-bottom:5pt;margin-left:0pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:31.6pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">a.</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The Company&#8217;s derivative financial liability, represented by warrants, is measured at fair value and classified as level 3. Fair value adjustments are recognized in profit or loss as financial income or expenses. The following table presents the change in this level 3 derivative liability for the six months ended June 30, 2024, and June 30, 2023</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">:</span></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 49.6pt;"><span style="font-size:8pt;margin-bottom:5pt;margin-left:0pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:94.1pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:70.28%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:41.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Derivative</b><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">financial&#160;instruments</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:41.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six Months Ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="4" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:58.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:41.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">U.S.&#160;dollars&#160;in&#160;thousands</b></p></td></tr><tr><td style="vertical-align:top;width:58.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0.05pt 0pt 0.05pt 0pt;">Balance at beginning of the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"> 741</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"> 2,623</p></td></tr><tr><td style="vertical-align:top;width:58.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0.05pt 0pt 0.05pt 0pt;">Initial recognition of financial liability </p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"> 9,860</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"> 7,083</p></td></tr><tr><td style="vertical-align:top;width:58.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0.05pt 0pt 0.05pt 0pt;">Initial recognition of unrecognized day 1 loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (952)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:58.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0.05pt 0pt 0.05pt 0pt;">Fair value adjustments recognized in profit or loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (7,108)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (8,071)</p></td></tr><tr><td style="vertical-align:top;width:58.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at end of the period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"> 2,541</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"> 1,635</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 72pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:5pt;margin-left:0pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 49.6pt;">The fair value of the warrants is computed using the Black-Scholes model. As of June 30,2024, it is based on the ADS price on that date and the following key parameters: risk-free interest rate of 4.35%-4.48% and volatility of 120.5%-133.6%. As of June 30,2023, it is based on the ADS price on that date and the following key parameters: risk-free interest rate of 4.17%-5.47% and volatility of 86.6%-99.5%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 89.55pt;"><span style="font-size:8pt;font-weight:bold;margin-bottom:5pt;margin-left:0pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:31.75pt;margin-top:0pt;padding-left:18pt;text-align:justify;text-indent:-18pt;"><span style="display:inline-block;font-size:8pt;min-width:10.8pt;text-indent:0pt;white-space:nowrap;">b.</span><span style="white-space:pre-wrap;">  </span>The carrying amount of cash equivalents, bank deposits, restricted cash, receivables, account payables and accrued expenses approximate their fair value due to their short-term characteristics<span style="font-size:8pt;">.</span></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Section Scope<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IFRS07_g3-5A_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140010815197760">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract', window );"><strong>SEGMENT INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory', window );">SEGMENT INFORMATION</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 4.55pt;"><b style="font-weight:bold;">NOTE 8 - SEGMENT INFORMATION: </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 49.6pt;">The Chief Executive Officer is the Company&#8217;s Chief Operating Decision Maker (&#8220;CODM&#8221;). The CODM allocates resources and assesses the Company&#8217;s performance based on the following segmentation: Commercial Operations and Research &amp; Development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 49.6pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 49.6pt;">Adjusted EBITDA represents net loss before depreciation, amortization, and financial income (expenses), adjusted to exclude share-based compensation, gains from early termination of leases, and other income, which includes income from service provided to HCRM and gain from the sale of Movantik&#174;.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 49.6pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 49.6pt;">The following table presents segment profitability and a reconciliation to the consolidated net income (loss) and comprehensive income (loss) for the periods indicated:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 49.65pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:75%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:4.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:18.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:18.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:39.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six Months Ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:18.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;width:0.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:18.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;width:0.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="4" style="vertical-align:bottom;width:39.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">U.S.&#160;dollars&#160;in&#160;thousands</b></p></td></tr><tr><td style="vertical-align:middle;width:56.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Commercial Operations Segment Adjusted EBITDA</p></td><td style="vertical-align:top;white-space:nowrap;width:4.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> (4,681)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> (11,031)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:56.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Research And Development Adjusted EBITDA</p></td><td style="vertical-align:top;width:4.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> (3,143)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> (5,550)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:56.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Financial income, net</p></td><td style="vertical-align:top;width:4.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> 5,360</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> 26,330</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:56.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Share-based compensation to employees and service providers</p></td><td style="vertical-align:top;width:4.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> (229)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> (849)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:56.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Depreciation</p></td><td style="vertical-align:top;width:4.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> (402)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> (1,055)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:56.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Amortization of intangible assets</p></td><td style="vertical-align:top;width:4.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> (16)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> (530)</p></td><td style="vertical-align:middle;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:56.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Gain from early termination of lease, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> 23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> 694</p></td><td style="vertical-align:middle;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:56.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Other income </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> 42,993</p></td><td style="vertical-align:middle;white-space:nowrap;width:0.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:56.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Consolidated Comprehensive income (loss) </p></td><td style="vertical-align:top;width:4.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> (3,088)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> 51,002</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 49.65pt;"><span style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating segments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IFRS08_g20-24_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140010815262608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EARNING (LOSS) PER SHARE<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_EarningsPerShareAbstract', window );"><strong>EARNING (LOSS) PER SHARE</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory', window );">EARNING (LOSS) PER SHARE</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">NOTE 9 - EARNING (LOSS) PER SHARE:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 49.6pt;">The basic and diluted earnings (loss) per share are the same since the effect of all potentially diluted ordinary shares for all reporting periods is anti-dilutive.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEarningsPerShareExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 33<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=33&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS33_g70-73A_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEarningsPerShareExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140010852067856">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>EVENT SUBSEQUENT TO JUNE 30, 2024<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract', window );"><strong>EVENT SUBSEQUENT TO JUNE 30,2024</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory', window );">EVENT SUBSEQUENT TO JUNE 30, 2024</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">NOTE 10 - EVENT SUBSEQUENT TO JUNE 30, 2024: </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 67.6pt;">On July 15, 2024, the Company and RedHill Inc signed a Global Termination Agreement with Movantik Acquisition Co., Valinor Pharma, LLC, and HCR Redhill SPV, LLC, affiliates of HCRM (the &#8220;Global Termination Agreement&#8221;). This agreement terminates the Credit Agreement from February 23, 2020, which was amended on February 2, 2023, as part of the transaction where the rights to Movantik&#174; were sold to HCRM in exchange for extinguishing all debt obligations under the Credit Agreement. The February 2023 agreement had placed a lien Talicia&#174; and Aemcolo&#174; assets and established an escrow account with restricted funds for Movantik&#174; liabilities (for further details, see note 1(a)(2) above and notes 14(a), 15(4), 15(5), and 15(6) to the annual financial statements as of December 31, 2023).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 49.6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 67.6pt;">The Global Termination Agreement terminates all existing credit ties, removing the aforementioned lien and restoring control over the restricted escrow funds. The Company received approximately $9.9 million in cash and gained full control over $0.7<span style="white-space:pre-wrap;"> million previously held in the restricted account.  Under the Global Termination Agreement, the Company assumed certain liabilities related to Movantik&#174; from the other parties and settled additional liabilities between the parties. This resulted in an increase of approximately $</span>12.2 million in the Company's future obligations, reflecting these assumed and settled amounts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 67.6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 49.65pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for events after the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 10<br> -IssueDate 2023-01-01<br> -Section Disclosure<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=10&amp;code=ifrs-tx-2023-en-r&amp;doctype=Standard&amp;dita_xref=IAS10_g17-22_TI<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140010818060992">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>BASIS OF PREPARATION OF THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (Policies)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rdhl_IfrsAccountingPoliciesAbstract', window );"><strong>SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory', window );">Basis of preparation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:4.5pt;text-align:justify;text-indent:-4.5pt;margin:0pt 0pt 0pt 67.7pt;"> <span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:4.5pt;text-align:justify;text-indent:-4.5pt;margin:0pt 0pt 0pt 49.6pt;"> &#160;<span style="font-size:10pt;">The Company&#8217;s condensed consolidated interim financial statements for the six months</span><span style="font-size:10pt;"> ended June 30, 2024 (the "Condensed Consolidated Interim Financial Statements"), have </span><span style="font-size:10pt;">been prepared</span><span style="font-size:10pt;"> </span><span style="font-size:10pt;">in accordance with</span><span style="font-size:10pt;"> International Accounting Standard IAS 34, &#8220;Interim Financial Reporting</span><span style="font-size:10pt;">&#8221;.</span><span style="font-size:10pt;"> These Condensed Consolidated Interim Financial Statements,</span><span style="direction:rtl;font-size:10pt;"> </span><span style="font-size:10pt;">that are unaudited, do not include all the information and disclosures that would otherwise be required in a complete set of annual financial statements and </span><span style="font-size:10pt;">should be read in conjunction with the annual financial statements as of December 31, 2023, and their accompanying notes, which have been prepared in accordance with International Financial Reporting Standards (&#8220;IFRS&#8221;) as published by the International Accounting Standards Board (&#8220;IASB&#8221;).</span><span style="font-size:10pt;"> The results of operations for the six months ended June 30, 2024, are not necessarily indicative of the results that may be expected for the entire fiscal year </span><span style="font-size:10pt;">or for</span><span style="font-size:10pt;"> any other interim period</span><span style="font-size:10pt;">.</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the basis used for the preparation of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 10<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_10_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rdhl_IfrsAccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>n/a</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rdhl_IfrsAccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rdhl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140010815211120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ALLOWANCE FOR DEDUCTIONS FROM REVENUES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rdhl_AllowanceForDeductionsFromRevenuesAbstract', window );"><strong>ALLOWANCE FOR DEDUCTIONS FROM REVENUES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rdhl_ScheduleOfMovementOfAllowanceForDeductionsFromRevenuesTableTextBlock', window );">Schedule of movement of allowance for deductions from revenue</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 67.75pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:69.55pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:85.5%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:34.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:18.89%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:34.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:18.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Rebates and patient discount programs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Product returns</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:34.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:middle;width:60.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">U.S.&#160;dollars&#160;in&#160;thousands</b></p></td></tr><tr><td style="vertical-align:bottom;width:34.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As of January 1, 2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 8,087</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,567</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 10,654</p></td></tr><tr><td style="vertical-align:bottom;width:34.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Increases </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,565</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 103</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 4,668</p></td></tr><tr><td style="vertical-align:bottom;width:34.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Decreases (utilized) </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,184)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (518)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (3,702)</p></td></tr><tr><td style="vertical-align:bottom;width:34.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Adjustments </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 423</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 408</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 831</p></td></tr><tr><td style="vertical-align:bottom;width:34.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">As of June  30, 2024</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 9,891</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,560</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 12,451</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:34.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:18.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Rebates and patient discount programs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Product returns</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total </b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:34.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:middle;width:60.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">U.S.&#160;dollars&#160;in&#160;thousands</b></p></td></tr><tr><td style="vertical-align:bottom;width:34.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As of January 1, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 46,636</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 1,234</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 47,870</p></td></tr><tr><td style="vertical-align:bottom;width:34.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Increases </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 16,918</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 759</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 17,677</p></td></tr><tr><td style="vertical-align:bottom;width:34.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Decreases (utilized) </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (48,598)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,072)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (49,670)</p></td></tr><tr><td style="vertical-align:bottom;width:34.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Adjustments </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 910</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (403)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 507</p></td></tr><tr><td style="vertical-align:bottom;width:34.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">As of June 30, 2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:18.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 15,866</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 518</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 16,384</p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rdhl_AllowanceForDeductionsFromRevenuesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>n.a.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rdhl_AllowanceForDeductionsFromRevenuesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rdhl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rdhl_ScheduleOfMovementOfAllowanceForDeductionsFromRevenuesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of movement of allowance for deductions from revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rdhl_ScheduleOfMovementOfAllowanceForDeductionsFromRevenuesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rdhl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140010810615168">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET REVENUES (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract', window );"><strong>NET REVENUES</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory', window );">Schedule of net revenues</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 4.55pt;"><span style="font-size:8pt;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:66.6pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:85.5%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:55.85%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:16.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:3.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:20.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:55.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:40.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six Months Ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:55.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:16.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;width:3.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;width:20.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="5" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:55.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;width:40.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">U.S&#160;dollars&#160;in&#160;thousands</b></p></td></tr><tr><td style="vertical-align:top;width:55.85%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sales of products </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:16.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 2,572</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"> 5,395</p></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of the disaggregation of revenue from contracts with customers. [Refer: Revenue from contracts with customers]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 15<br> -IssueDate 2023-01-01<br> -Paragraph 114<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=15&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_114&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140010815247264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract', window );"><strong>FINANCIAL INSTRUMENTS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory', window );">Schedule of change in derivative financial instrument</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 49.6pt;"><span style="font-size:8pt;margin-bottom:5pt;margin-left:0pt;margin-top:5pt;visibility:hidden;">&#8203;</span></p><div style="padding-left:94.1pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:70.28%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:58.2%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:20.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:17.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:58.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:41.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Derivative</b><b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;">&#160;</b><b style="font-weight:bold;">financial&#160;instruments</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:41.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Six Months Ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:58.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2023</b></p></td></tr><tr style="height:0pt;visibility:hidden;"><td colspan="4" style="padding:0pt;"></td></tr><tr><td style="vertical-align:bottom;width:58.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:41.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">U.S.&#160;dollars&#160;in&#160;thousands</b></p></td></tr><tr><td style="vertical-align:top;width:58.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0.05pt 0pt 0.05pt 0pt;">Balance at beginning of the period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"> 741</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"> 2,623</p></td></tr><tr><td style="vertical-align:top;width:58.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0.05pt 0pt 0.05pt 0pt;">Initial recognition of financial liability </p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"> 9,860</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"> 7,083</p></td></tr><tr><td style="vertical-align:top;width:58.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0.05pt 0pt 0.05pt 0pt;">Initial recognition of unrecognized day 1 loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (952)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:58.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0.05pt 0pt 0.05pt 0pt;">Fair value adjustments recognized in profit or loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (7,108)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"> (8,071)</p></td></tr><tr><td style="vertical-align:top;width:58.2%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0.05pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Balance at end of the period</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:20.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"> 2,541</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:17.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"> 1,635</p></td></tr></table></div><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of significant inputs for which market data are not available and that are developed using the best information available about the assumptions that market participants would use when measuring the fair value of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140010815211120">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION (Tables)<br></strong></div></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr><th class="th"><div>Jun. 30, 2024</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract', window );"><strong>SEGMENT INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsExplanatory', window );">Schedule of segment profitability and reconciliation to consolidated net income (loss) and comprehensive income (loss)</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 49.65pt;"><span style="font-size:8pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:75%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.45%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:4.39%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:18.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:18.75%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:39.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Six Months Ended June&#160;30,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:56.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:4.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:18.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2024</b></p></td><td style="vertical-align:bottom;width:0.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:18.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2023</b></p></td><td style="vertical-align:bottom;width:0.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="4" style="vertical-align:bottom;width:39.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">U.S.&#160;dollars&#160;in&#160;thousands</b></p></td></tr><tr><td style="vertical-align:middle;width:56.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Commercial Operations Segment Adjusted EBITDA</p></td><td style="vertical-align:top;white-space:nowrap;width:4.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> (4,681)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> (11,031)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:56.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Research And Development Adjusted EBITDA</p></td><td style="vertical-align:top;width:4.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> (3,143)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> (5,550)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:56.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Financial income, net</p></td><td style="vertical-align:top;width:4.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> 5,360</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> 26,330</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:56.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Share-based compensation to employees and service providers</p></td><td style="vertical-align:top;width:4.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> (229)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> (849)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:56.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Depreciation</p></td><td style="vertical-align:top;width:4.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> (402)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> (1,055)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:56.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Amortization of intangible assets</p></td><td style="vertical-align:top;width:4.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> (16)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.75%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> (530)</p></td><td style="vertical-align:middle;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:56.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Gain from early termination of lease, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> 23</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.75%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> 694</p></td><td style="vertical-align:middle;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:56.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Other income </p></td><td style="vertical-align:bottom;white-space:nowrap;width:4.39%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> 42,993</p></td><td style="vertical-align:middle;white-space:nowrap;width:0.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:56.45%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">Consolidated Comprehensive income (loss) </p></td><td style="vertical-align:top;width:4.39%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> (3,088)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:middle;white-space:nowrap;width:18.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"> 51,002</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 49.65pt;"><span style="font-size:1pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsExplanatory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The disclosure of operating segments. [Refer: Operating segments [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsExplanatory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140010809821776">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>GENERAL (Details) - ADS - shares<br></strong></div></th>
<th class="th"><div>Aug. 20, 2024</div></th>
<th class="th"><div>Mar. 23, 2023</div></th>
<th class="th"><div>Mar. 22, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rdhl_GeneralLineItems', window );"><strong>General [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rdhl_NumberOfOrdinarySharesIssuedInExchangeOfAmericanDepositoryReceipts', window );">Number of Ordinary Shares Issued in Exchange of American Depository Receipts</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">400<span></span>
</td>
<td class="nump">10<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ifrs-full_MajorOrdinaryShareTransactionsMember', window );">Major ordinary share transactions</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rdhl_GeneralLineItems', window );"><strong>General [Line Items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rdhl_NumberOfOrdinarySharesIssuedInExchangeOfAmericanDepositoryReceipts', window );">Number of Ordinary Shares Issued in Exchange of American Depository Receipts</a></td>
<td class="nump">10,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rdhl_GeneralLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rdhl_GeneralLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rdhl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rdhl_NumberOfOrdinarySharesIssuedInExchangeOfAmericanDepositoryReceipts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of ordinary shares issued in exchange of American Depository Receipts.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rdhl_NumberOfOrdinarySharesIssuedInExchangeOfAmericanDepositoryReceipts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rdhl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfOrdinarySharesAxis=dei_AdrMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfOrdinarySharesAxis=dei_AdrMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ifrs-full_MajorOrdinaryShareTransactionsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=ifrs-full_MajorOrdinaryShareTransactionsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140010852103072">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BASIS OF PREPARATION OF THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (Details)<br></strong></div></th>
<th class="th">
<div>Dec. 31, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NewIFRSsAxis=rdhl_Ias1AmendmentsMember', window );">IAS 1 Amendments</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems', window );"><strong>Disclosure of expected impact of initial application of new standards or interpretations [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rdhl_ReclassificationOfWarrantLiability', window );">Reclassification Of Warrant Liability</a></td>
<td class="nump">$ 741<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rdhl_ReclassificationOfWarrantLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of reclassification of warrant liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rdhl_ReclassificationOfWarrantLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rdhl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NewIFRSsAxis=rdhl_Ias1AmendmentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NewIFRSsAxis=rdhl_Ias1AmendmentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140010809904192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SIGNIFICANT EVENTS DURING THE CURRENT REPORTING PERIOD - Equity Offerings (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="2">6 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Apr. 03, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jan. 26, 2024 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Mar. 21, 2024 </div>
<div>ILS (&#8362;) </div>
<div>&#8362; / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceCosts', window );">Financial expense</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1,797,000<span></span>
</td>
<td class="nump">$ 2,347,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Proceeds from issuance of shares</a></td>
<td class="nump">$ 1,250,000<span></span>
</td>
<td class="nump">$ 8,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rdhl_WarrantsNumberIssued', window );">Warrants issued | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">600,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsForShareIssueCosts', window );">Placement agent fees and offering expenses.</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rdhl_AuthorisedShareCapital', window );">Authorised Share Capital | &#8362;</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 400,000,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=rdhl_IfrsWarrantMember', window );">Warrants.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rdhl_IfrsClassOfWarrantsOrRightExercisePriceOfWarrantsOrRights', window );">Exercise price of warrants | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Proceeds from issuance of shares</a></td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rdhl_WarrantsNumberIssued', window );">Warrants issued | shares</a></td>
<td class="nump">2,144,487<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rdhl_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights', window );">Warrants exercise price | $ / shares</a></td>
<td class="nump">$ 0.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rdhl_IfrsWarrantsAndRightsOutstandingTerm', window );">Warrants term</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_PaymentsForShareIssueCosts', window );">Placement agent fees and offering expenses.</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_ReserveOfEquityComponentOfConvertibleInstrumentsMember', window );">Equity component</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProceedsFromIssuingShares', window );">Proceeds from issuance of shares</a></td>
<td class="nump">$ 350,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ComponentsOfEquityAxis=rdhl_AmericanDepositoryShareMember', window );">ADS</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesIssued', window );">Number of shares issued | shares</a></td>
<td class="nump">2,144,487<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rdhl_IfrsSharesIssuedPricePerShare', window );">Purchase price (per share) | $ / shares</a></td>
<td class="nump">$ 0.58289<span></span>
</td>
<td class="nump">$ 0.80<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember', window );">Ordinary shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesAuthorised', window );">Number of shares authorised | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">39,994,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value per share | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.01<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_PreferenceSharesMember', window );">Preference shares [member]</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems', window );"><strong>Disclosure of classes of share capital [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfSharesAuthorised', window );">Number of shares authorised | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ParValuePerShare', window );">Par value per share | &#8362; / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">&#8362; 0.01<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfClassesOfShareCapitalLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfClassesOfShareCapitalLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of costs associated with financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesAuthorised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares authorised.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesAuthorised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares issued by the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ParValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 79<br> -Subparagraph a<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_79_a_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ParValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_PaymentsForShareIssueCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for share issue costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_PaymentsForShareIssueCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProceedsFromIssuingShares">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow from issuing shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 17<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_17_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProceedsFromIssuingShares</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rdhl_AuthorisedShareCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The nominal value of authorised share capital.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rdhl_AuthorisedShareCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rdhl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rdhl_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rdhl_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rdhl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rdhl_IfrsClassOfWarrantsOrRightExercisePriceOfWarrantsOrRights">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Exercise price per share or per unit of warrants or rights outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rdhl_IfrsClassOfWarrantsOrRightExercisePriceOfWarrantsOrRights</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rdhl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rdhl_IfrsSharesIssuedPricePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Per share or per unit amount of equity securities issued.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rdhl_IfrsSharesIssuedPricePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rdhl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rdhl_IfrsWarrantsAndRightsOutstandingTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rdhl_IfrsWarrantsAndRightsOutstandingTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rdhl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rdhl_WarrantsNumberIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of warrants issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rdhl_WarrantsNumberIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rdhl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=rdhl_IfrsWarrantMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=rdhl_IfrsWarrantMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=ifrs-full_ReserveOfEquityComponentOfConvertibleInstrumentsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=ifrs-full_ReserveOfEquityComponentOfConvertibleInstrumentsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ComponentsOfEquityAxis=rdhl_AmericanDepositoryShareMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ComponentsOfEquityAxis=rdhl_AmericanDepositoryShareMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_OrdinarySharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_PreferenceSharesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfShareCapitalAxis=ifrs-full_PreferenceSharesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140010810632592">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>ALLOWANCE FOR DEDUCTIONS FROM REVENUES (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentRefundsProvision', window );">Balance at Beginning of period</a></td>
<td class="nump">$ 10,654<span></span>
</td>
<td class="nump">$ 47,870<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInExistingProvisionsOtherProvisions', window );">Increases</a></td>
<td class="nump">4,668<span></span>
</td>
<td class="nump">17,677<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProvisionUsedOtherProvisions', window );">Decreases (Utilized)</a></td>
<td class="num">(3,702)<span></span>
</td>
<td class="num">(49,670)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions', window );">Adjustments</a></td>
<td class="nump">831<span></span>
</td>
<td class="nump">507<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentRefundsProvision', window );">Balance at end of period</a></td>
<td class="nump">12,451<span></span>
</td>
<td class="nump">16,384<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=rdhl_RebatesAndPatientDiscountProgramsMember', window );">Rebates and patient discount programs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentRefundsProvision', window );">Balance at Beginning of period</a></td>
<td class="nump">8,087<span></span>
</td>
<td class="nump">46,636<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInExistingProvisionsOtherProvisions', window );">Increases</a></td>
<td class="nump">4,565<span></span>
</td>
<td class="nump">16,918<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProvisionUsedOtherProvisions', window );">Decreases (Utilized)</a></td>
<td class="num">(3,184)<span></span>
</td>
<td class="num">(48,598)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions', window );">Adjustments</a></td>
<td class="nump">423<span></span>
</td>
<td class="nump">910<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentRefundsProvision', window );">Balance at end of period</a></td>
<td class="nump">9,891<span></span>
</td>
<td class="nump">15,866<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ClassesOfProvisionsAxis=rdhl_ProductReturnsMember', window );">Product returns</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOtherProvisionsLineItems', window );"><strong>Disclosure of other provisions [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentRefundsProvision', window );">Balance at Beginning of period</a></td>
<td class="nump">2,567<span></span>
</td>
<td class="nump">1,234<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInExistingProvisionsOtherProvisions', window );">Increases</a></td>
<td class="nump">103<span></span>
</td>
<td class="nump">759<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProvisionUsedOtherProvisions', window );">Decreases (Utilized)</a></td>
<td class="num">(518)<span></span>
</td>
<td class="num">(1,072)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions', window );">Adjustments</a></td>
<td class="nump">408<span></span>
</td>
<td class="num">(403)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_CurrentRefundsProvision', window );">Balance at end of period</a></td>
<td class="nump">$ 2,560<span></span>
</td>
<td class="nump">$ 518<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CurrentRefundsProvision">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of current provision for refunds. [Refer: Refunds provision]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2023-01-01<br> -Section Example 4 Refunds policy<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2023-en-r&amp;doctype=Illustrative%20Examples&amp;dita_xref=IAS37_IE_C_ex4_TI<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2023-01-01<br> -Paragraph 87<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_87&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CurrentRefundsProvision</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOtherProvisionsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOtherProvisionsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInExistingProvisionsOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in existing other provisions. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2023-01-01<br> -Paragraph 84<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_84_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInExistingProvisionsOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in other provisions through adjustments arising from the passage of time. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2023-01-01<br> -Paragraph 84<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_84_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProvisionUsedOtherProvisions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount used (ie incurred and charged against the provision) for other provisions. [Refer: Other provisions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 37<br> -IssueDate 2023-01-01<br> -Paragraph 84<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=37&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_84_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProvisionUsedOtherProvisions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=rdhl_RebatesAndPatientDiscountProgramsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=rdhl_RebatesAndPatientDiscountProgramsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfProvisionsAxis=rdhl_ProductReturnsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfProvisionsAxis=rdhl_ProductReturnsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140010810715024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SHARE-BASED PAYMENTS (Details)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 24, 2024 </div>
<div>USD ($) </div>
<div>shares </div>
<div>installment</div>
</th>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($) </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rdhl_ReversedExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets', window );">Shares forfeited, reversed expenses | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 300,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=rdhl_IfrsRestrictedStockUnitsRsuMember', window );">RSUs</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of RSUs granted</a></td>
<td class="nump">1,044,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement', window );">Number of RSU forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rdhl_NumberOfRsuQuarterlyInstallments', window );">Number Of RSU Quarterly Installments | installment</a></td>
<td class="nump">8<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted', window );">Fair value of RSU grant | $</a></td>
<td class="nump">$ 400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=rdhl_IfrsRestrictedStockUnitsRsuMember', window );">RSUs | Directors and chief executive officer</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted', window );">Number of RSUs granted</a></td>
<td class="nump">383,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted', window );">Fair value of RSU grant | $</a></td>
<td class="nump">$ 100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=rdhl_IfrsEmployeeStockOptionMember', window );">Share options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems', window );"><strong>Disclosure of terms and conditions of share-based payment arrangement [line items]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement', window );">Share options forfeited</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">24,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of share options forfeited in a share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 45<br> -Subparagraph b<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_45_b_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average fair value at the measurement date of granted equity instruments other than share options. [Refer: Weighted average [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 2<br> -IssueDate 2023-01-01<br> -Paragraph 47<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=2&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_47_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rdhl_NumberOfRsuQuarterlyInstallments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of quarterly installments in which RSUs will vest equally over a two-year period</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rdhl_NumberOfRsuQuarterlyInstallments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rdhl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rdhl_ReversedExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of reversed expense from share-based payment transactions in which the goods or services received did not qualify for recognition as assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rdhl_ReversedExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rdhl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=rdhl_IfrsRestrictedStockUnitsRsuMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=rdhl_IfrsRestrictedStockUnitsRsuMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfRelatedPartiesAxis=rdhl_DirectorsAndChiefExecutiveOfficerMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfRelatedPartiesAxis=rdhl_DirectorsAndChiefExecutiveOfficerMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=rdhl_IfrsEmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_TypesOfSharebasedPaymentArrangementsAxis=rdhl_IfrsEmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140010810383696">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>NET REVENUES (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Revenue', window );">Sale of products</a></td>
<td class="nump">$ 2,572,000<span></span>
</td>
<td class="nump">$ 5,395,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=rdhl_TaliciaMember', window );">Talicia</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rdhl_NetRevenue', window );">Net Revenue</a></td>
<td class="nump">3,500,000<span></span>
</td>
<td class="nump">5,600,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=rdhl_TaliciaMember', window );">Talicia | Gaelan Medical Trade LLC</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rdhl_NetRevenue', window );">Net Revenue</a></td>
<td class="nump">500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProductsAndServicesAxis=rdhl_MovantikMember', window );">Movantik</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RevenueAbstract', window );"><strong>Revenues</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rdhl_ContraRevenueForMovantik', window );">Contra Revenue For Movantik</a></td>
<td class="num">$ (900,000)<span></span>
</td>
<td class="num">$ (200,000)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Revenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 5<br> -IssueDate 2023-01-01<br> -Paragraph 33<br> -Subparagraph b<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=5&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_33_b_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 33<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_33_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 34<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_34&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B12<br> -Subparagraph b<br> -Clause v<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B12_b_v&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 82<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_82_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 10: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 103<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_103&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 11: http://www.xbrl.org/2003/role/exampleRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 102<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_102&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Revenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RevenueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RevenueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rdhl_ContraRevenueForMovantik">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Contra Revenue For Movantik</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rdhl_ContraRevenueForMovantik</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rdhl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rdhl_NetRevenue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net income arising in the course of an entity's ordinary activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rdhl_NetRevenue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rdhl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=rdhl_TaliciaMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=rdhl_TaliciaMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CounterpartiesAxis=rdhl_GaelanMedicalTradeLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CounterpartiesAxis=rdhl_GaelanMedicalTradeLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProductsAndServicesAxis=rdhl_MovantikMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProductsAndServicesAxis=rdhl_MovantikMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140010810131104">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>FINANCIAL INSTRUMENTS (Details)<br></strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th">
<div>Jun. 30, 2024 </div>
<div>USD ($)</div>
</th>
<th class="th">
<div>Jun. 30, 2023 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Balance at beginning of the period</a></td>
<td class="nump">$ 20,978,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Balance at the end of the period</a></td>
<td class="nump">$ 21,963,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=ifrs-full_InterestRateMeasurementInputMember', window );">Risk-free interest rate | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input</a></td>
<td class="nump">4.48<span></span>
</td>
<td class="nump">4.17<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=ifrs-full_InterestRateMeasurementInputMember', window );">Risk-free interest rate | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input</a></td>
<td class="nump">4.35<span></span>
</td>
<td class="nump">5.47<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember', window );">Volatility | Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input</a></td>
<td class="nump">120.5<span></span>
</td>
<td class="nump">86.6<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_UnobservableInputsAxis=ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember', window );">Volatility | Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_SignificantUnobservableInputLiabilities', window );">Significant unobservable input</a></td>
<td class="nump">133.6<span></span>
</td>
<td class="nump">99.5<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember', window );">Level 3 | At fair value | Financial liabilities at fair value through profit or loss | Warrants</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems', window );"><strong>Financial instruments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Balance at beginning of the period</a></td>
<td class="nump">$ 741,000<span></span>
</td>
<td class="nump">$ 2,623,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IssuesFairValueMeasurementLiabilities', window );">Initial recognition of financial liability</a></td>
<td class="nump">9,860,000<span></span>
</td>
<td class="nump">7,083,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementLiabilities', window );">Initial recognition of unrecognized day 1 loss</a></td>
<td class="num">(952,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities', window );">Fair value adjustments recognized in profit or loss</a></td>
<td class="num">(7,108,000)<span></span>
</td>
<td class="num">(8,071,000)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_Liabilities', window );">Balance at the end of the period</a></td>
<td class="nump">$ 2,541,000<span></span>
</td>
<td class="nump">$ 1,635,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfFinancialInstrumentsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfFinancialInstrumentsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The gains (losses) including exchange differences recognised in profit or loss on the fair value measurement of liabilities. [Refer: At fair value [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IncreaseDecreaseInFairValueMeasurementLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) in the fair value measurement of liabilities. [Refer: At fair value [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IncreaseDecreaseInFairValueMeasurementLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_IssuesFairValueMeasurementLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in fair value measurement of liabilities resulting from issues of those liabilities. [Refer: At fair value [member]]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -Clause iii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e_iii&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_IssuesFairValueMeasurementLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph e<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_e&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_SignificantUnobservableInputLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The value of significant unobservable input used in the measurement of the fair value of liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 13<br> -IssueDate 2023-01-01<br> -Paragraph 93<br> -Subparagraph d<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=13&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_93_d&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_SignificantUnobservableInputLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:decimalItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=ifrs-full_InterestRateMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=ifrs-full_InterestRateMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_BottomOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RangeAxis=ifrs-full_TopOfRangeMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_UnobservableInputsAxis=ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_UnobservableInputsAxis=ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_LevelsOfFairValueHierarchyAxis=ifrs-full_Level3OfFairValueHierarchyMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MeasurementAxis=ifrs-full_AtFairValueMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_CategoriesOfFinancialLiabilitiesAxis=ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ClassesOfLiabilitiesAxis=rdhl_FairValueOfWarrantsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ClassesOfLiabilitiesAxis=rdhl_FairValueOfWarrantsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140010810171328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>SEGMENT INFORMATION (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">6 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Jun. 30, 2024</div></th>
<th class="th"><div>Jun. 30, 2023</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract', window );"><strong>SEGMENT INFORMATION</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rdhl_CommercialOperationsSegmentAdjustedEarningsBeforeInterestTaxesDepreciationAndAmortisation', window );">Commercial Operations Segment Adjusted EBITDA</a></td>
<td class="num">$ (4,681)<span></span>
</td>
<td class="num">$ (11,031)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rdhl_ResearchAndDevelopmentAdjustedEarningsBeforeInterestTaxesDepreciationAndAmortisation', window );">Research And Development Adjusted EBITDA</a></td>
<td class="num">(3,143)<span></span>
</td>
<td class="num">(5,550)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_FinanceIncomeCost', window );">Financial income, net</a></td>
<td class="nump">5,360<span></span>
</td>
<td class="nump">26,330<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees', window );">Share-based compensation to employees and service providers</a></td>
<td class="num">(229)<span></span>
</td>
<td class="num">(849)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DepreciationExpense', window );">Depreciation</a></td>
<td class="num">(402)<span></span>
</td>
<td class="num">(1,055)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rdhl_AmortisationAndImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill', window );">Amortization of intangible assets</a></td>
<td class="num">(16)<span></span>
</td>
<td class="num">(530)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rdhl_GainLossOnTerminationOfLeases', window );">Gain from early termination of lease, net</a></td>
<td class="nump">23<span></span>
</td>
<td class="nump">694<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_MiscellaneousOtherOperatingIncome', window );">Other income</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">42,993<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_ProfitLoss', window );">Consolidated Comprehensive income (loss)</a></td>
<td class="num">$ (3,088)<span></span>
</td>
<td class="nump">$ 51,002<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DepreciationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of depreciation expense. Depreciation is the systematic allocation of depreciable amounts of tangible assets over their useful lives.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DepreciationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfOperatingSegmentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfOperatingSegmentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_FinanceIncomeCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of income or cost associated with interest and other financing activities of the entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 85<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_85&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_FinanceIncomeCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_MiscellaneousOtherOperatingIncome">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of miscellaneous other operating income. [Refer: Other operating income (expense)]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 112<br> -Subparagraph c<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_112_c&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_MiscellaneousOtherOperatingIncome</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 7<br> -IssueDate 2023-01-01<br> -Paragraph 18<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=7&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_18_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 32<br> -Subparagraph a<br> -Clause ii<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_32_a_ii&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 24<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_24_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 28<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_28_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IFRS<br> -Number 8<br> -IssueDate 2023-01-01<br> -Paragraph 23<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=8&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_23&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 12<br> -IssueDate 2023-01-01<br> -Paragraph B10<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=12&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_B10_b&amp;doctype=Appendix&amp;subtype=B<br> -URIDate 2023-03-23<br><br>Reference 7: http://www.xbrl.org/2003/role/exampleRef<br> -Name IFRS<br> -Number 17<br> -IssueDate 2023-01-01<br> -Paragraph 113<br> -Subparagraph b<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IFRS&amp;num=17&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_113_b&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 81A<br> -Subparagraph a<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_81A_a&amp;doctype=Standard<br> -URIDate 2023-03-23<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 106<br> -Subparagraph d<br> -Clause i<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_106_d_i&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rdhl_AmortisationAndImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of amortisation and  impairment loss recognised in profit or loss for intangible assets other than goodwill.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rdhl_AmortisationAndImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rdhl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rdhl_CommercialOperationsSegmentAdjustedEarningsBeforeInterestTaxesDepreciationAndAmortisation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commercial Operations Segment Amount of adjusted earnings before interest, taxes, depreciation, and Amortisation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rdhl_CommercialOperationsSegmentAdjustedEarningsBeforeInterestTaxesDepreciationAndAmortisation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rdhl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rdhl_GainLossOnTerminationOfLeases">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on termination of lease before expiration of lease term.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rdhl_GainLossOnTerminationOfLeases</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rdhl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rdhl_ResearchAndDevelopmentAdjustedEarningsBeforeInterestTaxesDepreciationAndAmortisation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Research and development Adjusted earnings before interest, taxes, depreciation, and Amortisation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rdhl_ResearchAndDevelopmentAdjustedEarningsBeforeInterestTaxesDepreciationAndAmortisation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rdhl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.24.2.u1</span><table class="report" border="0" cellspacing="2" id="idm140010809800624">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>EVENT SUBSEQUENT TO JUNE 30,2024 (Details) - The Agreement - Movantik Acquisition Co, Valinor Pharma, LLC, and HCR Redhill SPV, LLC<br></strong></div></th>
<th class="th">
<div>Jul. 15, 2024 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems', window );"><strong>Disclosure of non-adjusting events after reporting period</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rdhl_ProceedsReceivedFollowingGlobalTerminationAgreement', window );">Proceeds received following global termination agreement</a></td>
<td class="nump">$ 9,900,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_ifrs-full_RestrictedCashAndCashEquivalents', window );">Restricted cash and cash equivalents</a></td>
<td class="nump">700,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_rdhl_IncreaseInLiabilities', window );">Increase in future obligations</a></td>
<td class="nump">$ 12,200,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_RestrictedCashAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of cash and cash equivalents whose use or withdrawal is restricted. [Refer: Cash and cash equivalents]</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Name IAS<br> -Number 1<br> -IssueDate 2023-01-01<br> -Paragraph 55<br> -URI https://taxonomy.ifrs.org/xifrs-link?type=IAS&amp;num=1&amp;code=ifrs-tx-2023-en-r&amp;anchor=para_55&amp;doctype=Standard<br> -URIDate 2023-03-23<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_RestrictedCashAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>ifrs-full_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rdhl_IncreaseInLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of increase in liabilities following Global Termination Agreement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rdhl_IncreaseInLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rdhl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_rdhl_ProceedsReceivedFollowingGlobalTerminationAgreement">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow following global termination agreement signed between the company and Movantik acquisition Co, Valinor Pharma LLC, nd HCR Redhill SPV, LLC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">rdhl_ProceedsReceivedFollowingGlobalTerminationAgreement</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>rdhl_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=rdhl_GlobalTerminationAgreementMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">ifrs-full_NonadjustingEventsAfterReportingPeriodAxis=rdhl_GlobalTerminationAgreementMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_CounterpartyNameAxis=rdhl_MovantikAcquisitionValinorPharmaLlcHcrRedhillSpvLlcMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_CounterpartyNameAxis=rdhl_MovantikAcquisitionValinorPharmaLlcHcrRedhillSpvLlcMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>41
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=]W3CHG&K=!X#;[Q3X?#KHG&J]!TZVDF)_VN:Z3I%FA"1N/K>A(5M>5 TR
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M!Z.:60F]A%9JGZJ'-#ZH'C(*!?&Y'C[E>G@*-Y;&O%"N@GL!_]':-\*K^(+
M.7\N?<^E[[GT/:'2MS<C?6?!TXM;WD9N6\3[KC':US0N*&-7<LW(QU2ODRG8
M.9_ [/UH/I[Q[?K9)(2OFEDM(Q:02X&S022X_(O*\"K$">AD6R4)RU3393>*
M$IY"&V[I4_5*E=?EK[DHN#Q;Y.FOH70^+,_Y/%_GM,T+,T.W<DOJMI2^M28X
M2O2QS'!.'LL,.V<\DAVV=Z =-?OV77;D(Z4P4Y=#N!I"O@-MNIW<.CB>F)&Y
M"M-2D&_#^>G%>!KB.=D$N7V85VWGV-'1^^?!4;"C[SR6'<>(\J(A[J&&F,_#
M0X=Y>U^89Y7&4#04;6RL)"Q&MV"XU_$L%.!D8"V@!X.O40+R4E5@,5O& RN0
MHGQ,C$7H<.>77%_CT9+CVZ9EM6ZO*7<9;2)2.<)IF!-GJ\K>9;'!51W/55OR
ML+YJ/;053L_^6:W(GPP13A8+$DACE!>F2J+S&5.^YRM)Q%4XOT4SMA*7&+SC
MYL=Q3E.X$G:V#P(RN;LYJ7IE,6>F\M\M# DL6XA9$N)-7>W5YYN<KGHB=OJ7
M=\%@\OUPR4</Y3OG7_1=0ZY^]MWC^FZ3.TA,G'G%$0%T10(CE1P&%A<RY%#N
MDI &$P'-E,E$\ *"9*8<@)CZ"[WR#+DI%<ZM/CE_12R#ADY>TB42%(JP# 4A
M%W+C[^^3:G>,U_HL@6V$5#)DU1?*0XG!/3-R0]A4)?.NVB8+A=OB5,V[&KXF
M8$O#>FZ=+2?_VU[4/;07/4;SHYG@'K.'<YMZN,)%K/]8UA[Y,M\Y<-LZW@->
MYA,L0Z1^P7V*BH 1JV*^NJ]/^26<.[1[\8$@F_S6VZ3VW> ,?-2K6J5D*Q$_
M2P=\'Y(&8XQ;]#1?CQ1BK::QK<;:,0QY@%CS#*%F.-^'19H:,]6+K#F-"F]!
MU4#E/]O4#6CV#30<D05>,9FV-J/D3@H\W/[O#;#"Q([A[8N_ 5!+ P04
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MX?T@Z]I8=[0HJGJT%AJK6]5,\7\"I)F WS="Z$/'+-#^H41_ 5!+ P04
M" #F.!U9K''3L9X$  "@$   &    'AL+W=O<FMS:&5E=',O<VAE970R+GAM
M;+68;7.J.!3'OTJ&O;/3.],*"4_256>H8F57T0':N_N22EJ9B^ "UKO??A-
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M[4$ ^/,5(>QE((XCF@.NR;]02P,$%     @ YC@=62Y1-'9R"0  62@  !@
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M@6">+A# C8+&8<%V F$Z2D&)'&\W9YS$QG&=ED6*6:L 4ZT")@>C0T'QQNN
M':84JVJ$"E)NQ7PD9TP)LUMZDT%E5K;;LD]I'IP6J-F_*G:[;=0(+=[W^S ?
M%CQ39/5>7].:GHM6EMNV"#9KZC?5U.^/1U-O.//0Q9U77ETB?UP>&@W'=^6%
M]\]?_O/P@9TH20&(]*[WQ-#+1(#1=]J"7XL 4[V.]_XU^CD<__#0G7]_[TV]
M\<B;H:?/8I MPYL()#9M U"3N:DF\]OA [".5YW4R1Q&PSFZ]7[XXS%C)["<
M>%/_Z4Z*0^1RVW::F_42*[W?=UI6)F9-^J::]$\%,__I(0]^4T,12;YG])J*
M7F+E )06)+48,-7K\-FOR>2!'Z(.I_^&&7'_-'T<SGU(*_C'#UI!>**I-_+\
M9W[TRG%*88A+:[.Y_);8Z$9;:M74;JJI_30,DZ&O]E]D9D/P7[0Q]18:LVKR
MMM3D/0S_VL1YO-]*Y <65V1Y!8IRO[R",IOB@&V!+T^C"4NDW.9J16)B&"V[
MO%;-R=;IG'SLZ3NZX(P7$LI(CV01XXSHD,,9<@:Q0LY7F"G;J&"/O^@]C>]O
MK3#*XS>4EF?SF)W-HS\V&:Y.UK]R%??%^JKKO0];L+/T2T;$FX3K]@\.2Z3A
MUH438+W?U'Z6J"V VEK.%ZQ:6UAJ;7$8<;\A\J2^GO6PP)(IC;ZMM<QJJ]8:
MEEIK',-2[JFI>_HT(LGN@V68;8 ./CQ02Y!#0!.I1#]I])0O^3164:Q83MN'
M"U8M52RU5#F$>@O3G;S"O)*B.>M^A24*%UVW#;V%):U:O%AJ\:(X7F;W__<1
MLS0D9SV5V/5V]&F*Y%BY>_"15HKI"_]V+4=\B[C\N*EZ6GT?-^1?A36>W^K?
M1^57;G4WY4=WCP%]85%,\!*ZU+[UP"=:?L=6WA1DS3\%6Y"B("F_7.$@PI09
MP.]+0HK]#7M!]37AX']02P,$%     @ YC@=6;VD +%Q @  [P4  !@   !X
M;"]W;W)K<VAE971S+W-H965T-BYX;6RM5%UOFS 4_2M7K)I::0L$:#)U!"E?
M53,U'RKI^NS"34 %F]DFZ?[];$-8VJ75'OH"OO8]Q^=<N#?8,_XD4D0)ST5.
MQ<!*I2RO;%O$*19$=%B)5)UL&"^(5"'?VJ+D2!(#*G+;=9R>79",6F%@]E8\
M#%@E\XSBBH.HBH+PWR/,V7Y@=:W#QEVV3:7>L,.@)%N,4-Z7*ZXBNV5)L@*I
MR!@%CIN!->Q>C7V=;Q)^9K@71VO03AX9>]+!+!E8CA:$.<92,Q#UVN$8\UP3
M*1F_&DZKO5(#C]<']FOC77EY) +'+'_($ID.K&\6)+@A52[OV/X&&S^7FB]F
MN3!/V#>YC@5Q)20K&K!24&2T?I/GI@Y' ,5S&N V /<UP'\#X#4 SQBME1E;
M$R))&'"V!ZZS%9M>F-H8M'*34?T5(\G5::9P,APO%Y/I(II.0*VBY>UL,ERK
M8+983^]F<XC6*IQ/%^L(EM<P'D8W<'V[?(C@?$4X4IFBS&*27\!7N(\F<'YV
M 6>045BGK!*$)B*PI5*I[[+C1M&H5N2^H:@'<Z:(!4QI@LE+O*W<M1;=@\61
M^R[ACXIVP'.^@.NX_@D]X_^'>^_(\=J*>X;/^]B*GRID?9%_^B+=_U>B)#$.
M+-7@ OD.K?#SIV[/^7ZJ"A]$]J(F?EL3_SWV<(*Q&D$"]:_#=>,!VT"E8B($
MRE/6:[Y+PZ<GU2[L]IW WAT[^C?'[W;[;5*MU#[JG0+YUHP4 3&KJ*S_L7:W
MG5I#TZRO]D=JFM7#YR]-/0KGA&\S*B#'C:)T.GTEB=?CI0XD*TV'/C*I^MTL
M4S61D>L$=;YA3!X"?4$[X\,_4$L#!!0    ( .8X'5F6TON1]@D  )L9   8
M    >&PO=V]R:W-H965T<R]S:&5E=#<N>&ULK5EK;]LZ$OTKA"]PD0".7TD?
MMTD#.$D?*?I"D^Y^IB5:YE8B59*RD_WU>V9(R7+JY.(6^Z6U97(X<V;.F:%R
MMK'NAU\I%<1=51K_>K *H7XU'OMLI2KI1[96!K\LK:MDP%=7C'WME,QY4U6.
M9Y/)\W$EM1F<G_&SK^[\S#:AU$9]=<(W527=_84J[>;U8#IH'WS3Q2K0@_'Y
M62T+=:/"]_JKP[=Q9R77E3)>6R.<6KX>S*>O+DYH/2_XEU8;W_LL*)*%M3_H
MRW7^>C AAU2ILD 6)/Y;JTM5EF0(;OQ,-@?=D;2Q_[FU_I9C1RP+Z=6E+?^M
M\[!Z/7@Y$+E:RJ8,W^SFO4KQ/"-[F2T]_RLV<>WT>""RQ@=;I<WPH-(F_B_O
M$@Z]#2\GCVR8I0TS]CL>Q%Y>R2#/SYS="$>K88T^<*B\&\YI0TFY"0Z_:NP+
MY^_>?'[S;?[Q;!Q@C!Z-L[3Q(FZ</;+QN?AD35AY\<;D*M_=/X83G2>SUI.+
MV9,&/S1F)(XG0S&;S$Z>L'?<17;,]H[_>61QX\G^C42#5[Z6F7H]0)U[Y=9J
M</[G']/GD],GW#KIW#IYROKY.V64D^4^MY[>^/G+[1LQ%4<B!?9*_/G'R]GD
M^%3(D4A6NT?30_%-Y>]U68H+;>N51 &+CR$?B8.P4KQL-CF]M%4MS3U_FYX>
M#H4VF76U=3*H7( S\Z9 "8IC2LKDKZ$(ME#8[U"D825T\&*SLF5Y?V0W!CM\
ML_ ZUR#W<,_QUR;#\>GH]F=Z^,CYVH@K5<J-=&HHOH]N1N31!VD:V!?3O\BG
MZ0OL\4(*7ZM,RS+<BT5[7J::H#-@DL4H1>TT=$>7]V)IP:P882%]<%:;H'S0
M!JM;!]]=MVZ)7'L%XN,<0UXM65 :WST?=;#? ML>J-,7IU[,*^7@!P536Z\#
M>7\##V&O/6M^=>.[TS;**1&<S*.#E*[/TN?RI[B4-;:7XI-T/R#72V<K&,U4
MM4!&9B\8D-DP&BBU#[\8>%?:Q79_>WK\L3N?S7YH -.,R3A].>3 5W*MQ$(I
M*&D!L=]_P@,7/1**W^PZ^CA]QNP^'HDOAI9D*S$[CH^&;"5A)[*5- 6,TS.
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MAC1^B=]3%?U"1AI<.>4/8@*CWU]^P_J2BMRQK!M,ZG3X4'S\>-EE ,L^=2F
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M*!G$H06BF8Z-H?B^GDAKKO1\JY<[_4&!PCCH\PWGZF28 .TGRO0O4$L#!!0
M   ( .8X'5GBOR>Y#0(  ,@$   9    >&PO=V]R:W-H965T<R]S:&5E=#$Q
M+GAM;*64;6_:,!#'OXKE2GVUQL$\K*)))&B9NDET"-I->VF2@UA-[,QVFO;;
MSW9"1B6*)NT-N;/O?O>_<)>HD>I9YP &O9:%T#'.C:FFA.@TAY+I0%8@[,U.
MJI(9ZZH]T94"EOFDLB T#">D9%S@)/)G*Y5$LC8%%[!22-=ER=3;' K9Q'B
M#P=KOL^-.R!)5+$];, \52ME/=)3,EZ"T%P*I& 7X]E@.A^Y>!_P@T.CCVSD
M.ME*^>R<KUF,0R<("DB-(S#[>(%;* H'LC)^=TS<EW2)Q_:!_L7W;GO9,@VW
MLOC),Y/'^!JC#':L+LQ:-O?0]3-VO%06VO^BIHVEMF)::R/++MGZ)1?MD[UV
M[^$H8?Q1 NT2J-?=%O(J[YAA2:1D@Y2+MC1G^%9]MA7'A?M3-D;96V[S3+*Y
MGZT75_/99G&'5K-?R\7#XR8BQI+=/4D[RKRET \H$[24PN0:+40&V?M\8A7U
MLNA!UIR>!7ZK18"&X2=$0SHZPQOV;0X];_B?;;:4T6F*6Y"IKE@*,;8;H$&]
M $XN+P:3\.:,QE&O<72._L\:SU,>OC\NT!A=H5.X*;J\N*;A\ 8-@MZD 9*5
M6Q&-@E-MD*/I*D'M_0YIE,I:F';0^M-^36?M=/X-;W=\R=2>VSH%[&QJ&'P>
M8Z3:O6D=(RL_JUMI[.1[,[>?&E NP-[OI#0'QQ7H/U[)'U!+ P04    " #F
M.!U982AXI((#  !+"   &0   'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6RE
M5MMNVS@0_96!6A0)X$JR9#MI8AO(Q=WMHND&<=)]IJ61180BM205)W^_0TJ6
M;6R3 NV+)5[.X3DSU(RG&Z4?38EHX;D2TLR"TMKZ+(I,5F+%3*AJE+12*%TQ
M2T.]CDRMD>4>5(DHB>-)5#$N@_G4S]WJ^50U5G")MQI,4U5,OURB4)M9, RV
M$W=\75HW$<VG-5OC$NU#?:MI%/4L.:]0&JXD:"QFP<7P['+D]OL-WSENS-X[
M."<KI1[=X$L^"V(G" 5FUC$P>CSA%0KAB$C&OQUGT!_I@/OO6_;/WCMY63&#
M5TK\PW-;SH+3 '(L6"/LG=K\B9V?L>/+E##^%S;MWF$:0-88JZH.3 HJ+MLG
M>^[BL <XC5\!)!T@\;K;@[S*:V;9?*K5!K3;36SNQ5OU:!+'I4O*TFI:Y82S
M\V^+>[A;?%]\>U@LIY$E1C<?91WZLD4GKZ G<*.D+0TL9([Y(3XB);V<9"OG
M,GF3\*]&AI#& TCB9/0&7]K;2SU?^HOV6O3HQVCW09R9FF4X"^C&&]1/&,P_
MO!M.XO,WM(UZ;:.WV'^J[2?HO^\7,(&/L$]S!A_>G29Q>O[+SR5_/L@I4$;0
M9V2[PV7&_:3_PSZ$2\B5$$P;X!)LJ1K#9&Y@R00:4 746N5-9LV.;# ^2?K1
M>)!^&O>CZT9SN28:!$.JJE85'JIR:@9 IQQ,I0,/NU)5S>0+%8],:0?+B$.S
MCQJ?4#:MI*/W<?CIF#XM(7R5("8WE>RFJ/)12)Z8M/R1DG\R.A\0HZG1%Q3Q
M,B!;G"H:%R^0-PA6T;)MM#0$%53UG M.IG/:;BRG)03B_8PKW5 AA&&K&8X,
M(DAE$8;CH\EQ&T,D2;)A @HNF<PXO1G++%)A)$KF/5QCAM4*-:0=U7%(WK43
MJ61.QSN1DBI\;[S0J@)%['J7DR-7P\G#/1.<SFFM'L,&2>[[-!SW >ET%5P;
M"R43A=/0)H++3#3N1* 8[A#^..-O 47G#X:"2;C!G&=DYUZS'.'KUZL!;$J>
ME41)QB3@,W$9BAF0'FH#Z#-QH&XKY>%B<1B]D]^,WI=7+*:_&\=Q.-E&A:ZM
M$"T#?3EA%Y_P1Y4EVBOP%>JU;V.&KG,C;5OK^]F^4UZT#6*WO6VS-TRO.5U-
M@05!X_!D'(!N6U<[L*KV[6*E+#4?_UI2MT?M-M!ZH2C&W< =T/]_F/\'4$L#
M!!0    ( .8X'5E?NBG5 @0  *4)   9    >&PO=V]R:W-H965T<R]S:&5E
M=#$S+GAM;+U6;6_B.!#^*Z.LNNI*$)+PVA:0:+O5]G3M5:6]^VR2"?CJV)SM
M0+E??V,' CU1M-))]P5BSSR/G_',V!ZNE7XS"T0+[X609A0LK%U>MEHF76#!
M3*B6*,F2*UTP2T,];YFE1I9Y4"%:213U6@7C,A@/_=R3'@]5:067^*3!E$7!
M].8:A5J/@CC833SS^<*ZB=9XN&1SG*)]73YI&K5JEHP7* U7$C3FHV 27UYW
MG+]W^)WCVAQ\@XMDIM2;&]QGHR!R@E!@:AT#H[\5WJ 0CHAD_+7E#.HE'?#P
M>\=^YV.G6&;,X(T2?_#,+D;!(( ,<U8*^ZS6/W ;3]?QI4H8_POKRC=) DA+
M8U6Q!9."@LOJG[UO]^$ ,(@^ 21;0.)U5PMYE;?,LO%0JS5HYTUL[L.'ZM$D
MCDN7E*G59.6$L^.[^\?)X\W]Y%>X?YR^/+\^?']\F0Y;EJB=0RO=TEQ7-,DG
M-#UX4-(N#'R7&68?\2V25.M*=KJNDY.$OY0RA';4@"1*.B?XVG6<;<_7_J]Q
M5C2=XS2N12[-DJ4X"J@'#.H5!N.O7^)>='5"9*<6V3G%_O,B3],\_O;R'?K0
MA*-\E_#URR")VE? 0GA9(-RH8LGDQLW&_2M#-:WYBKEF@9Q+)E/.! C.9EQP
MNVE0*_K0I<4,9AM8,ZV9M*8!W$"!S)2:#,Q"SKB&%1,E I,9I((9PW/NC 8$
MKE! .X2[ Z_L3RIXZGAK@&FDA5(UE_QO0G )2ZUR;D%I$,H8Q[%7QV6J"G0V
M?*?CRJ"I0LN5H%.'RSE8-A,(6^$&+!G3!9-S=-1VP6M%A^'701.1]AC#WZ&H
M*AU=I0/5*=9UVO"!'DZU8;_=/_M_>VS_N316E]7>[!RG).:P[?8K[SR<J$K&
M;N8UG(:0T;8P;:K056E(M8%K)F@M=)F;X9Q+Z;9-Y3[L)4E2&?0[\9ZZT2/:
M>\FMD[=-E3]H"7.D;N"B,>A%-;S?B :?PDMYD/J,;2"N<GY^T4V^?=BO.+GZ
MK().5L]YOQ%'@SW7^: 1]>-OAYM ^?U7^$FC>[ !<:/7[M8C7VU[(5O@KC=<
M:U"%+DO7,Z7Q!4GF:\'2M^8T72B!U#LJ0Q'"Q#CT+I5569%R8G"W#VF2'CNY
MG5)0G+3Z"1*<,5MUFOU0^6^X@273K$"+VER"YN:MF6MTE4\S:"QHAZ1%.V&[
M>];LA)W!F2=:*4%UZ+-'UCB)0C+'[7;8.SNBL_T_ZHS[9\UNV.D?TSGHD;[F
MQ06)#>O\S$((CYW0K8.KLT ]]P\$EZQ2VNH6K6?K-\BDNGKW[M4#YH%I:AMW
MD.0$C<)^-Z @_*.@&EBU]!?Q3%FZUOWG@MY1J)T#V7.E[&[@%JA?9N-_ %!+
M P04    " #F.!U9&I"P5G,$  #>"@  &0   'AL+W=O<FMS:&5E=',O<VAE
M970Q-"YX;6RE5FUOXC@0_BM65JI:*0LA 4K+BT1I=[<G4:K2O?OL)A/B:Q+G
M;%/H_OJ;<4((O8).6JEJ//;,,\^,9P:/-E*]Z@3 L&V6YGKL),84U^VV#A/(
MN&[) G(\B:7*N$%1K=JZ4, C:Y2E;=_S^NV,B]R9C.S>HYJ,Y-JD(H='Q?0Z
MR[AZOX%4;L9.Q]EM/(E58FBC/1D5? 5+,#^+1X52NT:)1 :Y%C)G"N*Q,^U<
MWW1)WRK\*6"C&VM&D;Q(^4K"?31V/"($*82&$#A^WF &:4I 2..?"M.I79)A
M<[U#_V9CQUA>N(:93/\2D4G&SL!A$<1\G9HGN?D!53P]P@MEJNU_MBEU?<]A
MX5H;F57&R" 3>?GEVRH/#8/!,0._,O M[]*197G+#9^,E-PP1=J(1@L;JK5&
M<B*G2UD:A:<"[<QD>?=]?O?PS.X?OBV>YM/G^\7#J&T0F([;805R4X+X1T#Z
M;"YSDVAVET<0'=JWD5#-RM^QNO%/ OZQSELL\%SF>W[W!%Y01QE8O.#WHBQ!
MNI^#4'M<ZX*',':P_C6H-W F9U\Z?6]X@F*WIM@]A?Y_*9X&>5@\W[$!^\H^
M0;MF9U\&OA<,V7,";)8(B-G=%L(UM05;Q+$(03&AF:%CF14\?R>+SN505^J+
M A0W(E^Q6PB%[<LY?T6K<U+TO>%L<3NWR\[PHE7ZP1W&TU2&W(#&-M9RK4)<
M\3QB7&N@OT]=HB\[<_(0;-]%#-V18BP1;D,L-*QP/AA._7U- !FH4/!T1U3F
MI9\GO"VNPH2=\:P8(ODW'$8%F;;JI$RCO[';T,O=S?WS[129VDO.C68YSL94
M:LU> !D!-CT>H1]RX#*>267$KYV$[F*1(VOB(?)09L#.88M#% .]0(6='R,9
M;,-T'0'3"5?PM0P2#4BW@EOA6-4L5C)C&$'ZS@PHG +VE,F8I8!&NG0K,3FJ
M<NFR32(P8)3(@]XQL4A4NGC9K%#R340EE1^SI[E%(8^E&N5:\Q3(SUR^\=R(
M5RSWR^ZP=5!*^_LP_"4EV"IOU?60GUC@F4B%>2\O'M,;2LQ16F:1&) [W-,R
M%1&G!%':=PFD]%]84\J/@H1^%K!L#\_Q=BP,WKZ0$04=":J[:%_[O_M=BNW!
ML&,XJL".JH^:-+J:0O ?C9^M98M%F#VNB"M2EVN-,>HCI;RL\OFQ5'=XYUVW
M/^A<[.5.Q_6"QD;=!U-,9*,+CB,&;J<;-!![;J_G[>5O'RK=M9>V.^VY0=_;
MIZ#O!L%>7!ZI>=L769'*=ZBFQ(=RQ5S5='S_JD%NT&U(MXTF;63(\YOY<;U>
M;R]/&YU,12]PM.0K035-D\HT''?ZS:0$C91\K_OG>,,>IJE1&?VK?<DL&NU\
M4#H=?U]"7=^]NMK;SYK],SO1*8T+]@:#O=S#E'C^QTK][.>MW7AS8*VN[,M*
MXU6N<U,^/^K=^O$V+=\L>_7RY3?G:D5C+H483;W69<]AJGQ-E8*1A7W!O$B#
M[R&[3/ !"HH4\#R6TNP$<E _:2?_ E!+ P04    " #F.!U9K%?\.&4"  !M
M!0  &0   'AL+W=O<FMS:&5E=',O<VAE970Q-2YX;6RM5&%/VS 0_2NG("&0
M1A/2TK'21FI9!TP#JI9MGTUR:2P<.[,="O]^9R?-.@DJ3=J')'?VO>=W2=Z-
M-TH_F0+1PDLII)D$A;75* Q-6F#)3$]5*&DG5[IDEE*]#DVED64>5(HPCJ)A
M6#(N@V3LUQ8Z&:O:"BYQH<'49<GTZPR%VDR"TV"[L.3KPKJ%,!E7;(TKM-^K
MA:8L[%@R7J(T7$G0F$^"Z>EH-G#UON 'QXW9B<%U\JC4DTMNLDD0.4$H,+6.
M@='C&2]1"$=$,GZUG$%WI /NQEOV+[YWZN61&;Q4XB?/;#$)S@/(,&>UL$NU
MN<:VGS/'ERIA_!TV36U\%D!:&ZO*%DP*2BZ;)WMIW\,.X#QZ!Q"W@-CK;@[R
M*C\SRY*Q5AO0KIK87.!;]6@2QZ7[*"NK:9<3SB;SZ?+NYNX*CK[=KU;'L)@O
M874]7<['H25V5Q.F+=.L88K?81K"K9*V,#"7&69_XT-2U4F+M])F\5["K[7L
M03_Z '$4#_;P];M6^YZO_Q]:;9@&;S,YHXQ,Q5*<!.0$@_H9@^3PX'087>S1
M.>AT#O:Q_Y/._4QW]P]S^ 0G\![E" X/SN.H?P$/!;J_FZ? 9 89%[7%#)!I
MR>7:P)%0QAQ#A>3G@FD$=UG"&%;2C<NT23'/R6Z@<F!"0*4L2LLI?.THE<ZX
M)/LW/ 9HKOA:C972E@YSAW"5&>"&M%A^XI%DW=Y6[%OO.-RQ0(EZ[8UN(%6U
MM(T;NM5NEDP;"_TI;P;1+=-K+@T(S D:]3Z2=75C[B:QJO*&>E26[.G#@N8A
M:E= ^[FBOMO$'=!-V.0W4$L#!!0    ( .8X'5ET]&L\C00  $0*   9
M>&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;)U6:6_;.!#]*P.U*!+ ZSMIF\-
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MPQ+///8B@/V90[LT$S'0/APG_P)02P,$%     @ YC@=69P-:O<'!   (PD
M !D   !X;"]W;W)K<VAE971S+W-H965T,3<N>&ULG5;;CMLV$/V5@0($NX"Q
M\BV;8-<V(-\2!;'6L)P6?:2EL<5&(A626J__OD-*5K>HXZ1]L7F;,V?.##D:
M':7ZIC-$ R]%+O38RXPI'WQ?)QD63-_)$@7M[*4JF*&I.OBZ5,A29U3D?K_;
MO?<+QH4W&;FUM9J,9&5R+G"M0%=%P=1IBKD\CKV>=U[8\$-F[((_&97L@#&:
MK^5:T<QO45)>H-!<"E"X'WM![V$ZM.?=@=\X'O6K,=A(=E)^LY,P'7M=2PAS
M3(Q%8/3WC#/,<PM$-+XWF%[KTAJ^'I_1ERYVBF7'-,YD_CM/33;V/GB0XIY5
MN=G(XR=LXGEG\1*9:_<+Q^9LUX.DTD86C3$Q*+BH_]E+H\.O&/0;@[[C73MR
M+.?,L,E(R2,H>YK0[,"%ZJR)'!<V*;%1M,O)SDRF01S&\+2$]6:Q#C;!-GR*
M['3[:0&SIVB^B.+%W([BIR_A/-C2)(RVBTVX@F48!=$L#+Y O*6-U2+:QA!$
M<XC#CU&X#&=!M(5@-GOZ&FW#Z".L"6$6+F*X6<N<)QSU[<@W%(-EXB<-WVG-
MM_\#OO>PDL)D&A8BQ?2?]C[%W@K0/PLP[5\%_%R).QAT.]#O]H=7\ :MH .'
M-_@!7OQUM0HV?U@-?Z+#I>!K[.%E;'M!'W3)$AQ[= ,UJF?T)F_?].Z[CU>8
M#UOFPVOHDRG37(/< V&73#%[:RYQO(IRF2.\??.AWQT\PC9#F,FB9.)DEWKO
M'S4DDE(I-*9VI*DT4F9HPH5!Q0O8<\%$PED.VM &/0A& [U&8 A+\Q<HZH)
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M-@+/5N((6<X?"%NX@VYF+CKX>(@^HC:22R:X+-YJ2CHV@_]BT1'"O3> W1?
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M,!3]*Q:;IE9:RRN0IDN0FC1[J:FJI.T^NW"36 6<V2;II/WXV4 (- 2U&5_
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MK%VY%01'65(2N\CS C?!E#G3<39V+Z9CGJJ8,G(O@$R3!(N7*Q+S_<2!SNO
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M\MPH(<<_C:C3KFD<=]]?U:^KX#&89ZI@*O*_6*JSH=-S2 I+NL[UH]C^#DU
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MM6>'RD!%DM.)<>J"DF*+2"%DD)!7M$/)OO5,Y:.];3MK(7&5&/);)ANXMVW
M]4%. ]\E?D1<).^B8.&Y3BP+GA^3T%LB!1(#D/B,D-^Q CD ( ?GA!PHD$,
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M>K, O1GU9@%Z\\O'M@"]&?5F 7HSZLT"]&;4FP7HS:@W"]";46\6H#>CWBQ
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M4$L! A0#%     @ YC@=6;[X\H/O    *P(  !$              ( !KP
M &1O8U!R;W!S+V-O<F4N>&UL4$L! A0#%     @ YC@=69E<G",0!@  G"<
M !,              ( !S0$  'AL+W1H96UE+W1H96UE,2YX;6Q02P$"% ,4
M    " #F.!U9/^<W'L<"  "M"   &               @($."   >&PO=V]R
M:W-H965T<R]S:&5E=#$N>&UL4$L! A0#%     @ YC@=6:QQT[&>!   H!
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M965T-BYX;6Q02P$"% ,4    " #F.!U9EM+[D?8)  ";&0  &
M    @('K)@  >&PO=V]R:W-H965T<R]S:&5E=#<N>&UL4$L! A0#%     @
MYC@=67/_&F#1!P  ZQ4  !@              ("!%S$  'AL+W=O<FMS:&5E
M=',O<VAE970X+GAM;%!+ 0(4 Q0    ( .8X'5F@9_B:B 4  .\.   8
M          " @1XY  !X;"]W;W)K<VAE971S+W-H965T.2YX;6Q02P$"% ,4
M    " #F.!U9*-=H'%D#  "N"   &0              @('</@  >&PO=V]R
M:W-H965T<R]S:&5E=#$P+GAM;%!+ 0(4 Q0    ( .8X'5GBOR>Y#0(  ,@$
M   9              " @6Q"  !X;"]W;W)K<VAE971S+W-H965T,3$N>&UL
M4$L! A0#%     @ YC@=66$H>*2" P  2P@  !D              ("!L$0
M 'AL+W=O<FMS:&5E=',O<VAE970Q,BYX;6Q02P$"% ,4    " #F.!U97[HI
MU0($  "E"0  &0              @(%I2   >&PO=V]R:W-H965T<R]S:&5E
M=#$S+GAM;%!+ 0(4 Q0    ( .8X'5D:D+!6<P0  -X*   9
M  " @:),  !X;"]W;W)K<VAE971S+W-H965T,30N>&UL4$L! A0#%     @
MYC@=6:Q7_#AE @  ;04  !D              ("!3%$  'AL+W=O<FMS:&5E
M=',O<VAE970Q-2YX;6Q02P$"% ,4    " #F.!U9=/1K/(T$  !$"@  &0
M            @('H4P  >&PO=V]R:W-H965T<R]S:&5E=#$V+GAM;%!+ 0(4
M Q0    ( .8X'5F<#6KW!P0  ",)   9              " @:Q8  !X;"]W
M;W)K<VAE971S+W-H965T,3<N>&UL4$L! A0#%     @ YC@=61GG>&M( P
M/0@  !D              ("!ZEP  'AL+W=O<FMS:&5E=',O<VAE970Q."YX
M;6Q02P$"% ,4    " #F.!U9HCU*I$<"  !)!0  &0              @(%I
M8   >&PO=V]R:W-H965T<R]S:&5E=#$Y+GAM;%!+ 0(4 Q0    ( .8X'5D2
M)&S.X0(  )(&   9              " @>=B  !X;"]W;W)K<VAE971S+W-H
M965T,C N>&UL4$L! A0#%     @ YC@=678X/K)M P  , @  !D
M     ("!_V4  'AL+W=O<FMS:&5E=',O<VAE970R,2YX;6Q02P$"% ,4
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M+GAM;%!+ 0(4 Q0    ( .8X'5D24@&MZ ,  $T2   9              "
M@>EZ  !X;"]W;W)K<VAE971S+W-H965T,C8N>&UL4$L! A0#%     @ YC@=
M690'B$L= P  #PT  !D              ("!"'\  'AL+W=O<FMS:&5E=',O
M<VAE970R-RYX;6Q02P$"% ,4    " #F.!U9F;D,S*,$  !,%P  &0
M        @(%<@@  >&PO=V]R:W-H965T<R]S:&5E=#(X+GAM;%!+ 0(4 Q0
M   ( .8X'5F)>V&WN ,  %8+   9              " @3:'  !X;"]W;W)K
M<VAE971S+W-H965T,CDN>&UL4$L! A0#%     @ YC@=60'UQA*S @  S 4
M !D              ("!)8L  'AL+W=O<FMS:&5E=',O<VAE970S,"YX;6Q0
M2P$"% ,4    " #F.!U9A!AH^4<#   4%   #0              @ $/C@
M>&PO<W1Y;&5S+GAM;%!+ 0(4 Q0    ( .8X'5F7BKL<P    !,"   +
M          "  8&1  !?<F5L<R\N<F5L<U!+ 0(4 Q0    ( .8X'5D@;CW]
M,0,  )P4   /              "  6J2  !X;"]W;W)K8F]O:RYX;6Q02P$"
M% ,4    " #F.!U99(35>E<!  "1$@  &@              @ '(E0  >&PO
M7W)E;',O=V]R:V)O;VLN>&UL+G)E;'-02P$"% ,4    " #F.!U9.6DC=8(!
M  !,$P  $P              @ %7EP  6T-O;G1E;G1?5'EP97-=+GAM;%!+
4!08     )@ F $$*   *F0     !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.24.2.u1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>80</ContextCount>
  <ElementCount>144</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>29</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>7</UnitCount>
  <MyReports>
    <Report instance="rdhl-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.redhillbio.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="rdhl-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - CONDENSED CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveIncomeLoss</Role>
      <ShortName>CONDENSED CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE INCOME (LOSS)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="rdhl-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00200 - Statement - CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition</Role>
      <ShortName>CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="rdhl-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00300 - Statement - CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfChangesInEquity</Role>
      <ShortName>CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="rdhl-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00400 - Statement - CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows</Role>
      <ShortName>CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="rdhl-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00405 - Statement - CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlowsParenthetical</Role>
      <ShortName>CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="rdhl-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>10101 - Disclosure - GENERAL</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.redhillbio.com/role/DisclosureGeneral</Role>
      <ShortName>GENERAL</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="rdhl-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10201 - Disclosure - BASIS OF PREPARATION OF THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.redhillbio.com/role/DisclosureBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsAndSignificantAccountingPolicies</Role>
      <ShortName>BASIS OF PREPARATION OF THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="rdhl-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10301 - Disclosure - SIGNIFICANT EVENTS DURING THE CURRENT REPORTING PERIOD</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriod</Role>
      <ShortName>SIGNIFICANT EVENTS DURING THE CURRENT REPORTING PERIOD</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="rdhl-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10401 - Disclosure - ALLOWANCE FOR DEDUCTIONS FROM REVENUES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.redhillbio.com/role/DisclosureAllowanceForDeductionsFromRevenues</Role>
      <ShortName>ALLOWANCE FOR DEDUCTIONS FROM REVENUES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="rdhl-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10501 - Disclosure - SHARE-BASED PAYMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.redhillbio.com/role/DisclosureShareBasedPayments</Role>
      <ShortName>SHARE-BASED PAYMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="rdhl-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10601 - Disclosure - NET REVENUES</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.redhillbio.com/role/DisclosureNetRevenues</Role>
      <ShortName>NET REVENUES</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="rdhl-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10701 - Disclosure - FINANCIAL INSTRUMENTS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.redhillbio.com/role/DisclosureFinancialInstruments</Role>
      <ShortName>FINANCIAL INSTRUMENTS</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="rdhl-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10801 - Disclosure - SEGMENT INFORMATION</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.redhillbio.com/role/DisclosureSegmentInformation</Role>
      <ShortName>SEGMENT INFORMATION</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="rdhl-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10901 - Disclosure - EARNING (LOSS) PER SHARE</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.redhillbio.com/role/DisclosureEarningLossPerShare</Role>
      <ShortName>EARNING (LOSS) PER SHARE</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="rdhl-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>11001 - Disclosure - EVENT SUBSEQUENT TO JUNE 30, 2024</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.redhillbio.com/role/DisclosureEventSubsequentToJune302024</Role>
      <ShortName>EVENT SUBSEQUENT TO JUNE 30, 2024</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="rdhl-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>20202 - Disclosure - BASIS OF PREPARATION OF THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.redhillbio.com/role/DisclosureBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsAndSignificantAccountingPoliciesPolicies</Role>
      <ShortName>BASIS OF PREPARATION OF THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="rdhl-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>30403 - Disclosure - ALLOWANCE FOR DEDUCTIONS FROM REVENUES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.redhillbio.com/role/DisclosureAllowanceForDeductionsFromRevenuesTables</Role>
      <ShortName>ALLOWANCE FOR DEDUCTIONS FROM REVENUES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.redhillbio.com/role/DisclosureAllowanceForDeductionsFromRevenues</ParentRole>
      <Position>18</Position>
    </Report>
    <Report instance="rdhl-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>30603 - Disclosure - NET REVENUES (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.redhillbio.com/role/DisclosureNetRevenuesTables</Role>
      <ShortName>NET REVENUES (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.redhillbio.com/role/DisclosureNetRevenues</ParentRole>
      <Position>19</Position>
    </Report>
    <Report instance="rdhl-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>30703 - Disclosure - FINANCIAL INSTRUMENTS (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.redhillbio.com/role/DisclosureFinancialInstrumentsTables</Role>
      <ShortName>FINANCIAL INSTRUMENTS (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.redhillbio.com/role/DisclosureFinancialInstruments</ParentRole>
      <Position>20</Position>
    </Report>
    <Report instance="rdhl-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>30803 - Disclosure - SEGMENT INFORMATION (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.redhillbio.com/role/DisclosureSegmentInformationTables</Role>
      <ShortName>SEGMENT INFORMATION (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.redhillbio.com/role/DisclosureSegmentInformation</ParentRole>
      <Position>21</Position>
    </Report>
    <Report instance="rdhl-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>40101 - Disclosure - GENERAL (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.redhillbio.com/role/DisclosureGeneralDetails</Role>
      <ShortName>GENERAL (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.redhillbio.com/role/DisclosureGeneral</ParentRole>
      <Position>22</Position>
    </Report>
    <Report instance="rdhl-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>40201 - Disclosure - BASIS OF PREPARATION OF THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.redhillbio.com/role/DisclosureBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsAndSignificantAccountingPoliciesDetails</Role>
      <ShortName>BASIS OF PREPARATION OF THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.redhillbio.com/role/DisclosureBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsAndSignificantAccountingPoliciesPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="rdhl-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>40301 - Disclosure - SIGNIFICANT EVENTS DURING THE CURRENT REPORTING PERIOD - Equity Offerings (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodEquityOfferingsDetails</Role>
      <ShortName>SIGNIFICANT EVENTS DURING THE CURRENT REPORTING PERIOD - Equity Offerings (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>24</Position>
    </Report>
    <Report instance="rdhl-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>40401 - Disclosure - ALLOWANCE FOR DEDUCTIONS FROM REVENUES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.redhillbio.com/role/DisclosureAllowanceForDeductionsFromRevenuesDetails</Role>
      <ShortName>ALLOWANCE FOR DEDUCTIONS FROM REVENUES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.redhillbio.com/role/DisclosureAllowanceForDeductionsFromRevenuesTables</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="rdhl-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>40501 - Disclosure - SHARE-BASED PAYMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails</Role>
      <ShortName>SHARE-BASED PAYMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.redhillbio.com/role/DisclosureShareBasedPayments</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="rdhl-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>40601 - Disclosure - NET REVENUES (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.redhillbio.com/role/DisclosureNetRevenuesDetails</Role>
      <ShortName>NET REVENUES (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.redhillbio.com/role/DisclosureNetRevenuesTables</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="rdhl-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>40701 - Disclosure - FINANCIAL INSTRUMENTS (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails</Role>
      <ShortName>FINANCIAL INSTRUMENTS (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.redhillbio.com/role/DisclosureFinancialInstrumentsTables</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="rdhl-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>40801 - Disclosure - SEGMENT INFORMATION (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.redhillbio.com/role/DisclosureSegmentInformationDetails</Role>
      <ShortName>SEGMENT INFORMATION (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.redhillbio.com/role/DisclosureSegmentInformationTables</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="rdhl-20240630x6k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>41001 - Disclosure - EVENT SUBSEQUENT TO JUNE 30,2024 (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.redhillbio.com/role/DisclosureEventSubsequentToJune302024Details</Role>
      <ShortName>EVENT SUBSEQUENT TO JUNE 30,2024 (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.redhillbio.com/role/DisclosureEventSubsequentToJune302024</ParentRole>
      <Position>30</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File>rdhl-20240630.xsd</File>
    <File>rdhl-20240630_cal.xml</File>
    <File>rdhl-20240630_def.xml</File>
    <File>rdhl-20240630_lab.xml</File>
    <File>rdhl-20240630_pre.xml</File>
    <File doctype="6-K" isDefinitelyFs="true" isIfrs="true" original="rdhl-20240630x6k.htm">rdhl-20240630x6k.htm</File>
    <File doctype="6-K" isDefinitelyFs="true" isIfrs="true" original="rdhl-20240630xex99d2.htm">rdhl-20240630xex99d2.htm</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="8">http://xbrl.sec.gov/dei/2023</BaseTaxonomy>
    <BaseTaxonomy items="243">https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>49
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "rdhl-20240630x6k.htm rdhl-20240630xex99d2.htm": {
   "nsprefix": "rdhl",
   "nsuri": "http://www.redhillbio.com/20240630",
   "dts": {
    "schema": {
     "local": [
      "rdhl-20240630.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd",
      "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd",
      "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd",
      "https://xbrl.ifrs.org/taxonomy/2023-03-23/full_ifrs/full_ifrs-cor_2023-03-23.xsd",
      "https://xbrl.sec.gov/country/2023/country-2023.xsd",
      "https://xbrl.sec.gov/currency/2023/currency-2023.xsd",
      "https://xbrl.sec.gov/dei/2023/dei-2023.xsd"
     ]
    },
    "calculationLink": {
     "local": [
      "rdhl-20240630_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "rdhl-20240630_def.xml"
     ]
    },
    "labelLink": {
     "local": [
      "rdhl-20240630_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "rdhl-20240630_pre.xml"
     ]
    },
    "inline": {
     "local": [
      "rdhl-20240630x6k.htm",
      "rdhl-20240630xex99d2.htm"
     ]
    }
   },
   "keyStandard": 101,
   "keyCustom": 43,
   "axisStandard": 17,
   "axisCustom": 0,
   "memberStandard": 15,
   "memberCustom": 14,
   "hidden": {
    "total": 14,
    "http://xbrl.sec.gov/dei/2023": 8,
    "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full": 6
   },
   "contextCount": 80,
   "entityCount": 1,
   "segmentCount": 29,
   "elementCount": 253,
   "unitCount": 7,
   "baseTaxonomies": {
    "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full": 243,
    "http://xbrl.sec.gov/dei/2023": 8
   },
   "report": {
    "R1": {
     "role": "http://www.redhillbio.com/role/DocumentDocumentAndEntityInformation",
     "longName": "00090 - Document - Document and Entity Information",
     "shortName": "Document and Entity Information",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": null,
     "uniqueAnchor": null
    },
    "R2": {
     "role": "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveIncomeLoss",
     "longName": "00100 - Statement - CONDENSED CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE INCOME (LOSS)",
     "shortName": "CONDENSED CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE INCOME (LOSS)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "2",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw",
      "name": "ifrs-full:Revenue",
      "unitRef": "Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rdhl-20240630xex99d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw",
      "name": "ifrs-full:CostOfSales",
      "unitRef": "Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rdhl-20240630xex99d2.htm",
      "unique": true
     }
    },
    "R3": {
     "role": "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition",
     "longName": "00200 - Statement - CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION",
     "shortName": "CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "3",
     "firstAnchor": {
      "contextRef": "As_Of_6_30_2024_lm1Lh8C52kquuyx0qsrPDw",
      "name": "ifrs-full:CashAndCashEquivalents",
      "unitRef": "Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rdhl-20240630xex99d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2024_lm1Lh8C52kquuyx0qsrPDw",
      "name": "ifrs-full:CurrentRestrictedCashAndCashEquivalents",
      "unitRef": "Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rdhl-20240630xex99d2.htm",
      "unique": true
     }
    },
    "R4": {
     "role": "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfChangesInEquity",
     "longName": "00300 - Statement - CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN EQUITY",
     "shortName": "CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN EQUITY",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "4",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_Y7iGsPaVjkeiB7bpTvHRwg",
      "name": "ifrs-full:Equity",
      "unitRef": "Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rdhl-20240630xex99d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_Y7iGsPaVjkeiB7bpTvHRwg",
      "name": "ifrs-full:Equity",
      "unitRef": "Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rdhl-20240630xex99d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R5": {
     "role": "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows",
     "longName": "00400 - Statement - CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS",
     "shortName": "CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "",
     "menuCat": "Statements",
     "order": "5",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw",
      "name": "ifrs-full:ProfitLoss",
      "unitRef": "Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rdhl-20240630xex99d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw",
      "name": "ifrs-full:AdjustmentsForSharebasedPayments",
      "unitRef": "Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rdhl-20240630xex99d2.htm",
      "unique": true
     }
    },
    "R6": {
     "role": "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlowsParenthetical",
     "longName": "00405 - Statement - CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS (Parenthetical)",
     "shortName": "CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS (Parenthetical)",
     "isDefault": "false",
     "groupType": "statement",
     "subGroupType": "parenthetical",
     "menuCat": "Statements",
     "order": "6",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw",
      "name": "rdhl:DecreaseInRightOfUseAssetFromEarlyTerminationOfLease",
      "unitRef": "Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rdhl-20240630xex99d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw",
      "name": "rdhl:DecreaseInRightOfUseAssetFromEarlyTerminationOfLease",
      "unitRef": "Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rdhl-20240630xex99d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R7": {
     "role": "http://www.redhillbio.com/role/DisclosureGeneral",
     "longName": "10101 - Disclosure - GENERAL",
     "shortName": "GENERAL",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "7",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw",
      "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rdhl-20240630xex99d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw",
      "name": "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rdhl-20240630xex99d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R8": {
     "role": "http://www.redhillbio.com/role/DisclosureBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsAndSignificantAccountingPolicies",
     "longName": "10201 - Disclosure - BASIS OF PREPARATION OF THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES",
     "shortName": "BASIS OF PREPARATION OF THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "8",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw",
      "name": "rdhl:DisclosureOfBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rdhl-20240630xex99d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw",
      "name": "rdhl:DisclosureOfBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rdhl-20240630xex99d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R9": {
     "role": "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriod",
     "longName": "10301 - Disclosure - SIGNIFICANT EVENTS DURING THE CURRENT REPORTING PERIOD",
     "shortName": "SIGNIFICANT EVENTS DURING THE CURRENT REPORTING PERIOD",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "9",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw",
      "name": "rdhl:SignificantEventsDuringCurrentReportingPeriodTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rdhl-20240630xex99d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw",
      "name": "rdhl:SignificantEventsDuringCurrentReportingPeriodTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rdhl-20240630xex99d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R10": {
     "role": "http://www.redhillbio.com/role/DisclosureAllowanceForDeductionsFromRevenues",
     "longName": "10401 - Disclosure - ALLOWANCE FOR DEDUCTIONS FROM REVENUES",
     "shortName": "ALLOWANCE FOR DEDUCTIONS FROM REVENUES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "10",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw",
      "name": "rdhl:AllowanceForDeductionsFromRevenuesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rdhl-20240630xex99d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw",
      "name": "rdhl:AllowanceForDeductionsFromRevenuesDisclosureTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rdhl-20240630xex99d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R11": {
     "role": "http://www.redhillbio.com/role/DisclosureShareBasedPayments",
     "longName": "10501 - Disclosure - SHARE-BASED PAYMENTS",
     "shortName": "SHARE-BASED PAYMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "11",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rdhl-20240630xex99d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw",
      "name": "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rdhl-20240630xex99d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R12": {
     "role": "http://www.redhillbio.com/role/DisclosureNetRevenues",
     "longName": "10601 - Disclosure - NET REVENUES",
     "shortName": "NET REVENUES",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "12",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw",
      "name": "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rdhl-20240630xex99d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw",
      "name": "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rdhl-20240630xex99d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R13": {
     "role": "http://www.redhillbio.com/role/DisclosureFinancialInstruments",
     "longName": "10701 - Disclosure - FINANCIAL INSTRUMENTS",
     "shortName": "FINANCIAL INSTRUMENTS",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "13",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw",
      "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rdhl-20240630xex99d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw",
      "name": "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rdhl-20240630xex99d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R14": {
     "role": "http://www.redhillbio.com/role/DisclosureSegmentInformation",
     "longName": "10801 - Disclosure - SEGMENT INFORMATION",
     "shortName": "SEGMENT INFORMATION",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "14",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw",
      "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rdhl-20240630xex99d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw",
      "name": "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rdhl-20240630xex99d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R15": {
     "role": "http://www.redhillbio.com/role/DisclosureEarningLossPerShare",
     "longName": "10901 - Disclosure - EARNING (LOSS) PER SHARE",
     "shortName": "EARNING (LOSS) PER SHARE",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "15",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw",
      "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rdhl-20240630xex99d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw",
      "name": "ifrs-full:DisclosureOfEarningsPerShareExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rdhl-20240630xex99d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R16": {
     "role": "http://www.redhillbio.com/role/DisclosureEventSubsequentToJune302024",
     "longName": "11001 - Disclosure - EVENT SUBSEQUENT TO JUNE 30, 2024",
     "shortName": "EVENT SUBSEQUENT TO JUNE 30, 2024",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "",
     "menuCat": "Notes",
     "order": "16",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rdhl-20240630xex99d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw",
      "name": "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rdhl-20240630xex99d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R17": {
     "role": "http://www.redhillbio.com/role/DisclosureBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsAndSignificantAccountingPoliciesPolicies",
     "longName": "20202 - Disclosure - BASIS OF PREPARATION OF THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "shortName": "BASIS OF PREPARATION OF THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (Policies)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "policies",
     "menuCat": "Policies",
     "order": "17",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "rdhl:DisclosureOfBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rdhl-20240630xex99d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw",
      "name": "ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "rdhl:DisclosureOfBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rdhl-20240630xex99d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R18": {
     "role": "http://www.redhillbio.com/role/DisclosureAllowanceForDeductionsFromRevenuesTables",
     "longName": "30403 - Disclosure - ALLOWANCE FOR DEDUCTIONS FROM REVENUES (Tables)",
     "shortName": "ALLOWANCE FOR DEDUCTIONS FROM REVENUES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "18",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw",
      "name": "rdhl:ScheduleOfMovementOfAllowanceForDeductionsFromRevenuesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "rdhl:AllowanceForDeductionsFromRevenuesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rdhl-20240630xex99d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw",
      "name": "rdhl:ScheduleOfMovementOfAllowanceForDeductionsFromRevenuesTableTextBlock",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "rdhl:AllowanceForDeductionsFromRevenuesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rdhl-20240630xex99d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R19": {
     "role": "http://www.redhillbio.com/role/DisclosureNetRevenuesTables",
     "longName": "30603 - Disclosure - NET REVENUES (Tables)",
     "shortName": "NET REVENUES (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "19",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw",
      "name": "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rdhl-20240630xex99d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw",
      "name": "ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rdhl-20240630xex99d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R20": {
     "role": "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsTables",
     "longName": "30703 - Disclosure - FINANCIAL INSTRUMENTS (Tables)",
     "shortName": "FINANCIAL INSTRUMENTS (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "20",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw",
      "name": "ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rdhl-20240630xex99d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw",
      "name": "ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rdhl-20240630xex99d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R21": {
     "role": "http://www.redhillbio.com/role/DisclosureSegmentInformationTables",
     "longName": "30803 - Disclosure - SEGMENT INFORMATION (Tables)",
     "shortName": "SEGMENT INFORMATION (Tables)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "tables",
     "menuCat": "Tables",
     "order": "21",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw",
      "name": "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rdhl-20240630xex99d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw",
      "name": "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rdhl-20240630xex99d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R22": {
     "role": "http://www.redhillbio.com/role/DisclosureGeneralDetails",
     "longName": "40101 - Disclosure - GENERAL (Details)",
     "shortName": "GENERAL (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "22",
     "firstAnchor": {
      "contextRef": "Duration_3_23_2023_To_3_23_2023_ifrs-full_ClassesOfOrdinarySharesAxis_dei_AdrMember_xDmTu-XomE-QX_HsBKKWmA",
      "name": "rdhl:NumberOfOrdinarySharesIssuedInExchangeOfAmericanDepositoryReceipts",
      "unitRef": "Unit_Standard_shares_XGdimIWcf0OdGjo7fryoGw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rdhl-20240630xex99d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_3_23_2023_To_3_23_2023_ifrs-full_ClassesOfOrdinarySharesAxis_dei_AdrMember_xDmTu-XomE-QX_HsBKKWmA",
      "name": "rdhl:NumberOfOrdinarySharesIssuedInExchangeOfAmericanDepositoryReceipts",
      "unitRef": "Unit_Standard_shares_XGdimIWcf0OdGjo7fryoGw",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rdhl-20240630xex99d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R23": {
     "role": "http://www.redhillbio.com/role/DisclosureBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsAndSignificantAccountingPoliciesDetails",
     "longName": "40201 - Disclosure - BASIS OF PREPARATION OF THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "shortName": "BASIS OF PREPARATION OF THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "23",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_ifrs-full_NewIFRSsAxis_rdhl_Ias1AmendmentsMember_6IOwDM618kGNeECku1awvg",
      "name": "rdhl:ReclassificationOfWarrantLiability",
      "unitRef": "Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rdhl-20240630xex99d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2023_ifrs-full_NewIFRSsAxis_rdhl_Ias1AmendmentsMember_6IOwDM618kGNeECku1awvg",
      "name": "rdhl:ReclassificationOfWarrantLiability",
      "unitRef": "Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rdhl-20240630xex99d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R24": {
     "role": "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodEquityOfferingsDetails",
     "longName": "40301 - Disclosure - SIGNIFICANT EVENTS DURING THE CURRENT REPORTING PERIOD - Equity Offerings (Details)",
     "shortName": "SIGNIFICANT EVENTS DURING THE CURRENT REPORTING PERIOD - Equity Offerings (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "24",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw",
      "name": "ifrs-full:FinanceCosts",
      "unitRef": "Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rdhl-20240630xex99d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_4_3_2024_To_4_3_2024_xAzFjFHyA02Un3POz8VYMg",
      "name": "ifrs-full:ProceedsFromIssuingShares",
      "unitRef": "Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "span",
       "td",
       "tr",
       "table",
       "rdhl:SignificantEventsDuringCurrentReportingPeriodTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rdhl-20240630xex99d2.htm",
      "unique": true
     }
    },
    "R25": {
     "role": "http://www.redhillbio.com/role/DisclosureAllowanceForDeductionsFromRevenuesDetails",
     "longName": "40401 - Disclosure - ALLOWANCE FOR DEDUCTIONS FROM REVENUES (Details)",
     "shortName": "ALLOWANCE FOR DEDUCTIONS FROM REVENUES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "25",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_XGghR9I2w0KmrTtJVNkj1A",
      "name": "ifrs-full:CurrentRefundsProvision",
      "unitRef": "Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rdhl-20240630xex99d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_12_31_2022_jV2f_7krOUScpr2kI0mJcw",
      "name": "ifrs-full:CurrentRefundsProvision",
      "unitRef": "Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "rdhl:ScheduleOfMovementOfAllowanceForDeductionsFromRevenuesTableTextBlock",
       "rdhl:AllowanceForDeductionsFromRevenuesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rdhl-20240630xex99d2.htm",
      "unique": true
     }
    },
    "R26": {
     "role": "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails",
     "longName": "40501 - Disclosure - SHARE-BASED PAYMENTS (Details)",
     "shortName": "SHARE-BASED PAYMENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "26",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw",
      "name": "rdhl:ReversedExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets",
      "unitRef": "Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rdhl-20240630xex99d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw",
      "name": "rdhl:ReversedExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets",
      "unitRef": "Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "div",
       "ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rdhl-20240630xex99d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R27": {
     "role": "http://www.redhillbio.com/role/DisclosureNetRevenuesDetails",
     "longName": "40601 - Disclosure - NET REVENUES (Details)",
     "shortName": "NET REVENUES (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "27",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw",
      "name": "ifrs-full:Revenue",
      "unitRef": "Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rdhl-20240630xex99d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_ifrs-full_ProductsAndServicesAxis_rdhl_TaliciaMember_K2Ipuy8Jc065NyMxnj96Og",
      "name": "rdhl:NetRevenue",
      "unitRef": "Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rdhl-20240630xex99d2.htm",
      "unique": true
     }
    },
    "R28": {
     "role": "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails",
     "longName": "40701 - Disclosure - FINANCIAL INSTRUMENTS (Details)",
     "shortName": "FINANCIAL INSTRUMENTS (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "28",
     "firstAnchor": {
      "contextRef": "As_Of_12_31_2023_XGghR9I2w0KmrTtJVNkj1A",
      "name": "ifrs-full:Liabilities",
      "unitRef": "Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rdhl-20240630xex99d2.htm",
      "first": true
     },
     "uniqueAnchor": {
      "contextRef": "As_Of_6_30_2024_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_UnobservableInputsAxis_ifrs-full_InterestRateMeasurementInputMember_Vcvjf-Um0kSPabpRIwMIwA",
      "name": "ifrs-full:SignificantUnobservableInputLiabilities",
      "unitRef": "Unit_Standard_pure_yhcnVVwWa0i2EX2hTkNGPA",
      "xsiNil": "false",
      "lang": null,
      "decimals": "INF",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfFinancialInstrumentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rdhl-20240630xex99d2.htm",
      "unique": true
     }
    },
    "R29": {
     "role": "http://www.redhillbio.com/role/DisclosureSegmentInformationDetails",
     "longName": "40801 - Disclosure - SEGMENT INFORMATION (Details)",
     "shortName": "SEGMENT INFORMATION (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "29",
     "firstAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw",
      "name": "rdhl:CommercialOperationsSegmentAdjustedEarningsBeforeInterestTaxesDepreciationAndAmortisation",
      "unitRef": "Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
       "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rdhl-20240630xex99d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw",
      "name": "rdhl:CommercialOperationsSegmentAdjustedEarningsBeforeInterestTaxesDepreciationAndAmortisation",
      "unitRef": "Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "-3",
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "ifrs-full:DisclosureOfOperatingSegmentsExplanatory",
       "ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rdhl-20240630xex99d2.htm",
      "first": true,
      "unique": true
     }
    },
    "R30": {
     "role": "http://www.redhillbio.com/role/DisclosureEventSubsequentToJune302024Details",
     "longName": "41001 - Disclosure - EVENT SUBSEQUENT TO JUNE 30,2024 (Details)",
     "shortName": "EVENT SUBSEQUENT TO JUNE 30,2024 (Details)",
     "isDefault": "false",
     "groupType": "disclosure",
     "subGroupType": "details",
     "menuCat": "Details",
     "order": "30",
     "firstAnchor": {
      "contextRef": "Duration_7_15_2024_To_7_15_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_rdhl_GlobalTerminationAgreementMember_srt_CounterpartyNameAxis_rdhl_MovantikAcquisitionValinorPharmaLlcHcrRedhillSpvLlcMember_4pd8zpat4UqiB1Cifr2ikA",
      "name": "rdhl:ProceedsReceivedFollowingGlobalTerminationAgreement",
      "unitRef": "Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rdhl-20240630xex99d2.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "Duration_7_15_2024_To_7_15_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_rdhl_GlobalTerminationAgreementMember_srt_CounterpartyNameAxis_rdhl_MovantikAcquisitionValinorPharmaLlcHcrRedhillSpvLlcMember_4pd8zpat4UqiB1Cifr2ikA",
      "name": "rdhl:ProceedsReceivedFollowingGlobalTerminationAgreement",
      "unitRef": "Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg",
      "xsiNil": "false",
      "lang": null,
      "decimals": "0",
      "ancestors": [
       "p",
       "ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory",
       "div",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "rdhl-20240630xex99d2.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "rdhl_AcquisitionOfRightOfUseAssetsByMeansOfLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.redhillbio.com/20240630",
     "localname": "AcquisitionOfRightOfUseAssetsByMeansOfLeaseLiabilities",
     "crdr": "debit",
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of acquisition of right-of-use assets by means of lease liabilities.",
        "label": "Acquisition of Right of Use Assets by Means of Lease Liabilities",
        "terseLabel": "Acquisition of right-of-use assets by means of lease liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustedWeightedAverageShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustedWeightedAverageShares",
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average number of ordinary shares outstanding during the period (in thousands)",
        "verboseLabel": "WEIGHTED AVERAGE OF ORDINARY SHARE, diluted (in thousands)"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average number of ordinary shares outstanding plus the weighted average number of ordinary shares that would be issued on the conversion of all the dilutive potential ordinary shares into ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    },
    "rdhl_AdjustmentForIssuanceCostInRespectOfWarrants": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.redhillbio.com/20240630",
     "localname": "AdjustmentForIssuanceCostInRespectOfWarrants",
     "crdr": "debit",
     "calculation": {
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": {
       "parentTag": "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments for issuance cost in respect of warrants.",
        "label": "Adjustment For Issuance Cost In respect Of Warrants",
        "terseLabel": "Issuance costs in respect of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForAmortisationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForAmortisationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": {
       "parentTag": "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for amortisation expense",
        "terseLabel": "Amortization of intangible assets"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for amortisation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss); Depreciation and amortisation expense]"
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "rdhl_AdjustmentsForDecreaseIncreaseInAccruedExpenses": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.redhillbio.com/20240630",
     "localname": "AdjustmentsForDecreaseIncreaseInAccruedExpenses",
     "crdr": "debit",
     "calculation": {
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in accrued expenses to reconcile profit (loss) to net cash flow from (used in) operating activities.",
        "label": "Adjustments for decrease (increase) in accrued expenses",
        "verboseLabel": "Decrease in accrued expenses and other liabilities"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInInventories",
     "crdr": "debit",
     "calculation": {
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for decrease (increase) in inventories",
        "verboseLabel": "Decrease in inventories"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in inventories to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Inventories; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for decrease (increase) in other operating receivables",
        "verboseLabel": "Decrease (increase) in prepaid expenses and other receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in other operating receivables to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "ifrs-full_AdjustmentsForDecreaseIncreaseInTradeAccountReceivable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForDecreaseIncreaseInTradeAccountReceivable",
     "crdr": "debit",
     "calculation": {
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for decrease (increase) in trade accounts receivable",
        "terseLabel": "Decrease in trade receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in trade accounts receivable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "ifrs-full_AdjustmentsForDepreciationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForDepreciationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": {
       "parentTag": "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for depreciation expense",
        "terseLabel": "Depreciation"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for depreciation expense to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "rdhl_AdjustmentsForGainsFromEarlyTerminationOfLeasesNet": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.redhillbio.com/20240630",
     "localname": "AdjustmentsForGainsFromEarlyTerminationOfLeasesNet",
     "crdr": "debit",
     "calculation": {
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": {
       "parentTag": "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital",
       "weight": 1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustment for gains from early termination of leases, net.",
        "label": "Adjustments For Gains From Early Termination Of Leases Net",
        "terseLabel": "Gains from early termination of leases, net"
       }
      }
     },
     "auth_ref": []
    },
    "rdhl_AdjustmentsForGainsFromTransferOfRightsInMovantikAndExtinguishmentOfDebtObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.redhillbio.com/20240630",
     "localname": "AdjustmentsForGainsFromTransferOfRightsInMovantikAndExtinguishmentOfDebtObligations",
     "crdr": "debit",
     "calculation": {
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": {
       "parentTag": "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustment for gains from the transfer of rights In movantik And extinguishment of debt obligations",
        "label": "Adjustments For Gains From The Transfer Of Rights In Movantik And Extinguishment Of Debt Obligations",
        "terseLabel": "Gains from the transfer of rights in Movantik and extinguishment of debt obligations, (see below)"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives",
     "crdr": "credit",
     "calculation": {
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": {
       "parentTag": "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for gains (losses) on change in fair value of derivatives",
        "negatedLabel": "Fair value gains on derivative financial instruments"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for gains (losses) on changes in the fair value of derivatives to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: At fair value [member]; Derivatives [member]; Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "rdhl_AdjustmentsForIncreaseDecreaseInAllowanceForDeductionsFromRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.redhillbio.com/20240630",
     "localname": "AdjustmentsForIncreaseDecreaseInAllowanceForDeductionsFromRevenue",
     "crdr": "debit",
     "calculation": {
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in allowance for deductions from revenue.",
        "label": "Adjustments For Increase Decrease In Allowance For Deductions From Revenue",
        "terseLabel": "Increase (decrease) in allowance for deductions from revenue"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForIncreaseDecreaseInTradeAccountPayable": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForIncreaseDecreaseInTradeAccountPayable",
     "crdr": "debit",
     "calculation": {
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInWorkingCapital",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for increase (decrease) in trade accounts payable",
        "verboseLabel": "Decrease in accounts payable"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for increase (decrease) in trade accounts payable to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r126"
     ]
    },
    "rdhl_AdjustmentsForLossFromModificationOfWarrantsTermsAsPartOfNewIssuance.": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.redhillbio.com/20240630",
     "localname": "AdjustmentsForLossFromModificationOfWarrantsTermsAsPartOfNewIssuance.",
     "crdr": "debit",
     "calculation": {
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": {
       "parentTag": "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital",
       "weight": 1.0,
       "order": 9.0
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of loss due to from modification of warrants terms as part of a new issuance.",
        "label": "Adjustments For Loss From Modification Of Warrants Terms As Part Of A New Issuance.",
        "terseLabel": "Loss from modification of warrants terms as part of a new issuance, see note 3b"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForReconcileProfitLossAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForReconcileProfitLossAbstract",
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile profit (loss) [abstract]",
        "terseLabel": "Adjustments in respect of income and expenses not involving cash flow:"
       }
      }
     },
     "auth_ref": []
    },
    "rdhl_AdjustmentsForRevaluationOfBankDeposits": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.redhillbio.com/20240630",
     "localname": "AdjustmentsForRevaluationOfBankDeposits",
     "crdr": "credit",
     "calculation": {
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": {
       "parentTag": "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital",
       "weight": -1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments for revaluation of bank deposits.",
        "label": "Adjustments For Revaluation Of Bank Deposits",
        "negatedLabel": "Exchange differences and revaluation of bank deposits"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_AdjustmentsForSharebasedPayments": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsForSharebasedPayments",
     "crdr": "debit",
     "calculation": {
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": {
       "parentTag": "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments for share-based payments",
        "terseLabel": "Share-based compensation to employees and service providers"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments for share-based payments to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r127"
     ]
    },
    "ifrs-full_AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital",
     "crdr": "debit",
     "calculation": {
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to reconcile profit (loss) other than changes in working capital",
        "totalLabel": "Total adjustments in respect of income and expenses not involving cash flow"
       }
      },
      "en": {
       "role": {
        "documentation": "Adjustments, other than changes in working capital, to reconcile profit (loss) to net cash flow from (used in) operating activities. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "dei_AdrMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AdrMember",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureGeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ADS",
        "documentation": "American Depositary Receipt (or American Depositary Share, ADS)."
       }
      }
     },
     "auth_ref": [
      "r117"
     ]
    },
    "ifrs-full_AggregatedMeasurementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AggregatedMeasurementMember",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Aggregated measurement [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all types of measurement. It also represents the standard value for the 'Measurement' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r40",
      "r58"
     ]
    },
    "ifrs-full_AllLevelsOfFairValueHierarchyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AllLevelsOfFairValueHierarchyMember",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "All levels of fair value hierarchy [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all levels of the fair value hierarchy. It also represents the standard value for the 'Levels of fair value hierarchy' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r59"
     ]
    },
    "rdhl_AllowanceForDeductionsFromRevenuesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.redhillbio.com/20240630",
     "localname": "AllowanceForDeductionsFromRevenuesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n.a.",
        "label": "ALLOWANCE FOR DEDUCTIONS FROM REVENUES"
       }
      }
     },
     "auth_ref": []
    },
    "rdhl_AllowanceForDeductionsFromRevenuesDisclosureTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.redhillbio.com/20240630",
     "localname": "AllowanceForDeductionsFromRevenuesDisclosureTextBlock",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureAllowanceForDeductionsFromRevenues"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of allowance for deductions from revenues.",
        "label": "Allowance For Deductions From Revenues Disclosure [Text Block]",
        "terseLabel": "ALLOWANCE FOR DEDUCTIONS FROM REVENUES"
       }
      }
     },
     "auth_ref": []
    },
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.redhillbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "rdhl_AmericanDepositoryShareMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.redhillbio.com/20240630",
     "localname": "AmericanDepositoryShareMember",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodEquityOfferingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for American Depository Share",
        "label": "American Depository Share [Member]",
        "terseLabel": "ADS"
       }
      }
     },
     "auth_ref": []
    },
    "rdhl_AmortisationAndImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.redhillbio.com/20240630",
     "localname": "AmortisationAndImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.redhillbio.com/role/DisclosureSegmentInformationDetails": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": -1.0,
       "order": 7.0
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of amortisation and  impairment loss recognised in profit or loss for intangible assets other than goodwill.",
        "label": "Amortisation and Impairment Loss Recognised in Profit or Loss, Intangible Assets Other Than Goodwill",
        "negatedLabel": "Amortization of intangible assets"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_Assets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Assets",
     "crdr": "debit",
     "calculation": {
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets",
        "totalLabel": "TOTAL ASSETS"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of a present economic resource controlled by the entity as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r58",
      "r59",
      "r63",
      "r87",
      "r90"
     ]
    },
    "ifrs-full_AtFairValueMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "AtFairValueMember",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "At fair value"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for measurement based on fair value. Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r40",
      "r58"
     ]
    },
    "rdhl_AuthorisedShareCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.redhillbio.com/20240630",
     "localname": "AuthorisedShareCapital",
     "crdr": "credit",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodEquityOfferingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The nominal value of authorised share capital.",
        "label": "Authorised Share Capital"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_BasicEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BasicEarningsLossPerShare",
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LOSS PER ORDINARY SHARE, basic (U.S. dollars):",
        "verboseLabel": "EARNINGS (LOSS) PER ORDINARY SHARE, basic (U.S. dollars)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator) divided by the weighted average number of ordinary shares outstanding during the period (the denominator)."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30"
     ]
    },
    "ifrs-full_BottomOfRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "BottomOfRangeMember",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the bottom of a range."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r72",
      "r75",
      "r112",
      "r113",
      "r131"
     ]
    },
    "ifrs-full_CashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows",
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash and cash equivalents, value",
        "periodEndLabel": "BALANCE OF CASH AND CASH EQUIVALENTS AT THE END OF PERIOD",
        "periodStartLabel": "BALANCE OF CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD",
        "terseLabel": "Cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash on hand and demand deposits, along with short-term, highly liquid investments that are readily convertible to known amounts of cash and that are subject to an insignificant risk of changes in value. [Refer: Cash; Cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r9",
      "r45",
      "r57"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) financing activities",
        "totalLabel": "Net cash provided by financing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) financing activities, which are activities that result in changes in the size and composition of the contributed equity and borrowings of the entity."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r46"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInFinancingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInFinancingActivitiesAbstract",
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) financing activities [abstract]",
        "terseLabel": "FINANCING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivities",
     "crdr": "debit",
     "calculation": {
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) investing activities",
        "totalLabel": "Net cash used in investing activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) investing activities, which are the acquisition and disposal of long-term assets and other investments not included in cash equivalents."
       }
      }
     },
     "auth_ref": [
      "r41",
      "r46"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInInvestingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInInvestingActivitiesAbstract",
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) investing activities [abstract]",
        "terseLabel": "INVESTING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivities",
     "calculation": {
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": {
       "parentTag": "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) operating activities",
        "totalLabel": "Net cash used in operating activities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash flows from (used in) operating activities, which are the principal revenue-producing activities of the entity and other activities that are not investing or financing activities. [Refer: Revenue]"
       }
      }
     },
     "auth_ref": [
      "r41",
      "r46"
     ]
    },
    "ifrs-full_CashFlowsFromUsedInOperatingActivitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CashFlowsFromUsedInOperatingActivitiesAbstract",
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash flows from (used in) operating activities [abstract]",
        "terseLabel": "OPERATING ACTIVITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CategoriesOfFinancialLiabilitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CategoriesOfFinancialLiabilitiesAxis",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Categories of financial liabilities [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "ifrs-full_CategoriesOfRelatedPartiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CategoriesOfRelatedPartiesAxis",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Categories of related parties [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "rdhl_ChangesInAssetsAndLiabilityItemsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.redhillbio.com/20240630",
     "localname": "ChangesInAssetsAndLiabilityItemsAbstract",
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "No definition available.",
        "label": "Changes In Assets And Liability Items [Abstract]",
        "terseLabel": "Changes in assets and liability items:"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ChangesInIntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ChangesInIntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) in intangible assets other than goodwill",
        "terseLabel": "Decrease in Intangible asset"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in intangible assets other than goodwill. [Refer: Intangible assets other than goodwill]"
       }
      }
     },
     "auth_ref": [
      "r37"
     ]
    },
    "ifrs-full_ClassesOfLiabilitiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfLiabilitiesAxis",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of liabilities [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "ifrs-full_ClassesOfOrdinarySharesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfOrdinarySharesAxis",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureGeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of ordinary shares [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r29"
     ]
    },
    "ifrs-full_ClassesOfProvisionsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfProvisionsAxis",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureAllowanceForDeductionsFromRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of other provisions [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "ifrs-full_ClassesOfShareCapitalAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfShareCapitalAxis",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodEquityOfferingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Classes of share capital [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "ifrs-full_ClassesOfShareCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ClassesOfShareCapitalMember",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodEquityOfferingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share capital [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for share capital of the entity. It also represents the standard value for the 'Classes of share capital' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "rdhl_CommercialOperationsSegmentAdjustedEarningsBeforeInterestTaxesDepreciationAndAmortisation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.redhillbio.com/20240630",
     "localname": "CommercialOperationsSegmentAdjustedEarningsBeforeInterestTaxesDepreciationAndAmortisation",
     "crdr": "credit",
     "calculation": {
      "http://www.redhillbio.com/role/DisclosureSegmentInformationDetails": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commercial Operations Segment Amount of adjusted earnings before interest, taxes, depreciation, and Amortisation.",
        "label": "Commercial Operations Segment Adjusted EBITDA"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ComponentsOfEquityAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ComponentsOfEquityAxis",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodEquityOfferingsDetails",
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of equity [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "rdhl_ContraRevenueForMovantik": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.redhillbio.com/20240630",
     "localname": "ContraRevenueForMovantik",
     "crdr": "debit",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureNetRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Contra Revenue For Movantik",
        "label": "Contra Revenue For Movantik",
        "negatedLabel": "Contra Revenue For Movantik"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CostOfSales": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CostOfSales",
     "crdr": "debit",
     "calculation": {
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_GrossProfit",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cost of sales",
        "terseLabel": "COST OF REVENUES"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of all expenses directly or indirectly attributed to the goods or services sold. Attributed expenses include, but are not limited to, costs previously included in the measurement of inventory that has now been sold, such as depreciation and maintenance of factory buildings and equipment used in the production process, unallocated production overheads, and abnormal amounts of production costs of inventories."
       }
      }
     },
     "auth_ref": [
      "r0",
      "r22"
     ]
    },
    "ifrs-full_CounterpartiesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CounterpartiesAxis",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureNetRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparties [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "ifrs-full_CounterpartiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CounterpartiesMember",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureNetRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparties [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the parties to the transaction other than the entity. It also represents the standard value for the 'Counterparties' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r84"
     ]
    },
    "srt_CounterpartyNameAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "CounterpartyNameAxis",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureEventSubsequentToJune302024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Axis]"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentAccruedExpensesAndOtherCurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentAccruedExpensesAndOtherCurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current accrued expenses and other current liabilities",
        "terseLabel": "Accrued expenses and other current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current accrued expenses and other current liabilities. [Refer: Accruals; Other current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "ifrs-full_CurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets",
        "totalLabel": "Total current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that the entity (a) expects to realise or intends to sell or consume in its normal operating cycle; (b) holds primarily for the purpose of trading; (c) expects to realise within twelve months after the reporting period; or (d) classifies as cash or cash equivalents (as defined in IAS 7) unless the asset is restricted from being exchanged or used to settle a liability for at least twelve months after the reporting period. [Refer: Assets]"
       }
      }
     },
     "auth_ref": [
      "r12",
      "r52",
      "r109"
     ]
    },
    "ifrs-full_CurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentAssetsAbstract",
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current assets [abstract]",
        "terseLabel": "CURRENT ASSETS:"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentDerivativeFinancialLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentDerivativeFinancialLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current derivative financial liabilities",
        "terseLabel": "Derivative financial instruments"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current derivative financial liabilities. [Refer: Derivative financial liabilities]"
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "dei_CurrentFiscalYearEndDate": {
     "xbrltype": "gMonthDayItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "CurrentFiscalYearEndDate",
     "presentation": [
      "http://www.redhillbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current Fiscal Year End Date",
        "documentation": "End date of current fiscal year in the format --MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current",
        "terseLabel": "Lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "ifrs-full_CurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities",
        "totalLabel": "Total current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that: (a) the entity expects to settle in its normal operating cycle; (b) the entity holds primarily for the purpose of trading; (c) are due to be settled within twelve months after the reporting period; or (d) the entity does not have the right at the end of the reporting period to defer settlement for at least twelve months after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r13",
      "r54",
      "r109"
     ]
    },
    "ifrs-full_CurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentLiabilitiesAbstract",
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current liabilities [abstract]",
        "terseLabel": "CURRENT LIABILITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "rdhl_CurrentPrepaidExpensesAndReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.redhillbio.com/20240630",
     "localname": "CurrentPrepaidExpensesAndReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount recognised as a current asset for expenditures made prior to the period when the economic benefit will be realised, and the amount of receivables.",
        "label": "Current Prepaid Expenses and Receivables",
        "terseLabel": "Prepaid expenses and other receivables"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_CurrentRefundsProvision": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentRefundsProvision",
     "crdr": "credit",
     "calculation": {
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureAllowanceForDeductionsFromRevenuesDetails",
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current refunds provision",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at Beginning of period",
        "terseLabel": "Allowance for deductions from revenue"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current provision for refunds. [Refer: Refunds provision]"
       }
      }
     },
     "auth_ref": [
      "r104",
      "r105"
     ]
    },
    "ifrs-full_CurrentRestrictedCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "CurrentRestrictedCashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current restricted cash and cash equivalents",
        "terseLabel": "Restricted cash"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current restricted cash and cash equivalents. [Refer: Restricted cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "rdhl_DecreaseInInventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.redhillbio.com/20240630",
     "localname": "DecreaseInInventories",
     "crdr": "debit",
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of decrease in inventories during the period.",
        "label": "Decreases in Inventories",
        "terseLabel": "Decrease in Inventories"
       }
      }
     },
     "auth_ref": []
    },
    "rdhl_DecreaseInLeaseLiabilityFromEarlyTerminationOfLease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.redhillbio.com/20240630",
     "localname": "DecreaseInLeaseLiabilityFromEarlyTerminationOfLease",
     "crdr": "debit",
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents decrease in lease liability from early termination of lease.",
        "label": "Decrease In Lease Liability From Early Termination Of Lease",
        "terseLabel": "Decrease in lease liability (with corresponding decrease in right of use asset in amount of $170 in the six months ended June 30, 2024, and $4,117 in the six months ended June 30,2023) resulting from early termination of lease"
       }
      }
     },
     "auth_ref": []
    },
    "rdhl_DecreaseInRightOfUseAssetFromEarlyTerminationOfLease": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.redhillbio.com/20240630",
     "localname": "DecreaseInRightOfUseAssetFromEarlyTerminationOfLease",
     "crdr": "credit",
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlowsParenthetical"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents decrease in right of use asset from early termination of lease.",
        "label": "Decrease In Right Of Use Asset From Early Termination Of Lease",
        "terseLabel": "Decrease in right of use asset"
       }
      }
     },
     "auth_ref": []
    },
    "rdhl_DecreaseIncreaseInBorrowings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.redhillbio.com/20240630",
     "localname": "DecreaseIncreaseInBorrowings",
     "crdr": "debit",
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in borrowings.",
        "label": "Decrease Increase in Borrowings",
        "terseLabel": "Decrease in Borrowing"
       }
      }
     },
     "auth_ref": []
    },
    "rdhl_DecreaseIncreaseInPayablesInRespectOfIntangibleAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.redhillbio.com/20240630",
     "localname": "DecreaseIncreaseInPayablesInRespectOfIntangibleAssets",
     "crdr": "debit",
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjustments for decrease (increase) in payables in respect of intangible assets.",
        "label": "Decrease Increase In Payables In Respect Of Intangible Assets",
        "terseLabel": "Decrease in Payable in respect of Intangible asset"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DepreciationExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DepreciationExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.redhillbio.com/role/DisclosureSegmentInformationDetails": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": -1.0,
       "order": 6.0
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Depreciation expense",
        "negatedLabel": "Depreciation"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of depreciation expense. Depreciation is the systematic allocation of depreciable amounts of tangible assets over their useful lives."
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of expected impact of initial application of new standards or interpretations [abstract]"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsLineItems",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsAndSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of expected impact of initial application of new standards or interpretations [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DescriptionOfExpectedImpactOfInitialApplicationOfNewStandardsOrInterpretationsTable",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsAndSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of expected impact of initial application of new standards or interpretations [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the expected impact of the initial application of new standards or interpretations."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "ifrs-full_DilutedEarningsLossPerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DilutedEarningsLossPerShare",
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "LOSS PER ORDINARY SHARE, diluted (U.S. dollars):",
        "verboseLabel": "EARNINGS (LOSS) PER ORDINARY SHARE, diluted (U.S. dollars)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of profit (loss) attributable to ordinary equity holders of the parent entity (the numerator), divided by the weighted average number of ordinary shares outstanding during the period (the denominator), both adjusted for the effects of all dilutive potential ordinary shares. [Refer: Ordinary shares [member]; Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r29",
      "r30"
     ]
    },
    "rdhl_DirectorsAndChiefExecutiveOfficerMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.redhillbio.com/20240630",
     "localname": "DirectorsAndChiefExecutiveOfficerMember",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for directors and chief executive officers",
        "label": "Directors And Chief Executive Officer [member]",
        "terseLabel": "Directors and chief executive officer"
       }
      }
     },
     "auth_ref": []
    },
    "rdhl_DisclosureOfBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.redhillbio.com/20240630",
     "localname": "DisclosureOfBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "BASIS OF PREPARATION OF THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "auth_ref": []
    },
    "rdhl_DisclosureOfBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.redhillbio.com/20240630",
     "localname": "DisclosureOfBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsTextBlock",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsAndSignificantAccountingPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for basis of preparation of condensed consolidated interim financial statements.",
        "label": "Disclosure Of Basis Of Preparation Of Condensed Consolidated Interim Financial Statements [Text Block]",
        "terseLabel": "BASIS OF PREPARATION OF THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS AND SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsAndSignificantAccountingPoliciesPolicies"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of basis of preparation of financial statements [text block]",
        "terseLabel": "Basis of preparation"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the basis used for the preparation of the financial statements."
       }
      }
     },
     "auth_ref": [
      "r118"
     ]
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalLineItems",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodEquityOfferingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of classes of share capital [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfClassesOfShareCapitalTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfClassesOfShareCapitalTable",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodEquityOfferingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of classes of share capital [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to classes of share capital."
       }
      }
     },
     "auth_ref": [
      "r18"
     ]
    },
    "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "NET REVENUES"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureNetRevenuesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of disaggregation of revenue from contracts with customers [text block]",
        "terseLabel": "Schedule of net revenues"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of the disaggregation of revenue from contracts with customers. [Refer: Revenue from contracts with customers]"
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersLineItems",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureNetRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of disaggregation of revenue from contracts with customers [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersTable",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureNetRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of disaggregation of revenue from contracts with customers [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to the disaggregation of revenue from contracts with customers."
       }
      }
     },
     "auth_ref": [
      "r66"
     ]
    },
    "ifrs-full_DisclosureOfEarningsPerShareExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfEarningsPerShareExplanatory",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureEarningLossPerShare"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of earnings per share [text block]",
        "verboseLabel": "EARNING (LOSS) PER SHARE"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for earnings per share."
       }
      }
     },
     "auth_ref": [
      "r32"
     ]
    },
    "ifrs-full_DisclosureOfEntitysReportableSegmentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfEntitysReportableSegmentsExplanatory",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureSegmentInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of entity's operating segments [text block]",
        "terseLabel": "SEGMENT INFORMATION"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for operating segments."
       }
      }
     },
     "auth_ref": [
      "r95"
     ]
    },
    "ifrs-full_DisclosureOfEventsAfterReportingPeriodExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfEventsAfterReportingPeriodExplanatory",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureEventSubsequentToJune302024"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of events after reporting period [text block]",
        "verboseLabel": "EVENT SUBSEQUENT TO JUNE 30, 2024"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for events after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r24"
     ]
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "FINANCIAL INSTRUMENTS"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsExplanatory",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureFinancialInstruments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of financial instruments [text block]",
        "verboseLabel": "FINANCIAL INSTRUMENTS"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for financial instruments."
       }
      }
     },
     "auth_ref": [
      "r85"
     ]
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsLineItems",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about financial instruments [line items]",
        "terseLabel": "Financial instruments"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfFinancialInstrumentsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfFinancialInstrumentsTable",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of detailed information about financial instruments [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to details of financial instruments."
       }
      }
     },
     "auth_ref": [
      "r79",
      "r80",
      "r81"
     ]
    },
    "ifrs-full_DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureGeneral"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of general information about financial statements [text block]",
        "terseLabel": "General"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for general information about financial statements."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "EVENT SUBSEQUENT TO JUNE 30,2024"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodLineItems",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureEventSubsequentToJune302024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of non-adjusting events after reporting period [line items]",
        "terseLabel": "Disclosure of non-adjusting events after reporting period"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfNonadjustingEventsAfterReportingPeriodTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfNonadjustingEventsAfterReportingPeriodTable",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureEventSubsequentToJune302024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of non-adjusting events after reporting period [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to non-adjusting events after the reporting period."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "ifrs-full_DisclosureOfOperatingSegmentsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfOperatingSegmentsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SEGMENT INFORMATION"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfOperatingSegmentsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfOperatingSegmentsExplanatory",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureSegmentInformationTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of operating segments [text block]",
        "terseLabel": "Schedule of segment profitability and reconciliation to consolidated net income (loss) and comprehensive income (loss)"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of operating segments. [Refer: Operating segments [member]]"
       }
      }
     },
     "auth_ref": [
      "r87"
     ]
    },
    "ifrs-full_DisclosureOfOtherProvisionsLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfOtherProvisionsLineItems",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureAllowanceForDeductionsFromRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of other provisions [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfOtherProvisionsTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfOtherProvisionsTable",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureAllowanceForDeductionsFromRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of other provisions [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to other provisions."
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "ifrs-full_DisclosureOfRevenueFromContractsWithCustomersExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfRevenueFromContractsWithCustomersExplanatory",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureNetRevenues"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of revenue from contracts with customers [text block]",
        "terseLabel": "NET REVENUES"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for revenue from contracts with customers."
       }
      }
     },
     "auth_ref": [
      "r67",
      "r68"
     ]
    },
    "ifrs-full_DisclosureOfSharebasedPaymentArrangementsExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfSharebasedPaymentArrangementsExplanatory",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureShareBasedPayments"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of share-based payment arrangements [text block]",
        "terseLabel": "SHARE-BASED PAYMENTS"
       }
      },
      "en": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangements."
       }
      }
     },
     "auth_ref": [
      "r73"
     ]
    },
    "ifrs-full_DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory": {
     "xbrltype": "textBlockItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of significant unobservable inputs used in fair value measurement of liabilities [text block]",
        "terseLabel": "Schedule of change in derivative financial instrument"
       }
      },
      "en": {
       "role": {
        "documentation": "The disclosure of significant inputs for which market data are not available and that are developed using the best information available about the assumptions that market participants would use when measuring the fair value of liabilities."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "SHARE-BASED PAYMENTS"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementLineItems",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of terms and conditions of share-based payment arrangement [line items]"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "DisclosureOfTermsAndConditionsOfSharebasedPaymentArrangementTable",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Disclosure of terms and conditions of share-based payment arrangement [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to terms and conditions of share-based payment arrangements."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "dei_DocumentFiscalPeriodFocus": {
     "xbrltype": "fiscalPeriodItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalPeriodFocus",
     "presentation": [
      "http://www.redhillbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Period Focus",
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentFiscalYearFocus": {
     "xbrltype": "gYearItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentFiscalYearFocus",
     "presentation": [
      "http://www.redhillbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Fiscal Year Focus",
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.redhillbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "DocumentType",
     "presentation": [
      "http://www.redhillbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EarningsPerShareAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EarningsPerShareAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "EARNING (LOSS) PER SHARE"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EffectOfExchangeRateChangesOnCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EffectOfExchangeRateChangesOnCashAndCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Effect of exchange rate changes on cash and cash equivalents",
        "terseLabel": "EXCHANGE DIFFERENCES ON CASH AND CASH EQUIVALENTS"
       }
      },
      "en": {
       "role": {
        "documentation": "The effect of exchange rate changes on cash and cash equivalents held or due in a foreign currency. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r43",
      "r44"
     ]
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.redhillbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2023",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.redhillbio.com/role/DocumentDocumentAndEntityInformation"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r116"
     ]
    },
    "ifrs-full_EntitysTotalForRelatedPartiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EntitysTotalForRelatedPartiesMember",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Entity's total for related parties [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the standard value for the 'Categories of related parties' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r28"
     ]
    },
    "ifrs-full_Equity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Equity",
     "crdr": "credit",
     "calculation": {
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfChangesInEquity",
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equities",
        "periodEndLabel": "Balance at end of period",
        "periodStartLabel": "Balance at beginning of period",
        "totalLabel": "TOTAL EQUITY"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of residual interest in the assets of the entity after deducting all its liabilities."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r15",
      "r48",
      "r50",
      "r58",
      "r59",
      "r63"
     ]
    },
    "ifrs-full_EquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityAbstract",
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [abstract]",
        "terseLabel": "EQUITY:"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_EquityAndLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityAndLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity and liabilities",
        "totalLabel": "TOTAL LIABILITIES AND EQUITY"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of the entity's equity and liabilities. [Refer: Equity; Liabilities]"
       }
      }
     },
     "auth_ref": [
      "r11"
     ]
    },
    "ifrs-full_EquityMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "EquityMember",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodEquityOfferingsDetails",
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the residual interest in the assets of the entity after deducting all its liabilities. It also represents the standard value for the 'Components of equity' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ifrs-full_ExpenseFromSharebasedPaymentTransactionsWithEmployees": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ExpenseFromSharebasedPaymentTransactionsWithEmployees",
     "crdr": "debit",
     "calculation": {
      "http://www.redhillbio.com/role/DisclosureSegmentInformationDetails": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": -1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Expense from share-based payment transactions with employees",
        "negatedLabel": "Share-based compensation to employees and service providers"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense from share-based payment transactions with employees. [Refer: Expense from share-based payment transactions]"
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "rdhl_FairValueOfWarrantsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.redhillbio.com/20240630",
     "localname": "FairValueOfWarrantsMember",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for warrants",
        "label": "Fair Value Of Warrants [Member]",
        "terseLabel": "Warrants"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_FinanceCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinanceCosts",
     "crdr": "debit",
     "calculation": {
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_FinanceIncomeCost",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodEquityOfferingsDetails",
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance costs",
        "terseLabel": "FINANCIAL EXPENSES",
        "verboseLabel": "Financial expense"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of costs associated with financing activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r21"
     ]
    },
    "ifrs-full_FinanceIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinanceIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_FinanceIncomeCost",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance income",
        "terseLabel": "FINANCIAL INCOME"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income associated with interest and other financing activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "ifrs-full_FinanceIncomeCost": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinanceIncomeCost",
     "crdr": "credit",
     "calculation": {
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 2.0
      },
      "http://www.redhillbio.com/role/DisclosureSegmentInformationDetails": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureSegmentInformationDetails",
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Finance income (cost)",
        "terseLabel": "Financial income, net",
        "totalLabel": "FINANCIAL INCOME, net"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of income or cost associated with interest and other financing activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial liabilities at fair value through profit or loss"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the financial liabilities at fair value through profit or loss designated as such upon initial recognition or subsequently category. [Refer: Financial liabilities at fair value through profit or loss, designated upon initial recognition or subsequently]"
       }
      }
     },
     "auth_ref": [
      "r82"
     ]
    },
    "ifrs-full_FinancialLiabilitiesCategoryMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "FinancialLiabilitiesCategoryMember",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial liabilities, category [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregated categories of financial liabilities. It also represents the standard value for the 'Categories of financial liabilities' axis if no other member is used. [Refer: Financial assets]"
       }
      }
     },
     "auth_ref": [
      "r83"
     ]
    },
    "rdhl_GaelanMedicalTradeLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.redhillbio.com/20240630",
     "localname": "GaelanMedicalTradeLlcMember",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureNetRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Gaelan Medical Trade LLC.",
        "label": "Gaelan",
        "terseLabel": "Gaelan Medical Trade LLC"
       }
      }
     },
     "auth_ref": []
    },
    "rdhl_GainLossOnTerminationOfLeases": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.redhillbio.com/20240630",
     "localname": "GainLossOnTerminationOfLeases",
     "crdr": "credit",
     "calculation": {
      "http://www.redhillbio.com/role/DisclosureSegmentInformationDetails": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 8.0
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on termination of lease before expiration of lease term.",
        "label": "Gain from early termination of lease, net"
       }
      }
     },
     "auth_ref": []
    },
    "rdhl_GainsFromTransferOfRightsInMovantikAndExtinguishmentOfDebtObligations": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.redhillbio.com/20240630",
     "localname": "GainsFromTransferOfRightsInMovantikAndExtinguishmentOfDebtObligations",
     "crdr": "debit",
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gains From The Transfer Of The Rights In Movantik And Extinguishment Of Debt Obligations",
        "label": "Gains from the transfer of the rights in Movantik and extinguishment of debt obligations"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gains (losses) recognised in profit or loss, fair value measurement, liabilities",
        "terseLabel": "Fair value adjustments recognized in profit or loss"
       }
      },
      "en": {
       "role": {
        "documentation": "The gains (losses) including exchange differences recognised in profit or loss on the fair value measurement of liabilities. [Refer: At fair value [member]]"
       }
      }
     },
     "auth_ref": [
      "r61"
     ]
    },
    "rdhl_GeneralInformationAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.redhillbio.com/20240630",
     "localname": "GeneralInformationAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "N/A.",
        "label": "GENERAL"
       }
      }
     },
     "auth_ref": []
    },
    "rdhl_GeneralLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.redhillbio.com/20240630",
     "localname": "GeneralLineItems",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureGeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "General [Line Items]"
       }
      }
     },
     "auth_ref": []
    },
    "rdhl_GeneralTable": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.redhillbio.com/20240630",
     "localname": "GeneralTable",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureGeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "General information.",
        "label": "General [Table]"
       }
      }
     },
     "auth_ref": []
    },
    "rdhl_GlobalTerminationAgreementMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.redhillbio.com/20240630",
     "localname": "GlobalTerminationAgreementMember",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureEventSubsequentToJune302024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for global termination agreement signed by the company.",
        "label": "Global Termination Agreement [member]",
        "terseLabel": "The Agreement"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_GrossProfit": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "GrossProfit",
     "crdr": "credit",
     "calculation": {
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Gross profit",
        "totalLabel": "GROSS PROFIT"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of revenue less cost of sales. [Refer: Cost of sales; Revenue]"
       }
      }
     },
     "auth_ref": [
      "r97"
     ]
    },
    "ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "HistoricalVolatilityForSharesMeasurementInputMember",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Volatility"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the historical volatility for shares used as a measurement input."
       }
      }
     },
     "auth_ref": [
      "r111"
     ]
    },
    "rdhl_Ias1AmendmentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.redhillbio.com/20240630",
     "localname": "Ias1AmendmentsMember",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsAndSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for the narrow-scope amendments to IAS 1 \"Presentation of Financial Statements\".",
        "label": "IAS 1 Amendments [member]",
        "terseLabel": "IAS 1 Amendments"
       }
      }
     },
     "auth_ref": []
    },
    "rdhl_IfrsAccountingPoliciesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.redhillbio.com/20240630",
     "localname": "IfrsAccountingPoliciesAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "n/a",
        "label": "SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES"
       }
      }
     },
     "auth_ref": []
    },
    "rdhl_IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.redhillbio.com/20240630",
     "localname": "IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodEquityOfferingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "IFRS Class Of Warrant Or Right Exercise Price Of Warrants Or Rights",
        "terseLabel": "Warrants exercise price"
       }
      }
     },
     "auth_ref": []
    },
    "rdhl_IfrsClassOfWarrantsOrRightExercisePriceOfWarrantsOrRights": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.redhillbio.com/20240630",
     "localname": "IfrsClassOfWarrantsOrRightExercisePriceOfWarrantsOrRights",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodEquityOfferingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Exercise price per share or per unit of warrants or rights outstanding.",
        "label": "Ifrs Class of Warrants or Right, Exercise Price of Warrants or Rights",
        "terseLabel": "Exercise price of warrants"
       }
      }
     },
     "auth_ref": []
    },
    "rdhl_IfrsDecreaseInRestrictedCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.redhillbio.com/20240630",
     "localname": "IfrsDecreaseInRestrictedCash",
     "crdr": "debit",
     "calculation": {
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow associated with funds that are not available for withdrawal or use (such as funds held in escrow) and are associated with underlying transactions that are classified as investing activities.",
        "label": "IFRS Decrease In Restricted Cash",
        "terseLabel": "Decrease in restricted cash"
       }
      }
     },
     "auth_ref": []
    },
    "rdhl_IfrsEmployeeStockOptionMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.redhillbio.com/20240630",
     "localname": "IfrsEmployeeStockOptionMember",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "An arrangement whereby an employee is entitled to receive in the future, subject to vesting and other restrictions, a number of shares in the entity at a specified price, as defined in the agreement. Although there are variations, normally, after vesting, when an option is exercised, the employee-holder pays the strike value in cash to the issuing employer-entity and receives equity shares. The equity shares can be sold into the market for cash at the current market price without restriction. Options may be used to attract, retain and incentivize employees, in addition to their regular salary and other benefits.",
        "label": "Share options"
       }
      }
     },
     "auth_ref": []
    },
    "rdhl_IfrsRestrictedStockUnitsRsuMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.redhillbio.com/20240630",
     "localname": "IfrsRestrictedStockUnitsRsuMember",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share instrument which is convertible to stock or an equivalent amount of cash, after a specified period of time or when specified performance conditions are met.",
        "label": "RSUs"
       }
      }
     },
     "auth_ref": []
    },
    "rdhl_IfrsSharesIssuedPricePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "http://www.redhillbio.com/20240630",
     "localname": "IfrsSharesIssuedPricePerShare",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodEquityOfferingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Per share or per unit amount of equity securities issued.",
        "label": "IFRS Shares Issued Price Per Share",
        "terseLabel": "Purchase price (per share)"
       }
      }
     },
     "auth_ref": []
    },
    "rdhl_IfrsWarrantMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.redhillbio.com/20240630",
     "localname": "IfrsWarrantMember",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodEquityOfferingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Security that gives the holder the right to purchase shares of stock in accordance with the terms of the instrument, usually upon payment of a specified amount.",
        "label": "Warrants."
       }
      }
     },
     "auth_ref": []
    },
    "rdhl_IfrsWarrantsAndRightsOutstandingTerm": {
     "xbrltype": "durationItemType",
     "nsuri": "http://www.redhillbio.com/20240630",
     "localname": "IfrsWarrantsAndRightsOutstandingTerm",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodEquityOfferingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period between issuance and expiration of outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "IFRS Warrants And Rights Outstanding Term",
        "terseLabel": "Warrants term"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncomeStatementAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncomeStatementAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED INTERIM STATEMENTS OF COMPREHENSIVE INCOME (LOSS)"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges",
     "crdr": "debit",
     "calculation": {
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) in cash and cash equivalents before effect of exchange rate changes",
        "totalLabel": "INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in cash and cash equivalents before the effect of exchange rate changes on cash and cash equivalents held in foreign currencies. [Refer: Cash and cash equivalents; Effect of exchange rate changes on cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r45"
     ]
    },
    "ifrs-full_IncreaseDecreaseInExistingProvisionsOtherProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseInExistingProvisionsOtherProvisions",
     "crdr": "credit",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureAllowanceForDeductionsFromRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase in existing provisions, other provisions",
        "terseLabel": "Increases"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase in existing other provisions. [Refer: Other provisions]"
       }
      }
     },
     "auth_ref": [
      "r33"
     ]
    },
    "ifrs-full_IncreaseDecreaseInFairValueMeasurementLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseInFairValueMeasurementLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) in fair value measurement, liabilities",
        "terseLabel": "Initial recognition of unrecognized day 1 loss"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in the fair value measurement of liabilities. [Refer: At fair value [member]]"
       }
      }
     },
     "auth_ref": [
      "r63"
     ]
    },
    "ifrs-full_IncreaseDecreaseInWorkingCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseInWorkingCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) in working capital",
        "negatedTotalLabel": "Total changes in assets and liability items"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in working capital."
       }
      }
     },
     "auth_ref": [
      "r128"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughSharebasedPaymentTransactions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughSharebasedPaymentTransactions",
     "crdr": "credit",
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (decrease) through share-based payment transactions, equity",
        "terseLabel": "Share-based compensation to employees and service providers"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase (decrease) in equity resulting from share-based payment transactions. [Refer: Equity]"
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ifrs-full_IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions",
     "crdr": "credit",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureAllowanceForDeductionsFromRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase through adjustments arising from passage of time, other provisions",
        "terseLabel": "Adjustments"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase in other provisions through adjustments arising from the passage of time. [Refer: Other provisions]"
       }
      }
     },
     "auth_ref": [
      "r35"
     ]
    },
    "rdhl_IncreaseInLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.redhillbio.com/20240630",
     "localname": "IncreaseInLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureEventSubsequentToJune302024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of increase in liabilities following Global Termination Agreement.",
        "label": "Increase in future obligations"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_IntangibleAssetsOtherThanGoodwill": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IntangibleAssetsOtherThanGoodwill",
     "crdr": "debit",
     "calculation": {
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Intangible assets other than goodwill",
        "terseLabel": "Intangible assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of identifiable non-monetary assets without physical substance. This amount does not include goodwill. [Refer: Goodwill]"
       }
      }
     },
     "auth_ref": [
      "r6",
      "r37"
     ]
    },
    "ifrs-full_InterestRateMeasurementInputMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "InterestRateMeasurementInputMember",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Risk-free interest rate"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for an interest rate used as a measurement input."
       }
      }
     },
     "auth_ref": [
      "r110"
     ]
    },
    "ifrs-full_Inventories": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Inventories",
     "crdr": "debit",
     "calculation": {
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Current inventories",
        "terseLabel": "Inventory"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current inventories. [Refer: Inventories]"
       }
      }
     },
     "auth_ref": [
      "r7",
      "r27",
      "r99"
     ]
    },
    "ifrs-full_IssueOfEquity": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IssueOfEquity",
     "crdr": "credit",
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issue of equity",
        "terseLabel": "Issuance of ordinary shares, net of expenses"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase in equity through the issue of equity instruments."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "ifrs-full_IssuedCapital": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IssuedCapital",
     "crdr": "credit",
     "calculation": {
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issued capital",
        "terseLabel": "Ordinary shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal value of capital issued."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "ifrs-full_IssuedCapitalMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IssuedCapitalMember",
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary shares."
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing issued capital."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ifrs-full_IssuesFairValueMeasurementLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "IssuesFairValueMeasurementLiabilities",
     "crdr": "credit",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Issues, fair value measurement, liabilities",
        "terseLabel": "Initial recognition of financial liability"
       }
      },
      "en": {
       "role": {
        "documentation": "The increase in fair value measurement of liabilities resulting from issues of those liabilities. [Refer: At fair value [member]]"
       }
      }
     },
     "auth_ref": [
      "r62"
     ]
    },
    "ifrs-full_Level3OfFairValueHierarchyMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Level3OfFairValueHierarchyMember",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Level 3"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a category of the fair value hierarchy where inputs to the valuation techniques are unobservable inputs for the asset or liability. Unobservable inputs are inputs for which market data are not available and that are developed using the best information available about the assumptions that the market participants would use when pricing the asset or liability."
       }
      }
     },
     "auth_ref": [
      "r59"
     ]
    },
    "ifrs-full_LevelsOfFairValueHierarchyAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LevelsOfFairValueHierarchyAxis",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Levels of fair value hierarchy [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r26",
      "r59"
     ]
    },
    "ifrs-full_Liabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Liabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_EquityAndLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails",
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities",
        "periodEndLabel": "Balance at the end of the period",
        "periodStartLabel": "Balance at beginning of the period",
        "totalLabel": "TOTAL LIABILITIES"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits."
       }
      }
     },
     "auth_ref": [
      "r11",
      "r58",
      "r59",
      "r63",
      "r87",
      "r91"
     ]
    },
    "ifrs-full_LiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LiabilitiesAbstract",
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [abstract]",
        "terseLabel": "LIABILITIES"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_LiabilitiesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "LiabilitiesMember",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a present obligation of the entity to transfer an economic resource as a result of past events. Economic resource is a right that has the potential to produce economic benefits. It also represents the standard value for the 'Classes of liabilities' axis if no other member is used. [Refer: Liabilities]"
       }
      }
     },
     "auth_ref": [
      "r64"
     ]
    },
    "ifrs-full_MajorOrdinaryShareTransactionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "MajorOrdinaryShareTransactionsMember",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureGeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Major ordinary share transactions"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for major ordinary share transactions. [Refer: Ordinary shares [member]]"
       }
      }
     },
     "auth_ref": [
      "r102"
     ]
    },
    "ifrs-full_MeasurementAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "MeasurementAxis",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Measurement [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r39",
      "r40",
      "r58"
     ]
    },
    "ifrs-full_MiscellaneousOtherOperatingIncome": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "MiscellaneousOtherOperatingIncome",
     "crdr": "credit",
     "calculation": {
      "http://www.redhillbio.com/role/DisclosureSegmentInformationDetails": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Miscellaneous other operating income",
        "terseLabel": "Other income"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of miscellaneous other operating income. [Refer: Other operating income (expense)]"
       }
      }
     },
     "auth_ref": [
      "r121"
     ]
    },
    "rdhl_MovantikAcquisitionValinorPharmaLlcHcrRedhillSpvLlcMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.redhillbio.com/20240630",
     "localname": "MovantikAcquisitionValinorPharmaLlcHcrRedhillSpvLlcMember",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureEventSubsequentToJune302024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Movantik Acquisition, Valinor Pharma LLC, HCR Redhill SPV LLC.",
        "label": "Movantik Acquisition, Valinor Pharma LLC, HCR Redhill SPV LLC [member]",
        "terseLabel": "Movantik Acquisition Co, Valinor Pharma, LLC, and HCR Redhill SPV, LLC"
       }
      }
     },
     "auth_ref": []
    },
    "rdhl_MovantikMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.redhillbio.com/20240630",
     "localname": "MovantikMember",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureNetRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Movantik prescription medicine.",
        "label": "Movantik"
       }
      }
     },
     "auth_ref": []
    },
    "rdhl_NetRevenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.redhillbio.com/20240630",
     "localname": "NetRevenue",
     "crdr": "credit",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureNetRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net income arising in the course of an entity's ordinary activities.",
        "label": "Net Revenue"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NewIFRSsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NewIFRSsAxis",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsAndSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New IFRSs [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "ifrs-full_NewIFRSsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NewIFRSsMember",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsAndSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "New IFRSs [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for IFRSs that have been issued but are not yet effective. It also represents the standard value for the 'New IFRSs' axis if no other member is used. [Refer: IFRSs [member]]"
       }
      }
     },
     "auth_ref": [
      "r47"
     ]
    },
    "ifrs-full_NonadjustingEventsAfterReportingPeriodAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NonadjustingEventsAfterReportingPeriodAxis",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureEventSubsequentToJune302024Details",
      "http://www.redhillbio.com/role/DisclosureGeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-adjusting events after reporting period [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "ifrs-full_NonadjustingEventsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NonadjustingEventsMember",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureEventSubsequentToJune302024Details",
      "http://www.redhillbio.com/role/DisclosureGeneralDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-adjusting events after reporting period [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for events that occur between the end of the reporting period and the date when the financial statements are authorised for issue and are indicative of conditions that arose after the reporting period. It also represents the standard value for the 'Non-adjusting events after reporting period' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r23"
     ]
    },
    "ifrs-full_NoncurrentAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_Assets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current assets",
        "totalLabel": "Total non-current assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that do not meet the definition of current assets. [Refer: Current assets]"
       }
      }
     },
     "auth_ref": [
      "r12",
      "r53",
      "r109"
     ]
    },
    "ifrs-full_NoncurrentAssetsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentAssetsAbstract",
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current assets [abstract]",
        "terseLabel": "NON-CURRENT ASSETS:"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncurrentLeaseLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentLeaseLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current lease liabilities",
        "terseLabel": "Lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current lease liabilities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r70"
     ]
    },
    "ifrs-full_NoncurrentLiabilities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentLiabilities",
     "crdr": "credit",
     "calculation": {
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_Liabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current liabilities",
        "totalLabel": "Total non-current liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of liabilities that do not meet the definition of current liabilities. [Refer: Current liabilities]"
       }
      }
     },
     "auth_ref": [
      "r13",
      "r55",
      "r109"
     ]
    },
    "ifrs-full_NoncurrentLiabilitiesAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentLiabilitiesAbstract",
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current liabilities [abstract]",
        "terseLabel": "NON-CURRENT LIABILITIES:"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NoncurrentRestrictedCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NoncurrentRestrictedCashAndCashEquivalents",
     "crdr": "debit",
     "calculation": {
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Non-current restricted cash and cash equivalents",
        "terseLabel": "Restricted cash"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of non-current restricted cash and cash equivalents. [Refer: Restricted cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "rdhl_NoncurrentRoyaltyObligation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.redhillbio.com/20240630",
     "localname": "NoncurrentRoyaltyObligation",
     "crdr": "credit",
     "calculation": {
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentLiabilities",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent royalty obligation.",
        "label": "Noncurrent Royalty Obligation",
        "terseLabel": "Royalty obligation"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfInstrumentsOtherEquityInstrumentsGranted": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfInstrumentsOtherEquityInstrumentsGranted",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of other equity instruments granted in share-based payment arrangement",
        "terseLabel": "Number of RSUs granted"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) granted in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r77",
      "r130"
     ]
    },
    "rdhl_NumberOfOrdinarySharesIssuedInExchangeOfAmericanDepositoryReceipts": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.redhillbio.com/20240630",
     "localname": "NumberOfOrdinarySharesIssuedInExchangeOfAmericanDepositoryReceipts",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureGeneralDetails",
      "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodEquityOfferingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of ordinary shares issued in exchange of American Depository Receipts.",
        "label": "Number of Ordinary Shares Issued in Exchange of American Depository Receipts",
        "terseLabel": "Number of ordinary shares issued in exchange of ADS"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of other equity instruments forfeited in share-based payment arrangement",
        "terseLabel": "Number of RSU forfeited"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of other equity instruments (ie other than share options) forfeited in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r130"
     ]
    },
    "rdhl_NumberOfRsuQuarterlyInstallments": {
     "xbrltype": "integerItemType",
     "nsuri": "http://www.redhillbio.com/20240630",
     "localname": "NumberOfRsuQuarterlyInstallments",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of quarterly installments in which RSUs will vest equally over a two-year period",
        "label": "Number Of RSU Quarterly Installments"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of share options forfeited in share-based payment arrangement",
        "terseLabel": "Share options forfeited"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of share options forfeited in a share-based payment arrangement."
       }
      }
     },
     "auth_ref": [
      "r74"
     ]
    },
    "ifrs-full_NumberOfSharesAuthorised": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfSharesAuthorised",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodEquityOfferingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares authorised"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares authorised."
       }
      }
     },
     "auth_ref": [
      "r16"
     ]
    },
    "ifrs-full_NumberOfSharesIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "NumberOfSharesIssued",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodEquityOfferingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Number of shares issued"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of shares issued by the entity."
       }
      }
     },
     "auth_ref": [
      "r119"
     ]
    },
    "ifrs-full_OrdinarySharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OrdinarySharesMember",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureGeneralDetails",
      "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodEquityOfferingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ordinary shares"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for equity instruments that are subordinate to all other classes of equity instruments. It also represents the standard value for the 'Classes of ordinary shares' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r29",
      "r123"
     ]
    },
    "ifrs-full_OtherOperatingIncomeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherOperatingIncomeExpense",
     "crdr": "credit",
     "calculation": {
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": 1.0,
       "order": 5.0
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other operating income (expense)",
        "negatedLabel": "OTHER INCOME"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of operating income (expense) that the entity does not separately disclose in the same statement or note."
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "ifrs-full_OtherProvisionsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "OtherProvisionsMember",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureAllowanceForDeductionsFromRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other provisions [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for provisions other than provisions for employee benefits. It also represents the standard value for the 'Classes of other provisions' axis if no other member is used. [Refer: Provisions]"
       }
      }
     },
     "auth_ref": [
      "r36"
     ]
    },
    "ifrs-full_ParValuePerShare": {
     "xbrltype": "perShareItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ParValuePerShare",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodEquityOfferingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Par value per share"
       }
      },
      "en": {
       "role": {
        "documentation": "The nominal value per share."
       }
      }
     },
     "auth_ref": [
      "r17"
     ]
    },
    "ifrs-full_PaymentsForShareIssueCosts": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PaymentsForShareIssueCosts",
     "crdr": "credit",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodEquityOfferingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments for share issue costs",
        "terseLabel": "Placement agent fees and offering expenses."
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for share issue costs."
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "ifrs-full_PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Payments of lease liabilities, classified as financing activities",
        "negatedLabel": "Payment of principal with respect to lease liabilities"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for payment of lease liabilities, classified as financing activities. [Refer: Lease liabilities]"
       }
      }
     },
     "auth_ref": [
      "r108"
     ]
    },
    "ifrs-full_PreferenceSharesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PreferenceSharesMember",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodEquityOfferingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preference shares [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for equity instruments that are senior in some aspects to ordinary shares, but subordinate to debt instruments in terms of claim. [Refer: Ordinary shares [member]]"
       }
      }
     },
     "auth_ref": [
      "r123"
     ]
    },
    "ifrs-full_ProceedsFromIssueOfOrdinaryShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProceedsFromIssueOfOrdinaryShares",
     "crdr": "debit",
     "calculation": {
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issue of ordinary shares",
        "terseLabel": "Proceeds from issuance of ordinary shares and warrants, net of issuance costs"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from the issuing of ordinary shares. [Refer: Ordinary shares [member]]"
       }
      }
     },
     "auth_ref": [
      "r125"
     ]
    },
    "ifrs-full_ProceedsFromIssuingShares": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProceedsFromIssuingShares",
     "crdr": "debit",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodEquityOfferingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Proceeds from issuing shares",
        "terseLabel": "Proceeds from issuance of shares"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash inflow from issuing shares."
       }
      }
     },
     "auth_ref": [
      "r107"
     ]
    },
    "rdhl_ProceedsReceivedFollowingGlobalTerminationAgreement": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.redhillbio.com/20240630",
     "localname": "ProceedsReceivedFollowingGlobalTerminationAgreement",
     "crdr": "debit",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureEventSubsequentToJune302024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow following global termination agreement signed between the company and Movantik acquisition Co, Valinor Pharma LLC, nd HCR Redhill SPV, LLC.",
        "label": "Proceeds Received Following Global Termination Agreement",
        "terseLabel": "Proceeds received following global termination agreement"
       }
      }
     },
     "auth_ref": []
    },
    "rdhl_ProductReturnsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.redhillbio.com/20240630",
     "localname": "ProductReturnsMember",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureAllowanceForDeductionsFromRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stands for Product returns.",
        "label": "Product returns"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ProductsAndServicesAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProductsAndServicesAxis",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureNetRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Products and services [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r114"
     ]
    },
    "ifrs-full_ProductsAndServicesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProductsAndServicesMember",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureNetRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Products and services [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the entity's products and services. It also represents the standard value for the 'Products and services' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r92",
      "r114"
     ]
    },
    "ifrs-full_ProfitLoss": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLoss",
     "crdr": "credit",
     "calculation": {
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInOperatingActivities",
       "weight": 1.0,
       "order": 1.0
      },
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveIncomeLoss": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      },
      "http://www.redhillbio.com/role/DisclosureSegmentInformationDetails": {
       "parentTag": null,
       "weight": null,
       "order": null,
       "root": true
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureSegmentInformationDetails",
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows",
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfChangesInEquity",
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit (loss)",
        "terseLabel": "Comprehensive income (loss)",
        "totalLabel": "INCOME (LOSS) AND COMPREHENSIVE INCOME (LOSS) FOR THE PERIOD",
        "verboseLabel": "Consolidated Comprehensive income (loss)"
       }
      },
      "en": {
       "role": {
        "documentation": "The total of income less expenses from continuing and discontinued operations, excluding the components of other comprehensive income. [Refer: Other comprehensive income]"
       }
      }
     },
     "auth_ref": [
      "r1",
      "r19",
      "r42",
      "r49",
      "r51",
      "r87",
      "r89",
      "r109",
      "r115"
     ]
    },
    "ifrs-full_ProfitLossFromOperatingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProfitLossFromOperatingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Profit (loss) from operating activities",
        "totalLabel": "OPERATING INCOME (LOSS)"
       }
      },
      "en": {
       "role": {
        "documentation": "The profit (loss) from operating activities of the entity. [Refer: Profit (loss)]"
       }
      }
     },
     "auth_ref": [
      "r103",
      "r124"
     ]
    },
    "ifrs-full_PropertyPlantAndEquipment": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PropertyPlantAndEquipment",
     "crdr": "debit",
     "calculation": {
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, plant and equipment",
        "terseLabel": "Fixed assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of tangible assets that: (a) are held for use in the production or supply of goods or services, for rental to others, or for administrative purposes; and (b) are expected to be used during more than one period. Note that right-of-use assets are not included. [Contrast: Property, plant and equipment including right-of-use assets]"
       }
      }
     },
     "auth_ref": [
      "r5",
      "r25"
     ]
    },
    "ifrs-full_ProvisionUsedOtherProvisions": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ProvisionUsedOtherProvisions",
     "crdr": "debit",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureAllowanceForDeductionsFromRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Provision used, other provisions",
        "negatedLabel": "Decreases (Utilized)"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount used (ie incurred and charged against the provision) for other provisions. [Refer: Other provisions]"
       }
      }
     },
     "auth_ref": [
      "r34"
     ]
    },
    "ifrs-full_PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities",
     "crdr": "credit",
     "calculation": {
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInInvestingActivities",
       "weight": -1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Purchase of property, plant and equipment, classified as investing activities",
        "negatedLabel": "Purchase of fixed assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The cash outflow for the purchases of property, plant and equipment, classified as investing activities. [Refer: Property, plant and equipment]"
       }
      }
     },
     "auth_ref": [
      "r106"
     ]
    },
    "ifrs-full_RangeAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RangeAxis",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r72",
      "r75",
      "r112",
      "r113",
      "r131"
     ]
    },
    "ifrs-full_RangesMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RangesMember",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Ranges [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for aggregate ranges. It also represents the standard value for the 'Range' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r72",
      "r75",
      "r112",
      "r113",
      "r131"
     ]
    },
    "rdhl_RebatesAndPatientDiscountProgramsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.redhillbio.com/20240630",
     "localname": "RebatesAndPatientDiscountProgramsMember",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureAllowanceForDeductionsFromRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the information pertaining to Rebates and patient discount programs.",
        "label": "Rebates and patient discount programs"
       }
      }
     },
     "auth_ref": []
    },
    "rdhl_ReclassificationOfWarrantLiability": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.redhillbio.com/20240630",
     "localname": "ReclassificationOfWarrantLiability",
     "crdr": "credit",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsAndSignificantAccountingPoliciesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of reclassification of warrant liabilities.",
        "label": "Reclassification Of Warrant Liability"
       }
      }
     },
     "auth_ref": []
    },
    "rdhl_RepaymentOfPayableInRespectOfIntangibleAssetPurchase": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.redhillbio.com/20240630",
     "localname": "RepaymentOfPayableInRespectOfIntangibleAssetPurchase",
     "crdr": "credit",
     "calculation": {
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows": {
       "parentTag": "ifrs-full_CashFlowsFromUsedInFinancingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Repayment of payable in respect of intangible asset purchase",
        "label": "Repayment of payable in respect of intangible asset purchase",
        "negatedLabel": "Repayment of payable in respect of intangible asset purchase"
       }
      }
     },
     "auth_ref": []
    },
    "srt_RepurchaseAgreementCounterpartyNameDomain": {
     "xbrltype": "domainItemType",
     "nsuri": "http://fasb.org/srt/2023",
     "localname": "RepurchaseAgreementCounterpartyNameDomain",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureEventSubsequentToJune302024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Counterparty Name [Domain]"
       }
      }
     },
     "auth_ref": []
    },
    "rdhl_ResearchAndDevelopmentAdjustedEarningsBeforeInterestTaxesDepreciationAndAmortisation": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.redhillbio.com/20240630",
     "localname": "ResearchAndDevelopmentAdjustedEarningsBeforeInterestTaxesDepreciationAndAmortisation",
     "crdr": "credit",
     "calculation": {
      "http://www.redhillbio.com/role/DisclosureSegmentInformationDetails": {
       "parentTag": "ifrs-full_ProfitLoss",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureSegmentInformationDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Research and development Adjusted earnings before interest, taxes, depreciation, and Amortisation.",
        "label": "Research And Development Adjusted EBITDA"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_ResearchAndDevelopmentExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ResearchAndDevelopmentExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Research and development expenses, net",
        "terseLabel": "RESEARCH AND DEVELOPMENT EXPENSES"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expenditure directly attributable to research or development activities, recognised in profit or loss."
       }
      }
     },
     "auth_ref": [
      "r38"
     ]
    },
    "ifrs-full_ReserveOfEquityComponentOfConvertibleInstrumentsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "ReserveOfEquityComponentOfConvertibleInstrumentsMember",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodEquityOfferingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Equity component"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing components of convertible instruments classified as equity."
       }
      }
     },
     "auth_ref": [
      "r120"
     ]
    },
    "ifrs-full_RestrictedCashAndCashEquivalents": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RestrictedCashAndCashEquivalents",
     "crdr": "debit",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureEventSubsequentToJune302024Details"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted cash and cash equivalents"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of cash and cash equivalents whose use or withdrawal is restricted. [Refer: Cash and cash equivalents]"
       }
      }
     },
     "auth_ref": [
      "r122"
     ]
    },
    "ifrs-full_RetainedEarnings": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RetainedEarnings",
     "crdr": "credit",
     "calculation": {
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Retained earnings",
        "terseLabel": "Accumulated deficit"
       }
      },
      "en": {
       "role": {
        "documentation": "A component of equity representing the entity's cumulative undistributed earnings or deficit."
       }
      }
     },
     "auth_ref": [
      "r100",
      "r101"
     ]
    },
    "ifrs-full_RetainedEarningsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RetainedEarningsMember",
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accumulated deficit"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for a component of equity representing an entity's cumulative undistributed earnings or deficit."
       }
      }
     },
     "auth_ref": [
      "r3",
      "r98"
     ]
    },
    "ifrs-full_Revenue": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "Revenue",
     "crdr": "credit",
     "calculation": {
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_GrossProfit",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureNetRevenuesDetails",
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sale of products",
        "terseLabel": "NET REVENUES"
       }
      },
      "en": {
       "role": {
        "documentation": "The income arising in the course of an entity's ordinary activities. Income is increases in assets, or decreases in liabilities, that result in increases in equity, other than those relating to contributions from holders of equity claims."
       }
      }
     },
     "auth_ref": [
      "r20",
      "r56",
      "r78",
      "r86",
      "r88",
      "r92",
      "r93",
      "r94",
      "r96",
      "r97",
      "r109"
     ]
    },
    "ifrs-full_RevenueAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RevenueAbstract",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureNetRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Revenue [abstract]",
        "verboseLabel": "Revenues"
       }
      }
     },
     "auth_ref": []
    },
    "rdhl_ReversedExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.redhillbio.com/20240630",
     "localname": "ReversedExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets",
     "crdr": "credit",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of reversed expense from share-based payment transactions in which the goods or services received did not qualify for recognition as assets.",
        "label": "Reversed Expense From Share-based Payment Transactions In Which Goods Or Services Received Did Not Qualify For Recognition As Assets",
        "terseLabel": "Shares forfeited, reversed expenses"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_RightofuseAssets": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "RightofuseAssets",
     "crdr": "debit",
     "calculation": {
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_NoncurrentAssets",
       "weight": 1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Lease, Right-of-Use Asset",
        "terseLabel": "Right-of-use assets"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of assets that represent a lessee's right to use an underlying asset for the lease term that do not meet the definition of investment property. Underlying asset is an asset that is the subject of a lease, for which the right to use that asset has been provided by a lessor to a lessee."
       }
      }
     },
     "auth_ref": [
      "r69",
      "r71"
     ]
    },
    "ifrs-full_SalesAndMarketingExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SalesAndMarketingExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 3.0
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Sales and marketing expense",
        "verboseLabel": "SELLING AND MARKETING EXPENSES"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense relating to the marketing and selling of goods or services."
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "rdhl_ScheduleOfMovementOfAllowanceForDeductionsFromRevenuesTableTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.redhillbio.com/20240630",
     "localname": "ScheduleOfMovementOfAllowanceForDeductionsFromRevenuesTableTextBlock",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureAllowanceForDeductionsFromRevenuesTables"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of movement of allowance for deductions from revenues.",
        "label": "Schedule Of Movement Of Allowance For Deductions From Revenues [Table Text Block]",
        "terseLabel": "Schedule of movement of allowance for deductions from revenue"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SellingGeneralAndAdministrativeExpense": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SellingGeneralAndAdministrativeExpense",
     "crdr": "debit",
     "calculation": {
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveIncomeLoss": {
       "parentTag": "ifrs-full_ProfitLossFromOperatingActivities",
       "weight": -1.0,
       "order": 4.0
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Selling, general and administrative expense",
        "terseLabel": "GENERAL AND ADMINISTRATIVE EXPENSES"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of expense relating to selling, general and administrative activities of the entity."
       }
      }
     },
     "auth_ref": [
      "r124"
     ]
    },
    "ifrs-full_SharePremium": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SharePremium",
     "crdr": "credit",
     "calculation": {
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_Equity",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share premium",
        "terseLabel": "Additional paid-in capital"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount received or receivable from the issuance of the entity's shares in excess of nominal value."
       }
      }
     },
     "auth_ref": [
      "r100"
     ]
    },
    "ifrs-full_SharePremiumMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SharePremiumMember",
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Additional paid-in capital"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for the amount received or receivable from issuance of the entity's shares in excess of nominal value."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ifrs-full_SharebasedPaymentArrangementsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SharebasedPaymentArrangementsMember",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based payment arrangements [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for an agreement between the entity or another group entity or any shareholder of the group entity and another party (including an employee) that entitles the other party to receive (a) cash or other assets of the entity for amounts that are based on the price (or value) of equity instruments (including shares or share options) of the entity or another group entity; or (b) equity instruments (including shares or share options) of the entity or another group entity, provided that the specified vesting conditions, if any, are met. It also represents the standard value for the 'Types of share-based payment arrangements' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "rdhl_SignificantEventsDuringCurrentReportingPeriodAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://www.redhillbio.com/20240630",
     "localname": "SignificantEventsDuringCurrentReportingPeriodAbstract",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "N/A",
        "label": "SIGNIFICANT EVENTS DURING THE CURRENT REPORTING PERIOD"
       }
      }
     },
     "auth_ref": []
    },
    "rdhl_SignificantEventsDuringCurrentReportingPeriodTextBlock": {
     "xbrltype": "textBlockItemType",
     "nsuri": "http://www.redhillbio.com/20240630",
     "localname": "SignificantEventsDuringCurrentReportingPeriodTextBlock",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriod"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure of significant events during the current reporting period.",
        "label": "Significant Events During Current Reporting Period [Text Block]",
        "terseLabel": "SIGNIFICANT EVENTS DURING THE CURRENT REPORTING PERIOD"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_SignificantUnobservableInputLiabilities": {
     "xbrltype": "decimalItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "SignificantUnobservableInputLiabilities",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Significant unobservable input, liabilities",
        "terseLabel": "Significant unobservable input"
       }
      },
      "en": {
       "role": {
        "documentation": "The value of significant unobservable input used in the measurement of the fair value of liabilities."
       }
      }
     },
     "auth_ref": [
      "r60"
     ]
    },
    "ifrs-full_StatementOfCashFlowsAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfCashFlowsAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CASH FLOWS"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfChangesInEquityAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED INTERIM STATEMENTS OF CHANGES IN EQUITY"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityLineItems": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfChangesInEquityLineItems",
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [line items]",
        "terseLabel": "Statement of changes in equity"
       }
      },
      "en": {
       "role": {
        "documentation": "Line items represent concepts included in a table. These concepts are used to disclose reportable information associated with members defined in one or many axes of the table."
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_StatementOfChangesInEquityTable": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfChangesInEquityTable",
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Statement of changes in equity [table]"
       }
      },
      "en": {
       "role": {
        "documentation": "Schedule disclosing information related to changes in equity."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "ifrs-full_StatementOfFinancialPositionAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "StatementOfFinancialPositionAbstract",
     "lang": {
      "en-us": {
       "role": {
        "label": "CONDENSED CONSOLIDATED INTERIM STATEMENTS OF FINANCIAL POSITION"
       }
      }
     },
     "auth_ref": []
    },
    "rdhl_StockIssuedDuringPeriodValueRestrictedStockAward": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.redhillbio.com/20240630",
     "localname": "StockIssuedDuringPeriodValueRestrictedStockAward",
     "crdr": "credit",
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfChangesInEquity"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock related to restricted stock awards issued during the period.",
        "label": "Stock Issued During Period Value Restricted Stock Award",
        "terseLabel": "Issuance of ordinary shares for vested RSUs"
       }
      }
     },
     "auth_ref": []
    },
    "rdhl_SupplementalInformationInterestPaidInCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.redhillbio.com/20240630",
     "localname": "SupplementalInformationInterestPaidInCash",
     "crdr": "debit",
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplemental information on interest paid in cash.",
        "label": "Supplemental Information Interest Paid In Cash",
        "terseLabel": "SUPPLEMENTARY INFORMATION ON INTEREST PAID IN CASH"
       }
      }
     },
     "auth_ref": []
    },
    "rdhl_SupplementalInformationInterestReceivedInCash": {
     "xbrltype": "monetaryItemType",
     "nsuri": "http://www.redhillbio.com/20240630",
     "localname": "SupplementalInformationInterestReceivedInCash",
     "crdr": "debit",
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfCashFlows"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Supplemental information on interest received in cash.",
        "label": "Supplemental Information Interest Received in Cash",
        "terseLabel": "SUPPLEMENTARY INFORMATION ON INTEREST RECEIVED IN CASH"
       }
      }
     },
     "auth_ref": []
    },
    "rdhl_TaliciaMember": {
     "xbrltype": "domainItemType",
     "nsuri": "http://www.redhillbio.com/20240630",
     "localname": "TaliciaMember",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureNetRevenuesDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This member stands for Talicia prescription medicine.",
        "label": "Talicia"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_TopOfRangeMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TopOfRangeMember",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for top of a range."
       }
      }
     },
     "auth_ref": [
      "r65",
      "r72",
      "r75",
      "r112",
      "r113",
      "r131"
     ]
    },
    "ifrs-full_TradeAndOtherCurrentPayables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TradeAndOtherCurrentPayables",
     "crdr": "credit",
     "calculation": {
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentLiabilities",
       "weight": 1.0,
       "order": 1.0
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade and other current payables",
        "terseLabel": "Account payable"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current trade payables and current other payables. [Refer: Current trade payables; Other current payables]"
       }
      }
     },
     "auth_ref": [
      "r10"
     ]
    },
    "ifrs-full_TradeAndOtherCurrentReceivables": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TradeAndOtherCurrentReceivables",
     "crdr": "debit",
     "calculation": {
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition": {
       "parentTag": "ifrs-full_CurrentAssets",
       "weight": 1.0,
       "order": 2.0
      }
     },
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfFinancialPosition"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Trade and other current receivables",
        "terseLabel": "Trade receivables"
       }
      },
      "en": {
       "role": {
        "documentation": "The amount of current trade receivables and current other receivables. [Refer: Current trade receivables; Other current receivables]"
       }
      }
     },
     "auth_ref": [
      "r8",
      "r14"
     ]
    },
    "ifrs-full_TypesOfSharebasedPaymentArrangementsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "TypesOfSharebasedPaymentArrangementsAxis",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Types of share-based payment arrangements [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r76"
     ]
    },
    "ifrs-full_UnobservableInputsAxis": {
     "xbrltype": "stringItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "UnobservableInputsAxis",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unobservable inputs [axis]"
       }
      },
      "en": {
       "role": {
        "documentation": "The axis of a table defines the relationship between the members in the table and the line items or concepts that complete the table."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r129"
     ]
    },
    "ifrs-full_UnobservableInputsMember": {
     "xbrltype": "domainItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "UnobservableInputsMember",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureFinancialInstrumentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Unobservable inputs [member]"
       }
      },
      "en": {
       "role": {
        "documentation": "This member stands for all the unobservable inputs. It also represents the standard value for the 'Unobservable inputs' axis if no other member is used."
       }
      }
     },
     "auth_ref": [
      "r60",
      "r129"
     ]
    },
    "rdhl_WarrantsNumberIssued": {
     "xbrltype": "sharesItemType",
     "nsuri": "http://www.redhillbio.com/20240630",
     "localname": "WarrantsNumberIssued",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureSignificantEventsDuringCurrentReportingPeriodEquityOfferingsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of warrants issued during the period.",
        "label": "Warrants, Number Issued",
        "terseLabel": "Warrants issued"
       }
      }
     },
     "auth_ref": []
    },
    "ifrs-full_WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted": {
     "xbrltype": "monetaryItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted",
     "crdr": "credit",
     "presentation": [
      "http://www.redhillbio.com/role/DisclosureShareBasedPaymentsDetails"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average fair value at measurement date, other equity instruments granted",
        "terseLabel": "Fair value of RSU grant"
       }
      },
      "en": {
       "role": {
        "documentation": "The weighted average fair value at the measurement date of granted equity instruments other than share options. [Refer: Weighted average [member]]"
       }
      }
     },
     "auth_ref": [
      "r77"
     ]
    },
    "ifrs-full_WeightedAverageShares": {
     "xbrltype": "sharesItemType",
     "nsuri": "https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full",
     "localname": "WeightedAverageShares",
     "presentation": [
      "http://www.redhillbio.com/role/StatementCondensedConsolidatedInterimStatementsOfComprehensiveIncomeLoss"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Weighted average number of ordinary shares outstanding",
        "verboseLabel": "WEIGHTED AVERAGE OF ORDINARY SHARE, Basic (in thousands)"
       }
      },
      "en": {
       "role": {
        "documentation": "The number of ordinary shares outstanding at the beginning of the period, adjusted by the number of ordinary shares bought back or issued during the period multiplied by a time-weighting factor."
       }
      }
     },
     "auth_ref": [
      "r31"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "51",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_51&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r7": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "g",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_g&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r8": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_h&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r9": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r10": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "54",
   "Subparagraph": "k",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_54_k&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r11": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r12": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r13": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "69",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_69&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r14": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r15": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r16": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r17": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r18": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r19": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "81A",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_81A_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r20": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "82",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r21": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "82",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_82_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r22": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "99",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_99&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r23": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "10",
   "IssueDate": "2023-01-01",
   "Paragraph": "21",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2023-en-r&anchor=para_21&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r24": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "10",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS10_g17-22_TI",
   "URIDate": "2023-03-23"
  },
  "r25": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "73",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=16&code=ifrs-tx-2023-en-r&anchor=para_73_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r26": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "19",
   "IssueDate": "2023-01-01",
   "Paragraph": "142",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=19&code=ifrs-tx-2023-en-r&anchor=para_142&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r27": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "36",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=2&code=ifrs-tx-2023-en-r&anchor=para_36_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r28": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "24",
   "IssueDate": "2023-01-01",
   "Paragraph": "19",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=24&code=ifrs-tx-2023-en-r&anchor=para_19&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r29": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Paragraph": "66",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_66&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r30": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Paragraph": "67",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_67&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r31": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Paragraph": "70",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&anchor=para_70_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r32": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "33",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=33&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IAS33_g70-73A_TI",
   "URIDate": "2023-03-23"
  },
  "r33": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2023-01-01",
   "Paragraph": "84",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_84_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r34": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2023-01-01",
   "Paragraph": "84",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_84_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r35": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2023-01-01",
   "Paragraph": "84",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_84_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r36": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2023-01-01",
   "Paragraph": "84",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_84&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r37": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "118",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_118_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r38": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "38",
   "IssueDate": "2023-01-01",
   "Paragraph": "126",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=38&code=ifrs-tx-2023-en-r&anchor=para_126&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r39": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "40",
   "IssueDate": "2023-01-01",
   "Paragraph": "32A",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=40&code=ifrs-tx-2023-en-r&anchor=para_32A&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r40": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "41",
   "IssueDate": "2023-01-01",
   "Paragraph": "50",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=41&code=ifrs-tx-2023-en-r&anchor=para_50&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r41": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "10",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_10&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r42": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "18",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_18_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r43": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "25",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_25&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r44": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_28&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r45": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r46": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "50",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_50_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r47": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IAS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "30",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=8&code=ifrs-tx-2023-en-r&anchor=para_30_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r48": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "24",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_24_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r49": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "24",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_24_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r50": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_32_a_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r51": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "32",
   "Subparagraph": "a",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=1&code=ifrs-tx-2023-en-r&anchor=para_32_a_ii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r52": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_i&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r53": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "ii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_ii&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r54": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_iii&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r55": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "iv",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_iv&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r56": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B12",
   "Subparagraph": "b",
   "Clause": "v",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B12_b_v&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r57": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B13",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B13_a&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r58": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r59": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r60": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r61": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "e",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_e_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r62": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "e",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_e_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r63": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r64": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r65": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "14",
   "IssueDate": "2023-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=14&code=ifrs-tx-2023-en-r&anchor=para_33_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r66": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "114",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_114&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r67": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS15_g110-129_TI",
   "URIDate": "2023-03-23"
  },
  "r68": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Section": "Presentation",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS15_g105-109_TI",
   "URIDate": "2023-03-23"
  },
  "r69": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "47",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_47_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r70": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r71": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "16",
   "IssueDate": "2023-01-01",
   "Paragraph": "53",
   "Subparagraph": "j",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=16&code=ifrs-tx-2023-en-r&anchor=para_53_j&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r72": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "120",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_120&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r73": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "44",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_44&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r74": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "b",
   "Clause": "iii",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_b_iii&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r75": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r76": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r77": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "47",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_47_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r78": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "5",
   "IssueDate": "2023-01-01",
   "Paragraph": "33",
   "Subparagraph": "b",
   "Clause": "i",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=5&code=ifrs-tx-2023-en-r&anchor=para_33_b_i&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r79": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "31",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_31&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r80": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "35K",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_35K&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r81": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r82": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "8",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_8_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r83": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "8",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_8&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r84": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "B52",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_B52&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r85": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Section": "Scope",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS07_g3-5A_TI",
   "URIDate": "2023-03-23"
  },
  "r86": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r87": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "23",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_23&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r88": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r89": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r90": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r91": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "28",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_28_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r92": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "32",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_32&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r93": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "33",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_33_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r94": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Paragraph": "34",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&anchor=para_34&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r95": {
   "role": "http://www.xbrl.org/2003/role/disclosureRef",
   "Name": "IFRS",
   "Number": "8",
   "IssueDate": "2023-01-01",
   "Section": "Disclosure",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=8&code=ifrs-tx-2023-en-r&doctype=Standard&dita_xref=IFRS08_g20-24_TI",
   "URIDate": "2023-03-23"
  },
  "r96": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "102",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_102&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r97": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "103",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_103&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r98": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "108",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r99": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "68",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_68&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r100": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "78",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_78_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r101": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "IG6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_IG6&doctype=Implementation%20Guidance",
   "URIDate": "2023-03-23"
  },
  "r102": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "10",
   "IssueDate": "2023-01-01",
   "Paragraph": "22",
   "Subparagraph": "f",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=10&code=ifrs-tx-2023-en-r&anchor=para_22_f&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r103": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "32",
   "IssueDate": "2023-01-01",
   "Paragraph": "IE33",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=32&code=ifrs-tx-2023-en-r&anchor=para_IE33&doctype=Illustrative%20Examples",
   "URIDate": "2023-03-23"
  },
  "r104": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2023-01-01",
   "Paragraph": "87",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&anchor=para_87&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r105": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "37",
   "IssueDate": "2023-01-01",
   "Section": "Example 4 Refunds policy",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=37&code=ifrs-tx-2023-en-r&doctype=Illustrative%20Examples&dita_xref=IAS37_IE_C_ex4_TI",
   "URIDate": "2023-03-23"
  },
  "r106": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "16",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_16_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r107": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r108": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r109": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "12",
   "IssueDate": "2023-01-01",
   "Paragraph": "B10",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=12&code=ifrs-tx-2023-en-r&anchor=para_B10_b&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r110": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "B36",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_B36_a&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r111": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "B36",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_B36_b&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r112": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "B6",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_B6&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r113": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "IE63",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_IE63&doctype=Illustrative%20Examples",
   "URIDate": "2023-03-23"
  },
  "r114": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "15",
   "IssueDate": "2023-01-01",
   "Paragraph": "B89",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=15&code=ifrs-tx-2023-en-r&anchor=para_B89_a&doctype=Appendix&subtype=B",
   "URIDate": "2023-03-23"
  },
  "r115": {
   "role": "http://www.xbrl.org/2003/role/exampleRef",
   "Name": "IFRS",
   "Number": "17",
   "IssueDate": "2023-01-01",
   "Paragraph": "113",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=17&code=ifrs-tx-2023-en-r&anchor=para_113_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r116": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r117": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "15",
   "Subsection": "d-3"
  },
  "r118": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "10",
   "Subparagraph": "e",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_10_e&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r119": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "106",
   "Subparagraph": "d",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_106_d&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r120": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "108",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_108&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r121": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "112",
   "Subparagraph": "c",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_112_c&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r122": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "55",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_55&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r123": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "79",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_79_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r124": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "1",
   "IssueDate": "2023-01-01",
   "Paragraph": "85",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=1&code=ifrs-tx-2023-en-r&anchor=para_85&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r125": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "17",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_17&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r126": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "Subparagraph": "a",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20_a&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r127": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "Subparagraph": "b",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20_b&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r128": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IAS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "20",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IAS&num=7&code=ifrs-tx-2023-en-r&anchor=para_20&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r129": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "13",
   "IssueDate": "2023-01-01",
   "Paragraph": "93",
   "Subparagraph": "h",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=13&code=ifrs-tx-2023-en-r&anchor=para_93_h&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r130": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "2",
   "IssueDate": "2023-01-01",
   "Paragraph": "45",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=2&code=ifrs-tx-2023-en-r&anchor=para_45&doctype=Standard",
   "URIDate": "2023-03-23"
  },
  "r131": {
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef",
   "Name": "IFRS",
   "Number": "7",
   "IssueDate": "2023-01-01",
   "Paragraph": "7",
   "URI": "https://taxonomy.ifrs.org/xifrs-link?type=IFRS&num=7&code=ifrs-tx-2023-en-r&anchor=para_7&doctype=Standard",
   "URIDate": "2023-03-23"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>50
<FILENAME>0001558370-24-012527-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-24-012527-xbrl.zip
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MY[]HR*K$>DR_->0<+*FJ/J/&5T.>+#2KRA.@8.M9V/G8C!TQ]EY$#B*K8\C
ME\V$1A.W8&2=F78OS^C;ANHG=A ^]5AV$UN"!]U(B5V=PZ<]8O.IR#@_GDM$
M'%P^5/MJ\84(60048:K??#]"4JZM2",CCF8Q%L%JR'X:%Y>-B[=[TQ&^X:(,
M#0I%_@KNN)!47$DJKBZJ&4/B.I.2W_<1Y(??E/MDY?L=<LTRMQ.)_TU"[)X:
MALV^[4#V&S*QFS%*C9L(3O"KV@A*N:ZDG./PX5VG(>_#2/NN=\6.RM&D&_[F
MK3&K>@@Q>YNU+(3($L<8&Y@\>BF=I!,B;#E8R!GEXZ<S2,S!S-TXH"Y^N5[9
M% O$MKK *YGG '/.C$, =R1K=\QVUCXH 1#PZ^IYK1:^IZHC=QP(OVF&+#DJ
M/IV9>$9$&JLN[6WS?PX7:IX TW&8U2'+\<H_-XA^[^*U/*GM9:]*,J4Q#F(P
M+JT85P8DX42DR<%TF+<FD,5R<'2NS3E69:L^03-BR4.3\&W>!L*8NJ1E9PVE
M4<),PSM"%Z591EXG/LOI(JC&J[?3*C3+2.$N#ZAF_$R<]=I]$:%7%24Q%^Z
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MF7Q+"L%^ZQW >NQ/O>OWO9OK=Z^A>[$GD?VSP4<.X*\%^#U/UQ\^?+CD_YJ
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MM^Y.O>IC-BWS1N\6:\"0<(,<=7%!6741Y"X(K,<ZT."5>J=W'#RC,.+5PW'
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M;B7R8"MW) T"B(,12J?2, #4P;3SHD'1M<007=912W.:*XT:9A#?TA&U0^-
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M^LVGMDG-D$- 60)94"1T!0 #:,=(P;- _1WW4F!>J$D>-=[MG>?W)F5@CS_
M#]?P@Y 3_^4O-PYW,MK6\UW=\$-(@OP_?I?W>3UI -$ 2W/3E.NN$>+B/U;(
M(1CQWG"X^9_\:ROX8L3TG>L<\RF5Z)R<#_]B;>M_L2$K*3Y<ZCEGUZ"UOM$D
M^462CDCD(\#C4_OZ:5V#YC\):.37$-[__8/$VZ,FW08KT-S>.>Y1^.6-OHWM
M.<%JR5"\^E7%7ZAJ1>-P:ETEM4T5, 1,$I#)KP+V.,K(W3&=^_3HJ4DA.7Q2
M2GG!9XEB1F,GHYR7%'>KH "?" 0#:NF&0RQA/_@8OQ8F^<AJ'7R&6\M2%+;6
M*H VG 8]4I<YYLPV;WG\6L)C=AQ^G<KE+*M<J4&XM2R?U-;J)L$2#I< X/XU
M;V;[S']=T3V#"-/V'_1CGN(5#,.K=V5\A6J7-P:GUI52VE3I)% 20R4 =BB5
MN^'J[NK6G.^DO_TW?2UD^G(<=J4KX"RM=9E!F-6NB-26>A> )0(NX8#[U[R;
ML^MRK'?,,W3K%ZJ[Q2MMR5"\^E?%7Y1&*1B'4PLKJ6V<7)& B81, /2 *V^X
MYL=\W?&_E&UK+T?B5<4*[K*17V883D6L(K9U])=41 %Z:"V4X:>:'J;'3D43
M<SC,U\7$P"EH8QZY7>ECL"D92",UCMH4C%GZ/H?O[.=X-2^7DU#;4A_BU+!\
M$IMJ502- +BV>L1VKB>P^/HWQW:.KT*;KK__X9KKU.YL67^!$?%/UX;C_B4>
M(K1-_%V,F-N&<Z1KGR_\0&'!09K*>)S:J,PI:&?E8'S:JDYRXUAQ^7 [>UC/
M;@G_:;U<S&^U#?]E_K"9K>;W9+WAO][/'C9KLKSC0^X?5[//?/S\RXR/X;_/
MR)O%<KU^BTOO5_29VN?L_B?O<^QZG>$DK<?!AYCU-DMB4SU=ZQ8ESHZ<7,<\
M&WYVO>Z$$Y^Z'ET,PL[#;$-6LR^SAZ?9&I?IW#B>O]R!N+.A<M$8[":4PU':
MC!(#,)M2'IG-ZR\\'\S) V@CV5*G_"S7&UBA<-K4)]?QO$?7V;'BT"L]!KM-
MY7"4MJG$ ,PVE4=F4QT4L&"!XL!Z,:EDV=\ [*QX7$<>5\N[^0:7.:VH1[FV
M'C3;O.7KL>6<("2>?3M1VRN+^<IG83<Y):ZS\6')%,QFJ49X4\T.H1/=-HD9
MPR=4(O"NB$W[,6&5"+-7UF?KF;:Z^4RTAUMRRQ?+Q?(1MG=D]C^/L U$MG"*
MX(!+XEYWOU*?V?LJ(R^9@-V^JWA-FW;1:,Q674ESF\VA)ZSY&((.;;D/*WZF
M[M:ILN/^F)TM%O.'3\*"[[75?\\V\!M2^Z461[3_1&WJZA:7AF8>F2W*,GSV
M3"NM674Z>MNN)8>,I2O-16WW]3AH;!@2S1792T3"(>@I5'UZ!86U?2!!?)H]
MS%;:0G@([?9^_C!?;U;:!G*V.-W$TC]0=WFB( 9[+U/=5;ZA? YVAZ# <=H+
ME$S ;/HJ9#=5<P&;."%PP@1T\B:P\>R11#MN\V\5CL#TYO-L%1R]X#)BF798
M.)YWQY4]8E\SN&MC/BM))ZO,Q&[0RMRGS;IR&F;C5B>^J;9+#.2-Q7&\)2#S
MA+WK$9Z1LFW]\[]\G,'"S>-[Q(>M=\R&F^_2SQ4**SL*NT'G<I4VWM00S(::
M3VA3I0R@!>OM2*%TQRS-'[2'FSF/F3&NK &O<%Y6O(AF!DW$O%(\Y5J7&#$!
MXTK3V=:V#( VKFEUQ%!D605;S^$R<CU\44RW"E(*.%R&=(_ L9HC#49.Q'E<
M<E>R/L.P";B1'&*[6:?)&_ IW6Z*&R[7'7('!BCYZ^_,KGHCT -WF8 DCSLT
M^WV%#=($G,HE/T5;=<QN)(?*3C;?(_F-#MFY<8XGEQ[X6@T' :%3[(^Y.OF#
MULRET@,B\5]2JTWNEBNR^3PCC[/5?'D[6D#6Z9=K>X[%3-$-4/V;'MF%?M0]
M9LQTUV;VW@,Y/%)W?=#=XBQ*V0SL#K:2V[2_+1R.V?U6$]U4PQ>B&F^V(LO5
M+0\.5K^0]6=MQ0.#+: D;Y[>K=\1T[$LW?7>_C2:3?<G@)FV>I@_?%J'3DQ5
M%KA,_I999^ZC:AE]^1SL9J_ <=KP2R9@-GT5LCLW?E,B16/^?0I!Q0'DRP.7
M"_B9LOV!$ZEQB>I[*H13O(<J&HW=[$NY3!M\[E#,IEY.<%/]#J$278(E]OFX
MA0J''7%<D]FZ^TH\@8HX9Q_:34.[[=%,O2<AS.:?/L,-5.W+;*5]FL&EGJR1
M?Y2K/+.)?W#.'I<#-A/7S+^>/2Z;>J9>-0N[R2MQG3;]TBF878 :X<.Z F*>
M7?C'/U!RDKTM2HUD.%_1L[04?$84&"#V&M'M_N4NRFX_.AZ#UJ^5K1L4)V/W
M(75DD*F35IB)V:/4HG^0=@_Q(<3C<CW?S)</N.PEZ'.F>1[UO4H#*1J-W2)*
MN<Q<9,\;BEGGRPENV_].%V#)KWK!*P-#'6+TQ.73:@4W][3U>K999[?\8YNF
M[L$-1OAG]K<S>]8M+H"2AA)%P]$;9RF?&>O,'8O:/,LI;JRY')ZXG&/ #S2&
M?$7X#^=>2@I/85_K"E/MA^./VH*OI"(PO='6\O:M^&'VYZ?Y%VTA5EQM(P[E
M9OPS/JZ_LSDI"AYNN#YJ87R<?9H_0,:O7W&H./"![0"9+Y?+UXKRA8L9?!-5
MU[DKST?O[>M)(C<XJYJ,>CVHR4+; ,Z-$$D34;"5@6.ZWD6Q2HL EV?8N+I)
M.=/BPELD$8-R[K=E_<.JYV'W!(J<ISU Q23,EJ]*>E,U%_"%?3OB5J<1>8 (
MQTB&/@SGQ7RJF+AK'BQH-OR[[__]A^^%C<)?0A_UZ-*3SLS@!BKTI"BVT3KS
M<-IH;<[!1I4GC6NCX2NZXC&PIM]<>XT]<$L].F=IGL[>9O ZK^X1/3);D7DA
M.\>5MR-,YI_AK.((JG[BNP^7^$[RF.+E0&WQ.X?'5R5FD"VU*52?OL##P%LP
M$-T"/%?"2?@Q"<XN:3SO^O 2>:YQ.'&'P5" A81HA"!6(_G'X=@/V:9)MN4B
MT<YI]A@7S>UG+A?'+;OTGAZ#TY>6<I1MJ1T-P!S'Y)'9UC!9#'.D&*5+KD)8
MK9\MZO&L1RW3/@&SRN6JY$P'LVGE$]K-&<Y(%S2Z94D\VYX.D9"M6P]<9VN=
MJ99,P&YZ5;RFK;!H-&:#K*2YJ2)SP-=I-1[_C+4_9I</UZB/6F/.&V?H:X&8
MCF$WR].KSY^&\?>>HDZZ \09^P$E@CII_^A""RW_]9$SYW/F@7'18[I0<F4S
ML'N#2FXO+GGG#\=LZ]5$M[@"+B!?D1/ %N9,0^CC70GOB=L[]DTD,O$%YBLH
MFW9V9X]6;(!S!F*WT"+>,D\99$9AML="6ANW 8QZ'BXH_\,5$1BNG=WUDT>)
M0#+6:P5=LQIQQD&B-,6Y[7/.V-8*.!;G@IN#;G]R'!-.*TJR=-4SL1NK,O?9
M['#%-,SFK$Y\\YQKB"'<3\L##I\C(?L RVBYY<&YQV7PV<R"<@IB N9<Q%MY
M\@NSL1;2VEVR:Z1D=.><R7RT7<7?V%=IRXUN,J969F#XS:HCE=/&-*"NS&:Y
M@;<U1"H8EZDLF+YEEN@\7GERDS\6NQ&5<)BVJ)R!F,VKC-S&/6-BF.,?S_3"
MX%S[.%_,-W-LS]D$Q\9US+%T"G:KK.8WMZ1A8C:J0'7;8@<+D\GVR6]PGIJP
M8&2'JGE5WX_Z:_UK#8E)V,U8A>?J"PWA#,RFK$1WUU<93@$"1/<8.N-9,PQ1
MC!WPB,N60T<&J?.$-ZMT?)?CL5MP!:?YJW!F,&:[K2*YY?H[\D+;-5<"8#*F
M0&F6W'6X9YJ\/9#T4#7LM0Z@B1AR;=GDEPZK0IF Z=?GI74!LL28=__$N S;
M1^XP,YATM#92P>%X5G1WMDWOT76>F7=YGTYE_$3<2!&G!?T)TH,GX!0*26[?
M?T  )J<0\IB=:7KB]:-NB5>"=)]0L.%=<"=SW,XS_3/[D>Z9#4VJ^V6Y3BN)
MCIG5+,MY$>S"15R3FF<#[@U[\AU5ESY3^Z+7$@[7?,N_CF?Q)'K4";%&(%@Y
M>R)N6TT*N4Z\?.H$7+HB VT=O!FA(;OH/3$TX5S/0KC-8Y[9GN^*)@,XH[8Z
M"9PI&KURVF92YMR'[?9MILK70[MD+GU'%.T6*JY%JG/(634+NXDJ<5U4.C>Q
MTTXUPKLHJD-UZ-DSVXF[I'C//A,R4#TR*9TR(;-6.C@I'C\1@^[ZH"%ES16'
M#B,8,L9SE8*.;8D[JLZK;OFORZW%]H7MOLJ'X[0[53ZCMFPE8Y%W8U.AO'%R
M)^I^9D=8B"O1$"?",VP_M#X9CF&3 #B)H0_?^ZQ/5E<77R/: *%>;##5L*!&
M1#"Y8*"O.&#TW7D_/%Y>FD&[25<QSFF99*4A3L3\.HU&^S4TQ=/)+CE*'-*)
MEK#R5#+N%COJR61/C&Z3IY']LJK@.CMUF.*Z%-J[&M ]Q'^M3%U>#,/N*O/Y
M2GO+]!C,#K. TJ8Z*<&-GVWLFJT_/\TWOR#+)LX][PR-MDZ,NYU"261'83>O
M7*XR/2^20S ;5SZAC;LY"&C$D.#&:EK1*4O+]).[N.Q+O*'[Z-(C.Q\+Y9$9
MA-VZ\GC*//::&('9MG+I;*J' A@Y26@C65:G#&FF*9ZWY3MJZ/%_S>P"OS%V
M^S7JZ\RFYDQW(48O:;]V.1"[K17QEFF_EAF%V>8*:6W>SE,")#2 .%:SM:X9
MTPSC?#Q;.C0J->F.&2Q[!PK%[JPB?IZ D:7YR-N%83:H#(6M=EWCIJDZX@1E
MS7SWO&T'*I&O3DAUQ)O,1<EM,D9'IW']54C:%PR>AA/,YS$W,94:B=]!%M#;
M,DD%%^O&/TSKA<.+U+!X"AJC>7+WZU.H]5CN;@Z<6>K-;<7,L=)4[*:KSG]F
MFUXY#[-9UZ"^<3'[\N%V]K">W1+^TWJYF-]J&_[+_&$S6\WOR7K#?[T7#Z+#
M:^F?M8=/W$KF#Q,SD@TT!6D@YG#>=,TCQ;FJ;8A)TS2,-.F-$UTA? @\#8F!
M,%L\/0#G-CY@R1[:C'T_R3F>'!ON32UW@9/XQDKN*!4-QZ[KY7QF[BKECL6L
MV144-W;S$5C0Z%"-=0X:F19+GN_I<4O=0B%E!F'7V#R>\O8;<@1F[<REL^TA
M^%& 0Z:'J0.\"G7,'XM=*TLX+#E'QJ^C9>1V= ";+6H?.^Y-'(E5J&KN4.R:
M6LQ?\9DL?CTMH?:?[3BS0FD+AV-7W'(^RP\X\2MP!<7_L&>"Q9O/!1?'G']6
MO.M2FXM=KVM(0#7E$$W$K/%UR.\K]<!'4L( U5A%H^-+ 9<_F-N&"S=R;ZG\
M=W-PG?/^(-9WX,9\U%^!E8VKVYXN6V 51Z_-@&'W&&UDE'W)K3XDS#ZE%3^-
M:V0#I.2-&:!]2WR)6&YQK@5J:*<MC-!/(+_*-\+!*FO'D-<Z(1/#.4++47$M
MEO@.H<>3Y;S2H 6I1]UG9E#9L='D["#S5; Y#C.+Y5OHQ"CTWB6/JYPD1C@$
MM3_();15,7R<\AVS&KY3GD2%$&?+22=FKHA-1<@0M@7NKC/&VG>,KS*W='MV
M^7[G4=0C?=&M,XV?6Q>CM!?=-3/": H#I^FUDDC46*,N .3=-AJST]00!&30
M=@]@$I?*33-?D]P(7?"9#@AY!"WOQIB"O,0USV&[= PN* &*!!>#)$HB<1(I
MPQ@KD6,%WN&;>@PNF1)?*IKV/G.D7"BK]1.R0":Y"=6]PYWEO%3W_ZN8A-/7
MUN.Y.-^2G8$Y"%*B>YB2)VW]F=PMEC\CNS8>B>6.*\D3WY?,[27WY7QQLO<:
MW_4\*S[[5Q<,=AMI)I=,U4@M&)CMJ"$GC2V+HR,[P"=;O+\YPX:9V6^)$V(E
M>H1V_.OO XMG^3A;:9OYPR>BW6SF7S"VWM3,OYX]7W3?OG/<%06;8Q9]=)T=
M\Q>.5^U1ZD# [DQJ2R/SJK;J=,PNI#X3S4^O(TQR#Q.@@EP:QT7>6!S;V_&]
MQC@283;LZD[4$/D-9AO.43[R&+V 9#L^__NS8SV#GS5"7XS:PURD;8M/1A0F
M3LN?%/->YD8N9TW'>Y30WH6)P(8UY_1BK-O2O?/^#W,JD9;4+3UQW\\$*\%+
M<HHRSI\Y+:]0PGV96\B9-AV_4$9\5X[!3. (UTP4CJ$/YI,P,9NZ=G1<GWD-
M3#U_YK1,O83[,E//F38=4R\COBM3UQ,X4)EZ+\P+F'^7S(J=@<\!L2W?-^F>
M1QN]HE5P!)IFYI/.;)$X$946.^HN=RNV/_C>W+YWGG7;9U\UVYQ]@V3*F7D'
MF<Z]I5L_[E2>C?9[1(/3-?0MU^BLM0<<R(]C^^2XO:<2CFH/1,E4*9S%^@%I
M8,:N(([,;7(,R".:V.PG"82!)B<QT:B_E\U.X4DN;AE[A!-%!%4$R"(;+N20
M-K+<D54DY/NDD-,4PD"@,?':P[ [2K22_E2IOBPA65U)?:_(&X]2PAEW7M[V
MOG3-=-=ZW5#WR&R!?KD3;^MX#S2;X&X.97H+CX)4JM:5$A#37#94&.I^5:"
ME?@Q6C 9\<*5+'4;MFYG5-%<.'.!EB3P@J.6F E'C<9%]RF>3^JJ@CD-(-B
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MF<KV^!G43XYCOC"KI/2A#@B<JTD;>62J>I3G8SY#:L!%Q\??V=L.7O)-X7V
M?*PKN<-))^D.YQF1]!%?%C^V5#H0IU57\Y83!:)Y&ZE&G-?I0TC1<IE<6A-O
M_Q#S[(HK%GQ-/%&7.>9885L?#QUYTM)Z?>5)->KJZR&G8O8Z\2'AO\'M.:_X
M^ER%CZD':!(^J(%L<GQ4#2B3\6%->.KY_8_@'J97<1%SX+3A.")+;%SC'6R(
M.+A=)@3$MZN)0$7+:V$VJ!,=14@LDDU&=X:(X<)_/_*-LO/"EVI%-YL:/REO
M>LEIB=.,!T_.-^:0WK,+W$88QW9R'?)^Z<LXIS%\#-ZJ#VZ33';G=S[I3+Y1
MLH$KUSOJ!D<TW-'>.\^Z[;.OT$7S&Z3&SLP[R,X*MW3K+[<6VPOMSW5070%&
M[,DZE5WD\CJ!BMPW=LMC4],25,B\/1Q$A[1 # 2_2XH@. II(IPHDJ8*!@-=
M)$'8H*X6DRA%ZAP2"WXH2AXSP>^N%"5+B%(T%TZ+4B0MN"B=0E%V$F!ECJ ;
MG\+6@H/8C;613$Z@I@X$N9-JQ5+')[$Y9V-(#V,'E%6J.XH0T#)1!X/Y0'8,
M(>5J48>!)+6IFRJN+.@,7#T:L:^LYC*.XPJ'(O=["H0WOO_^7AO6+_7(RZ?9
MPVRE+7#5 ]PRS[ <[^S2Y2Z/=^?L!WT-=&O-54"41'NS;_#@ Q#Z6GAJV@5D
MG(;=@_32106MP6*N->B.N<8K7$0!+&U[24/J-H8.5(1]-OAG7D0'^=7GFQ"R
MY7;Z=:P6X>-+,,#:X68KP=)'W6,>/,Q"3[H;A#8WCFW"F^0F_\%S+&9"QR=Q
M&8,=<W@MBR3Z0X736PTAWWA7UP\>Y %0WUPW-5/[O3[LI@ZI'#YJZ_F:+._(
MXVKVJ*V"VU5W9/-Y1FZ6#[>SA_7L%GY:+Q?S6VTC;IIN9JOY/0G>1] 69+WA
M'\ UK;6XNK^>?WJ8W\UOM(<-T6YNED\/XL&Z1P[A9C[K\"9_QT+=\.7K(ZQ>
M WR!25S_/,[Q0L)]><<(T3^7>[QDN\UM,@Z1\4#0C&-".![= IFR96-$J&A\
M')(*/T6TRJN[[)@;,0Z<5\,JZT30O=P101K\D" .?HW((TGZ2$ @B2@DZT1$
M#D22C\-'Y+@%/NE%;\WV-MLQ0[?]&10O>K>B"/7F[+K\MQ4].2Z<!#V*>M2R
M:+\I(,3+52O9Q+T;FD!!OM"TXZE%CG+8)@VC<)DT_=D7X1%NGU9@_<*A/*U6
M_&^$NYKE2OH$[DF6MR-YA-(@MS&D?Q2?4!R@-@/SC^05^@XN>0SIQ?00^BQ/
M;N,K%H8DB[@A7:-<NAA)9@FT1.(E$C$),),(-9&X1X[^QI+3R,Y8LRSG!5Z
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M,T&"A+SPGPDRP)70@! 8%9)"8EI(2,RP7@65\*(@5%)!YI'P9HK"&[X:&I4
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M0I9OIS$).[_S7[_V.PZSXI@RVMYU%U2$D9#<0.;F$LK&X;2Y2LZBR"%O$/*
MH93DYK7502L[>91N1^F$:#\4M.4Q>9S [0X&R2[APT8*O3 ? KTB01IEGI<\
M&2 JZ)6[ 5)"76:$_C$30IWE@_Y!TT'_/QM4(QLT5#((]D\R&92X<;,,TCS9
M5- RD0I:8DH%#22MB'F:TK%>RAX]S38EV<M8*S?4/19)1&$><G>JRGE>O63A
MI FX26466F2*X,V7+?5?*+7C/0>\I4>_G9@;W35,>,#HWJ%XID^X WK<.N8K
M?':V^1=J,IBF6\396BQX"-N%K),((UUJTJ.X:TRVK_*%C1UUQ4=P*LOA^HGZ
M2NZ$30H5FLP6[9'A^3_XHZC)%$_9$(.Z/K1%]AWB&,;9O8)"S]\\VK_8]_;M
MQO[,_UG_ALBNRE>BZH5^TX\GBU[Q41]^^;?[#S_<_B9N[.P%W9@Y\EUPS1BZ
M*[]2G4/>P<."1\?V#SQR! 'X!\:'<N&9^NO UR\'41&Q$$3^C:,)O#M)("*
M:1QWWSO_$>O^)8]C9])D1;)WY\@4HM@[W#C>1;2M. 7G*E"'WTPRK7 \ZFQ:
M-=6-W7T 6OA &?N*_2$Q /Q8";4>^;5T0S[TK>]%QWY*/>&TG1U?<<1;:-].
MU/8N[\VC*O;1SO[!<7E4J5KPDYJ W:JK>"TK_(E'8[;H2IH[*P#2(]BX]/E1
MEZ_4%QQ<EP[$KK]%O&77HO0HS/I:2&OS=<<ESP Q3KIT>!DBTOEDY6A>O%@X
M$J>**7 7WWO('89\BUM!=)O&.=QC,=B 2JV#*WL1KG3%[[ [MIXXCL$&]QH"
MP+@6@62U]](_4/?1=9Z9I]"[O'HB3@NNSWMQE7_>+,R+B#+MW53T.X""G"(<
MR#O>Q,)0ZW=S,1Z[PE=P6M ,)#T8LWI7D=Q!GYM+E4;8ZB9CVE5/M!:,QJ[-
MI5QF'FG-&XI9D\L);JK'RPOE[;P5R(IN=9]"YO>1AY@\T(05 6I<.3-[5S^6
M] Y7GXI3,YOPGVB^J30/^>:A+A<=%4DE7^<\R7,G41KED( @D5\\29+$^YZB
MZOH4$#5T?\ZA9*3 >G>&SZDWSX:_HO[9+5ARRL8A-NDRSB+[S1N$W%A+26[<
M$BCN8A# )ZY$,*R5]<)<AB-<05_)WFY1ZQY_R62<5MI,!LJ[^L74;NU7TM_7
M[M[">D]_;ALNY2S<4ODO/*W*/)\'";&8,E(KE'0S6-@MIX6$TH;4 !!FNVK#
M3N/JG@"G?'E78DO8V=6%Y8U4)#"F;) MOA&'3QXU53U)Q23L+D.%YXN+=(4S
M,#L!);I;!)42%#ESZ#T;]X^279ON^=[0K*@!ZI/KT&=XY,V3SRSV=VHBNQ*;
M]6Z;@^N<]X<-.U)Q$+_<W3LV?=7,OYX]'S9:30.(!H"QNX:N9%<>6M2%BMG%
M=,9;ZZ##EYB)'J'RB.YR+#P($9=@3[KGZ7NQ!? Y>6C#D<%%&$-&%ITD-X=0
M?PW)QYOP1D#8W0UX,(.Z3PW*J_>B2E.]"J I9.S.K#/I%6<<&H'%[,ZZ8ZZ;
M7(7L)@ZI\.@F3-QH\%H0$O42UV-2<!8L;#C6"AF65S#4 (#=..O*(FV#JK,Q
MFUIM'AJ7\ $B!:/!61-1*I^*"@FUN=A-I88$TE:B,!&S@=0AO]4S0:4FT<NC
M*ROJ^2Z#YU?7\);&D\U\;^6=RQ]AJ9J$4X_K\9RZ=%PZ _DAK3K]K50W\<(*
M>3DPXT"8!Z%2^! #U%+(YUH<EX=1HEO=LVX)-8]:V!FZ=[@B^HX'6ZG76&1[
MFG"_"!!>#M1.#Q %''#+.1&? 5U'.L(S+OT*?+5^ZK@7Y>QXLIQ72@6U2W&+
MN]P%E$U ;OZ5O*9,OW#T!,R^FO;&B0H[M<GAUL@7R%=AUP%.,'_^$?,M;I[<
M]EUJ4+AD#Q?Z#Y3LSC[?6%T1[[S]*S7$^T[/5)Y3B9N<(B'D!E8DSZST1"NK
ML#.V!";PO$*#@933@%X=?)I'3+IC-CPP+H?K>Y<*NM\1S?(/(E<%^*CP%\^Z
MR_0 I0T^Q;)>0Y\4D'@EW0_GUI$-#UC<(L2\DB0%8K@.7K+B2[JL- ..OM+@
M!@LG"%P><"^JT().>,%D]SID##HR2/EY49M/(8%W!*[%I/Y$X$F,+4?$$<,#
MZ1+T47>_4E]4U0B,7%;P9^/LNO %!A_+%CKP@I9S]I/B?T>D^GA\Y"M AY,&
M(%OW?5<W_"NH:(%F#4 JXS;("7]F?X_EX(GN#;HI/7/ ,(.O>'^V=)=X.O__
M:^*[WU*;?VN73U?U[[O[LQJY4$J=09;@N]%]NG=<!AO!%;7@;.=1=Z&+;/E-
MAJII.->"NGQG[C64SL&\D5&DO/$MAPB\?-M>(."N3V! N:>?"0?K;1Q?M^X<
M-RV3BCV]VESL!E!# FDK4)B(V13JD-^X-9W \1N^\ ,6L?A>&$7GN_I;QD,%
M/E@DS ^,[F;?J''FRS%=[G9\>7>+ WOUJ3BUN@G_4;"O. ]YV%^7B^:WL7/?
MG3-#]/*D! B R%A2 /U9@(1>CG<+0[JA)!+A$=VT!"82H2(!KB)[[_>$>R0Y
ME*@ KBB@S5GCHE9E?!OH.'UN3U+L[J1[,;7B^_8,CGSB;6$MXD]U; H2&CSV
MVU%.K#FWRX1<^,VU@XG=ICN06$FCKWH ,=MO%VQUU"XLS"]!/";Q0^:MPFA'
M*K@;4VSK?&'A]%B)9\Q%S:%\A#SQUT_0S52ADV -0%/Q375ED^^05*%,P0O5
MYJ6]ZY%)^^ @(CX*]LA>HL+O@T80&ISCA@+"Z7?R)=%5S-06^E0\5"=2S'=;
MK4!/P9=UPV"/#FY"818667*_URK@*LA\AVRNO/.?S[K+!6,)/G7+$HSF9<44
MYN#T,K4XCI+<51.09[>5R6^OHW\+X0MC#Q& C<OJ-K%VOS#+$D4AX!B@4(0X
MSZ)TS7]QKN%EB:!R;="$]U!"6DI#CG"0)!)<X<S/%!Z1H*;&OQU]3^]T)ELA
M:_X]U2'?!33?ZCYMMKGJ##Q.5].7'-,133>P,8<T'7/8^.F3@ RB2SK(CA,2
M%*3I/CG&M(A7>:XJ]W8C135(Q'D72R\(;818NFR(^ S",&?R40MXH5;$:1\3
M<=H&GEO29:7DW/X95JA/CF-Z2W=-W6=F4&\EZP?-6V8^.#YWVA;;O8K"!\/9
MVR*[KWD:/-24&R>-001.;SCN=Y)H]S@P!<A#P_'DT::A?7SUP0WH#]^ND3?E
M\_:3?H*+.!Z%:MX], .W([R G;!JV"0F,XGM^!#6 DM!+5+$%%1)BU?:!F]E
M.;5O+:28!"03H)DD;V\%9),DW3PV)H)R(DB'US1#XDE(/>'D$TX_"1@@G .2
M8(%H'I%,#%\\,KWO2;[*$Z<9KBXL#-D>)5D"P'_6]WN7RD<6H5;WF=IG(?8;
MQQ85]][/S#_<G#W?.7*NU'LL- :-<S7N0W[%M2?-X&+>DW3(73=5)V:*B'!E
MY&3(!=$("1&W5(@1DH*SST+0[A6J>4(?6'J=HG@\=NNKX/2BBUO>8,QV4D5R
MRX; LLXJ"MLP7I7(D4#%!8FR&1/4Y[++$(7#)Z;3W;:YSFIUYW<=-CR"-)A>
M?*,A.P"GVA7S$FWW4Y\BWXKGT]KQ38, "8%G' R7R7NX1VKR/]ITV$ULQ_Q*
M:-T9R;WSK-L^^UIL)1<C$)M)/C>1G:0_1FXH!<1V;"DA%@RFTC''(3A<D=(-
MY/2H>U*Y/YTW%*?UJ?"7N2=],0YS-%1";>/[T"F0**/Z-(D5 7W!X&GI:UD8
MGS=R.CK;D5/-:FWG4?LGG7+2[F$!TJV-JYMT81G%T4GY<)S*I\IG%+>4C$4>
MQ*A0WG%$(U&2 "<12,EB<3-L+-,GXQ+V\.<\_?-T^:WA6A!;)<07M2X#MP*/
MT^_U)<<.CV064[L/W &'(Q_-6%@O! >BU+:>H+SPZ[@<A]W\"CA+VU%F$&:#
M*"*U31D':.ZO>@"QEXX<S]3=.E5UC#VQUF&'4.EF0K_CN&':)2^"*!F+TV:4
M.(SB]**!R(/T2K*;;Q8!, G-Z2Z1;QPT&)\\@]7O:F'AL\T-+>H'"/)X2WV*
MV%E<<A'?KXH^0NX0<@AM4\=J4Q_:OO)X+WKI*6BV:W#:/1$^0G/@L"&>XYK,
M%@U?#6@4"XFF83?O'?+/085F@RNZ36XB[KBX;8/I5N(&A'K18-ELG(;:4 K%
M^\S"J9BCYGH,=+1+A$;0EK@.+5KRR_+R+324WH4DI&X1H:S<6W"#MCPNM?!6
MT6=&7:YWA]?2\[S*:=BM18WOM)F4S\%L'XJ4-S4,"1Z,(G'%[A"B0'D>J%E6
ML5 JC@?5YF*W@!H22)N!PD3,ME"'_,;/1E@6L2J,HOEQ8]_+P0\-;$)A(G:#
M4.4]9U$HF879%)1I;[4PD!]PZ7CBUG1IC',Y#KL&%W"65MC,(,SZ641JXS*Z
MQ)5_E$%)<.I$S02E5<%(Z1SL&JO <2;X*)Z 69-5R&X<;$2P4STM< 88FA\M
M-E6*G3,2O3H7<9=1XNPPU*I;2&QCA?43(3$N]4P^'!0EDA9,WS*+U7HDJF0R
M=B6N(X/B!Z.*9F)6]5KT=_-X5)PJM&(\*(.3/($$O%1M#I6F8C<+=?[31E$]
M#[-)U*"^<6.I/!.X(D: !6D@D^L?XJ5R<W#AO<U'U]DQ?^DN',^[I1[;VQ"G
M/9T<>PY]0'0KT1*DA3%UC'B*IMB'[*L-N4NL4W,#O?#>J1.!-G^)Y*LOJ20G
M02;TC[(XH;C<RHT%[:EX_*$<=!9/P&[&5;QF@LN"T9C-II+FQD&D! P1)/:X
M,<%ZU1E"SDCL.ES(7>:4(#L,L]86$]OX'""IHYW?LXN6H>7N9]&$WL_7M,K!
M.)5-C<>H-*]P)/)*O6JZ.[Y=]Q)@&;0>KS\N17]> 1HZEH? R:_W8SW$V1^K
M/^=_<R,O=$^VLX4>0%#E-;=/9[\\<"L<CM,+J?*97O?RQV)>_"HH;JJR2;"$
M";@HH[5+]BN"MI()TU/DLA"N:/2TE+DC#YRKSBCS='/H\4 ]?Z7[-''V*J11
MH=I*4[$KN3K_:76OGH=9\6M0W_CZ(?.^7N]<"OHOD1&78\.E_9^9Q]%!'X(O
MCL5#;[X'@T;4LFET37-H!@N[?;204-I@&@#";$%MV&EJ4C$F7%:T@K?A2H/Y
MY CL&G_!3>:R?/@Q9NV\)+*Q&P=(*$-Q05E5^)T9- G=*PVSDR/0:V!7X;0$
MAC2"_NCXOG-<[@21%>J8/Q:[5I9PF%;.G(&8=;2,W,8UU,QFQ_,1EXING).:
M?N8,Q*Z<1;RE-3,["K-:%M+:6"?YZHU.)ZON)"]J]5"K@H!=BVM+H]X-]<74
MFIVI,3'6376KL)%9O^=&8\CJ+D\$N%S)W//.U$N4X4>[[\3!>G$N3'$V=A=2
M2PJ99*;*5,RNHQX#34U!8KE*ULPE;A1=)4N-1G(+ \E!5BNF'H[,K=5'EJ>:
MVX;+)4)OJ?QW;C?V&0T@H?<?3:63/1BI"0:U7VG,3'/;DIC(&S/ ^19::"%V
M.2.(*-?]G.W@#W^'=V[U5_(!8?WR)YU'45#_+5Y!!6H]:L[M9&5X4Y_4"6CL
M3JH[^:6]5GNXF-U8A]PU[_K.22!O+$'$V]!V/;'KRMPXP!Q@(9#D72P<W?SK
MV?/EIC3A_"XDBLL'KAFG<\<,W?8O"G!4')WZ?.S>K*8DTBY+<3)FOU27A:8F
MD\##PX1L:18&OX)#$KC\1#+'M3Q15_>9O5_3?<VFI853L7L'=?Z+D\'Y\S#[
MA!K4=Y/^=4(DQ NPX&Q%6BJ8>J<EI=,G;18USDF*YT[6//HZ(<DS$5QG(".*
MHLOW-8Y'ZD(&-6#'L;V 'TU$^M2<Z:[-D7L?Z<YQ:5C&N]&_4>^6GO@>@(EI
MFFUJ1\?UF5?R%$1_R'"ZD&%DG'@BI"=,R"\J]L]W\[<M0LI(3!H):",<U9G_
M R\4!&02&M!)MH+0J)+]BOA ZQ4Q$]1>B5?NDP0/^Y3!9.4>2GOV<;ZYU;IS
MIROJ4>C6RMFYA4:KSJD?3]H3'L1.M$_)1OZS#R3(76>O+#=_1TP2)=R;&9,5
M&^ZDW"1N&7/ Y#9/QHV=8X\[TMFW$[4]\0*EN/<"O)B/^BM0OG%UVX-7?;BK
MAU<I9\>3Y;S2DK1N4V@X_61'4DIO7QN!PKR;;<=04VL+L,KG2CW >RT0DY/$
M3/P$:OF**0V1#_S8V]BB6B>D8SA'($'61_I.+!/AT2&3S P*)T_/S.2[=UR^
M*NF] U$6)Q9RQV+W,R4<9I)@EP,Q^X@R<AOG=!(P"95 1[/LOAGL;D>5C'EX
MI#(_GG3FBO-MQRL\#^=!%.>!;2VJ>1[UO:5_H.[FH-N?',=\859NE-8;)IQ6
M/(!THWU5/VB0[ZQZ9KK-FYEZG'=*$"G65,(B.D4=1VG9C&C:Q2*2B2YH)@X0
M37Q.-=D'9 ^[X4(J>BTK[)@P A2054K6CY&L%Z)$*2:02 J)()$ C20D<HR7
M@5&+^^]Z6*UYH:C=K5)0HP5,+>T-=8_,%CB7NP54IV:WGTH3$*\92KQ&KK]T
M-'(/KD9["_4,G/">XY%UBF\)['-B9**;K*C-#O)</'!D;N8C&#^L?^U7, !=
M;I2I[EJON?*X@G>?<6WW[IEG4(OS3)VS]&;1"?%<O$]=&(VKS,3I$!IPGWGZ
MK&H:YFVB.O'-K_8G, 1Q55P.()\]'ZD4HG_F9723R^38F9U$&<B#8\O#6\[X
M[!FJ,[0=%]^*GB#ZL/>/U&6.J5X[6 \>=K?04E+%I50U@&%V(6U9ZJ;"R';L
MZP@UH0(WT0$YW_X%V,E)H&]1J%@4.UO.5K<2@82V=VGQ.XNJ<W!:1BV.XR"Z
M8@+V.%J5_([;B>\%WE3\J(>8";R%PO?96QY?'J@X:-#MUX'#Z+[E(A&0! 82
MH2AJ;=5O_#"4/M"8T;:APT[WM@*)Y_HB:GA/+=^#W\"9R=" __*7&]C.4?>D
MN_[K@W[,ZTY8,@RGNZKB"SQ4T1A\RVXEI<VKS6*@!*"27[4NNA>JJAX/$;A\
M#IR62.NS?-XZ1[ZMSA%(G;EXE;2V!$+-59Z(4YWKD]^ACDO('8:"]\ZS;OOL
MJV;\[<P\<<W^B\ZG.>[C07>/^L(R/AL\(#8/S++6IV?^>W&,V 883D7O1D91
M5-D8$O)PLSU?'<>A(4$D0=$5"6@BDBBR6-Q<D<\W*Q(01M:/7^"/PX:DX\FN
ME9!&#&9Q28S<.%FA74FIP7EC1G+BDZEGUA:UKB'6AXES*>A48FVS;(NIW6)L
MRM8(V38+U9W'R0BNNYCTT74,2DVH8Z#LF9IWCF4Y+QQ3<18C;YEH!@:G\VDK
MER@";0 #>>S9AJ,VV2Y#]P[03)8CXR%G@%,M 4K]%TKM9!94Q I1=*&71A<R
MN"B(+8:-7<>0?8B3A$A)A)6495^'CU-'E8X;2D=--W'%I"OJ^2XS?&K><"O3
M;/'/C!O%LV[!$E2X<BI,Q.G@Z_.>>3&D8A;F.%&9]A87[P($TFN#LQ4_T!A)
M=^%+V"MS;A?W.2L=B%-#JWF+@HS<4<C#B'*:NRG]9F';5V:G7JS?*2U@PR[M
M_<ACGI# [NR+7<;68GO9+2#!X!_>QQ3QS<W7/_U+^)< UI_^'U!+ P04
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M*V=&6WA"5A".T$>00B-XP28/N@*Y;C>MG%@E2>0>_J%(=?/,*I LNWGEI*M
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M)FU/TYZU6D?\*X/\AF66LR)5"VG"")@)I;GX;QPK#OC!8H&T%0:J$!KR4KU
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M 'EHM8WV7<MX2IHB1ON^UF\]MEL/K3NC/:@9=W>=E_:@U7ZL=?$(=ZUF46]
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M.:98BY2Z94 NZ/@]>SP)FQ_(M^P =;&"1%M_9>:.9QZLPM(O@#&:S(KT2H
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M3_LI6QX]I6F;3B*E02V<>;4=SGQHM8WV7<MXJK7:_4'OI5)5.%@<4PI=I@U
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MVF\O[6:M4?\[^4!5/,9M+&CJ;\%8HOP,C!%>NSTT(V:(.^[2:).2&UEMR.^
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M07+S!/Z@CR,8?6.0MCOM%(<&H7(/1-5.KO15[>9D->>;>>JZ9_SHZNRP3Q1
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MU2U]Q@C#/JVV(JN +/'T9-7XC;XC[ 4A[QIW)8F*=VJU'(XRLA>IP.HS=R3
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M;J]:/3,?@\Q <BK)I'/18G[]/>=$Y (( B9*8O3S=*F02T2<??_M_Y1*'7?
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M8G8<H(0("<='G2N4.M8HZCDQ94JER\,CDUHD.8F T/P0GA8,[%& 7Y-NQX-
MA*]"/P6V;@B@A26@95>_AGU#NCR(!=)O3&\()C3I^8![W+7_2^BX'FV=@D7
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M"C@-H .3R9"\-&Y"WV./ ^$B2?0HG8"\$+X8HH_YP?9U=I>V--:Q-!KKI9[
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M8F\9>5Z2(R&U@(84S>%IM+T>5WY+4"B1%>(XG@@48S*BR'C!TMRHAW2(^WW
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ME:.JUK=W7]\^]P*E;@\]R^[#7F)-^Y'[/L?D2=3  \:#I*4P!^W[D=E!$($
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MF36;Y5HCH69%WWB(^SW/&L./03AT_OC_4$L#!!0    ( .8X'5D_9A_[DJ0
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MB! P L?OD46,.'%V3D0J$1)&0)6@\(@3Q^/$^UL;GPN7OC=Q>YIJX:]&*K=
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M0S<?DVJI7%FH/<;J6:$FWL4ZJF=H,<CRF&Z@NS;UV!_HGH#8^HJ XY8:WCJ
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M<%Q3CK/:DV G<DY=@<O:HZ^XD,O6>W,UC@U;0!G%<V/)?X1#]TA6F] ;5J5
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M,62=#U@1??66PE$LT6&YKL)Q-*%078: KU16H0A<TW&LPY :.!:;3N&(ULO
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M#V!=2K/LD*CY3K-T$NJT[DS0?=,A4.IO:N5PM$SPR&>;\=%$KLH%(FW7F<2
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MLRZCG9T]1H]OT8U^;MHU3$E.3]L8UDEV66CT@HYF].X&:(11(XP:_HC@DTJ
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MT9WTN6*>;R!!'B*/DA=MAX<=##B%8@(1A%.7U73+8.(L@@,"P@!#%>7((7$
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MB*F;HQD$;X; ;66 XF<U$Y@'RM:]T<:$GIZ\C<G;AY94=.^I<7 )]_J0V^,
M7L02=#.L60@<^/CQNX1D.UT " U8@6A?Y]S,Q.W>'"BZCF-QGVX 41]IN+,!
M/I2R!R:8V4[; ?>T2T+6TU"0#6(NJ.A%7LLCYW 18E?4Q"%"=*9XJV3+R9W
MS\6<A(^IUK]WCT[7L\0=&;PH%'VC\[2M!08H0?A,N2]K.^5C]WZ+VZ!,T#$(
MNJ[/707FO="+@4;<BDC<QDLY!!&<%.;-/K1?$NW=M N+CO/Y"LXJ<C1%+]?*
M9G;:X5M1P*6R\>;,:!PO<O8NO2\CT"$J?#\^P!71&'!/#%&PUO#7(X"00_KN
M<3,J88%*:.!Z!%Z6X#HWL+5Q H\6W !CU$5HCBHOX /SGQ5(=+^V.RHF(A?,
M.-L]UPE>PN(O^C>?[+R;!G^%DYTJ[NE#4\%S'=8YGG?3AXDJ %Z$ +9[QG ]
M4%Z'7XK2B7=Q"LCZ85ZV-=8-+/OPC_P&5)NQC8@K:L76K=M[Q4JK3Z4RK"Q,
MTQ6E*VNJ&EX],W6-W>?\8OJT>ZR>KTK/[<DREN7*B?1S(M/,MFJ?=HRRSI*:
M0,*"+N,LZ%[S[J7_^$3%ZU&37%5LY5'L=?EH"4+Q*'F#OE$)^QG=>)Z?\J];
M)X8/'R2NZ2&@-!&@ J9[>N?N)=:;ZWMX%#,DN$<Z7M H]Y)\F3^KL[P"VG%&
MS_ 3X7%RPG/$-97MI:QQE@?UE#4=<9.4.N!ZW3RH9T8__F%2H50J>GO$98 1
MRIE' -);3L*9*))$MRMZ7.<[$CPNO56T;EZQ6F1&R:MJ)1<OS874_!WY<Y/T
M5A>,1X3!#YX=UIY2?*&D-8:<8,]7XUZ8S36H$<)IY&YH\O5\[()G3P!!'#O>
M\)_R783Y]]1Q#BB >'B#J)ILE*KH17K!T>5&-!OK3Q=M]1-.ST\*L7[?%@0N
MMLB2\31#)=/=U"O9@^HQ?GOR:XH7T/!@U%UJ78_$CI);\<=R8=[DZ209GG3Y
MTBI'/H%ZX[;EU@$OUCT2\(KVHGB#]B([-6258/ZB,, HDDRGBLC2QMI+WNH_
M<:3\$N='0DKIEVJ?, @_$068CRXF9;FEUT@X0E9I3%M6J00E$QVBHM%0-)FX
M'?'T]P4!^D36UD]+<'*JWDUDAGQ3*=M:=\8I0E$=LA<+ 4S8S>YC-9:@.H+Z
M4IU2S>S(F.(3GEB23M[0*<_?& 7X!T2WZ]>OEMAZ8;9H/BOEY LCUFNM1CA[
M]CB&3D_4:&7QRG"9IYI45SC9T*G%;0NU;Q\"^ 4(;#<@\ _B 9]9KC"K+R=U
M,I.I4?K2>BTK48SY$[';H;^3Q@,ZS0C>B K\?%#@10CF/"&!S48ZW!NKB4K'
M#K-1;C5+EZ?3T3TDT \)_$M#M?:2]))]S;WD"BN6I#L:4^=?DX^]ZH<K/WPV
M4*L_6KVR8JRF=,+)8DYM5M0*SS10_#)]0_+J[5@MGV*\,)SO'KUU&1KZ6" %
M78K)PUZ>M<C5R],+@,!SK*P62.G=D)\K$+N%:,6\QVS=8LQ6>PS\HHR"4P5"
M<[JR8)>2S^8A)TIK.Z)F+ABHLJ/G?PH41(H04%][$0>._MEZS_7#JRZ,D<^I
M5]+QY^?92[$U)&<@30W;VD1\ED>GBJW:N_<>Q4?<YC 30<:QXJBTZ/LZX0ML
M]/J&)F1#8PZ\;_W[<9M1[&Z&,JRX)GXO[[A7H5)EJ]M4Z.8377W*:(\ORI_$
MVWV()*AY+3]>L4R,*_?H)_,9&$U5QEJ".0YJ?) F#O6\N==UW:[KFKK7=;W7
M=;W7=;W7=;W7=?VB=5T/%DBZA0X/>_6W5XNUZ,7*KPUY7YD['D87YJT-EF"Y
M4]\.,4X70(^-&=Q/405>AYT@P'"&OO5J822@<?E5[*")-15DUY.*8U8.Q^7_
M^3;1Q]F4F/8/M.)XJW/,NIS9NBY90&'&_J1,F8!IN5]0E1A%4B2=8FBDU 3O
MF[;8KT1+)7%8TJIDOOH"&'(9;XR8$4I&V;Y36X3)F)V@$\J*-95NGA_,7THL
MO#.Z?6<F6L_%'I=6@FL]\4FNVDK$U7H#WAG?OK-K3'LCQM0YLOS(V*-$7-8'
M!MNG=]_>2DHB3T]F4F?2R:28>)QMQV(LQ/KD]IVBF4WW:F!>[L3KIIVHAZ%]
M )\9W;TS]5P/)\E!+=:17T=L<;:0D^IBT8_MWED@[6B]T9E,.=FFJ?Y@MJR*
M9;8?W[US6%::8\/HKCC^]36_2)7%20J,^HG=.ZNYRF0^D%X;I*TDRRLK\]P>
MP?5,[LZ].TSW^E5@C4A[*"E0!(4SV<4(WKFS\H.A+NF]:IGA0+[%,9F)^MC.
M+^"=.RL?E<=4JK\<OW3"2IV<&[E*=5A=]%.[;U=KM5[[D2N"SDKKU2=<+$L_
MU>!NDKM3:HNQ9'A5R \[_--C,]Y=]6--$I((M>=6LK?HQ.2%SDU>2\F!/2]F
MV@J+:O[NW"HH==98ZOUJAU?#:45>Z9U^#MZZ9^]C!EL9)J.MI0)E1"7-\;/Z
M.+KH4^O-/V?E/A:5[$1"-Z<;6<>E"@4ELN::J N(#<QU==C=PGVUWD08LU1^
MVNGV:OU2CLJ,\R]GZ!*^IRCO(12&$! 1W2R7MZ<G\>:/'MXIKP?MS##!5BI\
M%R(FCLCQ32++93L9U.R]1>2:?)5HHNIZ':[U<&+ ]T:?\]B9:D>>H7(B#F?;
M*))()=^>V-3KV.-4E,654IW(P[&^< KJ3O2YXYKT$HP\.L;E/R6?DIV#)<.E
MY0<\O[-6PA3'\-TJX(=5=X3\\'T>:Z/9[;*7+NB+V;.<4[ERNUKN%TQ>;M#G
M9Z^+$%D ^V[6V$Q%8NX[/Q!MZDP#X1C71$<@&N^LMD6)0=)T/ *D;\DG8Y'8
MOYT@4>^UGI/''9$?>OF&!^>M<$XF&DG"1P=$V%;L9F Y J]$><)#2#S>2GJ?
MP^C1#XY?!1U6O^O."(33^K<* PB(;0N<Q>_T3B-;Y\8/X,2@4VHS"/:#.Q&-
MT/1](RZX$6XX<R29NB_[#= _%6'N&W$+&T&3D53TOA.WL!,1DKEOQ UL!)6(
MQ.\HZ80[@<-9-C.>3@U<+[(0WF,S<- #0X:/*0!U#M!$T",%S0SO=_\?NW!G
MA927HY7DJ:<<!&^N!>;5<IDN">Q0)[P3X#,N@.\]^.RQ'!@(EENL:PHY'SD.
M4+,6U(4'Q1^-#&%B^DZ;4P"L*R[648>8;]//SO)=A(=<-/2%::QNZ,BU@YK9
MV89V*FIRL,F=FCX%)+XP-;51RRUBDXCNVORNS=^9LJBKZ.+_^Q'[\<;T)_ I
MJH=FXU#JTE^:3SJ15L2)#9"00]@PW50DS0T8&.LV)"C)_"PG!=DF&+P@B@ ,
MAY<E$Q9'*VRUH#T9Q5][=LZ&G4+XNW#U\O,)$#(^6@B>J3"H"5P@V)*X7/]9
MOVQ*W0OC#[2B=:$QJTEU!QAG75Q<=V&Q&SAL%SF]7BE6>AT@Y<V1L:SH]G(C
M<SS,?"ARV&\.-X1;9/I#\^.&F1_>";FR(#OJ[*F>5@1EI)3'.M!!NH%BIG_\
MDPR1>[-Z3P7C;XJ(3LDE'N"^J0G>+)>XX+[I8'N7)4JC!1M^&F;32NNU03])
MB^ZREFQ<A"7ZD\?>BU!52"5,50VF'2]F[3)BB2A*=H_%S\(2KBUR4Q2SC9XN
M:E[<U$I<GG>>\J-Q,U6D%V1Y8K2MTF-->:$NHQ(:=GY6++3 ,YFQ"V+/K+;F
M2@'1?QPW?(K'H@<8X'/H[Z)@J.C6SS6);V#17(8GWSMA_OH,^$YTTHD!W\RR
MN/JD4-6Y^*(OQLJBN)CF%W_ W1Y-9X'S;U'CX*!P7V!_F+PU!L;ZXSXP..ME
M1@R\I1,WQ,=^>+8:C\E1/XK 8!1JOGUY9"<"@W^;FGOWA/K.4@?08:%-MEHU
M@TIT[/9+JEEXZC8*Y='5^2<>SA<2(_IY1:["E5<U/2IIDV8#\D\4:4[F?+CQ
M;^.>=P^SOSWWO!4N>V4.R%?-&E^.2]&.W<@H)64X?.FT%Y #XDB#Q./[&E1]
M;<>AMUXF\=.V(-V_ NG7Z8#EM6?WO1V'B&U_WJ36NQJ0] ?3,8%T!&*DL_:T
M%=9CY.159-N308WA.XU^#"%&)D0E=TW%7]_7?W@U%'ES*W&C7'49+/E!%EH(
M@%3U<:U,AK7!LMM:YE9,C(4L!$%CC-I5F*=@H+NW\9:]C5=@H)/#R0\RP3AL
M*FE*?:*55;U*+U[38%ANHM3;.-(C"9(^Q 9?P.?(XGZ'3E;\W>OX,<AX._%9
MMV8$WCJ8W+8IVTY5.K3>N+T'2N34P&K-'.\+BA>SF-.E^KQ-KC)D5R]1^2Y/
M-N":(!<E?187RV4<E#>")._,]B4PYADXJT.69R)=S<8[='DD3*2Z,>VE%G !
MHJB9X2''S8T[+[]TQ.3UHVUOG2_/[@D] 6^MQA-NUK0**IEY+E'#U9+G5A/$
M6Q#>)IE]57R_ME-T@\N"M#TU ,X<6T=<VAH@"(;T BY/&VE\[76X@/MT4S(P
M4#)(NHUJ._P-HL$)FSD;(,[,5D_*S&I-N/(@(7=:C2006G\B6HX/PGFMV_/G
MZ"H]4N1FAFS+U5DE.T=UHR#.3862J4,RX^OY52\=AGEGFA,!VT9S0M>+XW2)
M [:H= V6 R_5/P&VQW-(5E7S4[7V"+B,U>P-J"(WF_8;D$/<,,U]G47OCM/S
M.T[OO!7@+75"5<;)3(Q69K:]6I(STZAG+Z-!5JD2]]3*5TI*>/32$BLORZ%2
M1_R!PCCI4#1V&MAY3X?[NF[<>W+[/;G]JZ<C7]]Q>4]N_S[4='UWVTTGMU_;
M-/R:"O[V5NW"*?#O&0E?BL$NF15_]11XYFNBW%/[7;^_R>JG'M*G=J+.AQ0K
MO99>F<YL$7WN9(R>4>M>)I/W>5X=LQ5V->D(+5)^+9>69&JZ0*7J4;1 /!1G
MXE\W8."RN>QW#CC2(YKLO#*@6Z<JG)"H\0LK)CT-Z,N0NYJ:M :M57?9 =&9
M;E*B]3RA6$3N*/\H1#.'$G=O_!#_1OV??Q5;O#S2PWY",?A.2YP:M%(D)R7Q
M,L[,=.*I])KG!(T$RU<U9K9+<E_&I(T2BQ*A9.*0N_]K'J*?(4_]VE.Z7A#I
M39W87#QDA@F&S)R\?%&?>;7TQ[%25NA6*9IE.H,ZW_^36A6GR44LS>JC:=9*
M-SKQ.FW:EEZ51+&!N@]!]$?%0ZD]R15?^1#]UE3D328G?1'6VPLM4\MX_256
MMKM*MY05,V9[9E:TZ_/9J)&(@>%S=Z:LIB]6H<HF7LD9YC,(.Q.Q?0VI[^?P
MWSJ!Z=I,)M:Z)6'1KQ@*_U1/%%)E38K5KI\<GXH]C6R^5+6YE:IF^J.>WI'R
MN!T>.I)/A.*)0Z7%OH '\;RY\'</XNVF$WXQ@/G1[,1"JSK@.AE1R?1K7#Q+
M#Z*-40.9QLB/F S%4N=)T[T%1^+?6!KI=CGF,KCP@^Q!+1*Q[+0@/W*99#4S
MG5+Y06LZ0NR!_8YDXF#V[MWQ^,4<CU?@CI,#N@]2^(A-E:=2WFPJY48CRV4U
MLYR)XN[$R/V8@LAMU_WXQPGJUW;6G25G_=J3NB4/Y T%9]V:!7?K /(,.8)/
M5&*^M![#=9).5W7#R"E*HX3;FJ.4'^HLZ0QW7^4'4X5NBDG_=IAZ B:$RPI?
MN\]7HU&-1",U$\E9,I<HMX;#DCE>(&[$Z?"[A2:^=%FF+QUD>6PJTDWQ[K45
M[-E=I"?0B*/F0(ZMF'2Z4TYD5$IH"1E]@#4B1-TQ\HL[2P/Y[V[Z^SW8<D^Z
MT%^=0'AR(%QA*\/>>#5ND+/E:B@_UZTX6;I,6XFD:@Z>M*BXXO(-EFL5;38<
MKH[Z%*XN3\5"R?BW#<:\D7).=U;Z-':M)PQ68OHO2TZ8/.NMQ=R8%,N7"7T;
MQ.5)E"V(5H?/Y^*ME&E;3\H"\<T;!4+OKM53)G_]Y4SS])RS^XM$=<K-U-?7
MEIIEEDKC,@4>5MDP6<@RG4<NO^BD'L>@^_CTR"+"C^/X+69/=>DM!/@?2X ;
M]X_;MOTV^\H[,ZC9$_@V<??SN0<MR0; :_=@6.I6FM214]@8\2E*=VW3# (S
MJF[:!K0B6F/!@&#'!!#IK) =P1J&H(T ]E-SRZDJ:(*E&RN7C ;]L%QIQFV=
M3),97:MVN56Q-&A R ,@P4WA:RS#!F<RI ^ED=7X-N>D:0X.;,7F;V*;]^^Y
M@P@3K0+;Y,)IML5EB3K;JW*U=NO!3T:[ CE](HD7LNL)Q^F)\L 5%0RMAW@B
MDEA?LO1I4*0[MU!;V8+(>)6'*^>2K,$)6 ]A?-/..IB0%%</LJ;*&@@/5%U4
M?D_@:WQ5P\2\1[O/02_?HYN@K(NX:\-KCKU(1YUR:2$"VM!$6L\2$.-#KI..
MU08F8B*S_Y27Y$FQ*PY)7LJ_Z(FAL=)1P=>]+!SO0XY=\[#W88VJVJLIPE0'
M&70-LXKP=TU@6E!DP(&W++@^:(QFT[1=S&6^/)/FO),:=H1NC.:%6C.<-#<R
M:8JUW(=T#Q11\,'\L*C!]]IX0-@+P<UL2)&!JWEG.7VE1#K2I"881C]39F5+
M[ T77/R%>LHUYYUBW1[A@^YH- 3QP8Y2(IJMCDE8.@$F4U5? ;>>!%QETU;A
MEEAFA&B/@0F<&Q>RJA)SN#2$K!V[H3(<NZ"J:/#]Q4K12X/,T%#"_2Y@RZ/6
M)*ZRWVU7T>O\#86/;]B"80%#Q=OH+H6Y=P-Y4.RD$J5B0[&E/CO)+Q/S?+7Q
MXY]=)$V F2VHQ,Q[-!%89I/0(;PDK(5.K(!@.%LZ%B1"((:";!!SY/1"'IY_
MG0FAG7^K%HFB*2<FI*4(M-PLT=$L'\MM&#WDA]BOBQ4!D%BX<,((Y. R8=<@
M:U6!@+0[&F%6L,!Q3!D/[&E"2*\,?M*S./I9>)DL,JQ,&XL?_Y"178Q(0%VB
MHHV _X?D)Y:=A 3?&R+PLGE?L-D6,87+ YP+@G-3A"AJ!-(1Z&%K"2Q,IQ#+
MPA^O'PDW_YKR. ,'.](-&=%$$ZCP$R0(:!"! !%DL;K6#>0YRHQE,.260+0M
M>0Z1UA#.W'!)X7Q$5E#Y?K9#TNV.7 3&4]*T'C.OUY?R>L>.C5FK37-QFQ]T
M&G-.F4V@E&>2S $9#T=)2-Z28HF J"&C3Z#V7OVO2> E)OPU)MQ%1H(>W6C"
MF1!0TDS,$&':@Q?X'*0V6$U#8B@/-,@W*E$% $4>NQ0GJ%AY; D=:ZU.7&)&
MI(N^\7Y%+ 3S@K+I:Q"C'LW:*;H$)N1D(LZ6=#[[W*-&-RGQ[.JPO>(&[4<E
MK)4HAN4*M7*S@23>;ETW3^)%3FH([X'% 4>%]_]4-+J+CH,HG#S>T+R;!4&S
M@/;, J@2D#S $D1>$A,XV;%) /AS:>-\"=H+F/N7D%@M .',&;73>S7T3\VY
ML6&M.7YJ,U$%2-5>MOZ8JM>&["G4R'[6S.G&$,!-D8K:H3GLU2W/=B+<>J5;
M)CE)D,,7DQ.L2@KJ%OH-\V&#@L(F$,/R,NSPR4,!_]/7JI9$:ZE55IGTLY-B
MGWWJJ.G%P</\CS*-\Q$]"(X.KN*F=>]>^O&//D6#-GVVQ?]@5>@8-\  :!><
MQ0L1$P&RPHJ0H-J"FDX@#("<[X@879VHX6U FLNWGD*$"@0)DSS\B4: Y11H
M4-T9 (I9$ZHV3\WYA'YJ/??')>F/42/8PFGB.0&)<^:8,_0)IK=T@-[:D-Q,
M9V)F4>N.97&<UW7)Y(T6,.90<4+>$0%4HU)6EFJZ!4TE%4HK2,+PNC[2,))E
M3=8T0<!D"BJ;\# YK:@T8$B!9^J9\2 >K]6PLMD-A/&4S=%>QA__1'QJP>KI
M/"[0X]05$X]0L4.NW>26MOB ^KK /$Y2[>N2ZYV,867[ :?T)Q=?\(\5=&M<
MJ0*RK=BS[(P>I/7,HC/JXZSP__N/$+A3JQ93V9&6B''VJ#X:YAOMRG.LT:=W
M[\RJ32J^&&0&"B]'Z2[/YO./X44?)T!LWBGDRD.^'V4ECAZVPWPX.1Z9Y4:?
MV7UFQ8XENE)6CW'=RF@T:KP\3QH]U$J7=.^\J-L=R2'-QO(G ]^$F-WLRM8X
M [=6AR/8ZWK75I4LDY7U+->-4U&CQ@^D9,)%##)\FL1:!^[KH]NHTSOJUT2T
M08G12"RVSVV_I0$_X\4_^(CX'J?^P1\08:+&M8DF]\C5.ISKVS]X*.![_R]*
M,O!O830RP @_^),D1+-\N,:5RB8IVX"1J'1<JRJ+LY_>[*&*#Y0J_7/S9L/:
MB,<C<6<,^#C3N\<]IQ91%<*I"1Z\/X*S0K\;.R.;",LPWG%MRY@)6C?XO-DQ
M.;!! L5S[-_XS8;W6O=QE#NBH^+K8K%WXNL"4P\\'WE8AZJ^\%;-^XQ;R#P,
M#" HX05<A=]3W90=ED.N!8ATMIX9L/3\6X6!J:NVY=6JI$CRWY>MO_F10V('
M%SG__:,8!R:2N&_$)3?"F5,\0E+W9;_TLM^)_1JK3I.1^)W83[CL'PQF?U?9
M7K;$]&=C0,ZKY[Y&F6WFK3+;[Z8!D-=N)O&G9;9;\I*H.IYLSO=D.ZD&#!GR
M<@[^H,3VG4TNP2;)[25P=F[WOQ_N+>- JB],X4[#RP\U^_CB>^8B@Z^]9\Q>
MJ;,%:-ZR^M]HHK QS?_<1=E-BK+;T/C?1+UW(JUS--&P].DF3UP[F;HEJ  G
M>DZ=M**3E%)Q2/W:4[M"@HZK\^^9WM?LC^[Z\?=D[(BQ>*W-*D.[DZ\-C7%6
MXJS'T:B/,SSI4&Q/'; [,_Q)BF?\S@S7+GOP-C.8<\X:F@JM*H+*2/)<K'&#
M)W1^B](V0TPJ]K'DM3/EA<E:V(.LD6/QS<5#'O:<R[E!>C\^%/RF;5YB0L'P
M7,( (F(<G)AA&4+8<+86:^^?%XX@6@?*N>G(*";6B^99Q\55];F@6;+BM5JJ
MLK8^JLM"IQQ.)9,L.YM)#/NIN"/GA-8[LM4-[TU[PX,RBED9:0VSI)3)G%5*
MQ:MCI39"X4&[Q;]_^>'W:#O.OJYOUB_ZR+K6EK/2_+4A"%PYGB\WNM/BK/O\
MN7BN#ZUK<]'K1M-</4QFM&C\L3CKU[LU%JWKGHJ:_KJB('3OL1!.)Z*_0Y"V
MS2F*2I@#=15"20V0I>1UW)W;>A3^5%7U!>(G&2)5*'> :<GP*YP!D0,#(]@:
MCOAI D!HN@4(*O8S_LN+V!.<</6AK F:*,._3$NPG(A.0L#<E 4B7EB"<1_U
M*P*YT$"#U#6DC] @-6 1/@L.#7U"Z"@2<PVD?[JQ@VVH:N![G*G^<B(,;Y-=
MW9&Z5%6FBU-[E2R)9#Q66U67VDLJSG\XV-S)@P+6MB+:"-];3+3AM#ZUN7 V
MS-G#%WN1YE R0V17"?EDY.[F4#9,BQ@+ZA#MG"-(94U4;1R >;5USJ#B)L"8
M;N<0Y 6@"EH52 A)M0U! A55W,D;^, ND9DA64[VBJ;2+8:'(#%\-:;+QCEV
M:1Y3N'%#*BM*N=!5ZF1)*]=R.,CR+:BPG3J.@4+@)$Q4@6 @(#G^[06>8TRQ
M%0#/;"$!*@%-9S\$Q#LK"SQWXV%A$:CJ[X.NVI.>MKWI=:"C 7S@ !A4-7'[
M1 W]][\VS@M]!(UB:73CP</)@>5S5X;&D'D$PLYQI#"$KW\0U(6P,MVY)E(1
MQJ\A\>!C;;3$!$5&&.;?1.!OM"H[NX8"=0(+MYEXX/QL,US'N_C.N6@@H8&F
M<$118,^C)#2C=O;\SW>,.H@I]Z9#>+9^(D*[H5<NH S^TMNI6)P1J6T2N1@X
M/3R[VQCC09XYPE/7Y+*%8J5"I(M\O< VJRQ1:6<C)RXH\,X 49AEBVCS1+O
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M/(!W#^$<@Q+%KJR_^B/"W3[81_ 4G^Z_73UXYSQ+B&R?L6V==UTZ.;J]/FY
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M)3MKX&;4!!?D/$VA*+K/4#NMU )UO?T#T( S&<=GK&_?>XOENZ3=IJ%U?/;
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M6]79719V@^*]-'0L''#8/*0:U:$K%^,B[8G#1='I.B9$CZ000?YRZL]#BC'
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M ^#&7^CHQZ,*>&TNZ[8)9<$80*4K:]LRQ55@$8+H^%KUD-#;PE"F"<&[1(C
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M,#(T,#8S,%]D968N>&UL4$L! A0#%     @ YC@=6?9*,R!J1   (?8# !4
M             ( !K3L  ')D:&PM,C R-# V,S!?;&%B+GAM;%!+ 0(4 Q0
M   ( .8X'5G8\JK?VR8  /.. @ 5              "  4J   !R9&AL+3(P
M,C0P-C,P7W!R92YX;6Q02P$"% ,4    " #F.!U963O0E'\<  !?_@  %
M            @ %8IP  <F1H;"TR,#(T,#8S,'@V:RYH=&U02P$"% ,4
M" #F.!U9*Q4NCW1%  "5L@, &               @ $)Q   <F1H;"TR,#(T
M,#8S,'AE>#DY9#$N:'1M4$L! A0#%     @ YC@=63]F'_N2I   ]N4& !@
M             ( !LPD! ')D:&PM,C R-# V,S!X97@Y.60R+FAT;5!+!08
1    "  ( !D"  ![K@$    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>rdhl-20240630x6k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2023"
  xmlns:ifrs-full="https://xbrl.ifrs.org/taxonomy/2023-03-23/ifrs-full"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:rdhl="http://www.redhillbio.com/20240630"
  xmlns:srt="http://fasb.org/srt/2023"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="rdhl-20240630.xsd" xlink:type="simple"/>
    <context id="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_NewIFRSsAxis_rdhl_Ias1AmendmentsMember_6IOwDM618kGNeECku1awvg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:NewIFRSsAxis">rdhl:Ias1AmendmentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_8_20_2024_To_8_20_2024_ifrs-full_ClassesOfOrdinarySharesAxis_dei_AdrMember_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_ifrs-full_MajorOrdinaryShareTransactionsMember_RX7kvctHAE2Q6Z9cdW-n0g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">dei:AdrMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">ifrs-full:MajorOrdinaryShareTransactionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-08-20</startDate>
            <endDate>2024-08-20</endDate>
        </period>
    </context>
    <context id="Duration_3_23_2023_To_3_23_2023_ifrs-full_ClassesOfOrdinarySharesAxis_dei_AdrMember_xDmTu-XomE-QX_HsBKKWmA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">dei:AdrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-23</startDate>
            <endDate>2023-03-23</endDate>
        </period>
    </context>
    <context id="Duration_3_22_2023_To_3_22_2023_ifrs-full_ClassesOfOrdinarySharesAxis_dei_AdrMember_bVgXh3NRiE65_Oa5kANs7A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfOrdinarySharesAxis">dei:AdrMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-03-22</startDate>
            <endDate>2023-03-22</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_CounterpartiesAxis_rdhl_GaelanMedicalTradeLlcMember_ifrs-full_ProductsAndServicesAxis_rdhl_TaliciaMember_0Cf0K8YIskWI-fe7fzrpxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CounterpartiesAxis">rdhl:GaelanMedicalTradeLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdhl:TaliciaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_ProductsAndServicesAxis_rdhl_TaliciaMember_K2Ipuy8Jc065NyMxnj96Og">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdhl:TaliciaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_ProductsAndServicesAxis_rdhl_TaliciaMember_bJeEtRwXpUOUmdyfShRWow">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdhl:TaliciaMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_7_15_2024_To_7_15_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_rdhl_GlobalTerminationAgreementMember_srt_CounterpartyNameAxis_rdhl_MovantikAcquisitionValinorPharmaLlcHcrRedhillSpvLlcMember_4pd8zpat4UqiB1Cifr2ikA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rdhl:MovantikAcquisitionValinorPharmaLlcHcrRedhillSpvLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">rdhl:GlobalTerminationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-07-15</startDate>
            <endDate>2024-07-15</endDate>
        </period>
    </context>
    <context id="Duration_4_3_2024_To_4_3_2024_ifrs-full_ComponentsOfEquityAxis_rdhl_AmericanDepositoryShareMember_i9PW7CfORkKunWqEkaIlfA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">rdhl:AmericanDepositoryShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-03</startDate>
            <endDate>2024-04-03</endDate>
        </period>
    </context>
    <context id="Duration_1_26_2024_To_1_26_2024_ifrs-full_ComponentsOfEquityAxis_rdhl_AmericanDepositoryShareMember_6NQerov18ESxxuLFDfcOog">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">rdhl:AmericanDepositoryShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-26</startDate>
            <endDate>2024-01-26</endDate>
        </period>
    </context>
    <context id="As_Of_1_26_2024_ifrs-full_ComponentsOfEquityAxis_rdhl_IfrsWarrantMember_2DHClqF2Qk-paY34dAQVhQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">rdhl:IfrsWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-26</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_ProductsAndServicesAxis_rdhl_MovantikMember_vMAuogPiaUK-988AAqqd3A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdhl:MovantikMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_ProductsAndServicesAxis_rdhl_MovantikMember_NxqJvzQaaEK6GKQWpIqWZw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ProductsAndServicesAxis">rdhl:MovantikMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_3_21_2024_GMdZTmx5DEK7BZ7CRDSNdw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
        </entity>
        <period>
            <instant>2024-03-21</instant>
        </period>
    </context>
    <context id="As_Of_6_24_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_rdhl_DirectorsAndChiefExecutiveOfficerMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_rdhl_IfrsRestrictedStockUnitsRsuMember_o4Du92Jem0mmcqx2GDZY1g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">rdhl:DirectorsAndChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">rdhl:IfrsRestrictedStockUnitsRsuMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-24</instant>
        </period>
    </context>
    <context id="As_Of_6_24_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_rdhl_IfrsRestrictedStockUnitsRsuMember_w7Isi7m0tka2iRJ24DO5Fw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">rdhl:IfrsRestrictedStockUnitsRsuMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-24</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_UnobservableInputsAxis_ifrs-full_InterestRateMeasurementInputMember_teenRBiuRkGg1uO4tRE-mQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:InterestRateMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_UnobservableInputsAxis_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_mTVtiUNnuUSkyBFbN8TE6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_UnobservableInputsAxis_ifrs-full_InterestRateMeasurementInputMember_Vcvjf-Um0kSPabpRIwMIwA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:InterestRateMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_UnobservableInputsAxis_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_zejd0Q0P70OkmQekwOSjkw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_UnobservableInputsAxis_ifrs-full_InterestRateMeasurementInputMember_41fW1aKaCUmxWkrY4H-2hg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:InterestRateMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_UnobservableInputsAxis_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_KazBZZXGN0muagfyEB6zqQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:TopOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_UnobservableInputsAxis_ifrs-full_InterestRateMeasurementInputMember_oOWejR1pzEKHOWOqEBCqlw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:InterestRateMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_UnobservableInputsAxis_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_wfwD34Lnw0G6p7TDXvEZ7A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:RangeAxis">ifrs-full:BottomOfRangeMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:UnobservableInputsAxis">ifrs-full:HistoricalVolatilityForSharesMeasurementInputMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_7_15_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_rdhl_GlobalTerminationAgreementMember_srt_CounterpartyNameAxis_rdhl_MovantikAcquisitionValinorPharmaLlcHcrRedhillSpvLlcMember_ZmyihQPxD0iGrsKP1MNtWw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">rdhl:MovantikAcquisitionValinorPharmaLlcHcrRedhillSpvLlcMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:NonadjustingEventsAfterReportingPeriodAxis">rdhl:GlobalTerminationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-07-15</instant>
        </period>
    </context>
    <context id="Duration_4_3_2024_To_4_3_2024_ifrs-full_ComponentsOfEquityAxis_rdhl_IfrsWarrantMember_MJAPHqwRZkK8j3cPNSQ-DQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">rdhl:IfrsWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-03</startDate>
            <endDate>2024-04-03</endDate>
        </period>
    </context>
    <context id="Duration_4_3_2024_To_4_3_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfEquityComponentOfConvertibleInstrumentsMember_eYL19KtWRk2RX2MXCnVjkw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:ReserveOfEquityComponentOfConvertibleInstrumentsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-04-03</startDate>
            <endDate>2024-04-03</endDate>
        </period>
    </context>
    <context id="Duration_4_3_2024_To_4_3_2024_xAzFjFHyA02Un3POz8VYMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
        </entity>
        <period>
            <startDate>2024-04-03</startDate>
            <endDate>2024-04-03</endDate>
        </period>
    </context>
    <context id="Duration_1_26_2024_To_1_26_2024_ifrs-full_ComponentsOfEquityAxis_rdhl_IfrsWarrantMember_try5X0D-VEimOWrLlTXBdw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">rdhl:IfrsWarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-26</startDate>
            <endDate>2024-01-26</endDate>
        </period>
    </context>
    <context id="Duration_1_26_2024_To_1_26_2024__j6PCY90FUmwW0bnS-0ZyQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
        </entity>
        <period>
            <startDate>2024-01-26</startDate>
            <endDate>2024-01-26</endDate>
        </period>
    </context>
    <context id="As_Of_4_3_2024_ifrs-full_ComponentsOfEquityAxis_rdhl_AmericanDepositoryShareMember_nhnjGt_XE0ij6Oga9k_JNw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">rdhl:AmericanDepositoryShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-04-03</instant>
        </period>
    </context>
    <context id="As_Of_1_26_2024_ifrs-full_ComponentsOfEquityAxis_rdhl_AmericanDepositoryShareMember_earRV5J5lEem3IOZmkajMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">rdhl:AmericanDepositoryShareMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-01-26</instant>
        </period>
    </context>
    <context id="As_Of_3_21_2024_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_PreferenceSharesMember_RA41LoI2wE2KQ4D5_pwTlQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:PreferenceSharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-21</instant>
        </period>
    </context>
    <context id="As_Of_3_21_2024_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember_Ej8jvZlqGkeT63oCOmaVmg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfShareCapitalAxis">ifrs-full:OrdinarySharesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-03-21</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_rdhl_IfrsEmployeeStockOptionMember_ITJCorKc8UWnxsVgxsWbxA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">rdhl:IfrsEmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_rdhl_IfrsRestrictedStockUnitsRsuMember_5fNRhXT34kedMYDPV9PNfA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">rdhl:IfrsRestrictedStockUnitsRsuMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_6_24_2024_To_6_24_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_rdhl_DirectorsAndChiefExecutiveOfficerMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_rdhl_IfrsRestrictedStockUnitsRsuMember_HlO_DU02TUiIerX8stVCzQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfRelatedPartiesAxis">rdhl:DirectorsAndChiefExecutiveOfficerMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">rdhl:IfrsRestrictedStockUnitsRsuMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-24</startDate>
            <endDate>2024-06-24</endDate>
        </period>
    </context>
    <context id="Duration_6_24_2024_To_6_24_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_rdhl_IfrsRestrictedStockUnitsRsuMember_sjZ0svU9fUaW52OaNR-8sQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:TypesOfSharebasedPaymentArrangementsAxis">rdhl:IfrsRestrictedStockUnitsRsuMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-06-24</startDate>
            <endDate>2024-06-24</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember_ifrs-full_ClassesOfLiabilitiesAxis_rdhl_FairValueOfWarrantsMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_bh9izY_nwk2QNVQRdIq8MQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">rdhl:FairValueOfWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember_ifrs-full_ClassesOfLiabilitiesAxis_rdhl_FairValueOfWarrantsMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_KpTPdCsFCkCR24LGQXoX_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">rdhl:FairValueOfWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember_ifrs-full_ClassesOfLiabilitiesAxis_rdhl_FairValueOfWarrantsMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_0zRaQna2fk2MTgU3jRhH5w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">rdhl:FairValueOfWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember_ifrs-full_ClassesOfLiabilitiesAxis_rdhl_FairValueOfWarrantsMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_Y9wiYGhs4U-MxGWOO7SysA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">rdhl:FairValueOfWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_hQziAgWDuESfatZXZuDWKg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_WUJJNdtgkUmTbxC0es9vGA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_WC_VpnnmJEurMcXdPGqAAA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_ME6JQrLs4kCObaTBOn_26Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_f7VpnqzdG0eBMbQ0_PH15g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_FdLWqdRnzEeYm1z5Q53cfg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_ClassesOfProvisionsAxis_rdhl_RebatesAndPatientDiscountProgramsMember_qttEPmHMoE6w_c5KccwpGw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">rdhl:RebatesAndPatientDiscountProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_ClassesOfProvisionsAxis_rdhl_ProductReturnsMember_HT0SSNr17UuTj9RHXWQHKg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">rdhl:ProductReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_ClassesOfProvisionsAxis_rdhl_RebatesAndPatientDiscountProgramsMember__3ztoVhkKk2SJ4D3UbPO_A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">rdhl:RebatesAndPatientDiscountProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_ClassesOfProvisionsAxis_rdhl_ProductReturnsMember_9x6Pj5KuWkWJDcCsTqsLnA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">rdhl:ProductReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2024_To_6_30_2024_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember_ifrs-full_ClassesOfLiabilitiesAxis_rdhl_FairValueOfWarrantsMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_XsHFmv9nQky9EyNZwd-RWw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">rdhl:FairValueOfWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2024-01-01</startDate>
            <endDate>2024-06-30</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember_ifrs-full_ClassesOfLiabilitiesAxis_rdhl_FairValueOfWarrantsMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_JUJ1h0rhhUi0IPjIFY9Y2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:CategoriesOfFinancialLiabilitiesAxis">ifrs-full:FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfLiabilitiesAxis">rdhl:FairValueOfWarrantsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:LevelsOfFairValueHierarchyAxis">ifrs-full:Level3OfFairValueHierarchyMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="ifrs-full:MeasurementAxis">ifrs-full:AtFairValueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_iXJ3_uR3qkyjYahn5cu1hg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_ULnTaRXf1k2sfiQlt2ZrxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_pt7V-puUQUK2FnS6Bj5qwA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_LOEJOyxWXU26M6zuQvwiJw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_ZNNvPFR40UGCID0ZfJxAmQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_WIaiT8u6y0CHEd67KoeeuQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_cnP-pEbtykmp58TplJXbRw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_QWxXKkKqr0CvPrcIr11d4g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_MYPHkdkUC02VHj9u1f1FRA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_t4QHHZ5Wp0OEOQnVhfCjxQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:SharePremiumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_ZgoHvobcPU2rpUbaBgakWg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_Y7iGsPaVjkeiB7bpTvHRwg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ComponentsOfEquityAxis">ifrs-full:IssuedCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_ClassesOfProvisionsAxis_rdhl_RebatesAndPatientDiscountProgramsMember_CqyXkqtSmEKb7iUSQ8eaSw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">rdhl:RebatesAndPatientDiscountProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_ifrs-full_ClassesOfProvisionsAxis_rdhl_ProductReturnsMember_QRm2PIhBJEeuckWrAEejMg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">rdhl:ProductReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_ClassesOfProvisionsAxis_rdhl_RebatesAndPatientDiscountProgramsMember_uIEoPLILYUedGsgrxLouxA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">rdhl:RebatesAndPatientDiscountProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_ifrs-full_ClassesOfProvisionsAxis_rdhl_ProductReturnsMember_JgwA-XfDBkSzQ2XdwWxN8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">rdhl:ProductReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_ifrs-full_ClassesOfProvisionsAxis_rdhl_RebatesAndPatientDiscountProgramsMember_LALfYhyhQ0qxyfiZPt60JA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">rdhl:RebatesAndPatientDiscountProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_ifrs-full_ClassesOfProvisionsAxis_rdhl_ProductReturnsMember_P7rAd3_jxEamZoSwvrmIKw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">rdhl:ProductReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_ClassesOfProvisionsAxis_rdhl_RebatesAndPatientDiscountProgramsMember_vf1AdzJz3Uqw4ZUCrYrNWQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">rdhl:RebatesAndPatientDiscountProgramsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_ifrs-full_ClassesOfProvisionsAxis_rdhl_ProductReturnsMember_8Uz3eWP1LEa7NOwt5dXb2Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
            <segment>
                <xbrldi:explicitMember dimension="ifrs-full:ClassesOfProvisionsAxis">rdhl:ProductReturnsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2023_XZFu_w7MpEqlzzSlD3xkQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
        </entity>
        <period>
            <instant>2023-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_jV2f_7krOUScpr2kI0mJcw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2024_lm1Lh8C52kquuyx0qsrPDw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
        </entity>
        <period>
            <instant>2024-06-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2023_XGghR9I2w0KmrTtJVNkj1A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
        </entity>
        <period>
            <instant>2023-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001553846</identifier>
        </entity>
        <period>
            <startDate>2023-01-01</startDate>
            <endDate>2023-06-30</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_shares_XGdimIWcf0OdGjo7fryoGw">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_CKQZNDkEe0eDAz2GdtdFSg">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Divide_ILS_shares_LnWGktS0CkGllLF6Jva9vA">
        <divide>
            <unitNumerator>
                <measure>iso4217:ILS</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_pure_yhcnVVwWa0i2EX2hTkNGPA">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Standard_ILS_19CAiapBLkWinll-yZ3PnA">
        <measure>iso4217:ILS</measure>
    </unit>
    <unit id="Unit_Standard_installment_wykoJbCfrk-_WeAKgSm6lA">
        <measure>rdhl:installment</measure>
    </unit>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      id="Tc_s0pP6sPyDkuJetUda52EoQ_2_1">0001553846</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      id="Tc_HK_UcVhzCEmrb5mNgLQ2bQ_3_1">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      id="Tc_MTX1Z99tJkKfRjYNAjcHTg_4_1">2024</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      id="Tc_V9DSx8kOwkGvWGvfQ9qEKg_5_1">Q2</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      id="Tc_tb2-lXCIREWbfbV83Pavlw_6_1">false</dei:AmendmentFlag>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      id="Tc_jC7umccUU0ytNG16r8Tz9w_7_1">RedHill Biopharma Ltd.</dei:EntityRegistrantName>
    <dei:DocumentType
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      id="Tc_W35658ZSGkquL37jqtNpkw_8_1">6-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      id="Tc_BP9nG0iBWk-aJHaM3gy7SA_9_1">2024-06-30</dei:DocumentPeriodEndDate>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      decimals="2"
      id="Hidden_CBPMNzwfuUORcl_djyrohw"
      unitRef="Unit_Divide_USD_shares_CKQZNDkEe0eDAz2GdtdFSg">0.00</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:DilutedEarningsLossPerShare
      contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw"
      decimals="2"
      id="Hidden_IpNvRjpMP0apmTzhzb5k4g"
      unitRef="Unit_Divide_USD_shares_CKQZNDkEe0eDAz2GdtdFSg">0.04</ifrs-full:DilutedEarningsLossPerShare>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      decimals="-3"
      id="Hidden_kZxc1tjo6ki8z7duotg_RQ"
      unitRef="Unit_Standard_shares_XGdimIWcf0OdGjo7fryoGw">11760458000</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:AdjustedWeightedAverageShares
      contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw"
      decimals="-3"
      id="Hidden_Hy0KM8Qg3kS14kbM4Z6Obw"
      unitRef="Unit_Standard_shares_XGdimIWcf0OdGjo7fryoGw">1277931000</ifrs-full:AdjustedWeightedAverageShares>
    <ifrs-full:CurrentDerivativeFinancialLiabilities
      contextRef="As_Of_12_31_2023_XGghR9I2w0KmrTtJVNkj1A"
      decimals="-3"
      id="Hidden_E1bPtC31Lk21mAsoCYSzDA"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">741000</ifrs-full:CurrentDerivativeFinancialLiabilities>
    <ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_rdhl_IfrsEmployeeStockOptionMember_ITJCorKc8UWnxsVgxsWbxA"
      decimals="0"
      id="Hidden_nMtd2n9yDkm_DmI_AXUlBw"
      unitRef="Unit_Standard_shares_XGdimIWcf0OdGjo7fryoGw">24000</ifrs-full:NumberOfShareOptionsForfeitedInSharebasedPaymentArrangement>
    <ifrs-full:Revenue
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      decimals="-3"
      id="Tc_IHuYtkXDgEiTBPTUvVeOCA_5_3"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">2572000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw"
      decimals="-3"
      id="Tc_IyTPWMIuc0u6y55nGUJJXw_5_5"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">5395000</ifrs-full:Revenue>
    <ifrs-full:CostOfSales
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      decimals="-3"
      id="Tc_9xd_r5bivkiNWi-bqqJUUQ_6_3"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">1404000</ifrs-full:CostOfSales>
    <ifrs-full:CostOfSales
      contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw"
      decimals="-3"
      id="Tc_97gpHXR4-UKy0Es5ao6xhQ_6_5"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">2418000</ifrs-full:CostOfSales>
    <ifrs-full:GrossProfit
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      decimals="-3"
      id="Tc_gGPDUfmH5UiBM6FXSTuULw_7_3"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">1168000</ifrs-full:GrossProfit>
    <ifrs-full:GrossProfit
      contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw"
      decimals="-3"
      id="Tc_7CUneKiLk0-jlYt2rZdPVQ_7_5"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">2977000</ifrs-full:GrossProfit>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      decimals="-3"
      id="Tc_dJlBJJfeyUikk973x2Gvxw_8_3"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">659000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw"
      decimals="-3"
      id="Tc_pyNYwcFNEUWIMgvWZEJ1Mg_8_5"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">2331000</ifrs-full:ResearchAndDevelopmentExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      decimals="-3"
      id="Tc_kuT99nBNrku0o4EEXl_dEw_9_3"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">3487000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SalesAndMarketingExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw"
      decimals="-3"
      id="Tc_ap2TM926pEiJI7mZ4fhveQ_9_5"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">9632000</ifrs-full:SalesAndMarketingExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      decimals="-3"
      id="Tc_82E-5Xc4Fki6gjSOnEsYPA_10_3"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">5470000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:SellingGeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw"
      decimals="-3"
      id="Tc_X36HKp1Xaka3UnSWGoGBCg_10_5"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">9335000</ifrs-full:SellingGeneralAndAdministrativeExpense>
    <ifrs-full:OtherOperatingIncomeExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw"
      decimals="-3"
      id="Tc_eYL-bKB2w0-wRCm7eoUkBg_11_5"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">42993000</ifrs-full:OtherOperatingIncomeExpense>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      decimals="-3"
      id="Tc_cfXgUWwiw0GBic3AZmFQRQ_12_3"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">-8448000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:ProfitLossFromOperatingActivities
      contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw"
      decimals="-3"
      id="Tc_IqwokPSlZUuu6a5AB41Cvw_12_5"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">24672000</ifrs-full:ProfitLossFromOperatingActivities>
    <ifrs-full:FinanceIncome
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      decimals="-3"
      id="Tc_jLxtsxHsR0K2r2_P-Z_Y_g_13_3"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">7157000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceIncome
      contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw"
      decimals="-3"
      id="Tc_A03AdLYNjEmaSHe05zDzxw_13_5"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">28677000</ifrs-full:FinanceIncome>
    <ifrs-full:FinanceCosts
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      decimals="-3"
      id="Tc_HURuSj0gWkKT53m2U1fCEQ_14_3"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">1797000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceCosts
      contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw"
      decimals="-3"
      id="Tc_FhUgL7QGCE6sq7I_KDkE6g_14_5"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">2347000</ifrs-full:FinanceCosts>
    <ifrs-full:FinanceIncomeCost
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      decimals="-3"
      id="Tc_VP7fxodCeEKj0RZe5rEdGg_15_3"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">5360000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:FinanceIncomeCost
      contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw"
      decimals="-3"
      id="Tc_az7cnhcNkUu3erf1vda51w_15_5"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">26330000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      decimals="-3"
      id="Tc_PbQL8KUp0kGZ-B2SAR6s8A_16_3"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">-3088000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw"
      decimals="-3"
      id="Tc_gWPi29_u_ECuQeMWBOLPgA_16_5"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">51002000</ifrs-full:ProfitLoss>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      decimals="2"
      id="Tc_MEEAkvXTeEWs7RKK5Xrizw_17_3"
      unitRef="Unit_Divide_USD_shares_CKQZNDkEe0eDAz2GdtdFSg">0.00</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:BasicEarningsLossPerShare
      contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw"
      decimals="2"
      id="Tc_Qd37aRWMs0ywW9g3QzgJvw_17_5"
      unitRef="Unit_Divide_USD_shares_CKQZNDkEe0eDAz2GdtdFSg">0.04</ifrs-full:BasicEarningsLossPerShare>
    <ifrs-full:WeightedAverageShares
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      decimals="-3"
      id="Tc_Fzz9dGzCxkucKZe72K0iog_18_3"
      unitRef="Unit_Standard_shares_XGdimIWcf0OdGjo7fryoGw">11760458000</ifrs-full:WeightedAverageShares>
    <ifrs-full:WeightedAverageShares
      contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw"
      decimals="-3"
      id="Tc_8ERgVYraMUas4crENwAqUA_18_5"
      unitRef="Unit_Standard_shares_XGdimIWcf0OdGjo7fryoGw">1277931000</ifrs-full:WeightedAverageShares>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_6_30_2024_lm1Lh8C52kquuyx0qsrPDw"
      decimals="-3"
      id="Tc_59TH-dCVm0CFBONBtHiTcg_6_2"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">7277000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_12_31_2023_XGghR9I2w0KmrTtJVNkj1A"
      decimals="-3"
      id="Tc_wqWWHAwzlUKw2wMEP6bF7A_6_4"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">5569000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CurrentRestrictedCashAndCashEquivalents
      contextRef="As_Of_6_30_2024_lm1Lh8C52kquuyx0qsrPDw"
      decimals="-3"
      id="Tc_rFEso0AEP0yw4MRXcc89YA_7_2"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">739000</ifrs-full:CurrentRestrictedCashAndCashEquivalents>
    <ifrs-full:CurrentRestrictedCashAndCashEquivalents
      contextRef="As_Of_12_31_2023_XGghR9I2w0KmrTtJVNkj1A"
      decimals="-3"
      id="Tc_6p1QWWdkbUq_tIDvY5C-vw_7_4"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">790000</ifrs-full:CurrentRestrictedCashAndCashEquivalents>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="As_Of_6_30_2024_lm1Lh8C52kquuyx0qsrPDw"
      decimals="-3"
      id="Tc_GJEYznSuQEybrkQzMva2rg_8_2"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">974000</ifrs-full:TradeAndOtherCurrentReceivables>
    <ifrs-full:TradeAndOtherCurrentReceivables
      contextRef="As_Of_12_31_2023_XGghR9I2w0KmrTtJVNkj1A"
      decimals="-3"
      id="Tc_R5WwssLSDUKBHyHAdoWjAA_8_4"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">2591000</ifrs-full:TradeAndOtherCurrentReceivables>
    <rdhl:CurrentPrepaidExpensesAndReceivables
      contextRef="As_Of_6_30_2024_lm1Lh8C52kquuyx0qsrPDw"
      decimals="-3"
      id="Tc_peKmoFEf5EGIKBFrT13u-w_9_2"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">2909000</rdhl:CurrentPrepaidExpensesAndReceivables>
    <rdhl:CurrentPrepaidExpensesAndReceivables
      contextRef="As_Of_12_31_2023_XGghR9I2w0KmrTtJVNkj1A"
      decimals="-3"
      id="Tc_4bUSnCF77Ei_ytU6g11hFQ_9_4"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">2801000</rdhl:CurrentPrepaidExpensesAndReceivables>
    <ifrs-full:Inventories
      contextRef="As_Of_6_30_2024_lm1Lh8C52kquuyx0qsrPDw"
      decimals="-3"
      id="Tc_gpmozm_FQUKCb1LTDe2_og_10_2"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">3804000</ifrs-full:Inventories>
    <ifrs-full:Inventories
      contextRef="As_Of_12_31_2023_XGghR9I2w0KmrTtJVNkj1A"
      decimals="-3"
      id="Tc_DP3FOd1WYkSbbJ1QB2ZJcA_10_4"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">4389000</ifrs-full:Inventories>
    <ifrs-full:CurrentAssets
      contextRef="As_Of_6_30_2024_lm1Lh8C52kquuyx0qsrPDw"
      decimals="-3"
      id="Tc_396beK-5sk2S-z1xthFvYQ_11_2"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">15703000</ifrs-full:CurrentAssets>
    <ifrs-full:CurrentAssets
      contextRef="As_Of_12_31_2023_XGghR9I2w0KmrTtJVNkj1A"
      decimals="-3"
      id="Tc_AxYdcVTSkkW4IFqbFjdcCA_11_4"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">16140000</ifrs-full:CurrentAssets>
    <ifrs-full:NoncurrentRestrictedCashAndCashEquivalents
      contextRef="As_Of_6_30_2024_lm1Lh8C52kquuyx0qsrPDw"
      decimals="-3"
      id="Tc_Ez2DC1AaTEW_xHG8Iglhgg_13_2"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">143000</ifrs-full:NoncurrentRestrictedCashAndCashEquivalents>
    <ifrs-full:NoncurrentRestrictedCashAndCashEquivalents
      contextRef="As_Of_12_31_2023_XGghR9I2w0KmrTtJVNkj1A"
      decimals="-3"
      id="Tc_mIdJA2NRX0WSOjmIFIj27A_13_4"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">147000</ifrs-full:NoncurrentRestrictedCashAndCashEquivalents>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_6_30_2024_lm1Lh8C52kquuyx0qsrPDw"
      decimals="-3"
      id="Tc_blqvq4zZq06T5hIJLKkESA_14_2"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">147000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:PropertyPlantAndEquipment
      contextRef="As_Of_12_31_2023_XGghR9I2w0KmrTtJVNkj1A"
      decimals="-3"
      id="Tc_39MTpr3lL0KIjCnokq2QPQ_14_4"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">193000</ifrs-full:PropertyPlantAndEquipment>
    <ifrs-full:RightofuseAssets
      contextRef="As_Of_6_30_2024_lm1Lh8C52kquuyx0qsrPDw"
      decimals="-3"
      id="Tc_6O4WU0p4CkqLWGqn9eznKw_15_2"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">469000</ifrs-full:RightofuseAssets>
    <ifrs-full:RightofuseAssets
      contextRef="As_Of_12_31_2023_XGghR9I2w0KmrTtJVNkj1A"
      decimals="-3"
      id="Tc_xH52XkFFvEap8Od9YRKexQ_15_4"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">989000</ifrs-full:RightofuseAssets>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_6_30_2024_lm1Lh8C52kquuyx0qsrPDw"
      decimals="-3"
      id="Tc_AVH4QjFT9EK_JuO87tlLHg_16_2"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">5562000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:IntangibleAssetsOtherThanGoodwill
      contextRef="As_Of_12_31_2023_XGghR9I2w0KmrTtJVNkj1A"
      decimals="-3"
      id="Tc_bHCbK5uLAkibbP4JNQEomw_16_4"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">5578000</ifrs-full:IntangibleAssetsOtherThanGoodwill>
    <ifrs-full:NoncurrentAssets
      contextRef="As_Of_6_30_2024_lm1Lh8C52kquuyx0qsrPDw"
      decimals="-3"
      id="Tc_OmU3tWRXF0WSDnOzBTE68g_17_2"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">6321000</ifrs-full:NoncurrentAssets>
    <ifrs-full:NoncurrentAssets
      contextRef="As_Of_12_31_2023_XGghR9I2w0KmrTtJVNkj1A"
      decimals="-3"
      id="Tc_hRguDc2fb0ai3z4Nsmt-GA_17_4"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">6907000</ifrs-full:NoncurrentAssets>
    <ifrs-full:Assets
      contextRef="As_Of_6_30_2024_lm1Lh8C52kquuyx0qsrPDw"
      decimals="-3"
      id="Tc_cz0z2ErcPkeKien7sD6AZw_18_2"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">22024000</ifrs-full:Assets>
    <ifrs-full:Assets
      contextRef="As_Of_12_31_2023_XGghR9I2w0KmrTtJVNkj1A"
      decimals="-3"
      id="Tc_KJOhZPaNJUOritMMTQG6oQ_18_4"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">23047000</ifrs-full:Assets>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="As_Of_6_30_2024_lm1Lh8C52kquuyx0qsrPDw"
      decimals="-3"
      id="Tc_CJchPB-pU0S_8iZ6MHXbCw_22_2"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">1912000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:TradeAndOtherCurrentPayables
      contextRef="As_Of_12_31_2023_XGghR9I2w0KmrTtJVNkj1A"
      decimals="-3"
      id="Tc_iAHGNprs0Eigi8QVL-II_g_22_4"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">3278000</ifrs-full:TradeAndOtherCurrentPayables>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="As_Of_6_30_2024_lm1Lh8C52kquuyx0qsrPDw"
      decimals="-3"
      id="Tc_EisQOu-nPkm6BrG4Hym9fA_23_2"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">368000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentLeaseLiabilities
      contextRef="As_Of_12_31_2023_XGghR9I2w0KmrTtJVNkj1A"
      decimals="-3"
      id="Tc_-QfYoNCR5EWKdDwlaiugaw_23_4"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">718000</ifrs-full:CurrentLeaseLiabilities>
    <ifrs-full:CurrentRefundsProvision
      contextRef="As_Of_6_30_2024_lm1Lh8C52kquuyx0qsrPDw"
      decimals="-3"
      id="Tc_Qq2GQUHfPEeHEJmpS2S5mw_24_2"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">12451000</ifrs-full:CurrentRefundsProvision>
    <ifrs-full:CurrentRefundsProvision
      contextRef="As_Of_12_31_2023_XGghR9I2w0KmrTtJVNkj1A"
      decimals="-3"
      id="Tc_CY2qftGRB06dnpXdWpv1AQ_24_4"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">10654000</ifrs-full:CurrentRefundsProvision>
    <ifrs-full:CurrentDerivativeFinancialLiabilities
      contextRef="As_Of_6_30_2024_lm1Lh8C52kquuyx0qsrPDw"
      decimals="-3"
      id="Tc_RVyn0awL_Uuhrp36L8MBKQ_25_2"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">2541000</ifrs-full:CurrentDerivativeFinancialLiabilities>
    <ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities
      contextRef="As_Of_6_30_2024_lm1Lh8C52kquuyx0qsrPDw"
      decimals="-3"
      id="Tc_-mIeUGrTZUSTaCNEEZtdRg_26_2"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">3961000</ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities>
    <ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities
      contextRef="As_Of_12_31_2023_XGghR9I2w0KmrTtJVNkj1A"
      decimals="-3"
      id="Tc_SHVcar7RDEO41014PWzxcw_26_4"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">4592000</ifrs-full:CurrentAccruedExpensesAndOtherCurrentLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="As_Of_6_30_2024_lm1Lh8C52kquuyx0qsrPDw"
      decimals="-3"
      id="Tc_bvjPWSuzTEimuacHokoiXw_27_2"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">21233000</ifrs-full:CurrentLiabilities>
    <ifrs-full:CurrentLiabilities
      contextRef="As_Of_12_31_2023_XGghR9I2w0KmrTtJVNkj1A"
      decimals="-3"
      id="Tc_oE4xtPd08keVTXjdCmefew_27_4"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">19983000</ifrs-full:CurrentLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="As_Of_6_30_2024_lm1Lh8C52kquuyx0qsrPDw"
      decimals="-3"
      id="Tc_8xk7F0SinUuEDS2kXXR4Xw_30_2"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">190000</ifrs-full:NoncurrentLeaseLiabilities>
    <ifrs-full:NoncurrentLeaseLiabilities
      contextRef="As_Of_12_31_2023_XGghR9I2w0KmrTtJVNkj1A"
      decimals="-3"
      id="Tc_LsOL-BJCWU2PJcDTqP0mNQ_30_4"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">455000</ifrs-full:NoncurrentLeaseLiabilities>
    <rdhl:NoncurrentRoyaltyObligation
      contextRef="As_Of_6_30_2024_lm1Lh8C52kquuyx0qsrPDw"
      decimals="-3"
      id="Tc_9olrIa7HbEeLJtBBOHLcNg_31_2"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">540000</rdhl:NoncurrentRoyaltyObligation>
    <rdhl:NoncurrentRoyaltyObligation
      contextRef="As_Of_12_31_2023_XGghR9I2w0KmrTtJVNkj1A"
      decimals="-3"
      id="Tc_H8sa_AMm6kK6ufSz9A-vTg_31_4"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">540000</rdhl:NoncurrentRoyaltyObligation>
    <ifrs-full:NoncurrentLiabilities
      contextRef="As_Of_6_30_2024_lm1Lh8C52kquuyx0qsrPDw"
      decimals="-3"
      id="Tc_Kp8N1qQJ0Eq24lP2z0YoRg_32_2"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">730000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:NoncurrentLiabilities
      contextRef="As_Of_12_31_2023_XGghR9I2w0KmrTtJVNkj1A"
      decimals="-3"
      id="Tc_yJ5QiaFPS0yoH4xlTDHdyg_32_4"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">995000</ifrs-full:NoncurrentLiabilities>
    <ifrs-full:Liabilities
      contextRef="As_Of_6_30_2024_lm1Lh8C52kquuyx0qsrPDw"
      decimals="-3"
      id="Tc_aOIfcx4iTkOX9Ex6kc50Pw_33_2"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">21963000</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="As_Of_12_31_2023_XGghR9I2w0KmrTtJVNkj1A"
      decimals="-3"
      id="Tc_ovssZoXDVECV_gCsujKBAw_33_4"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">20978000</ifrs-full:Liabilities>
    <ifrs-full:IssuedCapital
      contextRef="As_Of_6_30_2024_lm1Lh8C52kquuyx0qsrPDw"
      decimals="-3"
      id="Tc_4FpDUTZDCUi2nj1j_H9azg_36_2"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">34785000</ifrs-full:IssuedCapital>
    <ifrs-full:IssuedCapital
      contextRef="As_Of_12_31_2023_XGghR9I2w0KmrTtJVNkj1A"
      decimals="-3"
      id="Tc_jvEtrgtb5k254tmktaJCJg_36_4"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">21441000</ifrs-full:IssuedCapital>
    <ifrs-full:SharePremium
      contextRef="As_Of_6_30_2024_lm1Lh8C52kquuyx0qsrPDw"
      decimals="-3"
      id="Tc_LRHQsHdAlUqL4Yl15PjA3g_37_2"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">375333000</ifrs-full:SharePremium>
    <ifrs-full:SharePremium
      contextRef="As_Of_12_31_2023_XGghR9I2w0KmrTtJVNkj1A"
      decimals="-3"
      id="Tc_P-zfEkgnhEuFlcPpxxHbQQ_37_4"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">388363000</ifrs-full:SharePremium>
    <ifrs-full:RetainedEarnings
      contextRef="As_Of_6_30_2024_lm1Lh8C52kquuyx0qsrPDw"
      decimals="-3"
      id="Tc_lb3TqREIdEGlxu0yEyS-rQ_38_2"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">-410057000</ifrs-full:RetainedEarnings>
    <ifrs-full:RetainedEarnings
      contextRef="As_Of_12_31_2023_XGghR9I2w0KmrTtJVNkj1A"
      decimals="-3"
      id="Tc_ry-ZwPdYz0i_azEIPwv7lg_38_4"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">-407735000</ifrs-full:RetainedEarnings>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2024_lm1Lh8C52kquuyx0qsrPDw"
      decimals="-3"
      id="Tc_691opR9nu0KZziByI-ToUg_39_2"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">61000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2023_XGghR9I2w0KmrTtJVNkj1A"
      decimals="-3"
      id="Tc_cNqY8diLmUKzxfWq7jjxVA_39_4"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">2069000</ifrs-full:Equity>
    <ifrs-full:EquityAndLiabilities
      contextRef="As_Of_6_30_2024_lm1Lh8C52kquuyx0qsrPDw"
      decimals="-3"
      id="Tc_aC9jSRzFdEGf_EgJb1GRAA_40_2"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">22024000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:EquityAndLiabilities
      contextRef="As_Of_12_31_2023_XGghR9I2w0KmrTtJVNkj1A"
      decimals="-3"
      id="Tc_K0Nn7opQHEKIFVnLH-XmDA_40_4"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">23047000</ifrs-full:EquityAndLiabilities>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_WIaiT8u6y0CHEd67KoeeuQ"
      decimals="-3"
      id="Tc_RR-JeU2MgEa1dt-6kbX_Rg_5_2"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">21441000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_LOEJOyxWXU26M6zuQvwiJw"
      decimals="-3"
      id="Tc_qkhsS9bN6E6GmXBZcgU7Wg_5_4"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">388363000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_ZNNvPFR40UGCID0ZfJxAmQ"
      decimals="-3"
      id="Tc_M6_kXZ8fcEmCvUREo3QM3w_5_6"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">-407735000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2023_XGghR9I2w0KmrTtJVNkj1A"
      decimals="-3"
      id="Tc_KpCyryYzqE2XizdcmtneJA_5_8"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">2069000</ifrs-full:Equity>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_f7VpnqzdG0eBMbQ0_PH15g"
      decimals="-3"
      id="Tc_KqrmsEsfU0WvrfqCNa9Glw_8_6"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">766000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      decimals="-3"
      id="Tc_Rbrh8EGGjEGKYrB_-A7R2g_8_8"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">766000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IssueOfEquity
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_WUJJNdtgkUmTbxC0es9vGA"
      decimals="-3"
      id="Tc_6iRtFwwE50y1GIMmihErtA_9_2"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">13135000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_hQziAgWDuESfatZXZuDWKg"
      decimals="-3"
      id="Tc_oVbc44vzCUCyZPbMhhyDvQ_9_4"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">-12821000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      decimals="-3"
      id="Tc_K7pjw45dv0mJ7kBYXYMj-w_9_8"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">314000</ifrs-full:IssueOfEquity>
    <rdhl:StockIssuedDuringPeriodValueRestrictedStockAward
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_WUJJNdtgkUmTbxC0es9vGA"
      decimals="-3"
      id="Tc_ebCiXzfHlkK2K-cxD4pHog_10_2"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">209000</rdhl:StockIssuedDuringPeriodValueRestrictedStockAward>
    <rdhl:StockIssuedDuringPeriodValueRestrictedStockAward
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_hQziAgWDuESfatZXZuDWKg"
      decimals="-3"
      id="Tc_AwduUyepdkaMc08ZKToBOA_10_4"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">-209000</rdhl:StockIssuedDuringPeriodValueRestrictedStockAward>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_f7VpnqzdG0eBMbQ0_PH15g"
      decimals="-3"
      id="Tc_ZLO3Fo2LN0OJF7n-IRNYUQ_11_6"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">-3088000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      decimals="-3"
      id="Tc_lgJEm-n0Ak-WdLHI-nubgg_11_8"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">-3088000</ifrs-full:ProfitLoss>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_pt7V-puUQUK2FnS6Bj5qwA"
      decimals="-3"
      id="Tc_gzce8UUkNEaGlPacorlckQ_12_2"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">34785000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_iXJ3_uR3qkyjYahn5cu1hg"
      decimals="-3"
      id="Tc_e3M83fcXaEOs9r-OOaqD3w_12_4"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">375333000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_ULnTaRXf1k2sfiQlt2ZrxQ"
      decimals="-3"
      id="Tc_gpKMIrbafku5w1Fh_TLqfg_12_6"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">-410057000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2024_lm1Lh8C52kquuyx0qsrPDw"
      decimals="-3"
      id="Tc_7OBztrKvrEWl3IH0LCa7eA_12_8"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">61000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_Y7iGsPaVjkeiB7bpTvHRwg"
      decimals="-3"
      id="Tc_ahUMq4g3dkKxPD1axp87Jg_14_2"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">2835000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_t4QHHZ5Wp0OEOQnVhfCjxQ"
      decimals="-3"
      id="Tc_rlN1rug_5kyhYHHC8LROHQ_14_4"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">382625000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2022_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_ZgoHvobcPU2rpUbaBgakWg"
      decimals="-3"
      id="Tc_LdD1cGyeLUSleiUtJEj1sw_14_6"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">-433860000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_12_31_2022_jV2f_7krOUScpr2kI0mJcw"
      decimals="-3"
      id="Tc_GzjTaCoGb0m6MEW6UFzgDQ_14_8"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">-48400000</ifrs-full:Equity>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_FdLWqdRnzEeYm1z5Q53cfg"
      decimals="-3"
      id="Tc_aiilqI4eEkm2tlpEz5Vbhg_16_6"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">849000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions
      contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw"
      decimals="-3"
      id="Tc_S-AdjDmLZk-G5z3NIRCF0A_16_8"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">849000</ifrs-full:IncreaseDecreaseThroughSharebasedPaymentTransactions>
    <ifrs-full:IssueOfEquity
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_ME6JQrLs4kCObaTBOn_26Q"
      decimals="-3"
      id="Tc_94DxTy_C2kSfEhWQCb52Cw_17_2"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">1761000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_WC_VpnnmJEurMcXdPGqAAA"
      decimals="-3"
      id="Tc_zs3bJVhTlECU1wDDIRu9QQ_17_4"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">-1741000</ifrs-full:IssueOfEquity>
    <ifrs-full:IssueOfEquity
      contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw"
      decimals="-3"
      id="Tc_KsU1bCKU1UegFAoOkFyYrg_17_8"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">20000</ifrs-full:IssueOfEquity>
    <rdhl:StockIssuedDuringPeriodValueRestrictedStockAward
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_ME6JQrLs4kCObaTBOn_26Q"
      decimals="-3"
      id="Tc_j29MvVGShECT35RpWjIJAA_18_2"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">24000</rdhl:StockIssuedDuringPeriodValueRestrictedStockAward>
    <rdhl:StockIssuedDuringPeriodValueRestrictedStockAward
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_WC_VpnnmJEurMcXdPGqAAA"
      decimals="-3"
      id="Tc_LEJrivB64EKClqNfJDDIDA_18_4"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">-24000</rdhl:StockIssuedDuringPeriodValueRestrictedStockAward>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_FdLWqdRnzEeYm1z5Q53cfg"
      decimals="-3"
      id="Tc_4gLwXJyBi0exeLF-w82Naw_19_6"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">51002000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw"
      decimals="-3"
      id="Tc_bgTPa6H_FECXVVkOaOq6mw_19_8"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">51002000</ifrs-full:ProfitLoss>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_IssuedCapitalMember_MYPHkdkUC02VHj9u1f1FRA"
      decimals="-3"
      id="Tc_lhLrBVCd5U6XnjRb0G1msQ_20_2"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">4620000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_SharePremiumMember_cnP-pEbtykmp58TplJXbRw"
      decimals="-3"
      id="Tc_lL2u4slWckCiR7vieY5rTA_20_4"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">380860000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2023_ifrs-full_ComponentsOfEquityAxis_ifrs-full_RetainedEarningsMember_QWxXKkKqr0CvPrcIr11d4g"
      decimals="-3"
      id="Tc_m2lKEGdk_EuEKco-JwwBwQ_20_6"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">-382009000</ifrs-full:Equity>
    <ifrs-full:Equity
      contextRef="As_Of_6_30_2023_XZFu_w7MpEqlzzSlD3xkQg"
      decimals="-3"
      id="Tc_NjwidpXu4Uq8uRcTT_pWYw_20_8"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">3471000</ifrs-full:Equity>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      decimals="-3"
      id="Tc_Qr7xrBrxi0SjxTEz8fViJg_6_3"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">-3088000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw"
      decimals="-3"
      id="Tc_k7Ej2BpK4UumAm4Kj06jbg_6_5"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">51002000</ifrs-full:ProfitLoss>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      decimals="-3"
      id="Tc_uJxE4YkKRUGEsRxEXtc2AA_8_3"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">229000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForSharebasedPayments
      contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw"
      decimals="-3"
      id="Tc_x6zy5vsqBEahMGOBGE096w_8_5"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">849000</ifrs-full:AdjustmentsForSharebasedPayments>
    <ifrs-full:AdjustmentsForDepreciationExpense
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      decimals="-3"
      id="Tc_qZAuJ5oLiUOo4OHHS0XajA_9_3"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">402000</ifrs-full:AdjustmentsForDepreciationExpense>
    <ifrs-full:AdjustmentsForDepreciationExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw"
      decimals="-3"
      id="Tc_7e0nOVIQSEuE_Tqh1at84A_9_5"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">1055000</ifrs-full:AdjustmentsForDepreciationExpense>
    <ifrs-full:AdjustmentsForAmortisationExpense
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      decimals="-3"
      id="Tc_a4rJonszj0eg-FwuakpITg_10_3"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">16000</ifrs-full:AdjustmentsForAmortisationExpense>
    <ifrs-full:AdjustmentsForAmortisationExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw"
      decimals="-3"
      id="Tc_-YrQI27j6U61PpFH360Dfg_10_5"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">530000</ifrs-full:AdjustmentsForAmortisationExpense>
    <rdhl:AdjustmentsForGainsFromTransferOfRightsInMovantikAndExtinguishmentOfDebtObligations
      contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw"
      decimals="-3"
      id="Tc_i4Zq1hUBvEy69dAe6ktwNw_11_5"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">-56082000</rdhl:AdjustmentsForGainsFromTransferOfRightsInMovantikAndExtinguishmentOfDebtObligations>
    <rdhl:AdjustmentsForGainsFromEarlyTerminationOfLeasesNet
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      decimals="-3"
      id="Tc_RR7VbBedpUudRZDjsytIlw_12_3"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">-23000</rdhl:AdjustmentsForGainsFromEarlyTerminationOfLeasesNet>
    <rdhl:AdjustmentsForGainsFromEarlyTerminationOfLeasesNet
      contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw"
      decimals="-3"
      id="Tc_sBJLEcaTekC2pRAhLw8EEA_12_5"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">-694000</rdhl:AdjustmentsForGainsFromEarlyTerminationOfLeasesNet>
    <ifrs-full:AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      decimals="-3"
      id="Tc_D1NzShwtF0iawuutBOc4vg_13_3"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">7108000</ifrs-full:AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives>
    <ifrs-full:AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives
      contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw"
      decimals="-3"
      id="Tc_7KWALyT3HESYFReA0wtUoA_13_5"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">8071000</ifrs-full:AdjustmentsForGainsLossesOnChangeInFairValueOfDerivatives>
    <rdhl:AdjustmentsForLossFromModificationOfWarrantsTermsAsPartOfNewIssuance.
      contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw"
      decimals="-3"
      id="Tc_6tuHXxJuqkeBzH19p1SIjQ_14_5"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">1084000</rdhl:AdjustmentsForLossFromModificationOfWarrantsTermsAsPartOfNewIssuance.>
    <rdhl:AdjustmentForIssuanceCostInRespectOfWarrants
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      decimals="-3"
      id="Tc_BhVeyvbmg06pBQ5OPrmrMg_15_3"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">1497000</rdhl:AdjustmentForIssuanceCostInRespectOfWarrants>
    <rdhl:AdjustmentForIssuanceCostInRespectOfWarrants
      contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw"
      decimals="-3"
      id="Tc_RbpdL7d_50C09OIEnTLUFg_15_5"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">922000</rdhl:AdjustmentForIssuanceCostInRespectOfWarrants>
    <rdhl:AdjustmentsForRevaluationOfBankDeposits
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      decimals="-3"
      id="Tc_i7ryXCyOc0OefIjrlhcn4A_16_3"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">4000</rdhl:AdjustmentsForRevaluationOfBankDeposits>
    <rdhl:AdjustmentsForRevaluationOfBankDeposits
      contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw"
      decimals="-3"
      id="Tc_k-_NLAi1gECsMkZ9YB8VWw_16_5"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">13000</rdhl:AdjustmentsForRevaluationOfBankDeposits>
    <ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      decimals="-3"
      id="Tc_KLr_IUQRHk-0PvQnjFSndw_17_3"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">-4991000</ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital>
    <ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital
      contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw"
      decimals="-3"
      id="Tc_de6W5O-RjEWVje3OQKkrfg_17_5"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">-60420000</ifrs-full:AdjustmentsToReconcileProfitLossOtherThanChangesInWorkingCapital>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      decimals="-3"
      id="Tc_WUONFxYCRUWDHBfhZUK13g_19_3"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">1617000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable
      contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw"
      decimals="-3"
      id="Tc_XfAH66wfiEmAL-rhUsrfGQ_19_5"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">31618000</ifrs-full:AdjustmentsForDecreaseIncreaseInTradeAccountReceivable>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      decimals="-3"
      id="Tc_HVw3FqBIsk-fd_qL2oPA3A_20_3"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">-108000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables
      contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw"
      decimals="-3"
      id="Tc_Bj7hqwcTc0CQd8qn9221tA_20_5"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">1337000</ifrs-full:AdjustmentsForDecreaseIncreaseInOtherOperatingReceivables>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      decimals="-3"
      id="Tc_2knrArhlvki5D__zjA46AA_21_3"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">585000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForDecreaseIncreaseInInventories
      contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw"
      decimals="-3"
      id="Tc_ep2H0pR5S0u4f035mPyxpA_21_5"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">1837000</ifrs-full:AdjustmentsForDecreaseIncreaseInInventories>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      decimals="-3"
      id="Tc_WUxiAh6qBEGGm6iPrChhqg_22_3"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">-1366000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
    <ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable
      contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw"
      decimals="-3"
      id="Tc_u1BpEDKrRU6CRUee2a-ZnA_22_5"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">-1118000</ifrs-full:AdjustmentsForIncreaseDecreaseInTradeAccountPayable>
    <rdhl:AdjustmentsForDecreaseIncreaseInAccruedExpenses
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      decimals="-3"
      id="Tc_1TCv17L7yEKDr0tvKo5wDg_23_3"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">-631000</rdhl:AdjustmentsForDecreaseIncreaseInAccruedExpenses>
    <rdhl:AdjustmentsForDecreaseIncreaseInAccruedExpenses
      contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw"
      decimals="-3"
      id="Tc_CUHOUpky2UCt0z6hldkALQ_23_5"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">-10545000</rdhl:AdjustmentsForDecreaseIncreaseInAccruedExpenses>
    <rdhl:AdjustmentsForIncreaseDecreaseInAllowanceForDeductionsFromRevenue
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      decimals="-3"
      id="Tc_WGJDeFYV-kWVujxFm8nN2w_24_3"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">1797000</rdhl:AdjustmentsForIncreaseDecreaseInAllowanceForDeductionsFromRevenue>
    <rdhl:AdjustmentsForIncreaseDecreaseInAllowanceForDeductionsFromRevenue
      contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw"
      decimals="-3"
      id="Tc_d5MUR4qRr0W-_Nn5VEi9ug_24_5"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">-31486000</rdhl:AdjustmentsForIncreaseDecreaseInAllowanceForDeductionsFromRevenue>
    <ifrs-full:IncreaseDecreaseInWorkingCapital
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      decimals="-3"
      id="Tc_mdmgAwSh1k-Rji9wEO2e2g_25_3"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">-1894000</ifrs-full:IncreaseDecreaseInWorkingCapital>
    <ifrs-full:IncreaseDecreaseInWorkingCapital
      contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw"
      decimals="-3"
      id="Tc_3TpvvOiaE0yT0vt01jxrSw_25_5"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">8357000</ifrs-full:IncreaseDecreaseInWorkingCapital>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      decimals="-3"
      id="Tc_cvTxl98auEquL8N37r1SvQ_26_3"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">-6185000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:CashFlowsFromUsedInOperatingActivities
      contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw"
      decimals="-3"
      id="Tc_FJGMLVptpEeBIQgCeOeWug_26_5"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">-17775000</ifrs-full:CashFlowsFromUsedInOperatingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      decimals="-3"
      id="Tc_OCmEFm1kfE6DuHooCpbDDw_28_3"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">1000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities
      contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw"
      decimals="-3"
      id="Tc_uPd4NZKq8UOjOWTj-T_Tmg_28_5"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">7000</ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      decimals="-3"
      id="Tc_PPAmOHt90kam4XU5_5ib1A_29_3"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">-1000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:CashFlowsFromUsedInInvestingActivities
      contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw"
      decimals="-3"
      id="Tc_3W2lOTSamk-s2C-GI7-srA_29_5"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">-7000</ifrs-full:CashFlowsFromUsedInInvestingActivities>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      decimals="-3"
      id="Tc__diuj9_nIU-U6IbP2XF1Sg_31_3"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">8263000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <ifrs-full:ProceedsFromIssueOfOrdinaryShares
      contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw"
      decimals="-3"
      id="Tc_KuqvKVEMBkqn5m73_7fpJA_31_5"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">5097000</ifrs-full:ProceedsFromIssueOfOrdinaryShares>
    <rdhl:RepaymentOfPayableInRespectOfIntangibleAssetPurchase
      contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw"
      decimals="-3"
      id="Tc_LovhidJqekiLtH92Ukt6bA_32_5"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">6555000</rdhl:RepaymentOfPayableInRespectOfIntangibleAssetPurchase>
    <rdhl:IfrsDecreaseInRestrictedCash
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      decimals="-3"
      id="Tc_9W5ThIvfikOUFvX00bCf7A_33_3"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">51000</rdhl:IfrsDecreaseInRestrictedCash>
    <rdhl:IfrsDecreaseInRestrictedCash
      contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw"
      decimals="-3"
      id="Tc_1eQUOgG6QUS41TSwKbMGjQ_33_5"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">6860000</rdhl:IfrsDecreaseInRestrictedCash>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      decimals="-3"
      id="Tc_RN-jdGpr50CLibpnDgeS_A_34_3"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">414000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities
      contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw"
      decimals="-3"
      id="Tc_2_BT-UHptUSbCi2FDG4oqA_34_5"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">589000</ifrs-full:PaymentsOfLeaseLiabilitiesClassifiedAsFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      decimals="-3"
      id="Tc_ItOF8mFUik-1u8Sy2TBraA_35_3"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">7900000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:CashFlowsFromUsedInFinancingActivities
      contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw"
      decimals="-3"
      id="Tc_yhVhwkock0qupJXt4grPcA_35_5"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">4813000</ifrs-full:CashFlowsFromUsedInFinancingActivities>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      decimals="-3"
      id="Tc_zOcUjhtm9U6tNSbjRvO4Zw_36_3"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">1714000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges
      contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw"
      decimals="-3"
      id="Tc_xSGX1GockEWnFZ1qtvzMbQ_36_5"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">-12969000</ifrs-full:IncreaseDecreaseInCashAndCashEquivalentsBeforeEffectOfExchangeRateChanges>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      decimals="-3"
      id="Tc_M-iqo1KRlECfdsakrNcesQ_37_3"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">-6000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents
      contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw"
      decimals="-3"
      id="Tc_aVQlq6wrKU6I9838pbPp7Q_37_5"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">-3000</ifrs-full:EffectOfExchangeRateChangesOnCashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_12_31_2023_XGghR9I2w0KmrTtJVNkj1A"
      decimals="-3"
      id="Tc_6li-fIsBj0ecUeaAM9-hDw_38_3"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">5569000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_12_31_2022_jV2f_7krOUScpr2kI0mJcw"
      decimals="-3"
      id="Tc_RTU4Pftw9k-qfHgujSK_3g_38_5"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">19968000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_6_30_2024_lm1Lh8C52kquuyx0qsrPDw"
      decimals="-3"
      id="Tc_knuwef9OtUGuNrsnlH_YOA_39_3"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">7277000</ifrs-full:CashAndCashEquivalents>
    <ifrs-full:CashAndCashEquivalents
      contextRef="As_Of_6_30_2023_XZFu_w7MpEqlzzSlD3xkQg"
      decimals="-3"
      id="Tc_3U-13Q-qkEec8JcZQX07iQ_39_5"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">6996000</ifrs-full:CashAndCashEquivalents>
    <rdhl:SupplementalInformationInterestReceivedInCash
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      decimals="-3"
      id="Tc_BYyh_R8y2kKI09qzpeT_cQ_40_3"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">38000</rdhl:SupplementalInformationInterestReceivedInCash>
    <rdhl:SupplementalInformationInterestReceivedInCash
      contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw"
      decimals="-3"
      id="Tc_yKhgqrglo02yuRyLJEeVcQ_40_5"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">123000</rdhl:SupplementalInformationInterestReceivedInCash>
    <rdhl:SupplementalInformationInterestPaidInCash
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      decimals="-3"
      id="Tc_h8mKaEd--EO6YROCSL4dAg_41_3"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">28000</rdhl:SupplementalInformationInterestPaidInCash>
    <rdhl:SupplementalInformationInterestPaidInCash
      contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw"
      decimals="-3"
      id="Tc_UJnqSXUNoEyirso7SxS2qg_41_5"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">315000</rdhl:SupplementalInformationInterestPaidInCash>
    <rdhl:AcquisitionOfRightOfUseAssetsByMeansOfLeaseLiabilities
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      decimals="-3"
      id="Tc_aP3AsdcVLkOJbt_RBCaaJA_43_3"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">5000</rdhl:AcquisitionOfRightOfUseAssetsByMeansOfLeaseLiabilities>
    <rdhl:AcquisitionOfRightOfUseAssetsByMeansOfLeaseLiabilities
      contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw"
      decimals="-3"
      id="Tc_7kyJl1_PXkWeMim2-BwinA_43_5"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">224000</rdhl:AcquisitionOfRightOfUseAssetsByMeansOfLeaseLiabilities>
    <rdhl:DecreaseInRightOfUseAssetFromEarlyTerminationOfLease
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      decimals="-3"
      id="Narr_5cbyLmrvikqw0KPunJ8RRw"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">170000</rdhl:DecreaseInRightOfUseAssetFromEarlyTerminationOfLease>
    <rdhl:DecreaseInRightOfUseAssetFromEarlyTerminationOfLease
      contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw"
      decimals="-3"
      id="Narr_VnD4WMaD2kOH4sN7QO7HlQ"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">4117000</rdhl:DecreaseInRightOfUseAssetFromEarlyTerminationOfLease>
    <rdhl:DecreaseInLeaseLiabilityFromEarlyTerminationOfLease
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      decimals="-3"
      id="Tc_vPC259inZUuQIUM-bMsYIQ_44_3"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">193000</rdhl:DecreaseInLeaseLiabilityFromEarlyTerminationOfLease>
    <rdhl:DecreaseInLeaseLiabilityFromEarlyTerminationOfLease
      contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw"
      decimals="-3"
      id="Tc_OYR6e0To2ka2gdH8ogT5oQ_44_5"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">4811000</rdhl:DecreaseInLeaseLiabilityFromEarlyTerminationOfLease>
    <ifrs-full:ChangesInIntangibleAssetsOtherThanGoodwill
      contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw"
      decimals="-3"
      id="Tc_ey_vXf-eQkyWUJq-pwgCeA_46_5"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">-59503000</ifrs-full:ChangesInIntangibleAssetsOtherThanGoodwill>
    <rdhl:DecreaseInInventories
      contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw"
      decimals="-3"
      id="Tc_EZbPQ59ZH0a_PXc4SM7PYg_47_5"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">-4233000</rdhl:DecreaseInInventories>
    <rdhl:DecreaseIncreaseInPayablesInRespectOfIntangibleAssets
      contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw"
      decimals="-3"
      id="Tc_uasSedCM3EuMIWpjGt_B1g_48_5"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">4602000</rdhl:DecreaseIncreaseInPayablesInRespectOfIntangibleAssets>
    <rdhl:DecreaseIncreaseInBorrowings
      contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw"
      decimals="-3"
      id="Tc_nPmMc4aQ20SVIlj4TCZnUg_49_5"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">115216000</rdhl:DecreaseIncreaseInBorrowings>
    <rdhl:GainsFromTransferOfRightsInMovantikAndExtinguishmentOfDebtObligations
      contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw"
      decimals="-3"
      id="Tc_hc_WBSMPeUmTJalOgh0HAw_50_5"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">56082000</rdhl:GainsFromTransferOfRightsInMovantikAndExtinguishmentOfDebtObligations>
    <ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      id="Tb_4mzlYWHZKUWB1j4pR-L3Cg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 1 - GENERAL:&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 144pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:49.65pt;margin-top:0pt;padding-left:94.35pt;text-align:justify;text-indent:-94.35pt;"&gt;&lt;span style="display:inline-block;font-size:8pt;font-weight:bold;min-width:21.25pt;text-indent:0pt;white-space:nowrap;"&gt;a.&lt;/span&gt;&lt;b style="font-size:8pt;font-weight:bold;"&gt;General&lt;/b&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 144pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:49.6pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;RedHill Biopharma Ltd. (the &#x201c;Company&#x201d;), incorporated on August 3, 2009, together with its wholly-owned subsidiary, RedHill Biopharma Inc. (&#x201c;RedHill Inc.&#x201d;), incorporated in Delaware, U.S. on January 19, 2017, is a specialty biopharmaceutical company primarily focused on gastrointestinal (&#x201c;GI&#x201d;) diseases and infectious diseases. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 67.75pt;"&gt;The Company&#x2019;s American Depositary Shares (&#x201c;ADSs&#x201d;) were traded on the Nasdaq Capital Market from December 27, 2012, were listed on the Nasdaq Global Market (&#x201c;Nasdaq&#x201d;) from July 20, 2018, and have been again listed on the Nasdaq Capital Market since November 15, 2023. On March 23, 2023, the Company changed the ADS ratio from 1 ADS representing 10 ordinary shares to 1 ADS representing 400 ordinary shares. On August 20, 2024, after the condensed consolidated interim financial statements date, the Company changed the ADS to ordinary share ratio from 1 ADS representing 400 ordinary shares to 1 ADS representing 10,000 ordinary shares. The ADSs and per ADS amounts in these interim financial statements reflect the old ratio of 1 ADS to 400 ordinary shares.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 67.75pt;"&gt;The Company&#x2019;s registered address is 21 Ha&#x2019;arba&#x2019;a St, Tel-Aviv, Israel&lt;span style="direction:rtl;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:10pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:49.6pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;2)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Since the Company established its commercial presence in the U.S. in 2017, it has promoted or commercialized various GI-related products that were either developed internally or acquired through in-licensing agreements. As of the date of approval of these condensed consolidated interim financial statements, the Company commercializes in the U.S., mainly Talicia&#xae;, for the treatment of Helicobacter pylori infection in adults, the first product approved by the U.S. Food and Drug Administration (&#x201c;FDA&#x201d;) being developed primarily&lt;/span&gt;&lt;span style="direction:rtl;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;internally by the Company. Until &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;F&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;ebruary&lt;/span&gt;&lt;span style="direction:rtl;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;1,&lt;/span&gt;&lt;span style="direction:rtl;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;2023, the Company commercialized Movantik&#xae; in the U.S, for the treatment of opioid-induced constipation. See also note 15(6) in the annual financial statements as of December 31, 2023 regarding the transfer of the Company&#x2019;s rights in Movantik&#xae; to HCR Collateral Management, LLC (&#x201c;HCRM&#x201d;) in exchange for all the Company&#x2019;s debt obligations under the Credit Agreement with HCRM (see also note 10). The Company also continues to advance the development of part of its late-stage therapeutic candidates. &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:49.6pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;3)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Through June 30, 202&lt;/span&gt;&lt;span style="direction:rtl;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;4&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;, the Company has an accumulated deficit and negative working capital, and its activities have been funded primarily through public and private offerings of the Company&#x2019;s securities and secured borrowing (now fully extinguished, see note 15(6) in the annual financial statements as of December 31, 2023&lt;/span&gt;&lt;span style="direction:rtl;font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;(&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;. There is no assurance that the Company&#x2019;s business will generate sustainable positive cash flows to fund its business.&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;"&gt; &lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:10pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 67.6pt;"&gt;The Company plans to further fund its future operations through commercialization and out-licensing of its therapeutic candidates, commercialization of in-licensed or acquired products and raising additional capital through equity or debt financing or through other non-dilutive financing. Furthermore, the Company is actively pursuing and in discussions with multiple parties regarding strategic business development transactions, including potential divestment of certain of the Company&#x2019;s assets and/or its commercial operations, which the Company expects would provide it with additional capital, although there is no guarantee that the Company will complete such a transaction on favorable terms. The Company&#x2019;s current cash resources are not sufficient to complete the research and development of any of its therapeutic candidates and to fully support its commercial operations until generation of sustainable positive cash flows. Management expects that the Company will incur additional losses as it continues to focus its resources on advancing the development of its therapeutic candidates, as well as advancing its commercial operations, based on a prioritized plan that will result in negative cash flows from operating activities. Management believes that there is presently insufficient funding available to allow &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 67.6pt;"&gt;the Company to fund its activities for a period exceeding one year from the date of this filing. These conditions and events indicate that a material uncertainty exists that may cast significant doubt (or raise substantial doubt as contemplated by PCAOB standards) about the Company&#x2019;s ability to continue as a going concern. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 67.7pt;"&gt;&lt;span style="font-size:8pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 67.7pt;"&gt;The accompanying condensed consolidated interim financial statements have been prepared assuming that the Company will continue as a going concern and do not include any adjustments that might result from the outcome of this uncertainty.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 67.7pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:49.6pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;4)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;In October 2023, Israel was attacked by a terrorist organization and entered a state of war. As of the date of these &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;condensed consolidated interim financial statements&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;, the war in Israel is ongoing and continues to evolve. During six months ended of June 30,2024, the impact of this war on the Company results and financial condition was immaterial, but such impact may increase&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:13.5pt;text-indent:-13.5pt;margin:0pt 0pt 0pt 49.6pt;"&gt;&lt;b style="font-weight:bold;white-space:pre-wrap;"&gt;b.      Approval of the condensed consolidated interim financial statements:&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 50.4pt;"&gt;&lt;span style="font-size:8pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 67.75pt;"&gt;These condensed consolidated interim financial statements were approved by the Board of Directors (the "BoD") on August 28, 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:4.5pt;margin:0pt 0pt 0pt 4.5pt;"&gt;&lt;span style="font-size:8pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfGeneralInformationAboutFinancialStatementsExplanatory>
    <rdhl:NumberOfOrdinarySharesIssuedInExchangeOfAmericanDepositoryReceipts
      contextRef="Duration_3_22_2023_To_3_22_2023_ifrs-full_ClassesOfOrdinarySharesAxis_dei_AdrMember_bVgXh3NRiE65_Oa5kANs7A"
      decimals="INF"
      id="Narr_Pu9Wckb7N0CtuyLj3xnpJA"
      unitRef="Unit_Standard_shares_XGdimIWcf0OdGjo7fryoGw">10</rdhl:NumberOfOrdinarySharesIssuedInExchangeOfAmericanDepositoryReceipts>
    <rdhl:NumberOfOrdinarySharesIssuedInExchangeOfAmericanDepositoryReceipts
      contextRef="Duration_3_23_2023_To_3_23_2023_ifrs-full_ClassesOfOrdinarySharesAxis_dei_AdrMember_xDmTu-XomE-QX_HsBKKWmA"
      decimals="INF"
      id="Narr_wrAzlaeq_UWg8MYLiYpuqA"
      unitRef="Unit_Standard_shares_XGdimIWcf0OdGjo7fryoGw">400</rdhl:NumberOfOrdinarySharesIssuedInExchangeOfAmericanDepositoryReceipts>
    <rdhl:NumberOfOrdinarySharesIssuedInExchangeOfAmericanDepositoryReceipts
      contextRef="Duration_3_23_2023_To_3_23_2023_ifrs-full_ClassesOfOrdinarySharesAxis_dei_AdrMember_xDmTu-XomE-QX_HsBKKWmA"
      decimals="INF"
      id="Narr_x_5qjAF92kqkEpPeLb5GKw"
      unitRef="Unit_Standard_shares_XGdimIWcf0OdGjo7fryoGw">400</rdhl:NumberOfOrdinarySharesIssuedInExchangeOfAmericanDepositoryReceipts>
    <rdhl:NumberOfOrdinarySharesIssuedInExchangeOfAmericanDepositoryReceipts
      contextRef="Duration_8_20_2024_To_8_20_2024_ifrs-full_ClassesOfOrdinarySharesAxis_dei_AdrMember_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_ifrs-full_MajorOrdinaryShareTransactionsMember_RX7kvctHAE2Q6Z9cdW-n0g"
      decimals="INF"
      id="Narr_WuUS12iyDkij3wWm_EIGOQ"
      unitRef="Unit_Standard_shares_XGdimIWcf0OdGjo7fryoGw">10000</rdhl:NumberOfOrdinarySharesIssuedInExchangeOfAmericanDepositoryReceipts>
    <rdhl:NumberOfOrdinarySharesIssuedInExchangeOfAmericanDepositoryReceipts
      contextRef="Duration_3_23_2023_To_3_23_2023_ifrs-full_ClassesOfOrdinarySharesAxis_dei_AdrMember_xDmTu-XomE-QX_HsBKKWmA"
      decimals="INF"
      id="Narr_2KoCtSP40UWdK-datSWmng"
      unitRef="Unit_Standard_shares_XGdimIWcf0OdGjo7fryoGw">400</rdhl:NumberOfOrdinarySharesIssuedInExchangeOfAmericanDepositoryReceipts>
    <rdhl:DisclosureOfBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsTextBlock
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      id="Tb_Wd6CCzVXeEK8P7ZVJpee0g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:67.5pt;text-indent:-67.5pt;margin:0pt 0pt 0pt 4.5pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 2 - BASIS OF PREPARATION OF THE CONDENSED CONSOLIDATED INTERIM FINANCIAL STATEMENTS AND &lt;/b&gt;&lt;b style="font-weight:bold;"&gt;SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;:&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:4.5pt;text-align:justify;text-indent:-4.5pt;margin:0pt 0pt 0pt 67.7pt;"&gt; &lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:49.6pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;a.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-style:normal;font-weight:normal;white-space:pre-wrap;"&gt;  &lt;/span&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt; &lt;/b&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;BASIS OF PREPARATION&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:4.5pt;text-align:justify;text-indent:-4.5pt;margin:0pt 0pt 0pt 67.7pt;"&gt; &lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:4.5pt;text-align:justify;text-indent:-4.5pt;margin:0pt 0pt 0pt 49.6pt;"&gt; &#160;&lt;span style="font-size:10pt;"&gt;The Company&#x2019;s condensed consolidated interim financial statements for the six months&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; ended June 30, 2024 (the "Condensed Consolidated Interim Financial Statements"), have &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;been prepared&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;in accordance with&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; International Accounting Standard IAS 34, &#x201c;Interim Financial Reporting&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;&#x201d;.&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; These Condensed Consolidated Interim Financial Statements,&lt;/span&gt;&lt;span style="direction:rtl;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;that are unaudited, do not include all the information and disclosures that would otherwise be required in a complete set of annual financial statements and &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;should be read in conjunction with the annual financial statements as of December 31, 2023, and their accompanying notes, which have been prepared in accordance with International Financial Reporting Standards (&#x201c;IFRS&#x201d;) as published by the International Accounting Standards Board (&#x201c;IASB&#x201d;).&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; The results of operations for the six months ended June 30, 2024, are not necessarily indicative of the results that may be expected for the entire fiscal year &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;or for&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; any other interim period&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:4.5pt;text-align:justify;text-indent:-4.5pt;margin:0pt 0pt 0pt 49.6pt;"&gt;&lt;span style="font-weight:bold;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:49.6pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;b.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;SIGNIFICANT ACCOUNTING POLICIES&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:49.6pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;General&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 67.6pt;"&gt;&lt;span style="font-weight:bold;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 67.6pt;"&gt;The accounting policies applied in the preparation of the Condensed Consolidated Interim Financial Statements are consistent with those applied in the preparation of the annual financial statements as of December 31, 2023, except for the reclassification of derivative financial instruments from non-current liabilities to current liabilities, as described in note 2b(2).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 67.6pt;"&gt;&lt;span style="font-weight:bold;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:49.6pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;2)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;b style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:bold;"&gt;New international financial reporting standards, amendments to standards and new interpretations&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 67.6pt;"&gt;&lt;span style="font-weight:bold;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 67.6pt;"&gt;&lt;i style="font-style:italic;"&gt;Classification of Liabilities as Current or Non-Current (Amendment to IAS 1)&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="font-style:italic;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 67.6pt;"&gt;The narrow-scope amendments to IAS 1, &#x201c;Presentation of Financial Statements,&#x201d; clarify that liabilities are classified as either current or noncurrent, depending on the rights that exist at the end of the reporting period. Classification is unaffected by the entity&#x2019;s expectations or events after the reporting date. The amendments also clarify what IAS 1 means when it refers to the settlement&#x2019; of a liability. The amendments may affect the classification of liabilities, particularly for entities that previously considered &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 67.6pt;"&gt;management&#x2019;s intentions to determine classification and for some liabilities that can be converted into equity. The Company adopted these amendments effective January 1, 2024. The impact on the Company&#x2019;s financial statements of these amendments was the reclassification of the Company&#x2019;s derivative financial instruments from non-current to current as of its effective date. The Company has retrospectively applied the amendments in these interim financial statements and, accordingly, has retrospectively adjusted the comparative balance sheet for December 31, 2023 to reclassify its warrant liabilities ($741 as of December 31, 2023) from non-current to current. Adoption of the amendments had no other impact on the Company&#x2019;s financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 67.6pt;"&gt;&lt;i style="font-style:italic;"&gt;IFRS 18, Presentation and Disclosure in the Financial Statements&lt;/i&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 67.6pt;"&gt;This standard replaces the international accounting standard IAS 1, &#x201c;Presentation of Financial Statements.&#x201d; As part of the new disclosure requirements, companies will be required to present new defined subtotals in the statements of income, as follows: (1) operating profit and (2) profit before financing and tax. In addition, income statement items will be classified into three defined categories: operating, investment and financing. The standard also includes a requirement to provide a separate disclosure in the financial statements regarding the use of management-defined performance measures (&#x201c;non-GAAP measures&#x201d;), and specific instructions were added for the grouping and splitting of items in the financial statements and in the notes to the financial statements. IFRS 18 is effective for annual reporting periods beginning on or after January 1, 2027, with an option for early adoption.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:4.5pt;text-align:justify;text-indent:-4.5pt;margin:0pt 0pt 0pt 49.6pt;"&gt;&lt;span style="font-size:8pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</rdhl:DisclosureOfBasisOfPreparationOfCondensedConsolidatedInterimFinancialStatementsTextBlock>
    <ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      id="Tb_zaPOJ8Bhe0uVx1tkDTbU9w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:4.5pt;text-align:justify;text-indent:-4.5pt;margin:0pt 0pt 0pt 67.7pt;"&gt; &lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;padding-left:4.5pt;text-align:justify;text-indent:-4.5pt;margin:0pt 0pt 0pt 49.6pt;"&gt; &#160;&lt;span style="font-size:10pt;"&gt;The Company&#x2019;s condensed consolidated interim financial statements for the six months&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; ended June 30, 2024 (the "Condensed Consolidated Interim Financial Statements"), have &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;been prepared&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;in accordance with&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; International Accounting Standard IAS 34, &#x201c;Interim Financial Reporting&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;&#x201d;.&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; These Condensed Consolidated Interim Financial Statements,&lt;/span&gt;&lt;span style="direction:rtl;font-size:10pt;"&gt; &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;that are unaudited, do not include all the information and disclosures that would otherwise be required in a complete set of annual financial statements and &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;should be read in conjunction with the annual financial statements as of December 31, 2023, and their accompanying notes, which have been prepared in accordance with International Financial Reporting Standards (&#x201c;IFRS&#x201d;) as published by the International Accounting Standards Board (&#x201c;IASB&#x201d;).&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; The results of operations for the six months ended June 30, 2024, are not necessarily indicative of the results that may be expected for the entire fiscal year &lt;/span&gt;&lt;span style="font-size:10pt;"&gt;or for&lt;/span&gt;&lt;span style="font-size:10pt;"&gt; any other interim period&lt;/span&gt;&lt;span style="font-size:10pt;"&gt;.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfBasisOfPreparationOfFinancialStatementsExplanatory>
    <rdhl:ReclassificationOfWarrantLiability
      contextRef="As_Of_12_31_2023_ifrs-full_NewIFRSsAxis_rdhl_Ias1AmendmentsMember_6IOwDM618kGNeECku1awvg"
      decimals="0"
      id="Narr_p2afodfCrUepds61oPoxfg"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">741</rdhl:ReclassificationOfWarrantLiability>
    <rdhl:SignificantEventsDuringCurrentReportingPeriodTextBlock
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      id="Tb_TxhrHEFwnUCLgxWJyLPscw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:67.7pt;text-align:justify;text-indent:-67.7pt;margin:0pt 0pt 12pt 4.3pt;"&gt;&lt;b style="font-weight:bold;background:#ffffff;"&gt;NOTE &lt;/b&gt;&lt;b style="font-weight:bold;background:#ffffff;"&gt;3 - SIGNIFICANT EVENTS DURING THE CURRENT REPORTING PERIOD:&lt;/b&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:49.6pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;a.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;On January 26, 2024, the Company issued &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;10,000,000&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; ADSs at a purchase price of $&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;0.80&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; per ADS and warrants to purchase &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;10,000,000&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; ADSs at an exercise price of $&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;1.00&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; per ADS. These warrants may be exercised in cash or on a cashless basis, are immediately exercisable, and expire in &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;five years&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;. The Company also issued to the placement agent warrants to purchase &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;600,000&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; ADSs under the same terms. The gross proceeds from the offering were $&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;8&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; million, before deducting approximately $&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;0.9&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; million in fees and expenses.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 67.6pt;"&gt;&lt;span style="background:#ffffff;"&gt;The warrants were classified as a financial liability due to a net settlement provision. These derivatives were recognized and subsequently measured at fair value through profit or loss. Upon initial recognition the fair value of the warrants was adjusted to reflect the unrecognized day 1 loss. This unrecognized day 1 loss is amortized over the warrants&#x2019; contractual life. Consequently, $&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;0.9&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; million of issuance costs allocated to the warrants, were included directly in the Consolidated Statements of Comprehensive Income (Loss). See also note 7.&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:12pt;margin-top:14pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:49.6pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;b.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;On March 21, 2024, the Annual General Meeting of shareholders approved the increase of the authorized share capital of the Company to NIS &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;400,000,000&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; divided into (i) &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;39,994,000,000&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; registered Ordinary Shares of NIS &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;0.01&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; par value each, and (ii) &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;6,000,000&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; preferred shares of NIS &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;0.01&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; par value each.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:49.6pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:8pt;font-weight:bold;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;c.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;On April 3, 2024, the Company issued &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;2,144,487&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; ADSs at a purchase price of $&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;0.58289&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; per ADS and warrants to purchase &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;2,144,487&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; ADSs at an exercise price of $&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;0.75&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; per ADS. These warrants may be exercised in cash or on a cashless basis, are &#160;immediately exercisable and expire in &lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;five years&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;. The gross proceeds from the offering were $&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;1.25&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; million, before deducting offering expenses approximately $&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;0.1&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt; million in expesnses.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:14pt 0pt 0pt 67.6pt;"&gt;&lt;span style="background:#ffffff;"&gt;The warrants were classified as a financial liability due to a net settlement provision. These derivatives were recognized and subsequently measured at fair value through profit or loss. The consideration, net of issue expenses, was allocated to the various issued instruments. Out of the gross consideration, $&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;0.9&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; million was allocated to the warrants. The remainder of approximately $&lt;/span&gt;&lt;span style="background:#ffffff;"&gt;0.35&lt;/span&gt;&lt;span style="background:#ffffff;"&gt; million was allocated to &lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 67.6pt;"&gt;&lt;span style="background:#ffffff;"&gt;equity. Issuance expenses allocated &#160;to the liability instruments were recorded directly in the Consolidated Statements of Comprehensive Income (Loss) and , while those allocated to equity were recorded against additional paid in capital. See also note 7.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-align:justify;margin:14pt 0pt 12pt 67.6pt;"&gt;&lt;span style="font-size:10pt;margin-bottom:5pt;margin-left:0pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</rdhl:SignificantEventsDuringCurrentReportingPeriodTextBlock>
    <ifrs-full:NumberOfSharesIssued
      contextRef="As_Of_1_26_2024_ifrs-full_ComponentsOfEquityAxis_rdhl_AmericanDepositoryShareMember_earRV5J5lEem3IOZmkajMg"
      decimals="INF"
      id="Narr_LL2Br5xQYU2Djay0QOQ5rA"
      unitRef="Unit_Standard_shares_XGdimIWcf0OdGjo7fryoGw">10000000</ifrs-full:NumberOfSharesIssued>
    <rdhl:IfrsSharesIssuedPricePerShare
      contextRef="Duration_1_26_2024_To_1_26_2024_ifrs-full_ComponentsOfEquityAxis_rdhl_AmericanDepositoryShareMember_6NQerov18ESxxuLFDfcOog"
      decimals="INF"
      id="Narr_kAKMjULyZEKqc_T4Xw3b4A"
      unitRef="Unit_Divide_USD_shares_CKQZNDkEe0eDAz2GdtdFSg">0.80</rdhl:IfrsSharesIssuedPricePerShare>
    <rdhl:WarrantsNumberIssued
      contextRef="Duration_1_26_2024_To_1_26_2024_ifrs-full_ComponentsOfEquityAxis_rdhl_IfrsWarrantMember_try5X0D-VEimOWrLlTXBdw"
      decimals="INF"
      id="Narr_YGzVqQobakWIoavQiPl2tA"
      unitRef="Unit_Standard_shares_XGdimIWcf0OdGjo7fryoGw">10000000</rdhl:WarrantsNumberIssued>
    <rdhl:IfrsClassOfWarrantsOrRightExercisePriceOfWarrantsOrRights
      contextRef="As_Of_1_26_2024_ifrs-full_ComponentsOfEquityAxis_rdhl_IfrsWarrantMember_2DHClqF2Qk-paY34dAQVhQ"
      decimals="INF"
      id="Narr_Ti9TtibxTUeWIRbQfbQ8Kg"
      unitRef="Unit_Divide_USD_shares_CKQZNDkEe0eDAz2GdtdFSg">1.00</rdhl:IfrsClassOfWarrantsOrRightExercisePriceOfWarrantsOrRights>
    <rdhl:IfrsWarrantsAndRightsOutstandingTerm
      contextRef="Duration_1_26_2024_To_1_26_2024_ifrs-full_ComponentsOfEquityAxis_rdhl_IfrsWarrantMember_try5X0D-VEimOWrLlTXBdw"
      id="Narr_FUyIZvI0gEaIqnh-vU1HxA">P5Y</rdhl:IfrsWarrantsAndRightsOutstandingTerm>
    <rdhl:WarrantsNumberIssued
      contextRef="Duration_1_26_2024_To_1_26_2024__j6PCY90FUmwW0bnS-0ZyQ"
      decimals="INF"
      id="Narr_tWanCXKwl0uaw2ONGVB5Wg"
      unitRef="Unit_Standard_shares_XGdimIWcf0OdGjo7fryoGw">600000</rdhl:WarrantsNumberIssued>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="Duration_1_26_2024_To_1_26_2024__j6PCY90FUmwW0bnS-0ZyQ"
      decimals="0"
      id="Narr_lcDcQSTqLEuY2HMH-e0Cbw"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">8000000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:PaymentsForShareIssueCosts
      contextRef="Duration_1_26_2024_To_1_26_2024__j6PCY90FUmwW0bnS-0ZyQ"
      decimals="0"
      id="Narr_vdlPacfxr0-t7fHlVxlW5A"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">900000</ifrs-full:PaymentsForShareIssueCosts>
    <ifrs-full:PaymentsForShareIssueCosts
      contextRef="Duration_1_26_2024_To_1_26_2024_ifrs-full_ComponentsOfEquityAxis_rdhl_IfrsWarrantMember_try5X0D-VEimOWrLlTXBdw"
      decimals="0"
      id="Narr_nkoKNKsDpUOS4eE9D6RqrQ"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">900000</ifrs-full:PaymentsForShareIssueCosts>
    <rdhl:AuthorisedShareCapital
      contextRef="As_Of_3_21_2024_GMdZTmx5DEK7BZ7CRDSNdw"
      decimals="INF"
      id="Narr_j_VX16P4s0yLukVcYWO4Jw"
      unitRef="Unit_Standard_ILS_19CAiapBLkWinll-yZ3PnA">400000000</rdhl:AuthorisedShareCapital>
    <ifrs-full:NumberOfSharesAuthorised
      contextRef="As_Of_3_21_2024_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember_Ej8jvZlqGkeT63oCOmaVmg"
      decimals="INF"
      id="Narr_hDOeP9tpgEm9lbEYWGePCg"
      unitRef="Unit_Standard_shares_XGdimIWcf0OdGjo7fryoGw">39994000000</ifrs-full:NumberOfSharesAuthorised>
    <ifrs-full:ParValuePerShare
      contextRef="As_Of_3_21_2024_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_OrdinarySharesMember_Ej8jvZlqGkeT63oCOmaVmg"
      decimals="INF"
      id="Narr_NX9OHJnQfEauvyhY-AFQ1g"
      unitRef="Unit_Divide_ILS_shares_LnWGktS0CkGllLF6Jva9vA">0.01</ifrs-full:ParValuePerShare>
    <ifrs-full:NumberOfSharesAuthorised
      contextRef="As_Of_3_21_2024_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_PreferenceSharesMember_RA41LoI2wE2KQ4D5_pwTlQ"
      decimals="INF"
      id="Narr___uaaE5wD06B318BW9z0Yw"
      unitRef="Unit_Standard_shares_XGdimIWcf0OdGjo7fryoGw">6000000</ifrs-full:NumberOfSharesAuthorised>
    <ifrs-full:ParValuePerShare
      contextRef="As_Of_3_21_2024_ifrs-full_ClassesOfShareCapitalAxis_ifrs-full_PreferenceSharesMember_RA41LoI2wE2KQ4D5_pwTlQ"
      decimals="INF"
      id="Narr_6VKHvRO280-mWOJyF0XePQ"
      unitRef="Unit_Divide_ILS_shares_LnWGktS0CkGllLF6Jva9vA">0.01</ifrs-full:ParValuePerShare>
    <ifrs-full:NumberOfSharesIssued
      contextRef="As_Of_4_3_2024_ifrs-full_ComponentsOfEquityAxis_rdhl_AmericanDepositoryShareMember_nhnjGt_XE0ij6Oga9k_JNw"
      decimals="INF"
      id="Narr_G4wmKiSoN0merAkQpStJJQ"
      unitRef="Unit_Standard_shares_XGdimIWcf0OdGjo7fryoGw">2144487</ifrs-full:NumberOfSharesIssued>
    <rdhl:IfrsSharesIssuedPricePerShare
      contextRef="Duration_4_3_2024_To_4_3_2024_ifrs-full_ComponentsOfEquityAxis_rdhl_AmericanDepositoryShareMember_i9PW7CfORkKunWqEkaIlfA"
      decimals="INF"
      id="Narr_7uRWVM571UaljMp1RDgrpA"
      unitRef="Unit_Divide_USD_shares_CKQZNDkEe0eDAz2GdtdFSg">0.58289</rdhl:IfrsSharesIssuedPricePerShare>
    <rdhl:WarrantsNumberIssued
      contextRef="Duration_4_3_2024_To_4_3_2024_ifrs-full_ComponentsOfEquityAxis_rdhl_IfrsWarrantMember_MJAPHqwRZkK8j3cPNSQ-DQ"
      decimals="INF"
      id="Narr_UYcn2kwz3ECXNdPkEiro1w"
      unitRef="Unit_Standard_shares_XGdimIWcf0OdGjo7fryoGw">2144487</rdhl:WarrantsNumberIssued>
    <rdhl:IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights
      contextRef="Duration_4_3_2024_To_4_3_2024_ifrs-full_ComponentsOfEquityAxis_rdhl_IfrsWarrantMember_MJAPHqwRZkK8j3cPNSQ-DQ"
      decimals="INF"
      id="Narr_ZAEHqPxmP0CCN1oxtzKk4Q"
      unitRef="Unit_Divide_USD_shares_CKQZNDkEe0eDAz2GdtdFSg">0.75</rdhl:IfrsClassOfWarrantOrRightExercisePriceOfWarrantsOrRights>
    <rdhl:IfrsWarrantsAndRightsOutstandingTerm
      contextRef="Duration_4_3_2024_To_4_3_2024_ifrs-full_ComponentsOfEquityAxis_rdhl_IfrsWarrantMember_MJAPHqwRZkK8j3cPNSQ-DQ"
      id="Narr_RQB-Yhl7LUu-A4EyqBKppg">P5Y</rdhl:IfrsWarrantsAndRightsOutstandingTerm>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="Duration_4_3_2024_To_4_3_2024_xAzFjFHyA02Un3POz8VYMg"
      decimals="0"
      id="Narr__gyzAc5NkU-8IFlRLlLO3Q"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">1250000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:PaymentsForShareIssueCosts
      contextRef="Duration_4_3_2024_To_4_3_2024_xAzFjFHyA02Un3POz8VYMg"
      decimals="0"
      id="Narr_2J5ifYGAt0yjXjeXGdhkyw"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">100000</ifrs-full:PaymentsForShareIssueCosts>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="Duration_4_3_2024_To_4_3_2024_ifrs-full_ComponentsOfEquityAxis_rdhl_IfrsWarrantMember_MJAPHqwRZkK8j3cPNSQ-DQ"
      decimals="0"
      id="Narr_B6ZZqjISf0qeB1fTnmcZig"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">900000</ifrs-full:ProceedsFromIssuingShares>
    <ifrs-full:ProceedsFromIssuingShares
      contextRef="Duration_4_3_2024_To_4_3_2024_ifrs-full_ComponentsOfEquityAxis_ifrs-full_ReserveOfEquityComponentOfConvertibleInstrumentsMember_eYL19KtWRk2RX2MXCnVjkw"
      decimals="0"
      id="Narr_1vNGhyA35EKY2XsZerRliw"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">350000</ifrs-full:ProceedsFromIssuingShares>
    <rdhl:AllowanceForDeductionsFromRevenuesDisclosureTextBlock
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      id="Tb_NYmahA1GpUWYN_JF1ChGjw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 4&lt;/b&gt;&lt;b style="direction:rtl;font-weight:bold;"&gt;:&lt;/b&gt;&lt;b style="font-weight:bold;"&gt; - ALLOWANCE FOR DEDUCTIONS FROM REVENUES:&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 67.75pt;"&gt;&lt;span style="font-size:8pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 67.7pt;"&gt;The following table shows the movement of the allowance for deductions from revenues:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 67.75pt;"&gt;&lt;span style="font-size:8pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:69.55pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:85.5%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:18.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:18.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Rebates and patient discount programs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Product returns&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:middle;width:60.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;U.S.&#160;dollars&#160;in&#160;thousands&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;As of January 1, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 8,087&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2,567&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 10,654&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Increases &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4,565&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 103&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4,668&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Decreases (utilized) &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,184)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (518)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,702)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Adjustments &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 423&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 408&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 831&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;As of June  30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 9,891&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2,560&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 12,451&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:18.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Rebates and patient discount programs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Product returns&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:middle;width:60.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;U.S.&#160;dollars&#160;in&#160;thousands&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;As of January 1, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 46,636&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,234&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 47,870&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Increases &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 16,918&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 759&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 17,677&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Decreases (utilized) &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (48,598)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,072)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (49,670)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Adjustments &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 910&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (403)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 507&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;As of June 30, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 15,866&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 518&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 16,384&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</rdhl:AllowanceForDeductionsFromRevenuesDisclosureTextBlock>
    <rdhl:ScheduleOfMovementOfAllowanceForDeductionsFromRevenuesTableTextBlock
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      id="Tb_oaowqZiFlEKTMK_HsOiQ2w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 67.75pt;"&gt;&lt;span style="font-size:8pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:69.55pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:85.5%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:18.89%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:18.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Rebates and patient discount programs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Product returns&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:middle;width:60.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;U.S.&#160;dollars&#160;in&#160;thousands&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;As of January 1, 2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 8,087&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2,567&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 10,654&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Increases &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4,565&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 103&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 4,668&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Decreases (utilized) &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,184)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (518)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (3,702)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Adjustments &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 423&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 408&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 831&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;As of June  30, 2024&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 9,891&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.94%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2,560&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.65%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 12,451&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:18.89%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Rebates and patient discount programs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.94%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Product returns&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.65%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:34.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:middle;width:60.92%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;U.S.&#160;dollars&#160;in&#160;thousands&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;As of January 1, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 46,636&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 1,234&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 47,870&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Increases &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 16,918&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.94%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 759&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.65%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 17,677&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Decreases (utilized) &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.89%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (48,598)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.94%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,072)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.65%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (49,670)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Adjustments &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.89%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 910&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.94%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (403)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.65%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 507&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:34.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;As of June 30, 2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.22%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:18.89%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 15,866&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.94%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 518&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.65%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 16,384&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</rdhl:ScheduleOfMovementOfAllowanceForDeductionsFromRevenuesTableTextBlock>
    <ifrs-full:CurrentRefundsProvision
      contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfProvisionsAxis_rdhl_RebatesAndPatientDiscountProgramsMember_uIEoPLILYUedGsgrxLouxA"
      decimals="-3"
      id="Tc_kw0UlqXPBkakgkKhoeoeBQ_3_2"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">8087000</ifrs-full:CurrentRefundsProvision>
    <ifrs-full:CurrentRefundsProvision
      contextRef="As_Of_12_31_2023_ifrs-full_ClassesOfProvisionsAxis_rdhl_ProductReturnsMember_JgwA-XfDBkSzQ2XdwWxN8Q"
      decimals="-3"
      id="Tc__mVYjaMk0k-1Mr3T6IDuKQ_3_4"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">2567000</ifrs-full:CurrentRefundsProvision>
    <ifrs-full:CurrentRefundsProvision
      contextRef="As_Of_12_31_2023_XGghR9I2w0KmrTtJVNkj1A"
      decimals="-3"
      id="Tc_QuGqIHSeZ0CuHcYsMSvkHQ_3_6"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">10654000</ifrs-full:CurrentRefundsProvision>
    <ifrs-full:IncreaseDecreaseInExistingProvisionsOtherProvisions
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_ClassesOfProvisionsAxis_rdhl_RebatesAndPatientDiscountProgramsMember_qttEPmHMoE6w_c5KccwpGw"
      decimals="-3"
      id="Tc_kqYCg3ProU6rcV_-qyhh0g_4_2"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">4565000</ifrs-full:IncreaseDecreaseInExistingProvisionsOtherProvisions>
    <ifrs-full:IncreaseDecreaseInExistingProvisionsOtherProvisions
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_ClassesOfProvisionsAxis_rdhl_ProductReturnsMember_HT0SSNr17UuTj9RHXWQHKg"
      decimals="-3"
      id="Tc_6-GH7g2Zy0y-LzlBgJnmRQ_4_4"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">103000</ifrs-full:IncreaseDecreaseInExistingProvisionsOtherProvisions>
    <ifrs-full:IncreaseDecreaseInExistingProvisionsOtherProvisions
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      decimals="-3"
      id="Tc_GMsNOK6d4UuQCkJkffjUTw_4_6"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">4668000</ifrs-full:IncreaseDecreaseInExistingProvisionsOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_ClassesOfProvisionsAxis_rdhl_RebatesAndPatientDiscountProgramsMember_qttEPmHMoE6w_c5KccwpGw"
      decimals="-3"
      id="Tc_k2DupS-o50mzcATmbN3OUQ_5_2"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">3184000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_ClassesOfProvisionsAxis_rdhl_ProductReturnsMember_HT0SSNr17UuTj9RHXWQHKg"
      decimals="-3"
      id="Tc_wae0lohNK0-nbxWSxFy35A_5_4"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">518000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      decimals="-3"
      id="Tc_h-skB1lX2kyPM2wzBefKRw_5_6"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">3702000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_ClassesOfProvisionsAxis_rdhl_RebatesAndPatientDiscountProgramsMember_qttEPmHMoE6w_c5KccwpGw"
      decimals="-3"
      id="Tc_jsIFodPvT0yC0WoJ1GWO0Q_6_2"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">423000</ifrs-full:IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_ClassesOfProvisionsAxis_rdhl_ProductReturnsMember_HT0SSNr17UuTj9RHXWQHKg"
      decimals="-3"
      id="Tc_U0Kqc2MD6U2KgamdPrpY9w_6_4"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">408000</ifrs-full:IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      decimals="-3"
      id="Tc_yhmEqRtHl0CZJ1fyxOEymw_6_6"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">831000</ifrs-full:IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions>
    <ifrs-full:CurrentRefundsProvision
      contextRef="As_Of_6_30_2024_ifrs-full_ClassesOfProvisionsAxis_rdhl_RebatesAndPatientDiscountProgramsMember_CqyXkqtSmEKb7iUSQ8eaSw"
      decimals="-3"
      id="Tc_zPuvZ4yBgkiRC0TiMqLDvg_7_2"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">9891000</ifrs-full:CurrentRefundsProvision>
    <ifrs-full:CurrentRefundsProvision
      contextRef="As_Of_6_30_2024_ifrs-full_ClassesOfProvisionsAxis_rdhl_ProductReturnsMember_QRm2PIhBJEeuckWrAEejMg"
      decimals="-3"
      id="Tc_DllGplNVeECtRYb1IEqp_Q_7_4"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">2560000</ifrs-full:CurrentRefundsProvision>
    <ifrs-full:CurrentRefundsProvision
      contextRef="As_Of_6_30_2024_lm1Lh8C52kquuyx0qsrPDw"
      decimals="-3"
      id="Tc_y9JEXSGLJk-gjScLjxfkPQ_7_6"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">12451000</ifrs-full:CurrentRefundsProvision>
    <ifrs-full:CurrentRefundsProvision
      contextRef="As_Of_12_31_2022_ifrs-full_ClassesOfProvisionsAxis_rdhl_RebatesAndPatientDiscountProgramsMember_vf1AdzJz3Uqw4ZUCrYrNWQ"
      decimals="-3"
      id="Tc_ZvMhALAymUaS0izKJx09pw_10_2"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">46636000</ifrs-full:CurrentRefundsProvision>
    <ifrs-full:CurrentRefundsProvision
      contextRef="As_Of_12_31_2022_ifrs-full_ClassesOfProvisionsAxis_rdhl_ProductReturnsMember_8Uz3eWP1LEa7NOwt5dXb2Q"
      decimals="-3"
      id="Tc_l9mSbSyWxUe4qos1ctZm1A_10_4"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">1234000</ifrs-full:CurrentRefundsProvision>
    <ifrs-full:CurrentRefundsProvision
      contextRef="As_Of_12_31_2022_jV2f_7krOUScpr2kI0mJcw"
      decimals="-3"
      id="Tc_B7XJzGEan0exzl5sTJi_iA_10_6"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">47870000</ifrs-full:CurrentRefundsProvision>
    <ifrs-full:IncreaseDecreaseInExistingProvisionsOtherProvisions
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ClassesOfProvisionsAxis_rdhl_RebatesAndPatientDiscountProgramsMember__3ztoVhkKk2SJ4D3UbPO_A"
      decimals="-3"
      id="Tc_JqPgpDtBQU6P2sutoMdccQ_11_2"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">16918000</ifrs-full:IncreaseDecreaseInExistingProvisionsOtherProvisions>
    <ifrs-full:IncreaseDecreaseInExistingProvisionsOtherProvisions
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ClassesOfProvisionsAxis_rdhl_ProductReturnsMember_9x6Pj5KuWkWJDcCsTqsLnA"
      decimals="-3"
      id="Tc_gQ75efZWqkypjtHMA7z0qQ_11_4"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">759000</ifrs-full:IncreaseDecreaseInExistingProvisionsOtherProvisions>
    <ifrs-full:IncreaseDecreaseInExistingProvisionsOtherProvisions
      contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw"
      decimals="-3"
      id="Tc_95XguOJMuEyllC_gYoUdGA_11_6"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">17677000</ifrs-full:IncreaseDecreaseInExistingProvisionsOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ClassesOfProvisionsAxis_rdhl_RebatesAndPatientDiscountProgramsMember__3ztoVhkKk2SJ4D3UbPO_A"
      decimals="-3"
      id="Tc_hHSMbEUCckC_NE6D2b4QgQ_12_2"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">48598000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ClassesOfProvisionsAxis_rdhl_ProductReturnsMember_9x6Pj5KuWkWJDcCsTqsLnA"
      decimals="-3"
      id="Tc_1w75DpHiVEC8MCpp1GbSpg_12_4"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">1072000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:ProvisionUsedOtherProvisions
      contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw"
      decimals="-3"
      id="Tc_gA9KpdGsRkKQQDEDnsKC4A_12_6"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">49670000</ifrs-full:ProvisionUsedOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ClassesOfProvisionsAxis_rdhl_RebatesAndPatientDiscountProgramsMember__3ztoVhkKk2SJ4D3UbPO_A"
      decimals="-3"
      id="Tc_X17vxtV-P02BMorrFkkQJA_13_2"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">910000</ifrs-full:IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ClassesOfProvisionsAxis_rdhl_ProductReturnsMember_9x6Pj5KuWkWJDcCsTqsLnA"
      decimals="-3"
      id="Tc_9n1Q7Q9qc0q8F7KSffJshw_13_4"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">-403000</ifrs-full:IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions>
    <ifrs-full:IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions
      contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw"
      decimals="-3"
      id="Tc_gRbi5y3BBUK7Cl1aSaCobA_13_6"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">507000</ifrs-full:IncreaseDecreaseThroughTimeValueOfMoneyAdjustmentOtherProvisions>
    <ifrs-full:CurrentRefundsProvision
      contextRef="As_Of_6_30_2023_ifrs-full_ClassesOfProvisionsAxis_rdhl_RebatesAndPatientDiscountProgramsMember_LALfYhyhQ0qxyfiZPt60JA"
      decimals="-3"
      id="Tc_8lsbXn4cyEGQAESIuA--Mg_14_2"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">15866000</ifrs-full:CurrentRefundsProvision>
    <ifrs-full:CurrentRefundsProvision
      contextRef="As_Of_6_30_2023_ifrs-full_ClassesOfProvisionsAxis_rdhl_ProductReturnsMember_P7rAd3_jxEamZoSwvrmIKw"
      decimals="-3"
      id="Tc_b6im4AHctUOGF6S9sutXkw_14_4"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">518000</ifrs-full:CurrentRefundsProvision>
    <ifrs-full:CurrentRefundsProvision
      contextRef="As_Of_6_30_2023_XZFu_w7MpEqlzzSlD3xkQg"
      decimals="-3"
      id="Tc_yD-0HD3UVEGwU9VheWVXVA_14_6"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">16384000</ifrs-full:CurrentRefundsProvision>
    <ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      id="Tb_-iLR6uo0B0ConMWEyIJbQA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE &lt;/b&gt;&lt;b style="direction:rtl;font-weight:bold;"&gt;5&lt;/b&gt;&lt;b style="font-weight:bold;"&gt; - SHARE-BASED PAYMENTS:&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="direction:rtl;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:67.7pt;margin-top:0pt;padding-left:18pt;text-align:justify;text-indent:-18pt;"&gt;&lt;span style="display:inline-block;min-width:17.35pt;text-indent:0pt;white-space:nowrap;"&gt;1.&lt;/span&gt;On June 24, 2024, the BoD granted 1,044,000 RSUs to employees and consultants. These RSUs will vest in 8 equal quarterly installments over two years and had a fair value of $0.4 million on the grant date, based on the ADS price on that date. In addition, the BoD approved the grant of 383,000 RSUs for directors and the Company's Chief Executive Officer in the same terms, subject to Annual General Meeting approval. The fair value of these RSUs on the date of approval was $0.1 million.&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 144pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:67.7pt;margin-top:0pt;padding-left:18pt;text-align:justify;text-indent:-18pt;"&gt;&lt;span style="display:inline-block;min-width:17.35pt;text-indent:0pt;white-space:nowrap;"&gt;2.&lt;/span&gt;During the six months ended June 30, 2024, approximately 24,000 &lt;span style="-sec-ix-hidden:Hidden_nMtd2n9yDkm_DmI_AXUlBw;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;options&lt;/span&gt;&lt;/span&gt; and RSUs were forfeited, mainly due to a reduction in the number of employees, leading to an expense reversal of approximately $0.3 million&lt;span style="direction:rtl;font-size:8pt;"&gt;.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfSharebasedPaymentArrangementsExplanatory>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="Duration_6_24_2024_To_6_24_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_rdhl_IfrsRestrictedStockUnitsRsuMember_sjZ0svU9fUaW52OaNR-8sQ"
      decimals="INF"
      id="Narr_CKAitcYfwE6j1XFRvUIPug"
      unitRef="Unit_Standard_shares_XGdimIWcf0OdGjo7fryoGw">1044000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <rdhl:NumberOfRsuQuarterlyInstallments
      contextRef="Duration_6_24_2024_To_6_24_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_rdhl_IfrsRestrictedStockUnitsRsuMember_sjZ0svU9fUaW52OaNR-8sQ"
      decimals="INF"
      id="Narr_OeIU97JIQkud_AmGx7vGMQ"
      unitRef="Unit_Standard_installment_wykoJbCfrk-_WeAKgSm6lA">8</rdhl:NumberOfRsuQuarterlyInstallments>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted
      contextRef="As_Of_6_24_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_rdhl_IfrsRestrictedStockUnitsRsuMember_w7Isi7m0tka2iRJ24DO5Fw"
      decimals="0"
      id="Narr_7aByrOmYtE2ZajmwCAi2rw"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">400000</ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted
      contextRef="Duration_6_24_2024_To_6_24_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_rdhl_DirectorsAndChiefExecutiveOfficerMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_rdhl_IfrsRestrictedStockUnitsRsuMember_HlO_DU02TUiIerX8stVCzQ"
      decimals="INF"
      id="Narr_oUu5hAtT2E6uObUQvEkqmg"
      unitRef="Unit_Standard_shares_XGdimIWcf0OdGjo7fryoGw">383000</ifrs-full:NumberOfInstrumentsOtherEquityInstrumentsGranted>
    <ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted
      contextRef="As_Of_6_24_2024_ifrs-full_CategoriesOfRelatedPartiesAxis_rdhl_DirectorsAndChiefExecutiveOfficerMember_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_rdhl_IfrsRestrictedStockUnitsRsuMember_o4Du92Jem0mmcqx2GDZY1g"
      decimals="0"
      id="Narr_uMfTyEbTVk-nJ13AEHNKRQ"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">100000</ifrs-full:WeightedAverageFairValueAtMeasurementDateOtherEquityInstrumentsGranted>
    <ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_TypesOfSharebasedPaymentArrangementsAxis_rdhl_IfrsRestrictedStockUnitsRsuMember_5fNRhXT34kedMYDPV9PNfA"
      decimals="INF"
      id="Narr_Zu7-Sz2Ss0m70fjsEatL9g"
      unitRef="Unit_Standard_shares_XGdimIWcf0OdGjo7fryoGw">24000</ifrs-full:NumberOfOtherEquityInstrumentsForfeitedInSharebasedPaymentArrangement>
    <rdhl:ReversedExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      decimals="0"
      id="Narr_-f8pLl2e30aO3PChb66NNQ"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">300000</rdhl:ReversedExpenseFromShareBasedPaymentTransactionsInWhichGoodsOrServicesReceivedDidNotQualifyForRecognitionAsAssets>
    <ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      id="Tb_nyLD3DioDEW614rNObd87w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 4.55pt;"&gt;&lt;b style="font-size:10pt;font-weight:bold;"&gt;NOTE &lt;/b&gt;&lt;b style="direction:rtl;font-size:10pt;font-weight:bold;"&gt;6&lt;/b&gt;&lt;b style="font-size:10pt;font-weight:bold;"&gt; - NET REVENUES:&lt;/b&gt;&lt;b style="font-weight:bold;"&gt; &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 4.55pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:66.6pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:85.5%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:55.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:16.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:20.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:40.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six Months Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:16.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:20.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="5" style="padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;width:40.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;U.S&#160;dollars&#160;in&#160;thousands&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:55.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Sales of products &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2,572&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 5,395&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 67.7pt;"&gt;During the six months ended June 30, 2024, and June 30, 2023, the Company recorded contra-revenues of ($0.9) million and ($0.2) million for Movantik&#xae;, respectively, primarily due to returns following its divestiture on February 1, 2023 (see note 15(6) in the annual financial statements as of December 31, 2023). Correspondingly, net revenues from other products (mainly Talicia&#xae;) were $3.5 million in the first half of 2024, including $0.5&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 67.7pt;"&gt; million from sales to Gaelan Medical Trade LLC, which has an exclusive license for Talicia&#xae; in the UAE (see note 15(7) in the annual financial statements as of December 31, 2023). In the first half of 2023, net revenues from other products (mainly Talicia&#xae;) were $5.6 million, all from U.S. sales&lt;span style="direction:rtl;"&gt;.&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfRevenueFromContractsWithCustomersExplanatory>
    <ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      id="Tb_2AO-NEJKs0iue3d1B6nMkw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 4.55pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:66.6pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:85.5%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:55.85%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:16.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:20.61%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:40.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six Months Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:16.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:3.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:20.61%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="5" style="padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:55.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;width:40.39%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;U.S&#160;dollars&#160;in&#160;thousands&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:55.85%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Sales of products &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:16.01%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 2,572&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.61%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3.5pt 0pt 0pt;"&gt; 5,395&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfDisaggregationOfRevenueFromContractsWithCustomersExplanatory>
    <ifrs-full:Revenue
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      decimals="-3"
      id="Tc_c56NTAkfuUGNfrhDdEtVgg_4_2"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">2572000</ifrs-full:Revenue>
    <ifrs-full:Revenue
      contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw"
      decimals="-3"
      id="Tc_svEtfsk2lkal3divcNEbXw_4_4"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">5395000</ifrs-full:Revenue>
    <rdhl:ContraRevenueForMovantik
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_ProductsAndServicesAxis_rdhl_MovantikMember_vMAuogPiaUK-988AAqqd3A"
      decimals="0"
      id="Narr_CksLgnQsJkK0FtJ96MhkNg"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">900000</rdhl:ContraRevenueForMovantik>
    <rdhl:ContraRevenueForMovantik
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ProductsAndServicesAxis_rdhl_MovantikMember_NxqJvzQaaEK6GKQWpIqWZw"
      decimals="0"
      id="Narr_RwYW4BEP-0Cn46VIq_PWNA"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">200000</rdhl:ContraRevenueForMovantik>
    <rdhl:NetRevenue
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_ProductsAndServicesAxis_rdhl_TaliciaMember_K2Ipuy8Jc065NyMxnj96Og"
      decimals="0"
      id="Narr_-wmnfpPpuE-D-EufjuwBEg"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">3500000</rdhl:NetRevenue>
    <rdhl:NetRevenue
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_CounterpartiesAxis_rdhl_GaelanMedicalTradeLlcMember_ifrs-full_ProductsAndServicesAxis_rdhl_TaliciaMember_0Cf0K8YIskWI-fe7fzrpxQ"
      decimals="0"
      id="Narr_v5kEhQdKkkKHWkP0JnKNFQ"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">500000</rdhl:NetRevenue>
    <rdhl:NetRevenue
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_ProductsAndServicesAxis_rdhl_TaliciaMember_bJeEtRwXpUOUmdyfShRWow"
      decimals="0"
      id="Narr_avWYk9V2t0mxOKJyFI-sWw"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">5600000</rdhl:NetRevenue>
    <ifrs-full:DisclosureOfFinancialInstrumentsExplanatory
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      id="Tb_HYoVg0ENRESBK2QI1W3ttg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 4.55pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE &lt;/b&gt;&lt;b style="direction:rtl;font-weight:bold;"&gt;7&lt;/b&gt;&lt;b style="font-weight:bold;"&gt; - FINANCIAL INSTRUMENTS:&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 72pt;"&gt;&lt;span style="direction:rtl;font-size:8pt;font-weight:bold;margin-bottom:5pt;margin-left:0pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:31.6pt;"&gt;&lt;/td&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;a.&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The Company&#x2019;s derivative financial liability, represented by warrants, is measured at fair value and classified as level 3. Fair value adjustments are recognized in profit or loss as financial income or expenses. The following table presents the change in this level 3 derivative liability for the six months ended June 30, 2024, and June 30, 2023&lt;/span&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;:&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 49.6pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:5pt;margin-left:0pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:94.1pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:70.28%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:41.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Derivative&lt;/b&gt;&lt;b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;financial&#160;instruments&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:41.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six Months Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="4" style="padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:41.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;U.S.&#160;dollars&#160;in&#160;thousands&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:58.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Balance at beginning of the period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"&gt; 741&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"&gt; 2,623&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:58.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Initial recognition of financial liability &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"&gt; 9,860&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"&gt; 7,083&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:58.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Initial recognition of unrecognized day 1 loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (952)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:58.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Fair value adjustments recognized in profit or loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (7,108)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (8,071)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:58.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance at end of the period&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"&gt; 2,541&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"&gt; 1,635&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 72pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:5pt;margin-left:0pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 49.6pt;"&gt;The fair value of the warrants is computed using the Black-Scholes model. As of June 30,2024, it is based on the ADS price on that date and the following key parameters: risk-free interest rate of 4.35%-4.48% and volatility of 120.5%-133.6%. As of June 30,2023, it is based on the ADS price on that date and the following key parameters: risk-free interest rate of 4.17%-5.47% and volatility of 86.6%-99.5%.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 89.55pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;margin-bottom:5pt;margin-left:0pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-left:31.75pt;margin-top:0pt;padding-left:18pt;text-align:justify;text-indent:-18pt;"&gt;&lt;span style="display:inline-block;font-size:8pt;min-width:10.8pt;text-indent:0pt;white-space:nowrap;"&gt;b.&lt;/span&gt;&lt;span style="white-space:pre-wrap;"&gt;  &lt;/span&gt;The carrying amount of cash equivalents, bank deposits, restricted cash, receivables, account payables and accrued expenses approximate their fair value due to their short-term characteristics&lt;span style="font-size:8pt;"&gt;.&lt;/span&gt;&lt;/div&gt;</ifrs-full:DisclosureOfFinancialInstrumentsExplanatory>
    <ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      id="Tb_Syux20ySOUCz8dM5jitteA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:12pt;margin:0pt 0pt 0pt 49.6pt;"&gt;&lt;span style="font-size:8pt;margin-bottom:5pt;margin-left:0pt;margin-top:5pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;div style="padding-left:94.1pt;"&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:70.28%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:58.2%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:41.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Derivative&lt;/b&gt;&lt;b style="font-family:'Calibri','Helvetica','sans-serif';font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;b style="font-weight:bold;"&gt;financial&#160;instruments&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:41.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six Months Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr style="height:0pt;visibility:hidden;"&gt;&lt;td colspan="4" style="padding:0pt;"&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:58.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:41.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;U.S.&#160;dollars&#160;in&#160;thousands&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:58.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Balance at beginning of the period&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"&gt; 741&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"&gt; 2,623&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:58.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Initial recognition of financial liability &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"&gt; 9,860&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"&gt; 7,083&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:58.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Initial recognition of unrecognized day 1 loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (952)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:58.2%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0.05pt 0pt 0.05pt 0pt;"&gt;Fair value adjustments recognized in profit or loss&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.43%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (7,108)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.01%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 0pt 0.05pt 0pt;"&gt; (8,071)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:58.2%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Balance at end of the period&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:20.43%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"&gt; 2,541&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.01%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0.05pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:17.34%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0.05pt 3.5pt 0.05pt 0pt;"&gt; 1,635&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;/div&gt;</ifrs-full:DisclosureOfSignificantUnobservableInputsUsedInFairValueMeasurementOfLiabilitiesExplanatory>
    <ifrs-full:Liabilities
      contextRef="As_Of_12_31_2023_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember_ifrs-full_ClassesOfLiabilitiesAxis_rdhl_FairValueOfWarrantsMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_KpTPdCsFCkCR24LGQXoX_Q"
      decimals="0"
      id="Tc_FAabSX24wUuJ8a2PE9JtzA_5_1"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">741000</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="As_Of_12_31_2022_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember_ifrs-full_ClassesOfLiabilitiesAxis_rdhl_FairValueOfWarrantsMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_Y9wiYGhs4U-MxGWOO7SysA"
      decimals="0"
      id="Tc_POPR3bw-60ywOUCTTNA2lg_5_3"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">2623000</ifrs-full:Liabilities>
    <ifrs-full:IssuesFairValueMeasurementLiabilities
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember_ifrs-full_ClassesOfLiabilitiesAxis_rdhl_FairValueOfWarrantsMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_XsHFmv9nQky9EyNZwd-RWw"
      decimals="-3"
      id="Tc_6vQuU5-sfU2e5kepDP8Opw_6_1"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">9860000</ifrs-full:IssuesFairValueMeasurementLiabilities>
    <ifrs-full:IssuesFairValueMeasurementLiabilities
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember_ifrs-full_ClassesOfLiabilitiesAxis_rdhl_FairValueOfWarrantsMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_JUJ1h0rhhUi0IPjIFY9Y2g"
      decimals="-3"
      id="Tc_m_v_3tYfFU23L8xsp9j2pg_6_3"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">7083000</ifrs-full:IssuesFairValueMeasurementLiabilities>
    <ifrs-full:IncreaseDecreaseInFairValueMeasurementLiabilities
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember_ifrs-full_ClassesOfLiabilitiesAxis_rdhl_FairValueOfWarrantsMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_XsHFmv9nQky9EyNZwd-RWw"
      decimals="-3"
      id="Tc_fh8ExVxwUk2feD8aDpWncg_7_1"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">-952000</ifrs-full:IncreaseDecreaseInFairValueMeasurementLiabilities>
    <ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities
      contextRef="Duration_1_1_2024_To_6_30_2024_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember_ifrs-full_ClassesOfLiabilitiesAxis_rdhl_FairValueOfWarrantsMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_XsHFmv9nQky9EyNZwd-RWw"
      decimals="-3"
      id="Tc_iAf3AA77hEOzfjBkuqScOA_8_1"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">-7108000</ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities>
    <ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities
      contextRef="Duration_1_1_2023_To_6_30_2023_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember_ifrs-full_ClassesOfLiabilitiesAxis_rdhl_FairValueOfWarrantsMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_JUJ1h0rhhUi0IPjIFY9Y2g"
      decimals="-3"
      id="Tc_H76om1eC4EWSLP22O9VjFg_8_3"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">-8071000</ifrs-full:GainsLossesRecognisedInProfitOrLossFairValueMeasurementLiabilities>
    <ifrs-full:Liabilities
      contextRef="As_Of_6_30_2024_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember_ifrs-full_ClassesOfLiabilitiesAxis_rdhl_FairValueOfWarrantsMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_bh9izY_nwk2QNVQRdIq8MQ"
      decimals="-3"
      id="Tc_5CacmIEMrEurR3NjtQoIzA_9_1"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">2541000</ifrs-full:Liabilities>
    <ifrs-full:Liabilities
      contextRef="As_Of_6_30_2023_ifrs-full_CategoriesOfFinancialLiabilitiesAxis_ifrs-full_FinancialLiabilitiesAtFairValueThroughProfitOrLossDesignatedUponInitialRecognitionCategoryMember_ifrs-full_ClassesOfLiabilitiesAxis_rdhl_FairValueOfWarrantsMember_ifrs-full_LevelsOfFairValueHierarchyAxis_ifrs-full_Level3OfFairValueHierarchyMember_ifrs-full_MeasurementAxis_ifrs-full_AtFairValueMember_0zRaQna2fk2MTgU3jRhH5w"
      decimals="-3"
      id="Tc_TXxiqn2njUmxv94nOD7XQA_9_3"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">1635000</ifrs-full:Liabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="As_Of_6_30_2024_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_UnobservableInputsAxis_ifrs-full_InterestRateMeasurementInputMember_teenRBiuRkGg1uO4tRE-mQ"
      decimals="INF"
      id="Narr_x6JaRnNtRUKWPDFnU_m1LQ"
      unitRef="Unit_Standard_pure_yhcnVVwWa0i2EX2hTkNGPA">4.35</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="As_Of_6_30_2024_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_UnobservableInputsAxis_ifrs-full_InterestRateMeasurementInputMember_Vcvjf-Um0kSPabpRIwMIwA"
      decimals="INF"
      id="Narr_OBs_yVvLWkCZkDciWi1Y9Q"
      unitRef="Unit_Standard_pure_yhcnVVwWa0i2EX2hTkNGPA">4.48</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="As_Of_6_30_2024_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_UnobservableInputsAxis_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_zejd0Q0P70OkmQekwOSjkw"
      decimals="INF"
      id="Narr_qYh5Febm50OTYOKGfJey1Q"
      unitRef="Unit_Standard_pure_yhcnVVwWa0i2EX2hTkNGPA">120.5</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="As_Of_6_30_2024_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_UnobservableInputsAxis_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_mTVtiUNnuUSkyBFbN8TE6Q"
      decimals="INF"
      id="Narr_nRiNiuvSqEer7t3T0JxlzA"
      unitRef="Unit_Standard_pure_yhcnVVwWa0i2EX2hTkNGPA">133.6</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="As_Of_6_30_2023_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_UnobservableInputsAxis_ifrs-full_InterestRateMeasurementInputMember_oOWejR1pzEKHOWOqEBCqlw"
      decimals="INF"
      id="Narr_EfxwI1XXP0qOI4DnZe_K6Q"
      unitRef="Unit_Standard_pure_yhcnVVwWa0i2EX2hTkNGPA">4.17</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="As_Of_6_30_2023_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_UnobservableInputsAxis_ifrs-full_InterestRateMeasurementInputMember_41fW1aKaCUmxWkrY4H-2hg"
      decimals="INF"
      id="Narr_k2bnVLsdM0W_gfWm7DwpUQ"
      unitRef="Unit_Standard_pure_yhcnVVwWa0i2EX2hTkNGPA">5.47</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="As_Of_6_30_2023_ifrs-full_RangeAxis_ifrs-full_BottomOfRangeMember_ifrs-full_UnobservableInputsAxis_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_wfwD34Lnw0G6p7TDXvEZ7A"
      decimals="INF"
      id="Narr_kbJjbgPwYkKLAyrHPaKRDw"
      unitRef="Unit_Standard_pure_yhcnVVwWa0i2EX2hTkNGPA">86.6</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:SignificantUnobservableInputLiabilities
      contextRef="As_Of_6_30_2023_ifrs-full_RangeAxis_ifrs-full_TopOfRangeMember_ifrs-full_UnobservableInputsAxis_ifrs-full_HistoricalVolatilityForSharesMeasurementInputMember_KazBZZXGN0muagfyEB6zqQ"
      decimals="INF"
      id="Narr_Rs8i3b-C3UmLwgHx8xfHmA"
      unitRef="Unit_Standard_pure_yhcnVVwWa0i2EX2hTkNGPA">99.5</ifrs-full:SignificantUnobservableInputLiabilities>
    <ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      id="Tb_m1dm6O1U_Eana8iHznkBug">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 4.55pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 8 - SEGMENT INFORMATION: &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 0pt 72pt;"&gt;&lt;span style="font-size:8pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 49.6pt;"&gt;The Chief Executive Officer is the Company&#x2019;s Chief Operating Decision Maker (&#x201c;CODM&#x201d;). The CODM allocates resources and assesses the Company&#x2019;s performance based on the following segmentation: Commercial Operations and Research &amp;amp; Development.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 49.6pt;"&gt;&lt;span style="font-size:8pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 49.6pt;"&gt;Adjusted EBITDA represents net loss before depreciation, amortization, and financial income (expenses), adjusted to exclude share-based compensation, gains from early termination of leases, and other income, which includes income from service provided to HCRM and gain from the sale of Movantik&#xae;.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 49.6pt;"&gt;&lt;span style="font-size:8pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 49.6pt;"&gt;The following table presents segment profitability and a reconciliation to the consolidated net income (loss) and comprehensive income (loss) for the periods indicated:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 49.65pt;"&gt;&lt;span style="font-size:8pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:75%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:56.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:18.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:18.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:39.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six Months Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:18.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:18.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;width:39.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;U.S.&#160;dollars&#160;in&#160;thousands&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:56.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Commercial Operations Segment Adjusted EBITDA&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:4.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt; (4,681)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt; (11,031)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:56.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Research And Development Adjusted EBITDA&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:4.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt; (3,143)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt; (5,550)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:56.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Financial income, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:4.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt; 5,360&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt; 26,330&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:56.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Share-based compensation to employees and service providers&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:4.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt; (229)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt; (849)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:56.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:4.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt; (402)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt; (1,055)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:56.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Amortization of intangible assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:4.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt; (16)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt; (530)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:56.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Gain from early termination of lease, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt; 23&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt; 694&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:56.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Other income &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt; 42,993&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:0.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:56.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Consolidated Comprehensive income (loss) &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:4.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt; (3,088)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt; 51,002&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 49.65pt;"&gt;&lt;span style="font-size:1pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfEntitysReportableSegmentsExplanatory>
    <ifrs-full:DisclosureOfOperatingSegmentsExplanatory
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      id="Tb_3zz09U1ZhUK4t9FCSXfwmQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 49.65pt;"&gt;&lt;span style="font-size:8pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:75%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:56.45%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.39%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:18.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:18.75%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:39.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Six Months Ended June&#160;30,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:4.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:18.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2024&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:18.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2023&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:0.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;width:39.15%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;U.S.&#160;dollars&#160;in&#160;thousands&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:56.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Commercial Operations Segment Adjusted EBITDA&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;white-space:nowrap;width:4.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt; (4,681)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt; (11,031)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:56.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Research And Development Adjusted EBITDA&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:4.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt; (3,143)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt; (5,550)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:56.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Financial income, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:4.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt; 5,360&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt; 26,330&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:56.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Share-based compensation to employees and service providers&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:4.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt; (229)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt; (849)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:56.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Depreciation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:4.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt; (402)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt; (1,055)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:56.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Amortization of intangible assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:4.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt; (16)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.75%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt; (530)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:56.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Gain from early termination of lease, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt; 23&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.75%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt; 694&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:56.45%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Other income &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:4.39%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt; 42,993&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:0.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;width:56.45%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;Consolidated Comprehensive income (loss) &lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:top;width:4.39%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt; (3,088)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:18.75%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt; 51,002&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 49.65pt;"&gt;&lt;span style="font-size:1pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfOperatingSegmentsExplanatory>
    <rdhl:CommercialOperationsSegmentAdjustedEarningsBeforeInterestTaxesDepreciationAndAmortisation
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      decimals="-3"
      id="Tc_7NeqacTkO0adXvUMYiFm3Q_4_2"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">-4681000</rdhl:CommercialOperationsSegmentAdjustedEarningsBeforeInterestTaxesDepreciationAndAmortisation>
    <rdhl:CommercialOperationsSegmentAdjustedEarningsBeforeInterestTaxesDepreciationAndAmortisation
      contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw"
      decimals="-3"
      id="Tc_Iaur1kmRSk-spN2-gfuTyg_4_4"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">-11031000</rdhl:CommercialOperationsSegmentAdjustedEarningsBeforeInterestTaxesDepreciationAndAmortisation>
    <rdhl:ResearchAndDevelopmentAdjustedEarningsBeforeInterestTaxesDepreciationAndAmortisation
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      decimals="-3"
      id="Tc_XYnLcFYcFEOOc32BKEVwKA_5_2"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">-3143000</rdhl:ResearchAndDevelopmentAdjustedEarningsBeforeInterestTaxesDepreciationAndAmortisation>
    <rdhl:ResearchAndDevelopmentAdjustedEarningsBeforeInterestTaxesDepreciationAndAmortisation
      contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw"
      decimals="-3"
      id="Tc_ySaacoAA90CkgnfC_hgNqA_5_4"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">-5550000</rdhl:ResearchAndDevelopmentAdjustedEarningsBeforeInterestTaxesDepreciationAndAmortisation>
    <ifrs-full:FinanceIncomeCost
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      decimals="-3"
      id="Tc_MPcFByruxUSVgP9r2i4kyw_6_2"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">5360000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:FinanceIncomeCost
      contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw"
      decimals="-3"
      id="Tc_YrsGrE3RME2zo-We8yY7PQ_6_4"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">26330000</ifrs-full:FinanceIncomeCost>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      decimals="-3"
      id="Tc_vjrHoG5aKkOWZwhEjzRheg_7_2"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">229000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees
      contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw"
      decimals="-3"
      id="Tc_-i1dPPY4c0yDcqTVaPxanw_7_4"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">849000</ifrs-full:ExpenseFromSharebasedPaymentTransactionsWithEmployees>
    <ifrs-full:DepreciationExpense
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      decimals="-3"
      id="Tc_sCKRrvKZZUeJSQE66PVgCw_8_2"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">402000</ifrs-full:DepreciationExpense>
    <ifrs-full:DepreciationExpense
      contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw"
      decimals="-3"
      id="Tc_GnbgtYYX20KFAw5YvZlGdw_8_4"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">1055000</ifrs-full:DepreciationExpense>
    <rdhl:AmortisationAndImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      decimals="-3"
      id="Tc_3OjfHZTK9E6TXcPLye8_1A_9_2"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">16000</rdhl:AmortisationAndImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <rdhl:AmortisationAndImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill
      contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw"
      decimals="-3"
      id="Tc_cQsLVlBoAES8AsnsRcCPIQ_9_4"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">530000</rdhl:AmortisationAndImpairmentLossRecognisedInProfitOrLossIntangibleAssetsOtherThanGoodwill>
    <rdhl:GainLossOnTerminationOfLeases
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      decimals="-3"
      id="Tc_G-MqpYtDKkW6Kn0amGQtuw_10_2"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">23000</rdhl:GainLossOnTerminationOfLeases>
    <rdhl:GainLossOnTerminationOfLeases
      contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw"
      decimals="-3"
      id="Tc_vzeeio5WpEi7Y0QrftD_yQ_10_4"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">694000</rdhl:GainLossOnTerminationOfLeases>
    <ifrs-full:MiscellaneousOtherOperatingIncome
      contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw"
      decimals="-3"
      id="Tc_12GszC-yC02XsQIsLZJngg_11_4"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">42993000</ifrs-full:MiscellaneousOtherOperatingIncome>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      decimals="-3"
      id="Tc_7v9xgXmwFkSk2akpVTJ1ew_12_2"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">-3088000</ifrs-full:ProfitLoss>
    <ifrs-full:ProfitLoss
      contextRef="Duration_1_1_2023_To_6_30_2023_cNWJaw_LrkOXP7H9Knd5Nw"
      decimals="-3"
      id="Tc_xHK1kJ9fWEy9RpAsPxNQbw_12_4"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">51002000</ifrs-full:ProfitLoss>
    <ifrs-full:DisclosureOfEarningsPerShareExplanatory
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      id="Tb_IpMCxmASyEi58xa3Ng0uZw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 9 - EARNING (LOSS) PER SHARE:&lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 49.6pt;"&gt;The basic and diluted earnings (loss) per share are the same since the effect of all potentially diluted ordinary shares for all reporting periods is anti-dilutive.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfEarningsPerShareExplanatory>
    <ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory
      contextRef="Duration_1_1_2024_To_6_30_2024_JDM8JelSrkCmilHocd1mYw"
      id="Tb_kC4833ZAMU6oeI1r39ibQA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;NOTE 10 - EVENT SUBSEQUENT TO JUNE 30, 2024: &lt;/b&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 67.6pt;"&gt;On July 15, 2024, the Company and RedHill Inc signed a Global Termination Agreement with Movantik Acquisition Co., Valinor Pharma, LLC, and HCR Redhill SPV, LLC, affiliates of HCRM (the &#x201c;Global Termination Agreement&#x201d;). This agreement terminates the Credit Agreement from February 23, 2020, which was amended on February 2, 2023, as part of the transaction where the rights to Movantik&#xae; were sold to HCRM in exchange for extinguishing all debt obligations under the Credit Agreement. The February 2023 agreement had placed a lien Talicia&#xae; and Aemcolo&#xae; assets and established an escrow account with restricted funds for Movantik&#xae; liabilities (for further details, see note 1(a)(2) above and notes 14(a), 15(4), 15(5), and 15(6) to the annual financial statements as of December 31, 2023).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 49.6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 67.6pt;"&gt;The Global Termination Agreement terminates all existing credit ties, removing the aforementioned lien and restoring control over the restricted escrow funds. The Company received approximately $9.9 million in cash and gained full control over $0.7&lt;span style="white-space:pre-wrap;"&gt; million previously held in the restricted account.  Under the Global Termination Agreement, the Company assumed certain liabilities related to Movantik&#xae; from the other parties and settled additional liabilities between the parties. This resulted in an increase of approximately $&lt;/span&gt;12.2 million in the Company's future obligations, reflecting these assumed and settled amounts.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 67.6pt;"&gt;&lt;span style="margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 49.65pt;"&gt;&lt;span style="font-size:8pt;margin-left:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</ifrs-full:DisclosureOfEventsAfterReportingPeriodExplanatory>
    <rdhl:ProceedsReceivedFollowingGlobalTerminationAgreement
      contextRef="Duration_7_15_2024_To_7_15_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_rdhl_GlobalTerminationAgreementMember_srt_CounterpartyNameAxis_rdhl_MovantikAcquisitionValinorPharmaLlcHcrRedhillSpvLlcMember_4pd8zpat4UqiB1Cifr2ikA"
      decimals="0"
      id="Narr_mRGLEbtEzk-3mkJEqKnsDw"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">9900000</rdhl:ProceedsReceivedFollowingGlobalTerminationAgreement>
    <ifrs-full:RestrictedCashAndCashEquivalents
      contextRef="As_Of_7_15_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_rdhl_GlobalTerminationAgreementMember_srt_CounterpartyNameAxis_rdhl_MovantikAcquisitionValinorPharmaLlcHcrRedhillSpvLlcMember_ZmyihQPxD0iGrsKP1MNtWw"
      decimals="0"
      id="Narr_6KM9kNLh_U-cI1d-v5_HVw"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">700000</ifrs-full:RestrictedCashAndCashEquivalents>
    <rdhl:IncreaseInLiabilities
      contextRef="Duration_7_15_2024_To_7_15_2024_ifrs-full_NonadjustingEventsAfterReportingPeriodAxis_rdhl_GlobalTerminationAgreementMember_srt_CounterpartyNameAxis_rdhl_MovantikAcquisitionValinorPharmaLlcHcrRedhillSpvLlcMember_4pd8zpat4UqiB1Cifr2ikA"
      decimals="0"
      id="Narr_WImpO6wWjk-xyLKO-8jOww"
      unitRef="Unit_Standard_USD_AeOPwE0CYEieUd1w99pUxg">12200000</rdhl:IncreaseInLiabilities>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
